GENE	MUTATION_REMARK	GENOMIC_MUTATION_ID	FUSION_ID	MUTATION_AA_SYNTAX	DISEASE	ACTIONABILITY_RANK	DEVELOPMENT_STATUS	DRUG_COMBINATION	TESTING_REQUIRED	TRIAL_STATUS	TRIAL_ID	TRIAL_NAME	COMPLETION_STATUS	TRIAL_PRIMARY_COMPLETION_DATE	PATIENT_PRESCREENING	RESULTS_AVAILABILITY	PROGRESSION_REMARK	SOURCE_TYPE	SOURCE	TREATMENT_HISTORY	PATIENT_AGE	PRIMARY_OUTCOME_MEASURE	NUMBER_OF_PATIENTS	TREATED_NUMBER	CONTROL_NUMBER	CONTROL_TREATMENT	ORR_TREAT	ORR_CON	ORR_CI	ORR_PVAL	DOR_TREAT	DOR_CON	DOR_CI	DOR_PVAL	PFS_TREAT	PFS_CON	PFS_HR	PFS_CI	PFS_PVAL	TTP_TREAT	TTP_CON	TTP_HR	TTP_CI	TTP_PVAL	DCR_TREAT	DCR_CON	DCR_PVAL	OS_TREAT	OS_CON	OS_HR	OS_CI	OS_PVAL	OBJ_RR_TREAT	CR_COUNT	PR_COUNT	SD_COUNT	RFS_TREAT	RFS_CON	RFS_HR	RFS_CI	RFS_PVAL	BLOOD_RESPONSE	RESPONSE_VALUE	TIMEPOINT
ABL1	ABL1 T315I	59323790		p.T315I	haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Ponatinib		Unknown					Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203469s033lbl.pdf			Major cytogenetic response	64	64																																						Major cytogenetic	70	
ABL1	ABL1 T315I	59323790		p.T315I	haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Rebastinib		Completed	NCT00827138		PCD	01-JAN-13	Yes	Yes	No benefit of treatment	1	27927766			Maximum tolerated dose/toxicity	4	4																																								
ABL1	ABL1 T315I	59323790		p.T315I	haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	HQP1351		Recruiting	NCT03883087		ECD	01-FEB-21	Yes	Yes		4	NCT03883087			Major cytogenetic response	40	40																																								
ABL1	ABL1 T315I	59323790		p.T315I	haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Chemotherapy + Ponatinib		Not yet recruiting	NCT04501614		ECD	01-MAR-25	Yes	No		4	NCT04501614	Previously-treated	Pediatric	Complete remission	68	68																																								
ABL1	ABL1 T315I	59323790		p.T315I	haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Panobinostat		Completed	NCT00449761		PCD	01-AUG-08	Yes	Yes		2	10.1182/blood.V112.11.4254.4254	Previously-treated		Complete hematologic response	1	1																																						Complete hematologic	100	
ABL1	ABL1 T315I	59323790		p.T315I	haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	HQP1351		Active, not recruiting	NCT03883100		ECD	01-MAR-21	Yes	No		4	NCT03883100			Major hematologic response	23	23																																								
ABL1	ABL1_unspecified				NS / other / neoplasm	3	Phase 2	Nilotinib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
ABRAXAS1	ABRAXAS1_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
ABRAXAS1	ABRAXAS1_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
ABRAXAS1	ABRAXAS1_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
AKT1	AKT1_E17K	62571334 + 104666437		p.E17K	breast / carcinoma / NS	3	Phase 1	Capivasertib		Active, not recruiting	NCT01226316		PCD	01-APR-19	Yes	Yes		1	32312891	Untreated		Maximum tolerated dose/toxicity	20	20				20							5.4																				4									
AKT1	AKT1_E17K	62571334 + 104666437		p.E17K	breast / carcinoma / NS	3	Phase 1	BAY1125976		Completed	NCT01915576		PCD	01-JUL-16	Yes	Yes		4	NCT01915576			Maximum tolerated dose/toxicity	6	6																																3								
AKT1	AKT1_E17K	62571334 + 104666437		p.E17K	breast / carcinoma / NS	3	Phase 1	Capivasertib + Fulvestrant		Active, not recruiting	NCT01226316		PCD	01-APR-19	Yes	Yes		1	32312891	Untreated		Maximum tolerated dose/toxicity	15	15				20							5.6																				3									
AKT1	AKT1_E17K	62571334 + 104666437		p.E17K	breast / carcinoma / NS	3	Phase 1	Capivasertib + Fulvestrant		Active, not recruiting	NCT01226316		PCD	01-APR-19	Yes	Yes		1	32312891	Previously-treated		Maximum tolerated dose/toxicity	28	28				36							5																				10									
AKT1	AKT1_unspecified				NS / carcinoma / neuroendocrine carcinoma	3	Phase 2	Everolimus		Terminated	NCT02315625		PCD	01-MAY-19	No	Yes	Slow accrual	4	NCT02315625			Progression free survival	16	16																																								
AKT1	AKT1_unspecified				NS / other / neoplasm	3	Phase 1	ARQ751		Active, not recruiting	NCT02761694		ECD	01-DEC-20	Yes	No		4	NCT02761694			Maximum tolerated dose/toxicity	100	100																																								
AKT1	AKT1_unspecified				NS / other / neoplasm	3	Phase 1	ARQ751 + Paclitaxel		Active, not recruiting	NCT02761694		ECD	01-DEC-20	Yes	No		4	NCT02761694			Maximum tolerated dose/toxicity	100	100																																								
AKT1	AKT1_unspecified				NS / other / neoplasm	3	Phase 1	ARQ751 + Fulvestrant		Active, not recruiting	NCT02761694		ECD	01-DEC-20	Yes	No		4	NCT02761694			Maximum tolerated dose/toxicity	100	100																																								
AKT1	AKT1_unspecified				NS / other / neoplasm	3	Phase 2	MK2206		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
AKT1	AKT1_unspecified				NS / other / neoplasm	3	Phase 2	Ipatasertib		Recruiting	NCT02465060	MATCH Subprotocol Z1K	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
AKT1	AKT1_unspecified				NS / other / neoplasm	3	Phase 2	Capivasertib + Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	No	No		4	NCT02576444			Overall Response Rate	64	64																																								
AKT1	AKT1_unspecified				NS / other / neoplasm	3	Phase 2	Temsirolimus		Recruiting	NCT02693535	TAPUR group 6	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
AKT1	AKT1_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
AKT1	AKT1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFIRI + Panitumumab		Active, not recruiting	NCT01312857		ECD	01-MAR-21	No	No		4	NCT01312857			Disease free survival, relapse free survival, regression free survival, recurrence free survival	75	75																																								
AKT1	AKT1_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 2	MK2206		Completed	NCT01283035		PCD	01-DEC-14	Expression level	Yes		4	NCT01283035			Overall Response Rate	5	5			0																													4								
AKT1	AKT1_unspecified				prostate / carcinoma / NS	3	Unknown	Celecoxib		Unknown	NCT02208583		ECD	01-DEC-16	Yes	No		4	NCT02208583	Previously-treated		Progression free survival	150	150																																								
AKT2	AKT2_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
AKT2	AKT2_unspecified				NS / other / neoplasm	3	Phase 2	Ipatasertib		Recruiting	NCT02465060	MATCH Subprotocol Z1K	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
ALK	ALK_C1156Y	66562303		p.C1156Y	lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_C1156Y	66562303		p.C1156Y	lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_C1156Y	66562303		p.C1156Y	lung / carcinoma / non small cell carcinoma	3	Phase 2	Alectinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_F1174			p.F1174X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_F1174			p.F1174X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_F1174			p.F1174X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Alectinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_G1202.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_G1202.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_I1171.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_I1171.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_I1171.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_L1196.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_L1196.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ensartinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_L1196.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_L1196.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Alectinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_L1196.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_L1198F	66556391		p.L1198F	lung / carcinoma / non small cell carcinoma	3	Phase 2	Crizotinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_V1180.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_V1180.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Brigatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_V1180.				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lorlatinib		Recruiting	NCT03737994		ECD	01-DEC-25	Yes	No		4	NCT03737994	Previously-treated		Overall Response Rate	660	660																																								
ALK	ALK_unspecified				NS / malignant melanoma / NS	3	Phase 2	Ceritinib		Suspended	NCT03501368		ECD	01-JUN-21	No	No		4	NCT03501368			Overall Response Rate	27	27																																								
ALK	ALK_unspecified				NS / malignant melanoma / NS	3	Phase 2	Ceritinib		Terminated	NCT02587650		PCD	01-JUL-18	Yes	Yes	Lack of funding	4	NCT02587650			Overall Response Rate	1	1																																								
ALK	ALK_unspecified				NS / malignant melanoma / NS	3	Phase 3	Ensartinib		Active, not recruiting	NCT03420508		ECD	01-JAN-22	Yes	No		4	NCT03420508			Disease control rate, Clinical benefit rate	18	18																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 1	ASP3026		Completed	NCT01284192		PCD	01-FEB-14	Yes	Yes		1	26966027			Maximum tolerated dose/toxicity	16	16			50		25-75																										8	7								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Capivasertib		Recruiting	NCT02465060	MATCH Subprotocol Y	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Oxazolidine		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Entrecitinib		Recruiting	NCT02650401	STARTRK-NG	ECD	01-AUG-29	Yes	No		4	NCT02650401	Previously-treated	Pediatric	Overall Response Rate	68	68																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Entrecitinib		Recruiting	NCT02568267	STARTRK-2	ECD	01-DEC-22	Yes	No		4	NCT02568267			Overall Response Rate	500	500																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Ensartinib		Recruiting	NCT03155620	Subprotocol F	ECD	01-SEP-27	Yes	No		4	NCT03155620		Pediatric	Overall Response Rate	1000	1000																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Ensartinib		Recruiting	NCT03213652		ECD	01-SEP-24	Yes	No		4	NCT03213652			Overall Response Rate	98	98																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Brigatinib		Recruiting	NCT03868423		ECD	01-DEC-20	Yes	No		4	NCT03868423			Overall Response Rate	20	20																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Alectinib		Not yet recruiting	NCT04551521	CRAFT	ECD	01-APR-24	Yes	No		4	NCT04551521			Disease control rate, Clinical benefit rate	175	175																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Crizotinib		Recruiting	NCT02693535	TAPUR group 3	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Crizotinib		Active, not recruiting	NCT04439266	MATCH-Subprotocol F	ECD	01-JUN-21	Yes	No		4	NCT04439266			Overall Response Rate	35	35																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Crizotinib		Recruiting	NCT03297606	CAPTUR group 3	ECD	01-SEP-21	Yes	No		4	NCT03297606			Overall Response Rate	720	720																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 2	Crizotinib		Recruiting	NCT02465060	MATCH Subprotocol F	ECD	01-JUN-22	Yes	No		4	NCT02465060			Overall Response Rate	6452	6452																																								
ALK	ALK_unspecified				NS / neoplasm / NS	3	Phase 3	Alectinib		Active, not recruiting	NCT03194893		ECD	01-JUN-24	Expression level	No		4	NCT03194893			Maximum tolerated dose/toxicity	200	200																																								
ALK	ALK_unspecified				autonomic ganglia / neuroblastoma / NS	3	Phase 1	Ceritinib		Recruiting	NCT02780128	NEPENTHE	ECD	01-JUL-21	Yes	No		4	NCT02780128			Maximum tolerated dose/toxicity	131	131																																								
ALK	ALK_unspecified				autonomic ganglia / neuroblastoma / NS	3	Phase 1	Cyclophosphamide + Lorlatinib + Topotecan		Recruiting	NCT03107988		ECD	01-MAY-20	No	No		4	NCT03107988		Pediatric	Maximum tolerated dose/toxicity	40	40																																								
ALK	ALK_unspecified				autonomic ganglia / neuroblastoma / NS	3	Phase 1	Ceritinib + Ribociclib		Recruiting	NCT02780128	NEPENTHE	ECD	01-JUL-21	Yes	No		4	NCT02780128			Maximum tolerated dose/toxicity	131	131																																								
ALK	ALK_unspecified				autonomic ganglia / neuroblastoma / NS	3	Phase 1	Lorlatinib		Recruiting	NCT03107988		ECD	01-MAY-20	Yes	No		4	NCT03107988			Maximum tolerated dose/toxicity	40	40																																								
ALK	ALK_unspecified				autonomic ganglia / neuroblastoma / NS	3	Phase 1	Lorlatinib		Recruiting	NCT03107988		ECD	01-MAY-20	No	No		4	NCT03107988		Pediatric	Maximum tolerated dose/toxicity	40	40																																								
ALK	ALK_unspecified				autonomic ganglia / neuroblastoma / NS	3	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Yes	No		4	NCT02034981			Overall Response Rate	246	246																																								
ALK	ALK_unspecified				autonomic ganglia / neuroblastoma / NS	3	Phase 2	Crizotinib		Completed	NCT00939770		PCD	01-DEC-18	Yes	Yes		1	23598171			Maximum tolerated dose/toxicity	11	11																														1		2								
ALK	ALK_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Ceritinib		Terminated	NCT02374489		PCD	01-JAN-18	Expression level	Yes	No benefit of treatment	4	NCT02374489			Overall Response Rate	9	9																																								
ALK	ALK_unspecified				biliary tract / carcinoma / adenocarcinoma	7	Phase 2	Ceritinib		Terminated	NCT02374489		PCD	01-JAN-18	Expression level	Yes	No benefit of treatment	4	NCT02374489			Overall Response Rate	9	9																																								
ALK	ALK_unspecified				breast / carcinoma / NS	3	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Yes	No		4	NCT02034981			Overall Response Rate	246	246																																								
ALK	ALK_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 1	Ceritinib		Unknown	NCT02605746		PCD	01-NOV-18	No	No		4	NCT02605746			Maximum tolerated dose/toxicity	10	10																																								
ALK	ALK_unspecified				eye / malignant melanoma / NS	3	Phase 2	Crizotinib		Active, not recruiting	NCT02223819		ECD	01-AUG-22	No	No		4	NCT02223819	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	34	34																																								
ALK	ALK_unspecified				eye / malignant melanoma / NS	3	Phase 2	Crizotinib		Active, not recruiting	NCT02223819		ECD	01-AUG-22	No	No		4	NCT02223819	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	34	34																																								
ALK	ALK_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	7	Phase 2	Ceritinib		Terminated	NCT02638909		PCD	01-MAR-18	Yes	Yes	Slow enrollment	4	NCT02638909			Disease control rate, Clinical benefit rate	4	4																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Crizotinib		Completed	NCT01829503		PCD	01-OCT-15	No	Yes		4	NCT01829503			Overall Response Rate	39	39																														26	6									
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / NS	3	Phase 2	Crizotinib		Unknown	NCT02419287		ECD	01-MAR-21	Yes	No		4	NCT02419287			Overall Response Rate	12	12																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Crizotinib		Completed	NCT00939770		PCD	01-DEC-18	Yes	Yes		1	23598171		Pediatric	Maximum tolerated dose/toxicity	9	9																														6	1	1								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Cyclophosphamide + Prednisone + Rituximab + Toripalimab + Vincristine + doxorubicin hydrochloride		Not yet recruiting	NCT04058470	TREND	ECD	01-DEC-22	Yes	No		4	NCT04058470	Untreated		Overall Response Rate	140	140																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Crizotinib + Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + doxorubicin hydrochloride		Suspended	NCT01979536		ECD	01-MAR-21	Yes	No		4	NCT01979536	Untreated		Maximum tolerated dose/toxicity	140	140																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Brentuximab vedotin + Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + doxorubicin hydrochloride		Suspended	NCT01979536		ECD	01-MAR-21	Yes	No		4	NCT01979536	Untreated		Maximum tolerated dose/toxicity	140	140																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Onalespib lactate		Active, not recruiting	NCT02572453		ECD	01-OCT-21	Yes	No		4	NCT02572453	Previously-treated		Overall Response Rate	50	50																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Brentuximab vedotin  + Ceritinib		Withdrawn	NCT02729961		ECD	01-JUL-23	Yes	No		4	NCT02729961			Overall Response Rate	0	0																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Brentuximab vedotin  + Imatinib		Active, not recruiting	NCT02462538 		ECD	01-JUN-21	Yes	No		4	NCT02462538	Previously-treated		Maximum tolerated dose/toxicity	10	10																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Nivolumab		Recruiting	NCT03703050	NIVO-ALCL	ECD	01-JAN-24	Yes	No		4	NCT03703050			Overall Response Rate	38	38																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Brigatinib		Withdrawn	NCT03719898		PCD	01-MAR-20	Yes	Yes	Slow accrual	4	NCT03719898			Overall Response Rate	0	0																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Lorlatinib		Recruiting	NCT03505554	CRU3	ECD	01-DEC-20	Yes	No		4	NCT03505554			Overall Response Rate	12	12																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Crizotinib		Active, not recruiting	NCT01524926	CREATE	PCD	01-DEC-17	Yes	No		4	NCT01524926			Clinical activity	582	582																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.2504			Overall Response Rate	22	22			54.5		34-75																																			
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 3	Cerdulatinib 		Withdrawn	NCT04021082	CELTIC-1	ECD	01-DEC-22	Yes	No		4	NCT04021082			Overall Response Rate	0	0																																								
ALK	ALK_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / anaplastic large cell lymphoma	3	Phase 4	Autologous Hematopoietic Stem Cell Transplantation + Crizotinib + Etoposide 		Recruiting	NCT03707847		ECD	01-FEB-20	Yes	No		4	NCT03707847	Previously-treated		Overall Response Rate	20	20																																								
ALK	ALK_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Crizotinib		Active, not recruiting	NCT01524926	CREATE	PCD	01-DEC-17	Yes	No		4	NCT01524926			Clinical activity	582	582																																								
ALK	ALK_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Yes	No		4	NCT02034981			Overall Response Rate	246	246																																								
ALK	ALK_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Ceritinib		Terminated	NCT02638909		PCD	01-MAR-18	Yes	Yes	Slow accrual	4	NCT02638909			Disease control rate, Clinical benefit rate	0	0																																								
ALK	ALK_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Ascrinvacumab		Terminated	NCT01911273		PCD	01-JUL-14	No	Yes	Development discontinued	3	NCT01911273	Previously-treated		Overall survival	3			Best supportive care																																						
ALK	ALK_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + Crizotinib		Unknown	NCT02946359	CAMAR	ECD	01-OCT-17	Yes	No		4	NCT02946359	Untreated		Progression free survival	60	60																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Crizotinib	Required	Completed	NCT00932893		PCD	01-MAR-20	Yes	Yes		1	23724913			Progression free survival	347	173	174	Chemotherapy									7.7	3	.49	0.37-0.64	<0.001																									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Brigatinib	Not required	Active, not recruiting	NCT02094573	ALTA	PCD	01-FEB-16	Yes	Yes		4	NCT02094573	Previously-treated		Overall Response Rate	222	222			53.6		42.6-64.5																																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Alectinib	Required	Active, not recruiting	NCT02075840	ALEX	PCD	01-FEB-17	Yes	Yes		1	28586279	Untreated		Progression free survival	303	152	151	Crizotinib									68.4	48.7	.47	0.34-0.65	<0.001																									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Alectinib	Required	Completed	NCT01801111	NP28673	PCD	01-OCT-14	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf	Previously-treated		Overall Response Rate	138	138			44				11.2																								61									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Alectinib	Required	Completed	NCT01588028	NP28761	PCD	01-OCT-14	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf	Previously-treated		Maximum tolerated dose/toxicity	87	87			38		28-49		7.5																								33									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Lorlatinib	Not required	Active, not recruiting	NCT01970865		PCD	01-MAR-17	Yes	Yes		1	30413378	Previously-treated		Overall Response Rate	198	198			47.0		39.9-54.2																									4	89	58								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Lorlatinib	Not required	Active, not recruiting	NCT01970865		PCD	01-MAR-17	Yes	Yes		1	30413378	Untreated		Overall Response Rate	30	30			90.0		73.5-97.9																									1	26									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Ceritinib	Required	Active, not recruiting	NCT01828099	ASCEND-4	PCD	01-JUN-16	Yes	Yes		1	28126333	Untreated		Progression free survival	375	189	187	Chemotherapy									16.6	8.1	.55	5.8-11.1	<0.00001																									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Ceritinib	Required	Completed	NCT01283516 	ASCEND-1	PCD	01-MAY-16	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Previously-treated		Maximum tolerated dose/toxicity	163	163			55		47-62		7.4		5.4-10.1																					2	86									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Crizotinib	Required	Completed	NCT01154140		PCD	01-NOV-13	Yes	Yes		1	25470694	Untreated		Progression free survival	343	172	171	Chemotherapy	74	45		<0.001					10.9	7	.45	0.35-0.60	<0.001																									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Out of trials human study	Pemetrexed		Unknown					Yes	Yes		1	21642865			Unknown	15	15			46.7													9.2															7	6								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ipilimumab + Nivolumab		Active, not recruiting	NCT04013542		ECD	01-FEB-21	Yes	No		4	NCT04013542			Maximum tolerated dose/toxicity	20	20																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Lorlatinib + Temozolomide		Recruiting	NCT04541407		ECD	01-MAY-23	Yes	No		4	NCT04541407			Maximum tolerated dose/toxicity	33	33																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Pembrolizumab + Stereotactic Body Radiation Therapy		Active, not recruiting	NCT03436056	PRIMING	ECD	01-MAR-21	No	No		4	NCT03436056			Maximum tolerated dose/toxicity	24	24																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	DV281		Completed	NCT03326752		PCD	01-SEP-19	Yes	No		4	NCT03326752			ORR, DOR	26	26																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Itraconazole + Rifampicin		Active, not recruiting	NCT00585195	PROFILE 1001	PCD	01-APR-20	Yes	No		4	NCT00585195			Maximum tolerated dose/toxicity	596	596																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Anlotinib + Carboplatin + Pemetrexed		Recruiting	NCT03790228	ALTER-L012	ECD	01-OCT-20	Yes	No		4	NCT03790228			Progression free survival	43	43																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Brigatinib + Midazolam		Active, not recruiting	NCT03420742		PCD	01-MAR-20	Yes	No		4	NCT03420742			Maximum tolerated dose/toxicity	24	24																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Everolimus		Recruiting	NCT02321501		ECD	01-JUN-23	Yes	No		4	NCT02321501			Maximum tolerated dose/toxicity	66	66																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alkotinib		Recruiting	NCT03607188		ECD	01-FEB-21	No	No		4	NCT03607188			Maximum tolerated dose/toxicity	18	18																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Pembrolizumab		Terminated	NCT02511184		PCD	01-DEC-17	Yes	Yes	Slow accrual	4	NCT02511184			Maximum tolerated dose/toxicity	9	9																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Luminespib		Completed	NCT01752400		PCD	01-JUN-17	Yes	Yes		4	NCT01752400			Overall Response Rate	6	6			0								1.43			1.3-2.8																										
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	PLB1003		Unknown	NCT03130881		ECD	01-DEC-20	Yes	No		4	NCT03130881			Maximum tolerated dose/toxicity	60	60																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Binimetinib + Brigatinib		Not yet recruiting	NCT04005144		ECD	01-AUG-22	Yes	No		4	NCT04005144			Maximum tolerated dose/toxicity	18	18																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Conteltinib		Unknown	NCT02695550		ECD	01-MAR-18	Yes	Yes		1	32181989			Maximum tolerated dose/toxicity	13	13			77								13			9.98-16.00							85									1	10									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Ganetespib		Active, not recruiting	NCT01579994		PCD	01-DEC-20	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.8064			Maximum tolerated dose/toxicity	12	12																															8	2								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Ribociclib		Completed	NCT02292550		PCD	01-SEP-18	Yes	Yes		3	https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Dose-determination-results-from-a-Phase-Ib-II-study-of-ceritinib-CER-ribociclib-RIB-in-ALK-positive-ALK-non-small-cell-lung-cancer-NSCLC			Maximum tolerated dose/toxicity	27	27			48.1																											1	12									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Luminespib		Completed	NCT01772797		PCD	01-JAN-16	Yes	No		4	NCT01772797			Maximum tolerated dose/toxicity	22	22																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Nivolumab		Active, not recruiting	NCT02393625		ECD	01-JUN-21	Yes	No		4	NCT02393625			Maximum tolerated dose/toxicity	57	57																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alectinib + Atezolizumab		Completed	NCT02013219		PCD	01-FEB-20	Yes	No		4	NCT02013219			Maximum tolerated dose/toxicity	52	52																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Atezolizumab + Erlotinib		Completed	NCT02013219		PCD	01-FEB-20	Yes	Yes		2	10.1016/j.jtho.2016.11.1841			Maximum tolerated dose/toxicity	28	28			75.0		51-91		9.7		4.2-11.7		11.3			8.4-NE							90																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Nivolumab		Completed	NCT01998126		PCD	01-MAY-17	Yes	No		4	NCT01998126			Maximum tolerated dose/toxicity	14	14																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Ipilimumab		Completed	NCT01998126		PCD	01-MAY-17	Yes	Yes	Serious adverse events	1	31346927			Maximum tolerated dose/toxicity	3	3											24.1																													
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ensartinib		Active, not recruiting	NCT02959619		ECD	01-DEC-19	Yes	No		4	NCT02959619			Maximum tolerated dose/toxicity	24	24																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Brigatinib		Recruiting	NCT03707938	BRIGHTSTAR	ECD	01-JAN-23	Yes	No		4	NCT03707938	Untreated		Maximum tolerated dose/toxicity	35	35																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alectinib		Terminated	NCT03131206		PCD	01-AUG-18	Yes	Yes	Slow accrual, no benefit of treatment	4	NCT03131206			Overall Response Rate	5	5			20		0.52-71.63																																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib		Withdrawn	NCT02277457		ECD	01-JUN-21	Yes	No		4	NCT02277457			Unknown	0	0																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Dacomitinib		Completed	NCT01121575		PCD	01-FEB-14	No	Yes		1	26899759			Maximum tolerated dose/toxicity	70	70																															1	32								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ipilimumab + Nivolumab		Completed	NCT03256136		PCD	01-AUG-19	Yes	Yes		4	NCT03256136			Overall Response Rate	1	1			0								.7										0																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Nivolumab + Pemetrexed		Completed	NCT03256136		PCD	01-AUG-19	Yes	Yes		4	NCT03256136			Overall Response Rate	1	1			100								2.8										100																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pembrolizumab + Recombinant EphB4-HSA fusion protein		Recruiting	NCT03049618		ECD	01-MAY-21	Yes	No		4	NCT03049618			Overall Response Rate	50	50																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Nivolumab + Plinabulin		Terminated	NCT02846792		PCD	01-JUL-18	Yes	Yes	Changed business priorities	4	NCT02846792			Overall Response Rate	5	5																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Pemetrexed		Recruiting	NCT03778138	ALTER-L025	ECD	01-DEC-19	Yes	No		4	NCT03778138			Progression free survival	51	51																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Avelumab + Axitinib + Palbociclib		Recruiting	NCT03386929	SPRING	ECD	01-OCT-23	Yes	No		4	NCT03386929			Progression free survival	130	130																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Docetaxel + Sintilimab		Recruiting	NCT03798743	Success	ECD	01-JUN-21	Yes	No		4	NCT03798743	Previously-treated		Overall Response Rate	30	30																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Radiotherapy		Not yet recruiting	NCT04193007	BRATR	ECD	01-DEC-21	Yes	No		4	NCT04193007			Progression free survival	100	100																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	WX-0593		Recruiting	NCT03389815		ECD	01-JUN-20	Yes	No		4	NCT03389815			Maximum tolerated dose/toxicity	48	48																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Repotrectinib		Recruiting	NCT04094610		ECD	01-DEC-22	Yes	No		4	NCT04094610			Maximum tolerated dose/toxicity	75	75																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	EphB4-HSA Fusion Protein + Pembrolizumab		Recruiting	NCT03049618		ECD	01-MAR-21	Yes	No		4	NCT03049618			Overall Response Rate	50	50																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Avelumab + Lorlatinib		Active, not recruiting	NCT02584634	Javelin Lung 101	ECD	01-DEC-21	Yes	Yes		4	NCT02584634			Overall Response Rate	43	43			46.4		27.5-66.1																									1	12									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Stereotactic Body Radiation Therapy		Recruiting	NCT02314364		ECD	01-NOV-21	Yes	No		4	NCT02314364			Maximum tolerated dose/toxicity	30	30																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ganetespib		Completed	NCT01562015		PCD	01-AUG-14	Yes	Yes		4	NCT01562015			Overall Response Rate	12	12			37.5		8.5-75.5						0													0																
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed		Not yet recruiting	NCT04042558		ECD	01-JUN-21	Yes	No		4	NCT04042558			Overall Response Rate	149	149																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Luminespib		Completed	NCT01922583		PCD	01-FEB-17	Yes	No		4	NCT01922583			Overall Response Rate	31	31																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Chemotherapy + Pembrolizumab		Active, not recruiting	NCT03242915		ECD	01-AUG-21	Yes	No		4	NCT03242915	Previously-treated		Overall Response Rate	33	33																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Durvalumab + Ensartinib		Completed	NCT02898116		PCD	01-AUG-17	Yes	Yes	Slow accrual	4	NCT02898116			Maximum tolerated dose/toxicity	2	2																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib + Cobimetinib		Recruiting	NCT03202940		ECD	01-NOV-21	Yes	No		4	NCT03202940			Maximum tolerated dose/toxicity	31	31																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Retaspimycin		Terminated	NCT01228435		PCD	01-FEB-12	Yes	Yes	Slow accrual	4	NCT01228435			Response rate	3	3																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib + Trametinib		Recruiting	NCT03087448		ECD	01-JUN-21	Yes	No		4	NCT03087448			Overall Response Rate	69	69																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib + Bevacizumab		Not yet recruiting	NCT03779191		ECD	01-JUL-22	Yes	No		4	NCT03779191			Progression free survival	40	40																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib + Bevacizumab		Recruiting	NCT02521051		ECD	01-NOV-20	Yes	No		4	NCT02521051			Maximum tolerated dose/toxicity	43	43																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Erlotinib		Completed	NCT00965731		PCD	01-DEC-11	No	Yes	Changed business priorities	4	NCT00965731			Progression free survival	27	27		Erlotinib																																						
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Pemetrexed		Terminated	NCT02134912		PCD	01-SEP-16	Yes	Yes	Development discontinued	4	NCT02134912	Previously-treated		Unknown	1	1																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Onalespib lactate		Completed	NCT01712217		PCD	01-DEC-16	Yes	Yes	No benefit of treatment	2	10.1200/JCO.2016.34.15_suppl.9059			Overall Response Rate	136	68	68		55.4	45.3							8.84	8.74																												
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Recruiting	NCT04415320		ECD	01-DEC-20	Yes	No		4	NCT04415320			Overall Response Rate	37	37																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Unknown	NCT03215693		ECD	01-SEP-18	Yes	Yes		1	31628085	Previously-treated		Overall Response Rate	156	156			52																																					
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Completed	NCT01625234		PCD	01-SEP-20	Yes	Yes		2	10.1158/1078-0432.CCR-17-2398			Maximum tolerated dose/toxicity	60	60			66		47.4-71.4		12.8		5.6-24.4		9.2			5.6-11.7																	36	13								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Unknown	NCT03753685		ECD	01-JUL-20	Yes	No		4	NCT03753685			Overall Response Rate	37	37																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Completed	NCT01449461		PCD	01-NOV-15	Yes	Yes		1	27836716	Untreated		Overall Response Rate	8	8			100																											3	5									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Completed	NCT01449461		PCD	01-NOV-15	Yes	Yes		1	27836716	Previously-treated		Overall Response Rate	71	71			62								13.2			9.1-18.7																4	40	11								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Active, not recruiting	NCT03410108	J-ALTA	PCD	01-SEP-20	Yes	Yes		2	10.1200/JCO.2020.38.15_suppl.9537			Overall Response Rate	72	72			30.6				6.1				7.3										78.7																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Recruiting	NCT03535740	ALTA-2	PCD	01-SEP-20	Yes	No		4	NCT03535740	Previously-treated		Overall Response Rate	104	104																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Recruiting	NCT02706626	ALTA-1L	ECD	01-JAN-22	Yes	No		4	NCT02706626	Previously-treated		Overall Response Rate	120	120																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib		Completed	NCT03155009	ATALK	PCD	01-SEP-19	Yes	Yes		3	https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection			Overall Response Rate	39	39			51.3																											4	16									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib		Recruiting	NCT02314481	DARWIN II	ECD	01-NOV-24	Yes	No		4	NCT02314481			Progression free survival	119	119																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib		Completed	NCT01871805		PCD	01-OCT-14	Yes	Yes		1	29748847			Maximum tolerated dose/toxicity	134	134																								29.1			21.3-39.0													
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Not yet recruiting	NCT04127110	ALKALINE	ECD	01-DEC-23	Yes	No		4	NCT04127110			Progression free survival	100	100																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Recruiting	NCT02927340		ECD	01-MAY-21	Yes	No		4	NCT02927340			Disease control rate, Clinical benefit rate	30	30																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Recruiting	NCT03909971		PCD	01-AUG-20	Yes	No		4	NCT03909971	Previously-treated		Overall Response Rate	100	100																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02336451	ASCEND-7 Arm 5	PCD	01-FEB-19	Yes	Yes		4	NCT02336451			Overall Response Rate	18	18			16.7		3.6-41.4																66.7																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02336451	ASCEND-7 Arm 4	PCD	01-FEB-19	Yes	Yes		4	NCT02336451	Untreated		Overall Response Rate	44	44			59.1		43.2-73.7																70.5																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02336451	ASCEND-7 Arm 3	PCD	01-FEB-19	Yes	Yes		4	NCT02336451	Previously-treated, platinum-resistant		Overall Response Rate	12	12			50.0		21.1-78.9																66.7																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02336451	ASCEND-7 Arm 2	PCD	01-FEB-19	Yes	Yes		4	NCT02336451	Previously-treated, platinum-resistant		Overall Response Rate	40	40			30.0		16.6-46.5																82.5																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT01685060	ASCEND-2	PCD	01-MAR-16	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.8059	Previously-treated		Overall Response Rate	140	140			38.6		30.5-47.2																																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT01685138	ASCEND-3	PCD	01-JAN-18	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.8060	Untreated		Overall Response Rate	124	124			63.7				9.3				11.1																													
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02040870	ASCEND-6	PCD	01-JUL-17	Yes	Yes		3	https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib	Previously-treated		Maximum tolerated dose/toxicity	103	103			42		31.2-50.9						5.7			5.4-7.5							80																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Active, not recruiting	NCT02513667		ECD	01-AUG-21	Yes	No		4	NCT02513667			Progression free survival	33	33																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02450903		PCD	01-JUL-17	Yes	Yes		4	NCT02450903	Previously-treated		Unknown	20	20			25		8.7-49.1		6.3		3.5-9.2		3.7			1.9-5.3							70.0																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02336451	ASCEND-7 Arm 1	PCD	01-FEB-19	Yes	Yes		4	NCT02336451	Previously-treated, platinum-resistant		Overall Response Rate	42	42			35.7		21.6-52.0																66.7																			
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02276027		PCD	01-OCT-19	Yes	Yes		4	NCT02276027			Overall Response Rate	26	26			73.1																																					
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Withdrawn	NCT01500824		ECD	01-MAY-16	Yes	No		4	NCT01500824			Overall Response Rate	0	0																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Completed	NCT00932451		PCD	01-MAR-15	Yes	Yes		4	NCT00932451			Overall Response Rate	1069	1069			54.1		50.8-57.4		11.8		10.4-12.8		8.4			7.1-9.7							70.8			21.8			19.4-24.0						6.1			2.7-16.4				
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Withdrawn	NCT03088930		PCD	01-MAY-18	Yes	Yes	Slow accrual	4	NCT03088930			Unknown	0	0																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Completed	NCT00939770		PCD	01-DEC-18	Yes	Yes		1	23598171	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	2	2																															1	1								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Recruiting	NCT02664935		ECD	01-OCT-22	No	No		4	NCT02664935			ORR, PFS, DOR	549	549																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capivasertib		Recruiting	NCT02664935		ECD	01-OCT-22	No	No		4	NCT02664935			PFS, ORR	549	549																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Crizotinib		Recruiting	NCT02201992	ALCHEMIST	ECD	01-MAY-22	Yes	No		4	NCT02201992			Overall survival	168			Best supportive care																																						
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Atezolizumab + Carboplatin + Nab-paclitaxel		Active, not recruiting	NCT02367781		PCD	01-MAR-18	No	Yes		4	NCT02367781			OS, PFS	723	451	228	Carboplatin + Nab-paclitaxel									7	5.5	.64	0.54-0.77	<0.0001																									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Chemotherapy + Toripalimab		Recruiting	NCT03856411		ECD	01-APR-21	Yes	No		4	NCT03856411			Progression free survival	450			Chemotherapy																																						
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel		Not yet recruiting	NCT03991403		ECD	01-DEC-22	Yes	No		4	NCT03991403			Progression free survival	228			Chemotherapy																																						
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	TQ-B3139		Not yet recruiting	NCT04009317		ECD	01-OCT-21	Yes	No		4	NCT04009317			Progression free survival	260	260																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Ensartinib		Active, not recruiting	NCT02767804	eXalt3	ECD	01-MAR-21	Yes	No		4	NCT02767804			Progression free survival	290	290		Crizotinib																																						
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Brigatinib		Active, not recruiting	NCT02737501	ALTA-1L	PCD	01-JUL-20	Yes	Yes		1	32780660			Progression free survival	275	137	138	Crizotinib									24	11	.49		<0.0001																									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Brigatinib		Recruiting	NCT03596866		ECD	01-SEP-21	Yes	No		4	NCT03596866	Previously-treated		Progression free survival	246	246																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alectinib		Completed	NCT02604342	ALUR	PCD	01-JAN-17	Yes	Yes		4	NCT02604342	Previously-treated		Progression free survival	119	79	40	Chemotherapy									10.9	1.4	.2	0.12-0.33	<0.001																									
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alectinib		Recruiting	NCT03456076		ECD	01-JUN-23	Yes	No		4	NCT03456076			Progression free survival	255	255		Chemotherapy																																						
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alectinib		Active, not recruiting	NCT02838420	ALESIA	PCD	01-MAY-18	Yes	Yes		3	https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC	Untreated		Progression free survival	187	125	62	Crizotinib										11.1	.37	0.13-0.38																										
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alectinib		Recruiting	NCT03178552	B-FAST Cohort A	ECD	01-SEP-21	Yes	No		4	NCT03178552			Overall Response Rate	700	700																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Lorlatinib		Recruiting	NCT03052608		PCD	01-MAR-20	Yes	No		4	NCT03052608 	Untreated		Progression free survival	280	280																																								
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Ceritinib		Active, not recruiting	NCT01828112	ASCEND-5	PCD	01-JAN-16	Yes	Yes		4	NCT01828112	Previously-treated		Progression free survival	29	11	18	Chemotherapy	54.5	0							9.8	1.6	.17	0.05-0.61																										
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Crizotinib		Recruiting	NCT02194738	ALCHEMIST	ECD	01-SEP-21	No	No		4	NCT02194738			Unknown	8300			Placebo																																						
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Crizotinib		Active, not recruiting	NCT01639001		PCD	01-JUN-15	Yes	Yes		4	NCT01639001	Untreated		Progression free survival	207	104	103	Chemotherapy	87.5	45.6		<0.0001					11.1	6.8	.4		<0.001									28.5	27.7	.9	0.56-1.45	0.33												
ALK	ALK_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 4	Lorlatinib		Recruiting	NCT04541706		ECD	01-DEC-22	Yes	No		4	NCT04541706			Maximum tolerated dose/toxicity	100	100																																								
ALK	ALK_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 1	Ceritinib + Gemcitabine		Active, not recruiting	NCT02227940		PCD	01-DEC-18	Yes	No		4	NCT02227940			Maximum tolerated dose/toxicity	38	38																																								
ALK	ALK_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 1	Ceritinib + Cisplatin + Gemcitabine		Active, not recruiting	NCT02227940		PCD	01-DEC-18	Yes	No		4	NCT02227940			Maximum tolerated dose/toxicity	38	38																																								
ALK	ALK_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 1	Ceritinib + Gemcitabine + Nab-paclitaxel		Active, not recruiting	NCT02227940		PCD	01-DEC-18	Yes	No		4	NCT02227940			Maximum tolerated dose/toxicity	38	38																																								
ALK	ALK_unspecified				prostate / carcinoma / NS	3	Phase 1	Crizotinib + Enzalutamide		Active, not recruiting	NCT02207504		PCD	01-FEB-18	No	No		4	NCT02207504	Previously-treated		Maximum tolerated dose/toxicity	24	24																																								
ALK	ALK_unspecified				soft tissue / inflammatory myofibroblastic tumour / NS	3	Phase 1	Ceritinib		Completed	NCT01742286		PCD	01-APR-19	Yes	Yes		1	30697903			Maximum tolerated dose/toxicity	2	2																														2										
ALK	ALK_unspecified				soft tissue / inflammatory myofibroblastic tumour / NS	3	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Yes	No		2	10.1200/JCO.2018.36.15_suppl.2504			Overall Response Rate	246	246																																								
ALK	ALK_unspecified				soft tissue / inflammatory myofibroblastic tumour / NS	3	Phase 2	Crizotinib		Completed	NCT00939770		PCD	01-DEC-18	Yes	Yes		1	23598171		Pediatric	Maximum tolerated dose/toxicity	7	7																															3	3								
ALK	ALK_unspecified				soft tissue / inflammatory myofibroblastic tumour / NS	3	Phase 2	Crizotinib		Active, not recruiting	NCT01524926	CREATE	PCD	01-DEC-17	Yes	No		4	NCT01524926			Clinical activity	582	582																																								
ALK	ALK_unspecified				soft tissue / inflammatory myofibroblastic tumour / NS	3	Phase 3	Crizotinib		Unknown	NCT03874273		ECD	01-FEB-21	No	No		4	NCT03874273		Pediatric	Overall Response Rate	25	25																																								
ALK	ALK_unspecified				soft tissue / inflammatory myofibroblastic tumour / NS	3	Phase 3	Crizotinib		Unknown	NCT03874273		ECD	01-FEB-21	Yes	No		4	NCT03874273		Pediatric	Overall Response Rate	25	25																																								
ALK	ALK_unspecified				thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Yes	No		4	NCT02034981			Overall Response Rate	246	246																																								
ALK	ALK_unspecified				thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Ceritinib		Withdrawn	NCT02289144		PCD	01-JAN-19	No	No	Development discontinued	4	NCT02289144			Time to treatment failure, Time to progression	0	0																																								
ALK	ALK_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 1	Denosumab		Recruiting	NCT03382574		ECD	01-NOV-21	Yes	No		4	NCT03382574			Change in Ki-67 expression	60	60																																								
ALK	ALK_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel		Active, not recruiting	NCT03394885		ECD	01-JAN-21	Yes	No		4	NCT03394885			Maximum tolerated dose/toxicity	18	18																																								
ALK	ALK_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Fluzoparib		Active, not recruiting	NCT03509636		ECD	01-JUN-19	Yes	No		4	NCT03509636			Overall Response Rate	113	113																																								
ALK	ALK_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	EphB4-HSA Fusion Protein + Pembrolizumab		Recruiting	NCT03049618		ECD	01-MAR-21	Yes	No		4	NCT03049618			Overall Response Rate	50	50																																								
ALK	ALK_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 3	Olaparib		Active, not recruiting	NCT03286842	LUCY	ECD	01-JUN-21	Yes	No		4	NCT03286842			Progression free survival	256																																									
ALK	ALK_unspecified				urinary tract / carcinoma / transitional cell carcinoma	3	Phase 2	Ascrinvacumab		Unknown	NCT01620970		PCD	01-JAN-13	No	No		3	NCT01620970			Progression free survival	45	45																																								
APC	APC_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	5-Fluorouracil + Midostaurin + Radiotherapy		Completed	NCT01282502		PCD	01-MAR-15	No	Yes		2	10.1200/JCO.2018.36.15_suppl.e15674			Maximum tolerated dose/toxicity	19	19																															3									
ARID1A	ARID1A_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
ARID1A	ARID1A_unspecified				NS / other / neoplasm	3	Phase 1	M4344		Recruiting	NCT02278250		ECD	01-JUN-21	Yes	No		4	NCT02278250			Maximum tolerated dose/toxicity	300	300																																								
ARID1A	ARID1A_unspecified				NS / other / neoplasm	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
ARID1A	ARID1A_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 5	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
ARID1A	ARID1A_unspecified				NS / other / neoplasm	3	Phase 2	Capivasertib + Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	No	No		4	NCT02576444			Overall Response Rate	64	64																																								
ARID1A	ARID1A_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
ARID1B	ARID1B_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
ARID2	ARID2_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
ASXL1	ASXL_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Enasidenib		Recruiting	NCT04522895		ECD	01-JUN-24	Yes	No		4	NCT04522895			Maximum tolerated dose/toxicity	60	60																																								
ASXL1	ASXL_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Mitoxantrone hydrochloride + Venetoclax		Not yet recruiting	NCT04330820	RELAX	ECD	01-JUN-22	No	No		4	NCT04330820	Previously-treated		Overall Response Rate	60	60																																								
ASXL1	ASXL_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
ASXL1	ASXL_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Ruxolitinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																																								
ASXL1	ASXL_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Chemotherapy + Lestaurtinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Overall Response Rate	29	29																																								
ASXL1	ASXL_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Azacitidine + Donor lymphocyte infusion + Lenalidomide		Completed	NCT02472691	AZALENA	PCD	01-APR-20	No	Yes		2	10.1182/blood-2018-99-113776	Previously-treated		Maximum tolerated dose/toxicity	24	24			68																																					
ASXL1	ASXL_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Azacitidine + Deferasirox		Terminated	NCT02159040		PCD	01-JUN-15	No	Yes	Serious adverse events	4	NCT02159040			Overall Response Rate	1	1																																								
ASXL1	ASXL_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant		Terminated	NCT03303950		PCD	01-MAY-19	No	Yes	Slow accrual	4	NCT03303950			Non-relapse mortality	6	6																																								
ASXL1	ASXL_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Pentraxin 2		Completed	NCT01981850		PCD	01-JUL-20	No	No		4	NCT01981850			Response rate	125	125																																								
ATM	ATM_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 1	Olaparib		Completed	NCT03155620	Subprotocol H	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 1	Ceralasertib + Trastuzumab Deruxtecan		Not yet recruiting	NCT04704661	DASH	ECD	01-MAR-23	Yes	No		4	NCT04704661			Maximum tolerated dose/toxicity	15	15																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 1	Elimusertib + Topotecan		Not yet recruiting	NCT04514497		ECD	01-AUG-24	Expression level	No		4	NCT04514497			Maximum tolerated dose/toxicity	87	87																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 1	Elimusertib + Irinotecan		Not yet recruiting	NCT04514497		ECD	01-AUG-24	Expression level	No		4	NCT04514497			Maximum tolerated dose/toxicity	87	87																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 1	Cisplatin + Elimusertib + Gemcitabine		Not yet recruiting	NCT04491942		ECD	01-JUN-21	Expression level	No		4	NCT04491942			Maximum tolerated dose/toxicity	68	68																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 1	M4344		Recruiting	NCT02278250		ECD	01-JUN-21	Yes	No		4	NCT02278250			Maximum tolerated dose/toxicity	300	300																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 1	SC10914		Unknown	NCT02940132		ECD	01-MAR-18	Expression level	No		4	NCT02940132			Maximum tolerated dose/toxicity	72	72																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Avelumab + Talazoparib		Active, not recruiting	NCT03565991		ECD	01-MAR-21	Yes	No		4	NCT03565991			Overall Response Rate	202	202																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Avelumab + Talazoparib		Active, not recruiting	NCT03330405		ECD	01-AUG-21	Yes	No		4	NCT03330405			Overall Response Rate	216	216																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	BAY1895344		Recruiting	NCT03188965		ECD	01-JAN-23	Expression level	No		4	NCT03188965			Maximum tolerated dose/toxicity	241	241																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Ceralasertib		Recruiting	NCT04564027	PLANETTE	ECD	01-JUN-23	Expression level	No		4	NCT04564027			Overall Response Rate	52	52																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Ceralasertib		Recruiting	NCT03682289		ECD	01-MAR-21	Yes	No		4	NCT03682289			Overall Response Rate	68	68																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	ART0380		Recruiting	NCT04657068		ECD	01-DEC-23	Expression level	No		4	NCT04657068			Maximum tolerated dose/toxicity	180	180																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	APG115 + Pembrolizumab		Recruiting	NCT03611868		ECD	01-DEC-21	Yes	No		4	NCT03611868			Overall Response Rate	143	143																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 2	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Ceralasertib + Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	No	No		4	NCT02576444			Overall Response Rate	64	64																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Talazoparib		Recruiting	NCT02286687		ECD	01-DEC-20	Yes	No		4	NCT02286687			Disease control rate, Clinical benefit rate	150	150																																								
ATM	ATM_unspecified				NS / other / neoplasm	3	Phase 2	Olaparib		Recruiting	NCT02693535	TAPUR group 14	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
ATM	ATM_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
ATM	ATM_unspecified				breast / carcinoma / NS	3	Phase 1	BAY1895344 + Pembrolizumab		Recruiting	NCT04095273	cohort 1a	ECD	01-JAN-23	Yes	No		4	NCT04095273			Maximum tolerated dose/toxicity	110	110																																								
ATM	ATM_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
ATM	ATM_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
ATM	ATM_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
ATM	ATM_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	01-JUN-23	Yes	No		4	NCT04335669			Complete response, Pathological complete response	820	820																																								
ATM	ATM_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / B cell neoplasm unspecified	3	Phase 2	PARP/Tankyrase inhibitor 2X-121		Completed	NCT01618136		PCD	01-JUL-15	Expression level	No		1	32523090			Maximum tolerated dose/toxicity	41	41																																								
ATM	ATM_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	3	Phase 1	Alvocidib		Terminated	NCT00377104		PCD	01-NOV-12	No	Yes		1	27118540			Maximum tolerated dose/toxicity	9	9											10.55																													
ATM	ATM_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	3	Phase 1	Ceralasertib		Completed	NCT01955668		PCD	01-DEC-13	Yes	No		4	NCT01955668			Maximum tolerated dose/toxicity	2	2																																								
ATM	ATM_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / mantle cell lymphoma	3	Phase 2	Radiotherapy		Recruiting	NCT04054167		ECD	01-MAY-21	Comparison with wt	No		4	NCT04054167			Overall Response Rate	80	80																																								
ATM	ATM_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / mantle cell lymphoma	3	Phase 2	Niraparib		Withdrawn	NCT01244009		ECD	01-AUG-13	No	No		4	NCT01244009			Overall Response Rate	0	0																																								
ATM	ATM_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
ATM	ATM_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	BAY1895344 + Pembrolizumab		Recruiting	NCT04095273	cohort 2a	ECD	01-JAN-23	Yes	No		4	NCT04095273			Maximum tolerated dose/toxicity	110	110																																								
ATM	ATM_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Elimusertib + FOLFIRI		Not yet recruiting	NCT04535401		ECD	01-DEC-22	Expression level	No		4	NCT04535401			Maximum tolerated dose/toxicity	90	90																																								
ATM	ATM_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Trifluridine and tipiracil hydrochloride		Recruiting	NCT04166604	LONGBOARD	ECD	01-NOV-21	No	No		4	NCT04166604			Maximum tolerated dose/toxicity	250	250																																								
ATM	ATM_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Ceralasertib + Olaparib		Recruiting	NCT02264678		ECD	01-JAN-24	Expression level	No		4	NCT02264678			Maximum tolerated dose/toxicity	117	117																																								
ATM	ATM_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	BAY1895344 + Pembrolizumab		Recruiting	NCT04095273	cohort 4	ECD	01-JAN-23	Yes	No		4	NCT04095273			Maximum tolerated dose/toxicity	110	110																																								
ATM	ATM_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
ATM	ATM_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03009682	SUKSES-B	ECD	01-SEP-21	Expression level	No		4	NCT03009682			Overall Response Rate	28	28																																								
ATM	ATM_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Talazoparib		Active, not recruiting	NCT03377556		ECD	01-MAY-22	Yes	No		4	NCT03377556			Overall Response Rate	64	64																																								
ATM	ATM_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Avelumab + Berzosertib + Carboplatin + Gemcitabine		Suspended	NCT04216316		ECD	01-AUG-21	Expression level	No		4	NCT04216316			Progression free survival	106			Avelumab + Carboplatin + Gemcitabine																																						
ATM	ATM_unspecified				pancreas / carcinoma / NS	3	Phase 2	Olaparib + Selumetinib		Unknown	NCT02511223		ECD	01-SEP-17	Expression level	No		4	NCT02511223			Overall Response Rate	24	24																																								
ATM	ATM_unspecified				pancreas / carcinoma / NS	3	Phase 2	Epacadostat + Pembrolizumab		Withdrawn	NCT03432676		ECD	01-APR-20	Yes	No		4	NCT03432676			Overall Response Rate	0	0																																								
ATM	ATM_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf	Previously-treated		Progression free survival	245	162	83	Enzalutamide	28	1		<0.0001					7.4	3.6	.34	0.25-0.47	<0.0001									19.1	14.7	.69	0.5-0.97	0.0175												
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Phase 2	Abiraterone acetate + Prednisone		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Phase 2	Abiraterone acetate + Olaparib + Prednisone		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Phase 2	Ceralasertib		Recruiting	NCT04564027	PLANETTE	ECD	01-JUN-23	Expression level	No		4	NCT04564027			Response rate	52	52																																								
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Phase 2	Carboplatin + Docetaxel + Rucaparib 		Recruiting	NCT03442556	PLATI-PARP	ECD	01-MAY-25	No	No		4	NCT03442556	Previously-treated		Progression free survival	20	20																																								
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Phase 2	Rucaparib 		Recruiting	NCT02952534	TRITON2	ECD	01-SEP-20	No	No		4	NCT02952534	Previously-treated		Overall Response Rate	360	360																																								
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Phase 3	Rucaparib 		Active, not recruiting	NCT02975934	TRITON3	ECD	01-FEB-22	No	No		4	NCT02975934	Previously-treated		Progression free survival	400			Best supportive care																																						
ATM	ATM_unspecified				prostate / carcinoma / NS	1	Phase 3	Abiraterone acetate + Olaparib		Recruiting	NCT03732820	PROpel	ECD	01-APR-21	No	No		4	NCT03732820			Progression free survival	904			Abiraterone acetate + Placebo																																						
ATM	ATM_unspecified				stomach / carcinoma / NS	3	Phase 1	BAY1895344 + Pembrolizumab		Recruiting	NCT04095273	cohort 3	ECD	01-JAN-23	Yes	No		4	NCT04095273			Maximum tolerated dose/toxicity	110	110																																								
ATM	ATM_unspecified				stomach / carcinoma / NS	3	Phase 1	Elimusertib + FOLFIRI		Not yet recruiting	NCT04535401		ECD	01-DEC-22	Expression level	No		4	NCT04535401			Maximum tolerated dose/toxicity	90	90																																								
ATM	ATM_unspecified				stomach / carcinoma / NS	3	Phase 2	Olaparib + Paclitaxel		Active, not recruiting	NCT01063517		PCD	01-MAY-12	Expression level	Yes		1	26282658	Previously-treated		Progression free survival	100	53	47	Paclitaxel + Placebo									3.91	3.55	.8	0.62-1.03	0.131									13.1	8.3	.56	0.41-0.75	0.005												
ATM	ATM_unspecified				stomach / carcinoma / NS	3	Phase 2	Carboplatin + Ceralasertib		Recruiting	NCT02264678		ECD	01-JAN-24	Expression level	No		4	NCT02264678			Maximum tolerated dose/toxicity	117	117																																								
ATM	ATM_unspecified				urinary tract / carcinoma / NS	3	Phase 1	Durvalumab + Olaparib		Active, not recruiting	NCT02546661	BISCAY module B	PCD	01-MAR-20	Yes	Yes		3	https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-bladder-cancer/115221-esmo-2019-biscay-an-adaptive-biomarker-directed-platform-study-in-metastatic-urothelial-cancer-with-durvalumab-in-combination-with-targeted-therapies.html	Previously-treated		Maximum tolerated dose/toxicity	14	14			35.7																																					
ATRX	ATRX_unspecified				NS / other / neoplasm	3	Phase 1	M4344		Recruiting	NCT02278250		ECD	01-JUN-21	Yes	No		4	NCT02278250			Maximum tolerated dose/toxicity	300	300																																								
ATR	ATR_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
ATR	ATR_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
ATR	ATR_unspecified				NS / neoplasm / NS	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
ATR	ATR_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
ATR	ATR_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
ATR	ATR_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
ATR	ATR_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
ATR	ATR_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Talazoparib		Active, not recruiting	NCT03377556		ECD	01-MAY-22	Yes	No		4	NCT03377556			Overall Response Rate	64	64																																								
ATR	ATR_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
ATR	ATR_unspecified				prostate / carcinoma / NS	3	Phase 2	Talazoparib		Active, not recruiting	NCT03148795	TALAPRO-1	PCD	01-APR-20	Yes	Yes		2	10.1200/JCO.2020.38.6_suppl.119	Previously-treated		Overall Response Rate	14	14			7.1								3.5																													
AXL	AXL_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
AXL	AXL_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	No		4	NCT02219711			Maximum tolerated dose/toxicity	260	260																																								
BAP1	BAP1_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
BAP1	BAP1_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
BAP1	BAP1_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
BAP1	BAP1_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
BARD1	BARD1_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
BARD1	BARD1_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
BARD1	BARD1_unspecified				NS / neoplasm / NS	3	Phase 2	Berzosertib		Recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
BARD1	BARD1_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
BARD1	BARD1_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
BARD1	BARD1_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
BARD1	BARD1_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
BARD1	BARD1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
BARD1	BARD1_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
BARD1	BARD1_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
BARD1	BARD1_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
BARD1	BARD1_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
PTEN	BCL2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Bortezomib + Dexamethasone + doxorubicin hydrochloride		Completed	NCT00872521		PCD	01-MAY-11	Comparison with wt	Yes		4	NCT00872521	Untreated		Overall Response Rate	89	77	12		80.5	83.3																																				
BCORL1	BCORL1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Gilteritinib		Recruiting	NCT03013998	BAML-16-001-S8 	ECD	01-DEC-21	No	No		4	NCT03013998			Complete remission	2000	2000																																								
BCOR	BCOR_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
BCR	BCR-ABL ?:? COSF1783		1783		NS / other / neoplasm	3	Phase 1	Dasatinib		Completed	NCT00316953		PCD	01-SEP-09	No	No		4	NCT00316953	Previously-treated		Time to treatment failure, Time to progression	48	48																																								
BCR	BCR-ABL ?:? COSF1783		1783		NS / other / neoplasm	3	Phase 2	Bosutinib		Recruiting	NCT03297606	CAPTUR group 3	ECD	01-SEP-21	Yes	No		4	NCT03297606			Overall Response Rate	720	720		Dabrafenib + Spartalizumab + Trametinib																																						
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Imatinib		Completed	NCT00004932		PCD	01-SEP-05	Yes	No		4	NCT00004932			Maximum tolerated dose/toxicity	31	31																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Hematopoietic Stem Cell Transplant + Nivolumab		Active, not recruiting	NCT01822509		PCD	01-DEC-18	No	No		4	NCT01822509	Previously-treated		Maximum tolerated dose/toxicity	71	71																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	CD45RA+ T cell depleted peripheral blood stem cells + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Radiotherapy + Rituximab + Tacrolimus		Recruiting	NCT02960646		ECD	01-NOV-20	No	No		4	NCT02960646			Donor engraftment, GVHD rate	12	12																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Anti-PR1/HLA-A2 monoclonal antibody Hu8F4		Recruiting	NCT02530034		ECD	01-JAN-22	No	No		4	NCT02530034			Maximum tolerated dose/toxicity	72	72																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Allogenic stem cell transplantation + Ipilimumab		Active, not recruiting	NCT01822509		PCD	01-DEC-18	No	Yes		1	27410923			Maximum tolerated dose/toxicity	22	22																														5	2									
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Allogenic stem cell transplantation + Ipilimumab		Completed	NCT00060372		PCD	01-APR-08	No	Yes		1	18974373			Donor engraftment, GVHD rate	21	21																														2	1									
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Lenalidomide + Melphalan + Mycophenolate mofetil + Natural killer cell immunotherapy + Radiotherapy + Rituximab + Tacrolimus + Umbilical cord blood transplant		Active, not recruiting	NCT01619761		ECD	01-NOV-21	No	No		4	NCT01619761			Maximum tolerated dose/toxicity	13	13																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	CD8+ and CD4+ donor memory T cells-expressing HA1-specific TCR + Fludarabine		Recruiting	NCT03326921		ECD	01-OCT-24	No	No		4	NCT03326921			Maximum tolerated dose/toxicity	24	24																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	EphB4-HSA Fusion Protein + Vincristine sulfate liposome		Recruiting	NCT03519984		ECD	01-MAY-20	No	No		4	NCT03519984	Previously-treated		Clinical activity	44	44																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Cytarabine + EphB4-HSA Fusion Protein		Recruiting	NCT03519984		ECD	01-MAY-20	No	No		4	NCT03519984	Previously-treated		Clinical activity	44	44																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Azacitidine + Belinostat		Not yet recruiting	NCT00351975		PCD	01-MAR-13	No	No		4	NCT04088188			Maximum tolerated dose/toxicity	56	56																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Adavosertib + Belinostat		Terminated	NCT02381548		PCD	01-MAY-18	No	No		4	NCT02381548	Previously-treated		Maximum tolerated dose/toxicity	20	20																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Sorafenib		Completed	NCT01445080		PCD	01-MAR-12	No	No		4	NCT01445080	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	70	70																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Alemtuzumab + Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy		Completed	NCT00118352		PCD	01-JUL-10	No	Yes	Primary outcome not met	4	NCT00118352			Donor engraftment, GVHD rate	12	12																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Bone marrow transplantation + Cyclophosphamide + Fludarabine + Mycophenolate mofetil + Natural killer cell immunotherapy + Radiotherapy + Tacrolimus		Completed	NCT00789776		PCD	01-MAY-17	No	Yes	1 yr RFS 71.4%	4	NCT00789776			Disease free survival, relapse free survival, regression free survival, recurrence free survival	35	35																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Sirolimus		Completed	NCT01251575		PCD	01-NOV-18	No	Yes	GVHD 29.4%	4	NCT01251575			Donor engraftment, GVHD rate	51	51																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Allogenic lymphocytes + Cyclosporine + Mycophenolate mofetil + Pentostatin		Completed	NCT00096161		PCD	01-FEB-15	No	Yes	Transplant ready=33%	4	NCT00096161			Transplant-ready patient rate	36	36																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Tacrolimus		Recruiting	NCT02861417		ECD	01-AUG-21	No	No		4	NCT02861417			Non-relapse mortality	204	204																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Tacrolimus + Thiotepa		Recruiting	NCT02861417		ECD	01-AUG-21	No	No		4	NCT02861417			Non-relapse mortality	204	204																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Hematopoietic Stem Cell Transplant + Methotrexate + Tacrolimus + Vorinostat		Completed	NCT01789255		PCD	01-MAR-14	No	No	GVHD rate 16.7%	4	NCT01789255			Donor engraftment, GVHD rate	12	12																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Cyclosporine + Hematopoietic Stem Cell Transplant + Sirolimus		Recruiting	NCT03246906		ECD	01-AUG-22	No	No		4	NCT03246906			Disease free survival, relapse free survival, regression free survival, recurrence free survival	160	160																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclosporine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Sirolimus		Recruiting	NCT03246906		ECD	01-AUG-22	No	No		4	NCT03246906			Disease free survival, relapse free survival, regression free survival, recurrence free survival	160	160																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Busulfan + Cyclophosphamide + Methotrexate + Peripheral blood stem cell transplantation  + Tacrolimus		Not yet recruiting	NCT03602898		ECD	01-SEP-23	No	No		4	NCT03602898			Donor engraftment, GVHD rate	240	240																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Busulfan + Cyclophosphamide + Cyclosporine + Methotrexate + Peripheral blood stem cell transplantation 		Not yet recruiting	NCT03602898		ECD	01-SEP-23	No	No		4	NCT03602898			Donor engraftment, GVHD rate	240	240																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Busulfan + Cyclophosphamide + Cyclosporine + Fludarabine + Peripheral blood stem cell transplantation 		Not yet recruiting	NCT03602898		ECD	01-SEP-23	No	No		4	NCT03602898			Donor engraftment, GVHD rate	240	240																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Busulfan + Cyclophosphamide + Fludarabine + Peripheral blood stem cell transplantation  + Tacrolimus		Not yet recruiting	NCT03602898		ECD	01-SEP-23	No	No		4	NCT03602898			Donor engraftment, GVHD rate	240	240																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Anti-thymocyte globulin + Cyclophosphamide + Cyclosporine + Methotrexate + Peripheral blood stem cell transplantation  + Radiotherapy + Tacrolimus		Not yet recruiting	NCT03602898		ECD	01-SEP-23	No	No		4	NCT03602898			Donor engraftment, GVHD rate	240	240																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Anti-thymocyte globulin + Cyclophosphamide + Methotrexate + Peripheral blood stem cell transplantation  + Radiotherapy + Tacrolimus		Not yet recruiting	NCT03602898		ECD	01-SEP-23	No	No		4	NCT03602898			Donor engraftment, GVHD rate	240	240																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Fludarabine + Triapine		Completed	NCT00381550		PCD	01-MAR-11	No	Yes		1	24362550			Response rate	37	37			49																					6.9																
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Anti-thymocyte globulin + Cyclophosphamide + Cytokine-treated Veto Cells + Fludarabine + Peripheral blood stem cell transplantation  + Radiotherapy		Recruiting	NCT03622788		ECD	01-JUL-21	No	No		4	NCT03622788			Maximum tolerated dose/toxicity	24	24																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Fludarabine + Radiotherapy + Thiotepa + Umbilical cord blood transplant		Not yet recruiting	NCT04083170		ECD	01-DEC-22	No	No		4	NCT04083170			Donor engraftment, GVHD rate	10	10																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Cyclosporine + Filgrastim + Fludarabine + Hematopoietic Stem Cell Transplant + Melphalan + Mycophenolate mofetil + Radiotherapy + Sirolimus		Not yet recruiting	NCT04195633		ECD	01-DEC-23	No	No		4	NCT04195633			Donor engraftment, GVHD rate	60	60																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Melphalan + Mycophenolate mofetil + Radiotherapy + Sirolimus		Recruiting	NCT03192397		ECD	01-JUL-21	No	No		4	NCT03192397			Donor engraftment, GVHD rate	30	30																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Anti-thymocyte globulin + Bortezomib + Tacrolimus		Terminated	NCT02877082		PCD	01-JUL-17	No	Yes	Serious adverse events	4	NCT02877082			Disease free survival, relapse free survival, regression free survival, recurrence free survival	5	5																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Tacrolimus		Recruiting	NCT03128359		ECD	01-JAN-22	No	No		4	NCT03128359			Disease free survival, relapse free survival, regression free survival, recurrence free survival	38	38																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Busulfan + Cyclophosphamide + Hematopoietic Stem Cell Transplant + Melphalan + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Tacrolimus		Recruiting	NCT03128359		ECD	01-JAN-22	No	No		4	NCT03128359			Disease free survival, relapse free survival, regression free survival, recurrence free survival	38	38																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Melphalan + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Tacrolimus		Recruiting	NCT03128359		ECD	01-JAN-22	No	No		4	NCT03128359			Disease free survival, relapse free survival, regression free survival, recurrence free survival	38	38																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Cyclosporine + Double-unit umbilical cord blood transplantation + Fludarabine + Mycophenolate mofetil + Radiotherapy + Thiotepa + Umbilical cord blood transplant		Recruiting	NCT00719888		ECD	01-JUN-23	No	No		4	NCT00719888			Overall survival	135	135																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Fludarabine + Treosulfan + Umbilical cord blood transplant		Active, not recruiting	NCT00796068		ECD	01-DEC-21	No	No		4	NCT00796068			Donor engraftment, GVHD rate	130	130																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Flotetuzumab		Withdrawn	NCT03739606		PCD	01-OCT-20	No	Yes	RSS recommendation	4	NCT03739606			Response rate	0	0																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Anti-thymocyte globulin + Busulfan + Clofarabine + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mycophenolate mofetil + Radiotherapy + Rituximab + Tacrolimus + Umbilical cord blood transplant		Recruiting	NCT03096782		ECD	01-OCT-20	No	No		4	NCT03096782			Donor engraftment, GVHD rate	25	25																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cladribine + Cytarabine + Gilteritinib + Idarubicin + Midostaurin + Venetoclax		Recruiting	NCT02115295		ECD	01-MAY-21	No	No		4	NCT02115295			Complete response, Pathological complete response	408	408																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Sirolimus + Tacrolimus		Completed	NCT00105001		PCD	01-MAY-11	No	Yes	GVHD incidence 63.8 vs 47.1%	4	NCT00105001			Donor engraftment, GVHD rate	66	44	32	Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Tacrolimus																																						
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Aldesleukin + Allogeneic CD56-positive CD3-negative natural killer cells + Busulfan + Fludarabine + Hematopoietic Stem Cell Transplant		Active, not recruiting	NCT01823198		ECD	01-JUN-21	No	No		4	NCT01823198			Maximum tolerated dose/toxicity	63	63																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Fludarabine + Hematopoietic Stem Cell Transplant + Methotrexate + Peripheral blood stem cell transplantation  + Radiotherapy + T cell depleted hematopoietic stem cell transplantation + Tacrolimus + Thiotepa		Active, not recruiting	NCT01858740		ECD	01-JAN-23	No	No		4	NCT01858740		Pediatric	Donor engraftment, GVHD rate	20	20																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Methotrexate + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Tacrolimus + Thiotepa		Suspended	NCT02220985		ECD	01-APR-25	No	No		4	NCT02220985			Donor engraftment, GVHD rate	84	84																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Allogeneic natural killer cell line NK-92 + Anti-thymocyte globulin + Busulfan + Clofarabine + Cyclophosphamide + Fludarabine + Melphalan + Radiotherapy + Rituximab + Umbilical cord blood transplant		Recruiting	NCT02727803		ECD	01-MAY-21	No	No		4	NCT02727803			Progression free survival	100	100																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Vodobatinib		Recruiting	NCT02629692		ECD	01-AUG-22	Yes	No		4	NCT02629692			Clinical activity	303	303																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Dexamethasone + Ponatinib + Venetoclax		Recruiting	NCT03576547		ECD	01-JAN-22	Yes	No		4	NCT03576547	Previously-treated		Overall Response Rate	38	38																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Blinatumomab + Chemotherapy + Ponatinib		Recruiting	NCT03147612		ECD	01-FEB-24	Yes	No		4	NCT03147612	Previously-treated		Complete molecular response	60	60																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Allogenic stem cell transplantation + Bone marrow transplantation + Cyclophosphamide + Fludarabine + Melphalan + Mycophenolate mofetil + Natural killer cell immunotherapy + Peripheral blood stem cell transplantation  + Radiotherapy + Tacrolimus		Active, not recruiting	NCT01904136		ECD	01-APR-21	No	No		4	NCT01904136			Maximum tolerated dose/toxicity	90	90																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Cytarabine + Dexamethasone + Leucovorin calcium + Mesna + Methotrexate + Nilotinib + Prednisone + Rituximab + Vincristine + doxorubicin hydrochloride		Withdrawn	NCT01670084		ECD	01-SEP-15	Yes	Yes	Slow accrual	4	NCT01670084	Untreated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	0	0																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Arsenic trioxide		Terminated	NCT00006092		PCD	01-MAR-03	Yes	Yes	Slow accrual	4	NCT00006092	Previously-treated		Overall Response Rate	2	2																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Radiotherapy		Recruiting	NCT03333486		ECD	01-SEP-22	No	No		4	NCT03333486			Overall survival	58	58																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Filgrastim + Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Tacrolimus		Recruiting	NCT01028716		ECD	01-JAN-23	No	No		4	NCT01028716			Unknown	50	50																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy + Sirolimus		Completed	NCT01231412		PCD	01-OCT-16	No	Yes	GVHD 24.4 vs 50.6	4	NCT01231412			Donor engraftment, GVHD rate	167	90	77	Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy																																						
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy		Completed	NCT00075478		PCD	01-FEB-14	No	Yes	3 yr OS 65% vs 54%	4	NCT00075478			Overall survival	85	41	44	Cyclosporine + Fludarabine + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy																								.57	0.3-1.1	0.09												
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Troxacitabine		Completed	NCT00012259		PCD	01-FEB-02	Yes	Yes		1	11821445			Response rate	16	16																														2	1									
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Imatinib		Unknown					No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf	Previously-treated		Complete hematologic response	532	532																																						Complete hematologic	95	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Bosutinib		Active, not recruiting	NCT02130557		PCD	01-AUG-16	No	Yes	p=0.02	1	29091516	Untreated		Major molecular response	205	116	89	Imatinib																																				Major molecular	47.2	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Bosutinib		Unknown					No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf	Previously-treated		Complete hematologic response	60	60																																						Complete hematologic	16.7	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Bosutinib		Unknown					No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf	Previously-treated		Complete hematologic response	72	72																																							30.2	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Bosutinib		Unknown					Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf			Major cytogenetic response	159	159																																						Major cytogenetic	59.5	6
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Dasatinib		Completed	NCT00481247	DASISION	PCD	01-DEC-09	No	Yes	CCyR 76.8 vs 66.2 p=0.007	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf	Untreated		Complete cytogenetic response	519	259	260	Imatinib																																				Complete cytogenetic	76.8	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Dasatinib		Active, not recruiting	NCT00777036		PCD	01-SEP-16	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf	Previously-treated		Major cytogenetic response	46	46																																						Major cytogenetic	98	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Dasatinib		Active, not recruiting	NCT00306202		PCD	01-MAY-11	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf	Untreated		Maximum tolerated dose/toxicity	51	51																																						Major cytogenetic	98	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Dasatinib		Active, not recruiting	NCT00123487		PCD	01-NOV-06	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf			Major hematologic response	33	33																																						Major hematologic	42	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Dasatinib		Active, not recruiting	NCT00123487		PCD	01-NOV-06	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf			Major hematologic response	75	75																																						Major hematologic	28	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Dasatinib		Completed	NCT00123487		PCD	01-NOV-06	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf			Major hematologic response	158	158																																						Major hematologic	66	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Dasatinib		Completed	NCT00123474		PCD	01-SEP-06	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf	Previously-treated		Major cytogenetic response	167	167																																						Major cytogenetic	63	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Nilotinib		Completed	NCT00471497	ENESTnd	PCD	01-SEP-09	Yes	Yes	MMR 44 vs 22% p<0.0001	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022068s031lbl.pdf	Untreated		Major molecular response	565	282	283	Imatinib																																				Major molecular	44	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Nilotinib		Completed	NCT01844765		PCD	01-JUN-16	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022068s031lbl.pdf	Untreated		Major molecular response	25	25																																						Major molecular	60	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Nilotinib		Completed	NCT01844765		PCD	01-JAN-16	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022068s031lbl.pdf	Previously-treated		Major molecular response	33	33																																						Major molecular	40.9	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Nilotinib		Completed	NCT00109707	CAMN107A2101	PCD	01-SEP-12	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022068s031lbl.pdf			Major cytogenetic response	321	321																																						Major cytogenetic	51	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Imatinib		Unknown					Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf	Untreated		Major molecular response	565	283	282	Nilotinib																																				Major molecular	22	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Imatinib		Unknown					Yes	Yes	PFS at 84 months 81.2 % [95% CI: 78, 85] vs 60.6 % [56, 65] HR 0.38, p<0.0001	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf	Untreated		Progression free survival	1106	553	553	Cytarabine + Interferon alpha-2B																																						
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Imatinib		Unknown					Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf	Previously-treated		Complete cytogenetic response	3	3																																						Complete cytogenetic	66	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Imatinib		Unknown					Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf	Previously-treated		Complete cytogenetic response	14	14																																						Complete cytogenetic	50	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Imatinib		Unknown					No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf	Untreated		Complete hematologic response	51	51																																						Complete hematologic	78	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Imatinib		Unknown					No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf			Complete hematologic response	260	260																								6.9														Complete hematologic	31	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Approved FDA	Imatinib		Unknown					No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf			Complete hematologic response	235	235																																						Complete hematologic	71	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Case study	Imatinib		Unknown					Yes	Yes		1	17301812			Unknown	1	1																																						Complete cytogenetic	100	33
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Out of trials human study	Cytarabine + Omacetaxine mepesuccinate		Unknown					Yes	Yes		1	11032593	Previously-treated		Unknown	85	85																																						Complete hematologic	72	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Dasatinib		Completed	NCT00345826		PCD	01-JUL-10	No	Yes		1	16775234			Unknown	40	40																																						Complete hematologic	92	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Cytarabine + Fludarabine + mPEG-R-crisantaspase		Not yet recruiting	NCT04526795		ECD	01-DEC-22	Yes	No		4	NCT04526795	Previously-treated		Maximum tolerated dose/toxicity	62	62																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Edetate calcium disodium		Active, not recruiting	NCT03630991		ECD	01-DEC-21	No	No		4	NCT03630991			Maximum tolerated dose/toxicity	20	20																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Succimer 		Active, not recruiting	NCT03630991		ECD	01-DEC-21	No	No		4	NCT03630991			Maximum tolerated dose/toxicity	20	20																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Everolimus + Imatinib		Completed	NCT00093639		PCD	01-AUG-06	Yes	No		4	NCT00093639	Previously-treated		Maximum tolerated dose/toxicity																																										
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Cyclosporine + Dasatinib		Terminated	NCT01426334	ESCAPE1b	PCD	01-JUN-12	Yes	No		4	NCT01426334			Maximum tolerated dose/toxicity	4	4																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	HSP70		Completed	NCT00030303		PCD	01-JAN-04	No	No		4	NCT00030303			Maximum tolerated dose/toxicity	20	20																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Nilotinib + Sonidegib		Completed	NCT01456676		PCD	01-FEB-14	No	No		4	NCT01456676	Previously-treated		Maximum tolerated dose/toxicity	11	11																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Recombinant interleukin-7 + Umbilical cord blood transplant		Not yet recruiting	NCT03941769		ECD	01-DEC-21	Yes	No		4	NCT03941769			Maximum tolerated dose/toxicity	21	21																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Decitabine + Ponatinib + Venetoclax		Recruiting	NCT04188405		ECD	01-SEP-24	Yes	No		4	NCT04188405			Overall Response Rate	30	30																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Asciminib + Imatinib		Unknown					No	Yes		2	10.1016/j.clml.2019.07.231	Previously-treated		Unknown	19	19																																						Major molecular	42	11
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Tanespimycin		Completed	NCT00100997		PCD	01-OCT-06	No	Yes		4	NCT00100997	Previously-treated		Unknown																																										
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Carboplatin + Topotecan + Veliparib		Active, not recruiting	NCT00217646		PCD	01-DEC-10	Yes	No		4	NCT00217646			Maximum tolerated dose/toxicity	50	50																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Topotecan + Veliparib		Active, not recruiting	NCT00217646		PCD	01-DEC-10	Yes	No		4	NCT00217646			Maximum tolerated dose/toxicity	50	50																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 1	Tipifarnib		Completed	NCT00022451				No	Yes		1	20860038	Previously-treated		Maximum tolerated dose/toxicity	29	29																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib		Completed	NCT00030394		PCD	01-OCT-07	Yes	Yes		4	NCT00030394			Response rate	51	51																																						Complete molecular, Deep molecular, MR 4.5 log	27	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Hydroxychloroquine + Imatinib		Unknown	NCT01227135	CHOICES	ECD	01-MAR-12	Yes	Yes	12m MMR 71.9 vs 66.7% p=0.43	1	31925317	Previously-treated		Molecular response	62	32	30	Imatinib																																				Major molecular	71.9	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib + Omacetaxine mepesuccinate		Terminated	NCT00114959		PCD	01-JUN-08	No	Yes	Slow accrual	4	NCT00114959			Clinical activity	15	15																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Bosutinib + Inotuzumab Ozogamicin		Recruiting	NCT02311998		ECD	01-APR-21	Yes	No		4	NCT02311998			Clinical activity	80	80																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Nilotinib + Ruxolitinib		Suspended	NCT02973711		ECD	01-AUG-21	No	No		4	NCT02973711			Complete molecular response	50	50																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Allogenic lymphocytes + Cyclosporine + Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Peripheral blood stem cell transplantation  + Radiotherapy		Completed	NCT00003145		PCD	01-MAR-05	No	No		4	NCT00003145			Donor engraftment, GVHD rate	18	18																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Cytarabine + Imatinib		Completed	NCT00015834		PCD	01-APR-03	No	No		4	NCT00015834			Hematological response	46	46																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Cytarabine + Imatinib		Unknown	NCT00028847	HOVON-51			No	Yes		1	20015886			Complete cytogenetic response	162	162																																						Complete cytogenetic	83.3	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Sargramostim + bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine		Completed	NCT00466726		PCD	01-JUL-14	No	Yes	14/43 pts had molecular response	4	NCT00466726	Previously-treated		Molecular response	57	57																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Decitabine + Imatinib		Completed	NCT00054431		PCD	01-MAY-07	No	Yes		1	17236224	Previously-treated		Overall Response Rate	80	80																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Omacetaxine mepesuccinate		Completed	NCT00006364		PCD	01-SEP-05	No	Yes		1	17154172	Previously-treated		Complete hematologic response	5	5																																						Complete hematologic	100	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib + Interferon alpha-2B		Completed	NCT00045422		PCD	01-OCT-03	No	Yes		1	21175313			Event free survival	159	159																																						Major molecular	64	24
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Inecalcitol		Unknown	NCT02949570	ICT10	PCD	01-FEB-18	No	No		4	NCT02949570			Complete molecular response	54	54																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib + PEG-interferon alfa-2b		Completed	NCT01725204	NordCML007	PCD	01-MAY-16	No	Yes		1	27133821	Untreated		Major molecular response	40	40																																						Major molecular	84	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib + Oblimersen sodium		Completed	NCT00049192		PCD	01-NOV-05	No	Yes	No benefit of treatment	1	18452072			Cytogenetic response	43	43																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib + Nilotinib		Completed	NCT00769327	CML0408	PCD	01-OCT-14	Yes	No		4	NCT00769327			Complete cytogenetic response	129	129																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Asciminib + Nilotinib		Recruiting	NCT03906292	CMLXI	ECD	01-NOV-22	No	No		4	NCT03906292			Complete molecular response	120	120																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Asciminib + Dasatinib		Recruiting	NCT03906292	CMLXI	ECD	01-NOV-22	No	No		4	NCT03906292			Complete molecular response	120	120																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Asciminib + Imatinib		Recruiting	NCT03578367		ECD	01-NOV-21	No	No		4	NCT03578367	Previously-treated		Molecular response	80	80																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Asciminib + Imatinib		Recruiting	NCT03906292	CMLXI	ECD	01-NOV-22	No	No		4	NCT03906292			Complete molecular response	120	120																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Bosutinib		Active, not recruiting	NCT03128411		PCD	01-MAR-19	No	Yes	Primary outcome met	1	32279228	Untreated		Major molecular response	60	60																																						Major molecular	55	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Bosutinib		Terminated	NCT02906696		PCD	01-AUG-19	No	Yes	Changed business priorities	4	NCT02906696	Previously-treated		Response rate	8	8																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Bosutinib		Recruiting	NCT02810990	BEST	ECD	01-NOV-19	No	No		4	NCT02810990	Previously-treated		Major molecular response	65	65																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	PEG-interferon alfa-2a		Terminated	NCT01392170		PCR	01-MAR-14	No	Yes	Slow accrual	4	NCT01392170			Major molecular response	2	2																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Allogenic lymphocytes + Cyclosporine + Dasatinib + Fludarabine + Hematopoietic Stem Cell Transplant + Imatinib + Mycophenolate mofetil + Nilotinib + Peripheral blood stem cell transplantation  + Radiotherapy		Completed	NCT00036738		PCD	01-JUL-14	Yes	Yes		4	NCT00036738			Disease free survival, relapse free survival, regression free survival, recurrence free survival	28	28																																	89							
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Bevacizumab + Cytarabine + Idarubicin		Terminated	NCT00023920		PCD	01-SEP-04	No	No		4	NCT00023920			Response rate	60	60																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Avelumab + Pioglitazone		Recruiting	NCT02767063	ACTIW	ECD	01-NOV-22	Yes	No		4	NCT02767063			Major molecular response	100	100																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Cytarabine + Omacetaxine mepesuccinate		Completed	NCT00003694		PCD	01-AUG-03	Yes	No		4	NCT00003694	Untreated		Disease control rate, Clinical benefit rate	60	60																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Nilotinib + Pembrolizumab		Recruiting	NCT03516279		ECD	01-AUG-21	No	No		4	NCT03516279	Previously-treated		% undetectable minimal residual disease (UMRD) 	40	40																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib + Pembrolizumab		Recruiting	NCT03516279		ECD	01-AUG-21	No	No		4	NCT03516279	Previously-treated		% undetectable minimal residual disease (UMRD) 	40	40																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib + Pembrolizumab		Recruiting	NCT03516279		ECD	01-AUG-21	No	No		4	NCT03516279	Previously-treated		% undetectable minimal residual disease (UMRD) 	40	40																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Radotinib		Completed	NCT01602952		PCD	01-OCT-12	Yes	Yes		1	24705186	Previously-treated		Complete hematologic response	77	77																																						Major cytogenetic	65	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib + Nilotinib + Ruxolitinib		Recruiting	NCT03654768	Arm 2	ECD	01-JAN-22	No	No		4	NCT03654768			Molecular response	84	84																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib + Nilotinib		Recruiting	NCT03654768	Arm 1	ECD	01-JAN-22	No	No		4	NCT03654768			Molecular response	84	84																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Asciminib + Tyrosine Kinase Inhibitor		Not yet recruiting	NCT04216563		ECD	01-DEC-25	No	No		4	NCT04216563			Molecular response	40	40																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib + Venetoclax		Recruiting	NCT02689440		ECD	01-DEC-40	No	No		4	NCT02689440			Major molecular response	140	140																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Pioglitazone + Tyrosine Kinase Inhibitor		Terminated	NCT02730195		PCD	01-JUL-18	No	Yes	Changed business priorities	4	NCT02730195	Previously-treated		Major molecular response	9	9																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Panobinostat		Completed	NCT00449761		PCD	01-AUG-08	Yes	Yes	No benefit of treatment	2	10.1182/blood.V112.11.4263.4263	Previously-treated		Hematological response	27	27																																						Major cytogenetic	0	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Panobinostat		Completed	NCT00451035		PCD	01-SEP-08	No	Yes	Primary outcome not met	2	10.1182/blood.V112.11.4254.4254	Previously-treated		Major cytogenetic response	29	29																																						Major cytogenetic	0	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Sargramostim		Completed	NCT00072579 		PCD	01-APR-06	Yes	No		4	NCT00072579	Previously-treated		Cytogenetic response																																										
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Sargramostim		Completed	NCT00072579		PCD	01-APR-06	No	No		4	NCT00072579			Cytogenetic response																																										
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Arsenic trioxide		Withdrawn	NCT00006091		PCD	01-JAN-02	No	No		4	NCT00006091	Previously-treated		Unknown	0	0																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Ibrutinib		Active, not recruiting	NCT03267186		ECD	01-JAN-22	No	No		4	NCT03267186			Disease free survival, relapse free survival, regression free survival, recurrence free survival	8	8																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Bortezomib		Terminated	NCT00023881		PCD	01-MAY-05	No	Yes	No benefit of treatment	4	NCT00023881			Unknown	7	7																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Ponatinib		Unknown	NCT01746836		ECD	01-DEC-30	No	Yes		2	10.3324/haematol.2015.132845	Previously-treated		Major cytogenetic response	50	50																																						Complete molecular, Deep molecular, MR 4.5 log	75	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Ponatinib		Recruiting	NCT02398825	OPUS	ECD	01-DEC-18	No	No		4	NCT02398825	Previously-treated		Major cytogenetic response	78	78																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Ponatinib		Active, not recruiting	NCT02467270	OPTIC	PCD	01-APR-20	No	No		4	NCT02467270	Previously-treated		Participants with <=1% BCR-ABL1 at 12m	283	283																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Bosutinib + Ruxolitinib		Active, not recruiting	NCT03610971		ECD	01-JAN-22	No	No		4	NCT03610971	Previously-treated		12 Month Treatment Free Remission	14	14																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib + Ruxolitinib		Recruiting	NCT03654768		ECD	01-JAN-22	No	No		4	NCT03654768			Complete molecular response	84	84																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib + Ruxolitinib		Active, not recruiting	NCT03610971		ECD	01-JAN-22	No	No		4	NCT03610971	Previously-treated		12 Month Treatment Free Remission	14	14																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib + Ruxolitinib		Active, not recruiting	NCT03610971		ECD	01-JAN-22	No	No		4	NCT03610971	Previously-treated		12 Month Treatment Free Remission	14	14																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Nilotinib + Ruxolitinib		Recruiting	NCT03654768		ECD	01-JAN-22	No	No		4	NCT03654768			Complete molecular response	84	84																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Nilotinib + Ruxolitinib		Active, not recruiting	NCT03610971		ECD	01-JAN-22	No	No		4	NCT03610971	Previously-treated		12 Month Treatment Free Remission	14	14																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Ruxolitinib		Terminated	NCT01751425		PCD	01-SEP-19	No	Yes	Changed business priorities	4	NCT01751425	Previously-treated		Major molecular response	48	48																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Tipifarnib		Completed	NCT02210858		PCD	01-NOV-04	No	No		4	NCT02210858			Erythroid response	31	31																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	PEG-proline-interferon alpha-2b		Recruiting	NCT03117816	ENDURE-CML-IX	ECD	01-SEP-21	No	No		4	NCT03117816			Disease free survival, relapse free survival, regression free survival, recurrence free survival	214	214																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib		Active, not recruiting	NCT00070499		PCD	01-NOV-10	Yes	Yes	MMR 4-log 27 vs 19% p=0.32	1	22915637	Previously-treated		Molecular response	246	123	123	Imatinib																																				Major molecular	27	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib		Unknown	NCT00112775				No	No		4	NCT00112775	Previously-treated		Major cytogenetic response																																										
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib		Active, not recruiting	NCT03079505		PCD	01-SEP-18	Yes	Yes	Protocol deviation	4	NCT03079505	Untreated		Major molecular response	10	10																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib		Active, not recruiting	NCT00254423		ECD	01-NOV-20	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.e18542			Major molecular response	150	150																																						Major molecular	87	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib		Completed	NCT01916785	OPTIM-DASA	PCD	01-DEC-13	No	No		4	NCT01916785			Maximum tolerated dose/toxicity	289	289																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Dasatinib		Terminated	NCT00320190		PCD	01-JAN-10	No	Yes	Slow accrual	4	NCT00320190			Major molecular response	52																																									
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Nilotinib		Completed	NCT01274351		PCD	01-AUG-19	Yes	Yes	12m MMR 66.1%	4	NCT01274351	Untreated		Major molecular response	112	112																																						Major molecular	66.1	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Nilotinib		Active, not recruiting	NCT01774630	NiloPost-STIM	ECD	01-DEC-21	No	No		4	NCT01774630	Previously-treated		Complete molecular response	31	31																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Nilotinib		Recruiting	NCT02917720	NAUT	ECD	01-SEP-25	No	No		4	NCT02917720	Previously-treated		Major molecular response	200	200																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Nilotinib		Completed	NCT00702403		PCD	01-DEC-13	Yes	Yes	50% of patients had serious adverse events	4	NCT00702403			Maximum tolerated dose/toxicity	40	40																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Nilotinib		Completed	NCT00809211		PCD	01-MAY-11	Yes	Yes		2	10.1182/blood.V114.22.3294.3294			Complete cytogenetic response	5	5																																						Complete cytogenetic	80	3
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib		Completed	NCT00006475		PCD	01-DEC-02	No	No		4	NCT00006475			Unknown																																										
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib		Completed	NCT00006053		PCD	01-MAR-03	No	No		4	NCT00006053	Previously-treated		Unknown																																										
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib		Completed	NCT00006052		PCD	01-JUN-03	No	No		4	NCT00006052			Unknown																																										
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 2	Imatinib		Completed	NCT00093639		PCD	01-AUG-06	Yes	No		4	NCT00093639	Previously-treated		Maximum tolerated dose/toxicity																																										
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 3	Imatinib		Completed	NCT00006343		PCD	01-MAR-07	Yes	Yes	18m PFS 92.1 vs 73.5% p<0.001, 18m CHR 96.8 vs 69.0	1	12637609	Untreated			1106	553	553	Cytarabine + Interferon alpha																																				Complete hematologic	96.8	18
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 3	Asciminib		Active, not recruiting	NCT03106779		ECD	01-OCT-21	No	No		4	NCT03106779	Previously-treated		Major molecular response	222	222																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 3	PEG-interferon alfa-2a		Active, not recruiting	NCT02381379		PCD	01-OCT-18	Yes	Yes		2	10.21203/rs.3.rs-92583/v1	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	30	15	15	Observation																															13.1	4.4						
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 3	Radotinib		Recruiting	NCT03459534		ECD	01-MAR-22	Yes	No		4	NCT03459534	Previously-treated		Major cytogenetic response	173	173																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 3	Dasatinib		Terminated	NCT04155411		ECD	01-JAN-22	No	Yes		4	NCT04155411	Untreated		Major molecular response	65	65																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 3	Nilotinib		Completed	NCT01061177		PCD	01-JUL-14	Yes	Yes	MR 38.3%	4	NCT01061177			Molecular response	1056	1056																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 3	Imatinib		Completed	NCT00055874		PCD	01-MAR-12	No	Yes	No benefit of treatment	1	21422420	Untreated		Overall survival	659	323	336	Imatinib + Interferon alpha-2B																																						
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 4	Nilotinib		Completed	NCT03332511	ENESTKorea	PCD	01-OCT-16	Yes	Yes		4	NCT03332511			Complete molecular response	110	110																																						Complete molecular, Deep molecular, MR 4.5 log	56.2	24
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 4	Dasatinib		Recruiting	NCT03625388		ECD	01-JUL-21	No	No		4	NCT03625388	Untreated		Major molecular response	100	100																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Phase 4	Nilotinib		Terminated	NCT02086487		PCD	01-AUG-16	No	Yes	Slow accrual	4	NCT02086487	Previously-treated		Major molecular response	98	98																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Unknown	Imatinib		Unknown					Yes	Yes		1	21354517	Untreated		Cytogenetic response	30	30																																						Major cytogenetic	96.7	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Unknown	Chemotherapy + Imatinib		Unknown					Yes	Yes		1	21354517			Major cytogenetic response	9	9																																						Major cytogenetic	33.3	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	1	Unknown	Dasatinib + PEG-interferon alfa-2b		Unknown		EUDRACT 2012-003389-42			No	Yes		2	10.1182/blood.V126.23.134.134			Complete molecular response																																								Major molecular	70	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic B cell leukaemia	3	Phase 1	Veliparib		Active, not recruiting	NCT01139970		PCD	01-MAR-14	No	Yes		1	27503200			Maximum tolerated dose/toxicity	48	48																								5.3			3.3-8.3			8		8								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic B cell leukaemia	3	Phase 2	Ibrutinib		Terminated	NCT02129062		PCD	01-NOV-15	No	Yes	Slow accrual	4	NCT02129062	Previously-treated		ORR, OS	3	3																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic B cell leukaemia	3	Phase 3	Dexamethasone + Mercaptopurine + Methotrexate + Vincristine		Active, not recruiting	NCT01190930		PCD	01-MAR-19	No	No	5yr DFS 95%	4	NCT01190930			Disease free survival, relapse free survival, regression free survival, recurrence free survival	1186	1186																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic T cell leukaemia	3	Phase 1	Veliparib		Active, not recruiting	NCT01139970		PCD	01-MAR-14	No	Yes		1	27503200	Previously-treated		Maximum tolerated dose/toxicity	48	48																								5.3			3.3-8.3			8		8								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Approved FDA	Imatinib		Unknown					Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf			Unknown	43	43																																						Complete hematologic	19	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Approved FDA	Dasatinib		Active, not recruiting	NCT01460160		PCD	01-MAY-17	No	Yes	3yr EFS = 64% (52.4-74.4)	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf			Event free survival	78	78																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Approved FDA	Dasatinib		Completed	NCT00123487		PCD	01-NOV-06	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf			Major hematologic response	40	40							4.6																															Major hematologic	38	24
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Approved FDA	Dasatinib		Completed	NCT00123474		PCD	01-SEP-06	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf			Major cytogenetic response	167	167																																						Major cytogenetic	63	12
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Approved FDA	Imatinib		Unknown	NCT00022737		PCD	01-OCT-06	No	Yes	4yr EFS 70% (95% CI 54-81)	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf			Event free survival	50	50																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Approved FDA	Imatinib		Unknown					No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf			Maximum tolerated dose/toxicity	2	2																														2										
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 1	Dasatinib		Completed	NCT00345826		PCD	01-JUL-10	Yes	Yes		1	16775234			Maximum tolerated dose/toxicity	8	8																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 1	Dasatinib + Nivolumab		Terminated	NCT02819804		PCD	01-AUG-17	Yes	Yes	Slow accrual, lack of funding	4	NCT02819804	Previously-treated		Maximum tolerated dose/toxicity	1	1																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 1	Ponatinib		Not yet recruiting	NCT04475731		ECD	01-NOV-22	Yes	No		4	NCT04475731			Response rate	67	67																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 1	Dasatinib + Dexamethasone + Ruxolitinib		Active, not recruiting	NCT02494882		ECD	01-JUN-21	Yes	Yes		2	10.1182/blood-2018-99-110537	Untreated		Clinical activity	12	12																																						Complete morphologic	100	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	MLN2480		Active, not recruiting	NCT02484430		ECD	01-MAY-21	Yes	No		4	NCT02484430	Previously-treated		Complete hematologic response	35	35																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Chemotherapy + Ponatinib		Not yet recruiting	NCT04501614		ECD	01-MAR-25	Yes	No		4	NCT04501614	Previously-treated	Pediatric	Complete remission	68	68																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Chemotherapy + Ponatinib		Recruiting	NCT04554459	Pona-CELL	ECD	01-SEP-24	Yes	No		4	NCT04554459	Untreated		Complete molecular response	32	32																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Blinatumomab  + Dasatinib		Recruiting	NCT02744768	D-ALBA	ECD	01-JUN-21	Yes	No		4	NCT02744768			Complete molecular response	60	60																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Allogenic stem cell transplantation + Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Etoposide + Filgrastim + Leucovorin calcium + Methotrexate + Methylprednisolone acetate + Peripheral blood stem cell transplantation  + Prednisone + Radiotherapy + Sirolimus + Tacrolimus + Vincristine + doxorubicin hydrochloride		Active, not recruiting	NCT00792948		PCD	01-JUN-16	Yes	No	1yr RFS 83%	4	NCT00792948			Disease free survival, relapse free survival, regression free survival, recurrence free survival	40	40																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Cyclophosphamide + Dexamethasone + Ponatinib + Vincristine + doxorubicin hydrochloride		Recruiting	NCT01424982		ECD	01-OCT-21	Yes	No		4	NCT01424982			Event free survival	100	100																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Blinatumomab  + Cytarabine + Methotrexate + Ponatinib		Recruiting	NCT03263572		ECD	01-NOV-23	Yes	No		4	NCT03263572	Previously-treated		Complete molecular response	60	60																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Blinatumomab  + Cytarabine + Methotrexate + Ponatinib		Recruiting	NCT03263572		ECD	01-NOV-23	Yes	No		4	NCT03263572	Untreated		Complete molecular response	60	60																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Blinatumomab  + Dasatinib + Prednisone		Suspended	NCT02143414		ECD	01-JUN-22	Yes	No		4	NCT02143414	Untreated		Overall survival	58	58																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Methotrexate + Prednisone + Vincristine + doxorubicin hydrochloride		Active, not recruiting	NCT00390793		PCD	01-AUG-20	Yes	Yes	2yr EFS 57%	1	20466853			Event free survival	107	107																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Chemotherapy + Nilotinib		Completed	NCT01528085		PCD	01-MAR-20	Yes	No		4	NCT01528085			Clinical activity	79	79																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Chemotherapy + Dasatinib		Completed	NCT02888990	EWALLPH01	PCD	01-MAY-11	Yes	Yes		1	27121472			Progression free survival	71	71																								25.8						67			19.1							
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Bosutinib + Inotuzumab Ozogamicin		Recruiting	NCT02311998		ECD	01-APR-21	Yes	Yes		3	https://www.cancertherapyadvisor.com/home/news/conference-coverage/american-society-of-hematology-ash/ash-2017/inotuzumab-ozogamicin-plus-bosutinib-may-be-safe-effective-for-relapsed-refractory-all-and-cml/			Complete cytogenetic response	14	14																																						Complete cytogenetic	71.4	
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 2	Dasatinib		Active, not recruiting	NCT01256398		PCD	01-NOV-17	Yes	Yes		4	NCT01256398	Untreated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	38	38																																	52.6			36.8-68.5				
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 3	Carmustine + Cyclophosphamide + Cytarabine + Dactinomycin + Mercaptopurine + Methotrexate + Mitoxantrone hydrochloride + Pegaspargase + Prednisone + Sargramostim + Vincristine + doxorubicin hydrochloride		Completed	NCT00002766		PCD	01-SEP-11	No	Yes	Complete remission 64% vs 59%	4	NCT00002766			Complete remission	163	78	85	Carmustine + Cyclophosphamide + Cytarabine + Dactinomycin + Idoxorubicin + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Sargramostim + Vincristine + doxorubicin hydrochloride																																						
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 3	Blinatumomab + Dexamethasone + Methotrexate + Ponatinib		Recruiting	NCT04530565		ECD	01-JUL-28	Yes	No		4	NCT04530565	Untreated		Overall survival	330			Cyclophosphamide + Cytarabine + Dexamethasone + Mesna + Methotrexate + Ponatinib + Prednisone + Vincristine + doxorubicin hydrochloride																																						
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 3	Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Dexrazoxane + Filgrastim + Hydrocortisone + Ifosfamide + Imatinib + Leucovorin calcium + Mercaptopurine + Methotrexate + Pegaspargase + Prednisolone + Vincristine		Recruiting	NCT03007147		ECD	01-JUN-28	Yes	No		4	NCT03007147			Disease free survival, relapse free survival, regression free survival, recurrence free survival	700																																									
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 3	Cytarabine + Dexamethasone + Imatinib + Methotrexate + Prednisone + Vincristine		Recruiting	NCT03589326	PhALLCON	ECD	01-MAY-21	Yes	No		4	NCT03589326	Untreated		% undetectable minimal residual disease (UMRD) 	320			Imatinib																																						
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 3	Asparaginase + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Etoposide + Filgrastim + Hydrocortisone sodium succinate + Ifosfamide + Leucovorin calcium + Mercaptopurine + Methotrexate + Methylprednisolone acetate + Pegaspargase + Prednisone + Radiotherapy + Vincristine		Completed	NCT00720109		PCD	01-DEC-14	Yes	Yes	EFS 79.8	4	NCT00720109			Event free survival	60	60																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 3	Allogenic stem cell transplantation + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Dexrazoxane + Etoposide + Filgrastim + Hydrocortisone + Ifosfamide + Imatinib + Leucovorin calcium + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Vincristine		Recruiting	NCT03007147		ECD	01-JUN-28	Yes	No		4	NCT03007147			Disease free survival, relapse free survival, regression free survival, recurrence free survival	700																																									
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 3	Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Dexrazoxane + Imatinib + Leucovorin calcium + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Thioguanine + Vincristine + doxorubicin hydrochloride		Recruiting	NCT03007147		ECD	01-JUN-28	Yes	No		4	NCT03007147			Disease free survival, relapse free survival, regression free survival, recurrence free survival	700																																									
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 3	Chemotherapy + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Vincristine		Recruiting	NCT03117751	TOT17	ECD	01-SEP-26	No	No		4	NCT03117751			Event free survival	1000																																									
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 3	Cyclophosphamide + Cytarabine + Dexamethasone + Dexrazoxane + Leucovorin calcium + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine + doxorubicin hydrochloride		Recruiting	NCT03020030		ECD	01-DEC-22	No	No		4	NCT03020030	Untreated		Complete remission	480	480																																								
BCR	BCR-ABL ?:? COSF1783		1783		haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	1	Phase 4	Chemotherapy + Flumatinib		Recruiting	NCT04375683		ECD	01-MAR-22	Yes	Yes		3	https://meetinglibrary.asco.org/record/178533/abstract			Complete remission	28	28																																								
BCR	BCR-ABL e13a2 (b2a2) COSF1757		1757		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Out of trials human study	Imatinib		Unknown					Yes	Yes		1	19714331			Unknown	34	34																																						Complete cytogenetic	58.8	
BCR	BCR-ABL e14a2 (b3a2) COSF1755		1755		haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Out of trials human study	Imatinib		Unknown					Yes	Yes		1	19714331			Unknown	53	53																																						Complete cytogenetic	28.3	
BIRC3	BIRC3_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	3	Phase 2	Ibrutinib + Rituximab		Active, not recruiting	NCT02232386	LLC1114	ECD	01-MAY-21	No	No		4	NCT02232386			Progression free survival	156	156																																								
BLM	BLM_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
BLM	BLM_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
BLM	BLM_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
BRAF	BRAF_Exon11,15				NS / mesothelioma / NS	3	Phase 2	Sorafenib		Completed	NCT00107432		PCD	01-JUN-07	Yes	No		4	NCT00107432			Overall Response Rate	44	44																																								
BRAF	BRAF_G466			p.G466?	lung / carcinoma / non small cell carcinoma	7	Phase 2	Vemurafenib		Recruiting	NCT02304809	AcSe	PCD	01-MAY-19	Yes	Yes	No benefit of treatment	2	10.1016/j.jtho.2018.08.302			Maximum tolerated dose/toxicity	4	4																																								
BRAF	BRAF_G469			p.G469X	lung / carcinoma / non small cell carcinoma	7	Phase 2	Vemurafenib		Recruiting	NCT02304809	AcSe	PCD	01-MAY-19	Yes	Yes	No benefit of treatment	2	10.1016/j.jtho.2018.08.302			Maximum tolerated dose/toxicity	4	4																																								
BRAF	BRAF_G596V	99951808		p.G596V	lung / carcinoma / non small cell carcinoma	3	Phase 2	Vemurafenib		Unknown		EURAF			Yes	Yes		1	26200454			Unknown	1	2																															1									
BRAF	BRAF_G596V	99951808		p.G596V	lung / carcinoma / non small cell carcinoma	3	Phase 2	Vemurafenib		Recruiting	NCT02304809	AcSe	ECD	01-FEB-16	Yes	Yes	No benefit of treatment	2	10.1016/j.jtho.2018.08.302			Maximum tolerated dose/toxicity	1	1																																								
BRAF	BRAF_K601				lung / carcinoma / non small cell carcinoma	7	Phase 2	Vemurafenib		Recruiting	NCT02304809	AcSe	PCD	01-MAY-19	Yes	Yes	No benefit of treatment	2	10.1016/j.jtho.2018.08.302			Maximum tolerated dose/toxicity	5	5																																								
BRAF	BRAF_K601E	56058494		p.K601E	NS / malignant melanoma / NS	4	Case study	Trametinib		Unknown					Yes	Yes		1	24933606			Unknown	4	4																															2									
BRAF	BRAF_L597R/S/Q	56070905 + 56072463 + 56121113		p.L597Q + p.L597R + p.L597S	NS / malignant melanoma / NS	3	Case study	Vemurafenib		Unknown					Yes	Yes		1	23715574			Unknown	1	1							4																								1									
BRAF	BRAF_L597R/S/Q	56070905 + 56072463 + 56121113		p.L597Q + p.L597R + p.L597S	NS / malignant melanoma / NS	3	Case study	TAK733		Unknown					Yes	Yes		1	22798288			Unknown	1	1																															1									
BRAF	BRAF_L597R/S/Q	56070905 + 56072463 + 56121113		p.L597Q + p.L597R + p.L597S	NS / malignant melanoma / NS	3	Case study	Trametinib		Unknown					Yes	Yes		1	27146499			Unknown	1	1																								17.0																
BRAF	BRAF_L597R/S/Q	56070905 + 56072463 + 56121113		p.L597Q + p.L597R + p.L597S	NS / malignant melanoma / NS	3	Case study	Trametinib		Unknown					Yes	Yes		1	24933606			Unknown	1	1																															1									
BRAF	BRAF_L597R/S/Q	56070905 + 56072463 + 56121113		p.L597Q + p.L597R + p.L597S	NS / malignant melanoma / NS	3	Phase 1	TAK733		Completed	NCT00948467		PCD	01-APR-13	Yes	Yes	Primary outcome not met	1	27650277			Maximum tolerated dose/toxicity	41																																1									
BRAF	BRAF_N581.				lung / carcinoma / non small cell carcinoma	7	Phase 2	Vemurafenib		Recruiting	NCT02304809	AcSe	PCD	01-MAY-19	Yes	Yes	No benefit of treatment	2	10.1016/j.jtho.2018.08.302			Maximum tolerated dose/toxicity	3	3																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 1	Cobimetinib + Vemurafenib		Active, not recruiting	NCT02721459		PCD	01-FEB-19	Yes	Yes		4	NCT02721459			Maximum tolerated dose/toxicity	25	25			72		51-88						8.1			4.7-NA																										
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 1	ASN003		Terminated	NCT02961283		PCD	01-FEB-19	Yes	No		4	NCT02961283			Disease control rate, Clinical benefit rate	24	24																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 1	E6201		Recruiting	NCT03332589		ECD	01-JAN-21	Yes	No		4	NCT03332589			Overall Response Rate	24	24																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 1	Cabozantinib + Vemurafenib		Terminated	NCT01835184		PCD	01-SEP-14	Yes	No		4	NCT01835184			Maximum tolerated dose/toxicity	5	5																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 1	Trientine hydrochloride + Vemurafenib		Withdrawn	NCT02068079		PCD	01-NOV-15	Yes	No		4	NCT02068079			Maximum tolerated dose/toxicity	0	0																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 1	Leflunomide + Vemurafenib		Terminated	NCT01611675		PCD	01-JAN-14	Yes	Yes	Serious adverse events	4	NCT01611675			Maximum tolerated dose/toxicity	3	3																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 1	Vemurafenib		Terminated	NCT01519323	BRIM-P			Yes	Yes	Slow accrual	4	NCT01519323		Pediatric	Maximum tolerated dose/toxicity	6	6																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 1	Ipilimumab + Vemurafenib		Terminated	NCT01400451		PCD	01-APR-13	Yes	Yes	Serious adverse events	4	NCT01400451			Maximum tolerated dose/toxicity	18	18																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Binimetinib + Encorafenib		Active, not recruiting	NCT02159066	LOGIC-2	ECD	01-JAN-22	Yes	No		4	NCT02159066	Previously-treated		Overall Response Rate	160	160																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Cobimetinib + Stereotactic radiotherapy + Vemurafenib		Recruiting	NCT03430947	RadioCoBRIM	ECD	01-JUL-22	Yes	No		4	NCT03430947			Overall Response Rate	32	32																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Cobimetinib + Vemurafenib + peginterferon alfa-2b		Completed	NCT01959633	VEMUPLINT	PCD	01-MAR-18	Yes	Yes		1	33407577			Maximum tolerated dose/toxicity	8	8																														1	1									
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Encorafenib + Ribociclib		Terminated	NCT01777776		PCD	01-APR-15	Yes	Yes	Changed business priorities	4	NCT01777776			PFS, ORR	26	26																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Cobimetinib + Decitabine + Vemurafenib		Terminated	NCT01876641		PCD	01-JUN-18	Yes	Yes	Lack of funding	4	NCT01876641			Maximum tolerated dose/toxicity	18	18																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Binimetinib + Encorafenib + Pembrolizumab		Recruiting	NCT02902042	IMMU-TARGET	ECD	01-SEP-23	Yes	No		4	NCT02902042			Progression free survival	145	145																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Bevacizumab + Cobimetinib + Vemurafenib		Terminated	NCT01495988		PCD	01-JAN-16	Yes	Yes	Slow accrual, changed business priorities, serious adverse events	1	NCT01495988			Maximum tolerated dose/toxicity	10	10																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Encorafenib		Terminated	NCT01820364		PCD	01-MAR-15	Yes	Yes	Changed business priorities	4	NCT01820364			Overall Response Rate	15	15																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Encorafenib		Completed	NCT01894672		PCD	01-MAR-16	Yes	Yes		4	NCT01894672			Response rate	7	7																														2	2	2								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Nivolumab		Recruiting	NCT03514901		ECD	01-APR-21	Yes	No		4	NCT03514901			Overall survival	120			Cobimetinib + Vemurafenib																																						
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Pembrolizumab		Recruiting	NCT03514901		ECD	01-APR-21	Yes	No		4	NCT03514901			Overall survival	120			Cobimetinib + Vemurafenib																																						
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Vemurafenib		Completed	NCT01378975		PCD	01-JUL-15	Yes	Yes		4	NCT01378975	Previously-treated		Overall Response Rate	56	56			17.9																												10	23								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Vemurafenib		Completed	NCT01378975		PCD	01-JUL-15	Yes	Yes		4	NCT01378975	Untreated		Overall Response Rate	90	90			18.8		10.5-27.3																									2	15	43								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Fotemustine + Vemurafenib		Completed	NCT01983124		PCD	01-APR-14	Yes	Yes		1	29552321	Previously-treated		Progression free survival	31	31											3.9										61.3			5.8						1	4	14								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Cobimetinib + Vemurafenib		Active, not recruiting	NCT02036086		ECD	01-OCT-22	Yes	No		4	NCT02036086			Clinical activity	24	24																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Cobimetinib + Vemurafenib		Withdrawn	NCT03005639		PCD	01-FEB-18	Yes	Yes	Changed business priorities	4	NCT03005639			CR, ORR	0	0																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Cobimetinib + Vemurafenib		Active, not recruiting	NCT02583516		PCD	01-SEP-19	Yes	No		4	NCT02583516	Untreated		Progression free survival	70	70																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Cobimetinib + Vemurafenib		Unknown	NCT02414750	REPOSIT	ECD	01-DEC-18	Yes	No		4	NCT02414750			Progression free survival	90	90																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Cobimetinib + Vemurafenib		Not yet recruiting	NCT03224208	VECODUE	ECD	01-MAR-21	Yes	No		4	NCT03224208	Previously-treated		Overall survival	62	62																																								
BRAF	BRAF_V600?			p.V600X	NS / malignant melanoma / NS	3	Phase 2	Cobimetinib + Vemurafenib		Active, not recruiting	NCT02537600	CONVERCE	PCD	01-NOV-19	Yes	No		4	NCT02537600			Overall Response Rate	43	43																																								
BRAF	BRAF_V600?			p.V600X	NS / other / neoplasm	2	Phase 1	Vemurafenib		Completed	NCT03155620	Subprotocol G	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
BRAF	BRAF_V600?			p.V600X	NS / other / neoplasm	2	Phase 1	JSI-1187-01		Recruiting	NCT04418167		ECD	01-MAY-23	Yes	No		4	NCT04418167			Maximum tolerated dose/toxicity	124	124																																								
BRAF	BRAF_V600?			p.V600X	NS / other / neoplasm	2	Phase 1	Binimetinib + Midazolam + PF07284890		Recruiting	NCT04543188		ECD	01-SEP-23	Yes	No		4	NCT04543188			Overall Response Rate	225	225																																								
BRAF	BRAF_V600?			p.V600X	NS / other / neoplasm	2	Phase 1	Binimetinib + PF07284890		Recruiting	NCT04543188		ECD	01-SEP-23	Yes	No		4	NCT04543188			Overall Response Rate	225	225																																								
BRAF	BRAF_V600?			p.V600X	NS / other / neoplasm	2	Phase 1	PF07284890		Recruiting	NCT04543188		ECD	01-SEP-23	Yes	No		4	NCT04543188			Overall Response Rate	225	225																																								
BRAF	BRAF_V600?			p.V600X	NS / other / neoplasm	2	Phase 1	BGB-3245		Recruiting	NCT04249843		ECD	01-MAY-23	No	No		4	NCT04249843			Overall Response Rate	69	69																																								
BRAF	BRAF_V600?			p.V600X	NS / other / neoplasm	2	Phase 2	Dabrafenib + Trametinib		Active, not recruiting	NCT04439292	MATCH-Subprotocol H	PCD	01-DEC-19	Yes	Yes	Primary outcome met	1	32758030			Overall Response Rate	29	29			38		22.9-54.9	<0.001					11.4			8.4-16.3																										
BRAF	BRAF_V600?			p.V600X	NS / other / neoplasm	2	Phase 2	Vemurafenib		Recruiting	NCT03220035		ECD	01-DEC-23	Yes	No		4	NCT03220035	Previously-treated	Pediatric	Overall Response Rate	49	49																																								
BRAF	BRAF_V600?			p.V600X	central nervous system / glioma / NS	3	Phase 2	Dabrafenib + Radiotherapy + Trametinib		Recruiting	NCT03919071		ECD	01-JUN-22	Yes	No		4	NCT03919071			Event free survival	58	58																																								
BRAF	BRAF_V600?			p.V600X	large intestine / carcinoma / adenocarcinoma	3	Phase 1	ASN003		Terminated	NCT02961283		PCD	01-FEB-19	Yes	No		4	NCT02961283			Disease control rate, Clinical benefit rate	24	24																																								
BRAF	BRAF_V600?			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 1	Pexidartinib + Vemurafenib		Terminated	NCT01826448		PCD	01-SEP-14	Yes	Yes	No benefit of treatment, protocol violation	4	NCT01826448			Maximum tolerated dose/toxicity	13	13																																								
BRAF	BRAF_V600?			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 1	ASN003		Terminated	NCT02961283		PCD	01-FEB-19	Yes	No		4	NCT02961283			Disease control rate, Clinical benefit rate	24	24																																								
BRAF	BRAF_V600?			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 1	Atezolizumab + Cobimetinib + Vemurafenib		Active, not recruiting	NCT01656642		PCD	01-MAR-20	Yes	Yes		1	31171876			Maximum tolerated dose/toxicity	39	39			71.8																											8	20	4								
BRAF	BRAF_V600?			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 1	Atezolizumab + Vemurafenib		Active, not recruiting	NCT01656642		PCD	01-MAR-20	Yes	Yes		1	31171876			Maximum tolerated dose/toxicity	17	17			76.5																											3	10	2								
BRAF	BRAF_V600?			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 1	Aldesleukin + Interferon alfa-2B + Vemurafenib		Completed	NCT01603212		PCD	01-JUL-17	Yes	No		4	NCT01603212			Maximum tolerated dose/toxicity	6	6																																								
BRAF	BRAF_V600?			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Vemurafenib		Recruiting	NCT02314481	DARWIN II	ECD	01-NOV-24	Yes	No		4	NCT02314481			Progression free survival	119	119																																								
BRAF	BRAF_V600?			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 2	Encorafenib		Withdrawn	NCT02109653		ECD	01-NOV-17	Yes	No		4	NCT02109653			Overall Response Rate	0	0																																								
BRAF	BRAF_V600?			p.V600X	lung / carcinoma / non small cell carcinoma	3	Phase 3	Atezolizumab + Cobimetinib + Vemurafenib		Recruiting	NCT03178552	B-FAST Cohort E	ECD	01-SEP-21	Yes	No		4	NCT03178552			Unknown	700	700																																								
BRAF	BRAF_V600?			p.V600X	thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Vemurafenib		Completed	NCT01286753		PCD	01-NOV-14	Yes	Yes		4	NCT01286753	Untreated		Best overall response	26	26			42.3																																					
BRAF	BRAF_V600?			p.V600X	thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Vemurafenib		Completed	NCT01286753		PCD	01-NOV-14	Yes	Yes		4	NCT01286753	Previously-treated		Best overall response	22	22			27.3																																					
BRAF	BRAF_V600D/K/R				NS / malignant melanoma / NS	3	Phase 2	Dabrafenib + Trametinib		Completed	NCT02039947	COMBI-MB Cohort C	PCD	01-MAY-17	Yes	Yes	IRR 44%	1	28592387			Intracranial Response Rate	16	16																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Approved FDA	Atezolizumab + Cobimetinib + Vemurafenib	Not required	Active, not recruiting	NCT02908672	IMspire150	PCD	01-OCT-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s028lbl.pdf	Untreated		Progression free survival	514	256	258	Trametinib	66	65			20.4	12.5			15.1	10.6	.78	0.63-0.97	0.025									28.8	25.1	.85	0.64-1.11	0.23												
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Approved FDA	Dabrafenib	Required	Completed	NCT01227889	BREAK-3	PCD	01-DEC-11	Yes	Yes		1	22735384	Untreated		Progression free survival	250	187	63	Dacarbazine	52.0	17							5.1	2.7	.33	0.2-0.54	<0.0001																									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Approved FDA	Vemurafenib	Required	Completed	NCT01006980	BRIM-3	PCD	01-DEC-10	Yes	Yes		1	21639808	Untreated		OS, PFS	675	337	338	Dacarbazine	48.4	5.5							5.3	1.6	.26	0.35-0.62	<0.0001									77	64	.47	0.20-0.33	<0.0001												
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Approved FDA	Vemurafenib	Required	Completed	NCT00949702	BRIM-2	PCD	01-SEP-10	Yes	Yes		4	NCT00949702	Previously-treated		Best overall response	132	132			53.0		44-62		6.7		5.6-8.6		6.8			5.6-8.1																8	62									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Case study	Dabrafenib + Trametinib		Unknown					Yes	Yes		1	23413975			Unknown	1	1																															1									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Case study	Tanespimycin		Unknown					Yes	Yes		1	18375819			Unknown	1	1																																1								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 1	Cobimetinib + Vemurafenib		Completed	NCT01271803		PCD	01-OCT-13	Yes	Yes		1	25037139	Previously-treated		Maximum tolerated dose/toxicity	66	66			15								2.8			2.6-3.4																	10									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 1	Hydroxychloroquine + Vemurafenib		Completed	NCT01897116		PCD	01-JUL-16	Yes	No		4	NCT01897116			Maximum tolerated dose/toxicity	8	8																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 1	Ipilimumab + XL281		Completed	NCT01245556		PCD	01-NOV-12	Yes	Yes		2	10.1200/jco.2012.30.15_suppl.2521			Maximum tolerated dose/toxicity	8	8																																1								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 1	Cobimetinib + Vemurafenib		Completed	NCT01271803		PCD	01-OCT-13	Yes	Yes		1	25037139	Untreated		Maximum tolerated dose/toxicity	63	63			88								13.7			10.1-17.5																6	49									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 2	Dabrafenib		Completed	NCT02039947	COMBI-MB Cohort A	PCD	01-MAY-17	Yes	Yes	IRR 58%	1	28592387	Previously-treated		Intracranial Response Rate	76	76																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 2	Cetuximab + FOLFIRI + Vemurafenib		Recruiting	NCT03727763	IMPROVEMENT	ECD	01-DEC-20	Yes	No		4	NCT03727763			Overall Response Rate	30	30																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 2	Aldesleukin + Vemurafenib		Terminated	NCT01754376	COMBAT 1	PCD	01-FEB-15	Yes	Yes	Changed business priorities	4	NCT01754376			Progression free survival	6	6																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 2	Cetuximab + Irinotecan + Vemurafenib		Active, not recruiting	NCT02164916		PCD	01-NOV-17	Yes	Yes		4	NCT02164916			Progression free survival	99	49	50	Cetuximab + Irinotecan									4.3	2	.48	0.31-0.75	0.001																									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 2	RAF265		Completed	NCT00304525	CHIR-265-MEL01	PCD	01-NOV-13	No	Yes in vitro		1	26396681			Maximum tolerated dose/toxicity	104	104																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 2	RAF265		Completed					Comparison with wt	Yes		1	28719152			Maximum tolerated dose/toxicity	72	39	33		10.3	9.1																																				
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 2	Dabrafenib		Completed	NCT02039947	COMBI-MB Cohort B	PCD	01-MAY-17	Yes	Yes	IRR 56%	1	28592387	Untreated		Intracranial Response Rate	16	16																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 3	Atezolizumab + Cobimetinib + Vemurafenib		Terminated	NCT02303951	NEO-VC	PCD	01-MAY-20	Yes	Yes	Slow accrual	4	NCT02303951			Percent of patients who become resectable	47																																									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / malignant melanoma / NS	1	Phase 3	Atezolizumab + Cobimetinib + Vemurafenib		Recruiting	NCT02902029	ImmunoCobiVem	ECD	01-MAR-22	Yes	No		4	NCT02902029			Time to Second Objective Disease Progression	176																																									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / neoplasm / NS	3	Phase 1	Binimetinib + RAF265		Completed	NCT01352273		PCD	01-SEP-13	Yes	Yes		4	NCT01352273			Maximum tolerated dose/toxicity	69	69																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / neoplasm / NS	3	Phase 1	ABM-1310		Recruiting	NCT04190628		ECD	01-DEC-21	Yes	No		4	NCT04190628			Maximum tolerated dose/toxicity	27	27																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / neoplasm / NS	3	Phase 1	RO5212054		Completed	NCT01143753		PCD	01-JUN-12	Yes	Yes		2	10.1016/S0959-8049(12)72377-8			Maximum tolerated dose/toxicity	44	44																															14	18								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / neoplasm / NS	3	Phase 2	PLX8394		Terminated	NCT02012231		PCD	01-SEP-14	Yes	No		4	NCT02012231			Maximum tolerated dose/toxicity	5	5																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / neoplasm / NS	3	Phase 2	MLN2480		Completed	NCT01425008		PCD	01-APR-17	No	Yes	No benefit of treatment	3	https://meetinglibrary.asco.org/record/82731/abstract			Maximum tolerated dose/toxicity	149	149																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / neoplasm / NS	3	Phase 2	MLN2480		Terminated	NCT01981187	SIGNATURE	PCD	01-SEP-15	Yes	No		4	NCT01981187			Disease control rate, Clinical benefit rate	12	12																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	NS / neoplasm / NS	3	Phase 2	PLX8394		Recruiting	NCT02428712		ECD	01-FEB-22	Yes	Yes	No benefit of treatment	3	http://mct.aacrjournals.org/content/17/1_Supplement/B176			Absorption rate	100	100																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	central nervous system / glioma / NS	3	Phase 1	Vemurafenib		Active, not recruiting	NCT01748149		ECD	01-DEC-21	Yes	No		4	NCT01748149	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	40	40																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	central nervous system / glioma / astrocytoma Grade I	4	Case study	Vemurafenib		Unknown					Yes	Yes		1	24821190		Pediatric	Unknown	1	1																															1									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	haematopoietic and lymphoid tissue / lymphoid neoplasm / Langerhans cell histiocytosis	3	Phase 2	Cladribine + Cytarabine + Vemurafenib		Recruiting	NCT03585686		ECD	01-MAR-21	Yes	No		4	NCT03585686				12	12																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Case study	Vemurafenib		Unknown					Yes	Yes		1	23733763			Unknown	1	1																															1									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Case study	Vemurafenib		Unknown					Yes	Yes		1	22621641			Unknown	1	1																														1										
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Case study	Vemurafenib		Unknown					Yes	Yes		1	24428489			Unknown	1	1																														1										
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Out of trials human study	Vemurafenib		Unknown					Yes	Yes		1	26941398			Unknown	15	15			95.0																											6										
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Phase 2	Dabrafenib + Trametinib		Active, not recruiting	NCT02034110	BRF117019	ECD	01-AUG-21	Yes	No		4	NCT02034110			Overall Response Rate	206	206																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Phase 2	Binimetinib + Encorafenib		Recruiting	NCT04324112		ECD	01-APR-24	Yes	No		4	NCT04324112			Complete response, Pathological complete response	45	45																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	haematopoietic and lymphoid tissue / lymphoid neoplasm / juvenile xanthogranuloma	1	Approved FDA	Vemurafenib	Required	Completed	NCT01524978	VE-BASKET	PCD	01-OCT-16	Yes	Yes		1	30120160			Overall Response Rate	26	22			54.5																											1	11									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	haematopoietic and lymphoid tissue / lymphoid neoplasm / juvenile xanthogranuloma	1	Phase 2	Dabrafenib + Trametinib		Not yet recruiting	NCT03794297		ECD	01-NOV-21	Yes	No		4	NCT03794297			Overall Response Rate	18	18																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	haematopoietic and lymphoid tissue / lymphoid neoplasm / malignant histiocytosis	3	Phase 3	Cobimetinib		Recruiting	NCT04007848	COBRAH	ECD	01-SEP-21	Comparison with wt	No		4	NCT04007848			Metabolic response	54			Placebo																																						
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Approved FDA	Cetuximab + Encorafenib		Active, not recruiting	NCT02928224	BEACON	PCD	01-FEB-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf			Overall survival	441	220	221	Cetuximab + Irinotecan	20.0	2.0		0.0001	6.1				4.2	1.5	.4		<0.0001									15.3						2	10									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 1	Panitumumab + Vemurafenib		Completed	NCT01791309		PCD	01-MAR-15	Yes	Yes		2	10.1200/jco.2015.33.3_suppl.611 			Overall Response Rate	16	16																															2	8								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 1	Cetuximab + Encorafenib		Unknown					Yes	Yes		1	28363909	Previously-treated		Unknown	26	26			19.2																											1	4	15								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 1	Alpelisib + Cetuximab + Encorafenib		Unknown					Yes	Yes		1	28363909	Previously-treated		Unknown	28	28			17.9																												5	21								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Dabrafenib + Spartalizumab + Trametinib		Unknown	NCT03668431		ECD	01-MAR-21	Yes	No		4	NCT03668431			Overall Response Rate	25																																									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Bevacizumab + FOLFOXIRI 		Recruiting	NCT04034459	AIO-KRK-0116	ECD	01-NOV-22	Yes	No		4	NCT04034459			Overall Response Rate	99	99																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + FOLFOXIRI 		Recruiting	NCT04034459	AIO-KRK-0116	ECD	01-NOV-22	Yes	No		4	NCT04034459			Overall Response Rate	99	99																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Binimetinib + Encorafenib + Nivolumab		Recruiting	NCT04044430		ECD	01-AUG-25	Yes	No		4	NCT04044430			Radiographic response rate	38	38																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + XL281		Completed	NCT01086267		PCD	01-AUG-11	Yes	No		4	NCT01086267			Maximum tolerated dose/toxicity	17	17		XL281																																						
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Fotemustine + Vemurafenib		Completed	NCT01983124		PCD	01-APR-13	Yes	Yes		1	29552321	Previously-treated		Progression free survival	31	31											3.9										61.3									1	4	14								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Cetuximab + Encorafenib + WNT974		Completed	NCT02278133		PCD	01-MAY-16	Yes	No		4	NCT02278133			Maximum tolerated dose/toxicity	20	20																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 2	Dabrafenib + Panitumumab + Trametinib		Completed	NCT01750918		PCD	01-JUN-20	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.103			Progression free survival	35	35			26																											1	8	20								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 3	Binimetinib + Cetuximab + Encorafenib		Active, not recruiting	NCT03693170	ANCHOR-CRC	ECD	01-DEC-21	Yes	No		4	NCT03693170	Untreated		Overall Response Rate	95	95																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 3	Binimetinib + Cetuximab + Encorafenib		Active, not recruiting	NCT02928224	BEACON	PCD	01-FEB-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf			Overall survival	441	224	221	Cetuximab + Irinotecan	29	2.0							4.3	1.51												9.03						2	10									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	large intestine / carcinoma / adenocarcinoma	1	Phase 3	Binimetinib + Cetuximab + Encorafenib		Recruiting	NCT03803553		ECD	01-FEB-22	Yes	No		4	NCT03803553			Disease free survival, relapse free survival, regression free survival, recurrence free survival	500																																									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Dabrafenib + Trametinib	Required	Active, not recruiting	NCT01336634	BRF113928	PCD	01-OCT-15	Yes	Yes		1	29438093	Untreated		Overall Response Rate	36	36			61																											1	21									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Dabrafenib + Trametinib	Required	Active, not recruiting	NCT01336634	BRF113928	PCD	01-OCT-15	Yes	Yes		1	29438093	Previously-treated		Overall Response Rate	57	57		Dabrafenib	63				12.6																							2	36									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Dabrafenib + Trametinib		Recruiting	NCT03543306		ECD	01-JUN-20	Yes	No		4	NCT03543306			Overall Response Rate	27	27																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Vemurafenib		Completed		EURAF			Yes	Yes		1	26200454			Unknown	25	25			54.0																		96									2	11	10								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Vemurafenib		Completed	NCT01524978	VE-BASKET	PCD	01-OCT-16	Yes	Yes		2	10.1200/JCO.2017.35.15_suppl.9074 	Untreated		Best overall response	8	8			37.5																																					
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Vemurafenib		Completed	NCT01524978	VE-BASKET	PCD	01-OCT-16	Yes	Yes		2	10.1200/JCO.2017.35.15_suppl.9074 	Previously-treated		Best overall response	54	54			37.0								12.9																													
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	lung / carcinoma / non small cell carcinoma	1	Phase 2	Dabrafenib + Trametinib		Active, not recruiting	NCT04452877		ECD	01-NOV-21	Yes	No		4	NCT04452877			Overall Response Rate	20	20																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	pancreas / carcinoma / NS	3	Phase 2	Binimetinib + Encorafenib		Not yet recruiting	NCT04390243		ECD	01-DEC-23	Yes	No		4	NCT04390243			Overall Response Rate	29	29																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	pancreas / carcinoma / acinar carcinoma	4	Case study	Dabrafenib + Trametinib		Unknown					Yes	Yes		2	10.1200/PO.19.00343			Unknown	1	1																														1										
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	pituitary / craniopharyngioma / papillary	3	Phase 2	Cobimetinib + Vemurafenib		Recruiting	NCT03224767		ECD	01-DEC-21	Yes	No		4	NCT03224767			Response rate	36	36																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	skin / malignant melanoma / rhabdoid	4	Case study	Ipilimumab		Unknown					Yes	Yes		1	22713795			Unknown	1	1																															1									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / NS	3	Phase 1	Dabrafenib + Pazopanib		Active, not recruiting	NCT01713972		PCD	01-JUL-16	Expression level	Yes		2	10.1200/PO.17.00247			Maximum tolerated dose/toxicity	1	1																																1								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / NS	3	Phase 2	Dabrafenib + Radioiodine + Trametinib		Recruiting	NCT03244956		ECD	01-DEC-22	Yes	No		4	NCT03244956			Overall Response Rate	87	87																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Atezolizumab + Cobimetinib + Vemurafenib		Recruiting	NCT03181100		ECD	01-JUL-23	Yes	No		4	NCT03181100			Overall survival	50																																									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Cemiplimab + Dabrafenib + Trametinib		Recruiting	NCT04238624		ECD	01-JUN-22	Yes	No		4	NCT04238624			Overall Response Rate	15	15																																								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / papillary carcinoma	3	Approved FDA	Agerafenib		Completed	NCT01877811		PCD	01-DEC-18	No	Yes	4.45%  serious adverse events	2	10.1200/JCO.2016.34.15_suppl.2574			Maximum tolerated dose/toxicity	1	1																															1									
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / papillary carcinoma	3	Phase 1	XL281		Unknown					Yes	Yes		2	10.1200/jco.2009.27.15s.3513			Unknown	2	2																																2								
BRAF	BRAF_V600E	56056643 + 56059110		p.V600E	thyroid / carcinoma / papillary carcinoma	3	Phase 2	Vemurafenib		Active, not recruiting	NCT01709292		ECD	01-NOV-20	Yes	No		4	NCT01709292			ERK phosphorylation and tumor size	24	24																																								
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	central nervous system / glioma / NS	3	Phase 2	Dabrafenib + Hydroxychloroquine + Trametinib		Recruiting	NCT04201457		ECD	01-FEB-25	Yes	No		4	NCT04201457			Overall Response Rate	75	75																																								
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Dabrafenib + LTT462		Recruiting	NCT04294160		ECD	01-AUG-23	Yes	No		4	NCT04294160			Maximum tolerated dose/toxicity	280	280																																								
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Dabrafenib + LTT462 + Spartalizumab		Recruiting	NCT04294160		ECD	01-AUG-23	Yes	No		4	NCT04294160			Maximum tolerated dose/toxicity	280	280																																								
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Dabrafenib + LTT462 + TNO155		Recruiting	NCT04294160		ECD	01-AUG-23	Yes	No		4	NCT04294160			Maximum tolerated dose/toxicity	280	280																																								
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Dabrafenib + LTT462 + LXH254		Recruiting	NCT04294160		ECD	01-AUG-23	Yes	No		4	NCT04294160			Maximum tolerated dose/toxicity	280	280																																								
BRAF	BRAF_V600E/D/K	56056643 + 56059110 + 56057713 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Dabrafenib + LTT462  + Trametinib		Recruiting	NCT04294160		ECD	01-AUG-23	Yes	No		4	NCT04294160			Maximum tolerated dose/toxicity	280	280																																								
BRAF	BRAF_V600E/D/K/R	56056643 + 56059110 + 56057713 + 56058419 + 56115685 + 56288520 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K + p.V600R	NS / malignant melanoma / NS	3	Phase 2	Dabrafenib + Trametinib		Completed	NCT02039947	COMBI-MB Cohort D	PCD	01-MAY-17	Yes	Yes	IRR 59%	1	28592387			Intracranial Response Rate	17	17																																								
BRAF	BRAF_V600E/D/K/R	56056643 + 56059110 + 56057713 + 56058419 + 56115685 + 56288520 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K + p.V600R	NS / neoplasm / NS	3	Phase 2	Dabrafenib + Trametinib		Recruiting	NCT02465060	MATCH Subprotocol H	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
BRAF	BRAF_V600E/D/K/R	56056643 + 56059110 + 56057713 + 56058419 + 56115685 + 56288520 + 56059623 + 56293156		p.V600D + p.V600E + p.V600K + p.V600R	NS / neoplasm / NS	3	Phase 2	Cobimetinib + Vemurafenib		Recruiting	NCT02693535	TAPUR group 9	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Approved FDA	Dabrafenib + Trametinib	Required	Active, not recruiting	NCT01682083	COMBI-AD	PCD	01-JUN-17	Yes	Yes		1	28891408			Disease free survival, relapse free survival, regression free survival, recurrence free survival	870	438	432	Placebo																															58	39	.47	0.39-0.58	p<0.0001			
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Approved FDA	Trametinib	Required	Completed	NCT01245062	METRIC	PCD	01-OCT-11	Yes	Yes		4	NCT01245062			Progression free survival	322	214	108	Chemotherapy									4.8	1.5	.47	0.34-0.65	0.0001																									
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Approved FDA	Cobimetinib + Vemurafenib	Required	Active, not recruiting	NCT01689519	coBRIM	PCD	01-MAY-14	Yes	Yes		1	26984388	Untreated		Progression free survival	495	247	248	Vemurafenib	70.0	50		<0.001					12.3	7.2	.56	0.45-0.70	<0.001									22.3	17.4	.69	0.54-0.88	0.0032												
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Approved FDA	Cobimetinib + Vemurafenib	Required	Terminated	NCT02303951	NEO-VC	PCD	01-MAY-20	Yes	Yes	Slow accrual	4	NCT02303951			Percent of patients who become resectable	47																																									
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Approved FDA	Binimetinib + Encorafenib	Required	Active, not recruiting	NCT01909453	COLUMBUS	PCD	01-SEP-16	Yes	Yes		1	30219628			Progression free survival	383	192	191	Vemurafenib	63.0	40							14.9	7.3	.54	0.41-0.71	<0.0001																									
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Approved FDA	Dabrafenib + Trametinib	Required	Active, not recruiting	NCT01597908	COMBI-v	PCD	01-APR-14	Yes	Yes		4	NCT01597908	Untreated		Overall survival	704	352	352	Vemurafenib	64.0	51							11.4	7.3	.56	0.46-0.69	<0.001									Not reached	17.2	.69	0.53-0.89	0.005												
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Approved FDA	Dabrafenib + Trametinib	Required	Completed	NCT01584648	COMBI-d	PCD	01-AUG-13	Yes	Yes		4	NCT01584648			Progression free survival	423	211	212	Dabrafenib	66.0	51							9.3	8.8	.75	0.57-0.99	0.035									25.1	18.7	.71	0.55-0.92	0.01												
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 1	Vemurafenib + XL888		Active, not recruiting	NCT01657591		PCD	01-SEP-16	Yes	No		4	NCT01657591			Maximum tolerated dose/toxicity	21	21																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 1	Dabrafenib + Talimogene laherparepvec + Trametinib		Active, not recruiting	NCT03088176		ECD	01-NOV-20	Yes	No		4	NCT03088176	Untreated		Maximum tolerated dose/toxicity	4	4																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 1	Dabrafenib + Phenformin + Trametinib		Recruiting	NCT03026517		ECD	01-JAN-21	Yes	No		4	NCT03026517			Disease free survival, relapse free survival, regression free survival, recurrence free survival	40	40																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 1	Vemurafenib + peginterferon alfa-2b		Completed	NCT01943422		PCD	01-NOV-16	Yes	No		4	NCT01943422			Maximum tolerated dose/toxicity	7	7																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 1	Cobimetinib + Pembrolizumab + Vemurafenib		Active, not recruiting	NCT02818023		ECD	01-MAY-21	Yes	No		4	NCT02818023			Maximum tolerated dose/toxicity	30	30																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 1	Vemurafenib + Voruciclib		Suspended	NCT01841463		ECD	01-MAR-15	Yes	Yes	Changed business priorities	4	NCT01841463			Maximum tolerated dose/toxicity	100	100																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Dabrafenib + Trametinib		Completed	NCT01726738		PCD	01-SEP-18	No	No	64.7% serious adverse events	4	NCT01726738			Unknown	17	17			76																																					
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Dabrafenib + Tazemetostat hydrobromide + Trametinib		Not yet recruiting	NCT04557956		ECD	01-SEP-23	Yes	No		4	NCT04557956			Progression free survival	18	18																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Binimetinib + Encorafenib + Stereotactic radiotherapy		Recruiting	NCT03898908	EBRAIN-MEL	ECD	01-OCT-21	Yes	No		4	NCT03898908			Overall Response Rate	38	38																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Dabrafenib + Lacnotuzumab + Trametinib		Active, not recruiting	NCT03455764		ECD	01-SEP-21	Yes	No		4	NCT03455764			Maximum tolerated dose/toxicity	43	43																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Tazemetostat hydrobromide		Not yet recruiting	NCT04557956		ECD	01-SEP-23	Yes	No		4	NCT04557956			Progression free survival	18	18																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Buparlisib + Vemurafenib		Completed	NCT01512251		PCD	01-DEC-13	Yes	Yes	Serious adverse events	2	10.1200/jco.2014.32.15_suppl.9101			Progression free survival	8	8																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Cobimetinib + IMC-CS4 + Vemurafenib		Active, not recruiting	NCT03101254		ECD	01-JUN-21	Yes	No		4	NCT03101254			Progression free survival	5	5																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Selumetinib		Completed	NCT00866177		PCD	01-SEP-13	No	No		4	NCT00866177			Clinical activity	167	167																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Vemurafenib		Terminated	NCT01474551		PCD	01-MAR-13	Yes	Yes	Slow accrual	4	NCT01474551			Overall Response Rate	2	2																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Cobimetinib + Ipilimumab + Nivolumab + Vemurafenib		Recruiting	NCT02968303	COWBOY	ECD	01-OCT-22	Yes	No		4	NCT02968303			Clinical activity	200			Afatinib																																						
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Ipilimumab + Vemurafenib		Completed	NCT01673854		PCD	01-JUL-14	Yes	Yes	74% serious adverse events	1	27532019	Untreated		Maximum tolerated dose/toxicity	70												4.5													18.5																
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Adoptive cell transfer + Aldesleukin + Lymphodepletion + Vemurafenib		Active, not recruiting	NCT01659151	MCC-16992	ECD	01-DEC-21	Yes	No		4	NCT01659151			Overall Response Rate	17																																									
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Dabrafenib + Pembrolizumab + Trametinib		Unknown	NCT02625337	IMPemBra	ECD	01-JUN-18	Yes	No		4	NCT02625337			Maximum tolerated dose/toxicity	32																																									
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Dabrafenib + Pembrolizumab + Trametinib		Active, not recruiting	NCT03149029		ECD	01-DEC-21	No	No		4	NCT03149029			Overall Response Rate	16																																									
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Binimetinib + Encorafenib + Ipilimumab + Nivolumab		Recruiting	NCT03235245	EBIN	ECD	01-APR-22	Yes	No		4	NCT03235245			Progression free survival	270			Afatinib																																						
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Binimetinib + Encorafenib + Ipilimumab + Nivolumab		Active, not recruiting	NCT02631447	SECOMBIT	ECD	01-APR-21	Yes	No		4	NCT02631447			Overall survival	251																																									
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 2	Dabrafenib + Spartalizumab + Trametinib		Recruiting	NCT04310397		ECD	01-FEB-22	Yes	No		4	NCT04310397			Disease free survival, relapse free survival, regression free survival, recurrence free survival	45	45																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / malignant melanoma / NS	1	Phase 3	Dabrafenib + Spartalizumab + Trametinib		Active, not recruiting	NCT02967692	COMBI-i	PCD	01-AUG-20	Yes	No		4	NCT02967692	Untreated		Progression free survival	568																																									
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	NS / neoplasm / NS	3	Phase 2	Atezolizumab + Cobimetinib + Vemurafenib		Not yet recruiting	NCT04551521	CRAFT	ECD	01-APR-24	Yes	No		4	NCT04551521			Disease control rate, Clinical benefit rate	175	175																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	central nervous system / glioma / NS	3	Phase 2	Binimetinib + Encorafenib		Recruiting	NCT03973918		ECD	01-JUL-22	Yes	No		4	NCT03973918			Radiographic response rate	62	62																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Phase 2	Vemurafenib		Recruiting	NCT02304809	AcSe	PCD	01-MAY-19	Yes	Yes		3	https://academic.oup.com/annonc/article/27/suppl_6/55PD/2798781			Overall Response Rate	4	4			100																											2	2									
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Binimetinib + Encorafenib		Active, not recruiting	NCT02834364	GMMG-BIRMA	ECD	01-DEC-20	Yes	No		4	NCT02834364			Maximum tolerated dose/toxicity	12	12																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	thyroid / carcinoma / NS	3	Phase 1	Dabrafenib + Lapatinib		Active, not recruiting	NCT01947023		ECD	01-JUL-22	Yes	No		4	NCT01947023			Maximum tolerated dose/toxicity	21	21																																								
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	thyroid / carcinoma / anaplastic carcinoma	1	Approved FDA	Dabrafenib + Trametinib	Required	Active, not recruiting	NCT02034110	BRF117019	ECD	01-AUG-21	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s010lbl.pdf			Overall Response Rate	23	23			61.0																											1	13									
BRAF	BRAF_V600E/K	56056643 + 56059110 + 56057713		p.V600E + p.V600K	thyroid / carcinoma / anaplastic carcinoma	1	Phase 1	Dabrafenib + Intensity-Modulated Radiation Therapy + Trametinib		Recruiting	NCT03975231		ECD	01-DEC-21	Yes	No		4	NCT03975231			Maximum tolerated dose/toxicity	20	20																																								
BRAF	BRAF_V600E/M	56056643 + 56059110 + 56075762		p.V600E + p.V600M	thyroid / carcinoma / NS	3	Phase 2	Binimetinib + Encorafenib		Not yet recruiting	NCT04061980		ECD	01-JUL-22	Yes	No		4	NCT04061980			Overall Response Rate	40	40																																								
BRAF	BRAF_V600E/M	56056643 + 56059110 + 56075762		p.V600E + p.V600M	thyroid / carcinoma / NS	3	Phase 2	Binimetinib + Encorafenib + Nivolumab		Not yet recruiting	NCT04061980		ECD	01-JUL-22	Yes	No		4	NCT04061980			Overall Response Rate	40	40																																								
BRAF	BRAF_V600G.	56080151		p.V600G	lung / carcinoma / non small cell carcinoma	3	Phase 2	Vemurafenib		Completed	NCT01524978	VE-BASKET	PCD	01-OCT-16	Yes	Yes		1	26287849			Best overall response	5	5																																1								
BRAF	BRAF_V600K	56057713		p.V600K	NS / malignant melanoma / NS	3	Phase 2	Vemurafenib		Terminated	NCT01586195		PCD	01-APR-15	Yes	Yes		2	10.1200/jco.2014.32.15_suppl.9075			PFS, ORR	1	1																															1									
BRAF	BRAF_V600R	56058419 + 56115685 + 56288520		p.V600R	NS / malignant melanoma / NS	3	Case study	Dabrafenib + Trametinib		Unknown					Yes	Yes		1	31305324			Not defined	2	2																															1									
BRAF	BRAF_V600R	56058419 + 56115685 + 56288520		p.V600R	NS / malignant melanoma / NS	3	Case study	Dabrafenib		Unknown					Yes	Yes		1	23237741			Not defined	1	1																															1									
BRAF	BRAF_V600R	56058419 + 56115685 + 56288520		p.V600R	NS / malignant melanoma / NS	3	Case study	Dabrafenib		Unknown					Yes	Yes		1	27255157			Not defined	1	1																															1									
BRAF	BRAF_V600R	56058419 + 56115685 + 56288520		p.V600R	NS / malignant melanoma / NS	3	Case study	Vemurafenib		Unknown					Yes	Yes		1	23237741			Not defined	1	1																															1									
BRAF	BRAF_V600R	56058419 + 56115685 + 56288520		p.V600R	NS / malignant melanoma / NS	3	Case study	Vemurafenib		Unknown					Yes	Yes		1	31305324			Not defined	1	1																															1									
BRAF	BRAF_no_V600				NS / neoplasm / NS	3	Phase 2	Binimetinib + Encorafenib		Recruiting	NCT03839342	BEAVER	ECD	01-SEP-21	Yes	No		4	NCT03839342			Overall Response Rate	26	26																																								
BRAF	BRAF_no_V600				NS / neoplasm / NS	3	Phase 2	Ulixertinib		Recruiting	NCT02465060	MATCH Subprotocol Z1L	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
BRAF	BRAF_no_V600				NS / neoplasm / NS	3	Phase 2	Ulixertinib		Not yet recruiting	NCT04488003		ECD	01-AUG-23	Yes	No		4	NCT04488003			Overall Response Rate	528	528																																								
BRAF	BRAF_no_V600				NS / neoplasm / NS	3	Phase 2	Trametinib		Active, not recruiting	NCT04439279	MATCH-Subprotocol R	PCD	01-MAR-19	Yes	Yes		4	NCT04439279			Overall Response Rate	33	33			3								1.8			1.6-3.4																										
BRAF	BRAF_no_V600				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 1	Hydroxychloroquine + Ulixertinib		Recruiting	NCT04145297	UTAH	ECD	01-JAN-23	Yes	No		4	NCT04145297			Maximum tolerated dose/toxicity	12	12																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 1	Dabrafenib + Nivolumab + Trametinib		Withdrawn	NCT02357732		PCD	01-AUG-15	Yes	Yes	Changed business priorities	4	NCT02357732			Maximum tolerated dose/toxicity	0	0																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 1	Dabrafenib + Talimogene laherparepvec + Trametinib		Active, not recruiting	NCT03088176		ECD	01-NOV-20	Yes	No		4	NCT03088176	Previously-treated		Maximum tolerated dose/toxicity	4	4																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 1	Belvarafenib		Completed	NCT03118817		PCD	01-FEB-20	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3000			Overall Response Rate	6	6																															2									
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 1	Nivolumab + Trametinib		Withdrawn	NCT02357732		PCD	01-AUG-15	Yes	Yes	Changed business priorities	4	NCT02357732			Maximum tolerated dose/toxicity	0	0																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 1	Dabrafenib + Nivolumab		Withdrawn	NCT02357732		PCD	01-AUG-15	Yes	Yes	Changed business priorities	4	NCT02357732			Maximum tolerated dose/toxicity	0	0																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 1	Trametinib		Completed	NCT00687622		PCD	01-JUN-11	Yes	Yes		1	22805292 			Maximum tolerated dose/toxicity	36	36											5.7																			2	8									
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Dabrafenib + Nivolumab + Trametinib		Recruiting	NCT02910700	TRIDENT	ECD	01-DEC-21	Yes	No		4	NCT02910700			Maximum tolerated dose/toxicity	51			Erlotinib																																						
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Anti-PD-1 Checkpoint Inhibitor + PVSRIPO		Recruiting	NCT04577807		ECD	01-APR-23	Yes	No		4	NCT04577807			Overall Response Rate	56	56																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	PVSRIPO		Recruiting	NCT04577807		ECD	01-APR-23	Yes	No		4	NCT04577807			Overall Response Rate	56	56																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Nivolumab + SonoCloud		Recruiting	NCT04021420	SONIMEL01	ECD	01-JAN-22	No	No		4	NCT04021420			Maximum tolerated dose/toxicity	21	21																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Talimogene laherparepvec		Withdrawn	NCT03972046		PCD	01-FEB-20	Yes	Yes	Administrative issues	4	NCT03972046			Disease free survival, relapse free survival, regression free survival, recurrence free survival	0	0																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Adoptive cell transfer + Nivolumab		Recruiting	NCT03374839		ECD	01-MAR-23	No	No		4	NCT03374839			Maximum tolerated dose/toxicity	11	11																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Sorafenib + Temozolomide		Unknown	NCT00811759		ECD	01-MAY-09	Yes	No		4	NCT00811759			Progression free survival	58	58																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	SAR260301 + Vemurafenib		Completed	NCT01673737		PCD	01-FEB-15	Yes	No		4	NCT01673737			Maximum tolerated dose/toxicity	75	75																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Selumetinib		Completed	NCT00338130		PCD	01-SEP-07	Yes	Yes		1	22048237			Overall Response Rate	73	45	28	Temozolomide	11.1	10.7																																				
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Regorafenib		Terminated	NCT02587650		PCD	01-JUL-18	Yes	Yes	Lack of funding	4	NCT02587650			Overall Response Rate	1	1																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Sorafenib		Completed	NCT00119249		PCD	01-NOV-07	Yes	Yes	Response not correlated with mutation status	4	NCT00119249			Response rate	74	74																																								
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Trametinib		Active, not recruiting					Yes	Yes		4	NCT02296112																																													
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 2	Trametinib		Active, not recruiting	NCT02296112	NCI-2014-02185	PCD	01-AUG-18	Yes	Yes		4	NCT02296112			Overall Response Rate	2	2			50		0.026-0.974																										1									
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Phase 3	Binimetinib		Active, not recruiting	NCT01320085		PCD	01-JAN-14	Yes	Yes		1	22805292			Overall Response Rate	41	41																															2									
BRAF	BRAF_unspecified				NS / malignant melanoma / NS	3	Retrospective/Meta-analysis	Cyclophosphamide + Fludarabine + Interleukin-2 + Tumour infiltrating lymphocytes + Vemurafenib		Unknown					Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.e14024			Maximum tolerated dose/toxicity	55	55											3.7													15.9						6	14									
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 1	Agerafenib		Completed	NCT01877811		PCD	01-DEC-18	No	Yes		4	NCT01877811			Maximum tolerated dose/toxicity	143	143																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 1	HL-085 + Vemurafenib		Recruiting	NCT03781219		ECD	01-AUG-21	Yes	No		4	NCT03781219			Maximum tolerated dose/toxicity	45	45																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 1	Alpelisib + Binimetinib		Completed	NCT01449058		PCD	01-AUG-16	No	No		4	NCT01449058			Maximum tolerated dose/toxicity	139	139																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 1	KO-947		Active, not recruiting	NCT03051035		ECD	01-DEC-20	No	No		4	NCT03051035			Maximum tolerated dose/toxicity	100	100																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 1	Binimetinib + Dactolisib		Completed	NCT01337765		PCD	01-MAR-13	No	No		4	NCT01337765			Maximum tolerated dose/toxicity	29	29																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 1	ARQ 736		Completed	NCT01225536		PCD	01-JAN-13	Yes	No		4	NCT01225536			Maximum tolerated dose/toxicity	24	24																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 1	Crizotinib + Vemurafenib		Active, not recruiting	NCT01531361		ECD	01-JAN-21	Yes	No		4	NCT01531361			Maximum tolerated dose/toxicity	46	46																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 1	Sorafenib + Vemurafenib		Active, not recruiting	NCT01531361		ECD	01-JAN-21	Yes	No		4	NCT01531361			Maximum tolerated dose/toxicity	46	46																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Vemurafenib		Recruiting	NCT03239015	HETIAN64	ECD	01-JUN-23	Yes	No		4	NCT03239015			Overall Response Rate	300	300																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Cobimetinib + RMC4630		Recruiting	NCT03989115		ECD	01-MAR-22	Yes	No		4	NCT03989115			Maximum tolerated dose/toxicity	168	168																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Abemaciclib + LY3214996		Recruiting	NCT04534283		ECD	01-SEP-21	Yes	No		4	NCT04534283			Overall Response Rate	35	35																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Ascorbic acid		Recruiting	NCT03146962		ECD	01-JUN-21	No	No		4	NCT03146962			Disease control rate, Clinical benefit rate	50	50																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Dubermatinib		Recruiting	NCT02729298		ECD	01-DEC-21	Yes	No		4	NCT02729298			Maximum tolerated dose/toxicity	177	177																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Selumetinib		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Regorafenib		Recruiting	NCT02693535	TAPUR group 13	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Sorafenib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Trametinib		Recruiting	NCT02465060	MATCH Subprotocol R	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Dabrafenib		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Dabrafenib		Recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT03239015			Overall Response Rate	300	300																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Vemurafenib		Not yet recruiting	NCT04423185		ECD	01-JUL-22	Yes	No		4	NCT04423185			Overall Response Rate	770	770																																								
BRAF	BRAF_unspecified				NS / other / neoplasm	3	Phase 2	Vemurafenib		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
BRAF	BRAF_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Vemurafenib		Recruiting	NCT02304809	AcSe	PCD	01-MAY-19	Yes	Yes		3	https://academic.oup.com/annonc/article/27/suppl_6/55PD/2798781			Overall Response Rate	2	2			0																													1								
BRAF	BRAF_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Capecitabine + Cetuximab + Cisplatin		Completed	NCT00477711	EXTRA	PCD	01-DEC-08	No	No		4	NCT00477711	Untreated		Response rate	41	41																																								
BRAF	BRAF_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Phase 2	Vemurafenib		Active, not recruiting	NCT01711632		ECD	01-OCT-20	No	Yes		1	26387749	Previously-treated		Clinical activity	36	36			100								73													91.0						10										
BRAF	BRAF_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Phase 2	Obinutuzumab + Vemurafenib		Recruiting	NCT03410875		ECD	01-JAN-22	No	No		4	NCT03410875	Untreated		Complete response, Pathological complete response	30	30																																								
BRAF	BRAF_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Phase 2	PLX8394		Terminated	NCT02012231		PCD	01-SEP-14	Yes	No		4	NCT02012231			Maximum tolerated dose/toxicity	5	5																																								
BRAF	BRAF_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / hairy cell leukaemia	2	Phase 2	Vemurafenib		Unknown					No	Yes		1	26387749			Unknown	26	26			96.0																											9										
BRAF	BRAF_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Dabrafenib + Trametinib		Recruiting	NCT03091257		ECD	01-DEC-20	Yes	No		4	NCT03091257	Previously-treated		Progression free survival	60	60																																								
BRAF	BRAF_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Trametinib		Recruiting	NCT03091257		ECD	01-DEC-20	Yes	No		4	NCT03091257	Previously-treated		Progression free survival	60	60																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Approved FDA	Regorafenib	Not required	Completed	NCT01103323	CORRECT	PCD	01-JUL-11	No	Yes		1	23177514	Previously-treated		Overall survival	760	505	255	Placebo									2	1.7	.49	0.42-0.58	<0.0001									6.4	5	.77	0.64-0.94	0.01												
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Adavosertib + Irinotecan		Recruiting	NCT02906059		PCD	01-MAR-20	Yes	No		4	NCT02906059			Maximum tolerated dose/toxicity	7	7																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Siremadlin + Trametinib		Recruiting	NCT03714958	TRAHD	ECD	01-FEB-21	No	No		4	NCT03714958			Maximum tolerated dose/toxicity	24	24																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	5-Fluorouracil + Midostaurin + Radiotherapy		Completed	NCT01282502		PCD	01-MAR-15	No	Yes		2	10.1200/JCO.2018.36.15_suppl.e15674			Maximum tolerated dose/toxicity	19	19																															3									
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	5-Fluorouracil + Radiotherapy + Trametinib		Active, not recruiting	NCT01740648		ECD	01-DEC-21	No	Yes		1	32253228			Maximum tolerated dose/toxicity	18	18																														3			88.9							
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Belvarafenib		Completed	NCT03118817		PCD	01-APR-20	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3000			Overall Response Rate	7	7																															2									
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Regorafenib		Terminated	NCT02175654		PCD	01-FEB-16	Yes	Yes	Slow accrual	4	NCT02175654			Progression free survival	15	15																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Vinorelbine		Unknown	NCT03482362	EORTC1616	ECD	01-DEC-19	Yes	No		4	NCT03482362			Progression free survival	82	82																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Autologous Dendritic Cells vaccine + Avelumab		Completed	NCT03152565	AVEVAC	PCD	01-JUN-19	No	No		4	NCT03152565			Progression free survival	28	28																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Trifluridine and tipiracil hydrochloride		Recruiting	NCT03223779		ECD	01-JAN-23	No	No		4	NCT03223779			Disease free survival, relapse free survival, regression free survival, recurrence free survival	56	56																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Folfirinox		Unknown	NCT01442935		PCD	01-DEC-15	No	No		4	NCT01442935			Percent of patients who become resectable	256	256																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Ascorbic acid		Not yet recruiting	NCT04035096		ECD	01-DEC-21	Yes	No		4	NCT04035096			Radiographic response rate	40	40																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFIRI + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFIRI + Panitumumab		Active, not recruiting	NCT01312857		ECD	01-MAR-21	No	No		4	NCT01312857			Disease free survival, relapse free survival, regression free survival, recurrence free survival	75	75																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Panitumumab + Trametinib		Recruiting	NCT03087071		ECD	01-DEC-21	Yes	No		4	NCT03087071			Response rate	84	84																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Alpelisib + Cetuximab + Encorafenib		Completed	NCT01719380		PCD	01-OCT-15	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.3544			Progression free survival	156			SAR260301 + Vemurafenib	27	22							5.4	4.2																												
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	5-Fluorouracil + Cetuximab + Leucovorin calcium + Vemurafenib		Active, not recruiting	NCT02291289	MODUL	PCD	01-MAY-19	Yes	Yes		4	NCT02291289			Progression free survival	60	40	20	5-Fluorouracil + Bevacizumab + Capecitabine + Leucovorin calcium									9.99	11.6	.95	0.50-1.82 	0.87																									
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFOX-4		Unknown	NCT01442935		PCD	01-DEC-15	No	No		4	NCT01442935			Percent of patients who become resectable	256	256																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cabozantinib		Active, not recruiting	NCT03542877		ECD	01-MAR-22	No	No		4	NCT03542877	Previously-treated		Progression free survival	43	43																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFIRI		Unknown	NCT01442935		PCD	01-DEC-15	No	No		4	NCT01442935			Percent of patients who become resectable	256	256																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFOX + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
BRAF	BRAF_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab		Not yet recruiting	NCT02942706	BLOC-1	ECD	01-OCT-21	Yes	No		4	NCT02942706			Progression free survival	200																																									
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	LXH254 + Ribociclib		Recruiting	NCT02974725		ECD	01-JAN-22	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	195	195																																								
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	RO4987655		Unknown					Yes	No		1	24947927			Unknown	17	17																															4									
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	LTT462  + LXH254		Recruiting	NCT02974725		ECD	01-JAN-22	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	195	195																																								
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	LXH254 + Trametinib		Recruiting	NCT02974725		ECD	01-JAN-22	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	195	195																																								
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sorafenib		Completed	NCT00098540		PCD	01-MAY-07	Yes	No		4	NCT00098540			Response rate	46	46																																								
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Luminespib		Completed	NCT01922583		PCD	01-FEB-17	Yes	No		4	NCT01922583			Overall Response Rate	31	31																																								
BRAF	BRAF_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		Completed	NCT02276027		PCD	01-OCT-19	Yes	Yes		4	NCT02276027			Overall Response Rate	22	22			9.1																																					
BRAF	BRAF_unspecified				ovary / carcinoma / NS	3	Phase 1	RO5126766		Recruiting	NCT02407509		PCD	01-DEC-15	Yes	Yes		2	10.1200/JCO.2017.35.15_suppl.2506 	Previously-treated		Maximum tolerated dose/toxicity	1	1																															1									
BRAF	BRAF_unspecified				prostate / carcinoma / NS	3	Unknown	Vemurafenib		Unknown	NCT02208583		ECD	01-DEC-16	Yes	No		4	NCT02208583	Previously-treated		Progression free survival	150	150																																								
BRAF	BRAF_unspecified				skin / carcinoma / squamous cell carcinoma	3	Phase 2	Acitretin + Vemurafenib		Terminated	NCT02050321		PCD	01-DEC-14	Yes	Yes	Development discontinued	4	NCT02050321			Unknown	2	2																																								
BRAF	BRAF_unspecified				thyroid / carcinoma / NS	3	Approved FDA	Sorafenib	Not required	Completed	NCT00984282	DECISION	PCD	01-AUG-12	No	Yes		4	NCT00984282	Previously-treated		Progression free survival	417	207	210										10.8	5.8	.59	0.46-0.76	<0.001																									
BRAF	BRAF_unspecified				thyroid / carcinoma / NS	3	Phase 2	Sorafenib + Temsirolimus		Completed	NCT01025453		PCD	01-JAN-18	No	Yes		4	NCT01025453	Previously-treated		Overall Response Rate	31	31																															8	21								
BRAF	BRAF_unspecified				thyroid / carcinoma / NS	3	Phase 2	Sorafenib		Completed	NCT00095693		PCD	01-AUG-05	Yes	Yes	Serious adverse events	2	10.1200/jco.2013.31.15_suppl.e17009			Overall Response Rate	55	55																																								
BRAF	BRAF_unspecified				thyroid / carcinoma / NS	3	Phase 2	Everolimus + Sorafenib		Active, not recruiting	NCT01263951		PCD	01-DEC-18	No	Yes		2	10.1200/jco.2015.33.15_suppl.6072			Progression free survival	13	13																															1	18								
BRAF	BRAF_unspecified				thyroid / carcinoma / NS	3	Phase 2	Everolimus + Sorafenib		Active, not recruiting	NCT01141309		ECD	01-JUN-21	No	No		4	NCT01141309			Response rate	41	41																																								
BRAF	BRAF_unspecified				thyroid / carcinoma / NS	3	Phase 3	Sorafenib		Completed	NCT00984282	DECISION	PCD	01-AUG-12	Comparison with wt	Yes		1	26424760	Previously-treated		Overall Response Rate	34	92											20.5	8.9																												
BRAF	BRAF_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2			Completed	NCT02643056	S10PANI01	PCD	01-DEC-15	No	Yes		1	28592616	Previously-treated		Overall Response Rate	33	33			6								2.6										51			9.7							2	15								
BRCA1	BRCA1_unspecified				NS / malignant melanoma / NS	3	Phase 1	Temozolomide + Veliparib		Completed	NCT00526617		PCD	01-JUN-10	No	No		1	28497258			Maximum tolerated dose/toxicity	41	41																																								
BRCA1	BRCA1_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
BRCA1	BRCA1_unspecified				NS / malignant melanoma / NS	3	Phase 2	Nivolumab + Talazoparib		Recruiting	NCT04187833		ECD	01-JAN-24	Yes	No		4	NCT04187833			Best overall response	37	37																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 1	Olaparib		Completed	NCT03155620	Subprotocol H	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 1	SC10914		Unknown	NCT02940132		ECD	01-MAR-18	Yes	No		4	NCT02940132			Maximum tolerated dose/toxicity	72	72																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 1	Cellectra 2000 + INO5401 + INO9012		Not yet recruiting	NCT04367675		ECD	01-DEC-25	Yes	No		4	NCT04367675			Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 1	Cellectra 2000 + INO5401		Not yet recruiting	NCT04367675		ECD	01-DEC-25	Yes	No		4	NCT04367675			Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 1	Radiotherapy + Talazoparib		Recruiting	NCT03968406		ECD	01-OCT-21	No	No		4	NCT03968406			Maximum tolerated dose/toxicity	24	24																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 1	HWH340		Recruiting	NCT03415659		ECD	01-MAR-21	Yes	No		4	NCT03415659			Maximum tolerated dose/toxicity	85	85																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 1	Veliparib		Completed	NCT00892736		PCD	01-MAY-17	Yes	Yes		2	10.1200/jco.2014.32.15_suppl.2570	Previously-treated		Maximum tolerated dose/toxicity	28	28			40																		68																			
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Olaparib		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Avelumab + Talazoparib		Active, not recruiting	NCT03565991		ECD	01-MAR-21	Yes	No		4	NCT03565991			Overall Response Rate	202	202																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Avelumab + Talazoparib		Active, not recruiting	NCT03330405		ECD	01-AUG-21	Yes	No		4	NCT03330405			Overall Response Rate	216	216																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Bevacizumab + Durvalumab + Olaparib		Active, not recruiting	NCT02734004	MEDIOLA	ECD	01-AUG-22	Yes	No		4	NCT02734004			Overall Response Rate	427	427																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Niraparib + Sintilimab		Not yet recruiting	NCT04423185		ECD	01-JUL-22	Yes	No		4	NCT04423185			Overall Response Rate	770	770																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Adavosertib		Recruiting	NCT02465060	MATCH Subprotocol Z1I	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Adavosertib		Active, not recruiting	NCT04439227	MATCH-Subprotocol Z1I	ECD	01-APR-21	Yes	No		4	NCT04439227			Overall Response Rate	35	35																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Durvalumab + Olaparib		Active, not recruiting	NCT02734004	MEDIOLA	ECD	01-AUG-22	Yes	No		4	NCT02734004			Overall Response Rate	427	427																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Niraparib		Not yet recruiting	NCT04423185		ECD	01-JUL-22	Yes	No		4	NCT04423185			Overall Response Rate	770	770																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Rucaparib 		Recruiting	NCT04171700	LODESTAR	ECD	01-NOV-21	Yes	No		4	NCT04171700			Best overall response	220	220																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Talazoparib		Recruiting	NCT02693535	TAPUR group 19	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Talazoparib		Recruiting	NCT02286687		ECD	01-DEC-20	Yes	No		4	NCT02286687			Disease control rate, Clinical benefit rate	150	150																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Olaparib		Recruiting	NCT02693535	TAPUR group 14	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Olaparib		Recruiting	NCT03967938	1-2018 BSMO	ECD	01-DEC-23	Yes	No		4	NCT03967938			Overall Response Rate	540	540																																								
BRCA1	BRCA1_unspecified				NS / other / neoplasm	3	Phase 2	Olaparib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
BRCA1	BRCA1_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
BRCA1	BRCA1_unspecified				biliary tract / other / neoplasm	3	Phase 1	Veliparib		Terminated	NCT01282333		PCD	01-FEB-13	No	No		4	NCT01282333			Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				biliary tract / other / neoplasm	3	Phase 1	Fluorouracil + Irinotecan hydrochloride liposome + Leucovorin calcium + Rucaparib 		Recruiting	NCT03337087		ECD	01-AUG-21	No	No		4	NCT03337087			Overall Response Rate	110	110																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT02000622	OlympiAD	PCD	01-DEC-16	Yes	Yes		1	28578601			Progression free survival	302	205	97	Chemotherapy	59.9	28.8							7	4.2	.58	0.43-0.80	<0.001									19.3	17.1	.9														
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Approved FDA	Talazoparib	Required	Active, not recruiting	NCT01945775	EMBRACA	PCD	01-SEP-17	Yes	Yes		1	30110579	Previously-treated		Progression free survival	431	287	144	Chemotherapy	62.6	27.2	2.9-8.8	<0.001					8.6	5.6	.54	0.41-0.71	<0.001																									
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Veliparib + doxorubicin hydrochloride liposome		Completed	NCT01145430		PCD	01-MAY-17	No	No		4	NCT01145430	Previously-treated		Maximum tolerated dose/toxicity	45	45																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Onalespib lactate + Talazoparib		Withdrawn	NCT02627430		ECD	01-MAR-19	No	No		4	NCT02627430			Unknown	0	0																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Alpelisib + Olaparib		Active, not recruiting	NCT01623349		PCD	01-MAY-19	No	Yes	Clinical benefit	2	10.1200/jco.2014.32.15_suppl.2510	Previously-treated		Maximum tolerated dose/toxicity	118	118																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Buparlisib + Olaparib		Active, not recruiting	NCT01623349		PCD	01-MAY-19	No	Yes	Clinical benefit	2	10.1200/jco.2014.32.15_suppl.2510	Previously-treated		Maximum tolerated dose/toxicity	118	118																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Capivasertib + Olaparib		Active, not recruiting	NCT02208375		ECD	01-NOV-21	No	No		4	NCT02208375	Previously-treated		Maximum tolerated dose/toxicity	159	159																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Olaparib + Vistusertib		Active, not recruiting	NCT02208375		ECD	01-NOV-21	No	No		4	NCT02208375	Previously-treated		Maximum tolerated dose/toxicity	159	159																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Carboplatin + Olaparib		Terminated	NCT02561832		PCD	01-SEP-16	Yes	Yes	Changed business priorities	4	NCT02561832			Maximum tolerated dose/toxicity	15	15																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Niraparib		Completed	NCT03329937		PCD	01-JAN-20	Yes	Yes	Promising activity	2	10.1158/1538-7445.SABCS19-P3-11-03			Defined % decrease in tumour volume	21	21																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Cyclophosphamide + Veliparib		Active, not recruiting	NCT01351909		PCD	01-NOV-16	No	No		4	NCT01351909			Maximum tolerated dose/toxicity	35	35																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Cisplatin + Veliparib + Vinorelbine		Completed	NCT01104259		PCD	01-FEB-15	Yes	Yes		2	10.1200/jco.2014.32.15_suppl.2569			Maximum tolerated dose/toxicity	11	11			73																											2	6									
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Carboplatin + Paclitaxel + Veliparib		Completed	NCT01251874		PCD	01-APR-17	Yes	Yes		2	10.1200/jco.2014.32.15_suppl.1074			Maximum tolerated dose/toxicity	16	16																															4	10								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 1	Carboplatin + Paclitaxel + Veliparib		Completed	NCT01251874		PCD	01-APR-17	No	Yes		2	10.1200/jco.2014.32.15_suppl.1074			Maximum tolerated dose/toxicity	43	43																															8	21								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel		Not yet recruiting	NCT04499118		ECD	01-AUG-21	No	No		4	NCT04499118			Complete response, Pathological complete response	100	100																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	M4344 + Niraparib		Not yet recruiting	NCT04655183		ECD	01-SEP-23	Yes	No		4	NCT04655183			Overall Response Rate	164	164																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Adavosertib + Ceralasertib + Olaparib		Active, not recruiting	NCT03330847	VIOLETTE	ECD	01-SEP-21	Yes	No		4	NCT03330847			Progression free survival	268	268																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Famitinb + Fluzoparib		Recruiting	NCT03805399	FUTURE	ECD	01-JAN-22	Yes	No		4	NCT03805399			Overall Response Rate	140	140																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	SC10914		Recruiting	NCT04556292		ECD	01-MAR-22	Yes	No		4	NCT04556292			Overall Response Rate	78	78																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Aromatase inhibitors + Niraparib		Recruiting	NCT04240106	LUZERN	ECD	01-SEP-21	No	No		4	NCT04240106			Disease control rate, Clinical benefit rate	23	23																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Docetaxel + Epirubicin hydrochloride		Not yet recruiting	NCT04499118		ECD	01-AUG-21	No	No		4	NCT04499118			Complete response, Pathological complete response	100	100																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Docetaxel + doxorubicin hydrochloride		Not yet recruiting	NCT04499118		ECD	01-AUG-21	No	No		4	NCT04499118			Complete response, Pathological complete response	100	100																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Dostarlimab + Niraparib		Recruiting	NCT04584255		ECD	01-JUL-24	Yes	No		4	NCT04584255			Complete response, Pathological complete response	62	62																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Niraparib + Trastuzumab		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	HX008		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Durvalumab + Fulvestrant + Olaparib		Recruiting	NCT04053322	DOLAF	ECD	01-MAR-22	Yes	No		4	NCT04053322			Progression free survival	158	158																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib + Trastuzumab		Recruiting	NCT03931551	OPHELIA	ECD	01-SEP-22	Yes	No		4	NCT03931551			OS, PFS	20	20																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Pamiparib		Recruiting	NCT03575065		PCD	01-OCT-20	Yes	No		4	NCT03575065			Overall Response Rate	88	88																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT03025035		ECD	01-NOV-23	Yes	No		4	NCT03025035			Overall Response Rate	20	20																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Ceralasertib + Olaparib		Recruiting	NCT02264678		ECD	01-JAN-24	Yes	No		4	NCT02264678			Maximum tolerated dose/toxicity	117	117																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Recruiting	NCT04090567		ECD	01-JUL-21	Yes	No		4	NCT04090567			Overall Response Rate	60	60																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib + Sapacitabine		Recruiting	NCT03641755		ECD	01-JUN-22	Yes	No		4	NCT03641755			Overall Response Rate	64	64																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Adavosertib + Olaparib		Active, not recruiting	NCT03330847	VIOLETTE	ECD	01-JAN-21	Yes	No		4	NCT03330847			Progression free survival	150	150																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	AZD6738 + Olaparib		Active, not recruiting	NCT03330847	VIOLETTE	ECD	01-MAR-23	Yes	No		4	NCT03330847			Progression free survival	150	150																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Durvalumab + Olaparib		Recruiting	NCT03801369		ECD	01-DEC-23	No	No		4	NCT03801369			Overall Response Rate	28	28																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Durvalumab + Olaparib		Recruiting	NCT02484404		ECD	01-JAN-22	No	No		4	NCT02484404			Overall Response Rate	384	384																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Cediranib maleate + Durvalumab		Recruiting	NCT02484404		ECD	01-JAN-22	No	No		4	NCT02484404			Overall Response Rate	384	384																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Cediranib maleate + Durvalumab + Olaparib		Recruiting	NCT02484404		ECD	01-JAN-22	No	No		4	NCT02484404			Overall Response Rate	384	384																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Atezolizumab + Olaparib		Recruiting	NCT02849496		ECD	01-AUG-21	No	No		4	NCT02849496			Progression free survival	72	72																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Fulvestrant + Olaparib + Palbociclib		Not yet recruiting	NCT03685331		ECD	01-APR-24	Yes	No		4	NCT03685331			Progression free survival	54	54																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT02826512		ECD	01-AUG-21	Yes	No		4	NCT02826512			Progression free survival	39	39																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Niraparib + Trastuzumab		Not yet recruiting	NCT03368729		ECD	01-NOV-21	No	No		4	NCT03368729			Overall Response Rate	40	40																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Temozolomide + Veliparib		Active, not recruiting	NCT01506609	BROCADE	PCD	01-DEC-18	Yes	Yes		1	29045554			Progression free survival	193	94	99	Carboplatin + Paclitaxel	28.6	61.3							7.4	12.3	1.86	1.28-2.70	0.001									19.1	25.9	1.48	1.03-2.13	0.032												
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Temozolomide + Veliparib		Active, not recruiting	NCT01009788		ECD	01-DEC-20	Yes	No		4	NCT01009788			Overall Response Rate	64	64																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Cyclophosphamide + Veliparib		Completed	NCT01306032		PCD	01-DEC-14	Yes	Yes		4	NCT01306032	Previously-treated		Overall Response Rate	39	21	18	Cyclophosphamide	9.5	5.6																																				
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Cisplatin + Veliparib		Active, not recruiting	NCT02595905		ECD	01-OCT-21	Yes	No		4	NCT02595905			Progression free survival	333																																									
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel + Veliparib		Active, not recruiting	NCT01506609	BROCADE	PCD	01-DEC-18	Yes	Yes		1	29045554			Progression free survival	196	97	99	Carboplatin + Paclitaxel	77.8	61.3		0.027					14.1	12.3	.79	0.54-1.16	0.227									28.3	25.9	.75	0.50-1.12	0.156												
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel + Veliparib		Completed	NCT01818063		PCD	01-MAR-15	No	Yes	PCR 75 vs 60%	4	NCT01818063			Complete response, Pathological complete response	9	4	5	Carboplatin + Paclitaxel																																						
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel + Veliparib		Active, not recruiting	NCT01149083		ECD	01-DEC-20	Yes	Yes		1	28356425	Previously-treated		Response rate	22	22			14								5.2													14.5																
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel + Veliparib		Active, not recruiting	NCT01149083		ECD	01-DEC-20	No	Yes		1	28356425	Previously-treated		Response rate	27	27			56								8.7													18.8																
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Rucaparib 		Completed	NCT00664781		PCD	01-JAN-15	Yes	Yes		1	27002934			Defined % decrease in tumour volume	9	9																																4								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Rucaparib 		Active, not recruiting	NCT01074970	BRE09-146	PCD	01-DEC-18	No	Yes	No benefit of treatment, no effect of KRAS or BRAF mutation status	2	10.1200/jco.2015.33.15_suppl.1082			Disease free survival, relapse free survival, regression free survival, recurrence free survival	135																																									
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Rucaparib 		Unknown	NCT02505048	RUBY	PCD	01-FEB-19	Yes	No		4	NCT02505048			Disease control rate, Clinical benefit rate	41	41																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Talazoparib		Recruiting	NCT03990896		ECD	01-JUL-22	Yes	No		4	NCT03990896			Progression free survival	30	30																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Talazoparib		Terminated	NCT03499353		PCD	01-SEP-20	Yes	Yes	Changed business priorities	4	NCT03499353			Complete response, Pathological complete response	61	61																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Talazoparib		Terminated	NCT02034916	ABRAZO	PCD	01-SEP-16	Yes	Yes	Not stopped due to safety concerns	1	30563931			Overall Response Rate	83	83			28.0																											2	21	36								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Talazoparib		Active, not recruiting	NCT02282345		ECD	01-APR-21	Yes	No		4	NCT02282345	Untreated		Maximum tolerated dose/toxicity	33	33																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Active, not recruiting	NCT00679783		PCD	01-MAR-10	Yes	Yes		1	21862407	Previously-treated		Overall Response Rate	3	3			0																													2								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Completed	NCT02032823	OlympiA	PCD	01-MAR-20	Yes	No		4	NCT02032823	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	1836	1836																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Unknown	NCT02681562	OLTRE	PCD	01-JAN-18	Yes	No		4	NCT02681562			Unknown	45																																									
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Withdrawn	NCT01661868		PCD	01-AUG-12	Yes	Yes	Drug not available	4	NCT01661868			Response rate	0																																									
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT02849496		ECD	01-AUG-21	No	No		4	NCT02849496			Progression free survival	72	72																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 3	Olaparib		Active, not recruiting	NCT03402841	OPINION	PCD	01-OCT-20	Yes	No		4	NCT03402841	Previously-treated		Progression free survival	279	279																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	01-JUN-23	Yes	No		4	NCT04335669			Complete response, Pathological complete response	820	820																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 3	Apatinib + Fluzoparib		Recruiting	NCT04296370		ECD	01-JUN-22	Yes	No		4	NCT04296370			Progression free survival	474			Fluzoparib																																						
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 3	Chemotherapy + Olaparib		Recruiting	NCT03150576	PARTNER	ECD	01-JAN-22	Yes	No		4	NCT03150576			Complete response, Pathological complete response	527	527																																								
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 3	Niraparib		Active, not recruiting	NCT01905592	BRAVO	PCD	01-AUG-18	Yes	Yes		4	NCT01905592	Previously-treated		Progression free survival	206	135	71	Best supportive care									4.1	3.1				4.3	2.6							14.5	14.8															
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 3	Atezolizumab + Chemotherapy + Niraparib		Recruiting	NCT03598270	ANITA	ECD	01-NOV-23	No	No		4	NCT03598270	Previously-treated		Progression free survival	414																																									
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 3	Chemotherapy + Niraparib		Recruiting	NCT03598270	ANITA	ECD	01-NOV-23	No	No		4	NCT03598270	Previously-treated		Progression free survival	414			Chemotherapy																																						
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 3	Carboplatin + Cyclophosphamide + Paclitaxel + Veliparib + doxorubicin hydrochloride		Active, not recruiting	NCT02032277		PCD	01-MAR-16	No	Yes	Primary outcome not met	1	29501363			Complete response, Pathological complete response	474	316	158	Carboplatin + Cyclophosphamide + Paclitaxel																																						
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 3	Carboplatin + Paclitaxel + Veliparib		Active, not recruiting	NCT02163694	BROCADE3	PCD	01-APR-19	Yes	Yes		1	32861273			Progression free survival	266	177	89	Carboplatin + Paclitaxel									14.5	13.1	.72	0.53-0.97																										
BRCA1	BRCA1_unspecified				breast / carcinoma / NS	1	Phase 4	Choriogonadotropin alfa		Completed	NCT03495609		PCD	01-DEC-18	No	No		4	NCT03495609			Altered genomic signature	33	33																																								
BRCA1	BRCA1_unspecified				central nervous system / glioma / NS	3	Phase 2	Veliparib		Recruiting	NCT03581292		ECD	01-OCT-24	No	No		4	NCT03581292			Event free survival	115	115																																								
BRCA1	BRCA1_unspecified				central nervous system / glioma / NS	3	Phase 2	Olaparib + Temozolomide		Recruiting	NCT03212742	OLA-TMZ-RTE-01	ECD	01-JAN-22	No	No		4	NCT03212742			Overall survival	79	79																																								
BRCA1	BRCA1_unspecified				endometrium / carcinoma / NS	3	Phase 1	Olaparib + Vistusertib		Active, not recruiting	NCT02208375		ECD	01-NOV-21	No	No		4	NCT02208375	Previously-treated		Maximum tolerated dose/toxicity	159	159																																								
BRCA1	BRCA1_unspecified				endometrium / carcinoma / NS	3	Phase 1	Copanlisib + Niraparib		Recruiting	NCT03586661		ECD	01-APR-21	No	No		4	NCT03586661	Previously-treated		Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				endometrium / carcinoma / NS	3	Phase 1	Capivasertib + Olaparib		Active, not recruiting	NCT02208375		ECD	01-NOV-21	No	No		4	NCT02208375	Previously-treated		Maximum tolerated dose/toxicity	159	159																																								
BRCA1	BRCA1_unspecified				endometrium / carcinoma / NS	3	Phase 2	Cediranib maleate + Olaparib		Suspended	NCT03660826		ECD	01-SEP-22	No	No		4	NCT03660826			Progression free survival	120	120																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Olaparib	Usage dependent	Suspended					No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558s009lbl.pdf	Previously-treated		Clinical activity	137	137							7.9		5.6-9.6																					3	44									
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Bevacizumab + Chemotherapy + Olaparib		Active, not recruiting	NCT02477644	PAOLA-1	PCD	01-MAR-19	No	No		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf?utm_source=Salesforce%20Marketing%20Cloud&utm_medium=Email&utm_campaign=&sfmc_s=0031I000016IMUlQAO			Progression free survival	806			Placebo																																						
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Niraparib	Not required	Active, not recruiting	NCT01847274	NOVA	PCD	01-JUN-16	Yes	Yes		4	NCT01847274	Previously-treated		Progression free survival	203	138	65	Placebo									21	5.5	.27	0.17-0.41	<0.0001																									
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Rucaparib 	Usage dependent	Active, not recruiting					Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf	Previously-treated		Overall Response Rate	106	106			54																																					
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Rucaparib 		Active, not recruiting	NCT01968213	ARIEL3	PCD	01-APR-17	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf	Previously-treated		Progression free survival	564	375	189										10.8	5.4	.36	0.3-0.45	<0.0001																									
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Olaparib	Usage dependent	Active, not recruiting	NCT03534453	Study 19	ECD	01-DEC-21	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558s009lbl.pdf	Previously-treated		Progression free survival	265	136	129	Placebo									8.4	4.8	.35	0.25-0.49	<0.0001									29.8	27.8	.73	0.55-0.95													
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Olaparib	Usage dependent	Active, not recruiting	NCT01874353	SOLO-2	PCD	01-SEP-16	Yes	Yes		1	28754483	Previously-treated		Progression free survival	327	196	99	Placebo									19.1	5.5	.3	0.22-0.41	<0.0001																									
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Olaparib	Usage dependent	Active, not recruiting	NCT01844986	SOLO-1	PCD	01-MAY-18	Yes	Yes		4	NCT01844986	Previously-treated		Progression free survival	450	260	131	Placebo										13.8	.3	0.23-0.41	<0.0001																									
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 1	Talazoparib		Active, not recruiting	NCT02316834	POSITION	ECD	01-FEB-21	No	No		4	NCT02316834			Unknown	30	30																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 1	Bevacizumab + Cisplatin + Olaparib + Paclitaxel		Active, not recruiting	NCT02121990		PCD	01-AUG-20	No	No		4	NCT02121990	Untreated		Maximum tolerated dose/toxicity	17	17																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 1	Copanlisib + Niraparib		Recruiting	NCT03586661		ECD	01-APR-21	No	No		4	NCT03586661	Previously-treated		Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 1	Floxuridine + Veliparib		Active, not recruiting	NCT01749397		PCD	01-OCT-17	No	No		4	NCT01749397			Maximum tolerated dose/toxicity	29	29																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 1	Bevacizumab + Carboplatin + Veliparib + doxorubicin hydrochloride liposome		Completed	NCT01459380		PCD	01-JUN-16	No	No		4	NCT01459380	Previously-treated		Maximum tolerated dose/toxicity	41	41																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 1	Bevacizumab + Carboplatin + Paclitaxel + Veliparib		Active, not recruiting	NCT00989651		PCD	01-SEP-16	No	No		4	NCT00989651	Untreated		Maximum tolerated dose/toxicity	431	431																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 1	Onalespib lactate + Talazoparib		Withdrawn	NCT02627430		ECD	01-MAR-19	No	No		4	NCT02627430			Unknown	0	0																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 1	Capivasertib + Olaparib		Active, not recruiting	NCT02208375		ECD	01-NOV-21	No	No		4	NCT02208375		159	Maximum tolerated dose/toxicity	159	150																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 1	Olaparib + Vistusertib		Active, not recruiting	NCT02208375		ECD	01-NOV-21	No	No		4	NCT02208375		159	Maximum tolerated dose/toxicity	159	150																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 1	Niraparib		Completed	NCT03551171		PCD	01-MAY-18	No	Yes	Primary outcome met	1	31439812			Maximum tolerated dose/toxicity	36	36																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT02489006	NEO	ECD	01-JUN-21	No	No		4	NCT02489006			Unknown	71	71																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Nivolumab + Rucaparib 		Terminated	NCT03824704	ARIES	PCD	01-AUG-20	No	Yes	Slow accrual	4	NCT03824704			Overall Response Rate	1	1																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Talazoparib + Temozolomide		Unknown	NCT02836028		ECD	01-JUN-20	No	No		4	NCT02836028			Overall Response Rate	0	0																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Bevacizumab + Carboplatin + Paclitaxel + Rucaparib 		Active, not recruiting	NCT03462212	MITO25	PCD	01-MAY-19	No	No		4	NCT03462212	Previously-treated		Progression free survival	290																																									
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel + Rucaparib 		Active, not recruiting	NCT03462212	MITO25	PCD	01-MAY-19	No	No		4	NCT03462212	Previously-treated		Progression free survival	290																																									
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Mirvetuximab Soravtansine + Rucaparib 		Recruiting	NCT03552471		ECD	01-AUG-21	No	No		4	NCT03552471			Maximum tolerated dose/toxicity	42	42																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Olaparib + doxorubicin hydrochloride liposome		Recruiting	NCT03161132	ROLANDO	PCD	01-FEB-20	No	No		4	NCT03161132	Previously-treated		Progression free survival	32	32																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Durvalumab + Olaparib + Tremelimumab		Recruiting	NCT02953457		ECD	01-DEC-20	Yes	No		4	NCT02953457	Previously-treated		Progression free survival	36	36																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT01116648		PCD	01-OCT-18	No	No		4	NCT01116648	Previously-treated		Progression free survival	155			Olaparib																																						
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT02889900	CONCERTO	PCD	01-AUG-19	No	No		4	NCT02889900			Overall Response Rate	62	62																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT02345265		PCD	01-MAY-20	No	No		4	NCT02345265	Previously-treated		Progression free survival	72	72																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Bevacizumab + Chemotherapy + Niraparib		Active, not recruiting	NCT03326193	OVARIO	ECD	01-DEC-20	No	No		4	NCT03326193	Previously-treated		Progression free survival	105	105																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Niraparib		Active, not recruiting	NCT03759587		PCD	01-MAR-19	No	Yes	Primary outcome met	1	33470063	Previously-treated		Maximum tolerated dose/toxicity	4	4																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Niraparib		Completed	NCT03759600		PCD	01-JUL-19	No	Yes		4	NCT03759600	Previously-treated		Overall Response Rate	2	2			35																																					
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Cyclophosphamide + Veliparib		Completed	NCT01306032		PCD	01-DEC-14	No	Yes	No benefit of treatment	1	25589624	Previously-treated		Progression free survival	6	6																															1									
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Talazoparib		Unknown	NCT02836028		ECD	01-JUN-20	No	No		4	NCT02836028			Overall Response Rate	0	0																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Veliparib		Completed	NCT01540565		PCD	01-JAN-18	Yes	Yes		4	NCT01540565	Previously-treated		Maximum tolerated dose/toxicity	50	50			26									8.18																												
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 2	Olaparib		Active, not recruiting	NCT02983799		ECD	01-AUG-20	No	No		4	NCT02983799	Previously-treated		Overall Response Rate	272	272																																								
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 3	Olaparib		Active, not recruiting	NCT02446600		PCD	01-FEB-20	No	No		4	NCT02446600	Previously-treated		Progression free survival	579			Chemotherapy																																						
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 3	Cediranib maleate + Olaparib		Active, not recruiting	NCT02446600		PCD	01-FEB-20	No	No		4	NCT02446600	Previously-treated		Progression free survival	579			Chemotherapy																																						
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 3	Cediranib maleate + Olaparib		Recruiting	NCT02502266	COCOS	ECD	01-JUN-23	No	No		4	NCT02502266	Previously-treated		Progression free survival	680																																									
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 3	Atezolizumab + Chemotherapy + Niraparib		Recruiting	NCT03598270	ANITA	ECD	01-NOV-23	No	No		4	NCT03598270	Previously-treated		Progression free survival	414																																									
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 3	Chemotherapy + Niraparib		Recruiting	NCT03598270	ANITA	ECD	01-NOV-23	No	No		4	NCT03598270	Previously-treated		Progression free survival	414			Chemotherapy																																						
BRCA1	BRCA1_unspecified				fallopian tube / carcinoma / NS	1	Phase 3	Rucaparib 		Recruiting	NCT02855944	ARIEL4	ECD	01-JUN-22	Yes	No		4	NCT02855944	Previously-treated		Progression free survival	345			Chemotherapy																																						
BRCA1	BRCA1_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Niraparib		Recruiting	NCT03840967		ECD	01-MAY-21	No	No		4	NCT03840967	Previously-treated		Overall Response Rate	43	43																																								
BRCA1	BRCA1_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Olaparib + Ramucirumab		Recruiting	NCT03008278		ECD	01-JUN-21	No	No		4	NCT03008278			Overall Response Rate	49	49																																								
BRCA1	BRCA1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Talazoparib		Completed	NCT01399840		PCD	01-MAR-14	No	No		4	NCT01399840			Maximum tolerated dose/toxicity	33	33																																								
BRCA1	BRCA1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
BRCA1	BRCA1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Carboplatin + Topotecan + Veliparib		Recruiting	NCT03289910		ECD	01-JUN-21	No	No		4	NCT03289910			Overall Response Rate	60	60																																								
BRCA1	BRCA1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Carboplatin + Topotecan + Veliparib		Recruiting	NCT03289910		ECD	01-JUN-21	No	No		4	NCT03289910			Overall Response Rate	60	60																																								
BRCA1	BRCA1_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / mantle cell lymphoma	7	Phase 2	Niraparib		Withdrawn	NCT01244009		ECD	01-AUG-13	No	No		4	NCT01244009			Unknown	0																																									
BRCA1	BRCA1_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Fluorouracil + Irinotecan hydrochloride liposome + Leucovorin calcium + Rucaparib 		Recruiting	NCT03337087		ECD	01-AUG-21	Yes	No		4	NCT03337087			Overall Response Rate	110	110																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine		Unknown	NCT02750995	AZACTA	ECD	01-APR-20	No	No		4	NCT02750995			Maximum tolerated dose/toxicity	15	15																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	WT1, PRAME and Survivin-specific allogenic cytotoxic T cells		Recruiting	NCT02203903	RESOLVE	ECD	01-NOV-24	No	No		4	NCT02203903			Maximum tolerated dose/toxicity	90	90																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	WT1, NY-ESO-1, PRAME and Survivin-specific allogenic CTLs		Recruiting	NCT02494167	ADSPAM	ECD	01-APR-22	Expression level	No		4	NCT02494167			Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Galinpepimut-S + Montanide + Sargramostim		Completed	NCT00398138		PCD	01-JUN-09	Expression level	Yes	Specific T-cell response in 7 pts	1	20400682 			Immune response	8	8																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	PR1 leukemia peptide vaccine		Completed	NCT00270452		PCD	01-OCT-07	No	Yes	No adverse events >2	4	17875804			Maximum tolerated dose/toxicity	9	9																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Acetaminophen + Diphenhydramine + Donor lymphocyte infusion + Interleukin-4 + Keyhole limpet hemocyanin + WT1 peptide vaccine + WT1 peptide-loaded allogenic DC vaccine		Completed	NCT00923910		PCD	01-OCT-13	Expression level	Yes	No adverse events >2	1	27634018			Maximum tolerated dose/toxicity	10	10																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	WT1-sensitized allogenic T cells		Active, not recruiting	NCT00620633		PCD	01-FEB-21	Expression level	Yes		3	https://www.globenewswire.com/news-release/2015/09/24/770637/10150431/en/Atara-Bio-s-T-Cell-Product-Candidate-Activated-Against-Wilms-Tumor-1-Protein-Demonstrates-Encouraging-Results-in-Patients-With-Plasma-Cell-Leukemia.html			Maximum tolerated dose/toxicity	22	22																														3	1	2								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Montanide + Sargramostim + WT1 124-138 peptide vaccine  + WT1 126-134 peptide vaccine  + WT1 235-243 peptide vaccine  + WT1 247-261 peptide vaccine 		Terminated	NCT00672152		PCD	01-APR-13	No	Yes	Slow accrual	4	NCT00672152			Maximum tolerated dose/toxicity	22	22																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Sargramostim + WT1 126-134 peptide vaccine 		Completed	NCT00433745		PCD	01-NOV-09	No	Yes	All patients had cellular immune response	4	NCT00433745			Target-specific T cell activity 	4	4																															1									
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	WT1-specific TCR transduced autologous T cell infusion		Completed	NCT01621724		PCD	01-MAY-18	No	No		4	NCT01621724			Immune response	7	7																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	NEXI-001 multi antigen allogeneic CTLs		Recruiting	NCT04284228		ECD	01-OCT-22	No	No		4	NCT04284228			PFS, ORR	22	22																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Aldesleukin + Hematopoietic Stem Cell Transplant + WT1-specific allogenic cytotoxic T cells		Completed	NCT00052520		PCD	01-APR-11	No	No		4	NCT00052520			Maximum tolerated dose/toxicity	37	37																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Aldesleukin + Cyclophosphamide + Fludarabine + WT1-sensitized allogenic T cells		Active, not recruiting	NCT01640301		ECD	01-SEP-29	Expression level	No		4	NCT01640301			Clinical activity	45	45																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Aldesleukin + WT1-sensitized allogenic T cells		Active, not recruiting	NCT01640301		ECD	01-SEP-29	Expression level	No		4	NCT01640301			Clinical activity	45	45																																								
BRCA1	BRCA1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Hematopoietic Stem Cell Transplant + WT1-A10/AS01B immunotherapeutic GSK2130579A		Completed	NCT01819558	ALLO-WT1	PCD	01-MAR-15	Expression level	No		4	NCT01819558			Maximum tolerated dose/toxicity	2	2																																								
BRCA1	BRCA1_unspecified				liver / carcinoma / hepatocellular carcinoma	7	Phase 2	Temozolomide + Veliparib		Terminated	NCT01205828		PCD	01-OCT-14	No	Yes	No benefit of treatment	4	NCT01205828			Disease control rate, Clinical benefit rate	16	16																																								
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Cisplatin + Gemcitabine + Veliparib		Terminated	NCT01282333		PCD	01-FEB-13	No	No		4	NCT01282333			Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Olaparib		Unknown	NCT01788332		ECD	01-DEC-18	No	No		4	NCT01788332			Progression free survival	70	70																																								
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cyclodextrin-based polymer-camptothecin CRLX101 + Olaparib		Recruiting	NCT02769962		ECD	01-JUL-23	No	No		4	NCT02769962			Overall Response Rate	123	123																																								
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Durvalumab + Olaparib		Active, not recruiting	NCT03775486	ORION	ECD	01-JUN-21	No	No		4	NCT03775486			Progression free survival	401			Durvalumab																																						
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Paclitaxel + Veliparib		Completed	NCT01560104		PCD	01-SEP-14	No	Yes		1	27803064			Progression free survival	158			Chemotherapy					6.9	4.3	0.16-1.42	0.18	5.8	4.2	.72	0.45-1.15	0.17									11.7	9.1	.8	0.54-1.18	0.27												
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Rucaparib 		Recruiting	NCT03845296		ECD	01-JUL-21	Yes	No		4	NCT03845296			Overall Response Rate	80	80																																								
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Olaparib		Unknown	NCT02679963	PIPSeN	ECD	01-JAN-20	No	No		4	NCT02679963			Progression free survival	600	600																																								
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Talazoparib		Active, not recruiting	NCT02154490	Lung-MAP	ECD	01-APR-22	No	No		4	NCT02154490	Previously-treated		Progression free survival	1864	1864																																								
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Carboplatin + Paclitaxel + Veliparib		Completed	NCT02264990		PCD	01-FEB-20	No	Yes		4	NCT02264990			Overall survival	80	40	40	Chemotherapy	22.5	30.0	0.23-1.90	0.455					6.3	5.2	.65	0.388-1.080	0.26									11.2	9.2	.64	0.396-1.048	0.113 												
BRCA1	BRCA1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Carboplatin + Paclitaxel + Veliparib		Completed	NCT0210654		PCD	01-JUL-19	No	Yes	Primary outcome not met	3	https://www.fiercebiotech.com/biotech/abbvie-parp-inhibitor-veliparib-flunks-two-phase-3-trials			Overall survival	970																																									
BRCA1	BRCA1_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03009682	SUKSES-B	ECD	01-SEP-21	Yes	No		4	NCT03009682			Overall Response Rate	28	28																																								
BRCA1	BRCA1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Talazoparib		Active, not recruiting	NCT03377556		ECD	01-MAY-22	Yes	No		4	NCT03377556			Overall Response Rate	64	64																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Approved FDA	Olaparib	Required	Unknown					Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558s009lbl.pdf	Previously-treated		Clinical activity	137	137							7.9		5.6-9.6																					3	44									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Approved FDA	Bevacizumab + Chemotherapy + Olaparib		Active, not recruiting	NCT02477644	PAOLA-1	PCD	01-MAR-19	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf?utm_source=Salesforce%20Marketing%20Cloud&utm_medium=Email&utm_campaign=&sfmc_s=0031I000016IMUlQAO			Progression free survival	806	537	269	Placebo									37.2	21.7	.31	0.20-0.47																										
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Approved FDA	Niraparib	Not required	Active, not recruiting	NCT01847274	NOVA	PCD	01-JUN-16	Yes	Yes		4	NCT01847274	Previously-treated		Progression free survival	203	138	65	Placebo									21	5.5	.27	0.17-0.41	<0.0001																									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Approved FDA	Rucaparib 	Usage dependent	Active, not recruiting					Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf	Previously-treated		Overall Response Rate	106	106			54																																					
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Approved FDA	Rucaparib 	Usage dependent	Active, not recruiting	NCT01968213	ARIEL3	PCD	01-APR-17	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf	Previously-treated		Progression free survival	564	375	189										10.8	5.4	.36	0.3-0.45	<0.0001																									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT00753545	Study 19	PCD	01-JUN-10	No	Yes		4	NCT00753545	Previously-treated		Progression free survival	265	136	139	Placebo									8.4	4.8	.35	0.25-0.49	<0.00001																									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT03534453	Study 19	ECD	01-DEC-21	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558s009lbl.pdf	Previously-treated		Progression free survival	265	136	129	Placebo									8.4	4.8	.35	0.25-0.49	<0.0001									29.8	27.8	.73	0.55-0.95													
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT01874353	SOLO-2	PCD	01-SEP-16	Yes	Yes		1	28754483	Previously-treated		Progression free survival	327	196	99	Placebo									19.1	5.5	.3	0.22-0.41	<0.0001																									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT01844986	SOLO-1	PCD	01-MAY-18	Yes	Yes		4	NCT01844986	Previously-treated		Progression free survival	450	260	131	Placebo										13.8	.3	0.23-0.41	<0.0001																									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Olaparib		Active, not recruiting	NCT02855697	MOLTO	ECD	01-SEP-21	No	No		4	NCT02855697	Previously-treated		Maximum tolerated dose/toxicity	28	28																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Denosumab		Recruiting	NCT03382574		ECD	01-NOV-21	Yes	No		4	NCT03382574			Change in Ki-67 expression	60	60																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Olaparib + Selumetinib		Recruiting	NCT03162627		ECD	01-AUG-26	Yes	No		4	NCT03162627	Previously-treated		Maximum tolerated dose/toxicity	90	90																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Bevacizumab + Cisplatin + Olaparib + Paclitaxel		Active, not recruiting	NCT02121990		PCD	01-AUG-20	No	No		4	NCT02121990	Untreated		Maximum tolerated dose/toxicity	17	17																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Copanlisib + Niraparib		Recruiting	NCT03586661		ECD	01-APR-21	No	No		4	NCT03586661	Previously-treated		Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Floxuridine + Veliparib		Active, not recruiting	NCT01749397		PCD	01-OCT-17	No	No		4	NCT01749397			Maximum tolerated dose/toxicity	29	29																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Bevacizumab + Carboplatin + Veliparib + doxorubicin hydrochloride liposome		Completed	NCT01459380		PCD	01-JUN-16	No	No		4	NCT01459380	Previously-treated		Maximum tolerated dose/toxicity	41	41																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Bevacizumab + Carboplatin + Paclitaxel + Veliparib		Active, not recruiting	NCT00989651		PCD	01-SEP-16	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.5523	Untreated		Maximum tolerated dose/toxicity	424	424											14.6																													
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Onalespib lactate + Talazoparib		Unknown	NCT02627430		PCD	01-MAR-19	No	No		4	NCT02627430	Previously-treated		Maximum tolerated dose/toxicity	0	0																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Alpelisib + Olaparib		Active, not recruiting	NCT01623349		PCD	01-MAY-19	Yes	Yes		1	30880072	Previously-treated		Maximum tolerated dose/toxicity	10	10																															3	7								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Buparlisib + Olaparib		Active, not recruiting	NCT01623349		PCD	01-MAY-19	No	No		4	NCT01623349	Previously-treated		Maximum tolerated dose/toxicity	118	118																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Capivasertib + Olaparib		Active, not recruiting	NCT02208375		ECD	01-NOV-21	No	No		4	NCT02208375	Previously-treated		Maximum tolerated dose/toxicity	159	159																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Olaparib + Vistusertib		Active, not recruiting	NCT02208375		ECD	01-NOV-21	No	No		4	NCT02208375	Previously-treated		Maximum tolerated dose/toxicity	159	159																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Niraparib		Completed	NCT03551171		PCD	01-MAY-18	No	Yes	Primary outcome met	1	31439812			Maximum tolerated dose/toxicity	36	36																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Veliparib + doxorubicin hydrochloride liposome		Completed	NCT01145430		PCD	01-MAY-17	No	No		4	NCT01145430	Previously-treated		Maximum tolerated dose/toxicity	45	45																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Talazoparib		Not yet recruiting	NCT04598321	BrUOG 390	ECD	01-JUN-21	Yes	No		4	NCT04598321	Untreated		Clinical activity	30	30																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 1	Talazoparib		Active, not recruiting	NCT02316834	POSITION	ECD	01-FEB-21	No	No		4	NCT02316834			Unknown	30	30																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT02489006	NEO	ECD	01-JUN-21	No	No		4	NCT02489006			Unknown	71	71																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Avelumab + Talazoparib		Active, not recruiting	NCT03330405		ECD	01-AUG-21	Yes	No		4	NCT03330405			Overall Response Rate	216	216																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Senaparib		Recruiting	NCT04089189	SABRINA	ECD	01-MAR-22	Yes	No		4	NCT04089189			Overall Response Rate	100	100																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Fluzoparib		Active, not recruiting	NCT03509636		ECD	01-JUN-19	Yes	No		4	NCT03509636			Overall Response Rate	113	113																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel		Active, not recruiting	NCT03394885		ECD	01-JAN-21	Yes	No		4	NCT03394885			Maximum tolerated dose/toxicity	18	18																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Talazoparib + Temozolomide		Withdrawn	NCT02836028		PCD	01-JUN-20	No	No		4	NCT02836028			Overall Response Rate	0	0																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Bevacizumab + Carboplatin + Paclitaxel + Rucaparib 		Active, not recruiting	NCT03462212	MITO25	PCD	01-MAY-19	No	No		4	NCT03462212	Previously-treated		Progression free survival	234																																									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel + Rucaparib 		Active, not recruiting	NCT03462212	MITO25	PCD	01-MAY-19	No	No		4	NCT03462212	Previously-treated		Progression free survival	290																																									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Mirvetuximab Soravtansine + Rucaparib 		Recruiting	NCT03552471		ECD	01-AUG-21	No	No		4	NCT03552471			Maximum tolerated dose/toxicity	42	42																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Rucaparib  + Tremelimumab		Terminated	NCT03824704	ARIES	PCD	01-AUG-20	No	Yes	Slow accrual	4	NCT03824704			Overall Response Rate	1	1																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Olaparib + Trabectedin + doxorubicin hydrochloride liposome		Active, not recruiting	NCT03470805		ECD	01-JUN-21	No	No		4	NCT03470805	Previously-treated		Progression free survival	9	9																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Olaparib + Tremelimumab		Recruiting	NCT02571725		ECD	01-JUL-22	Yes	No		4	NCT02571725	Previously-treated		Overall Response Rate	50	50																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Olaparib + doxorubicin hydrochloride liposome		Recruiting	NCT03161132	ROLANDO	PCD	01-FEB-20	No	No		4	NCT03161132	Previously-treated		Progression free survival	32	32																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Durvalumab + Olaparib + Tremelimumab		Recruiting	NCT02953457		ECD	01-DEC-20	Yes	No		4	NCT02953457	Previously-treated		Progression free survival	36	36																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT01116648		PCD	01-OCT-18	Yes	Yes		2	10.1200/JCO.2017.35.15_suppl.5535	Previously-treated		Progression free survival	48	23	25	Olaparib									16.4	16.5	.75		0.42									44.2	40.1	.79	0.55													
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT01116648		PCD	01-OCT-18	No	Yes		2	10.1200/JCO.2017.35.15_suppl.5535	Previously-treated		Progression free survival	90	44	46	Olaparib									16.5	8.2	.5	0.30-0.83	0.007									44.2	33.3	.64	0.36-1.11													
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT02345265		PCD	01-MAY-20	No	Yes		2	10.1200/JCO.2018.36.15_suppl.5519	Previously-treated, platinum-resistant		Progression free survival	35	35			20		11-38		6														43										7									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Completed	NCT02340611	e-Volve	PCD	01-JUN-18	No	No		4	NCT02340611			Unknown	4	4																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Recruiting	NCT03117933	OCTOVA	ECD	01-MAR-21	No	No		4	NCT03117933	Previously-treated		Progression free survival	139	139																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT02889900	CONCERTO	PCD	01-AUG-19	No	Yes		2	10.1200/JCO.2020.38.15_suppl.6056			Overall Response Rate	60	60			15.3		7.2-27.0		8.3		5.6-10.30		5.1			3.5-5.5										13.2			9.4-16.4													
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT02345265		PCD	01-MAY-20	No	Yes		2	10.1200/JCO.2018.36.15_suppl.5519	Previously-treated, platinum-sensitive		Progression free survival	35	35			77		63-88																91									3	24									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Bevacizumab + Chemotherapy + Niraparib		Active, not recruiting	NCT03326193	OVARIO	ECD	01-DEC-20	No	Yes		4	NCT03326193	Previously-treated		Progression free survival	105	105																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Topotecan + Veliparib		Completed	NCT01012817		PCD	01-JAN-15	No	Yes		1	30104007	Previously-treated		Response rate	10	10																																7								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Topotecan + Veliparib		Completed	NCT01690598		PCD	01-JAN-15	No	No		4	NCT01690598	Previously-treated		Maximum tolerated dose/toxicity	22	22																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Adavosertib + Olaparib		Recruiting	NCT03579316	EFFORT	ECD	01-OCT-22	No	No		4	NCT03579316			Overall Response Rate	88	88																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Niraparib		Active, not recruiting	NCT03759587		PCD	01-MAR-19	No	Yes	Primary outcome met	1	33470063	Previously-treated		Maximum tolerated dose/toxicity	10	10																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Niraparib		Completed	NCT03759600		PCD	01-JUL-19	No	Yes		4	NCT03759600	Previously-treated		Overall Response Rate	13	13			35																		90																			
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Cyclophosphamide + Veliparib		Completed	NCT01306032		PCD	01-DEC-14	Yes	Yes	No benefit of treatment	4	NCT01306032	Previously-treated		Progression free survival	70	34	36	Cyclophosphamide	11.8	19.4																																				
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Rucaparib 		Completed	NCT00664781		PCD	01-JAN-15	Yes	Yes		1	27002934			Defined % decrease in tumour volume	16	16																														1	2	12								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Talazoparib		Terminated	NCT02326844		PCD	01-APR-16	Yes	Yes	Study was closed by the Cancer Therapy Evaluation Program (CTEP)	4	NCT02326844			Overall Response Rate	3	3																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Talazoparib		Unknown	NCT02836028		ECD	01-JUN-20	No	No		4	NCT02836028			Overall Response Rate	0	0																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Veliparib		Completed	NCT01472783		PCD	01-JAN-16	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.5532	Previously-treated		Response rate	32	32			65.7																											2	19									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Veliparib		Completed	NCT01540565		PCD	01-JAN-18	Yes	Yes		4	NCT01540565	Previously-treated		Maximum tolerated dose/toxicity	50	50			26								8.18																													
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT04377087		ECD	01-OCT-23	No	No		4	NCT04377087			Unknown	75	75																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Olaparib		Active, not recruiting	NCT01078662		PCD	01-JUL-12	Yes	Yes		4	NCT01078662			Overall Response Rate	193	193			35.9		28.7-43.7						7.03			3.65-11.24																										
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Olaparib		Active, not recruiting	NCT00679783		PCD	01-MAR-10	Yes	Yes		1	21862407	Previously-treated		Overall Response Rate	10	10																															4	5								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 2	Olaparib		Active, not recruiting	NCT02983799		ECD	01-AUG-20	No	No		4	NCT02983799	Previously-treated		Overall Response Rate	272	272																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Olaparib		Active, not recruiting	NCT02282020	SOLO3	PCD	01-OCT-18	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.5506	Previously-treated		Overall Response Rate	178	76			72	51	1.4-4.6	0.002					13.4	9.2	.62	0.43-0.91	0.013																									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Rucaparib  + Tremelimumab		Active, not recruiting	NCT03522246	ATHENA	ECD	01-DEC-24	No	No		4	NCT03522246	Previously-treated		Progression free survival	1012	1012																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Bevacizumab + Chemotherapy + Durvalumab + Olaparib		Recruiting	NCT03737643	DUO-O	ECD	01-JUN-23	No	No		4	NCT03737643	Untreated		Progression free survival	1374			Placebo																																						
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Cediranib maleate + Olaparib		Recruiting	NCT02502266	COCOS	ECD	01-JUN-23	No	No		4	NCT02502266	Previously-treated		Progression free survival	680			Chemotherapy																																						
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Cediranib maleate + Olaparib		Active, not recruiting	NCT02446600		PCD	01-FEB-20	No	Yes	Primary outcome not met	2	10.1200/JCO.2020.38.15_suppl.6003	Previously-treated		Progression free survival	376	189	187	Chemotherapy	69.4	71.3							10.4	10.3	.856	0.66-1.11	0.08																									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Cediranib maleate + Olaparib		Recruiting	NCT03278717	ICON9	ECD	01-DEC-23	No	No		4	NCT03278717	Previously-treated		Progression free survival	618			Olaparib																																						
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Bevacizumab + Niraparib + TSR042		Not yet recruiting	NCT03806049		ECD	01-JUN-22	No	No		4	NCT03806049	Previously-treated		Progression free survival	337			Bevacizumab + Niraparib																																						
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Rucaparib 		Recruiting	NCT02855944	ARIEL4	ECD	01-JUN-22	Yes	No		4	NCT02855944	Previously-treated		Progression free survival	345			Chemotherapy																																						
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Olaparib		Active, not recruiting	NCT02446600		PCD	01-FEB-20	No	Yes		2	10.1200/JCO.2020.38.15_suppl.6003	Previously-treated		Progression free survival	579	189	187	Chemotherapy	52.4	71.3							8.2	10.3	1.2	0.93-1.54																										
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Olaparib		Active, not recruiting	NCT03286842	LUCY	ECD	01-JUN-21	Yes	No		4	NCT03286842			Progression free survival	256																																									
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Olaparib		Active, not recruiting	NCT03402841	OPINION	PCD	01-OCT-20	Yes	No		4	NCT03402841	Previously-treated		Progression free survival	279	279																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 3	Olaparib		Active, not recruiting	NCT03286842	LUCY	ECD	01-JUN-21	Yes	Yes		2	10.1200/JCO.2020.38.15_suppl.1087			Progression free survival	95	95											6.8			5.9-8.3																										
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 4	Olaparib		Not yet recruiting	NCT04330040	SOLI	ECD	01-DEC-21	Yes	No		4	NCT04330040	Previously-treated		Maximum tolerated dose/toxicity	200	200																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / NS	1	Phase 4	Chemotherapy + Olaparib		Active, not recruiting	NCT02476968	ORZORA	PCD	01-APR-20	Yes	No		4	NCT02476968	Previously-treated		Progression free survival	178	178																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / carcinosarcoma	3	Phase 2	Pamiparib		Recruiting	NCT03933761	PRECISE	ECD	01-AUG-25	Yes	No		4	NCT03933761			Disease control rate, Clinical benefit rate	40	40																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 2	Olaparib + Tremelimumab		Suspended	NCT04034927		ECD	01-DEC-22	Yes	No		4	NCT04034927	Previously-treated		Progression free survival	170	170																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 2	Carboplatin + Olaparib + Paclitaxel		Recruiting	NCT04261465	NUVOLA	ECD	01-OCT-20	Yes	No		4	NCT04261465			Complete response, Pathological complete response	35	35																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 2	Ceralasertib + Olaparib		Recruiting	NCT02264678		ECD	01-JAN-24	Yes	No		4	NCT02264678			Maximum tolerated dose/toxicity	117	117																																								
BRCA1	BRCA1_unspecified				ovary / carcinoma / serous carcinoma	3	Phase 2	Pamiparib		Recruiting	NCT03933761	PRECISE	ECD	01-AUG-25	Yes	No		4	NCT03933761			Disease control rate, Clinical benefit rate	40	40																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT02184195	POLO	PCD	01-JAN-19	Yes	Yes		1	31157963			Progression free survival	154	92	62	Placebo									7.4	3.8	.53	0.35-0.82	0.004									18.9	18.1	.91	0.56-1.46	0.68												
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 1	Cisplatin + Gemcitabine + Veliparib		Terminated	NCT01282333		PCD	01-FEB-13	No	No		4	NCT01282333			Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 1	Fluorouracil + Irinotecan hydrochloride liposome + Leucovorin calcium + Rucaparib 		Recruiting	NCT03337087		ECD	01-AUG-21	Yes	No		4	NCT03337087			Overall Response Rate	110	110																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Veliparib		Active, not recruiting	NCT01585805		ECD	01-DEC-21	Yes	No		4	NCT01585805	Previously-treated		Response rate	107	107																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Epacadostat + Pembrolizumab		Withdrawn	NCT03432676		ECD	01-APR-20	Yes	No		4	NCT03432676			Overall Response Rate	0	0																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Dostarlimab + Niraparib		Not yet recruiting	NCT04493060		ECD	01-SEP-22	Yes	No		4	NCT04493060			Disease control rate, Clinical benefit rate	20	20																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Ascorbic acid + Autologous Hematopoietic Stem Cell Transplantation + Carmustine + Ethanol + Melphalan + Vitamin B12B		Not yet recruiting	NCT04150042		ECD	01-FEB-22	Yes	No		4	NCT04150042			Maximum tolerated dose/toxicity	10	10																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04548752		ECD	01-MAR-25	Yes	No		4	NCT04548752			Progression free survival	88			Olaparib																																						
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Avelumab + Binimetinib + Talazoparib		Terminated	NCT03637491		ECD	01-NOV-23	No	Yes	Lack of efficacy	4	NCT03637491			Overall Response Rate	36	36																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Cisplatin + Irinotecan + Mitomycin C + Olaparib		Completed	NCT01296763		PCD	01-JAN-14	No	Yes	Serious adverse events, no benefit of treatment	1	28454122			Maximum tolerated dose/toxicity	18	18			27																																					
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	FOLFOX-6 + Veliparib		Active, not recruiting	NCT01489865		ECD	01-DEC-20	No	No		4	NCT01489865			Maximum tolerated dose/toxicity	64	64																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	FOLFIRI + Veliparib		Active, not recruiting	NCT02890355		PCD	01-MAY-19	No	Yes		4	NCT02890355			Overall survival	107	59	58	FOLFIRI																						5.4	6.5	1.23	0.85-1.781	0.28												
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Cisplatin + Gemcitabine + Veliparib		Active, not recruiting	NCT01585805		ECD	01-DEC-21	Yes	No		4	NCT01585805	Previously-treated		Response rate	107	107																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Olaparib + Selumetinib		Active, not recruiting	NCT02677038		ECD	01-NOV-21	No	No		4	NCT02677038			Overall Response Rate	34	34																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Olaparib + Selumetinib		Unknown	NCT02511223		ECD	01-SEP-17	No	No		4	NCT02511223			Overall Response Rate	24	24																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT03553004	NIRA-PANC	ECD	01-JUN-21	No	No		4	NCT03553004			Overall Response Rate	18	18																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT03601923		ECD	01-FEB-22	Yes	No		4	NCT03601923			Progression free survival	32	32																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Rucaparib 		Active, not recruiting	NCT03140670		ECD	01-JUN-21	Yes	No		4	NCT03140670			Number of adverse events	50	50																																								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Rucaparib 		Completed	NCT02042378	RUCAPANC	PCD	01-APR-16	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.4110			Overall Response Rate	19	19			11																		32									1	1	4								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / NS	1	Phase 2	Veliparib		Unknown					Yes	Yes		1	29223478	Previously-treated		Unknown	11	11											1.7			1.57-1.83										3.1			1.9-4.1					4								
BRCA1	BRCA1_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort A	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Olaparib	Usage dependent	Suspended					No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558s009lbl.pdf	Previously-treated		Clinical activity	137	137							7.9		5.6-9.6																					3	44									
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Bevacizumab + Chemotherapy + Olaparib		Active, not recruiting	NCT02477644	PAOLA-1	PCD	01-MAR-19	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf?utm_source=Salesforce%20Marketing%20Cloud&utm_medium=Email&utm_campaign=&sfmc_s=0031I000016IMUlQAO			Progression free survival	806			Placebo																																						
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Niraparib	Not required	Active, not recruiting	NCT01847274	NOVA	PCD	01-JUN-16	Yes	Yes		4	NCT01847274	Previously-treated		Progression free survival	203	138	65	Placebo									21	5.5	.27	0.17-0.41	<0.0001																									
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Rucaparib 	Usage dependent	Active, not recruiting					Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf	Previously-treated		Overall Response Rate	106	106			54																																					
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Rucaparib 	Usage dependent	Active, not recruiting	NCT01968213	ARIEL3	PCD	01-APR-17	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf	Previously-treated		Progression free survival	564	375	189										10.8	5.4	.36	0.3-0.45	<0.0001																									
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Olaparib	Usage dependent	Active, not recruiting	NCT03534453	Study 19	ECD	01-DEC-21	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558s009lbl.pdf	Previously-treated		Progression free survival	265	136	129	Placebo									8.4	4.8	.35	0.25-0.49	<0.0001									29.8	27.8	.73	0.55-0.95													
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Olaparib	Usage dependent	Active, not recruiting	NCT01874353	SOLO-2	PCD	01-SEP-16	Yes	Yes		1	28754483	Previously-treated		Progression free survival	327	196	99	Placebo									19.1	5.5	.3	0.22-0.41	<0.0001																									
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Olaparib	Usage dependent	Active, not recruiting	NCT01844986	SOLO-1	PCD	01-MAY-18	Yes	Yes		4	NCT01844986	Previously-treated		Progression free survival	450	260	131	Placebo										13.8	.3	0.23-0.41	<0.0001																									
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 1	Talazoparib		Active, not recruiting	NCT02316834	POSITION	ECD	01-FEB-21	No	No		4	NCT02316834			Unknown	30	30																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 1	Bevacizumab + Cisplatin + Olaparib + Paclitaxel		Active, not recruiting	NCT02121990		PCD	01-AUG-20	No	No		4	NCT02121990	Untreated		Maximum tolerated dose/toxicity	17	17																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 1	Copanlisib + Niraparib		Recruiting	NCT03586661		ECD	01-APR-21	No	No		4	NCT03586661	Previously-treated		Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 1	Floxuridine + Veliparib		Active, not recruiting	NCT01749397		PCD	01-OCT-17	No	No		4	NCT01749397			Maximum tolerated dose/toxicity	29	29																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 1	Bevacizumab + Carboplatin + Veliparib + doxorubicin hydrochloride liposome		Completed	NCT01459380		PCD	01-JUN-16	No	No		4	NCT01459380	Previously-treated		Maximum tolerated dose/toxicity	41	41																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 1	Bevacizumab + Carboplatin + Paclitaxel + Veliparib		Active, not recruiting	NCT00989651		PCD	01-SEP-16	No	No		4	NCT00989651	Untreated		Maximum tolerated dose/toxicity	431	431																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 1	Onalespib lactate + Talazoparib		Withdrawn	NCT02627430		ECD	01-MAR-19	No	No		4	NCT02627430			Unknown	0	0																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 1	Capivasertib + Olaparib		Active, not recruiting	NCT02208375		ECD	01-NOV-21	No	No		4	NCT02208375	Previously-treated		Maximum tolerated dose/toxicity	159	159																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 1	Olaparib + Vistusertib		Active, not recruiting	NCT02208375		ECD	01-NOV-21	No	No		4	NCT02208375	Previously-treated		Maximum tolerated dose/toxicity	159	159																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 1	Niraparib		Completed	NCT03551171		PCD	01-MAR-18	No	Yes	Primary outcome met	1	31439812			Maximum tolerated dose/toxicity	36	36																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT02489006	NEO	ECD	01-JUN-21	No	No		4	NCT02489006			Unknown	71	71																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Nivolumab + Rucaparib 		Terminated	NCT03824704	ARIES	PCD	01-AUG-20	No	Yes	Slow accrual	4	NCT03824704			Overall Response Rate	1	1																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Talazoparib + Temozolomide		Unknown	NCT02836028		ECD	01-JUN-20	No	No		4	NCT02836028			Overall Response Rate	0	0																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Bevacizumab + Carboplatin + Paclitaxel + Rucaparib 		Active, not recruiting	NCT03462212	MITO25	PCD	01-MAY-19	No	No		4	NCT03462212	Previously-treated		Progression free survival	290																																									
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel + Rucaparib 		Active, not recruiting	NCT03462212	MITO25	PCD	01-MAY-19	No	No		4	NCT03462212	Previously-treated		Progression free survival	290																																									
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Mirvetuximab Soravtansine + Rucaparib 		Recruiting	NCT03552471		ECD	01-AUG-21	No	No		4	NCT03552471			Maximum tolerated dose/toxicity	42	42																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Olaparib + doxorubicin hydrochloride liposome		Recruiting	NCT03161132	ROLANDO	PCD	01-FEB-20	No	No		4	NCT03161132	Previously-treated		Progression free survival	32	32																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Durvalumab + Olaparib + Tremelimumab		Recruiting	NCT02953457		ECD	01-DEC-20	Yes	No		4	NCT02953457	Previously-treated		Progression free survival	36	36																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT01116648		PCD	01-OCT-18	No	No		4	NCT01116648	Previously-treated		Progression free survival	155			Olaparib																																						
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT02889900	CONCERTO	PCD	01-AUG-19	No	No		4	NCT02889900			Overall Response Rate	62	62																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT02345265		PCD	01-MAY-20	No	No		4	NCT02345265	Previously-treated		Progression free survival	72	72																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Bevacizumab + Chemotherapy + Niraparib		Active, not recruiting	NCT03326193	OVARIO	ECD	01-DEC-20	No	No		4	NCT03326193	Previously-treated		Progression free survival	105	105																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Topotecan + Veliparib		Completed	NCT01012817		PCD	01-JAN-15	No	Yes		1	30104007	Previously-treated		Response rate	10	10																																7								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Niraparib		Active, not recruiting	NCT03759587		PCD	01-MAR-19	No	Yes	Primary outcome met	1	33470063	Previously-treated		Maximum tolerated dose/toxicity	5	5																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Niraparib		Completed	NCT03759600		PCD	01-JUL-19	No	Yes		4	NCT03759600	Previously-treated		Overall Response Rate	5	5			35																																					
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Cyclophosphamide + Veliparib		Completed	NCT01306032		PCD	01-DEC-14	Yes	Yes	No benefit of treatment	1	25589624	Previously-treated		Progression free survival	4	4																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Talazoparib		Unknown	NCT02836028		ECD	01-JUN-20	No	No		4	NCT02836028			Overall Response Rate	0	0																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Veliparib		Completed	NCT01540565		PCD	01-JAN-18	Yes	Yes		4	NCT01540565	Previously-treated		Maximum tolerated dose/toxicity	50	50			26									8.18																												
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 2	Olaparib		Active, not recruiting	NCT02983799		ECD	01-MAY-20	No	No		4	NCT02983799	Previously-treated		Overall Response Rate	272	272																																								
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 3	Olaparib		Active, not recruiting	NCT02446600		PCD	01-FEB-20	No	No		4	NCT02446600	Previously-treated		Progression free survival	579			Chemotherapy																																						
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 3	Cediranib maleate + Olaparib		Active, not recruiting	NCT02446600		PCD	01-FEB-20	No	No		4	NCT02446600	Previously-treated		Progression free survival	579			Chemotherapy																																						
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 3	Cediranib maleate + Olaparib		Recruiting	NCT02502266	COCOS	ECD	01-JUN-23	No	No		4	NCT02502266	Previously-treated		Progression free survival	680																																									
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 3	Atezolizumab + Chemotherapy + Niraparib		Recruiting	NCT03598270	ANITA	ECD	01-NOV-23	No	No		4	NCT03598270	Previously-treated		Progression free survival	414			Chemotherapy																																						
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 3	Chemotherapy + Niraparib		Recruiting	NCT03598270	ANITA	ECD	01-NOV-23	No	No		4	NCT03598270	Previously-treated		Progression free survival	414			Chemotherapy																																						
BRCA1	BRCA1_unspecified				peritoneum / carcinoma / NS	1	Phase 3	Rucaparib 		Recruiting	NCT02855944	ARIEL4	ECD	01-JUN-22	Yes	No		4	NCT02855944	Previously-treated		Progression free survival	345			Chemotherapy																																						
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf	Previously-treated		Progression free survival	245	162	83	Enzalutamide	28	1		<0.0001					7.4	3.6	.34	0.25-0.47	<0.0001									19.1	14.7	.69	0.5-0.97	0.0175												
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 1	Niraparib + Radium Ra 223 dichloride 		Recruiting	NCT03076203		ECD	01-NOV-20	No	No		4	NCT03076203			Maximum tolerated dose/toxicity	14	14																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Terminated	NCT03570476		PCD	01-MAY-19	No	Yes	Slow accrual	4	NCT03570476			Complete response, Pathological complete response	15	15																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Abiraterone acetate + Prednisone		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Abiraterone acetate + Olaparib + Prednisone		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	SC10914		Recruiting	NCT04486937		ECD	01-DEC-21	Yes	No		4	NCT04486937	Previously-treated		Overall Response Rate	90	90																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Afuresertib + LAE001 + Prednisone		Recruiting	NCT04060394		ECD	01-SEP-21	Yes	No		4	NCT04060394	Previously-treated		Progression free survival	74	74																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Nivolumab		Recruiting	NCT03040791		ECD	01-JAN-21	No	No		4	NCT03040791			Prostate Specific Antigen (PSA) response rate 	29	29																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Carboplatin + Docetaxel + Rucaparib 		Recruiting	NCT03442556	PLATI-PARP	ECD	01-MAY-25	No	No		4	NCT03442556	Previously-treated		Progression free survival	20	20																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib + Radium Ra 223 dichloride 		Recruiting	NCT03317392	COMRADE	ECD	01-NOV-21	No	No		4	NCT03317392	Previously-treated		Progression free survival	120	120																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib + Testosterone		Recruiting	NCT03516812		ECD	01-MAR-21	No	No		4	NCT03516812			Prostate Specific Antigen (PSA) response rate 	30	30																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Docetaxel + Olaparib		Active, not recruiting	NCT03434158	IMANOL	ECD	01-FEB-22	No	No		4	NCT03434158			Progression free survival	16	16																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Cabazitaxel + Carboplatin + Olaparib		Active, not recruiting	NCT03263650		ECD	01-OCT-20	No	No		4	NCT03263650			Progression free survival	123	123																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Active, not recruiting	NCT02893917		ECD	01-DEC-20	No	No		4	NCT02893917			Progression free survival	90	90																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Durvalumab + Olaparib		Recruiting	NCT03810105		ECD	01-FEB-22	No	No		4	NCT03810105			Prostate Specific Antigen (PSA) response rate 	32	32																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Rucaparib 		Recruiting	NCT03533946	ROAR	ECD	01-JUL-23	Yes	No		4	NCT03533946	Previously-treated		Prostate Specific Antigen (PSA) response rate 	32	32																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Rucaparib 		Recruiting	NCT03413995	TRIUMPH	ECD	01-MAY-21	No	No		4	NCT03413995			Prostate Specific Antigen (PSA) response rate 	30	30																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Rucaparib 		Recruiting	NCT02952534	TRITON2	ECD	01-SEP-20	No	No		4	NCT02952534	Previously-treated		Overall Response Rate	360	360																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Talazoparib		Active, not recruiting	NCT03148795	TALAPRO-1	PCD	01-APR-20	Yes	Yes		2	10.1200/JCO.2020.38.6_suppl.119	Previously-treated		Overall Response Rate	20	20				50.0							8.2																													
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT04038502	COBRA	ECD	01-AUG-24	Yes	No		4	NCT04038502			Progression free survival	100	100																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT03432897	BrUOG 337	ECD	01-SEP-19	No	No		4	NCT03432897			Prostate Specific Antigen (PSA) response rate 	13	13																																								
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 3	Rucaparib 		Recruiting	NCT02975934	TRITON3	ECD	01-FEB-22	No	No		4	NCT02975934	Previously-treated		Progression free survival	400			Best supportive care																																						
BRCA1	BRCA1_unspecified				prostate / carcinoma / NS	1	Phase 3	Abiraterone acetate + Olaparib		Recruiting	NCT03732820	PROpel	ECD	01-APR-21	No	No		4	NCT03732820			Progression free survival	904			Abiraterone acetate + Placebo																																						
BRCA1	BRCA1_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Olaparib		Completed	NCT02882308	OPHELIA	PCD	01-DEC-19	No	No		4	NCT02882308			Change in Ki-67 expression	41	41																																								
BRCA1	BRCA1_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Cisplatin + Olaparib		Recruiting	NCT02882308	OPHELIA	ECD	01-OCT-19	No	No		4	NCT02882308			Change in Ki-67 expression	41	41																																								
BRCA1	BRCA1_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 3	Durvalumab + Olaparib		Recruiting	NCT02882308	OPHELIA	ECD	01-OCT-19	No	No		4	NCT02882308			Change in Ki-67 expression	41	41																																								
BRCA1	BRCA1_unspecified				urinary tract / carcinoma / NS	3	Phase 1	Durvalumab + Olaparib		Active, not recruiting	NCT02546661	BISCAY module B	PCD	01-MAR-20	Yes	Yes	Primary outcome not met	3	https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-bladder-cancer/115221-esmo-2019-biscay-an-adaptive-biomarker-directed-platform-study-in-metastatic-urothelial-cancer-with-durvalumab-in-combination-with-targeted-therapies.html	Previously-treated		Maximum tolerated dose/toxicity	14	14			37.5																																					
BRCA1	BRCA1_unspecified				urinary tract / papilloma / typical	3	Phase 1	Cisplatin + Gemcitabine + Veliparib		Terminated	NCT01282333		PCD	01-FEB-13	No	No		4	NCT01282333			Maximum tolerated dose/toxicity	44	44																																								
BRCA1	BRCA1_unspecified				urinary tract / papilloma / typical	3	Phase 2	Olaparib		Recruiting	NCT03375307		ECD	01-AUG-23	Yes	No		4	NCT03375307			Overall Response Rate	150	150																																								
BRCA1	BRCA1_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
BRCA1	BRCA1_unspecified				urinary tract / papilloma / typical	3	Phase 2	Niraparib		Recruiting	NCT03945084		ECD	01-DEC-21	Yes	No		4	NCT03945084			Progression free survival	77	77																																								
BRCA1	BRCA1_unspecified				urinary tract / papilloma / typical	3	Phase 2	Olaparib		Recruiting	NCT03448718		ECD	01-MAR-22	Yes	No		4	NCT03448718			Overall Response Rate	30	30																																								
BRCA2	BRCA2_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
BRCA2	BRCA2_unspecified				NS / malignant melanoma / NS	3	Phase 2	Nivolumab + Talazoparib		Recruiting	NCT04187833		ECD	01-JAN-24	Yes	No		4	NCT04187833			Best overall response	37	37																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 1	Olaparib		Completed	NCT03155620	Subprotocol H	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 1	SC10914		Unknown	NCT02940132		ECD	01-MAR-18	Yes	No		4	NCT02940132			Maximum tolerated dose/toxicity	72	72																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 1	Cellectra 2000 + INO5401 + INO9012		Not yet recruiting	NCT04367675		ECD	01-DEC-25	Yes	No		4	NCT04367675			Maximum tolerated dose/toxicity	44	44																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 1	Cellectra 2000 + INO5401		Not yet recruiting	NCT04367675		ECD	01-DEC-25	Yes	No		4	NCT04367675			Maximum tolerated dose/toxicity	44	44																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 1	Radiotherapy + Talazoparib		Recruiting	NCT03968406		ECD	01-OCT-21	No	No		4	NCT03968406			Maximum tolerated dose/toxicity	24	24																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 1	HWH340		Recruiting	NCT03415659		ECD	01-MAR-21	Yes	No		4	NCT03415659			Maximum tolerated dose/toxicity	85	85																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Avelumab + Talazoparib		Active, not recruiting	NCT03565991		ECD	01-MAR-21	Yes	No		4	NCT03565991			Overall Response Rate	202	202																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Avelumab + Talazoparib		Active, not recruiting	NCT03330405		ECD	01-AUG-21	Yes	No		4	NCT03330405			Overall Response Rate	216	216																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Bevacizumab + Durvalumab + Olaparib		Active, not recruiting	NCT02734004	MEDIOLA	ECD	01-AUG-22	Yes	No		4	NCT02734004			Overall Response Rate	427	427																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Niraparib + Sintilimab		Not yet recruiting	NCT04423185		ECD	01-JUL-22	Yes	No		4	NCT04423185			Overall Response Rate	770	770																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Adavosertib		Recruiting	NCT02465060	MATCH Subprotocol Z1I	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Adavosertib		Active, not recruiting	NCT04439227	MATCH-Subprotocol Z1I	ECD	01-APR-21	Yes	No		4	NCT04439227			Overall Response Rate	35	35																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Durvalumab + Olaparib		Active, not recruiting	NCT02734004	MEDIOLA	ECD	01-AUG-22	Yes	No		4	NCT02734004			Overall Response Rate	427	427																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Niraparib		Not yet recruiting	NCT04423185		ECD	01-JUL-22	Yes	No		4	NCT04423185			Overall Response Rate	770	770																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Rucaparib 		Recruiting	NCT04171700	LODESTAR	ECD	01-NOV-21	Yes	No		4	NCT04171700			Best overall response	220	220																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Talazoparib		Recruiting	NCT02693535	TAPUR group 19	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Talazoparib		Recruiting	NCT02286687		ECD	01-DEC-20	Yes	No		4	NCT02286687			Disease control rate, Clinical benefit rate	150	150																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Olaparib		Recruiting	NCT02693535	TAPUR group 14	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Olaparib		Recruiting	NCT03967938	1-2018 BSMO	ECD	01-DEC-23	Yes	No		4	NCT03967938			Overall Response Rate	540	540																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Olaparib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
BRCA2	BRCA2_unspecified				NS / other / neoplasm	3	Phase 2	Olaparib		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
BRCA2	BRCA2_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT02000622	OlympiAD	PCD	01-DEC-16	Yes	Yes		1	28578601			Progression free survival	302	205	97	Chemotherapy	59.9	28.8							7	4.2	.58	0.43-0.80	<0.001									19.3	17.1	.9														
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Paclitaxel		Not yet recruiting	NCT04499118		ECD	01-AUG-21	No	No		4	NCT04499118			Complete response, Pathological complete response	100	100																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	M4344 + Niraparib		Not yet recruiting	NCT04655183		ECD	01-SEP-23	Yes	No		4	NCT04655183			Overall Response Rate	164	164																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Adavosertib + Ceralasertib + Olaparib		Active, not recruiting	NCT03330847	VIOLETTE	ECD	01-SEP-21	Yes	No		4	NCT03330847			Progression free survival	268	268																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Famitinb + Fluzoparib		Recruiting	NCT03805399	FUTURE	ECD	01-JAN-22	Yes	No		4	NCT03805399			Overall Response Rate	140	140																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	SC10914		Recruiting	NCT04556292		ECD	01-MAR-22	Yes	No		4	NCT04556292			Overall Response Rate	78	78																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Aromatase inhibitors + Niraparib		Recruiting	NCT04240106	LUZERN	ECD	01-SEP-21	No	No		4	NCT04240106			Disease control rate, Clinical benefit rate	23	23																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Docetaxel + Epirubicin hydrochloride		Not yet recruiting	NCT04499118		ECD	01-AUG-21	No	No		4	NCT04499118			Complete response, Pathological complete response	100	100																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Docetaxel + doxorubicin hydrochloride		Not yet recruiting	NCT04499118		ECD	01-AUG-21	No	No		4	NCT04499118			Complete response, Pathological complete response	100	100																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Dostarlimab + Niraparib		Recruiting	NCT04584255		ECD	01-JUL-24	Yes	No		4	NCT04584255			Complete response, Pathological complete response	62	62																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Niraparib + Trastuzumab		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	HX008		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Durvalumab + Fulvestrant + Olaparib		Recruiting	NCT04053322	DOLAF	ECD	01-MAR-22	Yes	No		4	NCT04053322			Progression free survival	158	158																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib + Trastuzumab		Recruiting	NCT03931551	OPHELIA	ECD	01-SEP-22	Yes	No		4	NCT03931551			OS, PFS	20	20																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Pamiparib		Recruiting	NCT03575065		PCD	01-OCT-20	Yes	No		4	NCT03575065			Overall Response Rate	88	88																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT03025035		ECD	01-NOV-23	Yes	No		4	NCT03025035			Overall Response Rate	20	20																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Ceralasertib + Olaparib		Recruiting	NCT02264678		ECD	01-JAN-24	Yes	No		4	NCT02264678			Maximum tolerated dose/toxicity	117	117																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Cediranib maleate + Olaparib		Recruiting	NCT04090567		ECD	01-JUL-21	Yes	No		4	NCT04090567			Overall Response Rate	60	60																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Talazoparib		Recruiting	NCT03990896		ECD	01-JUL-22	Yes	No		4	NCT03990896			Progression free survival	30	30																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Talazoparib		Terminated	NCT03499353		PCD	01-SEP-20	Yes	Yes	Changed business priorities	4	NCT03499353			Complete response, Pathological complete response	61	61																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 2	Olaparib		Active, not recruiting	NCT00679783		PCD	01-MAR-10	Yes	Yes		1	21862407	Previously-treated		Overall Response Rate	5	5																																3								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Olaparib		Active, not recruiting	NCT03286842	LUCY	ECD	01-JUN-21	Yes	Yes		2	10.1200/JCO.2020.38.15_suppl.1087				63	63											8.5			7.6-11.0																										
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	01-JUN-23	Yes	No		4	NCT04335669			Complete response, Pathological complete response	820	820																																								
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Apatinib + Fluzoparib		Recruiting	NCT04296370		ECD	01-JUN-22	Yes	No		4	NCT04296370			Progression free survival	474			Fluzoparib																																						
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Carboplatin + Paclitaxel + Veliparib		Active, not recruiting	NCT02163694	BROCADE3	PCD	01-APR-19	Yes	Yes		1	32861273			Progression free survival	253	167	86	Carboplatin + Paclitaxel									14.7	12.6	.66	0.48-0.89																										
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 3	Carboplatin + Paclitaxel + Veliparib		Active, not recruiting	NCT00989261	ACE - Cohort 2	PCD	01-SEP-12	Yes	Yes		1	32861273				136	136																														62	39									
BRCA2	BRCA2_unspecified				breast / carcinoma / NS	1	Phase 4	Choriogonadotropin alfa		Completed	NCT03495609		PCD	01-DEC-18	No	No		4	NCT03495609			Altered genomic signature	33	33																																								
BRCA2	BRCA2_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Olaparib	Usage dependent	Active, not recruiting	NCT01844986	SOLO-1	PCD	01-MAY-18	Yes	Yes		4	NCT01844986	Previously-treated		Progression free survival	450	260	131	Placebo										13.8	.3	0.23-0.41	<0.0001																									
BRCA2	BRCA2_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Bevacizumab + Chemotherapy + Olaparib		Active, not recruiting	NCT02477644	PAOLA-1	PCD	01-MAR-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf?utm_source=Salesforce%20Marketing%20Cloud&utm_medium=Email&utm_campaign=&sfmc_s=0031I000016IMUlQAO			Progression free survival	806	537	269	Bevacizumab + Placebo									37.2	17.7	.33	0.25-0.45																										
BRCA2	BRCA2_unspecified				fallopian tube / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT01874353	SOLO-2	PCD	01-SEP-16	Yes	Yes		1	28754483	Previously-treated		Progression free survival	327	196	99	Placebo									19.1	5.5	.3	0.22-0.41	<0.0001																									
BRCA2	BRCA2_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
BRCA2	BRCA2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
BRCA2	BRCA2_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03009682	SUKSES-B	ECD	01-SEP-21	Yes	No		4	NCT03009682			Overall Response Rate	28	28																																								
BRCA2	BRCA2_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Talazoparib		Active, not recruiting	NCT03377556		ECD	01-MAY-22	Yes	No		4	NCT03377556			Overall Response Rate	64	64																																								
BRCA2	BRCA2_unspecified				ovary / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT01844986	SOLO-1	PCD	01-MAY-18	Yes	Yes		4	NCT01844986	Previously-treated		Progression free survival	450	260	131	Placebo										13.8	.3	0.23-0.41	<0.0001																									
BRCA2	BRCA2_unspecified				ovary / carcinoma / NS	1	Approved FDA	Bevacizumab + Chemotherapy + Olaparib	Required	Active, not recruiting	NCT02477644	PAOLA-1	PCD	01-MAR-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf?utm_source=Salesforce%20Marketing%20Cloud&utm_medium=Email&utm_campaign=&sfmc_s=0031I000016IMUlQAO			Progression free survival	806	537	269	Bevacizumab + Placebo									37.2	17.7	.33	0.25-0.45																										
BRCA2	BRCA2_unspecified				ovary / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT00753545	Study 19	PCD	01-JUN-10	No	Yes		4	NCT00753545	Previously-treated		Progression free survival	265	136	139	Placebo									8.4	4.8	.35	0.25-0.49	<0.00001																									
BRCA2	BRCA2_unspecified				ovary / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT01874353	SOLO-2	PCD	01-SEP-16	Yes	Yes		1	28754483	Previously-treated		Progression free survival	327	196	99	Placebo									19.1	5.5	.3	0.22-0.41	<0.0001																									
BRCA2	BRCA2_unspecified				ovary / carcinoma / NS	1	Phase 1	Talazoparib		Not yet recruiting	NCT04598321	BrUOG 390	ECD	01-JUN-21	Yes	No		4	NCT04598321	Untreated		Clinical activity	30	30																																								
BRCA2	BRCA2_unspecified				ovary / carcinoma / NS	1	Phase 2	Olaparib		Active, not recruiting	NCT00679783		PCD	01-MAR-10	Yes	Yes		1	21862407			Overall Response Rate	5	5																															3	1								
BRCA2	BRCA2_unspecified				ovary / carcinoma / NS	1	Phase 2	Avelumab + Talazoparib		Active, not recruiting	NCT03330405		ECD	01-AUG-21	Yes	No		4	NCT03330405			Overall Response Rate	216	216																																								
BRCA2	BRCA2_unspecified				ovary / carcinoma / NS	1	Phase 2	Senaparib		Recruiting	NCT04089189	SABRINA	ECD	01-MAR-22	Yes	No		4	NCT04089189			Overall Response Rate	100	100																																								
BRCA2	BRCA2_unspecified				ovary / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT04377087		ECD	01-OCT-23	No	No		4	NCT04377087			Unknown	75	75																																								
BRCA2	BRCA2_unspecified				ovary / carcinoma / NS	1	Phase 4	Olaparib		Not yet recruiting	NCT04330040	SOLI	ECD	01-DEC-21	Yes	No		4	NCT04330040	Previously-treated		Maximum tolerated dose/toxicity	200	200																																								
BRCA2	BRCA2_unspecified				ovary / carcinoma / carcinosarcoma	3	Phase 2	Pamiparib		Recruiting	NCT03933761	PRECISE	ECD	01-AUG-25	Yes	No		4	NCT03933761			Disease control rate, Clinical benefit rate	40	40																																								
BRCA2	BRCA2_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 2	Olaparib + Tremelimumab		Suspended	NCT04034927		ECD	01-DEC-22	Yes	No		4	NCT04034927	Previously-treated		Progression free survival	170	170																																								
BRCA2	BRCA2_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 2	Carboplatin + Olaparib + Paclitaxel		Recruiting	NCT04261465	NUVOLA	ECD	01-OCT-20	Yes	No		4	NCT04261465			Complete response, Pathological complete response	35	35																																								
BRCA2	BRCA2_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 2	Ceralasertib + Olaparib		Recruiting	NCT02264678		ECD	01-JAN-24	Yes	No		4	NCT02264678			Maximum tolerated dose/toxicity	117	117																																								
BRCA2	BRCA2_unspecified				ovary / carcinoma / serous carcinoma	3	Phase 2	Pamiparib		Recruiting	NCT03933761	PRECISE	ECD	01-AUG-25	Yes	No		4	NCT03933761			Disease control rate, Clinical benefit rate	40	40																																								
BRCA2	BRCA2_unspecified				pancreas / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT02184195	POLO	PCD	01-JAN-19	Yes	Yes		1	31157963			Progression free survival	154	92	62	Placebo									7.4	3.8	.53	0.35-0.82	0.004									18.9	18.1	.91	0.56-1.46	0.68												
BRCA2	BRCA2_unspecified				pancreas / carcinoma / NS	1	Phase 2	Olaparib + Selumetinib		Unknown	NCT02511223		ECD	01-SEP-17	No	No		4	NCT02511223			Overall Response Rate	24	24																																								
BRCA2	BRCA2_unspecified				pancreas / carcinoma / NS	1	Phase 2	Epacadostat + Pembrolizumab		Withdrawn	NCT03432676		ECD	01-APR-20	Yes	No		4	NCT03432676			Overall Response Rate	0	0																																								
BRCA2	BRCA2_unspecified				pancreas / carcinoma / NS	1	Phase 2	Dostarlimab + Niraparib		Not yet recruiting	NCT04493060		ECD	01-SEP-22	Yes	No		4	NCT04493060			Disease control rate, Clinical benefit rate	20	20																																								
BRCA2	BRCA2_unspecified				pancreas / carcinoma / NS	1	Phase 2	Ascorbic acid + Autologous Hematopoietic Stem Cell Transplantation + Carmustine + Ethanol + Melphalan + Vitamin B12B		Not yet recruiting	NCT04150042		ECD	01-FEB-22	Yes	No		4	NCT04150042			Maximum tolerated dose/toxicity	10	10																																								
BRCA2	BRCA2_unspecified				pancreas / carcinoma / NS	1	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04548752		ECD	01-MAR-25	Yes	No		4	NCT04548752			Progression free survival	88			Olaparib																																						
BRCA2	BRCA2_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort A	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
BRCA2	BRCA2_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Olaparib	Usage dependent	Active, not recruiting	NCT01844986	SOLO-1	PCD	01-MAY-18	Yes	Yes		4	NCT01844986	Previously-treated		Progression free survival	450	260	131	Placebo										13.8	.3	0.23-0.41	<0.0001																									
BRCA2	BRCA2_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Bevacizumab + Chemotherapy + Olaparib		Active, not recruiting	NCT02477644	PAOLA-1	PCD	01-MAR-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf?utm_source=Salesforce%20Marketing%20Cloud&utm_medium=Email&utm_campaign=&sfmc_s=0031I000016IMUlQAO			Progression free survival	806	537	269	Bevacizumab + Placebo									37.2	17.7	.33	0.25-0.45																										
BRCA2	BRCA2_unspecified				peritoneum / carcinoma / NS	1	Approved FDA	Olaparib	Required	Active, not recruiting	NCT01874353	SOLO-2	PCD	01-SEP-16	Yes	Yes		1	28754483	Previously-treated		Progression free survival	327	196	99	Placebo									19.1	5.5	.3	0.22-0.41	<0.0001																									
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf	Previously-treated		Progression free survival	245	162	83	Enzalutamide	28	1		<0.0001					7.4	3.6	.34	0.25-0.47	<0.0001									19.1	14.7	.69	0.5-0.97	0.0175												
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT04038502	COBRA	ECD	01-AUG-24	Yes	No		4	NCT04038502			Progression free survival	100	100																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Abiraterone acetate + Prednisone		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Abiraterone acetate + Olaparib + Prednisone		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	SC10914		Recruiting	NCT04486937		ECD	01-DEC-21	Yes	No		4	NCT04486937	Previously-treated		Overall Response Rate	90	90																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Afuresertib + LAE001 + Prednisone		Recruiting	NCT04060394		ECD	01-SEP-21	Yes	No		4	NCT04060394	Previously-treated		Progression free survival	74	74																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Nivolumab		Recruiting	NCT03040791		ECD	01-JAN-21	No	No		4	NCT03040791			Prostate Specific Antigen (PSA) response rate 	29	29																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Carboplatin + Docetaxel + Rucaparib 		Recruiting	NCT03442556	PLATI-PARP	ECD	01-MAY-25	No	No		4	NCT03442556	Previously-treated		Progression free survival	20	20																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Rucaparib 		Recruiting	NCT02952534	TRITON2	ECD	01-SEP-20	No	No		4	NCT02952534	Previously-treated		Overall Response Rate	360	360																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Talazoparib		Active, not recruiting	NCT03148795	TALAPRO-1	PCD	01-APR-20	Yes	Yes		2	10.1200/JCO.2020.38.6_suppl.119	Previously-treated		Overall Response Rate	20	20			50.0								8.2																													
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 3	Rucaparib 		Recruiting	NCT02975934	TRITON3	ECD	01-FEB-22	No	No		4	NCT02975934	Previously-treated		Progression free survival	400			Best supportive care																																						
BRCA2	BRCA2_unspecified				prostate / carcinoma / NS	1	Phase 3	Abiraterone acetate + Olaparib		Recruiting	NCT03732820	PROpel	ECD	01-APR-21	No	No		4	NCT03732820			Progression free survival	904			Abiraterone acetate + Placebo																																						
BRCA2	BRCA2_unspecified				urinary tract / carcinoma / NS	3	Phase 1	Durvalumab + Olaparib		Active, not recruiting	NCT02546661	BISCAY module B	PCD	01-MAR-20	Yes	Yes		3	https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-bladder-cancer/115221-esmo-2019-biscay-an-adaptive-biomarker-directed-platform-study-in-metastatic-urothelial-cancer-with-durvalumab-in-combination-with-targeted-therapies.html	Previously-treated		Maximum tolerated dose/toxicity	14	14			35.7																																					
BRCA2	BRCA2_unspecified				urinary tract / papilloma / typical	3	Phase 2	Niraparib		Recruiting	NCT03945084		ECD	01-DEC-21	Yes	No		4	NCT03945084			Progression free survival	77	77																																								
BRCA2	BRCA2_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
BRIP1	BRIP1_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
BRIP1	BRIP1_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
BRIP1	BRIP1_unspecified				NS / neoplasm / NS	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
BRIP1	BRIP1_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
BRIP1	BRIP1_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
BRIP1	BRIP1_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
BRIP1	BRIP1_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
BRIP1	BRIP1_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
BRIP1	BRIP1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
BRIP1	BRIP1_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
BRIP1	BRIP1_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
BRIP1	BRIP1_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
BRIP1	BRIP1_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
BRIP1	BRIP1_unspecified				prostate / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
BRIP1	BRIP1_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
CALR	CALR_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Pentraxin 2		Active, not recruiting	NCT01981850		PCD	01-JUL-20	No	No		4	NCT01981850			Clinical activity	125	125																																								
CBFB	CBFB-MYH11 fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Azacitidine + Belinostat		Not yet recruiting	NCT00351975		PCD	01-MAR-13	No	No		4	NCT04088188			Maximum tolerated dose/toxicity	56	56																																								
CBFB	CBFB-MYH11 fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Veliparib		Active, not recruiting	NCT01139970		PCD	01-MAR-14	No	Yes		1	27503200			Maximum tolerated dose/toxicity	48	48																								5.3			3.3-8.3			8		8								
CBFB	CBFB-MYH11 fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Carboplatin + Topotecan + Veliparib		Active, not recruiting	NCT00588991		PCD	01-FEB-14	No	No		4	NCT00588991			Maximum tolerated dose/toxicity	12	12																																								
CBFB	CBFB-MYH11 fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Topotecan + Veliparib		Active, not recruiting	NCT00588991		PCD	01-FEB-14	No	No		4	NCT00588991			Maximum tolerated dose/toxicity	12	12																																								
CBFB	CBFB-MYH11 fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine		Completed	NCT02450877	AZA-AML-004	PCD	01-OCT-18	No	No		3	https://ash.confex.com/ash/2020/webprogram/Paper137043.html		Pediatric	Progression free survival	4	4																																								
CBL	CBL_Exon8, Exon9				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Azacitidine + Quizartinib		Recruiting	NCT04493138		ECD	01-FEB-22	Yes	No		4	NCT04493138			ORR, OS	58	58																																								
CBL	CBL_unspecified				NS / malignant melanoma / NS	3	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	Yes		4	NCT02219711			Maximum tolerated dose/toxicity	2	2																															1									
CBL	CBL_unspecified				NS / other / neoplasm	3	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/Sitravatinib-demonstrates-activity-in-patients-with-novel-genetic-alterations-that-inactivate-CBL			Maximum tolerated dose/toxicity	12	12																															2									
CBL	CBL_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
CBL	CBL_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Ruxolitinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																																								
CBL	CBL_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	Yes		4	NCT02219711			Maximum tolerated dose/toxicity	2	2																															1									
CBL	CBL_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 2	MK2206		Completed	NCT01283035		PCD	01-DEC-14	Yes	Yes		4	NCT01283035			Overall Response Rate	5	5			0																													4								
RET	CCDC6-RET_fusion				large intestine / carcinoma / adenocarcinoma	3	Out of trials human study	Agerafenib		Unknown					Yes	Yes		1	29538669			Unknown	1	1																														1										
RET	CCDC6-RET_fusion				lung / carcinoma / non small cell carcinoma	4	Case study	Docetaxel + Nintedanib		Completed	NCT00876460		PCD	01-SEP-12	Yes	Yes		4	NCT00876460			Maximum tolerated dose/toxicity	1	1																																1								
CCND1	CCND1_unspecified				NS / other / neoplasm	3	Phase 2	Ribociclib + Siremadlin		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
CCND1	CCND1_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Bortezomib + Dexamethasone + doxorubicin hydrochloride		Completed	NCT00872521		PCD	01-MAY-11	Comparison with wt	Yes		4	NCT00872521	Untreated		Overall Response Rate	84	25	59		80.0	81.4																																				
CCND1	CCND1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	Palbociclib		Active, not recruiting	NCT02154490	Lung-MAP	PCD	01-APR-22	Expression level	Yes		1	31302234	Previously-treated			26	26																															2									
CCND3	CCND3_unspecified				NS / other / neoplasm	3	Phase 2	Ribociclib + Siremadlin		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
CCNE1	CCNE1_unspecified				NS / other / neoplasm	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
CCNE1	CCNE1_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 4B	ECD	01-APR-22	Expression level	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
CDK12	CDK12_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
CDK12	CDK12_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
CDK12	CDK12_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
CDK12	CDK12_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
CDK12	CDK12_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
CDK12	CDK12_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
CDK12	CDK12_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
CDK12	CDK12_unspecified				prostate / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
CDK12	CDK12_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
CDK2	CDK2_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
CDK4	CDK4_unspecified				NS / other / neoplasm	3	Phase 2	Abemaciclib		Recruiting	NCT02693535	TAPUR group 17	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
CDK4	CDK4_unspecified				NS / other / neoplasm	3	Phase 2	Ribociclib + Siremadlin		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
CDK4	CDK4_unspecified				NS / other / neoplasm	3	Phase 2	Palbociclib		Recruiting	NCT02693535	TAPUR group 4	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
CDK4	CDK4_unspecified				NS / other / neoplasm	3	Phase 2	Palbociclib		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
CDK4	CDK4_unspecified				NS / other / neoplasm	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
CDK6	CDK6_unspecified				NS / other / neoplasm	3	Phase 2	Abemaciclib		Recruiting	NCT02693535	TAPUR group 17	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
CDK6	CDK6_unspecified				NS / other / neoplasm	3	Phase 2	Ribociclib + Siremadlin		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
CDK6	CDK6_unspecified				NS / other / neoplasm	3	Phase 2	Palbociclib		Recruiting	NCT02693535	TAPUR group 4	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
CDK6	CDK6_unspecified				NS / other / neoplasm	3	Phase 2	Palbociclib		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
CDKN2A	CDKN2A_unspecified				NS / other / neoplasm	3	Phase 2	Abemaciclib		Recruiting	NCT02693535	TAPUR group 17	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
CDKN2A	CDKN2A_unspecified				NS / other / neoplasm	3	Phase 2	Palbociclib		Recruiting	NCT02693535	TAPUR group 4	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
CDKN2A	CDKN2A_unspecified				lung / carcinoma / non small cell carcinoma	7	Phase 2	Adavosertib		Terminated	NCT02688907		PCD	01-DEC-17	Yes	Yes	Change regimen	4	NCT02688907			Overall Response Rate	7	7																																								
CDKN2C	CDKN2C_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide		Recruiting	NCT03732703	MyDRUG Sub-Protocol A1	ECD	01-FEB-22	Yes	No		4	NCT03732703	Previously-treated		Overall Response Rate	228	228																																								
CEBPA	CEBPA_unspecified				NS / neoplasm / NS	3	Phase 1	MTL-CEBPA		Recruiting	NCT04105335	TIMEPOINT	ECD	01-DEC-21	No	No		4	NCT04105335			Maximum tolerated dose/toxicity	108	108																																								
CEBPA	CEBPA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	11	8	3	Cytarabine	38	0																																				
CEBPA	CEBPA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Cytarabine + Idarubicin + Lenalidomide		Completed	NCT01132586		PCD	01-JAN-14	No	No		4	NCT01132586			Maximum tolerated dose/toxicity	61	61																																								
CEBPA	CEBPA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Decitabine + Glasdegib		Active, not recruiting	NCT04051996	GLAD-AML	ECD	01-SEP-21	No	No		4	NCT04051996		Geriatric	Complete remission	1	1																																								
CEBPA	CEBPA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Daunorubicin + Omacetaxine mepesuccinate		Recruiting	NCT04415008		ECD	01-JUN-22	Yes	No		4	NCT04415008			Disease free survival, relapse free survival, regression free survival, recurrence free survival	50	50																																								
CEBPA	CEBPA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Clofarabine + Cytarabine		Completed	NCT00932412	CLARA	PCD	01-APR-16	No	No		4	NCT00932412			Disease free survival, relapse free survival, regression free survival, recurrence free survival	735			Cytarabine																																						
CEBPA	CEBPA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Cytarabine + Gemtuzumab Ozogamicin		Recruiting	NCT02473146	ALFA1401	ECD	01-APR-19	No	No		4	NCT02473146		Geriatric	Event free survival	225	225																																								
CEBPA	CEBPA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 4	Cytarabine + Idarubicin		Recruiting	NCT01296178	PETHEMA-LMA10	ECD	01-DEC-20	No	No		4	NCT01296178			Overall survival	200	200																																								
CEBPA	CEBPA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Approved FDA	Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin		Completed	NCT00927498	ALFA 0701	PCD	01-JUL-11	Yes	No	Rate of CR+CRp 88.9% vs 85.4% HR 1.37 95% CI 0.40-4.66 p=0.76, 2yr EFS 17.8% vs. 51.1%  HR 0.47 95% CI 0.27-0.81 p=0.006	1	22482940 			Event free survival	45	48																								68.3	46	.5	0.26-0.97	0.04					57.5	21.1	.43	0.23-0.79	0.006			
CEBPA	CEBPA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Decitabine + Glasdegib		Recruiting	NCT02400281	ARO-010	PCD	01-JUL-20	No	No		4	NCT04051996			Maximum tolerated dose/toxicity	28	28																																								
CEBPA	CEBPA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Cytarabine + Idarubicin + Pravastatin		Completed	NCT01831232		PCD	01-FEB-15	No	Yes	Primary outcome not met	4	NCT01831232	Untreated		Complete remission	24	24																														15										
CEBPA	CEBPA_unspecified				liver / NS / NS	3	Phase 1	MTL-CEBPA		Unknown	NCT02716012	OUTREACH	ECD	01-MAR-21	No	No		4	NCT02716012			Maximum tolerated dose/toxicity	51	51																																								
CHEK1	CHEK1_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
CHEK1	CHEK1_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
CHEK1	CHEK1_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
CHEK1	CHEK1_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
CHEK1	CHEK1_unspecified				prostate / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
CHEK2	CHEK2_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
CHEK2	CHEK2_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
CHEK2	CHEK2_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
CHEK2	CHEK2_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
CHEK2	CHEK2_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	01-JUN-23	Yes	No		4	NCT04335669			Complete response, Pathological complete response	820	820																																								
CHEK2	CHEK2_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
CHEK2	CHEK2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
CHEK2	CHEK2_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
CHEK2	CHEK2_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
CHEK2	CHEK2_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
CHEK2	CHEK2_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
CHEK2	CHEK2_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
CHEK2	CHK2_unspecified				NS / other / neoplasm	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
CHEK2	CHK2_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
CHEK2	CHK2_unspecified				NS / other / neoplasm	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
CHEK2	CHK2_unspecified				NS / other / neoplasm	3	Phase 2	Ceralasertib + Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	No	No		4	NCT02576444			Overall Response Rate	64	64																																								
CSF1R	CSF1R_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
CSF1R	CSF1R_unspecified				NS / other / neoplasm	3	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	Yes		1	32292573			Disease control rate, Clinical benefit rate	2	2																																1								
CSF1R	CSF1R_unspecified				NS / other / neoplasm	3	Phase 2	Nilotinib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
CSF1R	CSF1R_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
CSF1R	CSF1R_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
CSF1R	CSF1R_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	29	29		Erlotinib + Placebo									4.4	2.52	.55	0.16-1.92	0.17																									
CSF3R	CSF3R_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Ruxolitinib		Completed	NCT02092324		PCD	01-NOV-19	Comparison with wt	Yes	61.2% serious adverse events	4	NCT02092324			Clinical activity	48	26	22		15	0		0.1																																		
DAXX	DAXX_unspecified				NS / other / neoplasm	3	Phase 1	M4344		Recruiting	NCT02278250		ECD	01-JUN-21	Yes	No		4	NCT02278250			Maximum tolerated dose/toxicity	300	300																																								
ALK	DCTN1-ALK_fusion				soft tissue / smooth muscle tumour of uncertain malignant potential / NS	3	Phase 1	Crizotinib + Pazopanib		Active, not recruiting	NCT01548144		ECD	01-SEP-22	Yes	Yes		1	26062823			Maximum tolerated dose/toxicity	364	364																															1									
DDR1	DDR1_unspecified				NS / other / neoplasm	3	Phase 2	Nilotinib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
DDR2	DDR2_S768R, I638F, L239R	63371628 + 63374671 + 99057766		p.I638F + p.L239R + p.S768R	NS / neoplasm / NS	3	Phase 2	Dasatinib		Recruiting	NCT02465060	MATCH Subprotocol X	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
DDR2	DDR2_unspecified				NS / other / neoplasm	3	Phase 2	Nilotinib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
DDR2	DDR2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	No		4	NCT02219711			Maximum tolerated dose/toxicity	260	260																																								
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	21	15	6	Cytarabine	13	0																																				
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Decitabine + Peripheral blood stem cell transplantation  + Prophylactic donor lymphocytes		Not yet recruiting	NCT03771222		ECD	01-DEC-20	No	No		4	NCT03771222			Cumulative incidence of relapse	40	40																																								
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Gilteritinib		Recruiting	NCT03013998	BAML-16-001-S8 	ECD	01-DEC-21	No	No		4	NCT03013998			Complete remission	2000	2000																																								
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Mitoxantrone hydrochloride + Venetoclax		Not yet recruiting	NCT04330820	RELAX	ECD	01-JUN-22	No	No		4	NCT04330820	Previously-treated		Overall Response Rate	60	60																																								
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Decitabine + Glasdegib		Active, not recruiting	NCT04051996	GLAD-AML	ECD	01-SEP-21	No	No		4	NCT04051996		Geriatric	Complete remission	1	1																																								
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Cytarabine + Daunorubicin		Completed	NCT01802333		PCD	01-JUN-17	No	Yes	EFS 36 vs 37% p=0.84 primary outcome not met	4	NCT01802333	Untreated		Event free survival	477	261	216	Cytarabine + Idarubicin + Vorinostat																																						
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Cytarabine + Gemtuzumab Ozogamicin		Recruiting	NCT02473146	ALFA1401	ECD	01-APR-19	No	No		4	NCT02473146		Geriatric	Event free survival	225	225																																								
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Cytarabine + Idarubicin		Completed	NCT01802333	SWOG-S1203	PCD	01-JUN-17	No	Yes	EFS 41 vs 37% p=0.42 primary outcome not met	4	NCT01802333	Untreated		Event free survival	477	261	216	Cytarabine + Idarubicin + Vorinostat																																						
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Ruxolitinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																																								
DNMT3A	DNMT3A_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Azacitidine + Lenalidomide		Completed	NCT00352001		PCD	01-SEP-11	No	Yes		1	22915641			Overall Response Rate	1	1																														1										
EGFR	EGFR_C797S	51766493 + 51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	Phase 1	Dacomitinib		Recruiting	NCT03755102		ECD	01-NOV-22	Yes	No		4	NCT03755102			Overall Response Rate	24	24																																								
EGFR	EGFR_C797S	51766493 + 51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	Phase 1	Dacomitinib + Osimertinib		Recruiting	NCT03755102		ECD	01-NOV-22	Yes	No		4	NCT03755102			Overall Response Rate	24	24																																								
EGFR	EGFR_E690K			p.E690K	endometrium / carcinoma / NS	4	Case study	Lapatinib		Completed	NCT00096447	NCI-2012-02631 	PCD	01-MAR-11	Yes	Yes		1	22885469	Previously-treated		Progression free survival	1	1																															1									
EGFR	EGFR_E709K/A	51767260 + 51772956		p.E709A + p.E709K	lung / carcinoma / non small cell carcinoma	3	Case study	Afatinib		Unknown					Yes	Yes		1	26354527	Previously-treated		Unknown	4																	12.2																								
EGFR	EGFR_E709K/A	51767260 + 51772956		p.E709A + p.E709K	lung / carcinoma / non small cell carcinoma	3	Phase 2	Neratinib		Recruiting	NCT01953926	SUMMIT	ECD	01-MAR-22	Yes	No		1	29420467			Overall Response Rate	650	650																																								
EGFR	EGFR_E709_T710delinsD	51779132		p.E709_T710delinsD	lung / carcinoma / non small cell carcinoma	4	Case study	Afatinib		Unknown					Yes	Yes		1	28625646			Unknown	1																																1									
EGFR	EGFR_E709_T710delinsD	51779132		p.E709_T710delinsD	lung / carcinoma / non small cell carcinoma	7	Case study	Gefitinib		Unknown					Yes	Yes	No benefit of treatment	1	27785061			Unknown	5																																									
EGFR	EGFR_E709_T710delinsD	51779132		p.E709_T710delinsD	lung / carcinoma / non small cell carcinoma	7	Case study	Erlotinib		Unknown					Yes	Yes	No benefit of treatment	1	27785061			Unknown	5																																									
EGFR	EGFR_Exon19del				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Pemetrexed		Completed	NCT01469000		PCD	01-APR-15	Yes	Yes		1	27507876	Untreated		Progression free survival		65	40	Gefitinib									17.1	11.1	.67		0.078																54	3								
EGFR	EGFR_Exon19del,G719X,T790M,L858R				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Recruiting	NCT03433469		ECD	01-MAY-21	Yes	No		4	NCT03433469			Complete response, Pathological complete response	27	27																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 1	Afatinib + Pembrolizumab		Active, not recruiting	NCT02364609		PCD	01-APR-18	Yes	No		4	NCT02364609	Previously-treated		Maximum tolerated dose/toxicity	38	38																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 1	Patritumab deruxtecan		Active, not recruiting	NCT03260491		ECD	01-DEC-21	Yes	No		4	NCT03260491			Overall Response Rate	216	216																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 1	Gefitinib + Tremelimumab		Completed	NCT02040064		PCD	01-MAR-16	Yes	Yes		3	https://academic.oup.com/annonc/article/27/suppl_6/1245P/2800136	Previously-treated		Maximum tolerated dose/toxicity	24	24																																18								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 1	Navitoclax + Osimertinib		Active, not recruiting	NCT02520778		ECD	01-JUL-21	Yes	No		4	NCT02520778	Previously-treated		Maximum tolerated dose/toxicity	50	50																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Onalespib lactate		Active, not recruiting	NCT02535338		ECD	01-DEC-21	Yes	No		4	NCT02535338	Previously-treated		Maximum tolerated dose/toxicity	46	46																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib		Recruiting	NCT03382795		ECD	01-SEP-22	Yes	No		4	NCT03382795			Overall Response Rate	69	69																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Recruiting	NCT04233021	ORBITAL	ECD	01-JAN-22	Yes	No		4	NCT04233021			Overall Response Rate	113	113																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib		Recruiting	NCT03382795		ECD	01-SEP-22	Yes	No		4	NCT03382795			Overall Response Rate	69	69																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 1	Osimertinib		Completed	NCT02529995	AURAChinaPK	PCD	01-JAN-16	Yes	Yes		1	29239002	Previously-treated		Maximum tolerated dose/toxicity	16	16			75.0																																					
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 1	Fruquintinib + Genolimzumab		Recruiting	NCT03976856	Gxplore-015	ECD	01-DEC-21	Yes	No		4	NCT03976856			Maximum tolerated dose/toxicity	42	42																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 1	Osimertinib + Rifampicin		Active, not recruiting	NCT02197247		PCD	01-JUL-15	Yes	No		4	NCT02197247	Previously-treated		Maximum tolerated dose/toxicity	41	41																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 1	Itraconazole + Osimertinib		Active, not recruiting	NCT02157883		PCD	01-APR-15	Yes	Yes	23% serious adverse events	1	29381826	Previously-treated		Absorption rate	39	39																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib		Terminated	NCT02025218	NVALT 16	ECD	01-JAN-17	Yes	No		4	NCT02025218	Previously-treated		Disease control rate, Clinical benefit rate	21	21																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Vinorelbine		Unknown	NCT02319577		PCD	01-JUN-15	Yes	No		4	NCT02319577			Progression free survival	80	80		Gefitinib																																						
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Tepotinib 		Active, not recruiting	NCT01982955	INSIGHT	PCD	01-DEC-17	Yes	Yes		4	NCT01982955	Previously-treated		ORR, PFS, OR	55	31	24		45.2	33.3							10.15	4.37									83.9	70.8		17.25	18.69															
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed		Not yet recruiting	NCT04147351		ECD	01-SEP-21	Yes	No		4	NCT04147351			Overall Response Rate	22	22																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Luminespib		Completed	NCT01259089		PCD	01-JUL-12	Yes	Yes	Primary outcome not met, response independent of T790M status	1	25870087			MTD, ORR, Toxicity	25																																4									
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 3	Erlotinib + Radiotherapy		Unknown	NCT03074864	TREND	ECD	01-JUN-19	Yes	No		4	NCT03074864			Overall Response Rate	90	90																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,S768I,Exon19ins				lung / carcinoma / non small cell carcinoma	3	Phase 3	Gefitinib + Stereotactic Body Radiation Therapy		Active, not recruiting	NCT02893332	Sindas	ECD	01-DEC-20	Yes	No		4	NCT02893332	Untreated		Progression free survival	200	200																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dasatinib + Osimertinib		Active, not recruiting	NCT02954523		ECD	01-DEC-19	Yes	No		4	NCT02954523	Untreated		Progression free survival	10	10																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Afatinib + Cyclophosphamide + EGF-PTI		Active, not recruiting	NCT03623750	EPICAL	PCD	01-MAR-20	Yes	No		4	NCT03623750			Maximum tolerated dose/toxicity	30	30																																								
EGFR	EGFR_Exon19del,L858R,G719X,L861Q,T790M				lung / carcinoma / non small cell carcinoma	3	Unknown	Alflutinib		Active, not recruiting	NCT03127449		ECD	01-JUN-20	Yes	Yes		1	33077354	Previously-treated		Overall Response Rate	116	116			76.7																																					
EGFR	EGFR_Exon19del,T790M,L858R,G719X,L861Q,Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 1	Afatinib + Cetuximab		Completed	NCT01090011		PCD	01-JAN-13	Yes	Yes		1	29110849	Previously-treated		Maximum tolerated dose/toxicity	36	36											2.9																				4									
EGFR	EGFR_Exon19del,T790M,L858R,G719X,L861Q,Exon20ins				lung / carcinoma / non small cell carcinoma	3	Phase 1	Necitumumab + Osimertinib		Recruiting	NCT02496663		ECD	01-JUN-21	Yes	No		4	NCT02496663	Previously-treated		Maximum tolerated dose/toxicity	100	100																																								
EGFR	EGFR_Exon_19ins				lung / carcinoma / non small cell carcinoma	4	Case study	Gefitinib		Unknown					Yes	Yes		1	29483495			Unknown	1	1																															1									
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Case study	Erlotinib		Unknown					Yes	Yes		1	24353160			Unknown	3																																2	1								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Case study	Icotinib		Unknown					Yes	Yes		3	https://www.jto.org/article/S1556-0864(17)32886-1/fulltext			Unknown	18				33.3	0							9	1.2			p<0.001						100	16.2																		
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 1	JMT101		Recruiting	NCT04448379		ECD	01-DEC-21	Yes	No		4	NCT04448379			Maximum tolerated dose/toxicity	48	48																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		Recruiting	NCT03414814		ECD	01-JUN-22	Yes	No		4	NCT03414814	Previously-treated		Overall Response Rate	28																																									
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pyrotinib		Not yet recruiting	NCT04063462	PEER20	ECD	01-APR-21	Yes	No		4	NCT04063462	Previously-treated		Overall Response Rate	60	60																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	BDTX189		Recruiting	NCT04209465	MasterKey-01	ECD	01-JUN-23	Yes	No		4	NCT04209465			Overall Response Rate	200	200																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Tarloxotinib		Recruiting	NCT03805841	RAIN	ECD	01-MAR-21	Yes	No		4	NCT03805841			Overall Response Rate	60	60																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	CLN-081		Recruiting	NCT04036682		ECD	01-SEP-21	Yes	No		4	NCT04036682			Overall Response Rate	80	80																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Pirotinib		Recruiting	NCT03574402	TRUMP Arm 9	ECD	01-DEC-22	Yes	No		4	NCT03574402			Overall Response Rate	400	400																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Luminespib		Completed	NCT01922583		PCD	01-FEB-17	Yes	No		4	NCT01922583			Overall Response Rate	31	31																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Afatinib + Cetuximab		Active, not recruiting	NCT03727724	AFACET	ECD	01-SEP-21	Yes	No		4	NCT03727724			Disease control rate, Clinical benefit rate	37																																									
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Poziotinib		Recruiting	NCT04402008	SPI-POZ-104	ECD	01-JAN-25	Yes	No		4	NCT04402008			Overall Response Rate	76	76																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Poziotinib		Terminated	NCT04044170		PCD	01-APR-20	Yes	No		4	NCT04044170			Overall Response Rate	5	5																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Poziotinib		Recruiting	NCT03318939	ZENITH20	ECD	01-MAR-23	Yes	No		4	NCT03318939			Overall Response Rate	603																																									
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Poziotinib		Recruiting	NCT03066206	2016-0783	ECD	01-MAR-21	Yes	Yes		1	29686424			Overall Response Rate	11																																7									
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		Suspended	NCT03191149		ECD	01-JUL-22	Yes	No		4	NCT03191149	Previously-treated		Overall Response Rate	20	20																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 3	Entrecitinib		Recruiting	NCT03178552	B-FAST Cohort F	ECD	01-SEP-21	Yes	No		4	NCT03178552			Overall Response Rate	700	700																																								
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 3	Amivantamab + Carboplatin + Pemetrexed		Recruiting	NCT04538664	PAPILLON	ECD	01-JAN-22	Yes	No		4	NCT04538664			Progression free survival	300			Carboplatin + Pemetrexed																																						
EGFR	EGFR_Exon_20ins				lung / carcinoma / non small cell carcinoma	2	Phase 3	Mobocertinib		Recruiting	NCT04129502		ECD	01-JUN-22	Yes	No		4	NCT04129502			Progression free survival	318			Carboplatin + Pemetrexed																																						
EGFR	EGFR_G719?			p.G719X	lung / carcinoma / non small cell carcinoma	2	Case study	Gefitinib		Unknown					Yes	Yes		1	28184913			Unknown																															50											
EGFR	EGFR_G719?			p.G719X	lung / carcinoma / non small cell carcinoma	2	Case study	Gefitinib		Unknown					Yes	Yes		1	15118073			Unknown	1	1																															1									
EGFR	EGFR_G719?			p.G719X	lung / carcinoma / non small cell carcinoma	2	Phase 2	Neratinib		Completed	NCT00266877		PCD	01-JAN-09	Yes	Yes		1	20479403			Overall Response Rate	4	4																															3									
EGFR	EGFR_G719?			p.G719X	lung / carcinoma / non small cell carcinoma	2	Phase 2	Neratinib		Recruiting	NCT01953926	SUMMIT	ECD	01-MAR-22	Yes	No		1	29420467			Overall Response Rate	650	650																																								
EGFR	EGFR_G719?			p.G719X	lung / carcinoma / non small cell carcinoma	2	Phase 3	Afatinib		Completed					Yes	Yes		1	26051236			Unknown	18	18			77.8																																					
EGFR	EGFR_G719?			p.G719X	lung / carcinoma / non small cell carcinoma	2	Phase 3	Bevacizumab + Erlotinib		Recruiting	NCT02633189	BEVERLY	ECD	01-DEC-17	Yes	No		4	NCT02633189	Untreated		Progression free survival	200			Erlotinib																																						
EGFR	EGFR_G719X,L861Q,S768I	51766344 + 51768106		p.G719X + p.L861Q + p.S768I	lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Active, not recruiting	NCT03424759		PCD	01-DEC-17	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.9050 			Overall Response Rate	19	19																															10									
EGFR	EGFR_G719X,L861Q,S768I	51766344 + 51768106		p.G719X + p.L861Q + p.S768I	lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Recruiting	NCT03434418		ECD	01-JUN-21	Yes	No		1	NCT03434418	Untreated		Overall Response Rate	37	37																																								
EGFR	EGFR_L858R	51765161 + 51767322 + 51801258 + 51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Pemetrexed		Completed	NCT01469000		PCD	01-APR-15	Yes	Yes		1	27507876	Untreated		Progression free survival		52	23	Gefitinib									12.6	10.9	.58		0.054																39	11								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Afatinib	Required	Completed	NCT00949650	LUX-Lung 3	PCD	01-FEB-12	Yes	Yes		4	NCT00949650	Untreated		Progression free survival	345	230	115	Chemotherapy	56.5	22.6		0.0001					11.1	6.9	.58	0.43-0.78	p<0.001																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Osimertinib	Required	Active, not recruiting	NCT02296125	FLAURA	PCD	01-JUN-17	Yes	Yes		1	29151359	Untreated		Progression free survival	556	279	277	Gefitinib					17.2	8.5	7.3-9.8		18.9	10.2	.46	0.37-0.57	p<0.001									83	71															
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Dacomitinib	Required	Active, not recruiting	NCT01774721	ARCHER 1050 	PCD	01-JUL-16	Yes	Yes		1	29864379	Untreated		Progression free survival	452	227	225	Gefitinib									14.7	9.2	.59	0.47-0.74	p<0.0001									34.1	26.8	.76	0.582-0.993	p=0.044												
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Gefitinib	Required	Completed	NCT00322452	IPASS	PCD	01-APR-08	Yes	Yes		1	26980062	Untreated		Progression free survival	186	88	89	Chemotherapy	67.0	41	31-51		9.6	5.5			10.9	7.4	.54	0.38-0.79																										
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Gefitinib	Required	Completed	NCT01203917	IFUM EURTAC	PCD	01-AUG-12	Yes	Yes		4	NCT01203917	Untreated		Overall Response Rate	106	106			50.0	41-59			6		5.1-11.1																															
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Erlotinib	Required	Completed	NCT00036647	BR.21	PCD	01-JAN-04	No	Yes		1	16014882	Previously-treated		Not defined	731	488	243	Placebo									2.3	1.8	.59	0.5-0.7	p<0.001									6.7	4.7	.73	0.61-0.86	<0.01												
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Erlotinib	Required	Completed	NCT00556712	SATURN	PCD	01-NOV-10	No	Yes		1	20493771	Previously-treated		Progression free survival	884	437	447	Placebo									2.8	2.6	.71	2.8-3.1	p<0.0001									12.0	11	.81	0.7-0.95	0.0088												
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Erlotinib	Required	Completed	NCT00446225	EURTAC	PCD	01-DEC-09	Yes	Yes		1	22285168	Untreated		Progression free survival	174	86	87	Chemotherapy	65.0	17							10.4	5.2	.34	0.23-0.49	p<0.001																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Afatinib	Required	Completed	NCT01466660	LUX-Lung 7	PCD	01-APR-16	Yes	Yes		1	27083334	Untreated		Progression free survival, Time to treatment failure, Overall survival	319	160	159	Gefitinib	72.5	56.0	1.32-3.40	0.0018					11	10.9	.74	0.57-0.95	p=0.0178	13.7	5.5	.75	0.60-0.94	p=0.0136																				
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Approved other	Icotinib		Completed	NCT01040780	ICOGEN	PCD	01-MAR-10	No	Yes		1	23948351	Previously-treated		Progression free survival	395	200	199	Gefitinib									4.6	3.4	.84	0.67-1.05	p=0.13																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Case study	Erlotinib		Unknown					Yes	Yes		1	15329413			Unknown	7	7																															7									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Case study	Gefitinib		Unknown					Yes	Yes		1	15329413			Unknown	4	4																															4									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Case study	Gefitinib		Unknown					Yes	Yes		1	15118073			Unknown	4	4																															4									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Out of trials human study	Pemetrexed		Unknown					Comparison with wt	Yes		1	21642865			Unknown	80	43	37		4.7	16.2												1.4	2.9																							
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Sapanisertib		Recruiting	NCT02503722		ECD	01-AUG-21	Yes	No		4	NCT02503722			Maximum tolerated dose/toxicity	36	36																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Temozolomide		Recruiting	NCT04541407		ECD	01-SEP-23	Yes	No		4	NCT04541407			Maximum tolerated dose/toxicity	33	33																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Nazartinib + Ribociclib		Recruiting	NCT03333343		ECD	01-MAR-24	Yes	No		4	NCT03333343			Overall Response Rate	157	157																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	LHX254 + Nazartinib		Recruiting	NCT03333343		ECD	01-MAR-24	Yes	No		4	NCT03333343			Overall Response Rate	157	157																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Nazartinib + Trametinib		Recruiting	NCT03516214	EATON	ECD	01-NOV-20	Yes	No		4	NCT03516214			Maximum tolerated dose/toxicity	24	24																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Nazartinib + Trametinib		Recruiting	NCT03333343		ECD	01-MAR-24	Yes	No		4	NCT03333343			Overall Response Rate	157	157																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Gefitinib + Vorinostat		Unknown	NCT02151721	VICTORY-J 	ECD	01-FEB-18	Yes	No		4	NCT02151721	Previously-treated		Maximum tolerated dose/toxicity	12	12																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Savolitinib		Active, not recruiting	NCT02143466	TATTON	PCD	01-MAR-20	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	7	7			86		42-100																										24									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	AV-412		Terminated	NCT00381654		PCD	01-DEC-09	Yes	Yes	Primary outcome not met	4	NCT00381654	Previously-treated		Maximum tolerated dose/toxicity	27	27																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Selumetinib		Active, not recruiting	NCT02143466	TATTON	PCD	01-MAR-20	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	7	7			14		0-58																																			
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Durvalumab + Osimertinib		Active, not recruiting	NCT02143466	TATTON	PCD	01-MAR-20	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	8	8			38		9-76																										9	9								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Gefitinib + Nazartinib		Recruiting	NCT03333343		ECD	01-MAR-24	Yes	No		4	NCT03333343			Overall Response Rate	157	157																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Capmatinib + Nazartinib		Recruiting	NCT03333343		ECD	01-MAR-24	Yes	No		4	NCT03333343			Overall Response Rate	157	157																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Capmatinib + Erlotinib		Active, not recruiting	NCT01911507		PCD	01-AUG-20	Yes	No		4	NCT01911507	Previously-treated		Maximum tolerated dose/toxicity	35	35																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Gefitinib + Savolitinib		Active, not recruiting	NCT02374645		PCD	01-FEB-19	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.e20559 	Previously-treated		Maximum tolerated dose/toxicity	12	12																															2									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Zorifertinib		Active, not recruiting	NCT02228369	BLOOM	PCD	01-AUG-17	Yes	Yes		1	31809241	Previously-treated		Maximum tolerated dose/toxicity	41	41			41		26-58		8.3		5.6-16.5		8.6			5.4-13.7										11.0			8-18				17	17								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Zorifertinib		Active, not recruiting	NCT02228369	BLOOM	PCD	01-AUG-17	Yes	Yes	Promising clinical activity	1	29056570	Previously-treated		Maximum tolerated dose/toxicity	67	67																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	DS-1205c + Gefitinib		Completed	NCT03599518		PCD	01-APR-20	Yes	No		4	NCT03599518	Previously-treated		Maximum tolerated dose/toxicity	21																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 1	Afatinib + Xentuzumab		Completed	NCT02191891		PCD	01-APR-18	Yes	Yes		3	https://www.inoncology.com/sites/default/files/related_materials/park_1280.18_wclc_2016_1.pdf	Previously-treated		MTD, ORR, Toxicity	16																																2	11								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib		Unknown	NCT01933347	CTONG1304	PCD	01-OCT-16	Yes	No		2	10.1200/JCO.2017.35.15_suppl.9035	Previously-treated		Disease control rate, Clinical benefit rate	43	43			4.7								4.4										69.8			8.0																
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Atezolizumab + Bevacizumab		Recruiting	NCT04099836		ECD	01-NOV-23	Yes	No		4	NCT04099836	Previously-treated		Overall Response Rate	39	39																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ascorbic acid + Tyrosine Kinase Inhibitor		Recruiting	NCT03799094		ECD	01-DEC-20	Yes	No		4	NCT03799094			Progression free survival	150	150																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Gefitinib		Not yet recruiting	NCT04358562		ECD	01-MAY-22	Yes	No		4	NCT04358562			Progression free survival	240	240																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Durvalumab + Tremelimumab		Recruiting	NCT03994393	ILLUMINATE	ECD	01-NOV-20	Yes	No		4	NCT03994393			Overall Response Rate	100	100																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	ZN-e4		Recruiting	NCT03446417		ECD	01-JUN-22	Yes	No		4	NCT03446417			Maximum tolerated dose/toxicity	140	140																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Chemotherapy + Icotinib		Recruiting	NCT03396185		ECD	01-FEB-22	Yes	No		4	NCT03396185			Disease free survival, relapse free survival, regression free survival, recurrence free survival	30	30																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cisplatin + Icotinib + Pemetrexed		Completed	NCT03544814		PCD	01-JUN-17	Yes	No		4	NCT03544814			Progression free survival	99	99																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pemetrexed + Toripalimab		Active, not recruiting	NCT03513666		PCD	01-OCT-19	Yes	Yes		4	10.1200/JCO.2020.38.15_suppl.e21618	Previously-treated		Overall Response Rate	40	40			50				7				7										87.5										20	15								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Stereotactic radiotherapy		Recruiting	NCT03769103	LUOSICNS	ECD	01-APR-25	Yes	No		4	NCT03769103			Progression free survival	76	76																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Icotinib		Active, not recruiting	NCT03736837	ALTER-L004	ECD	01-APR-21	Yes	No		4	NCT03736837			Progression free survival	58	58																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Tyrosine Kinase Inhibitor		Recruiting	NCT03720873		ECD	01-JUN-21	Yes	No		4	NCT03720873			Progression free survival	90	90																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Carboplatin + Icotinib + Pemetrexed		Unknown	NCT03151161		ECD	01-DEC-18	Yes	No		4	NCT03151161			Clinical activity	118	118																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Carboplatin + Pemetrexed		Recruiting	NCT03706287		ECD	01-MAR-21	Yes	No		4	NCT03706287			Progression free survival	62	62																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Gefitinib		Unknown					Yes	Yes		1	25695221	Untreated		Unknown	42	42			73.8								14.4			10.1-19.2																2	29									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Gefitinib		Unknown	NCT02930954		ECD	01-DEC-18	Yes	No		4	NCT02930954	Untreated		Progression free survival	180	180																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Local Consolidation Therapy + Osimertinib		Recruiting	NCT03410043		ECD	01-JAN-22	Yes	No		4	NCT03410043	Untreated		Progression free survival	143	143																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Selumetinib		Recruiting	NCT03392246		ECD	01-JUN-21	Yes	No		4	NCT03392246	Untreated		Best overall response	25	25																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib + Thalidomide		Recruiting	NCT03341494		ECD	01-NOV-19	Yes	No		4	NCT03341494			Progression free survival	128	128																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cyclophosphamide + Fludarabine + Interleukin-2 + Tumour infiltrating lymphocytes + Vemurafenib		Unknown	NCT00801385		ECD	01-JUN-09	Yes	Yes		1	26898607			Response rate	47	47											11													26.1																
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed		Not yet recruiting	NCT04512430	Neo-DIANA	ECD	01-AUG-23	Yes	No		4	NCT04512430			Major pathologic response	26	26																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cisplatin + Pemetrexed		Unknown	NCT03050437		ECD	01-FEB-17	Yes	No		4	NCT03050437	Previously-treated		Progression free survival	96	96																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Ramucirumab		Recruiting	NCT03909334		ECD	01-JUN-21	Yes	No		4	NCT03909334	Untreated		Progression free survival	150			Osimertinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Fruquintinib + Gefitinib		Completed	NCT02976116		PCD	01-JUN-19	Yes	No		2	10.1093/annonc/mdz437.004	Untreated		Overall Response Rate	50	50																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Trastuzumab-emtansine		Recruiting	NCT03784599	TRAEMOS	ECD	01-DEC-21	Yes	No		4	NCT03784599	Previously-treated		Maximum tolerated dose/toxicity	58	58																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib + Nazartinib		Recruiting	NCT03292133		ECD	01-OCT-22	Yes	No		4	NCT03292133	Untreated		Progression free survival	11	11																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib + Nazartinib		Active, not recruiting	NCT02335944		ECD	01-OCT-20	Yes	No		4	NCT02335944			Overall Response Rate	177	177																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Capmatinib + Erlotinib		Terminated	NCT02468661		PCD	01-NOV-17	Yes	Yes	Slow accrual	4	NCT02468661	Previously-treated		Maximum tolerated dose/toxicity	23	23		Cisplatin + Pemetrexed																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Erlotinib + Linsitinib		Completed					Yes	Yes	No benefit of treatment	1	27686971	Untreated		Unknown	88	88		Erlotinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib + Osimertinib		Recruiting	NCT03122717		ECD	01-APR-21	Yes	Yes		4	NCT03122717	Untreated		Maximum tolerated dose/toxicity	64	64																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib + Olaparib		Completed	NCT01513174	GOAL	PCD	01-JUL-16	Yes	Yes	No benefit of treatment	2	10.1200/JCO.2018.36.15_suppl.9012 	Untreated		Maximum tolerated dose/toxicity	186	186		Gefitinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Berberine + Gefitinib		Recruiting	NCT03486496	Geber	ECD	01-JUN-19	Yes	No		4	NCT03486496			Progression free survival	50																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Erlotinib		Recruiting	NCT03126799	AvaTa	ECD	01-DEC-20	Yes	No		4	NCT03126799			Progression free survival	128			Erlotinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Erlotinib		Active, not recruiting	NCT01532089		PCD	01-FEB-20	Yes	Yes		4	NCT01532089			Progression free survival	88	43	45	Erlotinib									17.9	13.5	.81	0.5-1.31	0.39									32.4	50.6	1.41	0.71-2.81	0.33												
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib + Tegafur-gimeracil-oteracil potassium		Recruiting	NCT03457337		ECD	01-OCT-20	Yes	No		4	NCT03457337	Untreated		Progression free survival	200	200		Gefitinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib + Telaglenastat		Recruiting	NCT03831932		ECD	01-JUN-21	Yes	No		4	NCT03831932	Previously-treated		Overall Response Rate	53	53		Osimertinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ficlatuzumab + Gefitinib		Completed	NCT01039948		PCD	01-AUG-13	Yes	Yes	No benefit of treatment	1	27448761	Untreated		Overall Response Rate	188	94	94	Gefitinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Poziotinib		Terminated	NCT01819428		PCD	01-NOV-15	Yes	Yes	Slow accrual	4	NCT01819428	Untreated		Overall Response Rate	20																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Neratinib		Recruiting	NCT01953926	SUMMIT	ECD	01-MAR-22	Expression level	No		1	29420467			Overall Response Rate	650																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Neratinib		Completed	NCT00266877		PCD	01-JAN-09	Yes	Yes		1	20479403			Overall Response Rate		83			54.0				14																																	
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Neratinib		Completed	NCT00266877		PCD	01-JAN-09	No	Yes		1	20479403			Overall Response Rate		48			25.0				7.7																																	
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lapatinib		Terminated	NCT00073008	EGF20014	PCD	01-JUL-08	Yes	Yes	No benefit of treatment	1	20215545			Overall Response Rate																																										
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lazertinib		Active, not recruiting	NCT03046992		ECD	01-DEC-21	Yes	No		4	NCT03046992	Previously-treated		Overall Response Rate	230	230																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Olmutinib		Completed	NCT02444819		PCD	01-AUG-17	No	No		4	NCT02444819	Untreated		Overall Response Rate	33	33																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Tesevatinib		Completed	NCT02616393		PCD	01-JAN-19	Yes	Yes		2	10.1016/j.jtho.2016.11.1297	Previously-treated		Clinical activity	7	7																															6									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Tesevatinib		Completed	NCT00522145		PCD	01-OCT-09	No	No		1	22011666	Previously-treated		Response rate	41	41			3																																					
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Tesevatinib		Completed	NCT00364780		PCD	01-MAY-10	Yes	Yes		1	22722787	Untreated		Response rate	51	14	37										9.3	3.6												22.5	18.4		13.6-19.6	0.05												
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Not yet recruiting	NCT04591002		ECD	01-OCT-21	Yes	No		4	NCT04591002			Clinical activity	56	56																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT03769103	LUOSICNS	ECD	01-APR-25	Yes	No		4	NCT03769103			Progression free survival	76	76																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT03586453		ECD	01-MAR-21	Yes	No		4	NCT03586453			Biomarker discovery	30	30																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Dacomitinib		Recruiting	NCT04027647		ECD	01-JUN-22	Yes	No		4	NCT04027647			Progression free survival	118	118																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Icotinib		Recruiting	NCT03749213		ECD	01-FEB-22	Yes	No		4	NCT03749213			Overall Response Rate	36	36																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Icotinib		Unknown	NCT03346811		ECD	01-MAR-19	Yes	No		4	NCT03346811			Overall Response Rate	120	120																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Icotinib		Recruiting	NCT03349203		ECD	01-FEB-22	Yes	No		4	NCT03349203			Overall Response Rate	60	60																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib		Unknown	NCT03399669		ECD	01-JUN-18	Yes	No		4	NCT03399669	Previously-treated		Time to treatment failure, Time to progression	100	100																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 2	Gefitinib		Recruiting	NCT02347839	NEGOTIATE	ECD	01-JAN-20	Yes	No		4	NCT02347839			Percent of patients who become resectable	37	37																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Erlotinib		Completed	NCT00556712	SATURN	PCD	01-NOV-10	Expression level	Yes		1	20493771	Previously-treated		Progression free survival	618	307	311	Placebo									2.8	2.6	.69	0.58-0.82	p<0.0001																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Erlotinib + Niacinamaide		Active, not recruiting	NCT02416739		ECD	01-MAR-20	Yes	No		4	NCT02416739			Progression free survival	110			Erlotinib + Placebo																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Gefitinib + Niacinamaide		Active, not recruiting	NCT02416739		ECD	01-MAR-20	Yes	No		4	NCT02416739			Progression free survival	110			Gefitinib + Placebo																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Lazertinib + Placebo		Recruiting	NCT04487080	MARIPOSA	ECD	01-APR-24	Yes	No		4	NCT04487080	Untreated		Progression free survival	1000																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib + Placebo		Recruiting	NCT04487080	MARIPOSA	ECD	01-APR-24	Yes	No		4	NCT04487080	Untreated		Progression free survival	1000																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Amivantamab + Lazertinib		Recruiting	NCT04487080	MARIPOSA	ECD	01-APR-24	Yes	No		4	NCT04487080	Untreated		Progression free survival	1000																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Almonertinib + Carboplatin + Pemetrexed		Not yet recruiting	NCT04500717	ACROSS2	ECD	01-OCT-22	Yes	No		4	NCT04500717			Progression free survival	460			Almonertinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Almonertinib + Carboplatin + Pemetrexed		Not yet recruiting	NCT04500704	ACROSS1	ECD	01-DEC-21	Yes	No		4	NCT04500704			Progression free survival	166			Almonertinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Icotinib + Stereotactic radiotherapy		Recruiting	NCT04058704	SMART	ECD	01-DEC-22	Yes	No		4	NCT04058704			Overall survival	296			Icotinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Anlotinib + Gefitinib		Recruiting	NCT04028778	FL-ALTER	ECD	01-DEC-20	Yes	No		4	NCT04028778			Progression free survival	310			Gefitinib + Placebo																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Chemotherapy + Osimertinib		Recruiting	NCT03521154	LAURA	ECD	01-JUL-22	Yes	No		4	NCT03521154			Progression free survival	200																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Chemotherapy + Erlotinib	Required	Completed	NCT00883779	FASTACT-2	PCD	01-DEC-14	Yes	Yes		1	23782814	Untreated		Progression free survival	97	49	48	Chemotherapy	84	15							16.8	6.9	.25	0.16-0.39	p<0.0001									31.4	20.6	.48	0.27-0.84	0.0092												
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Gefitinib + Yiqi-yangyin-jiedu Decoction		Recruiting	NCT02929693	SHUTCM	ECD	01-JUN-19	Yes	No		4	NCT02929693			Progression free survival	198			Placebo																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Apatinib + Gefitinib		Recruiting	NCT02824458		ECD	01-DEC-23	Yes	No		4	NCT02824458	Untreated		Progression free survival	246			Gefitinib + Placebo																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Naquotinib		Terminated	NCT02588261	SOLAR	PCD	01-DEC-17	Yes	Yes	IDMC recommended study closure	4	NCT02588261	Untreated		Progression free survival	530	267	263	Erlotinib	33.0	47.9		1.0					9.26	9.59																												
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Naquotinib		Terminated	NCT02192697		PCD	01-JAN-16	Yes	Yes	Serious adverse events	4	NCT02588261	Previously-treated		Overall Response Rate	124																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Almonertinib		Recruiting	NCT03849768		ECD	01-DEC-21	Yes	No		4	NCT03849768	Untreated		Progression free survival	350																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alflutinib		Recruiting	NCT04143607		ECD	01-JAN-21	Yes	No		4	NCT04143607			Progression free survival	334			Gefitinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alflutinib		Active, not recruiting	NCT03787992	FLAG	ECD	01-JUN-21	Yes	No		4	NCT03787992	Untreated		Progression free survival	358																																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Zorifertinib		Recruiting	NCT03653546		ECD	01-JUN-21	Yes	No		4	NCT03653546	Previously-treated		Progression free survival	432			Gefitinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Abivertinib		Not yet recruiting	NCT03856697		ECD	01-MAR-22	Yes	No		4	NCT03856697	Untreated		Progression free survival	406			Gefitinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Bevacizumab + Erlotinib		Recruiting	NCT02633189	BEVERLY	ECD	01-DEC-17	Yes	No		4	NCT02633189	Untreated		Progression free survival	200			Erlotinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Bevacizumab + Erlotinib		Active, not recruiting	NCT02759614	Artemis	PCD	01-JUN-18	Yes	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/CTONG-1509-Phase-3-study-of-bevacizumab-with-or-without-erlotinib-in-untreated-Chinese-patients-with-advanced-EGFR-mutated-NSCLC	Untreated		Progression free survival	311	157	154	Erlotinib	86.3	84.7		0.74					18	11.3	.55	0.41-0.75	<0.001																									
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Afatinib + Cetuximab		Active, not recruiting	NCT02438722	SWOG S1403	PCD	01-SEP-18	Yes	No		3	https://www.jto.org/article/S1556-0864(16)32960-4/fulltext	Untreated		Overall survival	174			Afatinib																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Cisplatin + Gefitinib + Pemetrexed		Recruiting	NCT03381066		ECD	01-DEC-22	Yes	No		4	NCT03381066			Disease free survival, relapse free survival, regression free survival, recurrence free survival	225			Cisplatin + Vinorelbine																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Cisplatin + Gefitinib + Pemetrexed		Unknown	NCT02518802		ECD	01-JAN-18	Yes	No		4	NCT02518802			Disease free survival, relapse free survival, regression free survival, recurrence free survival	220			Cisplatin + Pemetrexed																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Olmutinib		Unknown		ELUXA3			Yes	No		5	https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-launches-ambitious-eluxa-trial-program-broadly-investigate	Untreated		Unknown																																										
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Nazartinib		Withdrawn	NCT03529084		ECD	01-AUG-20	Yes	No	Changed business priorities	4	NCT03529084	Untreated		Progression free survival	0	0																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Tesevatinib		Terminated	NCT01487174		PCD	01-MAY-14	No	No	Slow accrual	4	NCT01487174	Previously-treated		Overall survival																																										
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Recruiting	NCT04035486	FLAURA2	ECD	01-MAR-23	Yes	No		4	NCT04035486			Progression free survival	586			Carboplatin + Pemetrexed																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Not yet recruiting	NCT04351555	NeoADAURA	ECD	01-MAR-24	Yes	No		4	NCT04351555			Major pathologic response	328			Pemetrexed + Platinum-based chemotherapy																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 3	Erlotinib		Completed	NCT01024413		PCD	01-JUN-15	Yes	Yes		1	28103612			Progression free survival	256	128	128	Gefitinib									13	10.4		0.62-1.05	0.11									22.9	20.1		0.63-1.13	0.25												
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 4	Dacomitinib		Recruiting	NCT04511533		ECD	01-AUG-23	Yes	No		4	NCT04511533			Maximum tolerated dose/toxicity	100	100																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Phase 4	Beta-elemene + Tyrosine Kinase Inhibitor		Not yet recruiting	NCT04401059	SELECT-2	ECD	01-JUN-23	Yes	No		4	NCT04401059			Progression free survival	468			Tyrosine Kinase Inhibitor																																						
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Unknown	Apatinib + Erlotinib		Unknown	NCT03634059		ECD	01-AUG-19	Yes	No		4	NCT03634059	Untreated		Progression free survival	80	80																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Unknown	Apatinib + Icotinib		Unknown	NCT03634059		ECD	01-AUG-19	Yes	No		4	NCT03634059	Untreated		Progression free survival	80	80																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Unknown	Anlotinib + Gefitinib + Icotinib		Not yet recruiting	NCT03766490		ECD	01-DEC-19	Yes	No		4	NCT03766490	Previously-treated		Progression free survival	66	66																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / non small cell carcinoma	1	Unknown	Gefitinib + Radiotherapy		Not yet recruiting	NCT03381430	GRAY	ECD	01-MAR-23	Yes	No		4	NCT03381430			Disease free survival, relapse free survival, regression free survival, recurrence free survival	50	50																																								
EGFR	EGFR_L858R_Exon19del				lung / carcinoma / squamous cell carcinoma	3	Approved FDA	Afatinib	Required	Completed	NCT01523587	LUX-Lung 8		01-OCT-13	No	Yes		1	26156651	Previously-treated		Progression free survival	795	398	397	Erlotinib									2.4	1.9	.82	0.68-1.0	0.043									7.9	6.8	.81	0.61-0.95	0.008												
EGFR	EGFR_L861Q	51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	2	Phase 1	Capmatinib + Erlotinib		Active, not recruiting	NCT01911507		PCD	01-AUG-20	Yes	No		4	NCT01911507	Previously-treated		Maximum tolerated dose/toxicity	35	35																																								
EGFR	EGFR_L861Q	51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		Active, not recruiting	NCT03424759		PCD	01-DEC-17	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.9050 			Overall Response Rate	9	9																															7									
EGFR	EGFR_L861Q	51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	2	Phase 2	Capmatinib + Erlotinib		Terminated	NCT02468661		PCD	01-NOV-17	Yes	Yes	Slow accrual	4	NCT02468661	Previously-treated		Maximum tolerated dose/toxicity	23	23																																								
EGFR	EGFR_L861Q	51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	2	Phase 3	Afatinib		Completed					Yes	Yes		1	26051236			Unknown	16	16			56.3																																					
EGFR	EGFR_L861Q	51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	2	Phase 3	Bevacizumab + Erlotinib		Recruiting	NCT02633189	BEVERLY	ECD	01-DEC-17	Yes	No		4	NCT02633189	Untreated		Progression free survival	200			Erlotinib																																						
EGFR	EGFR_S768I	51768106		p.S768I	lung / carcinoma / non small cell carcinoma	2	Phase 2	Osimertinib		Active, not recruiting	NCT03424759		PCD	01-DEC-17	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.9050 			Overall Response Rate	8	8																															3									
EGFR	EGFR_S768I	51768106		p.S768I	lung / carcinoma / non small cell carcinoma	2	Phase 3	Afatinib		Completed					Yes	Yes		1	26051236			Unknown	8	8			100																																					
EGFR	EGFR_S768I	51768106		p.S768I	lung / carcinoma / non small cell carcinoma	2	Phase 3	Bevacizumab + Erlotinib		Recruiting	NCT02633189	BEVERLY	ECD	01-DEC-17	Yes	No		4	NCT02633189	Untreated		Progression free survival	200			Erlotinib																																						
EGFR	EGFR_S768I, V769L	51768106 + 51811749		p.S768I + p.V769L	lung / carcinoma / non small cell carcinoma	4	Case study	Gefitinib		Unknown					Yes	Yes		1	17045698			Unknown	1	1																															1									
EGFR	EGFR_T790M	51765492		p.T790M	NS / neoplasm / NS	3	Phase 2	Osimertinib		Recruiting	NCT02465060	MATCH Subprotocol E	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Approved FDA	Osimertinib		Active, not recruiting	NCT02151981	AURA3	PCD	01-APR-16	Yes	Yes		4	25923549	Untreated		Progression free survival	382	242	140	Chemotherapy	65.0	29		<0.001	11	4.2			10.1	4.4	.3	0.23-0.41	<0.001																									
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Case study	Afatinib		Completed	NCT00711594	LUX-Lung 4	PCD	01-NOV-13	Yes	Yes		1	22071596	Previously-treated		Unknown	1	1																																1								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Out of trials human study	Afatinib		Unknown					Comparison with wt	Yes		1	24035188			Unknown	21	13			5	38							3.2	4.6			0.33																									
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Sapanisertib		Recruiting	NCT04479306		ECD	01-JAN-23	Yes	No		4	NCT04479306	Previously-treated		Maximum tolerated dose/toxicity	40	40																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Alisertib + Osimertinib		Recruiting	NCT04479306		ECD	01-JAN-23	Yes	No		4	NCT04479306	Previously-treated		Maximum tolerated dose/toxicity	40	40																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	SH-1028		Unknown	NCT03618043		ECD	01-DEC-19	Yes	No		4	NCT03618043			Maximum tolerated dose/toxicity	14	14																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	SH-1028		Unknown	NCT03603262		ECD	01-DEC-19	Yes	No		4	NCT03603262	Previously-treated		Maximum tolerated dose/toxicity	85	85																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	D0316		Active, not recruiting	NCT03452150		ECD	01-MAY-21	Yes	No		4	NCT03452150	Previously-treated		Maximum tolerated dose/toxicity	50	50																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Avitinib		Completed	NCT03053219		PCD	01-JUL-18	Yes	No		4	NCT03053219			Overall Response Rate	7	7																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Savolitinib		Active, not recruiting	NCT02143466	TATTON	PCD	01-MAR-20	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	8	8			25		3-65																																			
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Selumetinib		Active, not recruiting	NCT02143466	TATTON	PCD	01-MAR-20	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	23	23			57		34-77																																			
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Afatinib + Ruxolitinib		Completed	NCT02145637		PCD	01-NOV-17	Yes	Yes		1	31319994	Previously-treated		Maximum tolerated dose/toxicity	20	20			25								4.9										100										5	15								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Durvalumab + Osimertinib		Active, not recruiting	NCT02143466	TATTON	PCD	01-MAR-20	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	13	13			54		25-81																										7	2								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Nazartinib + Nivolumab		Active, not recruiting	NCT02323126		ECD	01-DEC-21	Yes	No		4	NCT02323126	Previously-treated		Progression free survival	64																																									
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Osimertinib + Ramucirumab		Active, not recruiting	NCT02789345		PCD	01-OCT-17	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.9053	Previously-treated		Maximum tolerated dose/toxicity	25	25			76																		92									1	18	4								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Necitumumab + Osimertinib		Active, not recruiting	NCT02789345		PCD	01-OCT-17	Yes	No		4	NCT02789345	Previously-treated		Maximum tolerated dose/toxicity	74	74																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	BPI-7711		Active, not recruiting	NCT03386955		ECD	01-SEP-20	Yes	No		4	NCT03386955	Previously-treated		Maximum tolerated dose/toxicity	215	215																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Naquotinib		Completed	NCT02113813	8273-CL-0102	PCD	01-JUL-17	Yes	Yes		1	28954786	Previously-treated		Maximum tolerated dose/toxicity	110	110			30.7								6.8																													
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Abivertinib		Active, not recruiting	NCT02330367		ECD	01-DEC-20	Yes	Yes		1	30032814			Overall Response Rate	16	16			60.0								8.12													17.62							9	5								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Afatinib + Cetuximab		Completed	NCT01090011		PCD	01-JAN-13	Yes	Yes		1	29110849	Previously-treated		Maximum tolerated dose/toxicity	20	20											4.8																													
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 1	Olmutinib		Terminated	NCT04510415		PCD	01-DEC-18	Yes	Yes	Terminated by sponsor	4	NCT04510415	Previously-treated		Overall Response Rate	2	2																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Active, not recruiting	NCT01802632	AURA	PCD	01-MAY-15	Yes	Yes		4	25923549	Previously-treated		Overall Response Rate	127	127			61.0	21							9.6	2.8																												
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Almonertinib + Carboplatin + Pemetrexed		Not yet recruiting	NCT04592666	APPEAL	ECD	01-DEC-21	Yes	No		4	NCT04592666			Progression free survival	226	226																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Osimertinib		Not yet recruiting	NCT04438902	TRAIN	ECD	01-DEC-22	Yes	No		4	NCT04438902	Previously-treated		Progression free survival	30	30																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	ZN-e4		Recruiting	NCT03446417		ECD	01-JUN-22	Yes	No		4	NCT03446417			Maximum tolerated dose/toxicity	140	140																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	D0316		Recruiting	NCT03861156		ECD	01-DEC-21	Yes	No		4	NCT03861156			Overall Response Rate	286	286																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Avitinib		Recruiting	NCT03574402	TRUMP Arm 1	ECD	01-DEC-22	Yes	No		4	NCT03574402			Overall Response Rate	400	400																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Local Consolidation Therapy + Osimertinib		Recruiting	NCT03410043	NORTHSTAR	ECD	01-JAN-22	Yes	No		4	NCT03410043	Previously-treated		Progression free survival	143	143																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Luminespib		Completed	NCT01922583		PCD	01-FEB-17	Yes	No		4	NCT01922583			Overall Response Rate	31	31																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Emibetuzumab + Erlotinib		Active, not recruiting	NCT01897480		PCD	01-MAR-16	No	Yes	Primary outcome not met	2	https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9019	Untreated		Progression free survival	150			Erlotinib																																						
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Emibetuzumab + Erlotinib		Completed	NCT01900652		PCD	01-FEB-15	No	Yes	No benefit of treatment	3	https://meetinglibrary.asco.org/record/123487/abstract	Previously-treated		Overall Response Rate	111			Emibetuzumab																																						
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Itacitinib + Osimertinib		Active, not recruiting	NCT02917993		ECD	01-SEP-20	Yes	No		4	NCT02917993	Previously-treated		Overall Response Rate	59	59																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib + Erlotinib		Completed	NCT01866410	NCI 9303	PCD	01-MAR-18	Yes	Yes		1	30915273	Previously-treated		Overall Response Rate	37	37			10.8								3.6																				4	21								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Lerociclib + Osimertinib		Active, not recruiting	NCT03455829		ECD	01-APR-21	Yes	No		4	NCT03455829			Maximum tolerated dose/toxicity	30	30																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Aspirin + Osimertinib		Not yet recruiting	NCT03532698	COAST2	ECD	01-DEC-21	No	No		4	NCT03532698	Previously-treated		Overall Response Rate	100			Osimertinib																																						
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Aspirin + Osimertinib		Not yet recruiting	NCT03543683	COAST1	ECD	01-DEC-21	Yes	No		4	NCT03543683	Previously-treated		Progression free survival	330			Osimertinib																																						
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Osimertinib		Active, not recruiting	NCT02971501		ECD	01-JUL-21	Yes	No		4	NCT02971501			Progression free survival	112			Osimertinib																																						
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Bevacizumab + Osimertinib		Recruiting	NCT03133546	BOOSTER	ECD	01-MAY-22	Yes	No		4	NCT03133546	Previously-treated		Progression free survival	155			Osimertinib																																						
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	BPI-7711		Active, not recruiting	NCT03812809		ECD	01-SEP-20	Yes	No		4	NCT03812809			Overall Response Rate	226	226																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Malvertinib		Active, not recruiting	NCT02349633		PCD	01-MAY-20	Yes	Yes	Changed business priorities	3	https://www.jto.org/article/S1556-0864(16)32909-4/pdf	Previously-treated		Overall Response Rate	65	65																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Rociletinib		Terminated	NCT01526928		PCD	01-JUL-18	Yes	Yes		1	25923550	Previously-treated		Overall Response Rate	46	46			59																																					
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	BMS-690514		Completed	NCT00329004		PCD	01-JUL-09	Yes	Yes		1	23490650			Maximum tolerated dose/toxicity	1	1																															1									
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Recruiting	NCT03502850		ECD	01-JAN-21	Yes	No		4	NCT03502850			Overall Response Rate	507	507																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Alflutinib		Active, not recruiting	NCT03452592		ECD	01-JUN-20	Yes	No		4	NCT03452592			Overall Response Rate	220	220																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Erlotinib + Ruxolitinib		Completed	NCT02155465		PCD	01-OCT-17	Yes	Yes	No benefit of treatment	1	27613527	Previously-treated		Overall Response Rate	22	22																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Abivertinib		Recruiting	NCT03300115		ECD	01-JUN-19	Yes	No		4	NCT03300115			Overall Response Rate	222	222																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Poziotinib		Terminated	NCT01819428		PCD	01-NOV-15	Yes	Yes	Slow accrual	4	NCT01819428	Untreated		Overall Response Rate	20	20																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Canertinib		Completed	NCT00050830		PCD	01-JAN-03	No	Yes	Primary outcome not met	1	17761977	Previously-treated		Clinical activity	163	163																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Lazertinib		Active, not recruiting	NCT03046992		ECD	01-DEC-21	Yes	Yes		3	https://meetinglibrary.asco.org/record/161036/abstract	Previously-treated		Overall Response Rate	76	76			67.0		55.4-77.5																																			
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Olmutinib		Completed	NCT03228277		PCD	01-JUL-18	Yes	No		4	NCT03228277	Untreated		Overall Response Rate	25	25																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Olmutinib		Unknown	NCT01588145		PCD	01-AUG-17	Yes	Yes		5	https://www.boehringer-ingelheim.com/press-release/new-data-olmutinib-bi-1482694-presented-asco-2016	Previously-treated		Maximum tolerated dose/toxicity	38	38			54.0				8.3																																	
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Olmutinib		Terminated	NCT02485652	ELUXA 1	PCD	01-DEC-20	Yes	Yes		2	10.1093/annonc/mdx671.001	Previously-treated		Overall Response Rate	115	115			44.4								6.9										87.8																			
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Olmutinib		Completed	NCT02444819		PCD	01-AUG-17	Yes	No		4	NCT02444819	Untreated		Overall Response Rate	33	33																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT04563871	BLOSSOM	ECD	01-SEP-23	Yes	No		4	NCT04563871			Overall survival	80	80																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Not yet recruiting	NCT02824952		ECD	01-DEC-22	Yes	No		4	NCT02824952	Untreated		Overall Response Rate	40	40																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Unknown	NCT02811354	PLASMA	ECD	01-FEB-19	Yes	No		4	NCT02811354	Previously-treated		Overall Response Rate	108	108																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT02664935		ECD	01-OCT-22	Yes	No		4	NCT02664935			Overall Response Rate	549	549																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT03394118		ECD	01-DEC-20	Yes	No		4	NCT03394118			Overall Response Rate	63	63																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Active, not recruiting	NCT02094261	AURA2	PCD	01-MAY-15	Yes	Yes		4	NCT02094261	Previously-treated		Overall Response Rate	199	199			70.9				7.8				8.6										91.5																			
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Active, not recruiting	NCT02442349	AURA17	PCD	01-MAR-16	Yes	Yes		4	NCT02442349	Previously-treated		Overall Response Rate	171	171			60.2																		88.0																			
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Active, not recruiting	NCT02841579	AZENT	PCD	01-DEC-18	Yes	No		4	NCT02841579	Untreated		Maximum tolerated dose/toxicity	22	22																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 2	Osimertinib		Recruiting	NCT02856893	APPLE	ECD	01-FEB-22	Yes	No		4	NCT02856893			Progression free survival	159	159																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Unknown	NCT02972333	APOLLO	ECD	01-SEP-19	Yes	No		4	NCT02972333	Previously-treated		Progression free survival	150	150																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Durvalumab + Osimertinib		Active, not recruiting	NCT02454933	CAURAL	PCD	01-AUG-17	Yes	Yes	Serious adverse events	1	30763730	Previously-treated		Maximum tolerated dose/toxicity	29			Osimertinib																																						
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Erlotinib + Ramucirumab		Active, not recruiting	NCT02411448	RELAY	PCD	01-JAN-19	Yes	Yes	Met primary objective	5	https://bit.ly/2UtkdPW			Progression free survival	449	224	225	Erlotinib	76.3	74.4		0.7413 					19.4	12.4	.591	0.46-0.76	<0.0001						95.1	95.6	1.0																	
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Rociletinib		Terminated	NCT02322281	TIGER-3	PCD	01-MAR-18	No	Yes	Denied regulatory approval	2	10.1093/annonc/mdw140	Previously-treated		Progression free survival	149			Chemotherapy																																						
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Afatinib + Cetuximab		Active, not recruiting	NCT02438722	SWOG S1403	PCD	01-SEP-18	Yes	No		3	https://www.jto.org/article/S1556-0864(16)32960-4/fulltext	Untreated		OS, PFS	174			Afatinib																																						
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Olmutinib		Terminated	2015-005079-26	ELUXA2	PCD	01-AUG-16	Yes	No		5	https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-launches-ambitious-eluxa-trial-program-broadly-investigate	Previously-treated		Progression free survival	0	0		Chemotherapy																																						
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Olmutinib		Terminated		ELUXA3			Yes	Yes	Changed business priorities	3	https://www.hopkinsmedicine.org/singapore/_downloads/johns-hopkins-singapore-2016-research-report.pdf	Untreated		Unknown																																										
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Completed	NCT02959749		PCD	01-OCT-17	Yes	Yes		1	29858027	Previously-treated		Progression free survival	147	74	73	Bevacizumab + Docetaxel									10.2	2.95	.23	0.12-0.38	<0.001																									
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Completed	NCT02474355	ASTRIS	PCD	01-APR-19	Yes	Yes		3	https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/ASTRIS-A-real-world-treatment-study-of-osimertinib-in-patients-pts-with-EGFR-T790M-positive-non-small-cell-lung-cancer-NSCLC-European-subset			Overall survival	3020	3020											9.7																													
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 3	Osimertinib		Unknown	NCT03257124		ECD	01-DEC-18	Yes	No		4	NCT03257124	Previously-treated		ORR, OS	80	80																																								
EGFR	EGFR_T790M	51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Phase 4	Osimertinib		Completed	NCT03853551		PCD	01-APR-20	Yes	No		4	NCT03853551			Maximum tolerated dose/toxicity	60	60																																								
EGFR	EGFR_V769L	51811749		p.V769L	lung / carcinoma / non small cell carcinoma	3	Phase 3	Bevacizumab + Erlotinib		Recruiting	NCT02633189	BEVERLY	ECD	01-DEC-17	Yes	No		4	NCT02633189	Untreated		Progression free survival	200			Erlotinib																																						
EGFR	EGFR_no_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 1	Neoantigen vaccine + Tyrosine Kinase Inhibitor		Recruiting	NCT04487093		ECD	01-MAY-22	Yes	No		4	NCT04487093			Maximum tolerated dose/toxicity	20	20																																								
EGFR	EGFR_no_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 2	Glumetinib		Recruiting	NCT04338243		ECD	01-DEC-20	Yes	No		4	NCT04338243			Overall Response Rate	70	70																																								
EGFR	EGFR_no_T790M				lung / carcinoma / non small cell carcinoma	3	Phase 4	Afatinib + Osimertinib		Recruiting	NCT04413201	AFAMOSI	ECD	01-JUN-24	Yes	No		4	NCT04413201			Disease free survival, relapse free survival, regression free survival, recurrence free survival	126			Osimertinib																																						
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 1	Cetuximab + FATE NK100		Active, not recruiting	NCT03319459		ECD	01-OCT-21	Expression level	No		4	NCT03319459			Maximum tolerated dose/toxicity	100	100																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 1	HLX55		Recruiting	NCT04169178		ECD	01-DEC-22	Yes	No		4	NCT04169178			Overall Response Rate	98	98																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 1	ZZ06		Not yet recruiting	NCT04412616		ECD	01-JUN-22	Yes	No		4	NCT04412616			Maximum tolerated dose/toxicity	60	60																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 1	WSD0922-FU		Recruiting	NCT04197934		ECD	01-DEC-22	Yes	No		4	NCT04197934			Maximum tolerated dose/toxicity	72	72																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 1	Gatipotuzumab + Tomuzotuximab		Completed	NCT03360734	GATTO	PCD	01-MAY-20	Yes	No		4	NCT03360734			Maximum tolerated dose/toxicity	50	50																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 1	Neratinib + Trametinib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 1	Neratinib + Palbociclib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 1	Everolimus + Neratinib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 1	Serclutamab talirine		Active, not recruiting	NCT03234712		ECD	01-MAY-21	Expression level	No		4	NCT03234712			Maximum tolerated dose/toxicity	62	62																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Afatinib		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Erlotinib + Temozolomide		Withdrawn	NCT02689336		ECD	01-NOV-19	Yes	Yes		4	NCT02689336		Pediatric	Overall Response Rate	0	0																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Enfortumab vedotin		Recruiting	NCT04225117	EV-202	ECD	01-JUL-23	Yes	No		4	NCT04225117			Overall Response Rate	240	240																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Cetuximab + SNK01		Not yet recruiting	NCT04464967		ECD	01-AUG-22	Yes	No		4	NCT04464967			Overall Response Rate	154	154																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	SNK01 + Trastuzumab		Not yet recruiting	NCT04464967		ECD	01-AUG-22	Yes	No		4	NCT04464967			Overall Response Rate	154	154																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Osimertinib + RMC4630		Recruiting	NCT03989115		ECD	01-MAR-22	Yes	No		4	NCT03989115			Maximum tolerated dose/toxicity	168	168																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Anti-CTLA-4/PD-1 expressing EGFR-CAR-T		Unknown	NCT03182816		ECD	01-JAN-19	Yes	No		4	NCT03182816			Maximum tolerated dose/toxicity	40	40																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Cetuximab + FATE NK100		Recruiting	NCT02465060	MATCH Subprotocol C2	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Cetuximab + FATE NK100		Recruiting	NCT02465060	MATCH Subprotocol C1	ECD	01-JUN-22	Expression level	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Gefitinib		Recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT03239015			Overall Response Rate	300	300																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Erlotinib		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Erlotinib		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Afatinib		Recruiting	NCT02465060	MATCH Subprotocol A	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
EGFR	EGFR_unspecified				NS / other / neoplasm	3	Phase 2	Afatinib		Recruiting	NCT03810872		ECD	01-DEC-20	Yes	No		4	NCT03810872			Response rate	87	87																																								
EGFR	EGFR_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Varlitinib		Completed	NCT02609958	ASLAN001-005	PCD	01-JUL-17	No	No		4	NCT02609958	Previously-treated		Overall Response Rate	32	32																																								
EGFR	EGFR_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Varlitinib		Unknown					No	Yes		3	http://cancerres.aacrjournals.org/content/69/9_Supplement/3603			Unknown	1	1																															1									
EGFR	EGFR_unspecified				biliary tract / other / neoplasm	3	Phase 1	Erlotinib + Gemcitabine + Oxaliplatin		Completed	NCT01149122		PCD	01-JAN-12	No	Yes		1	22192731			Progression free survival	268	135	133	Gemcitabine + Oxaliplatin	30	16							5.8	4.2	.8	0.61-1.03	0.087									9.5	9.5	.93	0.69-1.25	0.611												
EGFR	EGFR_unspecified				biliary tract / other / neoplasm	3	Phase 2	Capecitabine + Varlitinib		Completed	NCT03231176		ECD	01-JUL-19	No	Yes		5	http://aslanpharma.com/app/uploads/2019/09/CSCO-2019_ASLAN001-008.pdf	Previously-treated		Overall Response Rate	61	61			10.8								2.7										70.2			5.8																
EGFR	EGFR_unspecified				biliary tract / other / neoplasm	3	Phase 3	Capecitabine + Varlitinib		Active, not recruiting	NCT03093870	TreeTop	ECD	01-JUL-19	No	No		5	http://aslanpharma.com/app/uploads/2018/06/2018-ASCO-ASLAN001-009.pdf	Previously-treated		ORR, PFS, OR	490			Capecitabine																																						
EGFR	EGFR_unspecified				bone / chordoma / NS	3	Phase 2	Afatinib		Recruiting	NCT03083678		ECD	01-MAR-20	Yes	No		4	NCT03083678			Progression free survival	40	40																																								
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Canertinib		Completed	NCT00051051		PCD	01-DEC-02	No	Yes	Primary outcome not met	1	19294387	Previously-treated		Clinical activity	168																																									
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Lapatinib + Paclitaxel + Trastuzumab		Completed	NCT01688609		PCD	01-DEC-13	No	Yes		4	NCT01688609			Complete response, Pathological complete response	18	18																														8										
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Carboplatin + Gemcitabine + Panitumumab		Completed	NCT00894504		PCD	01-SEP-14	No	Yes	No benefit of treatment, response not correlated with mutation status	1	27340049			Progression free survival	71	71			42.0								4.4													11.6						1	29									
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Capecitabine + Pyrotinib		Completed					No	Yes		3	http://cancerres.aacrjournals.org/content/78/4_Supplement/PD3-08			Unknown	128	65	63	Capecitabine + Lapatinib	78.5	57.1		0.01					18.1	7	.363	0.228-0.579	<0.0001																									
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 2	Poziotinib		Recruiting	NCT02544997		PCD	01-FEB-20	Yes	Yes	Primary outcome not met	4	NCT02544997	Previously-treated		Progression free survival	5	5																																								
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Pyrotinib		Active, not recruiting	NCT02973737		ECD	01-DEC-18	No	No		4	NCT02973737	Previously-treated		Progression free survival	350			Capecitabine																																						
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 3	Docetaxel + Pyrotinib + Trastuzumab		Recruiting	NCT03588091		ECD	01-SEP-19	No	No		4	NCT03588091			Complete response, Pathological complete response	294			Docetaxel + Trastuzumab																																						
EGFR	EGFR_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Pyrotinib		Active, not recruiting	NCT03080805	PHOEBE	PCD	01-MAR-19	No	Yes		2	10.1200/JCO.2020.38.15_suppl.1003	Previously-treated		Progression free survival	267	134	132	Capecitabine + Lapatinib	67.2	51.5	4.0-27.3	0.0091	11.1	7			12.5	6.8	.39	0.27-0.56	<0.0001						73.1	59.1																		
EGFR	EGFR_unspecified				central nervous system / NS / NS	3	Phase 1	EGFR806-CAR T cells		Recruiting	NCT03638167		ECD	01-MAR-22	Yes	No		4	NCT03638167			Maximum tolerated dose/toxicity	36	36																																								
EGFR	EGFR_unspecified				central nervous system / glioma / NS	3	Phase 1	AMG404 + AMG596		Active, not recruiting	NCT03296696		ECD	01-DEC-21	Yes	No		4	NCT03296696			Maximum tolerated dose/toxicity	30	30																																								
EGFR	EGFR_unspecified				central nervous system / glioma / NS	3	Phase 2	Poziotinib		Recruiting	NCT04172597		ECD	01-JUN-23	Yes	No		4	NCT04172597			Overall Response Rate	150	150																																								
EGFR	EGFR_unspecified				central nervous system / glioma / NS	3	Phase 2	Irinotecan + Panitumumab		Terminated	NCT01017653		PCD	01-OCT-11	No	Yes	No benefit of treatment	4	NCT01017653			Progression free survival	16	16																																								
EGFR	EGFR_unspecified				central nervous system / glioma / NS	3	Unknown	MAb-425		Completed					Expression level	Yes	Serious adverse events	1	9191875			Overall survival	8	8																															3									
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 1	Erlotinib		Terminated	NCT00227032		PCD	01-FEB-08	No	Yes	Loss of funding	4	NCT00227032			Progression free survival	10	10																																								
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 1	Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells		Suspended	NCT03283631	INTERCEPT	ECD	01-DEC-21	Yes	No		4	NCT03283631			Maximum tolerated dose/toxicity	24	24																																								
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 1	Depatuxizumab mafodotin  + Temozolomide		Completed	NCT01800695		PCD	01-JUN-17	Expression level	Yes		1	29075855	Previously-treated		Maximum tolerated dose/toxicity	202	202			6.8																																					
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Erlotinib		Completed	NCT00301418		PCD	01-MAY-14	No	Yes	No serious adverse events	1	16282176	Previously-treated		Maximum tolerated dose/toxicity	11	11																								5.49																
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Verteporfin		Recruiting	NCT04590664		ECD	01-AUG-23	Yes	No		4	NCT04590664	Previously-treated		OS, PFS	24	24																																								
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	GC1118		Recruiting	NCT03618667		ECD	01-DEC-20	Expression level	No		4	NCT03618667			Progression free survival	23	23																																								
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Afatinib + Temozolomide		Completed	NCT00727506		PCD	01-MAY-11	No	Yes	No benefit of treatment	1	25140039	Previously-treated		Progression free survival	151			Afatinib																																						
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Depatuxizumab mafodotin  + Temozolomide		Completed	NCT02343406	INTELLANCE 2	PCD	01-JUN-19	Expression level	Yes		2	10.1093/neuonc/noy148.072	Previously-treated		Progression free survival	255	255		Temozolomide																						40	28	.68	0.48-0.95	0.024												
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Tesevatinib		Active, not recruiting	NCT02844439		PCD	01-APR-20	No	No		4	NCT02844439			Progression free survival	40	40																																								
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Dacomitinib		Completed	NCT01520870		PCD	01-APR-15	Expression level	Yes	No benefit of treatment	1	28575464	Previously-treated		Progression free survival	49	49																																								
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 3	Depatuxizumab mafodotin  + Temozolomide		Recruiting	NCT02573324	Intellance1	ECD	01-JUN-21	Expression level	Yes	Enrollment stopped	3	https://news.abbvie.com/news/press-releases/abbvie-provides-update-on-depatuxizumab-mafodotin-depatux-m-an-investigational-medicine-for-newly-diagnosed-glioblastoma-an-aggressive-form-brain-cancer.htm	Untreated		Overall survival	691			Temozolomide																																						
EGFR	EGFR_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 3	Depatuxizumab mafodotin  + Temozolomide		Completed	NCT03419403	UNITE	PCD	01-SEP-19	Expression level	No		4	NCT03419403	Untreated		Change in ocular side effect management	40			Temozolomide																																						
EGFR	EGFR_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Capecitabine + Cetuximab + Cisplatin		Completed	NCT00477711	EXTRA	PCD	01-DEC-08	No	Yes		1	25234930	Untreated		Response rate	7	7											7.1													16.6																
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Approved FDA	Cetuximab		Completed	NCT00079066	CO.17	PCD	01-MAR-06	Expression level	No		4	NCT00079066	Previously-treated		Overall survival	572	287	285	Best supportive care	8.0	0																				6.1	4.6	.77	0.64-0.92	0.005												
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Approved FDA	Cetuximab + Irinotecan	Expression	Completed		BOND			Expression level	Yes		1	15269313			Unknown	329	218	111	Cetuximab	22.9	10.8		0.007	5.7	4.2													55.5	32.4	<0.001																	
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Approved FDA	Cetuximab + FOLFIRI	wt KRAS	Completed	NCT00154102	CRYSTAL	PCD	01-DEC-06	Expression level	Yes		1	19339720	Untreated		Progression free survival	1198	599	599	FOLFIRI									8.9	8	.85	0.72-0.99	0.048									19.9	18.6	.93	0.81-1.07	0.31												
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Approved FDA	Panitumumab	wt KRAS	Completed	NCT01001377	20080763	PCD	01-FEB-13	No	Yes		1	24739896	Previously-treated		Overall survival	1010	506	504	Cetuximab																						10.4	10	.97	0.84-1.11													
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Approved FDA	Panitumumab	wt KRAS	Completed	NCT01412957	20100007	PCD	01-JUN-14	No	Yes		1	27736842	Previously-treated		Overall survival	377	189	188	Best supportive care																						10.0	6.9	.7	0.53-0.93	0.0135												
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Approved FDA	Panitumumab	wt KRAS	Completed	NCT00113763	20020408	PCD	01-OCT-08	Expression level	Yes		1	17470858	Previously-treated		Progression free survival	463	231	232	Best supportive care	10	0		0.001					1.83	1.69																												
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Pelitinib		Unknown					Yes	Yes		1	16364494			Unknown	15	15																														2										
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Nazartinib + TNO155		Recruiting	NCT03114319		ECD	01-AUG-22	Yes	No		4	NCT03114319			Maximum tolerated dose/toxicity	255	255																																								
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Regorafenib		Recruiting	NCT03992456	PULSE	ECD	01-DEC-22	No	No		4	NCT03992456			Overall survival	120	120																																								
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Trifluridine and tipiracil hydrochloride		Recruiting	NCT03992456	PULSE	ECD	01-DEC-22	No	No		4	NCT03992456			Overall survival	120	120																																								
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Erlotinib + Pemetrexed		Recruiting	NCT03086538		ECD	01-DEC-20	Yes	No		4	NCT03086538			Overall Response Rate	29	29																																								
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	EGFR CAR-CD3-CD28-4-1BB-expressing autologous T-lymphocytes		Unknown	NCT03152435		ECD	01-SEP-19	Expression level	No		4	NCT03152435			Maximum tolerated dose/toxicity	20	20																																								
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Panitumumab + Trametinib		Recruiting	NCT03087071		ECD	01-DEC-21	Yes	No		4	NCT03087071			Response rate	84	84																																								
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFOX-4		Completed	NCT00202787		PCD	01-FEB-09	No	No		3	https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001700-12/results			Overall Response Rate	136	68	68	FOLFOX-4	47.1	54.4			6.7	9.6			8.05	10.09				8.77	9.45				95.6	88.2		19.52	26.38			0.02												
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Folfirinox + Panitumumab		Recruiting	NCT01328171	VOLFI	PCD	01-JUN-17	No	Yes		1	31609637	Untreated		Overall Response Rate	96	63	33	Folfirinox	87.3	60.6		0.004																																		
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + Erlotinib + FOLFOX		Completed					No	Yes		1	28979818	Previously-treated		Unknown	132	66	65	Bevacizumab + FOLFOX									9.6	6.9	1.15	0.88-1.39	0.021																									
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFIRI + Imgatuzumab		Completed	NCT01326000		PCD	01-DEC-13	Expression level	Yes	No benefit of treatment	2	10.1200/jco.2015.33.3_suppl.669 	Previously-treated		Progression free survival				FOLFIRI																																						
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Sym004		Completed	NCT02083653		PCD	01-OCT-16	No	Yes	Primary outcome not met	1	29423521	Previously-treated		Overall survival	254			Best supportive care																																						
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Sym004		Terminated	NCT03549338		PCD	01-MAR-19	No	Yes	Administrative reasons	4	NCT03549338	Previously-treated		Maximum tolerated dose/toxicity																																										
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Panitumumab		Recruiting	NCT03992456	PULSE	ECD	01-DEC-22	No	No		4	NCT03992456			Overall survival	120	120																																								
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Duligotuzumab + FOLFIRI		Completed	NCT01652482		PCD	01-NOV-14	No	Yes	No benefit of treatment	1	29506988	Previously-treated		Progression free survival																																										
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pelitinib		Completed	NCT00072748		PCD	01-OCT-04	No	Yes	Serious adverse events	1	24574860	Previously-treated		Not defined	63	63																																								
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab + FOLFIRI		Not yet recruiting	NCT02942706	BLOC-1	ECD	01-OCT-21	No	No		4	NCT02942706			Progression free survival	200			FOLFIRI																																						
EGFR	EGFR_unspecified				large intestine / carcinoma / adenocarcinoma	3	Unknown	FOLFIRI + Regorafenib		Completed	NCT03698253		PCD	01-JUN-18	Expression level	Yes		1	30594039			Progression free survival	28	28											2.5										46.4			9.6																
EGFR	EGFR_unspecified				liver / NS / NS	3	Phase 2	Bevacizumab + Erlotinib		Completed	NCT00365391		PCD	01-AUG-08	No	Yes		4	NCT00365391			Overall Response Rate	27	27			3.7																												1									
EGFR	EGFR_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Varlitinib		Recruiting	NCT03499626		ECD	01-MAY-19	Yes	No		4	NCT03499626			Maximum tolerated dose/toxicity	22	22																																								
EGFR	EGFR_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Erlotinib + Ruxolitinib		Completed	NCT02155465		PCD	01-OCT-17	Yes	Yes	No benefit of treatment	1	27613527	Previously-treated		Maximum tolerated dose/toxicity	22	22																															1									
EGFR	EGFR_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Cisplatin + Nimotuzumab + Pemetrexed		Recruiting	NCT03574402	TRUMP Arm 11	ECD	01-DEC-22	Expression level	No		4	NCT03574402			Response rate	400	400																																								
EGFR	EGFR_unspecified				lung / carcinoma / bronchioloalveolar adenocarcinoma	3	Phase 2	Gefitinib		Completed	NCT00029003		PCD	01-DEC-04	No	No		4	NCT00029003			Overall survival	90	90																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Approved other	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel		Recruiting	NCT04245085	ABC-lung	ECD	01-DEC-22	Yes	No		4	NCT04245085			Progression free survival	95			Atezolizumab + Bevacizumab + Pemetrexed																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Out of trials human study	Pemetrexed		Unknown					Comparison with wt	Yes		1	21111508	Previously-treated		Unknown	93	63			12.9	1.59							3.9	2.3	.677	0.485-0.943	0.021						51.6	38.1		30.8	25.8			0.439												
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Afatinib		Unknown	NCT03711422		ECD	01-SEP-20	Yes	No		4	NCT03711422			OS, PFS	25	25																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	BBP-398		Recruiting	NCT04528836		ECD	01-JUL-23	Yes	No		4	NCT04528836			Maximum tolerated dose/toxicity	60	60																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	BCA101		Recruiting	NCT04429542		ECD	01-DEC-22	Expression level	No		4	NCT04429542			Maximum tolerated dose/toxicity	292	292																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	BCA101 + Pembrolizumab		Recruiting	NCT04429542		ECD	01-DEC-22	Expression level	No		4	NCT04429542			Maximum tolerated dose/toxicity	292	292																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Individualized neoantigen peptides vaccine		Recruiting	NCT04397926		ECD	01-MAY-22	Yes	No		4	NCT04397926			Maximum tolerated dose/toxicity	20	20																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Alisertib + Osimertinib		Recruiting	NCT04085315		ECD	01-SEP-22	Yes	No		4	NCT04085315			Maximum tolerated dose/toxicity	36	36																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	TY9591		Recruiting	NCT04204473		ECD	01-JUN-22	Yes	No		4	NCT04204473			Overall Response Rate	126	126																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Afatinib + Talcum powder		Active, not recruiting	NCT03827070	DPTA	ECD	01-NOV-19	Yes	No		4	NCT03827070			Clinical activity	12	12																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Carboplatin + Pemetrexed + Zimberelimab		Recruiting	NCT03846310		ECD	01-JUN-21	Yes	No		4	NCT03846310			Maximum tolerated dose/toxicity	116	116																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Carboplatin + Etrumadenant + Pemetrexed + Zimberelimab		Recruiting	NCT03846310		ECD	01-JUN-21	Yes	No		4	NCT03846310			Maximum tolerated dose/toxicity	116	116																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Osimertinib + Palcitoclax		Recruiting	NCT04001777		ECD	01-APR-22	Yes	No		4	NCT04001777			Maximum tolerated dose/toxicity	60	60																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Niraparib + Osimertinib		Recruiting	NCT03891615		ECD	01-APR-22	Yes	No		4	NCT03891615			Maximum tolerated dose/toxicity	30	30																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Mobocertinib		Recruiting	NCT03807778		ECD	01-SEP-21	Yes	No		4	NCT03807778			Overall Response Rate	63	63																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Ipilimumab + Osimertinib		Recruiting	NCT04141644	Osi+Ipi	ECD	01-JUL-21	Yes	No		4	NCT04141644			Maximum tolerated dose/toxicity	26	26																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	JNJ-61186372 + Lazertinib		Recruiting	NCT04077463		ECD	01-FEB-22	Yes	No		4	NCT04077463			ORR, PFS, DOR	400	400																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Anlotinib + Erlotinib		Recruiting	NCT03628521		ECD	01-DEC-19	Yes	No		4	NCT03628521	Untreated		Overall Response Rate	80	80																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Pembrolizumab + Stereotactic Body Radiation Therapy		Active, not recruiting	NCT03436056	PRIMING	ECD	01-MAR-21	Yes	No		4	NCT03436056			Maximum tolerated dose/toxicity	24	24																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Osimertinib + Stereotactic radiotherapy		Recruiting	NCT03535363		ECD	01-MAR-21	Yes	No		4	NCT03535363			Maximum tolerated dose/toxicity	40	40																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	DV281		Completed	NCT03326752		PCD	01-SEP-19	No	No		4	NCT03326752			Maximum tolerated dose/toxicity	26	26																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Cisplatin + Etoposide + Osimertinib		Recruiting	NCT03567642		ECD	01-JUN-22	Yes	No		4	NCT03567642			Maximum tolerated dose/toxicity	30	30																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Capmatinib + Erlotinib		Active, not recruiting	NCT01911507		PCD	01-AUG-20	No	No		4	NCT01911507	Previously-treated		Maximum tolerated dose/toxicity	35	35																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Abemaciclib + Necitumumab		Completed	NCT02411591		PCD	01-JUN-17	No	Yes		4	NCT02411591	Previously-treated		Maximum tolerated dose/toxicity	57	57			5.3		1.1-14.6																										3	24								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Gefitinib + Savolitinib		Active, not recruiting	NCT02374645		PCD	01-FEB-18	Yes	No		4	NCT02374645	Previously-treated		Maximum tolerated dose/toxicity	64	64																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Cucurmin + Erlotinib		Unknown	NCT02321293		ECD	01-AUG-16	No	No		4	NCT02321293			Maximum tolerated dose/toxicity	20	20																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Cucurmin + Gefitinib		Unknown	NCT02321293	CURCUMIN	ECD	01-AUG-16	No	No		4	NCT02321293			Maximum tolerated dose/toxicity	20	20																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Buparlisib + Gefitinib		Active, not recruiting	NCT01570296		PCD	01-FEB-16	Expression level	Yes		2	10.1200/jco.2013.31.15_suppl.8107			Maximum tolerated dose/toxicity	10	10											2.8			2.3-8.1																										
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Dasatinib + Erlotinib		Completed	NCT00903734		PCD	01-JUL-15	Yes	No		4	NCT00903734			Maximum tolerated dose/toxicity	16	16																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Bortezomib + Erlotinib		Completed	NCT00903734		PCD	01-JUL-15	Yes	No		4	NCT00903734			Maximum tolerated dose/toxicity	16	16																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Cetuximab + Erlotinib		Completed	NCT00903734		PCD	01-JUL-15	Yes	No		4	NCT00903734			Maximum tolerated dose/toxicity	16	16																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Durvalumab + Gefitinib		Active, not recruiting	NCT02088112		ECD	01-DEC-21	No	Yes		2	10.1200/jco.2015.33.15_suppl.3047			Maximum tolerated dose/toxicity	56	56																															3									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Erlotinib + Momelotinib		Terminated	NCT02206763		PCD	01-JAN-17	Yes	Yes	Serious adverse events, no benefit of treatment	2	10.1016/j.jtho.2017.09.1294			Maximum tolerated dose/toxicity	11	11			54.5				7.1				9.2																				6	4								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Pacritinib		Terminated	NCT02342353		PCD	01-FEB-18	Yes	Yes	Drug unavailable	4	NCT02342353			Maximum tolerated dose/toxicity	8	8																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Crizotinib + Nivolumab		Completed	NCT01998126		PCD	01-MAY-17	Yes	No		4	NCT01998126			Maximum tolerated dose/toxicity	14	14																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Crizotinib + Ipilimumab		Completed	NCT01998126		PCD	01-MAY-17	Yes	Yes	Serious adverse events	1	31346927			Maximum tolerated dose/toxicity	11	11											17.9																													
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Nivolumab + Sym004		Withdrawn	NCT02924233		PCD	01-FEB-17	Expression level	Yes	Changed business priorities	4	NCT02924233			Maximum tolerated dose/toxicity																																										
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Matuzumab + Pemetrexed		Completed					Expression level	Yes		1	16533873			Unknown	18																															1	3									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Binimetinib + Erlotinib		Active, not recruiting	NCT01859026		PCD	01-AUG-19	Yes	No		4	NCT01859026			Maximum tolerated dose/toxicity	43	43																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Afatinib + Necitumumab		Recruiting	NCT03054038		ECD	01-DEC-21	Yes	No		4	NCT03054038	Previously-treated		Maximum tolerated dose/toxicity	60	60																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Dacomitinib + Osimertinib		Recruiting	NCT03755102		ECD	01-NOV-22	Yes	No		4	NCT03755102			Overall Response Rate	24	24																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Dacomitinib + Osimertinib		Active, not recruiting	NCT03810807		ECD	01-JAN-22	Yes	No		4	NCT03810807	Untreated		Maximum tolerated dose/toxicity	22	22																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Afatinib + Dasatinib		Completed	NCT01999985		PCD	01-MAR-17	No	Yes	No benefit of treatment	1	30880334	Previously-treated		Maximum tolerated dose/toxicity	25	25			0								3.7													14.7								6								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Naquotinib		Terminated	NCT03082300		PCD	01-MAY-17	Yes	Yes	SOLAR Study IDMC recommended closure	4	NCT03082300			Maximum tolerated dose/toxicity	3	3																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Almonertinib		Not yet recruiting	NCT04455594	ANSWER	ECD	01-JAN-23	Yes	No		4	NCT04455594			Overall Response Rate	168	168																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	DS-1205c + Osimertinib		Active, not recruiting	NCT03255083		ECD	01-APR-21	Yes	No		4	NCT03255083	Previously-treated		Maximum tolerated dose/toxicity	13	13																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Pelitinib		Unknown					Yes	Yes		1	16364494			Unknown																																	2									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Dacomitinib		Recruiting	NCT03755102		ECD	01-NOV-22	Yes	No		4	NCT03755102			Overall Response Rate	24	24																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ipilimumab + Nivolumab		Unknown	NCT03091491		ECD	01-DEC-19	Yes	No		4	NCT03091491			Overall Response Rate	184	184																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Nivolumab + Pemetrexed		Completed	NCT03256136		PCD	01-AUG-19	Yes	Yes		4	NCT03256136			Overall Response Rate	4	4			25								4.65										75																			
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Abemaciclib + Osimertinib		Recruiting	NCT04545710		ECD	01-SEP-22	Yes	No		4	NCT04545710	Previously-treated		Progression free survival	18	18																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Osimertinib + Pemetrexed		Not yet recruiting	NCT04335292	OCELOT	ECD	01-JUN-24	Yes	No		4	NCT04335292	Previously-treated		Overall Response Rate	200	200																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Cisplatin + Durvalumab + Stereotactic Body Radiation Therapy		Not yet recruiting	NCT04517526		ECD	01-NOV-22	Yes	No		4	NCT04517526			OS, PFS	60	60																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Necitumumab + Osimertinib + Trastuzumab		Not yet recruiting	NCT04285671		ECD	01-DEC-22	Yes	No		4	NCT04285671			Overall Response Rate	26	26																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Afatinib + Cisplatin + Pemetrexed		Not yet recruiting	NCT04470076	Neoafa	ECD	01-DEC-21	Yes	No		4	NCT04470076			Overall Response Rate	30	30																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Quaratusugene ozeplasmid		Not yet recruiting	NCT04486833	GEN-104	ECD	01-SEP-24	Yes	No		4	NCT04486833	Previously-treated		Progression free survival	100	100																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Osimertinib + Paclitaxel		Recruiting	NCT04410796		ECD	01-MAY-23	Yes	No		4	NCT04410796			Progression free survival	571	571																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Pemetrexed + Tislelizumab		Not yet recruiting	NCT04405674		ECD	01-APR-22	Yes	No		4	NCT04405674			Progression free survival	66	66																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Bevacizumab		Recruiting	NCT04426825		ECD	01-DEC-21	Yes	No		4	NCT04426825			Progression free survival	60	60																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Famitinb + HS-10296		Not yet recruiting	NCT03904823		ECD	01-AUG-20	Yes	No		4	NCT03904823			Overall Response Rate	58	58																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Apatinib + Tyrosine Kinase Inhibitor		Recruiting	NCT03811054		ECD	01-DEC-20	Yes	No		4	NCT03811054			Overall Response Rate	60	60																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	EMB-01		Recruiting	NCT03797391		ECD	01-SEP-21	Yes	No		4	NCT03797391			OS, PFS	73	73																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Anlotinib + Osimertinib		Active, not recruiting	NCT04029350	ALTN-03	ECD	01-JAN-20	Yes	No		4	NCT04029350			Progression free survival	53	53																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + RMC4630		Recruiting	NCT03989115		ECD	01-MAR-22	Yes	No		4	NCT03989115			Maximum tolerated dose/toxicity	168	168																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + RMC4630		Recruiting	NCT03989115		ECD	01-MAR-22	Yes	No		4	NCT03989115			Maximum tolerated dose/toxicity	168	168																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	DZD9008		Recruiting	NCT03974022	WU-KONG1	ECD	01-DEC-22	Yes	No		4	NCT03974022			Overall Response Rate	160	160																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Tepotinib		Recruiting	NCT03940703	INSIGHT2	ECD	01-NOV-22	Yes	No		4	NCT03940703			Overall Response Rate	120	120																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Mobocertinib		Recruiting	NCT03574402	TRUMP Arm 12	ECD	01-DEC-22	Yes	No		4	NCT03574402			Response rate	400	400																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pembrolizumab + Ramucirumab		Recruiting	NCT04120454		ECD	01-DEC-21	Yes	No		4	NCT04120454			Overall Response Rate	34	34																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	GC1118 + Paclitaxel		Not yet recruiting	NCT04077255		ECD	01-DEC-23	Yes	No		4	NCT04077255			Overall Response Rate	85	85																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Stereotactic Body Radiation Therapy		Recruiting	NCT03667820		ECD	01-APR-21	Yes	No		4	NCT03667820			Progression free survival	37	37																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Anlotinib + Sintilimab		Recruiting	NCT03765775		ECD	01-DEC-19	Yes	No		4	NCT03765775			Progression free survival	20	20																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	FCN-411		Recruiting	NCT03420079		ECD	01-DEC-20	Yes	No		4	NCT03420079			Maximum tolerated dose/toxicity	90	90																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dihydroartemisinin + Icotinib		Unknown	NCT03402464		ECD	01-JUN-19	Yes	No		4	NCT03402464			OS, PFS	30	30																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Afatinib + Tucidinostat		Recruiting	NCT03574402	TRUMP Arm 2	ECD	01-DEC-22	Yes	No		4	NCT03574402			Overall Response Rate	400	400																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	SH-1028		Unknown	NCT03823807		ECD	01-DEC-20	Yes	No		4	NCT03823807			Overall Response Rate	300	300																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	AZD4205 + Osimertinib		Completed	NCT03450330	JACKPOT1	PCD	01-SEP-19	Yes	No		4	NCT03450330			Maximum tolerated dose/toxicity	10	10																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Stereotactic radiotherapy		Not yet recruiting	NCT04519983		ECD	01-DEC-23	Yes	No		4	NCT04519983	Previously-treated		Overall Response Rate	30	30																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Stereotactic radiotherapy		Recruiting	NCT03497767	OUTRUN	ECD	01-AUG-23	Yes	No		4	NCT03497767			Progression free survival	80	80																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Stereotactic Body Radiation Therapy + Tyrosine Kinase Inhibitor		Recruiting	NCT03595644		ECD	01-OCT-20	Yes	No		4	NCT03595644			Progression free survival	72	72																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Ningetinib		Recruiting	NCT03758287		ECD	01-AUG-21	Yes	No		4	NCT03758287	Previously-treated		Overall Response Rate	158	158																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Apatinib + Chemotherapy		Not yet recruiting	NCT03758677		ECD	01-NOV-20	Yes	No		4	NCT03758677			Progression free survival	30	30																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Autologous T-Cells with enhanced TCRs specific for NY-ESO-1/LAGE-1a + Pembrolizumab		Recruiting	NCT03709706		ECD	01-MAY-25	No	No		4	NCT03709706			Overall Response Rate	54	54																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Autologous T-Cells with enhanced TCRs specific for NY-ESO-1/LAGE-1a		Recruiting	NCT03709706		ECD	01-MAY-25	No	No		4	NCT03709706			Overall Response Rate	54	54																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Avitinib		Recruiting	NCT03574402	TRUMP Arm 13	ECD	01-DEC-22	Expression level	No		4	NCT03574402			Response rate	400	400																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Apatinib + Camrelizumab		Unknown	NCT03083041		ECD	01-DEC-18	Yes	No		4	NCT03083041			Overall Response Rate	118	118																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	AVID100		Active, not recruiting	NCT03094169		ECD	01-NOV-20	Yes	No		4	NCT03094169			Clinical activity	90	90																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Icotinib + Stereotactic Body Radiation Therapy		Not yet recruiting	NCT03754530		ECD	01-JUN-20	Yes	No		4	NCT03754530			Progression free survival	162	162																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Icotinib + Stereotactic Body Radiation Therapy		Unknown	NCT03153358		ECD	01-NOV-17	Yes	No		4	NCT03153358			Progression free survival	60	60																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Cabozantinib		Recruiting	NCT03170960	Expansion Cohort 9	ECD	01-DEC-20	Yes	No		4	NCT03170960			Overall Response Rate	1732	1732																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	29	36		Erlotinib + Placebo									3.69	2.4	.86		0.32																									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Anlotinib + Docetaxel		Recruiting	NCT04619563		ECD	01-OCT-21	Yes	No		4	NCT04619563			Progression free survival	42	42																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Durvalumab + Pemetrexed		Recruiting	NCT03944772	ORCHARD	ECD	01-NOV-23	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	182	182																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Tepotinib 		Recruiting	NCT03940703	INSIGHT 2	ECD	01-NOV-22	Yes	No		4	NCT03940703	Previously-treated		Overall Response Rate	120	120																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Savolitinib		Recruiting	NCT03944772	ORCHARD	ECD	01-NOV-23	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	182	182																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib + Savolitinib		Recruiting	NCT03778229	SAVANNAH	ECD	01-OCT-21	Yes	No		4	NCT03778229	Previously-treated		Overall Response Rate	192	192																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cetuximab + Cilengitide + Cisplatin + Vinorelbine		Completed	NCT00842712	CERTO	PCD	01-JUL-13	No	Yes		4	NCT00842712	Untreated		Progression free survival		85	84	Cetuximab + Cisplatin + Vinorelbine									6.2	5	.72		0.0845																									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Cetuximab + Pemetrexed + Radiotherapy		Completed	NCT00117962		PCD	01-MAR-09	No	Yes		4	NCT00117962			Overall survival	109	53	48	Carboplatin + Pemetrexed																						54	48															
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Foretinib		Completed	NCT01068587		PCD	01-MAR-14	No	No		4	NCT01068587	Previously-treated		Overall Response Rate	31	31																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cetuximab + Natural killer cell immunotherapy		Completed	NCT02845856		PCD	01-JUL-17	Yes	Yes		1	29888109			Maximum tolerated dose/toxicity	54	27	27										6	4.5												9.5	7.5			<0.05												
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Carboplatin + Pemetrexed		Completed	NCT01344824		PCD	01-MAY-16	Yes	Yes		1	26774201			Progression free survival	6	6											7.1													31.3																
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Rociletinib + Trametinib		Terminated	NCT02580708		PCD	01-MAY-16	Yes	Yes	Development discontinued	4	NCT02580708			Unknown	7	7																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	MP0250 + Osimertinib		Terminated	NCT03418532		PCD	01-AUG-19	Yes	Yes	Changed business priorities	4	NCT03418532	Previously-treated		Overall Response Rate	8	8																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cetuximab + Chemotherapy + Radiotherapy		Completed	NCT00492206		PCD	01-FEB-12	No	Yes		4	NCT00492206			Overall survival	38	38											9.3			8.5-17.2										19.4			15.4-26													
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + MK2206		Completed	NCT01294306		PCD	01-AUG-15	Yes	Yes		4	NCT01294306	Previously-treated		DCR, ORR	45	45			9								4.4										40																			
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Apatinib + Erlotinib		Unknown	NCT02704767		ECD	01-JUN-19	Yes	No		4	NCT02704767	Untreated		Progression free survival	60	60																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Capecitabine + Cetuximab + Oxaliplatin		Completed	NCT00444678		PCD	01-AUG-12	Expression level	Yes		4	NCT00444678			Response rate	36	36			58.3													9.04			1.41-136.96																					
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed		Recruiting	NCT03647956		ECD	01-DEC-19	Yes	No		4	NCT03647956	Previously-treated		Overall Response Rate	40	40																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Durvalumab + Olaparib		Recruiting	NCT04538378		ECD	01-DEC-21	Yes	No		4	NCT04538378			Best overall response	14	14																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gemcitabine + Vandetanib		Completed	NCT00753714	ZELIG	PCD	01-APR-11	No	Yes	No benefit of treatment	2	10.1200/jco.2012.30.15_suppl.7550 		Geriatric	Progression free survival		61	63	Gemcitabine																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Fruquintinib		Completed	NCT02590965		PCD	01-AUG-15	Yes	Yes		1	29528793	Previously-treated		Progression free survival	91			Placebo																						8.4	5.5	.58	0.30-1.14	0.11												
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Fruquintinib		Unknown					No	Yes		5	https://www.chi-med.com/wp-content/uploads/2017/10/pre171031.pdf			Unknown													3.8	1.1	.34	0.2-0.57	0.001									8.1	5.5	.62	0.3-1.27	0.18												
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cisplatin + Panitumumab + Pemetrexed		Suspended	NCT01088620	CHAMP	PCD	01-JAN-14	No	Yes	Serious adverse events	1	26094080	Untreated		Progression free survival	134			Cisplatin + Pemetrexed																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cisplatin + Panitumumab + Pemetrexed		Active, not recruiting	NCT00979212		PCD	01-DEC-15	No	Yes	Serious adverse events	4	NCT00979212			Clinical activity	61	39	22	Carboplatin + Panitumumab									89.1	94.4																												
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cisplatin + Panitumumab + Pemetrexed		Completed	NCT01042288		PCD	01-DEC-14	No	Yes		2	10.1200/jco.2013.31.15_suppl.8062	Untreated		Time to treatment failure, Time to progression	60	60																															23	18								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cisplatin + Panitumumab + Pemetrexed		Terminated	NCT01038037	Lung-TRIO	PCD	01-JUN-13	No	Yes	Slow accrual	4	NCT01038037	Untreated		Overall Response Rate	23	23																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Fruquintinib + Gefitinib		Completed	NCT02976116	Cohort 2	PCD	01-JUN-19	Yes	Yes	12.5% serious adverse events	3	https://www.healio.com/hematology-oncology/lung-cancer/news/online/%7B142a1200-d0db-474b-bb8b-51684d2deea7%7D/fruquintinib-gefitinib-shows-promise-for-egfr--mutated-non-small-cell-lung-cancer	Untreated		Overall Response Rate	24	25			70.8								14.7																													
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Matuzumab + Pemetrexed		Completed	NCT00111839		PCD	01-JUL-07	Expression level	Yes		1	20978446	Previously-treated		Overall Response Rate	150			Gefitinib + Tremelimumab	11.0	5		0.332																																		
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cisplatin + Gemcitabine + Imgatuzumab + Pemetrexed		Completed	NCT01185847	GAIN-(L)	PCD	01-SEP-12	No	Yes		2	10.1200/jco.2012.30.15_suppl.7544			Progression free survival	14	14		Cisplatin + Pemetrexed																													6	7								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Capecitabine + Pyrotinib		Unknown	NCT02535507		ECD	01-DEC-16	No	Yes		3	https://www.jto.org/article/S1556-0864(16)31640-9/abstract	Previously-treated		Overall Response Rate	11	11											6.2																				6	3								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Erlotinib + Paclitaxel		Completed	NCT00126581		PCD	01-JUN-10	Yes	Yes		4	NCT00126581			Progression free survival	164	87	77	Carboplatin + Paclitaxel	73	70							17.2	14.1																												
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Nimotuzumab + Nivolumab		Recruiting	NCT02947386		ECD	01-DEC-19	No	No		4	NCT02947386			Overall Response Rate	54																																									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Metformin		Completed	NCT01864681		PCD	01-DEC-17	No	No		2	10.1200/JCO.2019.37.15_suppl.9035	Untreated		Progression free survival	224			Placebo	66	67							10.3	11.4												22	27.5															
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Celecoxib + Erlotinib		Completed	NCT00499655		PCD	01-DEC-16	Yes	Yes	Response not correlated with mutation status	1	26033830	Previously-treated		Progression free survival	26	12	14	Erlotinib + Placebo									9.2	9.2	.98		0.97																									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Trametinib		Active, not recruiting	NCT03076164		ECD	01-MAR-21	Yes	No		3	NCT03076164	Previously-treated		Overall Response Rate	24	24																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Fulvestrant + Gefitinib		Active, not recruiting	NCT01556191	LADIE	PCD	01-MAY-18	Yes	Yes	No benefit of treatment	2	10.1200/JCO.2018.36.15_suppl.9097			Progression free survival	204	100	104										9.9	10.1												22.1	29.9															
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Necitumumab + Osimertinib		Recruiting	NCT03944772	ORCHARD	ECD	01-NOV-23	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	182	182																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Osimertinib		Active, not recruiting	NCT02803203		ECD	01-JUN-21	Yes	No		4	NCT02803203			Progression free survival	50	50																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	BMS-690514		Completed					Yes	No		4	NCT01167244	Previously-treated		Overall Response Rate	11	11																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Almonertinib		Not yet recruiting	NCT04354961	ARISE	ECD	01-MAY-23	Yes	No		4	NCT04354961	Untreated		Progression free survival	134			Carboplatin + Paclitaxel																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Almonertinib		Not yet recruiting	NCT04553887	AUTUMN	ECD	01-MAY-23	Yes	No		4	NCT04553887	Untreated		Overall Response Rate	53	53																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	AZD4635 + Oleclumab		Active, not recruiting	NCT03381274		ECD	01-APR-21	Yes	No		4	NCT03381274	Previously-treated		Overall Response Rate	43	43																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Oleclumab + Osimertinib		Active, not recruiting	NCT03381274		ECD	01-APR-21	Yes	No		4	NCT03381274	Previously-treated		Overall Response Rate	43	43																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib + Osimertinib		Recruiting	NCT03944772	ORCHARD	ECD	01-NOV-23	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	182	182																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Zorifertinib		Recruiting	NCT03574402	TRUMP Arm 8	ECD	01-DEC-22	Yes	No		4	NCT03574402			Response rate	400	400																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Afatinib + Cetuximab		Active, not recruiting	NCT02716311	ACE-LUNG	PCD	01-FEB-19	Yes	Yes	No benefit of treatment	2	10.1200/JCO.2019.37.15_suppl.9079	Untreated		Time to treatment failure, Time to progression	118			Afatinib																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Hydroxychloroquine		Active, not recruiting	NCT00977470		PCD	01-MAY-15	Yes	Yes	No benefit of treatment	2	10.1200/jco.2014.32.15_suppl.8088 	Untreated		Progression free survival	76	76																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ficlatuzumab + Gefitinib		Completed	NCT01039948		PCD	01-AUG-13	No	Yes	No benefit of treatment	1	27448761			Overall Response Rate	203	203																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Canertinib		Completed	NCT00050830		PCD	01-JAN-03	No	Yes	Primary outcome not met	1	17761977	Previously-treated		Clinical activity	163																																									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lazertinib		Active, not recruiting	NCT04075396		ECD	01-AUG-21	Yes	No		4	NCT04075396			Maximum tolerated dose/toxicity	28	28																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pelitinib		Completed	NCT00067548		PCD	01-JAN-05	No	No	Serious adverse events	4	NCT00067548			Not defined	44	44																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Vandetanib		Completed	NCT00777179		PCD	01-JAN-10	No	Yes		1	24075125	Previously-treated		Progression free survival	117	75	42	Placebo	18.7	2.4							2.7	1.7		0.9-2.6																										
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Docetaxel + Vandetanib		Completed	NCT00687297	PrE0501	PCD	01-JAN-11	No	Yes	No benefit of treatment	1	23689430	Untreated		Progression free survival																																										
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Recruiting	NCT03804580		ECD	01-OCT-20	No	No		4	NCT03804580	Untreated		Overall Response Rate	100	100																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Recruiting	NCT03865511	MELROSE	ECD	01-APR-24	Yes	No		4	NCT03865511			Biomarker discovery	66	66																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Unknown	NCT03460275		ECD	01-DEC-20	Yes	No		4	NCT03460275			Clinical activity	100	100																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Recruiting	NCT02736513		ECD	01-DEC-22	No	No		4	NCT02736513			Overall Response Rate	40	40																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Active, not recruiting	NCT02504346	TREM	ECD	01-JAN-21	Yes	No		4	NCT02504346	Previously-treated		Overall Response Rate	200	200																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Osimertinib		Active, not recruiting	NCT03239340	ELIOS	ECD	01-JAN-22	Yes	No		4	NCT03239340	Untreated		Unknown	154	154																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dacomitinib		Not yet recruiting	NCT04339829	CTONG2001	ECD	01-AUG-23	Yes	No		4	NCT04339829			Progression free survival	60	60																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dacomitinib		Not yet recruiting	NCT04504071		ECD	01-MAR-22	Yes	No		4	NCT04504071			Overall Response Rate	30	30																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib		Completed	NCT00411047		PCD	01-JAN-07	Yes	No		4	NCT00411047	Untreated		Overall Response Rate	34	34																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Gefitinib		Unknown	NCT02804776	ECRU-LUNG	ECD	01-JUN-19	Yes	No		4	NCT02804776			Defined % decrease in tumour volume	40	40																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib		Completed	NCT00087412		PCD	01-JUL-07	No	No		4	NCT00087412			Overall survival	65	65																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Afatinib		Recruiting	NCT04201756		ECD	01-JUL-21	Yes	No		4	NCT04201756			Overall Response Rate	47	47																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ipilimumab + Nivolumab		Completed	NCT03256136		PCD	01-AUG-19	Yes	Yes		4	NCT03256136			Overall Response Rate	3	3			0								1.3										0																			
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Erlotinib		Recruiting	NCT02193282	ALCHEMIST	ECD	01-NOV-21	No	No		4	NCT02193282			Overall survival	450			Placebo																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Osimertinib + Pemetrexed + Platinum-based chemotherapy		Not yet recruiting	NCT04351555	NeoADAURA	ECD	01-MAR-24	Yes	No		4	NCT04351555			Major pathologic response	328			Pemetrexed + Platinum-based chemotherapy																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Carboplatin + Pemetrexed + Toripalimab		Recruiting	NCT03924050		ECD	01-JUN-21	Yes	No		4	NCT03924050			Progression free survival	350			Carboplatin + Pemetrexed																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Cisplatin + Pemetrexed + Placebo + Sintilimab		Recruiting	NCT03802240		ECD	01-MAY-21	Yes	No		4	NCT03802240	Previously-treated		Progression free survival	600			Cisplatin + Pemetrexed																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Cisplatin + IBI305  + Pemetrexed + Sintilimab		Recruiting	NCT03802240		ECD	01-MAY-21	Yes	No		4	NCT03802240	Previously-treated		Progression free survival	600			Cisplatin + Pemetrexed																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	SH-1028		Not yet recruiting	NCT04239833		ECD	01-JAN-22	Yes	No		4	NCT04239833			Progression free survival	240			Gefitinib																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	D0316		Recruiting	NCT04206072		ECD	01-FEB-21	Yes	No		4	NCT04206072			Progression free survival	360			Icotinib																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Carboplatin + Pembrolizumab + Pemetrexed		Active, not recruiting	NCT03515837		ECD	01-JUN-23	Yes	No		4	NCT03515837			OS, PFS	492			Carboplatin + Pemetrexed																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Stereotactic Body Radiation Therapy + Tyrosine Kinase Inhibitor		Not yet recruiting	NCT03727867		ECD	01-JUN-21	Yes	No		4	NCT03727867			Progression free survival	300			Stereotactic Body Radiation Therapy																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Endostatin + Tyrosine Kinase Inhibitor		Unknown	NCT03008109		ECD	01-NOV-17	Yes	No		4	NCT03008109			Progression free survival	80	80																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Carboplatin + Vinorelbine		Not yet recruiting	NCT03203590		ECD	01-JAN-26	Yes	No		4	NCT03203590			Disease free survival, relapse free survival, regression free survival, recurrence free survival	590			Gefitinib																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Erlotinib + Stereotactic Body Radiation Therapy		Recruiting	NCT02882984		ECD	01-MAR-20	No	No		4	NCT02882984			Progression free survival	325			Erlotinib + Radiotherapy																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Gefitinib + Stereotactic Body Radiation Therapy		Recruiting	NCT02882984		ECD	01-MAR-20	No	No		4	NCT02882984			Progression free survival	325			Gefitinib + Radiotherapy																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Gefitinib + Thalidomide		Unknown	NCT02387086	GELI	ECD	01-MAY-17	Yes	No		4	NCT02387086	Untreated		Progression free survival	380			Placebo																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Chemotherapy + Gefitinib		Completed	NCT01544179		PCD	01-MAY-14	Yes	Yes		1	26159065	Previously-treated		Progression free survival	265	133	132	Placebo	31.6	34.1		0.76					5.4	5.4												14.8	17.2	1.62	1.05-2.52	0.029												
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel		Recruiting	NCT04194203		ECD	01-SEP-22	Yes	No		4	NCT04194203			Progression free survival	306			Bevacizumab + Carboplatin + Paclitaxel																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Fruquintinib		Completed	NCT02691299	FALUCA	PCD	01-SEP-18	No	Yes		2	10.1016/j.lungcan.2020.06.016	Previously-treated		Overall survival	527	354	173	Placebo	13.8	0.6							3.7	1	.34	0.28?0.43	<0.001						66.7	24.9		8.9	10.4	1.2	0.82?1.28	0.841												
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Erlotinib + Onartuzumab		Completed	NCT02031744		PCD	01-JAN-16	No	No		4	NCT02031744	Previously-treated		Overall survival	530			Erlotinib																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Erlotinib + Onartuzumab		Completed	NCT01456325	METLung	PCD	01-JAN-16	No	No		1	27937096	Previously-treated		Overall survival	499	249	250	Erlotinib	8.4	9.6							2.7	2.6	.99	0.81-1.2	0.92									6.8	9.1	1.27	0.98-1.65	0.067												
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Carboplatin + Erlotinib + Paclitaxel		Completed		TRIBUTE			No	Yes	No benefit of treatment	1	16043829			Unknown	1059	526	533	Carboplatin + Paclitaxel																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	BPI-7711		Recruiting	NCT03866499		ECD	01-JAN-22	Yes	No		4	NCT03866499			Progression free survival	294																																									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Rociletinib		Terminated	NCT02186301	TIGER 1	PCD	01-JUN-17	Yes	Yes	Development discontinued	4	NCT02186301			Progression free survival		30	50																																							
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Bevacizumab + Erlotinib		Active, not recruiting	UMIN000017069	NEJ026			Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.9006 			Progression free survival	228	112	114	Erlotinib									16.9	13.3	.61	0.42-0.88	0.016																									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Lazertinib		Recruiting	NCT04248829	LASER301	ECD	01-DEC-22	Yes	No		4	NCT04248829			Progression free survival	380			Gefitinib																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Docetaxel + Vandetanib		Completed	NCT00312377	ZODIAC	PCD	01-AUG-08	Yes	Yes	Regulatory submissions withdrawn 6/2009	1	25057173	Previously-treated		Progression free survival	50	32	18	Docetaxel	56.3	27.8	0.8-13.89	0.058					7.6	5.9	.51	0.25-1.06	p=0.038										18.6	.46	0.14-1.57	p=0.155												
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Osimertinib		Active, not recruiting	NCT02511106	ADAURA	PCD	01-JAN-20	Yes	Yes		2	10.1200/JCO.2020.38.18_suppl.LBA5			Disease free survival, relapse free survival, regression free survival, recurrence free survival	682	339	343	Placebo																															89	53	.21	0.16-0.28	<0.0001			
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Gefitinib		Active, not recruiting	NCT01405079	ADJUVANT/CTONG1104	PCD	01-MAR-17	Yes	Yes		1	33332190			Progression free survival	222	111	111	Cisplatin + Vinorelbine																						75.5	62.8	.92	0.62-1.36	0.674					28.7	18	.6	0.42-0.87	0.0054			
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Gefitinib		Completed	NCT00252707		PCD	01-NOV-06	No	Yes		1	18779611	Previously-treated		Overall survival	484			Docetaxel									2	2	.81	0.65-1.02	0.077									11.5	14	1.12														
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Gefitinib		Unknown					Yes	Yes		1	22674612	Previously-treated		Progression free survival	33	16	17	Pemetrexed									15.7	2.9	.3	0.13-0.72	0.005																									
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Gefitinib		Unknown	NCT03656393	RCTACSCNSCLC	ECD	01-JUL-20	Yes	No		4	NCT03656393			Disease free survival, relapse free survival, regression free survival, recurrence free survival	48			Carboplatin + Vinorelbine																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Unknown	Osimertinib		Recruiting	NCT03969823		ECD	01-SEP-23	Yes	No		4	NCT03969823			Progression free survival	148	148																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Unknown	Carboplatin + Pemetrexed + Tyrosine Kinase Inhibitor		Recruiting	NCT04552613		ECD	01-JUL-23	Yes	No		4	NCT04552613	Previously-treated		OS, PFS	110	110																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Unknown	Chemotherapy + Icotinib		Not yet recruiting	NCT03983811		ECD	01-OCT-21	Yes	No		4	NCT03983811			Disease free survival, relapse free survival, regression free survival, recurrence free survival	174			Chemotherapy + Placebo																																						
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Unknown	Anlotinib + Tyrosine Kinase Inhibitor		Not yet recruiting	NCT04007835		ECD	01-JUL-21	Yes	No		4	NCT04007835			Progression free survival	120	120																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Unknown	Radiotherapy + Tyrosine Kinase Inhibitor		Recruiting	NCT03916913		ECD	01-JAN-22	Yes	No		4	NCT03916913	Previously-treated		Progression free survival	85	85																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Unknown	Radiotherapy + Tyrosine Kinase Inhibitor		Not yet recruiting	NCT03258671		ECD	01-DEC-20	Yes	No		4	NCT03258671			OS, PFS	160	160																																								
EGFR	EGFR_unspecified				lung / carcinoma / non small cell carcinoma	3	Unknown	Metformin + Tyrosine Kinase Inhibitor		Unknown	NCT03071705		ECD	01-APR-17	Yes	Yes		1	31486833			Progression free survival	139	69	70	Tyrosine Kinase Inhibitor	71	54.3		0.04					13.1	9.9	.6	0.4-0.94	0.03									31.7	17.5	.5	0.28-0.90	0.02												
EGFR	EGFR_unspecified				lung / carcinoma / squamous cell carcinoma	3	Approved FDA	Cisplatin + Gemcitabine + Necitumumab	Not required	Active, not recruiting	NCT00981058	SQUIRE	PCD	01-JUN-13	Expression level	Yes		1	27668058	Untreated		Overall survival	545	548		Cisplatin + Gemcitabine									5.7	5.5	.85	0.74-0.98	0.02									11.5	9.9	.84	0.74-0.96	0.01												
EGFR	EGFR_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 1	Afatinib		Recruiting	NCT04132102		ECD	01-APR-21	Yes	No		4	NCT04132102			Progression free survival	20	20																																								
EGFR	EGFR_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Afatinib + Cisplatin + Gemcitabine		Not yet recruiting	NCT04470076	Neoafa	ECD	01-DEC-21	Yes	No		4	NCT04470076			Overall Response Rate	30	30																																								
EGFR	EGFR_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Carboplatin + Gemcitabine + Nimotuzumab		Recruiting	NCT03574402	TRUMP Arm 10	ECD	01-DEC-22	Expression level	No		4	NCT03574402			Response rate	400	400																																								
EGFR	EGFR_unspecified				oesophagus / carcinoma / NS	2	Phase 2	Afatinib		Active, not recruiting	NCT03940976	ESCC-A01	ECD	01-JAN-21	Yes	No		4	NCT03940976			Overall Response Rate	40	40																																								
EGFR	EGFR_unspecified				oesophagus / carcinoma / NS	2	Phase 2	Larotinib		Active, not recruiting	NCT03888092		ECD	01-DEC-20	Expression level	No		4	NCT03888092			Maximum tolerated dose/toxicity	45	45																																								
EGFR	EGFR_unspecified				oesophagus / carcinoma / NS	2	Phase 2	Erlotinib + Radiotherapy		Completed	NCT00524121		PCD	01-MAY-10	No	Yes		4	NCT00524121	Untreated		Overall survival	17	17																								7.3																
EGFR	EGFR_unspecified				oesophagus / carcinoma / NS	2	Phase 2	Irinotecan + Panitumumab		Completed	NCT00836277		PCD	01-AUG-15	No	Yes		1	29769385	Previously-treated		Response rate	24	24											2.9													7.2							1									
EGFR	EGFR_unspecified				oesophagus / carcinoma / NS	2	Phase 2	Nimotuzumab		Completed	NCT02591784	BT-IST-ESO-002	PCD	01-DEC-11	No	Yes		1	22555809			Maximum tolerated dose/toxicity	63	33	30		47.8	15.4		0.014															60.9	26.9		0.017																
EGFR	EGFR_unspecified				ovary / carcinoma / NS	3	Phase 2	Gefitinib		Completed	NCT00023699		PCD	01-MAY-06	Yes	Yes		1	16061871	Previously-treated		Not defined	11	11			9.0																																					
EGFR	EGFR_unspecified				ovary / carcinoma / NS	3	Phase 2	Matuzumab		Completed	NCT00073541		PCD	01-MAR-04	Expression level	Yes	No benefit of treatment	1	17126894	Previously-treated		Not defined	32	32																																								
EGFR	EGFR_unspecified				pancreas / carcinoma / NS	3	Approved FDA	Erlotinib + Gemcitabine	Not required	Completed	NCT00040183	NCIC CTG PA.3 	PCD	01-JAN-04	No	Yes	Response not correlated with mutation status	1	17452677			Not defined	486	239	247	Gemcitabine																						6.2	5.91	.82	0.69-0.99	0.038												
EGFR	EGFR_unspecified				pancreas / carcinoma / NS	3	Phase 1	PKI-166		Completed					No	Yes		1	16203782			Unknown	54																																	11								
EGFR	EGFR_unspecified				pancreas / carcinoma / NS	3	Phase 2	Erlotinib		Terminated	NCT00470535		PCD	01-JAN-09	Yes	Yes	No benefit of treatment	4	NCT00470535			Progression free survival	18	18																																								
EGFR	EGFR_unspecified				pancreas / carcinoma / NS	3	Phase 2	Cabozantinib + Erlotinib		Terminated	NCT03213626		PCD	01-APR-19	Expression level	Yes	No benefit of treatment	4	NCT03213626			Overall Response Rate	7	7																																								
EGFR	EGFR_unspecified				pleura / mesothelioma / NS	3	Phase 2	Cetuximab + Chemotherapy		Completed	NCT00996567	MesoMab	PCD	01-SEP-15	Yes	Yes		2	10.1200/JCO.2017.35.15_suppl.e20030			Progression free survival	18	18											5.54													11.31							8									
EGFR	EGFR_unspecified				prostate / carcinoma / NS	3	Unknown	Gefitinib		Unknown	NCT02208583		ECD	01-DEC-16	Yes	No		4	NCT02208583	Previously-treated		Progression free survival	150	150																																								
EGFR	EGFR_unspecified				skin / carcinoma / squamous cell carcinoma	3	Phase 2	Cemiplimab + Cetuximab sarotalocan		Recruiting	NCT04305795		ECD	01-SEP-22	Expression level	No		4	NCT04305795			Overall Response Rate	74	74																																								
EGFR	EGFR_unspecified				stomach / carcinoma / NS	3	Phase 3	FOLFOX-6 + Varlitinib		Active, not recruiting	NCT03130790		PCD	01-DEC-18	Expression level	Yes	Primary outcome not met	3	https://www.targetedonc.com/view/varlitinib-falls-short-in-frontline-gastric-cancer-trial	Untreated		Overall survival	400			FOLFOX-6 + Placebo																																						
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / nasopharyngeal carcinoma	3	Phase 2	Cetuximab + Chemotherapy + Intensity-modulated radiation therapy		Completed	NCT01271439	REPLACE	PCD	01-JUN-12	No	No		4	NCT01271439 			Overall Response Rate	60	60																																								
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Approved FDA	Cetuximab	Not required	Completed		EMR 62202-016			No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf			Unknown	103	103			13.0				5.8																																	
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Approved FDA	Cetuximab + Radiotherapy	Not required	Terminated	NCT00004227	BONNER	PCD	01-MAR-07	Expression level	Yes	PO met LRC 24.4 vs 14.9 HR0.68 p=0.005	1	16467544			Locoregional control	424	213	211	Radiotherapy					24.4	14.9	0.52-0.89	0.005			.7	0.54-0.90	0.0006									49.0	29.3	.74	0.57-0.97	0.03												
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Approved FDA	Carboplatin + Cetuximab + Cisplatin + Fluorouracil	Not required	Completed	NCT00122460	EXTREME	PCD	01-MAR-07	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf	Untreated		Overall survival	442	222	220	Cisplatin + Fluorouracil	35.6	19.5	1.5-3.6	0.0001					5.5	3.3	.57	0.46-0.72	<0.0001									10.1	7.4	.8	0.64-0.89	0.034												
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 1	Erlotinib		Completed	NCT00079053		PCD	01-JAN-11	No	No		4	NCT00079053			Maximum tolerated dose/toxicity	19	19																																								
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 1	Bortezomib + Cetuximab + Cisplatin		Completed	NCT00629226		PCD	01-DEC-10	No	No		4	NCT00629226	Untreated		Maximum tolerated dose/toxicity	46	46																																								
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 1	Imgatuzumab		Completed	NCT01046266		PCD	01-JUN-12	No	Yes		1	28950289			Immune cell infiltration	21	21																														1										
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Cetuximab + Ficlatuzumab		Active, not recruiting	NCT03422536		ECD	01-MAY-21	No	No		4	NCT03422536			Progression free survival	74	74																																								
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Cetuximab sarotalocan + Pembrolizumab		Recruiting	NCT04305795		ECD	01-SEP-22	Expression level	No		4	NCT04305795			Overall Response Rate	74	74																																								
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Pimurutamab + Serplulimab		Not yet recruiting	NCT04297995		ECD	01-MAY-22	No	No		4	NCT04297995			Overall Response Rate	56	56																																								
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Nimotuzumab		Completed		h-R3/SCCHN/001/IND			No	Yes		1	24613543			Unknown	92			Radiotherapy	100	70		0.02																																		
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Panitumumab		Completed	NCT02643056	S10PANI01	PCD	01-DEC-15	No	Yes		1	28592616	Previously-treated		Overall Response Rate	33	33			6								2.6										51			9.7							2	15								
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 3	Best supportive care + Zalutumumab		Completed	NCT00382031	ZALUTE	PCD	01-DEC-09	No	Yes	Primary outcome not met	1	21377930	Previously-treated		Overall survival	286			Best supportive care									9.9	8.4	.63	0.47-0.84	0.0012									6.7	5.2			0.065												
EGFR	EGFR_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 3	Radiotherapy + Zalutumumab		Completed	NCT00496652	DAHANCA-19	PCD	01-JUL-12	No	Yes	No benefit of treatment	3	https://www.medscape.com/viewarticle/823574#vp_1	Untreated		Locoregional control	619			Radiotherapy																																						
EML4	EML4-ALK fusion				lung / carcinoma / non small cell carcinoma	3	Phase 2	Apatinib + Camrelizumab		Unknown	NCT03083041		ECD	01-DEC-18	No	No		4	NCT03083041			Overall Response Rate	118	118																																								
ALK	EML4-ALK_fusion				lung / carcinoma / non small cell carcinoma	3	Phase 2	Chemotherapy + Crizotinib		Terminated	NCT01822496		PCD	01-JUN-18	Yes	Yes	Slow accrual	4	NCT01822496			Progression free survival	59			Chemotherapy																																						
ALK	EML4-ALK_fusion				lung / carcinoma / non small cell carcinoma	3	Phase 2	Luminespib		Completed	NCT01124864		PCD	01-AUG-14	Yes	Yes		4	NCT01124864	Previously-treated		Overall Response Rate	22	22			31.8																																					
EMSY	EMSY_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
EPCAM	EPCAM_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
EPS8	EPS8_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 1	Chimeric antigen receptor T cells  + EPS8-specific DC vaccine		Recruiting	NCT03291444		ECD	01-MAR-21	Expression level	No		4	NCT03291444			Maximum tolerated dose/toxicity	30	30																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 1	Everolimus + Neratinib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 1	Ceralasertib + Trastuzumab Deruxtecan		Not yet recruiting	NCT04704661	DASH	ECD	01-MAR-23	Expression level	No		4	NCT04704661			Maximum tolerated dose/toxicity	15	15																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 1	Neratinib + Trametinib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 1	Neratinib + Palbociclib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 2	Afatinib		Recruiting	NCT02465060	MATCH Subprotocol B	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 2	Erlotinib + Temozolomide		Withdrawn	NCT02689336		ECD	01-NOV-19	Yes	Yes		4	NCT02689336		Pediatric	Overall Response Rate	0	0																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 2	Trastuzumab + Trastuzumab-emtansine		Recruiting	NCT02465060	MATCH Subprotocol Q	ECD	01-JUN-22	Expression level	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 2	Pertuzumab + Trastuzumab + Trastuzumab-emtansine		Recruiting	NCT02465060	MATCH Subprotocol J	ECD	01-JUN-22	Expression level	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 2	Atezolizumab + Pertuzumab + Trastuzumab		Not yet recruiting	NCT04551521	CRAFT	ECD	01-APR-24	Yes	No		4	NCT04551521			Disease control rate, Clinical benefit rate	175	175																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 2	Pertuzumab + Trastuzumab		Recruiting	NCT02693535	TAPUR group 8	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 2	Trastuzumab-emtansine		Recruiting	NCT02314481	DARWIN II	ECD	01-NOV-24	Expression level	No		4	NCT02314481			Progression free survival	119	119																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 2	Trastuzumab		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 2	Lapatinib		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
ERBB2	ERBB2_unspecified				NS / other / neoplasm	3	Phase 2	Lapatinib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	3	Approved FDA	Capecitabine + Lapatinib	HER2 expression	Completed	NCT00078572	100151	PCD	01-APR-06	Expression level	Yes		1	18188694	Previously-treated		Time to treatment failure, Time to progression	399	198	201	Capecitabine	23.7	13.9												6.23	4.29	.57	0.43-0.77	0.00013				17.3	15.2	.89	0.71-1.10	0.276												
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	3	Approved other	Cyclophosphamide + Epirubicin hydrochloride + Lapatinib + Paclitaxel		Unknown	NCT03273595		ECD	01-JUL-19	Expression level	No		4	NCT03273595			Complete response, Pathological complete response	100			Cyclophosphamide + Epirubicin hydrochloride + Paclitaxel + Trastuzumab																																						
ERBB2	ERBB2_unspecified				breast / carcinoma / NS	3	Phase 2	Capecitabine + Pyrotinib		Recruiting	NCT03805399	FUTURE	ECD	01-JAN-22	Yes	No		4	NCT03805399			Overall Response Rate	140	140																																								
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Luminespib		Completed	NCT01922583		PCD	01-FEB-17	Yes	No		4	NCT01922583			Overall Response Rate	31	31																																								
ERBB2	ERBB2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pyrotinib		Recruiting	NCT03574402	TRUMP Arm 7	ECD	01-DEC-22	Yes	No		4	NCT03574402			Response rate	400	400																																								
ERBB2	ERBB2_unspecified				prostate / carcinoma / NS	3	Unknown	Lapatinib		Unknown	NCT02208583		ECD	01-DEC-16	Yes	No		4	NCT02208583	Previously-treated		Progression free survival	150	150																																								
ERBB3	ERBB3_unspecified				NS / other / neoplasm	3	Phase 1	Everolimus + Neratinib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
ERBB3	ERBB3_unspecified				NS / other / neoplasm	3	Phase 1	Neratinib + Trametinib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
ERBB3	ERBB3_unspecified				NS / other / neoplasm	3	Phase 1	Neratinib + Palbociclib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
ERBB4	ERBB4_unspecified				NS / other / neoplasm	3	Phase 1	Everolimus + Neratinib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
ERBB4	ERBB4_unspecified				NS / other / neoplasm	3	Phase 1	Neratinib + Trametinib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
ERBB4	ERBB4_unspecified				NS / other / neoplasm	3	Phase 1	Neratinib + Palbociclib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
ERCC3	ERCC3_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
ETV6	ETV6_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	7	Phase 2	Azacitidine		Terminated	NCT02159040		PCD	01-JUN-15	No	Yes	Serious adverse events	4	NCT02159040			Overall Response Rate	1	1																																								
ETV6	ETV6_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	7	Phase 2	Azacitidine + Deferasirox		Terminated	NCT02159040		PCD	01-JUN-15	No	Yes	Serious adverse events	4	NCT02159040			Overall Response Rate	1	1																																								
EXO1	EXO1_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
EZH2	EZH2_unspecified				NS / malignant melanoma / NS	3	Phase 1	Tazemetostat hydrobromide		Not yet recruiting	NCT04557956		ECD	01-SEP-23	Yes	No		4	NCT04557956			Progression free survival	18	18																																								
EZH2	EZH2_unspecified				NS / malignant melanoma / NS	3	Phase 1	Dabrafenib + Tazemetostat hydrobromide + Trametinib		Not yet recruiting	NCT04557956		ECD	01-SEP-23	Yes	No		4	NCT04557956			Progression free survival	18	18																																								
EZH2	EZH2_unspecified				NS / other / neoplasm	3	Phase 1	Tazemetostat hydrobromide		Completed	NCT03155620	Subprotocol C	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
EZH2	EZH2_unspecified				NS / other / neoplasm	3	Phase 1	HH2853		Not yet recruiting	NCT04390737		ECD	01-JUN-22	No	No		4	NCT04390737			Maximum tolerated dose/toxicity	30	30																																								
EZH2	EZH2_unspecified				NS / other / neoplasm	3	Phase 1	EZH2 inhibitor GSK2816126		Terminated	NCT02082977		PCD	01-JUN-17	No	Yes	No benefit of treatment	4	NCT02082977			Maximum tolerated dose/toxicity	41	41																																								
EZH2	EZH2_unspecified				NS / other / neoplasm	3	Phase 2	Tazemetostat hydrobromide		Recruiting	NCT02601950		ECD	01-MAY-23	No	No		4	NCT02601950			Overall Response Rate	250	250																																								
EZH2	EZH2_unspecified				NS / other / neoplasm	3	Phase 2	Tazemetostat hydrobromide		Suspended	NCT03213665	Pediatric MATCH	ECD	01-SEP-24	Yes	No		4	NCT03213665		Pediatric	Overall Response Rate	49	49																																								
EZH2	EZH2_unspecified				NS / other / neoplasm	3	Phase 2	Tazemetostat hydrobromide		Active, not recruiting	NCT01897571		ECD	01-MAY-21	No	No		4	NCT01897571			Overall Response Rate	420	420																																								
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	7	Phase 2	Azacitidine		Terminated	NCT02159040		PCD	01-JUN-15	No	Yes	Serious adverse events	4	NCT02159040			Overall Response Rate	1	1																																								
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	7	Phase 2	Azacitidine + Deferasirox		Terminated	NCT02159040		PCD	01-JUN-15	No	Yes	Serious adverse events	4	NCT02159040			Overall Response Rate	1	1																																								
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Mitoxantrone hydrochloride + Venetoclax		Not yet recruiting	NCT04330820	RELAX	ECD	01-JUN-22	No	No		4	NCT04330820	Previously-treated		Overall Response Rate	60	60																																								
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Ruxolitinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																																								
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant		Terminated	NCT03303950		PCD	01-MAY-19	No	Yes	Slow accrual	4	NCT03303950			Non-relapse mortality	6	6																																								
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Pentraxin 2		Active, not recruiting	NCT01981850		PCD	01-JUL-20	No	No		4	NCT01981850			Clinical activity	125	125																																								
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / B cell lymphoma unspecified	3	Phase 2	Tazemetostat hydrobromide		Active, not recruiting	NCT03456726		ECD	01-DEC-20	Yes	No		4	NCT03456726	Previously-treated		Overall Response Rate	13	13																																								
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / NS	3	Phase 1	SHR2554		Unknown	NCT03603951		ECD	01-JUN-22	No	No		4	NCT03603951	Previously-treated		Maximum tolerated dose/toxicity	120	120																																								
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / follicular lymphoma	1	Approved FDA	Tazemetostat hydrobromide	Required	Active, not recruiting	NCT01897571		ECD	01-NOV-19	Comparison with wt	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf			Overall Response Rate	95	42	53		69	34			10.9	13																																
EZH2	EZH2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant		Terminated	NCT03303950		PCD	01-MAY-19	No	Yes	Slow accrual	4	NCT03303950			Non-relapse mortality	6	6																																								
EZH2	EZH2_unspecified				urinary tract / papilloma / typical	3	Phase 2	Pembrolizumab + Tazemetostat hydrobromide		Recruiting	NCT03854474		ECD	01-JUN-21	No	No		4	NCT03854474			Overall Response Rate	30	30																																								
FANCA	FANCA_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
FANCA	FANCA_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
FANCA	FANCA_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
FANCA	FANCA_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
FANCA	FANCA_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
FANCA	FANCA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
FANCA	FANCA_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
FANCA	FANCA_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
FANCA	FANCA_unspecified				prostate / carcinoma / NS	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
FANCA	FANCA_unspecified				prostate / carcinoma / NS	3	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
FANCA	FANCA_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
FANCC	FANCC_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
FANCC	FANCC_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
FANCC	FANCC_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
FANCC	FANCC_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
FANCC	FANCC_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
FANCD2	FANCD2_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
FANCD2	FANCD2_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
FANCD2	FANCD2_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
FANCD2	FANCD2_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
FANCD2	FANCD2_unspecified				prostate / carcinoma / NS	3	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
FANCE	FANCE_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
FANCE	FANCE_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
FANCE	FANCE_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
FANCE	FANCE_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
FANCF	FANCF_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
FANCF	FANCF_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
FANCF	FANCF_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
FANCF	FANCF_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
FANCG	FANCG_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
FANCL	FANCL_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
FANCL	FANCL_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
FANCL	FANCL_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
FANCL	FANCL_unspecified				prostate / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
FANCM	FANCM_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
FANCM	FANCM_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
FANCM	FANCM_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
FBXW7	FBXW7_unspecified				NS / other / neoplasm	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
FBXW7	FBXW7_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 4A	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
FEN1	FEN1_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
FGF1	FGF1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
FGF1	FGF1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	7	13		Erlotinib + Placebo									2.7	1.78	.45	0.05-4.10	0.23																									
FGFR3	FGFR-TACC_gene_fusion				central nervous system / NS / medulloblastoma	3	Phase 2	AZD4547		Completed	NCT02824133	TARGET	PCD	01-SEP-17	Yes	No		4	NCT02824133			Progression free survival	14	14																																								
FGFR1	FGFR1_K656E	58327161		p.K656E	central nervous system / glioma / NS	3	Phase 1	Infigratinib		Recruiting	NCT04424966		ECD	01-DEC-22	Yes	No		4	NCT04424966			Progression free survival	20	20																																								
FGFR1	FGFR1_TACC1 fusion				central nervous system / glioma / NS	3	Phase 2	Infigratinib		Completed	NCT01975701		PCD	01-OCT-18	No	Yes		4	NCT01975701	Previously-treated		Progression free survival	24	24			7.7								1.7			1.05-2.80										6.74			4.17-11.73				2	7								
FGFR1	FGFR1_unspecified				NS / malignant melanoma / NS	3	Phase 1	Bortezomib + Dexamethasone + Dovitinib		Withdrawn	NCT01680796		PCD	01-FEB-13	No	Yes	No benefit of treatment	4	NCT01680796	Previously-treated		Maximum tolerated dose/toxicity	0	0																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 1	Erdafitinib		Completed	NCT03155620	Subprotocol B	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1000	1000																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 1	Copanlisib + Rogaratinib		Completed	NCT03517956	ROCOCO	PCD	01-MAR-20	Expression level	No		4	NCT03517956			Maximum tolerated dose/toxicity	16	16																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 1	Rogaratinib		Completed	NCT02592785		PCD	01-FEB-17	No	Yes		2	10.1158/1535-7163.TARG-17-A099			Maximum tolerated dose/toxicity	9	9																					56										1	5								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 1	Rogaratinib		Completed	NCT01976741		PCD	01-MAR-19	No	Yes	Primary outcome met	1	31405822			Maximum tolerated dose/toxicity	168	168																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 1	Rogaratinib		Completed	NCT03788603		PCD	01-APR-20	No	No		4	NCT03788603			Maximum tolerated dose/toxicity	12	12																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Regorafenib		Recruiting	NCT02925234	DRUP	ECD	01-AUG-22	No	No		4	NCT02925234			Treatment rate	950	950																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	FGFR inhibitor debio 1347		Active, not recruiting	NCT03834220	FUZE	ECD	01-DEC-20	Yes	No		4	NCT03834220	Previously-treated		Overall Response Rate	63	63																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	ICP192		Recruiting	NCT04565275		ECD	01-OCT-22	Yes	No		4	NCT04565275			Overall Response Rate	45	45																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Pemigatinib		Recruiting	NCT04003623	FIGHT-208	ECD	01-OCT-21	Yes	No		4	NCT04003623			Overall Response Rate	50	50																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Pemigatinib		Recruiting	NCT03822117	FIGHT-207	ECD	01-DEC-21	Yes	No		4	NCT03822117			Overall Response Rate	170	170																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Futibatinib		Not yet recruiting	NCT04189445	Cohort A	ECD	01-JUN-22	Yes	No		4	NCT04189445			Overall Response Rate	115	115																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Futibatinib		Active, not recruiting	NCT02052778	FOENIX-101	PCD	01-DEC-19	Yes	No		4	NCT02052778			Overall Response Rate	100	100																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Derazantinib		Completed	NCT01752920		PCD	01-SEP-18	No	No		4	NCT01752920			Maximum tolerated dose/toxicity	119	119																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Infigratinib		Recruiting	NCT04233567		ECD	01-DEC-22	Yes	No		4	NCT04233567			Overall Response Rate	50	50																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Ponatinib		Recruiting	NCT02272998		ECD	01-DEC-21	Yes	No		4	NCT02272998			Overall Response Rate	45	45																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Erdafitinib		Recruiting	NCT02465060	MATCH Subprotocol K2	ECD	01-JUN-22	Expression level	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Erdafitinib		Recruiting	NCT02465060	MATCH Subprotocol K1	ECD	01-JUN-22	Expression level	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Erdafitinib		Recruiting	NCT03827850	FIND	ECD	01-SEP-21	Yes	No		4	NCT03827850			Overall Response Rate	50	50																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Erdafitinib		Recruiting	NCT03210714	Pediatric MATCH	ECD	01-DEC-24	Yes	No		4	NCT03210714		Pediatric	Response rate	49	49																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Erdafitinib		Not yet recruiting	NCT04083976		ECD	01-JUN-22	Yes	No		4	NCT04083976			Overall Response Rate	280	280																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	Yes		1	32292573			Disease control rate, Clinical benefit rate	8	8																														0	0	0								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	AZD4547		Active, not recruiting	NCT04439240	MATCH-Subprotocol W	PCD	01-JUN-19	Yes	No		4	NCT04439240			Overall Response Rate	52	52																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	AZD4547		Unknown	EudraCT201100371818				Expression level	Yes		1	27179038			Unknown	8	8																																1								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	AZD4547		Recruiting	NCT02465060	MATCH Subprotocol W	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
FGFR1	FGFR1_unspecified				NS / other / neoplasm	2	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
FGFR1	FGFR1_unspecified				autonomic ganglia / paraganglioma / NS	3	Phase 2	Pazopanib		Terminated	NCT01340794		PCD	01-NOV-14	Yes	Yes	Slow accrual	4	NCT01340794			Overall Response Rate	7	7																																								
FGFR1	FGFR1_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 1	Cisplatin + Gemcitabine + Ivosidenib		Not yet recruiting	NCT04088188		ECD	01-JUL-22	Yes	No		4	NCT04088188			Unknown	40	40																																								
FGFR1	FGFR1_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 1	Cisplatin + Gemcitabine + Pemigatinib		Not yet recruiting	NCT04088188		ECD	01-JUL-22	No	No		4	NCT04088188			Maximum tolerated dose/toxicity	40	40																																								
FGFR1	FGFR1_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Erdafitinib		Active, not recruiting	NCT02699606		ECD	01-JUL-21	Yes	No		4	NCT02699606			Overall Response Rate	35	35																																								
FGFR1	FGFR1_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Lenvatinib + Pembrolizumab		Not yet recruiting	NCT04550624		ECD	01-DEC-23	Yes	No		4	NCT04550624			Overall Response Rate	40	40																																								
FGFR1	FGFR1_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Infigratinib		Recruiting	NCT02150967	UPSTREAM	ECD	01-MAR-22	Yes	No		4	NCT02150967			Overall Response Rate	160	160																																								
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547		Unknown	NCT01795768		ECD	01-SEP-14	Expression level	Yes		2	10.1200/jco.2015.33.15_suppl.2508	Previously-treated		Defined % decrease in tumour volume	8	8			12.5																																					
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	Futibatinib		Recruiting	NCT04024436		ECD	01-JUN-21	Yes	No		4	NCT04024436			Overall Response Rate	168	168																																								
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	Letrozole + Nintedanib		Completed	NCT02619162		PCD	01-NOV-17	No	Yes	Primary outcome met	1	31126332	Previously-treated		Unknown	19	19																																								
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547 + Fulvestrant		Completed	NCT01202591	GLOW	PCD	01-SEP-14	Expression level	Yes	Slow accrual	2	NCT01202591	Previously-treated		Maximum tolerated dose/toxicity	9	5	4	Fulvestrant																																						
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547 + Letrozole		Completed	NCT01791985	RADICAL	PCD	01-NOV-16	No	Yes		2	10.1200/JCO.2017.35.15_suppl.1059	Previously-treated		Maximum tolerated dose/toxicity	56	56											3.1			2.4-5.4							25.0										2	11								
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547 + Anastrozole		Completed	NCT01791985	RADICAL	PCD	01-NOV-16	No	Yes		2	10.1200/JCO.2017.35.15_suppl.1059	Previously-treated		Maximum tolerated dose/toxicity	56	56											3.1			2.4-5.4							25.0										2	11								
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	Nintedanib + Pembrolizumab		Terminated	NCT02389764		PCD	01-JUN-18	No	Yes	Slow accrual	4	NCT02389764			Unknown	10	10																																								
FGFR1	FGFR1_unspecified				breast / carcinoma / NS	3	Phase 2	AZD4547		Completed	NCT01202591	GLOW	PCD	01-SEP-14	Expression level	Yes	Slow accrual	2	NCT01202591	Previously-treated		Maximum tolerated dose/toxicity	127																																									
FGFR1	FGFR1_unspecified				central nervous system / NS / medulloblastoma	3	Phase 2	Nintedanib		Completed	NCT01380782		PCD	01-JUL-13	No	Yes	No benefit of treatment	1	25338318	Previously-treated		Unknown													0																													
FGFR1	FGFR1_unspecified				central nervous system / NS / medulloblastoma	3	Phase 2	Infigratinib		Completed	NCT01975701		PCD	01-OCT-18	No	Yes		4	NCT01975701	Previously-treated		Progression free survival	24	24			7.7								1.7			1.05-2.80										6.74			4.17-11.73				2	7								
FGFR1	FGFR1_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
FGFR1	FGFR1_unspecified				endometrium / carcinoma / NS	3	Phase 2	Brivanib alaninate		Completed	NCT00888173		PCD	01-JUL-16	No	Yes		4	NCT00888173			PFS, ORR	45	45			18.6								30.2													10.7																
FGFR1	FGFR1_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 1	5-Fluorouracil + Brivanib alaninate + Leucovorin calcium		Completed	NCT01046864		PCD	01-JUN-14	No	No		4	NCT01046864			Maximum tolerated dose/toxicity	49	49																																								
FGFR1	FGFR1_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 1	Brivanib alaninate + FOLFIRI		Completed	NCT01046864		PCD	01-JUN-14	No	No		4	NCT01046864			Maximum tolerated dose/toxicity	49	49																																								
FGFR1	FGFR1_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 2	Regorafenib		Recruiting	NCT03627728	a-MANTRA	ECD	01-DEC-20	No	No		4	NCT03627728			Progression free survival	120			Placebo																																						
FGFR1	FGFR1_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 2	Paclitaxel + Rogaratinib		Not yet recruiting	NCT04077255		ECD	01-DEC-22	Yes	No		4	NCT04077255			Response rate	85	85																																								
FGFR1	FGFR1_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 2	Letrozole + Nintedanib		Completed	NCT01921673		PCD	01-JUN-16	No	No		4	NCT01921673			Progression free survival	14	14																																								
FGFR1	FGFR1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Futibatinib		Not yet recruiting	NCT04189445	Cohort C 	ECD	01-JUN-22	Yes	No		4	NCT04189445			Complete remission	115	115																																								
FGFR1	FGFR1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Nintedanib		Unknown	NCT01488344		ECD	01-NOV-14	No	Yes		1	27716819			Maximum tolerated dose/toxicity	12	12																								33.0							2									
FGFR1	FGFR1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine + Pevonedistat + Venetoclax		Recruiting	NCT03862157		ECD	01-JAN-24	No	No		4	NCT03862157	Untreated		Complete response, Pathological complete response	40	40																																								
FGFR1	FGFR1_unspecified				kidney / carcinoma / renal cell carcinoma	3	Phase 2	Dovitinib		Unknown	NCT01791387	DILIGENCE-1	ECD	01-JUN-15	Yes	No		4	NCT01791387			Progression free survival	30	30																																								
FGFR1	FGFR1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dovitinib		Completed	NCT01676714		PCD	01-JAN-16	No	Yes	Serious adverse events, no benefit of treatment	2	10.1200/jco.2016.34.4_suppl.616			Overall Response Rate	7	7			14.3																																					
FGFR1	FGFR1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pemigatinib		Not yet recruiting	NCT04096417		ECD	01-DEC-22	Yes	No		4	NCT04096417			Overall Response Rate	24	24																																								
FGFR1	FGFR1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Dovitinib		Terminated	NCT01888965		PCD	01-AUG-14	No	Yes	Serious adverse events	4	NCT01888965			Biomarker discovery	9	9																																								
FGFR1	FGFR1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Best supportive care + Nintedanib		Completed	NCT02149108	LUME-Colon 1	PCD	01-MAY-16	No	Yes	Primary outcome not met	1	30010751	Previously-treated		OS, PFS	765	384	381	Best supportive care + Placebo									1.5	1.4	.58	0.49-0.69	<0.0001									6.4	6	1.01	0.86-1.19	0.87												
FGFR1	FGFR1_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 1	Docetaxel + Nintedanib		Completed	NCT02668393		PCD	01-NOV-19	No	Yes	Slow accrual	4	NCT02668393	Previously-treated		Maximum tolerated dose/toxicity	14	14																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Lucitanib		Terminated	NCT02109016	US Breast	PCD	01-APR-16	Yes	No		4	NCT02109016			Overall Response Rate	18	18																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Regorafenib		Terminated	NCT01187615		PCD	01-JUN-12	No	Yes	Slow accrual	1	26003007			Maximum tolerated dose/toxicity	9	9																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Nintedanib + Pembrolizumab		Suspended	NCT02856425	PEMBIB	ECD	01-JUL-21	No	Yes	Serious adverse events	4	NCT02856425			Maximum tolerated dose/toxicity	18	18																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Pazopanib		Terminated	NCT02193152		PCD	01-DEC-19	No	Yes		4	NCT02193152			Overall Response Rate	12	12			16.7								3.1			0.81-11.0																										
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Nintedanib		Active, not recruiting	NCT02299141		PCD	01-JAN-20	Yes	Yes	Primary outcome not met	2	10.1200/JCO.2020.38.15_suppl.e21694 			Overall Response Rate	20	20			15								4.2										60			11.0							3	12								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	AZD4547		Recruiting	NCT02664935		ECD	01-OCT-22	No	No		4	NCT02664935			Overall Response Rate	549	549																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ponatinib		Unknown					Expression level	Yes	Serious adverse events	1	30297175			Unknown	4	4																																2								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	AZD4547 + Docetaxel		Completed	NCT01824901		PCD	01-JUL-14	Expression level	Yes	Serious adverse events	4	NCT01824901	Previously-treated		Maximum tolerated dose/toxicity	2	2																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Methotrexate + Regorafenib		Suspended	NCT03520842		ECD	01-JAN-21	Yes	Yes		4	NCT03520842			Progression free survival	18	18																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pazopanib		Completed	NCT00367679		PCD	01-APR-08	No	Yes		4	NCT00367679	Untreated		Defined % decrease in tumour volume	35	35																															3	31								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Nintedanib		Completed	NCT01948141		PCD	01-AUG-16	Expression level	Yes		4	NCT01948141	Previously-treated		Progression free survival	2	2											0													10.2			4-16.4													
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erdafitinib		Recruiting	NCT02699606		ECD	01-JUL-21	Yes	No		4	NCT02699606			Overall Response Rate	35	35																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dovitinib		Unknown	NCT01861197		ECD	01-JAN-15	No	Yes		1	27315356			Response rate	27	27			11.5																		50.0										3	10								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Dovitinib		Completed	NCT01676714		PCD	01-JAN-16	Yes	Yes		4	NCT01676714	Previously-treated		Unknown	7	7			14.3																																					
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	AZD4547		Active, not recruiting	NCT02117167	SAFIR02_Lung	PCD	01-DEC-18	No	No		4	NCT02117167			Progression free survival	999	999																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Docetaxel + Nintedanib		Terminated	NCT02231164	LUME-Columbus	PCD	01-DEC-15	No	No	Slow accrual	4	NCT02231164			Disease control rate, Clinical benefit rate	12			Placebo																																						
FGFR1	FGFR1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Pazopanib		Terminated	NCT01208064		PCD	01-JUN-15	No	Yes	No benefit of treatment	1	26074395			Overall survival	102	50	52										4.3	3.2	.67	0.43-1.03	0.068									17.4	12.3	.72	0.4-1.28	0.257												
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 1	AZD4547		Terminated	NCT00979134		PCD	01-FEB-14	Expression level	Yes		1	28615371	Previously-treated		Maximum tolerated dose/toxicity	15	15			8.0																					4.9							1									
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 1	Infigratinib		Completed	NCT01004224		PCD	01-OCT-18	Expression level	Yes		1	27870574			Maximum tolerated dose/toxicity	36	36																					50.0										4	14								
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	AZD4547		Unknown	NCT01795768		ECD	01-SEP-14	Yes	No		4	NCT01795768	Previously-treated		Defined % decrease in tumour volume	48	48																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Rogaratinib		Recruiting	NCT03762122		ECD	01-DEC-21	No	No		4	NCT03762122	Previously-treated		Progression free survival	24	24																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Erdafitinib		Recruiting	NCT00979134		PCD	01-FEB-14	Yes	No		4	NCT03827850	Previously-treated		Maximum tolerated dose/toxicity	15	15			8.0																					4.9							1									
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Active, not recruiting	NCT02154490	Lung-MAP	ECD	01-APR-22	Yes	No		4	NCT02154490	Previously-treated		PFS, ORR	1864	1864																																								
FGFR1	FGFR1_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Active, not recruiting	NCT02965378	SWOG S1400D	ECD	01-APR-22	Yes	Yes		1	31195180	Previously-treated		Overall Response Rate	1	1																															1									
FGFR1	FGFR1_unspecified				oesophagus / carcinoma / NS	3	Phase 2	Erdafitinib		Active, not recruiting	NCT02699606		ECD	01-JUL-21	Yes	No		4	NCT02699606			Overall Response Rate	35	35																																								
FGFR1	FGFR1_unspecified				pancreas / carcinoma / NS	3	Phase 2	Dovitinib		Terminated	NCT01888965		PCD	01-AUG-14	Yes	Yes	Serious adverse events	4	NCT01888965			Biomarker discovery	9	9																																								
FGFR1	FGFR1_unspecified				prostate / carcinoma / NS	3	Phase 2	Dovitinib		Terminated	NCT01994590		PCD	01-JUN-17	No	Yes	Drug unavailable	4	NCT01994590			Maximum tolerated dose/toxicity	4	4																																								
FGFR1	FGFR1_unspecified				salivary gland / carcinoma / NS	3	Phase 2	Nintedanib + Pembrolizumab		Unknown	NCT02558387		ECD	01-JUL-16	No	Yes		2	10.1200/JCO.2016.34.15_suppl.6090			Unknown	20	20							8.3				60										75											15								
FGFR1	FGFR1_unspecified				soft tissue / sarcoma / NS	2	Phase 3	Ifosfamide + Pazopanib + Radiotherapy + doxorubicin hydrochloride		Completed	NCT02180867	PAZNTIS	PCD	01-JUN-19	No	Yes	Primary outcome met	2	10.1200/JCO.2019.37.15_suppl.11070	Untreated		Pathologic Response	81	42	39																																							
FGFR1	FGFR1_unspecified				stomach / carcinoma / NS	3	Phase 2	AZD4547		Unknown	NCT01795768		ECD	01-SEP-14	Yes	No		4	NCT01795768			Defined % decrease in tumour volume	48	48																																								
FGFR1	FGFR1_unspecified				stomach / carcinoma / adenocarcinoma	3	Phase 2	Erdafitinib		Active, not recruiting	NCT02699606		ECD	01-JUL-21	Yes	No		4	NCT02699606			Overall Response Rate	35	35																																								
FGFR1	FGFR1_unspecified				stomach / carcinoma / adenocarcinoma	3	Phase 2	Paclitaxel + Rogaratinib		Not yet recruiting	NCT04077255		ECD	01-DEC-22	Yes	No		4	NCT04077255			Response rate	85	85																																								
FGFR1	FGFR1_unspecified				thyroid / carcinoma / NS	3	Phase 2	Pazopanib		Completed	NCT01813136	PAZOTHYR	PCD	01-JAN-19	No	Yes		2	10.1200/JCO.2020.38.15_suppl.6540			Time to treatment failure, Time to progression	168	168											14.7			9.3-17.4							89.4																			
FGFR1	FGFR1_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Rogaratinib		Recruiting	NCT03088059		ECD	01-JUN-21	No	No		4	NCT03088059			Overall Response Rate	340	340																																								
FGFR1	FGFR1_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Infigratinib		Terminated	NCT02706691		PCD	01-FEB-19	Expression level	Yes	Slow accrual	4	NCT02706691			Overall Response Rate	1	1																																								
FGFR1	FGFR1_unspecified				urinary tract / carcinoma / NS	3	Phase 1	AZD4547 + Durvalumab		Active, not recruiting	NCT02546661	BISCAY module A	PCD	01-MAR-20	Yes	Yes		3	https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-bladder-cancer/115221-esmo-2019-biscay-an-adaptive-biomarker-directed-platform-study-in-metastatic-urothelial-cancer-with-durvalumab-in-combination-with-targeted-therapies.html			Maximum tolerated dose/toxicity	36	21	15	AZD4547	28.6	20.0																																				
FGFR1	FGFR1_unspecified				urinary tract / carcinoma / NS	3	Phase 2	Erdafitinib		Recruiting	NCT04172675		ECD	01-OCT-22	Yes	No		4	NCT04172675			Disease free survival, relapse free survival, regression free survival, recurrence free survival	280			Chemotherapy																																						
FGFR1	FGFR1_unspecified				urinary tract / carcinoma / NS	3	Phase 2	Rogaratinib		Withdrawn	NCT04040725	BLASST-3	PCD	01-NOV-19	Expression level	No		4	NCT04040725			Clinical activity	0	0																																								
FGFR1	FGFR1_unspecified				urinary tract / papilloma / typical	3	Phase 1	Cetrelimab + Erdafitinib		Recruiting	NCT03473743		ECD	01-JUN-21	Yes	No		4	NCT03473743			Overall Response Rate	160	160																																								
FGFR1	FGFR1_unspecified				urinary tract / papilloma / typical	3	Phase 1	PRN1371		Terminated	NCT02608125		PCD	01-JUN-20	Yes	Yes	Changed business priorities	4	NCT02608125			Maximum tolerated dose/toxicity	45	45																																								
FGFR1	FGFR1_unspecified				urinary tract / papilloma / typical	3	Phase 2	Erdafitinib		Active, not recruiting	NCT02699606		ECD	01-JUL-21	Yes	No		4	NCT02699606			Overall Response Rate	35	35																																								
FGFR1	FGFR1_unspecified				urinary tract / papilloma / typical	3	Phase 2	Pemigatinib		Active, not recruiting	NCT02872714		ECD	01-MAR-21	Yes	No		4	NCT02872714	Previously-treated		Overall Response Rate	263	263																																								
FGFR1	FGFR1_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rogaratinib		Recruiting	NCT03473756	FORT-2	ECD	01-MAR-24	Expression level	No		4	NCT03473756			Maximum tolerated dose/toxicity	210	210																																								
FGFR1	FGFR1_unspecified				urinary tract / papilloma / typical	3	Phase 3	Rogaratinib		Active, not recruiting	NCT03410693	FORT-1	PCD	01-OCT-20	Expression level	Yes		4	NCT03410693			Overall survival	172	172																																								
FGFR2	FGFR2_P253R	60644274		p.P253R	upper aerodigestive tract / carcinoma / squamous cell carcinoma	4	Case study	Pazopanib		Unknown					Yes	Yes		1	23786770			Unknown	1	1																																1								
FGFR2	FGFR2_fusions_FGFR2-BICC1,FGFR2-CASP7				urinary tract / papilloma / typical	1	Approved FDA	Erdafitinib	Required	Active, not recruiting	NCT02365597	BLC2001	ECD	01-JUN-22	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf			Overall Response Rate	6	6			0																																					
FGFR2	FGFR2_fusions_FGFR2-BICC1,FGFR2-CASP7				urinary tract / papilloma / typical	1	Case study	Erdafitinib		Completed	NCT01703481		PCD	01-JUL-17	Yes	Yes		1	26324363			Maximum tolerated dose/toxicity	1	1																															1									
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	Sunitinib		Recruiting	NCT02450123		ECD	01-AUG-20	No	No		4	NCT02450123			Progression free survival	3	3																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	RLY4008		Recruiting	NCT04526106		ECD	01-APR-24	Yes	No		4	NCT04526106			Maximum tolerated dose/toxicity	125	125																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	Aprutumab		Completed	NCT01881217		PCD	01-MAR-16	No	No		4	NCT01881217			Maximum tolerated dose/toxicity	35	35																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	LY2874455		Completed	NCT01212107		PCD	01-AUG-14	No	No		4	NCT01212107			Maximum tolerated dose/toxicity	94	94																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	Bemarituzumab		Completed	NCT02318329		PCD	01-FEB-19	No	No		1	31094225			Maximum tolerated dose/toxicity	79	79																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	Aprutumab ixadotin		Terminated	NCT02368951		PCD	01-JUL-16	No	Yes	MTD below therapeutic threshold	1	31502117			Maximum tolerated dose/toxicity	20	20																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	Pazopanib		Recruiting	NCT02691767		PCD	01-JAN-18	Expression level	No		4	NCT02691767			Progression free survival	25	25																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	Pazopanib		Recruiting	NCT02450136		ECD	01-SEP-20	No	No		4	NCT02450136			Maximum tolerated dose/toxicity	5	5																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	Erdafitinib		Completed	NCT03155620	Subprotocol B	ECD	01-SEP-27	No	Yes		4	NCT03155620		Pediatric	Overall Response Rate	1000	1000																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	AZD4547		Terminated	NCT00979134		PCD	01-FEB-14	Expression level	Yes	Terminated - based on the analysis of data from Study D2610C00004	4	NCT00979134			Maximum tolerated dose/toxicity	95	95																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 1	Sunitinib		Recruiting	NCT02691793		ECD	01-DEC-20	No	No		4	NCT02691793			Progression free survival	25	25																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	FGFR inhibitor debio 1347		Active, not recruiting	NCT03834220	FUZE	ECD	01-DEC-20	Yes	No		4	NCT03834220	Previously-treated		Overall Response Rate	63	63																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	ICP192		Recruiting	NCT04565275		ECD	01-OCT-22	Yes	No		4	NCT04565275			Overall Response Rate	45	45																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	ICP192		Recruiting	NCT03758664		ECD	01-DEC-20	Yes	No		4	NCT03758664			Overall Response Rate	56	56																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Pemigatinib		Recruiting	NCT04003623	FIGHT-208	ECD	01-OCT-21	Yes	No		4	NCT04003623			Overall Response Rate	50	50																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Pemigatinib		Recruiting	NCT03822117	FIGHT-207	ECD	01-DEC-21	Yes	No		4	NCT03822117			Overall Response Rate	170	170																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Futibatinib		Not yet recruiting	NCT04189445	Cohort A	ECD	01-JUN-22	Yes	No		4	NCT04189445			Overall Response Rate	115	115																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Futibatinib		Active, not recruiting	NCT02052778	FOENIX-101	PCD	01-DEC-19	Yes	No		4	NCT02052778			Overall Response Rate	100	100																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Derazantinib		Completed	NCT01752920		PCD	01-SEP-18	No	No		4	NCT01752920			Maximum tolerated dose/toxicity	119	119																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Infigratinib		Recruiting	NCT04233567		ECD	01-DEC-22	Yes	No		4	NCT04233567			Overall Response Rate	50	50																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Ponatinib		Recruiting	NCT02272998		ECD	01-DEC-21	Yes	No		4	NCT02272998			Overall Response Rate	45	45																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Erdafitinib		Recruiting	NCT03827850	FIND	ECD	01-SEP-21	Yes	No		4	NCT03827850			Overall Response Rate	50	50																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Erdafitinib		Recruiting	NCT04083976		ECD	01-JUN-22	Yes	No		4	NCT04083976			Overall Response Rate	280	280																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Erdafitinib		Recruiting	NCT03210714		ECD	01-DEC-24	Yes	No		4	NCT03210714			Response rate	49	49																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	Yes		1	32292573			Disease control rate, Clinical benefit rate	7	7																																2								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	AZD4547		Active, not recruiting	NCT04439240	MATCH-Subprotocol W	PCD	01-JUN-19	Yes	No		4	NCT04439240			Overall Response Rate	52	52																																								
FGFR2	FGFR2_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Approved FDA	Pemigatinib	Required	Active, not recruiting	NCT02924376	FIGHT-202	ECD	01-JUN-20	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf 			Overall Response Rate	107	107			36				9.1																							3	35									
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Case study	Ponatinib		Unknown					Yes	Yes		1	24550739			Unknown	1	1																																1								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 1	Infigratinib		Completed	NCT01004224		PCD	01-OCT-18	Yes	Yes		1	27870574			Maximum tolerated dose/toxicity	3	3																																3								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 1	Cisplatin + Gemcitabine + Pemigatinib		Not yet recruiting	NCT04088188		ECD	01-JUL-22	No	No		4	NCT04088188			Maximum tolerated dose/toxicity	40	40																																								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 1	Cisplatin + Gemcitabine + Ivosidenib		Not yet recruiting	NCT04088188		ECD	01-JUL-22	Yes	No		4	NCT04088188			Maximum tolerated dose/toxicity	40	40																																								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 2	Infigratinib		Recruiting	NCT02150967		ECD	01-MAR-22	Yes	No		4	NCT02150967			Overall Response Rate	61	61			14.8								5.8			4.3-7.6							75.4										9	37								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 2	Lenvatinib + Pembrolizumab		Not yet recruiting	NCT04550624		ECD	01-DEC-23	Yes	No		4	NCT04550624			Overall Response Rate	40	40																																								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 2	E7090		Recruiting	NCT04238715		ECD	01-JUN-22	Yes	No		4	NCT04238715			Overall Response Rate	60	60																																								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 2	HMPL-453		Not yet recruiting	NCT04353375		ECD	01-DEC-22	Yes	No		4	NCT04353375			Overall Response Rate	29	29																																								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 2	Pemigatinib		Not yet recruiting	NCT04256980		ECD	01-APR-21	No	No		4	NCT04256980			Overall Response Rate	54	54																																								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 2	Futibatinib		Active, not recruiting	NCT02052778	FOENIX-101	PCD	01-DEC-19	Yes	Yes		1	31109923			Overall Response Rate	4	4																															2	2								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 2	Derazantinib		Completed	NCT01752920		PCD	01-SEP-18	Yes	Yes		1	30420614			Maximum tolerated dose/toxicity	29	29			20.7								5.7										82.8																			
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 2	Derazantinib		Recruiting	NCT03230318	FIDES-01	ECD	01-OCT-21	Yes	No		4	NCT03230318			Overall Response Rate	143	143																																								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 3	Ponatinib		Completed	NCT02265341		PCD	01-MAY-18	Yes	Yes		4	NCT02265341			Unknown	12	12											2.4										45.5																			
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 3	Pemigatinib		Recruiting	NCT03656536		ECD	01-OCT-23	Yes	No		4	NCT03656536			Progression free survival	432			Cisplatin + Gemcitabine																																						
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 3	Futibatinib		Not yet recruiting	NCT04093362	FOENIX-CCA3	ECD	01-MAR-22	Yes	No		4	NCT04093362			Progression free survival	216	216																																								
FGFR2	FGFR2_unspecified				biliary tract / carcinoma / adenocarcinoma	1	Phase 3	Infigratinib		Recruiting	NCT03773302	PROOF	ECD	01-SEP-23	Yes	No		4	NCT03773302			Progression free survival	384	384																																								
FGFR2	FGFR2_unspecified				breast / carcinoma / NS	3	Case study	Dovitinib		Unknown					Expression level	Yes		1	23658459 			Unknown	2	2																															2									
FGFR2	FGFR2_unspecified				breast / carcinoma / NS	3	Phase 2	Futibatinib		Recruiting	NCT04024436		ECD	01-JUN-21	Yes	No		4	NCT04024436			Overall Response Rate	168	168																																								
FGFR2	FGFR2_unspecified				central nervous system / NS / medulloblastoma	3	Phase 2	Infigratinib		Completed	NCT01975701		PCD	01-OCT-18	No	Yes		4	NCT01975701	Previously-treated		Progression free survival	24	24			7.7								1.7			1.05-2.80										6.74			4.17-11.73				2	7								
FGFR2	FGFR2_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
FGFR2	FGFR2_unspecified				endometrium / carcinoma / NS	3	Phase 1	Erdafitinib		Completed	NCT01703481		PCD	01-JUL-17	Yes	Yes		1	26324363			Maximum tolerated dose/toxicity	1	1																															1									
FGFR2	FGFR2_unspecified				endometrium / carcinoma / NS	3	Phase 2	Dovitinib		Completed	NCT01379534		PCD	01-MAR-14	Comparison with wt	Yes		4	NCT01379534			Progression free survival	52	21	31		4.5	16.1							4.1	2.7									63.6	51.6		20.2	9.3															
FGFR2	FGFR2_unspecified				endometrium / carcinoma / NS	3	Phase 2	FP1039		Withdrawn	NCT01244438		ECD	01-JUN-12	Yes	Yes	Slow accrual	4	NCT01244438			PFS, ORR	0	0																																								
FGFR2	FGFR2_unspecified				endometrium / carcinoma / NS	3	Phase 2	Brivanib alaninate		Completed	NCT00888173		PCD	01-JUL-16	No	Yes		4	NCT00888173			PFS, ORR	45	45			18.6		9-31						30.2			19-44										10.7																
FGFR2	FGFR2_unspecified				endometrium / carcinoma / NS	3	Phase 3	Ponatinib		Withdrawn	NCT01888562		ECD	01-JUL-18	Yes	Yes	Denied regulatory approval	4	NCT01888562			Overall Response Rate	0	0																																								
FGFR2	FGFR2_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 2	AZD4547		Unknown	EudraCT201100371818				Expression level	Yes		1	27179038			Unknown	9	9																															3									
FGFR2	FGFR2_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 2	Futibatinib		Not yet recruiting	NCT04189445	Cohort B	ECD	01-JUN-22	Expression level	No		4	NCT04189445			Overall Response Rate	115	115																																								
FGFR2	FGFR2_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 2	Paclitaxel + Rogaratinib		Not yet recruiting	NCT04077255		ECD	01-DEC-22	Yes	No		4	NCT04077255			Response rate	85	85																																								
FGFR2	FGFR2_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 2	Letrozole + Nintedanib		Completed	NCT01921673		PCD	01-JUN-16	No	No		4	NCT01921673			Progression free survival	14	14																																								
FGFR2	FGFR2_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 3	Bemarituzumab + FOLFOX-6		Active, not recruiting	NCT03343301	FIGHT	ECD	01-JUL-22	Expression level	No		4	NCT03343301			Maximum tolerated dose/toxicity	10	10																																								
FGFR2	FGFR2_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 3	Bemarituzumab + FOLFOX-6		Active, not recruiting	NCT03694522	FIGHT	ECD	01-MAR-21	Expression level	No		4	NCT03694522			Progression free survival	155			FOLFOX-6 + Placebo																																						
FGFR2	FGFR2_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pemigatinib		Not yet recruiting	NCT04096417		ECD	01-DEC-22	Yes	No		4	NCT04096417			Overall Response Rate	24	24																																								
FGFR2	FGFR2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		Terminated	NCT02299141		PCD	01-JAN-20	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12								
FGFR2	FGFR2_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Rogaratinib		Recruiting	NCT03762122		ECD	01-DEC-21	Expression level	No		4	NCT03762122			Progression free survival	24	24																																								
FGFR2	FGFR2_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Active, not recruiting	NCT02154490	Lung-MAP	PCD	01-APR-22	No	No		4	NCT02154490	Previously-treated		PFS, ORR	1864	1864																																								
FGFR2	FGFR2_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Active, not recruiting	NCT02965378		ECD	01-APR-22	No	No		4	NCT02965378			Overall Response Rate	42	42																																								
FGFR2	FGFR2_unspecified				oesophagus / carcinoma / NS	3	Phase 2	AZD4547		Unknown	NCT01795768		ECD	01-SEP-14	Expression level	Yes		4	10.1200/jco.2016.34.4_suppl.154	Previously-treated		Defined % decrease in tumour volume	9	9			33																																					
FGFR2	FGFR2_unspecified				stomach / carcinoma / adenocarcinoma	3	Phase 1	Bemarituzumab		Completed	NCT02318329		PCD	01-FEB-19	Expression level	Yes		1	31094225	Previously-treated, platinum-resistant		Maximum tolerated dose/toxicity	8	8			25																																					
FGFR2	FGFR2_unspecified				stomach / carcinoma / adenocarcinoma	3	Phase 1	Alofanib		Recruiting	NCT04071184		ECD	01-OCT-20	No	No		4	NCT04071184			Maximum tolerated dose/toxicity	50	50																																								
FGFR2	FGFR2_unspecified				stomach / carcinoma / adenocarcinoma	3	Phase 2	AZD4547		Terminated	NCT01457846	SHINE	PCD	01-AUG-13	Expression level	Yes	Slow accrual	4	NCT01457846			Progression free survival	960	960																																								
FGFR2	FGFR2_unspecified				stomach / carcinoma / adenocarcinoma	3	Phase 2	Dovitinib		Completed	NCT01719549	AMC1202	PCD	01-FEB-16	Expression level	No		4	NCT01719549			Response rate	19	19																																								
FGFR2	FGFR2_unspecified				stomach / carcinoma / adenocarcinoma	3	Phase 2	AZD4547		Terminated	NCT01457846	SHINE	PCD	01-AUG-13	Expression level	Yes	No benefit of treatment	1	29177434			Progression free survival	67	40	27	Paclitaxel									1.8	3.5	1.57		0.96																									
FGFR2	FGFR2_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Infigratinib		Terminated	NCT02706691		PCD	01-FEB-19	Expression level	Yes	Slow accrual	4	NCT02706691			Overall Response Rate	1	1																																								
FGFR2	FGFR2_unspecified				urinary tract / carcinoma / NS	3	Phase 1	AZD4547 + Durvalumab		Active, not recruiting	NCT02546661	BISCAY module A	PCD	01-MAR-20	Yes	Yes		3	https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-bladder-cancer/115221-esmo-2019-biscay-an-adaptive-biomarker-directed-platform-study-in-metastatic-urothelial-cancer-with-durvalumab-in-combination-with-targeted-therapies.html			Maximum tolerated dose/toxicity	36	21	15	AZD4547	28.6	20.0																																				
FGFR2	FGFR2_unspecified				urinary tract / carcinoma / NS	3	Phase 2	Erdafitinib		Recruiting	NCT04172675		ECD	01-OCT-22	Yes	No		4	NCT04172675			Disease free survival, relapse free survival, regression free survival, recurrence free survival	280			Chemotherapy																																						
FGFR2	FGFR2_unspecified				urinary tract / carcinoma / NS	3	Phase 2	Rogaratinib		Unknown	NCT04040725	BLASST-3	PCD	01-NOV-19	Yes	No		4	NCT01795768			Clinical activity	0	0																																								
FGFR2	FGFR2_unspecified				urinary tract / papilloma / typical	3	Phase 1	PRN1371		Terminated	NCT02608125		PCD	01-JUN-20	Yes	No	Changed business priorities	4	NCT02608125			Maximum tolerated dose/toxicity	45	45																																								
FGFR2	FGFR2_unspecified				urinary tract / papilloma / typical	3	Phase 2	Pemigatinib		Active, not recruiting	NCT02872714		ECD	01-MAR-21	Yes	No		4	NCT02872714	Previously-treated		Overall Response Rate	263	263																																								
FGFR3	FGFR3-TACC3 fusion				central nervous system / glioma / NS	3	Phase 1	Infigratinib		Recruiting	NCT04424966		ECD	01-DEC-22	Yes	No		4	NCT04424966			Progression free survival	20	20																																								
FGFR3	FGFR3-TACC3 fusion				central nervous system / glioma / NS	3	Phase 2	Infigratinib		Completed	NCT01975701		PCD	01-OCT-18	No	Yes		4	NCT01975701	Previously-treated		Progression free survival	24	24			7.7								1.7			1.05-2.80										6.74			4.17-11.73				2	7								
FGFR3	FGFR3-TACC3 fusion				urinary tract / papilloma / typical	4	Case study	Erdafitinib		Completed	NCT01703481		PCD	01-JUL-17	Yes	Yes		1	26324363			Maximum tolerated dose/toxicity	1	1																															1									
FGFR3	FGFR3_K650E	53390625		p.K650E	central nervous system / glioma / NS	3	Phase 1	Infigratinib		Recruiting	NCT04424966		ECD	01-DEC-22	Yes	No		4	NCT04424966			Progression free survival	20	20																																								
FGFR3	FGFR3_R248C,S249C,G370C,Y373C	53390026 + 53390089 + 53390174 + 53390662		p.G370C + p.R248C + p.S249C + p.Y373C	urinary tract / papilloma / typical	1	Approved FDA	Erdafitinib	Required	Active, not recruiting	NCT02365597	BLC2001	ECD	01-JUN-22	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	Previously-treated		Overall Response Rate	64	64			44.6																																					
FGFR3	FGFR3_S249C	53390026		p.S249C	lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Active, not recruiting	NCT02965378	SWOG S1400D	ECD	01-APR-22	Yes	Yes		1	31195180	Previously-treated		Overall Response Rate	1	1																															1									
FGFR3	FGFR3_fusions_FGFR3-TACC3,FGFR3-BAIAP2L1				urinary tract / papilloma / typical	1	Approved FDA	Erdafitinib	Required	Active, not recruiting	NCT02365597	BLC2001	ECD	01-JUN-22	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	Previously-treated		Overall Response Rate	18	18			11.1																																					
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 1	Erdafitinib		Completed	NCT03155620	Subprotocol B	ECD	01-SEP-27	No	Yes		4	NCT03155620		Pediatric	Overall Response Rate	1000	1000																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 1	LY3076226		Completed	NCT02529553		PCD	01-MAR-18	No	Yes	Development discontinued 2017	4	NCT02529553			Maximum tolerated dose/toxicity	25	25																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	FGFR inhibitor debio 1347		Active, not recruiting	NCT03834220	FUZE	ECD	01-DEC-20	Yes	No		4	NCT03834220	Previously-treated		Overall Response Rate	63	63																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	ICP192		Recruiting	NCT04565275		ECD	01-OCT-22	Yes	No		4	NCT04565275			Overall Response Rate	45	45																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Pemigatinib		Recruiting	NCT04003623	FIGHT-208	ECD	01-OCT-21	Yes	No		4	NCT04003623			Overall Response Rate	50	50																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Pemigatinib		Recruiting	NCT03822117	FIGHT-207	ECD	01-DEC-21	Yes	No		4	NCT03822117			Overall Response Rate	170	170																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Futibatinib		Not yet recruiting	NCT04189445	Cohort A	ECD	01-JUN-22	Yes	No		4	NCT04189445			Overall Response Rate	115	115																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Futibatinib		Active, not recruiting	NCT02052778	FOENIX-101	PCD	01-DEC-19	Yes	No		4	NCT02052778			Overall Response Rate	100	100																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Derazantinib		Completed	NCT01752920		PCD	01-SEP-18	No	No		4	NCT01752920			Maximum tolerated dose/toxicity	119	119																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Infigratinib		Recruiting	NCT04233567		ECD	01-DEC-22	Yes	No		4	NCT04233567			Overall Response Rate	50	50																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Ponatinib		Recruiting	NCT02272998		ECD	01-DEC-21	Yes	No		4	NCT02272998			Overall Response Rate	45	45																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Erdafitinib		Recruiting	NCT03827850	FIND	ECD	01-SEP-21	Yes	No		4	NCT03827850			Overall Response Rate	50	50																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Erdafitinib		Recruiting	NCT04083976		ECD	01-JUN-22	Yes	No		4	NCT04083976			Overall Response Rate	280	280																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Erdafitinib		Recruiting	NCT03210714		ECD	01-DEC-24	Yes	No		4	NCT03210714			Response rate	49	49																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	AZD4547		Active, not recruiting	NCT04439240	MATCH-Subprotocol W	PCD	01-JUN-19	Yes	No		4	NCT04439240			Overall Response Rate	52	52																																								
FGFR3	FGFR3_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
FGFR3	FGFR3_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 1	Cisplatin + Gemcitabine + Ivosidenib		Not yet recruiting	NCT04088188		ECD	01-JUL-22	Yes	No		4	NCT04088188			Maximum tolerated dose/toxicity	40	40																																								
FGFR3	FGFR3_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 1	Cisplatin + Gemcitabine + Pemigatinib		Not yet recruiting	NCT04088188		ECD	01-JUL-22	No	No		4	NCT04088188			Maximum tolerated dose/toxicity	40	40																																								
FGFR3	FGFR3_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Lenvatinib + Pembrolizumab		Not yet recruiting	NCT04550624		ECD	01-DEC-23	Yes	No		4	NCT04550624			Overall Response Rate	40	40																																								
FGFR3	FGFR3_unspecified				breast / carcinoma / NS	3	Case study	Dovitinib		Unknown					Expression level	Yes		1	23658459 			Unknown	2	2																																2								
FGFR3	FGFR3_unspecified				breast / carcinoma / NS	3	Phase 2	Futibatinib		Recruiting	NCT04024436		ECD	01-JUN-21	Yes	No		4	NCT04024436			Overall Response Rate	168	168																																								
FGFR3	FGFR3_unspecified				central nervous system / NS / medulloblastoma	3	Phase 2	Infigratinib		Completed	NCT01975701		PCD	01-OCT-18	No	Yes		4	NCT01975701	Previously-treated		Progression free survival	24	24			7.7								1.7			1.05-2.80										6.74			4.17-11.73				2	7								
FGFR3	FGFR3_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
FGFR3	FGFR3_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	Phase 2	Paclitaxel + Rogaratinib		Not yet recruiting	NCT04077255		ECD	01-DEC-22	Yes	No		4	NCT04077255			Response rate	85	85																																								
FGFR3	FGFR3_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide		Recruiting	NCT03732703	MyDRUG Sub-Protocol D1	ECD	01-FEB-22	Yes	No		4	NCT03732703	Previously-treated		Overall Response Rate	228	228																																								
FGFR3	FGFR3_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Dexamethasone + Erdafitinib		Terminated	NCT02952573		PCD	01-NOV-18	Comparison with wt	Yes	Slow accrual	4	NCT02952573	Previously-treated		Overall Response Rate	20	20																																								
FGFR3	FGFR3_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Bortezomib + Dexamethasone + doxorubicin hydrochloride		Completed	NCT00872521		PCD	01-MAY-11	Comparison with wt	Yes		4	NCT00872521	Untreated		Overall Response Rate	89	11	78		72.7	82.1																																				
FGFR3	FGFR3_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pemigatinib		Not yet recruiting	NCT04096417		ECD	01-DEC-22	Yes	No		4	NCT04096417			Overall Response Rate	24	24																																								
FGFR3	FGFR3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		Terminated	NCT02299141		PCD	01-JAN-20	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12								
FGFR3	FGFR3_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Rogaratinib		Recruiting	NCT03762122		ECD	01-DEC-21	Expression level	No		4	NCT03762122			Progression free survival	24	24																																								
FGFR3	FGFR3_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 3	AZD4547		Active, not recruiting	NCT02154490	Lung-MAP	PCD	01-APR-22	No	No		4	NCT02154490	Previously-treated		PFS, ORR	1864	1864																																								
FGFR3	FGFR3_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 1	Rogaratinib		Completed	NCT02592785		PCD	01-FEB-17	Yes	Yes		3	https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Phase-I-experience-with-rogaratinib-in-patients-with-head-and-neck-cancer-selected-based-on-FGFR-mRNA-overexpression 			Maximum tolerated dose/toxicity	7	7																															2									
FGFR3	FGFR3_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Infigratinib		Terminated	NCT02706691		PCD	01-FEB-19	Expression level	Yes	Slow accrual	4	NCT02706691			Overall Response Rate	1	1																																								
FGFR3	FGFR3_unspecified				urinary tract / carcinoma / NS	3	Phase 1	AZD4547 + Durvalumab		Active, not recruiting	NCT02546661	BISCAY module A	PCD	01-MAR-20	Yes	Yes		3	https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-bladder-cancer/115221-esmo-2019-biscay-an-adaptive-biomarker-directed-platform-study-in-metastatic-urothelial-cancer-with-durvalumab-in-combination-with-targeted-therapies.html			Maximum tolerated dose/toxicity	36	21	15	AZD4547	28.6	20.0																																				
FGFR3	FGFR3_unspecified				urinary tract / carcinoma / NS	3	Phase 1	Pembrolizumab + Vofatamab		Terminated	NCT02925533		PCD	01-JUN-17	No	Yes	Safety concerns	4	NCT02925533	Previously-treated		Maximum tolerated dose/toxicity	1	1																																								
FGFR3	FGFR3_unspecified				urinary tract / carcinoma / NS	3	Phase 2	Erdafitinib		Recruiting	NCT04172675		ECD	01-OCT-22	Yes	No		4	NCT04172675			Disease free survival, relapse free survival, regression free survival, recurrence free survival	280			Chemotherapy																																						
FGFR3	FGFR3_unspecified				urinary tract / carcinoma / NS	3	Phase 2	Pemigatinib		Recruiting	NCT03914794		ECD	01-MAY-22	No	No		4	NCT03914794			Complete response, Pathological complete response	43	43																																								
FGFR3	FGFR3_unspecified				urinary tract / carcinoma / NS	3	Phase 2	Rogaratinib		Unknown	NCT04040725	BLASST-3	PCD	01-NOV-19	Yes	No		4	NCT01795768			Clinical activity	0	0																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Case study	Rogaratinib		Active, not recruiting	NCT01976741		PCD	01-MAR-19	Yes	Yes		4	NCT03410693			Maximum tolerated dose/toxicity	5	5																															5									
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 1	Infigratinib		Completed	NCT01004224		PCD	01-OCT-18	Yes	Yes		1	27870574			Maximum tolerated dose/toxicity	8	8																					75.0										3	3								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 1	PRN1371		Terminated	NCT02608125		PCD	01-JUN-20	Yes	No	Changed business priorities	4	NCT02608125			Maximum tolerated dose/toxicity	45	45																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 1	Infigratinib		Recruiting	NCT04228042		ECD	01-DEC-21	No	No		4	NCT04228042			Maximum tolerated dose/toxicity	20	20																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Dovitinib		Completed	NCT00790426		PCD	01-APR-12	Comparison with wt	Yes	Primary outcome not met	1	25457633			Overall Response Rate	43	12	31		0	3.2							3	1.8									25	26																		
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Epacadostat		Not yet recruiting	NCT04586244	Optimus	ECD	01-DEC-23	Yes	No		4	NCT04586244			Change in CD3+ lymphocytes	90	90																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Retifanlimab		Not yet recruiting	NCT04586244	Optimus	ECD	01-DEC-23	Yes	No		4	NCT04586244			Change in CD3+ lymphocytes	90	90																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Epacadostat + Retifanlimab		Not yet recruiting	NCT04586244	Optimus	ECD	01-DEC-23	Yes	No		4	NCT04586244			Change in CD3+ lymphocytes	90	90																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Pemigatinib + Retifanlimab		Not yet recruiting	NCT04586244	Optimus	ECD	01-DEC-23	Yes	No		4	NCT04586244			Change in CD3+ lymphocytes	90	90																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Pembrolizumab + Vofatamab		Terminated	NCT03123055	FIERCE-22	PCD	01-DEC-19	No	No		4	NCT03123055	Previously-treated		Overall Response Rate	28	28																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Docetaxel + Vofatamab		Terminated	NCT02401542	FIERCE-21	PCD	01-NOV-19	Yes	Yes		4	NCT02401542	Previously-treated		Progression free survival	42	21	21	Vofatamab									4.4	4.45																												
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Futibatinib + Pembrolizumab		Recruiting	NCT04601857		ECD	01-SEP-23	Yes	No		4	NCT04601857			Overall Response Rate	46	46																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Pembrolizumab + Pemigatinib		Active, not recruiting	NCT04003610	FIGHT-205	ECD	01-NOV-22	Yes	No		4	NCT04003610			Progression free survival	7	7																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Pemigatinib		Not yet recruiting	NCT04586244	Optimus	ECD	01-DEC-23	Yes	No		4	NCT04586244			Change in CD3+ lymphocytes	90	90																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Pemigatinib		Active, not recruiting	NCT02872714		ECD	01-MAR-21	Yes	No		4	NCT02872714	Previously-treated		Overall Response Rate	263	263																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Pemigatinib		Active, not recruiting	NCT04003610	FIGHT-205	ECD	01-NOV-22	Yes	No		4	NCT04003610			Progression free survival	7	7																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Nintedanib		Unknown	NCT02278978		PCD	01-DEC-15	No	No		4	NCT02278978			Response rate	129	129																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 2	Dovitinib		Terminated	NCT01732107		PCD	01-MAR-17	No	Yes	Development discontinued	4	NCT01732107			Complete response, Pathological complete response	13	13																																								
FGFR3	FGFR3_unspecified				urinary tract / papilloma / typical	3	Phase 3	Infigratinib		Recruiting	NCT04197986		ECD	01-JAN-24	Yes	No		4	NCT04197986			Disease free survival, relapse free survival, regression free survival, recurrence free survival	218			Placebo																																						
FGFR4	FGFR4_unspecified				NS / other / neoplasm	3	Phase 1	Erdafitinib		Completed	NCT03155620	Subprotocol B	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
FGFR4	FGFR4_unspecified				NS / other / neoplasm	3	Phase 2	Erdafitinib		Recruiting	NCT03210714		ECD	01-DEC-24	Yes	No		4	NCT03210714			Response rate	49	49																																								
FGFR4	FGFR4_unspecified				NS / other / neoplasm	3	Phase 2	ICP192		Recruiting	NCT04565275		ECD	01-OCT-22	Yes	No		4	NCT04565275			Overall Response Rate	45	45																																								
FGFR4	FGFR4_unspecified				NS / other / neoplasm	3	Phase 2	Futibatinib		Not yet recruiting	NCT04189445	Cohort A	ECD	01-JUN-22	Yes	No		4	NCT04189445			Overall Response Rate	115	115																																								
FGFR4	FGFR4_unspecified				NS / other / neoplasm	3	Phase 2	Futibatinib		Active, not recruiting	NCT02052778	FOENIX-101	PCD	01-DEC-19	Yes	No		4	NCT02052778			Overall Response Rate	100	100																																								
FGFR4	FGFR4_unspecified				NS / other / neoplasm	3	Phase 2	Ponatinib		Recruiting	NCT02272998		ECD	01-DEC-21	Yes	No		4	NCT02272998			Overall Response Rate	45	45																																								
FGFR4	FGFR4_unspecified				NS / other / neoplasm	3	Phase 2	Erdafitinib		Recruiting	NCT03827850	FIND	ECD	01-SEP-21	Yes	No		4	NCT03827850			Overall Response Rate	50	50																																								
FGFR4	FGFR4_unspecified				NS / other / neoplasm	3	Phase 2	Erdafitinib		Recruiting	NCT04083976		ECD	01-JUN-22	Yes	No		4	NCT04083976			Overall Response Rate	280	280																																								
FGFR4	FGFR4_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
FGFR4	FGFR4_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Rogaratinib		Recruiting	NCT03762122		ECD	01-DEC-21	Expression level	No		4	NCT03762122			Progression free survival	24	24																																								
FGFR4	FGFR4_unspecified				urinary tract / carcinoma / NS	3	Phase 2	Erdafitinib		Recruiting	NCT04172675		ECD	01-OCT-22	Yes	No		4	NCT04172675			Disease free survival, relapse free survival, regression free survival, recurrence free survival	280			Chemotherapy																																						
FGFR4	FGFR4_unspecified				urinary tract / papilloma / typical	3	Phase 1	PRN1371		Terminated	NCT02608125		PCD	01-JUN-20	Yes	No	Changed business priorities	4	NCT02608125			Maximum tolerated dose/toxicity	45	45																																								
FLT1	FLT1_unspecified (VEGFR1_unspecified)				NS / other / neoplasm	3	Phase 2	Sorafenib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
FLT1	FLT1_unspecified (VEGFR1_unspecified)				NS / other / neoplasm	3	Phase 2	Pazopanib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
FLT1	FLT1_unspecified (VEGFR1_unspecified)				NS / other / neoplasm	3	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	No		1	32292573			Disease control rate, Clinical benefit rate	0	0																																								
FLT1	FLT1_unspecified (VEGFR1_unspecified)				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
FLT1	FLT1_unspecified (VEGFR1_unspecified)				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
FLT1	FLT1_unspecified (VEGFR1_unspecified)				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
FLT1	FLT1_unspecified (VEGFR1_unspecified)				NS / other / neoplasm	3	Phase 2	Regorafenib		Recruiting	NCT02693535	TAPUR group 13	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
FLT1	FLT1_unspecified (VEGFR1_unspecified)				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
FLT1	FLT1_unspecified (VEGFR1_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
FLT1	FLT1_unspecified (VEGFR1_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	23	30		Erlotinib + Placebo									2.89	2.59	1.1		0.56																									
FLT1	FLT1_unspecified (VEGFR1_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		Terminated	NCT02299141		PCD	01-JAN-20	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12								
FLT3	FLT3-ITD, NUP98-NSD1 fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Decitabine + Sorafenib		Recruiting	NCT03164057		ECD	01-JUN-25	No	No		4	NCT03164057	Untreated		OS, EFS	200	200																																								
FLT3	FLT3-ITD, WT1 unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine + Sorafenib		Recruiting	NCT03164057		ECD	01-JUN-25	No	No		4	NCT03164057	Untreated		OS, EFS	200	200																																								
FLT3	FLT3_D835?			p.D835X	haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Approved FDA	Chemotherapy + Gilteritinib		Active, not recruiting	NCT02421939	ADMIRAL	PCD	01-SEP-18	No	No		4	NCT02421939	Previously-treated		OS, EFS	371			Chemotherapy																																						
FLT3	FLT3_D835?			p.D835X	haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Crenolanib		Completed	NCT01657682	ARO-005	PCD	01-APR-19	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.7008	Untreated			6	6																								6.08																
FLT3	FLT3_I836			p.I836X	haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Approved FDA	Chemotherapy + Gilteritinib		Active, not recruiting	NCT02421939	ADMIRAL	PCD	01-SEP-18	No	No		4	NCT02421939	Previously-treated		OS, EFS	371			Chemotherapy																																						
FLT3	FLT3_internal tandem duplication,D835X				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Crenolanib		Completed	NCT01522469	ARO-004	PCD	01-AUG-14	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.7008	Previously-treated		ORR, PFS, DOR	3	3																								4.21																
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Azacitidine + Sorafenib		Completed	NCT02196857		PCD	01-NOV-18	Yes	Yes		4	NCT02196857			Composite complete remission	16	16																														4	5									
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Peripheral blood stem cell transplantation  + Prophylactic donor lymphocytes		Not yet recruiting	NCT03771222		ECD	01-DEC-20	No	No		4	NCT03771222			Cumulative incidence of relapse	40	40																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Approved FDA	Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin	Not required	Completed	NCT00927498	ALFA 0701	PCD	01-JUL-11	Yes	Yes	2?year OS 64.2 vs 33.9% HR 0.3 95% CI 0.13-0.73 p=0.005 2-year EFS 53.0 vs 12.3% HR 0.32 95% CI 0.15-0.69 p=0.002	1	22482940 			Event free survival	49	22	27		95.5	85.2	0.38-35.0	0.36																											55.9	14.5	.33	0.15-0.73	0.004			
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Approved FDA	Chemotherapy + Gilteritinib		Active, not recruiting	NCT02421939	ADMIRAL	PCD	01-SEP-18	No	Yes		1	31665578	Previously-treated		OS, EFS	328	215	113	Chemotherapy																																						
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 1	Veliparib		Active, not recruiting	NCT01139970		PCD	01-MAR-14	No	Yes		1	27503200	Previously-treated	Geriatric	Maximum tolerated dose/toxicity	48	48																								5.3			3.3-8.3			8		8								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 1	Rebastinib		Completed	NCT00827138		PCD	01-JAN-13	Yes	Yes	No benefit of treatment	1	27927766			Maximum tolerated dose/toxicity	5	5																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 1	Milademetan + Quizartinib		Recruiting	NCT03552029		ECD	01-NOV-23	Yes	No		4	NCT03552029			Response rate	156	156																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 1	KW-2449		Terminated	NCT00779480		PCD	01-APR-10	Yes	Yes	Serious adverse events	4	NCT00779480			Maximum tolerated dose/toxicity	14	14																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Sorafenib		Completed	NCT01445080		PCD	01-MAR-12	Yes	Yes	100% serious adverse events	4	NCT01445080	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	5	5																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Decitabine + Quizartinib + Venetoclax		Recruiting	NCT03661307		ECD	01-JAN-22	No	No		4	NCT03661307			Overall Response Rate	52	52																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	CPX-351 + Quizartinib		Not yet recruiting	NCT04209725		ECD	01-JAN-24	Yes	No		4	NCT04209725			Overall Response Rate	34	34																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Azacitidine + Sorafenib		Completed	NCT01254890		PCD	01-MAR-15	Yes	Yes		1	30028037	Untreated	Geriatric	Response rate	27	27																								8.3						7	14									
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Azacitidine + Sorafenib		Completed	NCT01254890		PCD	01-MAR-15	Yes	Yes		1	23613521	Previously-treated		Response rate	37	37																														6	11									
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Chemotherapy + Gilteritinib		Not yet recruiting	NCT04240002		ECD	01-APR-24	Yes	No		4	NCT04240002	Previously-treated	Pediatric	Composite complete remission	114	114																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Chemotherapy + Gilteritinib		Active, not recruiting	NCT02927262		ECD	01-JUN-21	Yes	No		4	NCT02927262	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	98	98																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Bortezomib + Sorafenib + Vorinostat		Completed	NCT01534260		PCD	01-AUG-16	Yes	Yes		4	NCT01534260			Overall Response Rate	15	15			40																																					
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Crenolanib		Completed	NCT01522469	ARO-004	PCD	01-AUG-14	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.7008	Previously-treated		ORR, PFS, DOR	9	9																								7.82																
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Cytarabine + Daunorubicin + Sorafenib		Active, not recruiting	NCT01253070		PCD	01-OCT-14	Yes	Yes		1	29034366		Geriatric	Overall survival	39	39																								15.0																
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Chemotherapy + Sunitinib		Completed	NCT00783653		PCD	01-JUL-13	Yes	Yes		1	25818407		Geriatric	Maximum tolerated dose/toxicity	22	22																														13										
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Quizartinib		Completed	NCT02984995		PCD	01-MAR-18	Yes	Yes	cCR 53.8%	4	NCT02984995			Composite complete remission	26	26			77.8				3.72		1.09-5.68															7.87																
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Quizartinib		Completed	NCT01565668		PCD	01-MAR-15	Yes	Yes		4	NCT01565668			Complete response, Pathological complete response	38	38																								6.3						1	17									
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Cytarabine + Daunorubicin + Midostaurin		Completed	NCT01477606		PCD	01-FEB-20	Yes	Yes	mEFS 13.2 (95% CI 10.0-18.3)	1	30563875			Event free survival	97	97																								37.7			32.0-44.3			86	30									
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Azacitidine		Completed	NCT02450877	AZA-AML-004	PCD	01-OCT-18	No	No		3	https://ash.confex.com/ash/2020/webprogram/Paper137043.html		Pediatric	Progression free survival	1	1																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Ponatinib		Recruiting	NCT03690115	PONALLO	ECD	01-DEC-21	Yes	No		4	NCT03690115			Disease free survival, relapse free survival, regression free survival, recurrence free survival	77	77																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Ponatinib		Recruiting	NCT02428543	PONATINIB-AML	ECD	01-NOV-20	Yes	No		4	NCT02428543	Previously-treated		Maximum tolerated dose/toxicity	49	49																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Midostaurin		Completed	NCT01883362	RADIUS	PCD	01-APR-18	Yes	Yes	18m RFS 89 vs 76%	2	10.1182/blood-2018-99-113582			Disease free survival, relapse free survival, regression free survival, recurrence free survival	60	30	30	Best supportive care																																						
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Midostaurin		Active, not recruiting	NCT01830361	MIDOKIT 	PCD	01-JAN-19	Yes	No		4	NCT01830361			Event free survival	18	18																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 2	Sorafenib		Recruiting	NCT03622541	AML004	PCD	01-DEC-19	Yes	No		4	NCT03622541			Complete remission	46	46																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 3	Quizartinib		Active, not recruiting	NCT02039726	QuANTUM-R	PCD	01-FEB-18	Yes	Yes		4	NCT02039726			Overall survival	245	122		Chemotherapy																						6.2	4.7	.76	0.58-0.98	0.019												
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 3	Cytarabine + Daunorubicin + Idarubicin + Quizartinib		Active, not recruiting	NCT02668653	QuANTUM-First 	ECD	01-APR-22	Yes	No		4	NCT02668653	Untreated		Event free survival	539	539		Cytarabine + Daunorubicin + Idarubicin + Placebo																																						
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Phase 3	Hematopoietic Stem Cell Transplant + Sorafenib		Completed	NCT02474290		PCD	01-JUL-18	Yes	Yes	2 yr relapse 11.9 vs 31.6% (HR 0.29; 95% CI 0.15-0.58; p<0.0001). 	1	32791048	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	202	100	102																																							
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Retrospective/Meta-analysis	Chemotherapy + Sorafenib		Unknown					Yes	Yes		2	10.1002/cncr.32387	Untreated		Clinical activity	183	79	104	Chemotherapy	98	83		0.057					35	8			0.019									42	13			0.026												
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Unknown	Sorafenib		Recruiting	NCT02156297		ECD	01-MAY-20	Yes	No		4	NCT02156297			PFS, ORR	100	100																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	2	Unknown	Hematopoietic Stem Cell Transplant + Sorafenib		Active, not recruiting	NCT01578109		ECD	01-DEC-25	Yes	No		4	NCT01578109			Maximum tolerated dose/toxicity	45	45																																								
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myeloproliferative neoplasm	3	Phase 1	Sorafenib		Completed	NCT00217646		PCD	01-DEC-10	Yes	Yes		1	20952518			Maximum tolerated dose/toxicity	50	50																														3	2									
FLT3	FLT3_internal_tandem_duplication				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	3	Phase 1	Cytarabine + Etoposide + Quizartinib		Completed	NCT01411267		PCD	01-APR-13	Yes	Yes		2	10.1158/1078-0432.CCR-15-1998	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	7	7																														1	2	4								
FLT3	FLT3_tyrosine_kinase_domain				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Chemotherapy + Sunitinib		Completed	NCT00783653		PCD	01-JUL-13	Yes	Yes		1	25818407		Geriatric	Maximum tolerated dose/toxicity	8	8																														5										
FLT3	FLT3_tyrosine_kinase_domain				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Daunorubicin + Sorafenib		Active, not recruiting	NCT01253070		PCD	01-OCT-14	Yes	Yes		1	29034366		Geriatric	Overall survival	15	15																								16.2																
FLT3	FLT3_unspecified				NS / malignant melanoma / NS	3	Phase 2	Flt3 ligand + Poly-ICLC + Rasdegafusp alfa		Active, not recruiting	NCT02129075		PCD	01-MAR-16	No	Yes	Primary outcome met	2	10.1200/JCO.2016.34.15_suppl.9589			Response rate	30	30																																								
FLT3	FLT3_unspecified				NS / malignant melanoma / NS	3	Phase 2	Poly-ICLC + Rasdegafusp alfa		Active, not recruiting	NCT02129075		PCD	01-MAR-16	No	Yes	Primary outcome met	2	10.1200/JCO.2016.34.15_suppl.9589			Response rate	30	30																																								
FLT3	FLT3_unspecified				NS / neoplasm / NS	3	Phase 2	Sorafenib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
FLT3	FLT3_unspecified				NS / neoplasm / NS	3	Phase 2	Ponatinib		Recruiting	NCT02272998		ECD	01-DEC-21	No	No		4	NCT02272998			Overall Response Rate	45	45																																								
FLT3	FLT3_unspecified				NS / neoplasm / NS	3	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	Yes		1	32292573			Disease control rate, Clinical benefit rate	7	7																																1								
FLT3	FLT3_unspecified				NS / neoplasm / NS	3	Phase 2	Irinotecan + Sorafenib		Withdrawn	NCT02747537		ECD	01-JAN-20	No	Yes		4	NCT02272998			Overall Response Rate	0	0																																								
FLT3	FLT3_unspecified				NS / neoplasm / NS	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	Yes	No		4	NCT02693535			Overall Response Rate	720	720																																								
FLT3	FLT3_unspecified				NS / neoplasm / NS	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 3	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
FLT3	FLT3_unspecified				NS / neoplasm / NS	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Regorafenib		Recruiting	NCT03042689		ECD	01-SEP-21	No	No		4	NCT03042689			Maximum tolerated dose/toxicity	16	16																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	LGH447 + Midostaurin		Completed	NCT02078609		PCD	01-APR-19	No	No		4	NCT01546038			Maximum tolerated dose/toxicity	70	70																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Everolimus + Midostaurin		Active, not recruiting	NCT00819546		ECD	01-DEC-21	No	No		4	NCT00819546	Previously-treated		Maximum tolerated dose/toxicity	29	29																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Midostaurin		Completed	NCT00045942		PCD	01-MAR-08	Yes	Yes		1	20733134			Maximum tolerated dose/toxicity	35	35																															1									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	E6201		Terminated	NCT02418000		PCD	01-JUN-17	No	Yes	No benefit of treatment	4	NCT02418000			Maximum tolerated dose/toxicity	27	27																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant + Radiotherapy		Recruiting	NCT03333486		ECD	01-SEP-22	No	No		4	NCT03333486			Overall survival	58	58																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cladribine + Cytarabine + Idarubicin + Venetoclax		Recruiting	NCT02115295		ECD	01-MAY-21	No	No		4	NCT02115295			Complete response, Pathological complete response	408	408																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Quizartinib		Recruiting	NCT04493138		ECD	01-FEB-22	Yes	No		4	NCT04493138			ORR, OS	58	58																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Quizartinib		Active, not recruiting	NCT01892371		ECD	01-NOV-20	No	No		4	NCT01892371			Overall Response Rate	200	200																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Azacitidine + Quizartinib		Active, not recruiting	NCT01892371		ECD	01-NOV-20	No	No		4	NCT01892371			Overall Response Rate	200	200																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Sorafenib		Completed	NCT00516828		PCD	01-MAR-10	No	No		4	NCT00516828		Geriatric	Maximum tolerated dose/toxicity	21	21																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Busulfan + Fludarabine + Radiotherapy		Unknown	NCT00815568		ECD	01-DEC-11	No	No		4	NCT00815568			Progression free survival	114	114																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	8	5	3	Cytarabine	20	0																																				
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Proton beam radiation therapy + Temozolomide		Suspended	NCT03092674		ECD	01-AUG-23	No	No		4	NCT03092674		Geriatric	Overall survival	1670	1670																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Cytarabine + Decitabine		Suspended	NCT03092674		ECD	01-AUG-23	No	No		4	NCT03092674		Geriatric	Overall survival	1670	1670																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Azacitidine + Nivolumab		Suspended	NCT03092674		ECD	01-AUG-23	No	No		4	NCT03092674		Geriatric	Overall survival	1670	1670																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Chemotherapy + Gilteritinib		Recruiting	NCT04027309	HOVON 156 AML	ECD	01-MAY-23	Yes	No		4	NCT04027309			Event free survival	768	768																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Azacitidine + Midostaurin		Suspended	NCT03092674		ECD	01-AUG-23	No	No		4	NCT03092674		Geriatric	Overall survival	1670	1670																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	Cytarabine + Daunorubicin + Midostaurin	Required	Active, not recruiting	NCT00651261	RATIFY	PCD	01-JUL-16	Yes	Yes		1	28644114	Untreated		Overall survival	717	360	357	Chemotherapy									8.2	3			0.002									74.7	25.6			0.009												
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	Gemtuzumab Ozogamicin		Unknown	NCT00091234	AML-19	ECD	01-DEC-13	No	Yes		1	26811524			Overall survival	237	118	119	Best supportive care																						4.9	3.6	.69	0.53-0.90	0.005												
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	Gemtuzumab Ozogamicin		Unknown		MyloFrance-1			No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s003lbl.pdf			Unknown	57																															15			11.6							
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	Decitabine + Venetoclax	Not required	Active, not recruiting	NCT02203773		ECD	01-SEP-21	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208573s011s014s015lbl.pdf	Untreated	Geriatric	Complete remission	13	13																														7	1									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	CPX-351	Not required	Completed	NCT01696084		PCD	01-DEC-15	No	Yes		1	30024784		Geriatric	Overall survival	43	22	21	Cytarabine + Daunorubicin																						10.25	4.6	.76	0.34-1.66													
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	Azacitidine + Venetoclax	Not required	Active, not recruiting	NCT02203773		ECD	01-SEP-21	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208573s011s014s015lbl.pdf	Untreated	Geriatric	Complete remission	67	67																														25	16									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	Chemotherapy + Gilteritinib		Active, not recruiting	NCT02421939	ADMIRAL	PCD	01-SEP-18	Yes	Yes	EFS in 189, 62 pts was 2.8 vs 0.7 HR 0.793 CI 0.577 to 1.089  p=0.0415 	1	31665578	Previously-treated		OS, EFS	371	247	124	Chemotherapy																						9.3	5.6	.64	0.49-0.83	0.0004												
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Cytarabine + Daunorubicin + Pacritinib		Completed	NCT02323607		PCD	01-JUL-18	Yes	No		4	NCT02323607			Maximum tolerated dose/toxicity	13	13																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	AMG553		Not yet recruiting	NCT03904069		ECD	01-AUG-29	Expression level	No		4	NCT03904069	Previously-treated		Maximum tolerated dose/toxicity	40	40																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin + Midostaurin		Recruiting	NCT04385290	MOSAIC	ECD	01-MAY-21	Yes	No		4	NCT04385290			Maximum tolerated dose/toxicity	214	214																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin + Midostaurin		Recruiting	NCT03900949		ECD	01-JAN-23	Yes	No		4	NCT03900949	Untreated		Maximum tolerated dose/toxicity	24	24																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Belinostat + Pevonedistat		Recruiting	NCT03772925		ECD	01-JUL-21	No	No		4	NCT03772925	Previously-treated		Maximum tolerated dose/toxicity	45	45																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Azacitidine + Nintedanib		Recruiting	NCT03513484		ECD	01-MAR-23	No	No		4	NCT03513484	Previously-treated		Maximum tolerated dose/toxicity	44	44																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	MAX-40279		Recruiting	NCT03412292	Maxinovel	ECD	01-NOV-20	No	No		4	NCT03412292			Maximum tolerated dose/toxicity	30	30																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Ningetinib		Recruiting	NCT03125876		ECD	01-JAN-19	Yes	No		4	NCT03125876	Previously-treated		Maximum tolerated dose/toxicity	34	34																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	SKLB1028		Unknown	NCT02859948		ECD	01-DEC-17	No	No		4	NCT02859948	Previously-treated		Maximum tolerated dose/toxicity	18	18																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Adavosertib + Belinostat		Terminated	NCT02381548		PCD	01-MAY-17	No	No		4	NCT02381548	Previously-treated		Maximum tolerated dose/toxicity	20	20																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	AMG-925		Terminated	NCT02335814		PCD	01-MAY-17	No	Yes	Changed business priorities	4	NCT02335814	Previously-treated		Maximum tolerated dose/toxicity	51	51																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Decitabine + Pacritinib		Completed	NCT02323607		PCD	01-JUL-18	Yes	No		4	NCT02323607			Maximum tolerated dose/toxicity	13	13																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Crenolanib + Sorafenib		Completed	NCT02270788	RELHEM2	PCD	01-OCT-16	No	No		4	NCT02270788	Previously-treated		Maximum tolerated dose/toxicity	10	10																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Hematopoietic Stem Cell Transplant + Sorafenib		Completed	NCT01398501		PCD	01-SEP-15	No	Yes	1yr PFS 85%, OS 95%	1	25239228			Maximum tolerated dose/toxicity	22	22																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Cytarabine + Daunorubicin + Quizartinib		Completed	NCT01390337		PCD	01-FEB-15	No	Yes		1	29139135	Untreated		Maximum tolerated dose/toxicity	19	19																														14	2									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Bortezomib + Cytarabine + Etoposide + Midostaurin + Mitoxantrone hydrochloride		Completed	NCT01174888		PCD	01-APR-14	No	Yes		1	26784138	Previously-treated		Maximum tolerated dose/toxicity	23	23																														13	6									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Decitabine + Midostaurin		Completed	NCT01130662		PCD	01-OCT-11	No	No		4	NCT01130662	Untreated	Geriatric	Maximum tolerated dose/toxicity	16	16																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Filgrastim + Plerixafor + Sorafenib		Completed	NCT00943943		PCD	01-MAR-17	Yes	No		4	NCT00943943			Maximum tolerated dose/toxicity	33	33																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	IMC-EB10 		Terminated	NCT00887926		PCD	01-AUG-10	No	Yes	No benefit of treatemtn	4	NCT00887926			Maximum tolerated dose/toxicity	26	26																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Quizartinib		Completed	NCT00462761	CP0001	PCD	01-MAR-09	Yes	Yes		1	24002496			Maximum tolerated dose/toxicity	17	17			53				2.31		0.92-6.69															4.15			2.54-6.23			4	5									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Cytarabine + Daunorubicin + Midostaurin		Completed	NCT00093600		PCD	01-JUN-11	No	No		4	NCT00093600	Untreated		Maximum tolerated dose/toxicity	69	69																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Tandutinib		Completed	NCT00064584		PCD	01-JAN-05	Yes	No		4	NCT00064584			Maximum tolerated dose/toxicity	60	60																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	AT9283		Completed	NCT01431664		PCD	01-JUL-14	No	Yes	Slow accrual	2	10.1002/pbc.26351	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	7	7																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Cytarabine + Daunorubicin + Pacritinib		Completed	NCT02323607		PCD	01-JUL-18	Yes	No		4	NCT02323607			Maximum tolerated dose/toxicity	13	13																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Imatinib		Completed	NCT00509093		PCD	01-MAY-14	No	Yes	15.6% serious adverse events	4	NCT00509093			Progression free survival	32	32											52.1																													
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Dubermatinib		Recruiting	NCT04518345		ECD	01-DEC-22	Yes	No		4	NCT04518345			Composite complete remission	46	46																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Anthracycline + Cytarabine + Siremadlin		Withdrawn	NCT03760445		ECD	01-JUN-23	No	Yes	Changed business priorities	4	NCT03760445			Complete response, Pathological complete response	0	0																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Gilteritinib + Venetoclax		Recruiting	NCT04140487		ECD	01-SEP-22	Yes	No		4	NCT04140487	Previously-treated		Overall Response Rate	42	42																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Venetoclax		Recruiting	NCT04062266		ECD	01-OCT-30	No	No		4	NCT04062266			Event free survival	50	50																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cladribine + Cytarabine + Idarubicin + Quizartinib		Recruiting	NCT04047641		ECD	01-FEB-22	No	No		4	NCT04047641			Event free survival	86	86																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cytarabine + Mitoxantrone hydrochloride + Quizartinib		Not yet recruiting	NCT03989713	Q-HAM	ECD	01-AUG-25	Yes	No		4	NCT03989713	Previously-treated		Composite complete remission	80	80																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Hematopoietic Stem Cell Transplant + Midostaurin		Terminated	NCT03951961	MAURITIUS	PCD	01-FEB-21	No	Yes	Slow accrual	4	NCT03951961	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	1	1																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	NMS-03592088		Recruiting	NCT03922100		ECD	01-SEP-23	No	No		4	NCT03922100			Overall Response Rate	140	140																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin + Midostaurin		Recruiting	NCT04385290	MOSAIC	ECD	01-MAY-21	Yes	No		4	NCT04385290			Event free survival	214	214																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Quizartinib + Venetoclax		Recruiting	NCT03735875		ECD	01-DEC-21	Yes	No		4	NCT03735875	Previously-treated		Composite complete remission	32	32																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Atezolizumab + Gilteritinib		Recruiting	NCT03730012		ECD	01-JUL-22	Yes	No		4	NCT03730012	Previously-treated		Complete remission	61	61																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Chemotherapy + Dexamethasone		Active, not recruiting	NCT03609060	DEXAML-02	ECD	01-AUG-25	No	No		4	NCT03609060		Geriatric	Event free survival	120	120																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Crenolanib + Cytarabine + Fludarabine		Withdrawn	NCT03324243	ARO-014	ECD	01-DEC-20	Yes	No		4	NCT03324243	Previously-treated	Pediatric	Event free survival	0	0																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	FF-10101		Recruiting	NCT03194685		ECD	01-JUL-22	No	No		4	NCT03194685	Previously-treated		Maximum tolerated dose/toxicity	99	99																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Omacetaxine mepesuccinate + Sorafenib		Completed	NCT03170895	AML008	PCD	01-FEB-20	Yes	No		4	NCT03170895			OS, EFS	5	5																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Omacetaxine mepesuccinate + Quizartinib		Recruiting	NCT03135054	AML005	PCD	01-OCT-20	Yes	No		4	NCT03135054			Complete remission	40	40																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	SKLB1028		Not yet recruiting	NCT04015024		ECD	01-APR-21	No	No		4	NCT04015024	Previously-treated		Overall Response Rate	30	30																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Ponatinib		Withdrawn	NCT02829840		ECD	01-JUL-21	Yes	No		4	NCT02829840			Maximum tolerated dose/toxicity	0	0																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	4G8-SDIEM		Active, not recruiting	NCT02789254	FLYSYN-101	ECD	01-JUL-21	No	No		4	NCT02789254			Maximum tolerated dose/toxicity	31	31																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cytarabine + Hematopoietic Stem Cell Transplant + Midostaurin		Recruiting	NCT02756962		ECD	01-JUL-24	Yes	No		4	NCT02756962			Disease free survival, relapse free survival, regression free survival, recurrence free survival	100	100																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cytarabine + Hematopoietic Stem Cell Transplant		Recruiting	NCT02756962		ECD	01-JUL-24	Yes	No		4	NCT02756962			Disease free survival, relapse free survival, regression free survival, recurrence free survival	100	100																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Selinexor + Sorafenib		Completed	NCT02530476		PCD	01-APR-19	No	Yes		4	29773601	Previously-treated		Maximum tolerated dose/toxicity	11	11																															6									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Selinexor + Sorafenib		Completed	NCT02530476		PCD	01-APR-19	No	Yes		4	29773601			Maximum tolerated dose/toxicity	14	14																															6									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Chemotherapy + Crenolanib		Completed	NCT02400281	ARO-010	PCD	01-JUL-20	Yes	No		4	NCT02400281			Maximum tolerated dose/toxicity	28	28																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Crenolanib + Hematopoietic Stem Cell Transplant		Recruiting	NCT02400255	ARO-009	ECD	01-JUN-21	Expression level	No		4	NCT02400255			Progression free survival	48	48																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cytarabine + Gilteritinib + Idarubicin		Active, not recruiting	NCT02310321		ECD	01-SEP-21	No	No		4	NCT02310321	Untreated		Complete remission	93	93																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Crenolanib + Cytarabine + Daunorubicin + Idarubicin		Active, not recruiting	NCT02283177	ARO-006	PCD	01-DEC-19	Yes	No		4	NCT02283177	Untreated		Maximum tolerated dose/toxicity	44	44																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cytarabine + Daunorubicin + Nilotinib		Active, not recruiting	NCT01806571		PCD	01-JUL-17	No	Yes	DFS 56.4%	4	NCT01806571	Untreated		Overall Response Rate	34	34			61.8																																					
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Crenolanib		Completed	NCT01657682	ARO-005	PCD	01-APR-19	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.7008	Previously-treated		Response rate	36	36			31																					3.09						6	5									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Decitabine + Midostaurin		Terminated	NCT02634827		PCD	01-MAR-17	Yes	Yes	Slow accrual	4	NCT02634827			Complete response, Pathological complete response	1	1																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Decitabine + Midostaurin		Terminated	NCT01846624		PCD	01-JUL-16	No	Yes	Slow accrual	4	NCT01846624	Untreated	Geriatric	Complete response, Pathological complete response	13	13																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Midostaurin		Completed	NCT01093573	CASE 1908	PCD	01-SEP-16	No	Yes	No patients with target mutation	1	32085993		Geriatric	Maximum tolerated dose/toxicity	24	24																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cyclophosphamide + Filgrastim + Fludarabine + Hematopoietic Stem Cell Transplant + Mycophenolate mofetil + Tacrolimus		Recruiting	NCT01028716		ECD	01-JAN-23	No	No		4	NCT01028716			Unknown	50	50																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Quizartinib		Recruiting	NCT03793478		ECD	01-MAY-27	No	No		4	NCT03793478			Complete response, Pathological complete response	65	65																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Quizartinib		Completed	NCT00989261	ACE - Cohort 1	PCD	01-SEP-12	Yes	Yes		1	29859851		Geriatric	Complete response, Pathological complete response	112	112																														63	23									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Tandutinib		Withdrawn	NCT00297921				Yes	No		4	NCT00297921	Untreated		Unknown	0	0																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Chemotherapy + Sorafenib		Completed	NCT00373373		PCD	01-JUL-09	No	No		4	NCT00373373	Untreated	Geriatric	Event free survival	200	200																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cytarabine + Nintedanib		Unknown	NCT01488344		PCD	01-NOV-14	No	Yes	1yr OS = 33%	1	27716819	Previously-treated	Geriatric	Overall Response Rate	12	12																														2	3									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Ponatinib		Withdrawn	NCT02829840		ECD	01-SEP-21	Yes	No		4	NCT02829840			Maximum tolerated dose/toxicity	0	0																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cytarabine + Idarubicin + Lestaurtinib		Completed	NCT00469859		PCD	01-MAR-10	Yes	No		4	NCT00469859	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	14	14																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Lestaurtinib		Unknown					Yes	Yes		1	16857985			Clinical activity	5	5																															3									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Lestaurtinib		Completed	NCT00030186		PCD	01-FEB-03	Yes	No		4	NCT00030186	Previously-treated		Clinical activity	37	37																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Chemotherapy + Lestaurtinib		Completed	NCT00079482		PCD	01-MAR-09	No	Yes		4	NCT00079482			Complete response, Pathological complete response	224	112	112	Chemotherapy																												29										
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Chemotherapy + Lestaurtinib		Completed	NCT00079482		PCD	01-MAR-09	Yes	Yes	No benefit of treatment	1	21270442	Previously-treated		Unknown	224	224																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Pexidartinib		Completed	NCT01349049		PCD	01-OCT-14	No	Yes		4	NCT01349049	Previously-treated		Overall survival	56	56																														2	8									
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Gilteritinib		Recruiting	NCT03836209		ECD	01-NOV-22	Yes	No		4	NCT03836209			Complete remission	179	179																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Gilteritinib		Recruiting	NCT03013998	BAML-16-001-S8 	ECD	01-DEC-21	No	No		4	NCT03013998			Complete remission	2000	2000																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Gilteritinib		Completed	NCT02014558		PCD	01-AUG-17	No	Yes	Best CR rate 16.7 vs 0%	4	NCT02014558	Previously-treated		Maximum tolerated dose/toxicity	24	12	12																																							
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Chemotherapy + Midostaurin		Suspended	NCT03591510		ECD	01-MAY-22	Yes	No		4	NCT03591510			Event free survival	52	52																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Midostaurin		Active, not recruiting	NCT03280030		PCD	01-MAR-20	Yes	No		4	NCT03280030	Untreated		Event free survival	71	71																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Midostaurin		Withdrawn	NCT02723435		PCD	01-APR-18	No	Yes	Logistical and administrative issues	4	NCT02723435		Geriatric	Event free survival	0	0																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Midostaurin		Terminated	NCT00866281		PCD	01-SEP-14	No	Yes	Slow accrual	4	NCT00866281			Maximum tolerated dose/toxicity	22	22																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Dasatinib		Active, not recruiting	NCT01238211	CALGB-10801	PCD	01-JUL-15	No	No		4	NCT01238211	Untreated		Maximum tolerated dose/toxicity	56	56																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Chemotherapy + Midostaurin		Recruiting	NCT03379727		ECD	01-JAN-22	Yes	No		4	NCT03379727	Untreated		Composite complete remission	300	300																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Gemtuzumab Ozogamicin		Recruiting	NCT02473146	ALFA1401	ECD	01-APR-19	No	No		4	NCT02473146		Geriatric	Event free survival	225	225																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Arsenic trioxide + Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone hydrochloride + Tretinoin		Active, not recruiting	NCT02339740		PCD	01-OCT-20	No	No		4	NCT02339740			Event free survival	158	158																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Cytarabine + Daunorubicin		Completed	NCT00428558		PCD	01-JUN-11	Yes	Yes	At 3 years, probabilities of durable remission, disease-free (DFS) and overall survival from CR were 64%, 61% and 84%, respectively	2	10.1182/blood.V118.21.410.410			Event free survival	198	198																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Ibrutinib		Recruiting	NCT03642236		ECD	01-AUG-22	Yes	No		4	NCT03642236	Previously-treated		CR, DFS, OS	122	122																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Crenolanib + Cytarabine + Daunorubicin		Recruiting	NCT03258931	ARO-021	ECD	01-NOV-22	Yes	No		4	NCT03258931	Untreated		Event free survival	510	510																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Gilteritinib + Hematopoietic Stem Cell Transplant		Recruiting	NCT02997202		ECD	01-APR-25	Yes	No		4	NCT02997202			Disease free survival, relapse free survival, regression free survival, recurrence free survival	356			Hematopoietic Stem Cell Transplant + Placebo																																						
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Azacitidine + Gilteritinib		Recruiting	NCT02752035		ECD	01-APR-21	Yes	No		4	NCT02752035	Untreated		Overall survival	250	250		Azacitidine																																						
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Chemotherapy + Crenolanib		Recruiting	NCT03250338	ARO-013	ECD	01-OCT-21	Yes	No		4	NCT03250338			Event free survival	322	322																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Crenolanib + Cytarabine + Hematopoietic Stem Cell Transplant + Mitoxantrone hydrochloride		Terminated	NCT02298166		PCD	01-MAR-20	Yes	Yes	Loss of funding	4	NCT02298166	Previously-treated		Event free survival	9			Chemotherapy																																						
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Bortezomib		Active, not recruiting	NCT01371981		PCD	01-MAR-19	No	Yes		1	32029509	Untreated		Event free survival	1097	555	542										47	44.8			0.24									67.2	63.6			0.36												
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Chemotherapy + Tretinoin		Withdrawn	NCT01067274	ALFA-073	ECD	01-APR-16	No	No		4	NCT01067274		Geriatric	Event free survival	0	0																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Daunorubicin + Midostaurin		Not yet recruiting	NCT04174612	AMELIORATE	ECD	01-FEB-22	Yes	No		4	NCT04174612			DCR, ORR	172	172																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Idasanutlin 		Terminated	NCT02545283	MIRROS	PCD	01-APR-20	No	Yes	No benefit of treatment	4	NCT02545283			Overall survival	447	447		Cytarabine + Placebo																																						
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Azacitidine + Pevonedistat		Recruiting	NCT04090736	PEVOLAM	ECD	01-JUN-23	No	No		4	NCT04090736	Untreated		Overall survival	466			Azacitidine																																						
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Hematopoietic Stem Cell Transplant + Iomab-B		Recruiting	NCT02665065	SIERRA	ECD	01-DEC-21	No	No		4	NCT02665065		Geriatric	Complete remission	150	150																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine		Recruiting	NCT03258931	ARO-021	ECD	01-NOV-22	Yes	No		4	NCT03258931	Untreated		Event free survival	510	510																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Gilteritinib		Recruiting	NCT03182244		ECD	01-APR-21	Yes	No		4	NCT03182244	Previously-treated		Overall survival	318	318																																								
FLT3	FLT3_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 4	Cytarabine + Fludarabine		Unknown	NCT02926586	CBF-AML-2016	ECD	01-JUL-19	No	No		4	NCT02926586			Disease free survival, relapse free survival, regression free survival, recurrence free survival	200	200																																								
FLT3	FLT3_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR	ECD	01-DEC-23	Expression level	Yes		3	https://www.abstractsonline.com/pp8/#!/6812/presentation/9947			Overall Response Rate	3378	3378			0								2.33																					2								
FLT3	FLT3_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Famitinb		Unknown	NCT02390947	FACT	PCD	01-FEB-19	No	No		4	NCT02390947			Overall survival	543	543																																								
FLT3	FLT3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
FLT3	FLT3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	17	13		Erlotinib + Placebo									3.69	2.79	1.46	0.25-7.96	0.65																									
FLT4	FLT4_unspecified (VEGFR3_unspecified)				NS / other / neoplasm	3	Phase 2	Sorafenib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
FLT4	FLT4_unspecified (VEGFR3_unspecified)				NS / other / neoplasm	3	Phase 2	Pazopanib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
FLT4	FLT4_unspecified (VEGFR3_unspecified)				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
FLT4	FLT4_unspecified (VEGFR3_unspecified)				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
FLT4	FLT4_unspecified (VEGFR3_unspecified)				NS / other / neoplasm	3	Phase 2	Regorafenib		Recruiting	NCT02693535	TAPUR group 13	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
FLT4	FLT4_unspecified (VEGFR3_unspecified)				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
FLT4	FLT4_unspecified (VEGFR3_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
FLT4	FLT4_unspecified (VEGFR3_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		Terminated	NCT02299141		PCD	01-JAN-20	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12								
GEN1	GEN1_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
GEN1	GEN1_unspecified				prostate / carcinoma / NS	3	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
GNA11	GNA11_unspecified				NS / neoplasm / NS	3	Phase 2	Trametinib		Recruiting	NCT02465060	MATCH Subprotocol S2	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
GNAQ	GNAQ_unspecified				NS / neoplasm / NS	3	Phase 2	Trametinib		Recruiting	NCT02465060	MATCH Subprotocol S2	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
HDAC2	HDAC2_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
HRAS	HRAS_G13V	54237051		p.G13V	skin / carcinoma / squamous cell carcinoma	3	Phase 2	Cetuximab		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	Yes	Yes		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																														1										
HRAS	HRAS_unspecified				NS / other / neoplasm	3	Phase 1	KO-947		Active, not recruiting	NCT03051035		ECD	01-DEC-20	No	No		4	NCT03051035			Maximum tolerated dose/toxicity	100	100																																								
HRAS	HRAS_unspecified				NS / other / neoplasm	3	Phase 1	Tazemetostat hydrobromide		Completed	NCT03155620	Subprotocol M	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
HRAS	HRAS_unspecified				NS / other / neoplasm	3	Phase 2	Sorafenib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
HRAS	HRAS_unspecified				NS / other / neoplasm	3	Phase 2	Selumetinib		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
HRAS	HRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Siremadlin + Trametinib		Recruiting	NCT03714958	TRAHD	ECD	01-FEB-21	No	No		4	NCT03714958			Maximum tolerated dose/toxicity	24	24																																								
HRAS	HRAS_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2			Completed	NCT02643056	S10PANI01	PCD	01-DEC-15	No	Yes		1	28592616	Previously-treated		Overall Response Rate	33	33			6								2.6										51			9.7							2	15								
IDH1	IDH1_R132?			p.R132X	NS / neoplasm / NS	3	Phase 1	IDH305		Active, not recruiting	NCT02381886		ECD	01-JUN-22	Yes	No		4	NCT02381886			Maximum tolerated dose/toxicity	166	166																																								
IDH1	IDH1_R132?			p.R132X	NS / neoplasm / NS	3	Phase 1	LY3410738		Recruiting	NCT04521686		ECD	01-FEB-23	Yes	No		4	NCT04521686			Maximum tolerated dose/toxicity	180	180																																								
IDH1	IDH1_R132?			p.R132X	NS / neoplasm / NS	3	Phase 1	BAY1436032		Active, not recruiting	NCT02746081		PCD	01-NOV-18	Yes	No		4	NCT02746081			Maximum tolerated dose/toxicity	81	81																																								
IDH1	IDH1_R132?			p.R132X	central nervous system / glioma / NS	3	Phase 1	BAY1436032		Active, not recruiting	NCT02746081		PCD	01-NOV-18	Yes	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/Safety-efficacy-PK-and-PD-biomarker-results-of-the-first-in-human-study-of-mutant-isocitrate-dehydrogenase-1-mIDH1-inhibitor-BAY-1436032-in-patients-pts-with-mIDH1-advanced-solid-tumours			Maximum tolerated dose/toxicity	55	55																														1	2									
IDH1	IDH1_R132?			p.R132X	central nervous system / glioma / NS	3	Phase 2	DS-1001b		Recruiting	NCT04458272		ECD	01-JUN-23	Yes	No		4	NCT04458272			Overall Response Rate	25	25																																								
IDH1	IDH1_R132?			p.R132X	central nervous system / glioma / astrocytoma	3	Phase 1	Radiotherapy + Telaglenastat + Temozolomide		Recruiting	NCT03528642		ECD	01-DEC-22	Yes	No		4	NCT03528642			Maximum tolerated dose/toxicity	40	40																																								
IDH1	IDH1_R132?			p.R132X	haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	BAY1436032		Completed	NCT03127735		PCD	01-DEC-18	Yes	Yes		1	32733012			Maximum tolerated dose/toxicity	27	27			15																					6.6			4.6-9.4			1	3	18								
IDH1	IDH1_R132H	61615239 + 61633011		p.R132H	central nervous system / glioma / NS	3	Phase 1	IDH1 R132H peptide vaccine		Completed	NCT02454634		PCD	01-SEP-17	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.2001			Maximum tolerated dose/toxicity	32	32																																28								
IDH1	IDH1_R132H	61615239 + 61633011		p.R132H	central nervous system / glioma / NS	3	Phase 1	Avelumab + IDH1 R132H peptide vaccine		Recruiting	NCT03893903	AMPLIFY-NEOVAC	ECD	01-AUG-21	Yes	No		4	NCT03893903			Maximum tolerated dose/toxicity	60	60																																								
IDH1	IDH1_R132H	61615239 + 61633011		p.R132H	central nervous system / glioma / NS	3	Phase 1	IDH1 R132H peptide vaccine		Unknown	NCT02771301		ECD	01-JAN-19	Yes	No		4	NCT02771301			Unknown	30	30																																								
IDH1	IDH1_R132H	61615239 + 61633011		p.R132H	central nervous system / glioma / NS	3	Retrospective/Meta-analysis	Cetuximab		Unknown					Yes	Yes	Superior PFS and OS in wt 	1	22199315	Previously-treated		Unknown	6	6											1.17													3.07																
IDH1	IDH1_R132H	61615239 + 61633011		p.R132H	central nervous system / glioma / NS	3	Retrospective/Meta-analysis	Bevacizumab		Unknown					Yes	Yes		1	22199315	Previously-treated		Unknown	5	5											3.23													10.16																
IDH1	IDH1_R132H	61615239 + 61633011		p.R132H	central nervous system / glioma / NS	3	Retrospective/Meta-analysis	Sunitinib		Unknown					Yes	Yes		1	22199315	Previously-treated		Unknown	6	6											1.03													6.4																
IDH1	IDH1_unspecified				NS / malignant melanoma / NS	3	Phase 4	Vorinostat		Not yet recruiting	NCT02645149	MatchMel	ECD	01-APR-23	Yes	No		4	NCT02645149			Clinical activity	1000	1000																																								
IDH1	IDH1_unspecified				NS / mesothelioma / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 1	Vorasidenib		Active, not recruiting	NCT02481154		ECD	01-DEC-21	Yes	No		4	NCT02481154			Maximum tolerated dose/toxicity	95	95																																								
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 1	Telaglenastat		Active, not recruiting	NCT02071862	CANTATA	PCD	01-MAR-19	Yes	No		4	NCT02071862			Maximum tolerated dose/toxicity	210	210																																								
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 1	Ivosidenib		Active, not recruiting	NCT02073994		ECD	01-JUN-21	Yes	No		4	NCT02073994			Maximum tolerated dose/toxicity	170	170																																								
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 1	Extended-release flucytosine + Vocimagene amiretrorepvec		Terminated	NCT02576665	Toca 6	PCD	01-MAY-19	Yes	No	Changed business priorities	2	NCT02576665	Previously-treated		Clinical activity	21	21																								9.4																
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 2	Olaparib		Recruiting	NCT03212274		ECD	01-JUL-21	Yes	No		4	NCT03212274			Overall Response Rate	145	145																																								
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 2	Ceralasertib + Olaparib		Recruiting	NCT03878095		ECD	01-MAR-23	Yes	No		4	NCT03878095			Overall Response Rate	50	50																																								
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 2	Ivosidenib + Nivolumab		Not yet recruiting	NCT04056910		ECD	01-SEP-22	Yes	No		4	NCT04056910			Progression free survival	35	35																																								
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 2	Ivosidenib		Not yet recruiting	NCT04195555		ECD	01-DEC-25	Yes	No		4	NCT04195555			Overall Response Rate	49	49																																								
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 2	Durvalumab + Olaparib		Recruiting	NCT03991832		ECD	01-SEP-22	Yes	No		4	NCT03991832			Overall Response Rate	78	78																																								
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
IDH1	IDH1_unspecified				NS / neoplasm / NS	3	Phase 2	Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	Yes	No		4	NCT02576444			Overall Response Rate	64	64																																								
IDH1	IDH1_unspecified				biliary tract / carcinoma / adenocarcinoma	2	Phase 1	Cisplatin + Gemcitabine + Ivosidenib		Not yet recruiting	NCT04088188		ECD	01-JUL-22	Yes	No		4	NCT04088188			Maximum tolerated dose/toxicity	40	40																																								
IDH1	IDH1_unspecified				biliary tract / carcinoma / adenocarcinoma	2	Phase 1	Cisplatin + Gemcitabine + Pemigatinib		Not yet recruiting	NCT04088188		ECD	01-JUL-22	Yes	No		4	NCT04088188			Maximum tolerated dose/toxicity	40	40																																								
IDH1	IDH1_unspecified				biliary tract / carcinoma / adenocarcinoma	2	Phase 2	Olaparib		Recruiting	NCT03212274		ECD	01-JUL-21	Yes	No		4	NCT03212274			Overall Response Rate	145	145																																								
IDH1	IDH1_unspecified				biliary tract / carcinoma / adenocarcinoma	2	Phase 2	Cisplatin + Gemcitabine + Olutasidenib		Recruiting	NCT03684811		ECD	01-SEP-21	Yes	No		4	NCT03684811			Maximum tolerated dose/toxicity	200	200																																								
IDH1	IDH1_unspecified				biliary tract / carcinoma / adenocarcinoma	2	Phase 2	Ceralasertib + Olaparib		Recruiting	NCT03878095		ECD	01-MAR-23	Yes	No		4	NCT03878095			Overall Response Rate	50	50																																								
IDH1	IDH1_unspecified				biliary tract / carcinoma / adenocarcinoma	2	Phase 2	Durvalumab + Olaparib		Recruiting	NCT03991832		ECD	01-SEP-22	Yes	No		4	NCT03991832			Overall Response Rate	78	78																																								
IDH1	IDH1_unspecified				biliary tract / carcinoma / adenocarcinoma	2	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
IDH1	IDH1_unspecified				biliary tract / carcinoma / adenocarcinoma	2	Phase 2	Dasatinib		Completed	NCT02428855		PCD	01-FEB-18	Yes	Yes		4	NCT02428855			Overall Response Rate	8	8			0								2			1.48-NA										8.75			4.78-NA													
IDH1	IDH1_unspecified				biliary tract / carcinoma / adenocarcinoma	2	Phase 3	Ivosidenib		Active, not recruiting	NCT02989857	ClarIDHy	PCD	01-JAN-19	Yes	Yes		4	NCT02989857			Progression free survival	186	124	61	Placebo	2.4	0							2.7	1.4	.37	0.25-0.54	0.001									10.8	9.7	.69		0.0008												
IDH1	IDH1_unspecified				biliary tract / carcinoma / adenocarcinoma	2	Retrospective/Meta-analysis	Olaparib		Unknown					Yes	Yes		2	10.1200/PO.20.00247				4	4																														0	0	0								
IDH1	IDH1_unspecified				bone / chondrosarcoma / NS	3	Phase 1	Chloroquine + Metformin		Completed	NCT02496741	MACIST	PCD	01-NOV-19	Yes	No		4	NCT02496741			Maximum tolerated dose/toxicity	15	15																																								
IDH1	IDH1_unspecified				bone / chondrosarcoma / NS	3	Phase 2	Ivosidenib		Recruiting	NCT04278781		ECD	01-MAR-23	Yes	No		4	NCT04278781	Previously-treated		Progression free survival	17	17																																								
IDH1	IDH1_unspecified				bone / chondrosarcoma / NS	3	Phase 2	Azacitidine + Olutasidenib		Recruiting	NCT03684811		ECD	01-SEP-21	Yes	No		4	NCT03684811			Maximum tolerated dose/toxicity	200	200																																								
IDH1	IDH1_unspecified				bone / chondrosarcoma / NS	3	Retrospective/Meta-analysis	Olaparib		Unknown					Yes	Yes		2	10.1200/PO.20.00247				5	5																															1	2								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 1	Pamiparib + Temozolomide		Recruiting	NCT03914742		ECD	01-APR-22	Yes	No		4	NCT03914742			Maximum tolerated dose/toxicity	100	100																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 1	Chloroquine + Metformin		Completed	NCT02496741	MACIST	PCD	01-NOV-19	Yes	No		4	NCT02496741			Maximum tolerated dose/toxicity	15	15																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 1	DS-1001b		Active, not recruiting	NCT03030066		ECD	01-JAN-22	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.2004			Maximum tolerated dose/toxicity	60	60																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 1	Diphtheria and tetanus toxoids adsorbed + PEPIDH1M vaccine + Temozolomide		Active, not recruiting	NCT02193347	RESIST	PCD	01-FEB-20	Yes	No		4	NCT02193347	Previously-treated		Maximum tolerated dose/toxicity	24	24																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 1	Ivosidenib + Vorasidenib		Active, not recruiting	NCT03343197		PCD	01-AUG-19	Yes	No		4	NCT03343197	Previously-treated		Overall survival	49	49																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 1	Lomustine + Procarbazine + Vincristine		Unknown	NCT02333513		ECD	01-DEC-17	Yes	No		4	NCT02333513	Previously-treated		Progression free survival	100	100																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 1	Vorasidenib		Active, not recruiting	NCT02481154		ECD	01-DEC-21	Yes	No		4	NCT02481154			Maximum tolerated dose/toxicity	95	95																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 1	Pamiparib + Temozolomide		Recruiting	NCT03749187	PNOC017	ECD	01-JUN-22	Yes	No		4	NCT03749187		Pediatric	Maximum tolerated dose/toxicity	78	78																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Olaparib		Recruiting	NCT03212274		ECD	01-JUL-21	Yes	No		4	NCT03212274			Overall Response Rate	145	145																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Intensity-modulated radiation therapy + Temozolomide		Recruiting	NCT03180502		ECD	01-JAN-25	Yes	No		4	NCT03180502			Clinical activity	120	120																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Chemotherapy + Temozolomide		Active, not recruiting	NCT01534845	KNOG-1101	PCD	01-FEB-15	No	Yes	Response not correlated with mutation status	1	31671938	Untreated		Progression free survival	84	40	44	Radiotherapy	21.9	18.8							19.5	15.9									81.3	81.3		43.7	36.7															
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Proton beam radiation therapy		Active, not recruiting	NCT01358058		ECD	01-AUG-21	Yes	No		4	NCT01358058			Progression free survival	63	63																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Ivosidenib + Nivolumab		Not yet recruiting	NCT04056910		ECD	01-SEP-22	Yes	No		4	NCT04056910			Progression free survival	35	35																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Proton beam radiation therapy + Temozolomide		Recruiting	NCT03180502		ECD	01-JAN-25	Yes	No		4	NCT03180502			Clinical activity	120	120																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Apatinib + Temozolomide		Active, not recruiting	NCT03741244	APAglio	ECD	01-OCT-22	Yes	No		4	NCT03741244	Untreated		Progression free survival	211	211																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Olutasidenib		Recruiting	NCT03684811		ECD	01-SEP-21	Yes	No		4	NCT03684811			Overall Response Rate	200	200																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	IDH305		Withdrawn	NCT02987010		ECD	01-JAN-19	Yes	Yes	Changed business priorities	4	NCT02987010			Radiographic response rate	0	0																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	IDH305		Withdrawn	NCT02977689		ECD	01-APR-20	Yes	Yes	Serious adverse events	4	NCT02977689			Radiographic response rate	0	0																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Azacitidine		Not yet recruiting	NCT03666559	AGIR	ECD	01-MAR-23	Yes	No		4	NCT03666559	Previously-treated		Progression free survival	63	63																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Nivolumab		Active, not recruiting	NCT03925246		ECD	01-DEC-20	Yes	No		4	NCT03925246			Progression free survival	43	43																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 2	Nivolumab		Recruiting	NCT03718767		ECD	01-FEB-25	Yes	No		4	NCT03718767			Progression free survival	95	95																																								
IDH1	IDH1_unspecified				central nervous system / glioma / NS	3	Phase 3	Vorasidenib		Recruiting	NCT04164901	INDIGO	ECD	01-OCT-24	Yes	No		4	NCT04164901			Progression free survival	366	366																																								
IDH1	IDH1_unspecified				central nervous system / glioma / astrocytoma	3	Phase 2	NovoTTF-200A		Not yet recruiting	NCT03450850		ECD	01-JUN-23	No	No		4	NCT03450850			Progression free survival	34	34																																								
IDH1	IDH1_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Olutasidenib		Recruiting	NCT03684811		ECD	01-SEP-21	Yes	No		4	NCT03684811			Maximum tolerated dose/toxicity	200	200																																								
IDH1	IDH1_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Ralimetinib + Temozolomide		Completed	NCT02364206	GLYRad	PCD	01-AUG-19	No	No		4	NCT02364206			Progression free survival	18	18																																								
IDH1	IDH1_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	DC vaccine loaded with glioma stem-like cells		Recruiting	NCT01567202		ECD	01-NOV-20	No	No		4	NCT01567202			Overall Response Rate	100	100																																								
IDH1	IDH1_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 3	Extended-release flucytosine + Vocimagene amiretrorepvec		Terminated	NCT02414165	Toca5	PCD	01-MAY-19	No	Yes		4	NCT02414165			Overall survival	403	403																																								
IDH1	IDH1_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Retrospective/Meta-analysis	Cetuximab		Unknown	NCT00782067	CPKC412D2201	PCD	01-DEC-14	Yes	Yes	Superior PFS and OS in wt 	1	22199315			Unknown	27												.67													0.9																
IDH1	IDH1_unspecified				eye / malignant melanoma / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Vorasidenib		Completed	NCT02492737		PCD	01-MAR-18	Yes	No		4	NCT02492737			Maximum tolerated dose/toxicity	46	46																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	HMPL306		Recruiting	NCT04272957		ECD	01-JUN-21	Yes	No		4	NCT04272957	Previously-treated		Maximum tolerated dose/toxicity	75	75																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	LY3410738		Recruiting	NCT04603001		ECD	01-FEB-23	Yes	No		4	NCT04603001			Overall Response Rate	220	220																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Ivosidenib		Recruiting	NCT02074839		ECD	01-DEC-20	Yes	No		4	NCT02074839			Maximum tolerated dose/toxicity	291	291																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Olaparib		Not yet recruiting	NCT03953898	PRIME	ECD	01-DEC-22	Yes	No		4	NCT03953898			Overall Response Rate	94	94																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	CPX-351 + Ivosidenib		Not yet recruiting	NCT04493164		ECD	01-JAN-23	Yes	No		4	NCT04493164			Overall Response Rate	30	30																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Ivosidenib + Venetoclax		Recruiting	NCT03471260		ECD	01-SEP-21	Yes	No		4	NCT03471260			Overall Response Rate	48	48																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Olutasidenib		Recruiting	NCT02719574		ECD	01-APR-20	Yes	No		4	NCT02719574			Complete response, Pathological complete response	500	500																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Azacitidine + Olutasidenib		Recruiting	NCT02719574		ECD	01-APR-20	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.7009 			Complete response, Pathological complete response	11	11																														2	6									
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Ivosidenib + Nivolumab		Suspended	NCT04044209		ECD	01-SEP-21	Yes	No		4	NCT04044209	Previously-treated		Overall Response Rate	45	45																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	ASTX727 + Olutasidenib		Unknown	NCT04013880	VICC HEM	ECD	01-MAR-21	Yes	Yes	Loss of funding	4	NCT04013880			Response rate	0	0																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Olutasidenib		Recruiting	NCT02719574		ECD	01-APR-20	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.7009 			Complete response, Pathological complete response	16	16																														2	9									
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	12	10	2	Cytarabine	50	0																																				
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Ivosidenib		Recruiting	NCT03839771	HOVON150AML	ECD	01-MAR-23	Yes	No		4	NCT03839771	Untreated		Progression free survival	968	968																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Enasidenib		Recruiting	NCT03839771	HOVON150AML	ECD	01-MAR-23	Yes	No		4	NCT03839771	Untreated		Progression free survival	968	968																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	Ivosidenib		Recruiting	NCT02074839		ECD	01-DEC-20	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf	Untreated		Maximum tolerated dose/toxicity	28	28																														8	4									
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	Ivosidenib		Recruiting	NCT02074839		ECD	01-DEC-20	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf	Previously-treated		Maximum tolerated dose/toxicity	174	174																														43	14									
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	IDH305		Withdrawn	NCT02826642		ECD	01-NOV-16	Yes	No		4	NCT02826642			Maximum tolerated dose/toxicity	0	0																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Cytarabine + Filgrastim + Fludarabine + Ivosidenib		Not yet recruiting	NCT04250051		ECD	01-DEC-21	Yes	No		4	NCT04250051			Maximum tolerated dose/toxicity	25	25																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Enasidenib		Active, not recruiting	NCT02632708		PCD	01-DEC-18	Yes	Yes		3	https://amlglobalportal.com/medical-information/ash-2018-ivosidenib-or-enasidenib-in-combination-with-induction-and-consolidation-therapy-in-newly-diagnosed-acute-myeloid-leukemia-with-idh-or-idh2-mutation	Untreated		Maximum tolerated dose/toxicity	89	89			72																																					
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Ivosidenib		Active, not recruiting	NCT02632708		PCD	01-DEC-18	Yes	Yes		3	https://amlglobalportal.com/medical-information/ash-2018-ivosidenib-or-enasidenib-in-combination-with-induction-and-consolidation-therapy-in-newly-diagnosed-acute-myeloid-leukemia-with-idh-or-idh2-mutation	Untreated		Maximum tolerated dose/toxicity	49	49			80																																					
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Ivosidenib		Recruiting	NCT04176393		ECD	01-FEB-21	Yes	No		4	NCT04176393			Maximum tolerated dose/toxicity	30	30																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Ivosidenib		Active, not recruiting	NCT02677922		ECD	01-DEC-20	Yes	No		4	NCT02677922	Untreated		Overall Response Rate	131	131																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Decitabine + Glasdegib		Active, not recruiting	NCT04051996	GLAD-AML	ECD	01-SEP-21	No	No		4	NCT04051996		Geriatric	Complete response, Pathological complete response	1	1																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + BI 836858		Recruiting	NCT03013998	BAML-16-001-S2	ECD	01-DEC-21	Yes	No		4	NCT03013998	Untreated		Overall Response Rate	2000	2000																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Enasidenib		Active, not recruiting	NCT02677922		ECD	01-DEC-20	Yes	No		4	NCT02677922	Untreated		Overall Response Rate	131	131																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Ivosidenib		Recruiting	NCT03013998	BAML-16-001-16	ECD	01-DEC-21	Yes	No		4	NCT03013998			Overall Response Rate	2000	2000																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Azacitidine + Ivosidenib		Recruiting	NCT03173248	AGILE	ECD	01-JUN-22	Yes	No		4	NCT03173248	Untreated		Overall survival	200	200																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Idarubicin		Completed	NCT01802333		PCD	01-JUN-17	No	Yes	EFS 41 vs 37% p=0.42 primary outcome not met	4	NCT01802333	Untreated		Event free survival	477	261	216																																							
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Daunorubicin		Completed	NCT01802333		PCD	01-JUN-17	No	Yes	EFS 36 vs 37% p=0.84 primary outcome not met	4	NCT01802333	Untreated		Event free survival	477	261	216																																							
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Idasanutlin 		Terminated	NCT02545283	MIRROS	PCD	01-APR-20	No	Yes	No benefit of treatment	4	NCT02545283	Previously-treated		Overall survival	447	447																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Azacitidine + Pevonedistat		Recruiting	NCT04090736	PEVOLAM	ECD	01-JUN-23	No	No		4	NCT04090736	Untreated		Overall survival	466			Azacitidine																																						
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Hematopoietic Stem Cell Transplant + Iomab-B		Recruiting	NCT02665065	SIERRA	ECD	01-DEC-21	Yes	No		4	NCT02665065		Geriatric	Complete response, Pathological complete response	150	150																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic eosinophilic leukaemia-hypereosinophilic syndrome	3	Phase 1	Ivosidenib		Recruiting	NCT03564821		ECD	01-JUL-21	Yes	No		4	NCT03564821			Progression free survival	22	22																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Ivosidenib		Recruiting	NCT03503409	IDIOME	ECD	01-JAN-22	Yes	No		4	NCT03503409			Overall Response Rate	68	68																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant		Terminated	NCT03303950		PCD	01-MAY-19	Yes	Yes	Slow accrual	4	NCT03303950			Clinical activity	6	6																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Pentraxin 2		Completed	NCT01981850		PCD	01-JUL-20	No	No		4	NCT01981850			Clinical activity	125	125																																								
IDH1	IDH1_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant		Terminated	NCT03303950		PCD	01-MAY-19	Yes	Yes	Slow accrual	4	NCT03303950			Clinical activity	6	6																																								
IDH1	IDH1_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 1	Telaglenastat		Completed	NCT02071862	CANTATA	PCD	01-MAR-19	No	Yes		2	10.1200/JCO.2019.37.7_suppl.549			Maximum tolerated dose/toxicity	12	12			42																		100										5	7								
IDH1	IDH1_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
IDH1	IDH1_unspecified				liver / other / neoplasm	3	Phase 1	Chloroquine + Metformin		Completed	NCT02496741	MACIST	PCD	01-NOV-19	Yes	No		4	NCT02496741			Maximum tolerated dose/toxicity	15	15																																								
IDH1	IDH1_unspecified				liver / other / neoplasm	3	Phase 2	Nivolumab + Olutasidenib		Recruiting	NCT03684811		ECD	01-SEP-21	Yes	No		4	NCT03684811			Overall Response Rate	200	200																																								
IDH1	IDH1_unspecified				liver / other / neoplasm	3	Phase 3	HuaChanSu + Icaritin		Unknown	NCT03236636		ECD	01-DEC-22	No	No		4	NCT03236636			Overall survival	312	312																																								
IDH1	IDH1_unspecified				liver / other / neoplasm	3	Phase 3	Icaritin + Sorafenib		Unknown	NCT03236649		ECD	01-DEC-22	No	No		4	NCT03236649			Overall survival	200	200																																								
IDH2	IDH2_R172?			p.R172X	central nervous system / glioma / astrocytoma	3	Phase 1	Radiotherapy + Telaglenastat + Temozolomide		Recruiting	NCT03528642		ECD	01-DEC-22	Yes	No		4	NCT03528642			Maximum tolerated dose/toxicity	40	40																																								
IDH2	IDH2_unspecified				NS / mesothelioma / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
IDH2	IDH2_unspecified				NS / neoplasm / NS	3	Phase 1	Vorasidenib		Active, not recruiting	NCT02481154		ECD	01-DEC-21	Yes	No		4	NCT02481154			Maximum tolerated dose/toxicity	95	95																																								
IDH2	IDH2_unspecified				NS / neoplasm / NS	3	Phase 1	Telaglenastat		Active, not recruiting	NCT02071862	CANTATA	PCD	01-MAR-19	Yes	No		4	NCT02071862			Maximum tolerated dose/toxicity	210	210																																								
IDH2	IDH2_unspecified				NS / neoplasm / NS	3	Phase 2	Olaparib		Recruiting	NCT03212274		ECD	01-JUL-20	Yes	No		4	NCT03212274			Overall Response Rate	145	145																																								
IDH2	IDH2_unspecified				NS / neoplasm / NS	3	Phase 2	Ceralasertib + Olaparib		Recruiting	NCT03878095		ECD	01-MAR-23	Yes	No		4	NCT03878095			Overall Response Rate	50	50																																								
IDH2	IDH2_unspecified				NS / neoplasm / NS	3	Phase 2	Enasidenib		Completed	NCT02273739		PCD	01-JUN-16	Yes	No		4	NCT02273739			Maximum tolerated dose/toxicity	21	21																																								
IDH2	IDH2_unspecified				NS / neoplasm / NS	3	Phase 2	Durvalumab + Olaparib		Recruiting	NCT03991832		ECD	01-SEP-22	Yes	No		4	NCT03991832			Overall Response Rate	78	78																																								
IDH2	IDH2_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
IDH2	IDH2_unspecified				NS / neoplasm / NS	3	Phase 2	Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	Yes	No		4	NCT02576444			Overall Response Rate	64	64																																								
IDH2	IDH2_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT03212274		ECD	01-JUL-21	Yes	No		4	NCT03212274			Overall Response Rate	145	145																																								
IDH2	IDH2_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Ceralasertib + Olaparib		Recruiting	NCT03878095		ECD	01-MAR-23	Yes	No		4	NCT03878095			Overall Response Rate	50	50																																								
IDH2	IDH2_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Durvalumab + Olaparib		Recruiting	NCT03991832		ECD	01-SEP-22	Yes	No		4	NCT03991832			Overall Response Rate	78	78																																								
IDH2	IDH2_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
IDH2	IDH2_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Dasatinib		Completed	NCT02428855		PCD	01-FEB-18	Yes	No		4	NCT02428855			Overall Response Rate	8	8																																								
IDH2	IDH2_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Retrospective/Meta-analysis	Olaparib		Unknown					Yes	Yes		2	10.1200/PO.20.00247				4	4																														0	0	0								
IDH2	IDH2_unspecified				bone / chondrosarcoma / NS	3	Phase 1	Chloroquine + Metformin		Completed	NCT02496741	MACIST	PCD	01-NOV-19	Yes	No		4	NCT02496741			Maximum tolerated dose/toxicity	15	15																																								
IDH2	IDH2_unspecified				bone / chondrosarcoma / NS	3	Retrospective/Meta-analysis	Olaparib		Unknown					Yes	Yes		2	10.1200/PO.20.00247				5	5																															1	2								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 1	Pamiparib + Temozolomide		Recruiting	NCT03914742		ECD	01-APR-22	Yes	No		4	NCT03914742			Maximum tolerated dose/toxicity	100	100																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 1	Chloroquine + Metformin		Completed	NCT02496741	MACIST	PCD	01-NOV-19	Yes	No		4	NCT02496741			Maximum tolerated dose/toxicity	15	15																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 1	Lomustine + Procarbazine + Vincristine		Unknown	NCT02333513		ECD	01-DEC-17	Yes	No		4	NCT02333513	Previously-treated		Progression free survival	100	100																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 1	Vorasidenib		Active, not recruiting	NCT02481154		ECD	01-DEC-21	Yes	No		4	NCT02481154			Maximum tolerated dose/toxicity	95	95																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 1	Pamiparib + Temozolomide		Recruiting	NCT03749187		ECD	01-JUN-22	Yes	No		4	NCT03749187		Pediatric	Maximum tolerated dose/toxicity	78	78																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 2	Olaparib		Recruiting	NCT03212274		ECD	01-JUL-21	Yes	No		4	NCT03212274			Overall Response Rate	145	145																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 2	Intensity-modulated radiation therapy + Temozolomide		Recruiting	NCT03180502		ECD	01-JAN-25	Yes	No		4	NCT03180502			Clinical activity	120	120																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 2	Proton beam radiation therapy + Temozolomide		Recruiting	NCT03180502		ECD	01-JAN-25	Yes	No		4	NCT03180502			Clinical activity	120	120																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 2	Azacitidine		Not yet recruiting	NCT03666559	AGIR	ECD	01-MAR-23	Yes	No		4	NCT03666559	Previously-treated		Progression free survival	63	63																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 2	Nivolumab		Active, not recruiting	NCT03925246		ECD	01-DEC-20	Yes	No		4	NCT03925246			Progression free survival	43	43																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 2	Nivolumab		Recruiting	NCT03718767		ECD	01-FEB-25	Yes	No		4	NCT03718767			Progression free survival	95	95																																								
IDH2	IDH2_unspecified				central nervous system / glioma / NS	3	Phase 3	Vorasidenib		Recruiting	NCT04164901		ECD	01-OCT-24	Yes	No		4	NCT04164901			Progression free survival	366	366																																								
IDH2	IDH2_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	DC vaccine loaded with glioma stem-like cells		Recruiting	NCT01567202		ECD	01-NOV-20	No	No		4	NCT01567202			Overall Response Rate	100	100																																								
IDH2	IDH2_unspecified				eye / malignant melanoma / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Vorasidenib		Completed	NCT02492737		PCD	01-MAR-18	Yes	No		4	NCT02492737			Maximum tolerated dose/toxicity	46	46																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	HMPL306		Recruiting	NCT04272957		ECD	01-JUN-21	Yes	No		4	NCT04272957	Previously-treated		Maximum tolerated dose/toxicity	75	75																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	LY3410738		Recruiting	NCT04603001		ECD	01-FEB-23	Yes	No		4	NCT04603001			Overall Response Rate	220	220																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Olaparib		Not yet recruiting	NCT03953898	PRIME	ECD	01-DEC-22	Yes	No		4	NCT03953898			Overall Response Rate	94	94																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Enasidenib + Ruxolitinib		Not yet recruiting	NCT04281498		ECD	01-MAR-22	Yes	No		4	NCT04281498			Overall Response Rate	32	32																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Enasidenib		Recruiting	NCT04522895		ECD	01-JUN-24	Yes	No		4	NCT04522895			Maximum tolerated dose/toxicity	60	60																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	17	12	5	Cytarabine	17	0																																				
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Ivosidenib		Recruiting	NCT03839771	HOVON150AML	ECD	01-MAR-23	Yes	No		4	NCT03839771	Untreated		Progression free survival	968	968																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Enasidenib		Recruiting	NCT03839771	HOVON150AML	ECD	01-MAR-23	Yes	No		4	NCT03839771	Untreated		Progression free survival	968	968																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	Enasidenib		Active, not recruiting	NCT01915498		PCD	01-JUL-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf			Maximum tolerated dose/toxicity	199	199							8.2		4.3-19.4																					19	4									
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Ivosidenib		Recruiting	NCT04176393		ECD	01-FEB-21	Yes	No		4	NCT04176393			Maximum tolerated dose/toxicity	30	30																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Enasidenib + Hematopoietic Stem Cell Transplant		Recruiting	NCT03728335		ECD	01-DEC-20	Yes	No		4	NCT03728335			Maximum tolerated dose/toxicity	15	15																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Enasidenib + Hematopoietic Stem Cell Transplant		Recruiting	NCT03515512		ECD	01-MAY-21	Yes	No		4	NCT03515512			Maximum tolerated dose/toxicity	22	22																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Enasidenib		Active, not recruiting	NCT02632708		PCD	01-DEC-18	Yes	Yes		3	https://amlglobalportal.com/medical-information/ash-2018-ivosidenib-or-enasidenib-in-combination-with-induction-and-consolidation-therapy-in-newly-diagnosed-acute-myeloid-leukemia-with-idh-or-idh2-mutation	Untreated		Maximum tolerated dose/toxicity	89	89			72																																					
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	Ivosidenib		Active, not recruiting	NCT02632708		PCD	01-DEC-18	Yes	Yes		3	https://amlglobalportal.com/medical-information/ash-2018-ivosidenib-or-enasidenib-in-combination-with-induction-and-consolidation-therapy-in-newly-diagnosed-acute-myeloid-leukemia-with-idh-or-idh2-mutation	Untreated		Maximum tolerated dose/toxicity	49	49			80																																					
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Enasidenib		Not yet recruiting	NCT04203316		ECD	01-OCT-29	Yes	No		4	NCT04203316	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	10	10																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	CPX-351 + Enasidenib		Recruiting	NCT03825796		ECD	01-SEP-21	Yes	No		4	NCT03825796	Previously-treated		Complete response, Pathological complete response	18	18																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Enasidenib + Venetoclax		Not yet recruiting	NCT04092179	ENAVEN-AML	ECD	01-AUG-23	Yes	No		4	NCT04092179			Overall Response Rate	48	48																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Enasidenib + Hematopoietic Stem Cell Transplant		Recruiting	NCT03881735		ECD	01-NOV-21	Yes	No		4	NCT03881735	Previously-treated		Event free survival	86	86																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Decitabine + Glasdegib		Active, not recruiting	NCT04051996	GLAD-AML	ECD	01-SEP-21	No	No		4	NCT04051996		Geriatric	Complete response, Pathological complete response	1	1																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + BI 836858		Recruiting	NCT03013998	BAML-16-001-S2	ECD	01-DEC-21	Yes	No		4	NCT03013998	Untreated		Overall Response Rate	2000	2000																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Enasidenib		Recruiting	NCT03683433		ECD	01-SEP-21	Yes	No		4	NCT03683433	Previously-treated		Overall Response Rate	50	50																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Enasidenib		Active, not recruiting	NCT02677922		ECD	01-DEC-20	Yes	No		4	NCT02677922	Untreated		Overall Response Rate	131	131																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Ivosidenib		Active, not recruiting	NCT02677922		ECD	01-DEC-20	Yes	No		4	NCT02677922	Untreated		Overall Response Rate	131	131																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Enasidenib		Recruiting	NCT02577406	IDHENTIFY	ECD	01-DEC-22	Yes	No		4	NCT02577406			Overall survival	319	319																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Idarubicin		Completed	NCT01802333		PCD	01-JUN-17	No	Yes	EFS 41 vs 37% p=0.42 primary outcome not met	4	NCT01802333	Untreated		Event free survival	477	261	216																																							
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Daunorubicin		Completed	NCT01802333		PCD	01-JUN-17	No	Yes	EFS 36 vs 37% p=0.84 primary outcome not met	4	NCT01802333	Untreated		Event free survival	477	261	216																																							
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Idasanutlin 		Terminated	NCT02545283	MIRROS	PCD	01-APR-20	No	Yes	No benefit of treatment	4	NCT02545283	Previously-treated		Overall survival	447	447																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Azacitidine + Pevonedistat		Recruiting	NCT04090736	PEVOLAM	ECD	01-JUN-23	No	No		4	NCT04090736	Untreated		Overall survival	466			Azacitidine																																						
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 1	Enasidenib + Hematopoietic Stem Cell Transplant		Recruiting	NCT03515512		ECD	01-MAY-21	Yes	No		4	NCT03515512			Maximum tolerated dose/toxicity	22	22																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Enasidenib		Recruiting	NCT03744390	GFM-IDEAL	ECD	01-FEB-23	Yes	No		4	NCT03744390			Overall Response Rate	68	68																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Azacitidine + Enasidenib		Recruiting	NCT03383575		ECD	01-FEB-22	Yes	No		4	NCT03383575			Overall Response Rate	105	105																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant		Terminated	NCT03303950		PCD	01-MAY-19	Yes	Yes	Slow accrual	4	NCT03303950			Clinical activity	6	6																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Pentraxin 2		Completed	NCT01981850		PCD	01-JUL-20	No	No		4	NCT01981850			Clinical activity	125	125																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Busulfan + Cyclophosphamide + Fludarabine + Hematopoietic Stem Cell Transplant		Terminated	NCT03303950		PCD	01-MAY-19	Yes	Yes	Slow accrual	4	NCT03303950			Clinical activity	6	6																																								
IDH2	IDH2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Dexamethasone + Enasidenib + Ixazomib + Pomalidomide		Recruiting	NCT03732703	MyDRUGSubProtocol B1	ECD	01-FEB-22	Yes	No		4	NCT03732703			Overall Response Rate	228	228																																								
IDH2	IDH2_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
IDH2	IDH2_unspecified				liver / other / neoplasm	3	Phase 1	Chloroquine + Metformin		Completed	NCT02496741	MACIST	PCD	01-NOV-19	Yes	No		4	NCT02496741			Maximum tolerated dose/toxicity	15	15																																								
IDH2	IDH2_unspecified				liver / other / neoplasm	3	Phase 3	HuaChanSu + Icaritin		Unknown	NCT03236636		ECD	01-DEC-22	No	No		4	NCT03236636			Overall survival	312	312																																								
IDH2	IDH2_unspecified				liver / other / neoplasm	3	Phase 3	Icaritin + Sorafenib		Unknown	NCT03236649		ECD	01-DEC-22	No	No		4	NCT03236649			Overall survival	200	200																																								
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	NS / neoplasm / NS	3	Phase 2	Erlotinib + Temozolomide		Withdrawn	NCT02689336		ECD	01-NOV-19	Yes	Yes		4	NCT02689336		Pediatric	Overall Response Rate	0	0																																								
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic-myeloproliferative neoplasm	3	Phase 2	Lestaurtinib		Unknown					Yes	Yes	Serious adverse events related to thrombosis	2	10.1182/blood.V114.22.753.753			Spleen volume reduction	18	18			83																																					
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic-myeloproliferative neoplasm	3	Phase 2	Mirabegron		Completed	NCT02311569		PCD	01-DEC-16	Yes	No		4	NCT02311569			Reduced allele burden	39	39																																								
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic-myeloproliferative neoplasm	3	Phase 2	Givinostat		Completed	NCT00606307		PCD	01-DEC-08	Yes	Yes		4	NCT00606307			Best overall response	25	25																														2	15									
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic-myeloproliferative neoplasm	3	Phase 2	Gandotinib		Active, not recruiting	NCT01594723		PCD	01-MAR-15	Yes	Yes		1	30025280			Overall Response Rate	33	33																															9									
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	2	Phase 1	Elotuzumab		Recruiting	NCT04517851		ECD	01-DEC-24	Yes	No		4	NCT04517851			Overall Response Rate	15	15																																								
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	2	Phase 2	Lestaurtinib		Completed	NCT00509899		PCD	01-DEC-07	Yes	Yes		1	20843246			Spleen volume reduction	61	61			51																																					
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	2	Phase 2	Panobinostat		Completed	NCT00931762		PCD	01-AUG-11	Comparison with wt	Yes		2	10.1111/bjh.12384			Overall Response Rate	35	23	12		0	0																																				
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	2	Phase 2	Pentraxin 2		Active, not recruiting	NCT01981850		PCD	01-JUL-20	No	No		4	NCT01981850			Clinical activity	125	125																																								
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	2	Phase 2	Gandotinib		Active, not recruiting	NCT01594723		PCD	01-MAR-15	Yes	Yes		1	30025280			Overall Response Rate	33	33																															9									
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	2	Phase 2	Fedratinib		Completed	NCT01420770		PCD	01-APR-14	Yes	Yes	Primary outcome met	2	10.1200/jco.2013.31.15_suppl.7109			Spleen volume reduction	31	31																																								
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	2	Phase 2	Momelotinib		Completed	NCT01423058		PCD	01-JUN-14	No	Yes		1	27634203			Maximum tolerated dose/toxicity	1	1																																						Complete molecular, Deep molecular, MR 4.5 log	100	
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / polycythaemia vera	3	Phase 2	Erlotinib		Terminated	NCT01038856		PCD	01-DEC-12	Yes	Yes	Terminated by sponsor	4	NCT01038856			Overall Response Rate	5	5																																								
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / polycythaemia vera	3	Phase 2	Givinostat + Hydroxyurea		Completed	NCT00928707		PCD	01-JUL-11	Yes	Yes		4	NCT00928707			Hematological response	45	45			54.5																																					
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / polycythaemia vera	3	Phase 2	Gandotinib		Active, not recruiting	NCT01594723		PCD	01-MAR-15	Yes	Yes		4	NCT01594723			Overall Response Rate	110	110			95.0																											4	15									
JAK2	JAK2_V617F	67569051 + 67586666		p.V617F	haematopoietic and lymphoid tissue / haematopoietic neoplasm / polycythaemia vera	3	Phase 2	Lestaurtinib		Completed	NCT00586651		PCD	01-OCT-09	Yes	Yes		1	24903629			Reduced allele burden	18	18			11																																					
JAK2	JAK2_unspecified				central nervous system / glioma / astrocytoma	2	Phase 1	Zotiraciclib		Recruiting	NCT03224104	STEAM	ECD	01-AUG-20	No	No		4	NCT03224104			Maximum tolerated dose/toxicity	81	81																																								
JAK2	JAK2_unspecified				central nervous system / glioma / astrocytoma	2	Phase 2	Temozolomide + Zotiraciclib		Recruiting	NCT02942264		PCD	01-AUG-20	No	Yes	Primary outcome met	2	10.1200/JCO.2019.37.15_suppl.2031			Maximum tolerated dose/toxicity	53	53																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute leukaemia of ambiguous lineage	3	Phase 1	AT9283		Completed	NCT01431664		PCD	01-JUL-14	No	Yes	No benefit of treatment	1	27905678	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	7	7																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute leukaemia of ambiguous lineage	3	Phase 2	Ruxolitinib		Terminated	NCT01251965		PCD	01-JUL-12	No	Yes	No benefit of treatment	4	NCT01251965	Previously-treated		Maximum tolerated dose/toxicity	27	27																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute leukaemic transformation of myeloproliferative neoplasm	3	Phase 2	Ruxolitinib		Completed	NCT00674479		PCD	01-MAR-17	No	Yes		1	22422826			Response rate	18	18																														2	1									
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Cytarabine + Leucovorin calcium + Methotrexate + Methylprednisolone sodium succinate + Rituximab + Ruxolitinib		Completed	NCT02779283		PCD	01-APR-18	No	No		4	NCT02779283	Untreated		Maximum tolerated dose/toxicity	7	7																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Gilteritinib		Recruiting	NCT03013998	BAML-16-001-S8 	ECD	01-DEC-21	No	No		4	NCT03013998			Complete remission	2000	2000																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Mitoxantrone hydrochloride + Venetoclax		Not yet recruiting	NCT04330820	RELAX	ECD	01-JUN-22	No	No		4	NCT04330820	Previously-treated		Overall Response Rate	60	60																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Idarubicin + Ruxolitinib		Recruiting	NCT03558607		ECD	01-APR-22	No	No		4	NCT03558607			Complete response, Pathological complete response	17	17																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic eosinophilic leukaemia-hypereosinophilic syndrome	3	Phase 2	Ruxolitinib		Not yet recruiting	NCT03801434		ECD	01-APR-21	No	No		4	NCT03801434			Overall Response Rate	25	25																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Nilotinib + Ruxolitinib		Not yet recruiting	NCT03610971		ECD	01-JAN-22	No	No		4	NCT03610971	Previously-treated		Unknown	14	14																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Bosutinib + Ruxolitinib		Not yet recruiting	NCT03610971		ECD	01-JAN-22	No	No		4	NCT03610971	Previously-treated		Unknown	14	14																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Ruxolitinib		Not yet recruiting	NCT03610971		ECD	01-JAN-22	No	No		4	NCT03610971	Previously-treated		Unknown	14	14																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Imatinib + Ruxolitinib		Not yet recruiting	NCT03610971		ECD	01-JAN-22	No	No		4	NCT03610971	Previously-treated		Unknown	14	14																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Ruxolitinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / essential thrombocythaemia	3	Phase 2	Gandotinib		Active, not recruiting	NCT01594723		PCD	01-MAR-15	Yes	Yes		1	30025280			Overall Response Rate	21	21			90																											3	16									
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic-myeloproliferative neoplasm	2	Phase 1	Ruxolitinib		Completed	NCT01164163	ADVL1011	PCD	01-OCT-14	No	Yes	Primary outcome met	2	10.1200/jco.2014.32.15_suppl.10019   		Pediatric	Maximum tolerated dose/toxicity	49	49																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic-myeloproliferative neoplasm	2	Phase 1	Ruxolitinib + Umbralisib		Recruiting	NCT02493530		ECD	01-DEC-20	No	No		4	NCT02493530			Maximum tolerated dose/toxicity	60	60																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic-myeloproliferative neoplasm	2	Phase 1	Ruxolitinib		Active, not recruiting	NCT01895842		PCD	01-APR-19	No	No	low but significant frequency of responses	1	30245189			Maximum tolerated dose/toxicity	31	31																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic-myeloproliferative neoplasm	2	Phase 2	Pacritinib		Terminated	NCT02469415		PCD	01-JUN-17	No	Yes	FDA clinical hold	4	NCT02469415			Overall Response Rate	3	3																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic-myeloproliferative neoplasm	2	Phase 2	Azacitidine + Ruxolitinib		Recruiting	NCT01787487		ECD	01-JUL-20	No	Yes		1	30185431			Overall Response Rate	125	125			72																																					
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Approved FDA	Ruxolitinib	Required	Unknown	NCT00934544	COMFORT-II	PCD	01-MAR-15	No	No		4	NCT00934544			Spleen volume reduction	219	146	73	Best supportive care	29	0		<0.0001																																		
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Approved FDA	Ruxolitinib	Required	Completed	NCT00952289	COMFORT-I 	PCD	01-NOV-10	No	Yes		4	NCT00952289			Spleen volume reduction	309	155	154	Placebo	65	1		<0.0001																																		
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 1	PIM447 + Ribociclib + Ruxolitinib		Completed	NCT02370706		PCD	01-SEP-20	No	No		4	NCT02370706			Maximum tolerated dose/toxicity	15	15																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 1	XL019		Terminated	NCT00522574				No	Yes	Serious adverse events	1	24374145			Maximum tolerated dose/toxicity	100	100																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 1	Panobinostat + Ruxolitinib		Active, not recruiting	NCT01433445		ECD	01-JUN-20	No	No		4	NCT01433445			Maximum tolerated dose/toxicity	61	61																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 1	Ruxolitinib + Umbralisib		Recruiting	NCT02493530	VICC HEM	ECD	01-DEC-20	No	No		4	NCT02493530			Maximum tolerated dose/toxicity	60	60																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Ruxolitinib		Terminated	NCT02091752		PCD	01-FEB-15	No	Yes	Slow accrual	4	NCT02091752	Previously-treated		Spleen volume reduction	3	3																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Parsaclisib + Ruxolitinib		Recruiting	NCT02718300		ECD	01-JAN-21	No	No		4	NCT02718300			Maximum tolerated dose/toxicity	90	90																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Itacitinib + Ruxolitinib		Active, not recruiting	NCT03144687		PCD	01-MAR-20	No	No		4	NCT03144687	Previously-treated		Spleen volume reduction	23	23																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	NS-018		Active, not recruiting	NCT01423851		ECD	01-NOV-20	No	No		2	10.1182/blood.V128.22.1936.1936			Maximum tolerated dose/toxicity	77	77																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Fedratinib		Completed	NCT00724334	TED12015	PCD	01-MAY-14	No	No		2	10.1182/blood.V122.21.2823.2823			Maximum tolerated dose/toxicity	43	43																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Pacritinib		Active, not recruiting	NCT03165734	PACIFICA	ECD	01-JUL-22	No	No		4	NCT03165734	Previously-treated		Spleen volume reduction	348			Best supportive care																																						
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Pacritinib		Completed	NCT00745550		PCD	01-JAN-12	No	Yes		1	25762180			Disease control rate, Clinical benefit rate	31	31			58.1																																					
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Lestaurtinib		Completed	NCT00509899		PCD	01-DEC-07	No	Yes		1	20843246			Spleen volume reduction	22	22			45																																					
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Lestaurtinib		Unknown	NCT00668421		PCD	01-SEP-13	No	Yes		1	25563429			Maximum tolerated dose/toxicity	16	16																															7	8								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Lestaurtinib		Completed	NCT00494585		PCD	01-MAY-20	No	Yes		1	20008298			Overall Response Rate	22	22																															6									
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Ruxolitinib		Completed	NCT00509899		PCD	01-DEC-07	No	Yes		4	NCT00509899			Spleen volume reduction	37	37			49																																					
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Ruxolitinib		Completed	NCT02966353	RELEASE	PCD	01-JUL-18	No	Yes	PO measure 56.0%	4	NCT02966353			Spleen volume reduction	51	51																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 3	Ruxolitinib		Completed	NCT02087059	AJP01	PCD	01-MAR-15	No	No		4	NCT02087059			Maximum tolerated dose/toxicity	51	51																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 3	Fedratinib		Completed	NCT01437787	JAKARTA	PCD	01-JUN-14	No	Yes	Serious adverse events	1	26181658			Spleen volume reduction	193	97	96	Placebo	40	1		<0.001																																		
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 3	Fedratinib		Recruiting	NCT03952039	FREEDOM2	ECD	01-MAR-22	No	No		4	NCT03952039			Spleen volume reduction	192			Best supportive care																																						
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 3	Fedratinib		Recruiting	NCT03755518	FREEDOM	ECD	01-JUN-23	No	No		4	NCT03755518	Previously-treated		Spleen volume reduction	110	110																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 3	Pacritinib		Terminated	NCT02055781	PERSIST-2	PCD	01-AUG-16	No	Yes		1	29522138			Spleen volume reduction	29	27	2	Placebo	18	3		0.001																																		
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 3	Momelotinib		Active, not recruiting	NCT01969838	Simplify 1	PCD	01-SEP-16	No	Yes		1	28930494			Spleen volume reduction	388	184	204	Ruxolitinib	26.5	29.0		0.011																																		
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 3	Momelotinib		Active, not recruiting	NCT02101268		PCD	01-JUL-16	No	No		1	29275119			Spleen volume reduction	156	104	52		7	6	-0.09-0.10	0.9																																		
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 3	Ruxolitinib		Terminated	NCT02598297	ReTHINK	PCD	01-OCT-17	No	Yes	Slow accrual	4	NCT02598297			Progression free survival	49			Placebo																																						
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / polycythaemia vera	3	Approved FDA	Ruxolitinib	Required	Completed	NCT01243944	RESPONSE	PCD	01-JAN-14	No	Yes		4	NCT01243944			Spleen volume reduction	222	110	112	Best supportive care	22.7	0.9		<0.0001																																		
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / polycythaemia vera	3	Phase 1	Ruxolitinib + Umbralisib		Recruiting	NCT02493530		ECD	01-DEC-20	No	No		4	NCT02493530			Maximum tolerated dose/toxicity	60	60																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / NK-T cell lymphoma	3	Phase 2	Ruxolitinib		Recruiting	NCT02974647		ECD	01-NOV-21	No	No		4	NCT02974647	Previously-treated		Disease control rate, Clinical benefit rate	62	62																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / NS	3	Phase 1	Pacritinib		Terminated	NCT03601819		PCD	01-MAR-20	No	Yes	Slow accrual	4	NCT03601819			Maximum tolerated dose/toxicity	5	5																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic B cell leukaemia	3	Phase 3	Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Mercaptopurine + Methotrexate + Nelarabine + Pegaspargase + Prednisone + Ruxolitinib + Vincristine + doxorubicin hydrochloride		Recruiting	NCT03117751		ECD	01-SEP-26	No	No		4	NCT03117751	Untreated		Event free survival	1000	1000																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic T cell leukaemia	3	Phase 3	Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Mercaptopurine + Methotrexate + Nelarabine + Pegaspargase + Prednisone + Ruxolitinib + Vincristine + doxorubicin hydrochloride		Recruiting	NCT03117751		ECD	01-SEP-26	No	No		4	NCT03117751	Untreated		Event free survival	1000	1000																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	3	Phase 1	Cytarabine + Leucovorin calcium + Methotrexate + Methylprednisolone sodium succinate + Rituximab + Ruxolitinib		Completed	NCT02779283		PCD	01-APR-18	No	No		4	NCT02779283	Untreated		Maximum tolerated dose/toxicity	7	7																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	3	Phase 1	Cyclophosphamide + Cytarabine + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Rituximab + Ruxolitinib + Thioguanine + Vincristine + doxorubicin hydrochloride		Not yet recruiting	NCT03571321		ECD	01-SEP-22	No	No		4	NCT03571321		Pediatric	Maximum tolerated dose/toxicity	15	15																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	3	Phase 2	Decitabine + Ruxolitinib		Recruiting	NCT02257138		ECD	01-FEB-21	No	No		4	NCT02257138	Previously-treated		Maximum tolerated dose/toxicity	34	34																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	3	Phase 2	Chemotherapy + Ruxolitinib		Recruiting	NCT02723994		ECD	01-FEB-24	No	No		4	NCT02723994	Untreated	Pediatric	Maximum tolerated dose/toxicity	170	170																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	3	Phase 2	Nilotinib + Ruxolitinib		Completed	NCT01914484		PCD	01-DEC-18	No	No		4	NCT01914484	Previously-treated		Maximum tolerated dose/toxicity	4	4																																								
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	3	Phase 3	Chemotherapy + Lestaurtinib		Completed	NCT00557193		PCD	01-SEP-17	No	Yes		4	NCT00557193	Untreated	Pediatric	Event free survival	121	67	54	Chemotherapy									35.8	38.9	1.11		0.67																									
JAK2	JAK2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Lenalidomide + Methylprednisolone acetate + Ruxolitinib		Recruiting	NCT03110822		ECD	01-MAR-22	No	Yes		2	10.1200/JCO.2019.37.15_suppl.8048	Previously-treated		Maximum tolerated dose/toxicity	106	106																																								
JAK2	JAK2_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 1	AZD1480		Terminated	NCT01219543		PCD	01-DEC-12	No	Yes	Serious adverse events, no benefit of treatment	1	23847256			Unknown	47	47																																								
JAK2	JAK2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cisplatin + Pemetrexed + Ruxolitinib		Terminated	NCT02119650		PCD	01-FEB-16	No	Yes	No benefit of treatment	4	NCT02119650			Overall survival	76	76		Placebo																																						
JAK2	JAK2_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 1	Ruxolitinib		Withdrawn	NCT02593929		ECD	01-JAN-18	No	No		4	NCT02593929			Unknown	0	0																																								
JAK2	JAK2_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Ruxolitinib		Recruiting	NCT03153982		ECD	01-JUN-22	No	No		4	NCT03153982			Defined % decrease in tumour volume	45	45																																								
KDR	KDR_unspecified (VEGFR2_unspecified)				NS / other / neoplasm	3	Phase 2	Sorafenib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
KDR	KDR_unspecified (VEGFR2_unspecified)				NS / other / neoplasm	3	Phase 2	Pazopanib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
KDR	KDR_unspecified (VEGFR2_unspecified)				NS / other / neoplasm	3	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	No		1	32292573			Disease control rate, Clinical benefit rate	8	8																																2								
KDR	KDR_unspecified (VEGFR2_unspecified)				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
KDR	KDR_unspecified (VEGFR2_unspecified)				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
KDR	KDR_unspecified (VEGFR2_unspecified)				NS / other / neoplasm	3	Phase 2	Regorafenib		Recruiting	NCT02693535	TAPUR group 13	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
KDR	KDR_unspecified (VEGFR2_unspecified)				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
KDR	KDR_unspecified (VEGFR2_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	No		4	NCT02219711			Maximum tolerated dose/toxicity	260	260																																								
KDR	KDR_unspecified (VEGFR2_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
KDR	KDR_unspecified (VEGFR2_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	30	32		Erlotinib + Placebo									3.92	2.84	.92		0.44																									
KDR	KDR_unspecified (VEGFR2_unspecified)				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		Terminated	NCT02299141		PCD	01-JAN-20	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12								
KEAP1	KEAP1_unspecified				NS / neoplasm / NS	3	Phase 2	Telaglenastat		Recruiting	NCT03872427		ECD	01-AUG-22	Yes	No		4	NCT03872427			Overall Response Rate	108	108																																								
RET	KIF5B-RET_fusion				lung / carcinoma / non small cell carcinoma	3	Case study	Vandetanib		Unknown					Yes	Yes		1	23584301			Unknown																																1										
RET	KIF5B-RET_fusion				lung / carcinoma / non small cell carcinoma	3	Case study	Everolimus + Vandetanib		Recruiting	NCT01582191		ECD	01-MAY-26	Yes	Yes		1	25982012			Maximum tolerated dose/toxicity	174	174																															1									
RET	KIF5B-RET_fusion				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cabozantinib		Recruiting	NCT01639508		ECD	01-JUL-21	Yes	No		4	NCT01639508			Overall Response Rate	68	68			20																												3									
RET	KIF5B-RET_fusion				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lenvatinib		Completed	NCT01877083		PCD	01-FEB-16	Yes	Yes		4	NCT01877083			Overall Response Rate	25	25			16		4.5-36.1						7.3			3.6-10.2																										
RET	KIF5B-RET_fusion				thyroid / carcinoma / medullary carcinoma	4	Case study	Selpercatinib		Unknown					Yes	Yes		1	29912274			Unknown	1	1																															1									
KIT	KIT_A502_Y503dup	55386625		p.A502_Y503dup	haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	4	Case study	Imatinib		Completed					Yes	Yes		1	23243287			Unknown	1	1																															1									
KIT	KIT_A502_Y503dup	55386625		p.A502_Y503dup	haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	4	Case study	Masitinib		Completed					Yes	Yes		1	22324351			Unknown	1	1																															1									
KIT	KIT_A502_Y503dup	55386625		p.A502_Y503dup	haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	4	Case study	Imatinib		Completed					Yes	Yes		1	21362052			Unknown	1	1																															1									
KIT	KIT_D579_H580insPYD			p.D579_H580insPYD	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed	NCT00424515	BUS255	PCD	01-JUL-11	Yes	Yes		1	23775962			Overall Response Rate	1	1																															1									
KIT	KIT_D816E	55420330 + 55423199		p.D816E	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Completed					Yes	Yes	No benefit of treatment	1	18294292			Unknown	1	1																																								
KIT	KIT_D816V	55386424		p.D816V	haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Dasatinib		Withdrawn	NCT03560908		ECD	01-DEC-20	Yes	Yes	Slow accrual	4	NCT03560908			Composite complete remission	0	0																																								
KIT	KIT_D816V	55386424		p.D816V	haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Approved FDA	Midostaurin	Not required	Completed	NCT00782067	CPKC412D2201	PCD	01-DEC-14	No	Yes		1	27355533			Overall Response Rate	16	16			75		48-93																																			
KIT	KIT_D816V	55386424		p.D816V	haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Approved FDA	Midostaurin	Not required	Completed	NCT00782067	CPKC412D2201	PCD	01-DEC-14	No	Yes		1	27355533			Overall Response Rate	73	73			63																																					
KIT	KIT_D816V	55386424		p.D816V	haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	4	Case study	Imatinib		Completed					Yes	Yes		1	23243287			Unknown	1	1																															1									
KIT	KIT_D816V	55386424		p.D816V	haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Phase 2	Nilotinib		Completed	NCT00109707	CAMN107A2101 	PCD	01-SEP-12	Yes	Yes		1	26002753			Maximum tolerated dose/toxicity	22	22			27.3																																					
KIT	KIT_D816V	55386424		p.D816V	haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Phase 2	Avapritinib + Best supportive care		Recruiting	NCT03731260	PIONEER	ECD	01-MAY-21	No	No		4	NCT03731260			Response rate	244			Best supportive care + Placebo																																						
KIT	KIT_D820E	55394297 + 55394417		p.D820E	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Completed					Yes	Yes	No benefit of treatment	1	19861442			Unknown	1	1																																								
KIT	KIT_D820E	55394297 + 55394417		p.D820E	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Sunitinib		Completed					Yes	Yes	No benefit of treatment	1	19861442			Unknown	1	1																																								
KIT	KIT_D820E	55394297 + 55394417		p.D820E	thymus / thymic carcinoma / NS	4	Case study	Sorafenib		Completed					Yes	Yes		1	19461405			Unknown	1	1																															1									
KIT	KIT_D820G	55387023		p.D820G	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Completed					Yes	Yes	No benefit of treatment	1	18488160			Unknown	1	1																																								
KIT	KIT_D820Y	55387253		p.D820Y	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed	NCT00424515	BUS255	PCD	01-JUL-11	Yes	Yes		1	23775962			Overall Response Rate	1	1																															1									
KIT	KIT_D820Y	55387253		p.D820Y	NS / malignant melanoma / NS	4	Case study	Nilotinib		Completed	NCT00788775		PCD	01-APR-11	Yes	Yes		1	25695690			Progression free survival	1	1																																1								
KIT	KIT_D820Y	55387253		p.D820Y	soft tissue / gastrointestinal stromal tumour / NS	3	Case study	Avapritinib		Completed					Yes	Yes		1	29093181			Unknown	1	1																															1									
KIT	KIT_D820Y	55387253		p.D820Y	soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Regorafenib		Active, not recruiting	NCT01068769		PCD	01-JUN-12	Yes	Yes		1	22614970	Previously-treated		Disease control rate, Clinical benefit rate	3	3																					100																			
KIT	KIT_E554_I571del	55394003		p.E554_I571del	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																16.4															1									
KIT	KIT_E554_K558del	55397632		p.E554_K558del	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	2	2																20.14															2									
KIT	KIT_Exon11				soft tissue / gastrointestinal stromal tumour / NS	2	Phase 2	Regorafenib		Active, not recruiting	NCT01068769		PCD	01-JUN-12	Yes	Yes		1	27371698	Previously-treated		Disease control rate, Clinical benefit rate	19	19											13.4										79																			
KIT	KIT_Exon11				soft tissue / gastrointestinal stromal tumour / NS	2	Phase 2	Sunitinib		Unknown					Yes	Yes		1	18955458			Unknown	44	44																					100																			
KIT	KIT_Exon11				soft tissue / gastrointestinal stromal tumour / NS	2	Phase 2	Imatinib		Unknown	UMIN000003114				Yes	Yes	R0 resection rate 91% primary outcome met	1	28535156			Percent of patients who become resectable	46	46																					100																			
KIT	KIT_Exon13				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Sunitinib		Unknown					Yes	Yes		1	18955458			Unknown	1	1																					100																			
KIT	KIT_Exon13				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Ponatinib		Unknown	NCT03171389	POETIG	ECD	01-SEP-18	No	No		4	NCT03171389	Previously-treated		Disease control rate, Clinical benefit rate	81	81																																								
KIT	KIT_Exon17				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Regorafenib		Completed	NCT02606097		PCD	01-MAY-18	Yes	Yes		1	28487491	Previously-treated		Disease control rate, Clinical benefit rate	19	19											22.1	5.5			0.0001						93.3										6	8								
KIT	KIT_Exon9				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Sunitinib		Unknown					Yes	Yes		1	18955458			Unknown	19	19																					100																			
KIT	KIT_Exon9, Exon11, Exon13, Exon14				NS / neoplasm / NS	3	Phase 2	Sunitinib		Recruiting	NCT02465060	MATCH Subprotocol V	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
KIT	KIT_F522C				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	4	Case study	Imatinib		Completed					Yes	Yes		1	23243287			Unknown	1	1																															1									
KIT	KIT_K550_K558del	55392408		p.K550_K558del	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	3	3																10.92															3									
KIT	KIT_K550_W557>FL			p.K550_W557>FL	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																13.8															1									
KIT	KIT_K558_V559del	55409503		p.K558_V559del	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																16.6															1									
KIT	KIT_K558_V559delinsN	55405007		p.K558_V559delinsN	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																51.4															1									
KIT	KIT_K558delinsNP	55400499 + 55402099 + 55408342		p.K558delinsNP	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																7.8															1									
KIT	KIT_K642E	55387507		p.K642E	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed	NCT00470470	NCI-2009-00216 	PCD	01-DEC-13	Yes	Yes		1	21642685			Overall Response Rate	4	4																														1										
KIT	KIT_K642E	55387507		p.K642E	NS / malignant melanoma / NS	4	Case study	Nilotinib		Completed	NCT00788775		PCD	01-APR-11	Yes	Yes		1	25695690			Progression free survival	3	3																															1	1								
KIT	KIT_K642E	55387507		p.K642E	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed	NCT00424515	BUS255	PCD	01-JUL-11	Yes	Yes		1	23775962			Overall Response Rate	2	2																																1								
KIT	KIT_K642E	55387507		p.K642E	skin / malignant melanoma / NS	4	Case study	Imatinib		Completed					Yes	Yes		1	18510589			Unknown	1	1																														1										
KIT	KIT_K642E	55387507		p.K642E	skin / malignant melanoma / NS	4	Case study	Imatinib		Completed					Yes	Yes	No benefit of treatment	1	24855380			Unknown	1	1																																								
KIT	KIT_K642E	55387507		p.K642E	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																8.29															1									
KIT	KIT_K642E	55387507		p.K642E	thymus / thymic carcinoma / NS	4	Case study	Sunitinib		Completed					Yes	Yes		1	24855380			Unknown	1	1																															1									
KIT	KIT_K642E,N882H	55387507 + 55389464		p.K642E + p.N822H	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																16.5															1									
KIT	KIT_L576P	55386593		p.L576P	NS / malignant melanoma / NS	4	Case study	Everolimus		Completed					Yes	Yes		1	22162580			Unknown	1	1																					100																			
KIT	KIT_L576P	55386593		p.L576P	NS / malignant melanoma / NS	4	Case study	Dasatinib		Completed					Yes	Yes		1	19671763			Unknown	2	2																															2									
KIT	KIT_L576P	55386593		p.L576P	NS / malignant melanoma / NS	4	Case study	Nilotinib		Completed	NCT00788775		PCD	01-APR-11	Yes	Yes		1	25695690			Progression free survival	2	2																															1									
KIT	KIT_L576P	55386593		p.L576P	NS / malignant melanoma / NS	4	Case study	Sunitinib		Completed					Yes	Yes		1	22261812			Unknown	2	2																														1	1									
KIT	KIT_L576P	55386593		p.L576P	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed	NCT00424515	BUS255	PCD	01-JUL-11	Yes	Yes		1	23775962			Overall Response Rate	3	3																															3									
KIT	KIT_L576P	55386593		p.L576P	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed	NCT00470470	NCI-2009-00216 	PCD	01-DEC-13	Yes	Yes		1	21642685			Overall Response Rate	7	7																														2	1									
KIT	KIT_L576P	55386593		p.L576P	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Completed					Yes	Yes	No benefit of treatment	1	19723893			Unknown	1	1																																								
KIT	KIT_L576P	55386593		p.L576P	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																24.6															1									
KIT	KIT_L576P	55386593		p.L576P	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Completed					Yes	Yes		1	26942271			Unknown	5	5																																	100							
KIT	KIT_L831P	55405654		p.L831P	NS / malignant melanoma / NS	4	Case study	Nilotinib		Completed	NCT00788775		PCD	01-APR-11	Yes	Yes		1	25695690			Progression free survival	1	1																																1								
KIT	KIT_M541L	55388500		p.M541L	haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic eosinophilic leukaemia-hypereosinophilic syndrome	4	Case study	Imatinib		Completed					Yes	Yes		1	25015329			Unknown	4	4																														4										
KIT	KIT_M552_W557del	55387606 + 55396714		p.M552_W557del	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																42.6															1									
KIT	KIT_N822K	55387147 + 55389584		p.N822K	NS / malignant melanoma / NS	4	Case study	Nilotinib		Completed	NCT00788775		PCD	01-APR-11	Yes	Yes		1	25695690			Progression free survival	1	1																																1								
KIT	KIT_N822K	55387147 + 55389584		p.N822K	soft tissue / gastrointestinal stromal tumour / NS	3	Case study	Imatinib		Completed					Yes	Yes	No benefit of treatment	1	26316776			Unknown	1	1																																								
KIT	KIT_N822K	55387147 + 55389584		p.N822K	soft tissue / gastrointestinal stromal tumour / NS	3	Case study	Imatinib		Completed					Yes	Yes	No benefit of treatment	1	16954519			Unknown	1	1																																								
KIT	KIT_N822K	55387147 + 55389584		p.N822K	soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Regorafenib		Active, not recruiting	NCT01068769		PCD	01-JUN-12	Yes	Yes		1	22614970	Previously-treated		Disease control rate, Clinical benefit rate	1	1																					100																			
KIT	KIT_P551_E554del	55388074		p.P551_E554del	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	2	2																37.8															2									
KIT	KIT_P577_D579del	55424904		p.P577_D579del	thymus / thymic carcinoma / NS	4	Case study	Sorafenib		Completed					Yes	Yes		1	20970876			Unknown	1	1																															1									
KIT	KIT_R634Q, K642E	55387507 + 55387888		p.K642E + p.R634Q	NS / malignant melanoma / NS	4	Case study	Nilotinib		Completed	NCT00788775		PCD	01-APR-11	Yes	Yes		1	25695690			Progression free survival	1	1																																1								
KIT	KIT_V530I	55396593		p.V530I	soft tissue / desmoid tumour-fibromatosis / NS	4	Case study	Imatinib		Completed					Yes	Yes		1	20339585			Unknown	1	1																														1										
KIT	KIT_V559A	55388782		p.V559A	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed	NCT00424515	BUS255	PCD	01-JUL-11	Yes	Yes	No benefit of treatment	1	23775962			Overall Response Rate	1	1																																								
KIT	KIT_V559A	55388782		p.V559A	NS / malignant melanoma / NS	4	Case study	Sunitinib		Completed					Yes	Yes		2	10.1200/jco.2009.27.15_suppl.e20017			Unknown	1	1																															1									
KIT	KIT_V559A	55388782		p.V559A	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed					Yes	Yes		1	19812602			Unknown	2	2																					100																			
KIT	KIT_V559G	55393324		p.V559G	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																16.4															1									
KIT	KIT_V559G	55393324		p.V559G	thymus / thymic carcinoma / NS	4	Case study	Sorafenib		Completed					Yes	Yes		1	27073655			Unknown	1	1																															1									
KIT	KIT_V559G	55393324		p.V559G	thymus / thymic carcinoma / NS	4	Case study	Sunitinib		Completed					Yes	Yes		1	27073655			Unknown	1	1																					100																			
KIT	KIT_V559_V560del	55396077		p.V559_V560del	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Completed	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																11.5															1									
KIT	KIT_V560D	55386785		p.V560D	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed	NCT00424515	BUS255	PCD	01-JUL-11	Yes	Yes		1	23775962			Overall Response Rate	1	1																															1									
KIT	KIT_V560D	55386785		p.V560D	skin / malignant melanoma / NS	4	Case study	Sorafenib		Completed					Yes	Yes		1	18936790			Unknown	1	1																														1										
KIT	KIT_V560D	55386785		p.V560D	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Completed	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	2	2																24.1															2									
KIT	KIT_V560G	55393278		p.V560G	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																25.2															1									
KIT	KIT_V560del	55391268		p.V560del	thymus / thymic carcinoma / NS	4	Case study	Imatinib		Completed					Yes	Yes		1	15201427			Unknown	1	1																															1									
KIT	KIT_V654A	55389496		p.V654A	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Completed					Yes	Yes	No benefit of treatment	1	16954519			Unknown	2	2																																								
KIT	KIT_V654A	55389496		p.V654A	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Completed					Yes	Yes	No benefit of treatment	1	18955458			Unknown	16	16																																								
KIT	KIT_W557G	55387014		p.W557G	NS / malignant melanoma / NS	4	Case study	Sunitinib		Completed					Yes	Yes		1	22261812			Unknown	1	1																															1									
KIT	KIT_W557G	55387014		p.W557G	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																16.8															1									
KIT	KIT_W557R	55386440 + 55389479		p.W557R	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed	NCT00424515	BUS255	PCD	01-JUL-11	Yes	Yes	No benefit of treatment	1	23775962			Overall Response Rate	1	1																																								
KIT	KIT_W557R	55386440 + 55389479		p.W557R	NS / malignant melanoma / NS	4	Case study	Imatinib		Completed					Yes	Yes		1	18421059			Unknown	1	1																															1									
KIT	KIT_W557_E561del	55388067		p.W557_E561del	soft tissue / gastrointestinal stromal tumour / NS	7	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																30.6															1									
KIT	KIT_W557_K558del	55387046 + 55422731		p.W557_K558del	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																29															1									
KIT	KIT_W557_V560delinsC	55402661		p.W557_V560delinsC	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																19.2															1									
KIT	KIT_W557_V560delinsF	55406504		p.W557_V560delinsF	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																33.8															1									
KIT	KIT_Y553N	55389622		p.Y553N	thymus / thymic carcinoma / NS	4	Case study	Imatinib		Completed					Yes	Yes		1	21969494			Unknown	1	1																															1									
KIT	KIT_Y553_K558del	55389527		p.Y553_K558del	soft tissue / gastrointestinal stromal tumour / NS	4	Case study	Imatinib		Unknown	NCT00237185	CSTI571B 2222	PCD	01-JUN-13	Yes	Yes		1	16954519			Best overall response	1	1																23															1									
KIT	KIT_exon11				NS / malignant melanoma / NS	4	Case study	Nilotinib		Completed	NCT01099514		PCD	01-DEC-13	Yes	Yes		1	26424760			Overall Response Rate	5	5																					100																			
KIT	KIT_exon17				NS / malignant melanoma / NS	4	Case study	Nilotinib		Completed	NCT01099514		PCD	01-DEC-13	Yes	Yes		1	26424760			Overall Response Rate	1	1																					100																			
KIT	KIT_unspecified				NS / malignant melanoma / NS	3	Phase 2	Regorafenib		Recruiting	NCT02501551		ECD	01-DEC-20	Yes	No		4	NCT02501551	Previously-treated		Disease control rate, Clinical benefit rate	36	36																																								
KIT	KIT_unspecified				NS / malignant melanoma / NS	3	Phase 2	Dasatinib		Active, not recruiting	NCT00700882	E2607	PCD	01-MAY-16	No	Yes	No benefit of treatment	1	28334439			Overall Response Rate	57	57											2.1													7.5							10									
KIT	KIT_unspecified				NS / malignant melanoma / NS	3	Phase 2	Dasatinib		Completed	NCT00436605	NCI-2009-00219	PCD	01-MAR-10	No	Yes		4	NCT00436605			Overall Response Rate	39	39			5.0								2																													
KIT	KIT_unspecified				NS / malignant melanoma / NS	3	Phase 2	Nilotinib		Completed	NCT01099514		PCD	01-DEC-13	No	Yes		1	26424760			Overall Response Rate	42	42			16.7		5.4-28.0																57.1									1	6	17								
KIT	KIT_unspecified				NS / malignant melanoma / NS	3	Phase 2	Sunitinib		Completed	NCT00577382	06-145	PCD	01-AUG-14	No	Yes	Response not correlated with expression level	1	26264378			Unknown	52	52																															4									
KIT	KIT_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
KIT	KIT_unspecified				NS / other / neoplasm	3	Phase 2	Imatinib + Spartalizumab		Recruiting	NCT03609424		ECD	01-AUG-20	No	No		4	NCT03609424	Previously-treated		Disease control rate, Clinical benefit rate	41	41																																								
KIT	KIT_unspecified				NS / other / neoplasm	3	Phase 2	Ponatinib		Recruiting	NCT02272998		ECD	01-DEC-21	Yes	No		4	NCT02272998			Overall Response Rate	45	45																																								
KIT	KIT_unspecified				NS / other / neoplasm	3	Phase 2	Pazopanib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
KIT	KIT_unspecified				NS / other / neoplasm	3	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	Yes		1	32292573			Disease control rate, Clinical benefit rate	23	23																															1									
KIT	KIT_unspecified				NS / other / neoplasm	3	Phase 2	Nilotinib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
KIT	KIT_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
KIT	KIT_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
KIT	KIT_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
KIT	KIT_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	4	3	1	Cytarabine	33	0																																				
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Nilotinib		Unknown					No	Yes	No benefit of treatment	3	http://www.bloodjournal.org/content/122/21/3961			Unknown																																										
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Semaxanib		Unknown					No	Yes	Development discontinued 2002	1	15158089			Unknown	33	33																															3									
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Sorafenib		Completed	NCT00893373		PCD	01-NOV-11	No	Yes	No effect on OS, high relapse rate	1	24487412			Event free survival	276	276																																								
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Dasatinib		Completed	NCT00850382	AMLSG 11-08	PCD	01-NOV-15	No	Yes		1	29720733			Maximum tolerated dose/toxicity	89	89																								74.7																
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Dasatinib		Active, not recruiting	NCT01238211	CALGB-10801	PCD	01-JUL-15	No	Yes	Response not correlated with mutation status	2	10.1182/blood.V124.21.8.8			Maximum tolerated dose/toxicity	56	56																																								
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Imatinib		Unknown					Expression level	Yes		1	14726395	Previously-treated		Unknown	21	21																														2										
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Imatinib		Unknown					No	Yes	No benefit of treatment	1	12767088			Unknown	10	10																																								
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Dasatinib		Recruiting	NCT02013648		ECD	01-FEB-21	No	No		4	NCT02013648			Event free survival	203																																									
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Chemotherapy + Midostaurin		Active, not recruiting	NCT03512197		ECD	01-JAN-21	No	No		4	NCT03512197			Unknown	512																																									
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	2	Approved FDA	Imatinib	Not required	Unknown					No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf			Unknown	28	28																														8	9									
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Approved FDA	Midostaurin	Not required	Completed	NCT00782067	CPKC412D2201	PCD	01-DEC-14	No	Yes		1	27355533			Overall Response Rate	57	57			58		44-71																																			
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Approved FDA	Midostaurin	Not required	Completed	NCT00782067	CPKC412D2201	PCD	01-DEC-14	No	Yes		1	27355533			Overall Response Rate	16	16			50		25-75																																			
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	2	Approved FDA	Midostaurin	Not required	Completed	NCT00782067	CPKC412D2201	PCD	01-DEC-14	No	Yes		1	27355533			Overall Response Rate	116	116			60		49-70						14.1													28.7																
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Case study	Dasatinib		Completed					Yes	Yes	No benefit of treatment	1	22324351			Unknown	1	1																																								
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Case study	Dasatinib		Completed					Yes	Yes	No benefit of treatment	1	19021706			Unknown	1	1																																								
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Case study	Dasatinib		Completed					Yes	Yes	No benefit of treatment	1	22173243			Unknown	1	1																																								
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	2	Phase 1	Avapritinib		Unknown					No	Yes	May be NCT02561988	3	https://learningcenter.ehaweb.org/eha/2018/stockholm/215059/maureen.conlan.avapritinib.28blu-28529.a.selective.kit.inhibitor.is.associated.html?f=topic=1574*media=3			Unknown	7	7			83																											2	3									
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	2	Phase 2	Avapritinib		Active, not recruiting	NCT03580655	PATHFINDER	ECD	01-MAY-22	No	No		4	NCT03580655			Overall Response Rate	103	103																																								
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	2	Phase 2	Masitinib		Unknown					No	Yes		1	21108325			Disease control rate, Clinical benefit rate	25	25																					56.0																			
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	2	Phase 2	Nilotinib		Completed	NCT00109707	CAMN107A2101 	PCD	01-SEP-12	Yes	Yes		1	26002753			Maximum tolerated dose/toxicity	37	37			21.6																																					
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	2	Phase 3	Masitinib		Completed	NCT00814073	AB06006 	ECD	01-DEC-12	No	Yes		1	28069279			Disease control rate, Clinical benefit rate	135			Placebo																			18.7	7.4	0.0076																	
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Phase 3	Best supportive care + Masitinib		Recruiting	NCT04333108		ECD	01-DEC-22	No	No		4	NCT04333108			Response rate	140			Best supportive care + Placebo																																						
KIT	KIT_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / mast cell neoplasm	3	Phase 3	Best supportive care + Masitinib		Recruiting	NCT04333108		ECD	01-DEC-22	No	No		4	NCT04333108			Response rate	140			Best supportive care + Placebo																																						
KIT	KIT_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Approved FDA	Sorafenib	Not required	Completed	NCT00073307	TARGET	PCD	01-SEP-06	No	Yes		1	17189398	Previously-treated		Overall survival	769	384	385	Placebo									5.49	2.76	.44	0.35-0.55	< 0.000001																									
KIT	KIT_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Approved FDA	Sunitinib	Not required	Completed	NCT00375674	S-TRAC 	PCD	01-APR-16	No	Yes		1	28967554			Disease free survival, relapse free survival, regression free survival, recurrence free survival	615	309	306	Placebo																															81.6	67.2	.76	0.59-0.98	0.03			
KIT	KIT_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Approved FDA	Sunitinib	Not required	Completed	NCT00083889	A6181034	PCD	01-SEP-08	No	Yes		1	20104222	Untreated		Progression free survival	750	375	375	Interferon alpha-2B	6.35	1.22		<0.001					10.9	5.1	.42	0.32-0.53	<0.000001																									
KIT	KIT_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Approved FDA	Sunitinib	Not required	Completed	NCT00054886		PCD	01-AUG-04	No	Yes		4	NCT00054886			Overall Response Rate	63	63			36.5		24.7-49.6																										23									
KIT	KIT_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Approved FDA	Sunitinib	Not required	Completed	NCT00077974	A6181006	PCD	01-SEP-08	No	Yes		1	16757724	Previously-treated		Overall Response Rate	106	106			34.0		25.0-43.8																										36									
KIT	KIT_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Approved FDA	Sorafenib	Not required	Completed					No	Yes		1	16636341			Unknown	38	32	6	Placebo									5.36	1.35	.29		0.0001																									
KIT	KIT_unspecified				large intestine / carcinoma / adenocarcinoma	3	Approved FDA	Regorafenib	Not required	Completed	NCT01103323	CORRECT	PCD	01-JUL-11	No	Yes		1	23177514	Previously-treated		Overall survival	760	505	255	Placebo									2	1.7	.49	0.42-0.58	<0.0001									6.4	5	.77	0.64-0.94	0.0102												
KIT	KIT_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Sunitinib		Completed	NCT00247676		PCD	01-FEB-08	No	Yes	4 serious adverse events - deaths possibly due to treatment	1	19586800			Unknown	37																																1									
KIT	KIT_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	No		4	NCT02219711			Maximum tolerated dose/toxicity	260	260																																								
KIT	KIT_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
KIT	KIT_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	26	20		Erlotinib + Placebo									4.5	2.33	1.34	0.42-4.30	0.69																									
KIT	KIT_unspecified				ovary / carcinoma / NS	3	Phase 1	OSI-930		Unknown					No	Yes		1	23403628			Unknown	2	2																															2									
KIT	KIT_unspecified				pancreas / carcinoid-endocrine tumour / NS	2	Approved FDA	Sunitinib	Not required	Terminated	NCT00428597	A6181111	PCD	01-APR-09	No	Yes		1	21306237			Progression free survival	171	86	85	Placebo	9.3	0		0.0066					11.4	5.5	.42	0.26-0.66	<0.00015																									
KIT	KIT_unspecified				pancreas / carcinoid-endocrine tumour / NS	2	Phase 2	Sunitinib		Terminated	NCT02315625	150040	PCD	01-MAY-19	Yes	Yes	Slow accrual	1	25991462			Progression free survival	16																																									
KIT	KIT_unspecified				skin / carcinoma / Merkel cell carcinoma	3	Phase 2	Imatinib		Completed	NCT00068783		PCD	01-JUL-07	Expression level	Yes	Primary outcome not met	1	20019577			Response rate	40	40											1			1.0-2.0										5.0			2.0-8.0				1									
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Approved FDA	Imatinib	Not required	Unknown	NCT00685828	EORTC-62005	PCD	01-FEB-02	Expression level	Yes		1	19193781			Progression free survival	1388												18.9													49.0						74	639									
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Approved FDA	Sunitinib	Not required	Completed	NCT00075218	A6181004	PCD	01-MAY-08	No	Yes		1	17046465	Previously-treated		Time to treatment failure, Time to progression	312	207	105	Placebo	1.6	0		0.006					5.6	1.4	.3	0.24-0.47	<0.0001	6.3	1.5	.33	0.23-0.47	<0.0001				16.8	14.98															
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Approved FDA	Sunitinib	Not required	Unknown	NCT00793871		PCD	01-APR-14	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021938s036lbl.pdf	Previously-treated		Unknown	55	55																															5									
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Approved FDA	Imatinib	Not required	Completed	NCT00041197	NCI-2012-02930	PCD	01-APR-07	Expression level	Yes		1	19303137			Disease free survival, relapse free survival, regression free survival, recurrence free survival	713	359	354	Placebo																															98	83	.35	0.22-0.53	p<0.0001			
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Approved FDA	Imatinib	Not required	Completed	NCT00116935		PCD	01-DEC-10	Expression level	Yes		1	22453568			Unknown	397																									94									75							
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Experimental	Ripretinib		Recruiting	NCT02571036		ECD	01-JUN-22	Yes	No		4	NCT02571036	Previously-treated		Overall Response Rate	320	320																																								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 1	Avapritinib		Active, not recruiting	NCT02508532	NAVIGATOR	PCD	01-MAR-20	No	No		1	NCT02508532	Previously-treated		Overall Response Rate	80	80																																								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 1	Dovitinib + Imatinib		Withdrawn	NCT02268435		ECD	01-AUG-16	No	Yes	Drug unavailable	4	NCT02268435			Maximum tolerated dose/toxicity	0	0																																								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 1	OSI-930		Unknown					No	Yes		1	23403628	Previously-treated		Unknown	19	19																																11								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Sorafenib		Completed	NCT01091207		PCD	01-DEC-10	No	Yes	NCCN Soft Tissue Sarcoma Guidelines section ?SARC-E page, Generally Accepted Systemic Therapy Agents and Regimens? includes sorafenib as a recommended therapy for GIST resistant to imatinib and sunitinib.	1	22270258	Previously-treated		Disease control rate, Clinical benefit rate	39	39											4.9										36			9.7							4	16								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Imatinib + Regorafenib		Unknown	NCT02365441	ALT GIST	ECD	01-DEC-19	No	No		4	NCT02365441	Untreated		Progression free survival	240	240																																								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Imatinib + doxorubicin hydrochloride		Unknown			PCD	01-JUL-10	Comparison with wt	Yes		1	20564079			Unknown	16	10											2.7	7												5.6	14.6															
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Pazopanib		Completed	NCT01524848		PCD	01-JAN-15	No	No		4	NCT01524848			Disease control rate, Clinical benefit rate	72	72																																								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Dovitinib		Completed	NCT01440959		PCD	01-MAR-13	No	Yes		4	NCT01440959			Disease control rate, Clinical benefit rate	30	30												3.6		3.5-3.7							13	4.7-30.3		9.7			6.0-13.4													
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Luminespib		Unknown	NCT01389583		ECD	01-MAY-15	No	Yes		2	10.1200/jco.2016.34.4_suppl.134	Previously-treated		Disease control rate, Clinical benefit rate	25	25											2.4			1.6-3.2										9.6			0-21.1													
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Imatinib		Completed	NCT00112632	APOLLON			Expression level	Yes	3yr PFS 85.2%	2	10.1200/jco.2012.30.15_suppl.10031			Disease control rate, Clinical benefit rate	39	39																																								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Paclitaxel		Recruiting	NCT03944304		ECD	01-AUG-21	Yes	No		4	NCT03944304			Disease control rate, Clinical benefit rate	40	40																																								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Regorafenib		Completed	NCT02889328		PCD	01-AUG-17	Yes	Yes		2	10.1200/JCO.2018.36.15_suppl.11537	Previously-treated		Disease control rate, Clinical benefit rate	25	25											7.3																				2	16								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Regorafenib		Active, not recruiting	NCT01068769		PCD	01-JUN-12	No	Yes		1	27371698	Previously-treated		Disease control rate, Clinical benefit rate	33	33											13.2										76.0										6	19								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Sorafenib		Active, not recruiting	NCT00265798		PCD	01-FEB-10	Expression level	Yes		2	10.1200/jco.2011.29.15_suppl.10009	Previously-treated		Overall Response Rate	38	38											5.2			3.4-7.4							68			11.6			8.8-14.3				5	21								
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 3	Regorafenib		Active, not recruiting	NCT03465722	VOYAGER	PCD	01-MAR-20	No	No		4	NCT03465722	Previously-treated		Progression free survival	476			Avapritinib																																						
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 3	Nilotinib		Completed	NCT00785785	ENESTg1		01-OCT-14	Yes	Yes	No benefit of treatment	1	22119758	Untreated		Progression free survival	674	324	320	Imatinib																																						
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 3	Avapritinib		Active, not recruiting	NCT03465722	VOYAGER	PCD	01-MAR-20	No	No		4	NCT03465722	Previously-treated		Progression free survival	476			Regorafenib																																						
KIT	KIT_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Retrospective/Meta-analysis	Sorafenib		Unknown					No	Yes		1	24137379	Previously-treated		Unknown	25	25											7.2													15.2																
KIT	KIT_unspecified				thymus / thymic carcinoma / NS	3	Phase 2	Imatinib		Unknown					Expression level	Yes	No benefit of treatment	2	10.1200/jco.2008.26.15_suppl.8116			Unknown																																										
KIT	KIT_unspecified				thymus / thymic carcinoma / NS	3	Phase 2	Sunitinib		Unknown					No	Yes		1	27237035			Unknown					20								3.3										55			12.3				0.043												
KIT	KIT_unspecified				thymus / thymic carcinoma / NS	3	Phase 2	Sunitinib		Active, not recruiting	NCT01621568	12-C-0118	ECD	01-APR-20	No	Yes		1	25592632			Overall Response Rate	23	23											7.2			3.4-15.2							91										6									
KMT2A	KMT2A_unspecified (MLL_unspecified)				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Pinometostat		Completed	NCT02141828		PCD	01-MAY-16	Yes	Yes	Primary outcome met	2	10.1182/blood.V128.22.2780.2780		Pediatric	Maximum tolerated dose/toxicity	18	18			0																																					
KMT2A	KMT2A_unspecified (MLL_unspecified)				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	SNDX-5613		Recruiting	NCT04065399	AUGMENT-101	ECD	01-JUL-22	Yes	No		4	NCT04065399	Previously-treated		Complete remission	186	186																																								
KMT2A	KMT2A_unspecified (MLL_unspecified)				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine + Entospletinib		Recruiting	NCT03013998	BAML-16-001-S4	ECD	01-DEC-21	Yes	No		4	NCT03013998			Response rate	2000	2000																																								
KMT2A	KMT2A_unspecified (MLL_unspecified)				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Daunorubicin + Pinometostat		Recruiting	NCT03724084		ECD	01-JUN-21	Yes	No		4	NCT03724084	Untreated	Pediatric	Complete response, Pathological complete response	37	37																																								
KMT2A	KMT2A_unspecified (MLL_unspecified)				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Entospletinib		Recruiting	NCT03013998	BAML-16-001-S4	ECD	01-DEC-21	Yes	No		4	NCT03013998			Response rate	2000	2000																																								
KRAS	KRAS_G12			p.G12X	pancreas / carcinoma / NS	3	Phase 1	mDC3/8-KRAS Vaccine		Recruiting	NCT03592888		ECD	01-OCT-21	Yes	No		4	NCT03592888			Maximum tolerated dose/toxicity	12	12																																								
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	7	Approved FDA	FOLFOX + Panitumumab	wt KRAS	Completed	NCT00364013	PRIME	PCD	01-AUG-09	No	Yes	PFS greater for control	1	20921465	Untreated		Progression free survival	440	221	219										7.3	8.8	1.29	1.04-1.62	0.02									15.5	19.3	1.24	0.98-1.57	0.068												
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	7	Phase 1	Pembrolizumab + Sargramostim + Zotiraciclib		Terminated	NCT02933944		PCD	01-FEB-19	No	Yes	Changed business priorities	4	NCT02933944			Maximum tolerated dose/toxicity	6	6																																								
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Pembrolizumab + Zotiraciclib		Terminated	NCT02933944		PCD	01-FEB-19	Yes	Yes	Changed business priorities	4	NCT02933944			Maximum tolerated dose/toxicity	6	6																																								
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	3	Phase 1	Zotiraciclib		Terminated	NCT02933944		PCD	01-FEB-19	Yes	Yes	Changed business priorities	4	NCT02933944			Maximum tolerated dose/toxicity	6	6																																								
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	7	Phase 1	Carboplatin + Olaparib		Completed	NCT02418624	REVIVAL	PCD	01-JAN-19	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3118			Maximum tolerated dose/toxicity	24	24																															14									
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	7	Phase 1	Cetuximab + Selumetinib		Completed	NCT01217450		PCD	01-DEC-12	Yes	Yes		1	26666244	Previously-treated		Unknown	4	4																															1	3								
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	7	Phase 2	Cetuximab + FOLFOX-4		Completed	NCT00125034	OPUS	PCD	01-MAR-07	Yes	Yes	PFS greater for control	1	19114683			Overall Response Rate	99	52	47										5.5	8.6	1.83	1.095-3.056	0.0192						85	85																		
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	7	Phase 3	Cetuximab		Completed	NCT00079066	CO.17	PCD	01-MAR-06	Yes	Yes	No benefit of treatment	1	18946061			Overall survival	151	75	76	FOLFIRI + Imgatuzumab									1.8	1.8												4.5	4.6	.98	0.7-1.37	0.89												
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	7	Phase 3	Cetuximab + FOLFIRI		Completed	NCT00154102	CRYSTAL	PCD	01-DEC-06	Comparison with wt	Yes	No benefit of treatment	1	21502544			Progression free survival	531	214	316	FOLFIRI									7.4	9.9												16.2	23.5															
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	large intestine / carcinoma / adenocarcinoma	7	Phase 3	Panitumumab		Completed	NCT00113763	20020408	PCD	01-OCT-08	Yes	Yes	No benefit of treatment	1	18316791			Progression free survival	184	84	100	Best supportive care									1.7	1.69	.99	0.73-1.36																										
KRAS	KRAS_G12,G13	55500243 + 55559231 + 55756103		p.G12X + p.G13=	lung / carcinoma / non small cell carcinoma	4	Phase 1	Cetuximab + Selumetinib		Completed	NCT01217450		PCD	01-DEC-12	Yes	Yes		1	26666244			Maximum tolerated dose/toxicity	1	1																																1								
KRAS	KRAS_G12,G13,Q61.				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Irinotecan + Simvastatin		Completed	NCT01281761		PCD	01-SEP-12	Yes	Yes	No benefit of treatment	1	24468885	Previously-treated		Unknown	52	52			1.9								3.7										65.4			12.8																
KRAS	KRAS_G12,G13,Q61.				lung / carcinoma / non small cell carcinoma	3	Phase 3	Sorafenib		Completed	NCT00411671	BATTLE	PCD	01-NOV-12	Yes	Yes		2	10.1200/jco.2010.28.15_suppl.7609	Previously-treated		Unknown	18	18																					61																			
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	MEK inhibitor + Sotorasib		Recruiting	NCT04185883	CodeBreak 101	ECD	01-MAY-23	Yes	No		4	NCT04185883			Maximum tolerated dose/toxicity	1003	1003																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	TAS0612		Recruiting	NCT04586270	Cohort D	ECD	01-JUN-23	Yes	No		4	NCT04586270			Overall Response Rate	200	200																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	GDC6036		Recruiting	NCT04449874		ECD	01-AUG-23	Yes	No		4	NCT04449874			Maximum tolerated dose/toxicity	236	236																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	JNJ74699157		Completed	NCT04006301		PCD	01-JUL-20	Yes	No		4	NCT04006301			Overall Response Rate	10	10																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	Chemotherapy + Sotorasib		Recruiting	NCT04185883	CodeBreak 101	ECD	01-MAY-23	Yes	No		4	NCT04185883			Maximum tolerated dose/toxicity	1003	1003																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	PD-1 inhibitor  + Sotorasib		Recruiting	NCT04185883	CodeBreak 101	ECD	01-MAY-23	Yes	No		4	NCT04185883			Maximum tolerated dose/toxicity	1003	1003																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	EGFR inhibitor + Sotorasib		Recruiting	NCT04185883	CodeBreak 101	ECD	01-MAY-23	Yes	No		4	NCT04185883			Maximum tolerated dose/toxicity	1003	1003																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	PD-L1 inhibitor + Sotorasib		Recruiting	NCT04185883	CodeBreak 101	ECD	01-MAY-23	Yes	No		4	NCT04185883			Maximum tolerated dose/toxicity	1003	1003																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	Pan-ErbB tyrosine kinase inhibitor  + Sotorasib		Recruiting	NCT04185883	CodeBreak 101	ECD	01-MAY-23	Yes	No		4	NCT04185883			Maximum tolerated dose/toxicity	1003	1003																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	SHP2 allosteric inhibitor + Sotorasib		Recruiting	NCT04185883	CodeBreak 101	ECD	01-MAY-23	Yes	No		4	NCT04185883			Maximum tolerated dose/toxicity	1003	1003																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 1	PD1 inhibitor  + Sotorasib		Recruiting	NCT04185883	CodeBreak 101	ECD	01-MAY-23	Yes	No		4	NCT04185883			Maximum tolerated dose/toxicity	1003	1003																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 2	MRTX849		Recruiting	NCT03785249		ECD	01-DEC-21	Yes	No		4	NCT03785249			Maximum tolerated dose/toxicity	391	391																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 2	MRTX849 + TNO155		Recruiting	NCT04330664	KRYSTAL 2	ECD	01-SEP-22	Yes	No		4	NCT04330664			Maximum tolerated dose/toxicity	148	148																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 2	D1553		Not yet recruiting	NCT04585035		ECD	01-NOV-22	Yes	No		4	NCT04585035			Maximum tolerated dose/toxicity	200	200																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 2	Lifirafenib + Mirdametinib		Recruiting	NCT03905148		ECD	01-AUG-22	Yes	No		4	NCT03905148			Maximum tolerated dose/toxicity	75	75																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 2	Erlotinib + LY3499446		Terminated	NCT04165031		PCD	01-OCT-20	Yes	Yes	Unexpected toxicity	4	NCT04165031			PFS, ORR	5	5																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 2	Cetuximab + LY3499446		Terminated	NCT04165031		PCD	01-OCT-20	Yes	Yes	Unexpected toxicity	4	NCT04165031			PFS, ORR	5	5																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 2	Abemaciclib + LY3499446		Terminated	NCT04165031		PCD	01-OCT-20	Yes	Yes	Unexpected toxicity	4	NCT04165031			PFS, ORR	5	5																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	NS / other / neoplasm	3	Phase 2	LY3499446		Terminated	NCT04165031		PCD	01-OCT-20	Yes	Yes	Unexpected toxicity	4	NCT04165031			PFS, ORR	5	5																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	lung / carcinoma / non small cell carcinoma	3	Phase 1	Sotorasib		Recruiting	NCT04380753	CodeBreak 105	ECD	01-OCT-21	Yes	No		4	NCT04380753			Maximum tolerated dose/toxicity	12	12																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	lung / carcinoma / non small cell carcinoma	3	Phase 2	Sotorasib		Recruiting	NCT03600883		ECD	01-NOV-21	Yes	No		4	NCT03600883	Untreated		Overall Response Rate	533	533																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	lung / carcinoma / non small cell carcinoma	3	Phase 2	MRTX849 + Pembrolizumab		Not yet recruiting	NCT04613596	KRYSTAL-7	ECD	01-OCT-22	Yes	No		4	NCT04613596			Overall Response Rate	120	120																																								
KRAS	KRAS_G12C	55497469 + 55544089 + 55952092		p.G12C	lung / carcinoma / non small cell carcinoma	3	Phase 3	Docetaxel + Sotorasib		Recruiting	NCT04303780	CodeBreak 200	ECD	01-NOV-21	Yes	No		4	NCT04303780			Progression free survival	650			Docetaxel																																						
KRAS	KRAS_G12D	55497369 + 55865099		p.G12D	NS / other / neoplasm	3	Phase 1	TAS0612		Recruiting	NCT04586270	Cohort E	ECD	01-JUN-23	Yes	No		4	NCT04586270			Overall Response Rate	200	200																																								
KRAS	KRAS_G12D	55497369 + 55865099		p.G12D	NS / other / neoplasm	3	Phase 2	Aldesleukin + Anti-RAS G12D TCR + Cyclophosphamide + Fludarabine		Suspended	NCT03745326		ECD	01-DEC-27	Yes	No		4	NCT03745326			Response rate	4	4																																								
KRAS	KRAS_G12D	55497369 + 55865099		p.G12D	large intestine / carcinoma / adenocarcinoma	4	Case study	Pembrolizumab + T-cell transfer 		Completed	NCT01174121		ECD	01-DEC-23	Yes	Yes		1	27959684			Unknown	1	1																															1									
KRAS	KRAS_G12D	55497369 + 55865099		p.G12D	large intestine / carcinoma / adenocarcinoma	4	Case study	MK-8353 + Pembrolizumab		Terminated	NCT01358331		PCD	01-MAY-14	Yes	Yes		1	29467321			Unknown	1	1																															1									
KRAS	KRAS_G12D	55497369 + 55865099		p.G12D	pancreas / carcinoma / NS	3	Phase 1	KRAS G12D siRNA exosomes		Not yet recruiting	NCT03608631		ECD	01-MAR-22	Yes	No		4	NCT03608631			Maximum tolerated dose/toxicity	28	28																																								
KRAS	KRAS_G12R	55497582 + 55539054		p.G12R	pancreas / carcinoma / NS	3	Phase 2	Selumetinib		Active, not recruiting	NCT03040986		ECD	01-DEC-21	Yes	No		4	NCT03040986			Overall Response Rate	180	180																																								
KRAS	KRAS_G12V	55497419 + 55556696 + 55588774		p.G12V	NS / other / neoplasm	3	Phase 2	Aldesleukin + Anti-RAS G12V TCR + Cyclophosphamide + Fludarabine		Suspended	NCT03190941		ECD	01-JUN-27	Yes	No		4	NCT03190941			Response rate	6	6																																								
KRAS	KRAS_G12V	55497419 + 55556696 + 55588774		p.G12V	pancreas / carcinoma / NS	3	Phase 2	Anti-PD-1 monoclonal antibody + Cyclophosphamide + Fludarabine + KRAS G12V-specific TCR transduced autologous T cells		Recruiting	NCT04146298		ECD	01-DEC-22	Yes	No		4	NCT04146298			Overall Response Rate	30	30																																								
KRAS	KRAS_unspecified				NS / malignant melanoma / NS	3	Phase 1	Atezolizumab + Cobimetinib		Completed	NCT01988896		PCD	01-NOV-19	Comparison with wt	Yes		1	30918950				82	57	25		9	8																																				
KRAS	KRAS_unspecified				NS / malignant melanoma / NS	3	Phase 2	Carboplatin + Paclitaxel + Pelareorep		Completed	NCT00984464	REO 020	PCD	01-FEB-14	No	Yes		1	28289863			Overall Response Rate	14	14			21																					43.0							3									
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 1	AZD4785		Completed	NCT03101839		PCD	01-JAN-19	Yes	Yes	Development discontinued	3	https://www.evaluate.com/vantage/articles/news/trial-results/astras-first-attempt-fails-theres-no-giving-kras			Maximum tolerated dose/toxicity	28	28																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 1	SCB313		Recruiting	NCT03869697		ECD	01-SEP-21	Yes	No		4	NCT03869697			Maximum tolerated dose/toxicity	16	16																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 1	HLX55		Recruiting	NCT04169178		ECD	01-DEC-22	Yes	No		4	NCT04169178			Overall Response Rate	98	98																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 1	Neratinib + Trametinib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 1	Neratinib + Palbociclib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 1	Everolimus + Neratinib		Recruiting	NCT03065387		ECD	01-OCT-22	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	120	120																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 1	KO-947		Active, not recruiting	NCT03051035		ECD	01-DEC-20	No	No		4	NCT03051035			Maximum tolerated dose/toxicity	100	100																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 1	ASN007		Completed	NCT03415126		PCD	01-JUN-20	No	No		4	NCT03415126			Overall Response Rate	49	49																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 1	Binimetinib + Dactolisib		Completed	NCT01337765		PCD	01-MAR-13	No	No		4	NCT01337765			Maximum tolerated dose/toxicity	29	29																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 1	BI 1701963		Not yet recruiting	NCT04111458		ECD	01-FEB-21	Yes	No		4	NCT04111458	Previously-treated		Maximum tolerated dose/toxicity	140	140																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 2	Sorafenib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 2	Atezolizumab + Cobimetinib + Hydroxychloroquine		Recruiting	NCT04214418	MEKiAUTO	ECD	01-SEP-22	Yes	No		4	NCT04214418			Maximum tolerated dose/toxicity	175	175																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 2	Canagliflozin + Serabelisib		Not yet recruiting	NCT04073680		ECD	01-JUL-21	Yes	No		4	NCT04073680			Response rate	60	60																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 2	Cobimetinib + RMC4630		Recruiting	NCT03989115		ECD	01-MAR-22	Yes	No		4	NCT03989115			Maximum tolerated dose/toxicity	168	168																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 2	Ascorbic acid		Recruiting	NCT03146962		ECD	01-JUN-21	No	No		4	NCT03146962			Disease control rate, Clinical benefit rate	50	50																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 2	Dubermatinib		Recruiting	NCT02729298		ECD	01-DEC-21	Yes	No		4	NCT02729298			Maximum tolerated dose/toxicity	177	177																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 2	Navitoclax + Trametinib		Recruiting	NCT02079740		ECD	01-MAR-21	Yes	No		4	NCT02079740			PFS, ORR	130	130																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 2	Adavosertib + Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	No	No		4	NCT02576444			Overall Response Rate	64	64																																								
KRAS	KRAS_unspecified				NS / other / neoplasm	3	Phase 2	Selumetinib		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
KRAS	KRAS_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Capecitabine + Gemcitabine + Oxaliplatin + Panitumumab		Completed	NCT00779454		PCD	01-MAR-16	Yes	No		4	NCT00779454			Progression free survival	72	72																																								
KRAS	KRAS_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Hydroxychloroquine + Trametinib		Not yet recruiting	NCT04566133		ECD	01-DEC-23	Yes	No		4	NCT04566133			Progression free survival	30	30																																								
KRAS	KRAS_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Capecitabine + Gemcitabine + Oxaliplatin		Completed	NCT00779454		PCD	01-MAR-16	Comparison with wt	Yes		1	31838939				24	13	11										3.1	9.8			0.12									8.4	14.3			0.18												
KRAS	KRAS_unspecified				breast / carcinoma / NS	3	Phase 2	Paclitaxel + Pelareorep		Completed	NCT01656538	IND213	PCD	01-NOV-16	No	Yes		5	https://immuno-oncologynews.com/reolysin/			Progression free survival	81	81																								17.4	10.4	.65	0.46-0.91	0.1												
KRAS	KRAS_unspecified				central nervous system / glioma / NS	3	Phase 1	Pelareorep		Completed	NCT00528684	REO 007	PCD	01-APR-10	No	Yes		1	24553100			Maximum tolerated dose/toxicity	15	15																2															1	10								
KRAS	KRAS_unspecified				central nervous system / glioma / NS	3	Phase 1	Pelareorep		Completed					No	Yes		1	18253152			Clinical activity	12	12																.99																1								
KRAS	KRAS_unspecified				central nervous system / glioma / astrocytoma	3	Phase 1	Pelareorep + Sargramostim		Active, not recruiting	NCT02444546	MC1472	PCD	01-JUL-18	No	No		4	NCT02444546			Maximum tolerated dose/toxicity	6	6																																								
KRAS	KRAS_unspecified				endometrium / carcinoma / NS	3	Phase 2	Everolimus		Completed	NCT00870337		PCD	01-MAY-11	Comparison with wt	Yes		1	23238879			Progression free survival	31	4	27										1.05	3.12			<0.001									2.3	9.3			0.034												
KRAS	KRAS_unspecified				endometrium / carcinoma / NS	3	Phase 2	Lifirafenib + Mirdametinib		Recruiting	NCT03905148		ECD	01-AUG-22	Yes	No		4	NCT03905148			Maximum tolerated dose/toxicity	75	75																																								
KRAS	KRAS_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Capecitabine + Cetuximab + Cisplatin		Completed	NCT00477711	EXTRA	PCD	01-DEC-08	No	No		4	NCT00477711	Untreated		Response rate	41	41																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	2	2	2	Cytarabine	0	0																																				
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Selumetinib		Completed	NCT00588809		PCD	01-APR-12	Yes	Yes	No benefit of treatment	1	24178622	Previously-treated		Response rate	1	1			0																																					
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Ruxolitinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / juvenile myelomonocytic leukaemia	3	Phase 2	Etanercept		Terminated	NCT00509600		PCD	01-APR-09	Yes	Yes	Slow accrual	4	NCT00509600			Response rate	1	1																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Out of trials human study	Bortezomib		Unknown					Comparison with wt	Yes		1	24335104			Unknown	74	17	57		53	40																																				
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Out of trials human study	Dexamethasone		Unknown					Comparison with wt	Yes		1	24335104			Unknown	31	9	22		33	36																																				
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Dabrafenib + Trametinib		Recruiting	NCT03091257		ECD	01-DEC-20	Yes	No		4	NCT03091257	Previously-treated		Progression free survival	60	60																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Carfilzomib + Dexamethasone + Nivolumab + Pelareorep		Recruiting	NCT03605719	IRB00104234	ECD	01-OCT-21	No	No		4	NCT03605719			Maximum tolerated dose/toxicity	62	62																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Carfilzomib + Dexamethasone + Pelareorep		Recruiting	NCT02101944	OSU-14031	ECD	01-OCT-21	No	Yes		2	10.1200/JCO.2020.38.15_suppl.8535			Maximum tolerated dose/toxicity	28	28																															2	2								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Pelareorep		Completed	NCT01533194	NCI-2012-00248	PCD	01-FEB-15	No	Yes	No benefit of treatment	1	25294913	Previously-treated		Maximum tolerated dose/toxicity	12	12																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Pelareorep + Pomalidomide		Active, not recruiting	NCT03015922		ECD	01-SEP-21	No	No		4	NCT03015922	Previously-treated		Maximum tolerated dose/toxicity	4	4																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Lenalidomide + Pelareorep		Active, not recruiting	NCT03015922		ECD	01-SEP-21	No	No		4	NCT03015922	Previously-treated		Maximum tolerated dose/toxicity	4	4																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Bortezomib + Dexamethasone + Pelareorep		Active, not recruiting	NCT02514382	REO 019	ECD	01-FEB-19	No	Yes		3	http://www.bloodjournal.org/content/128/22/4507?sso-checked=true			Maximum tolerated dose/toxicity	6	6																																3								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Trametinib		Recruiting	NCT03091257		ECD	01-DEC-20	Yes	No		4	NCT03091257	Previously-treated		Progression free survival	60	60																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Pelareorep		Completed	NCT00651157	NCI-2009-00233	PCD	01-DEC-11	No	Yes	Primary outcome not met	4	NCT00651157			Overall Response Rate	23	23																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Afuresertib + Bortezomib		Withdrawn	NCT01445587		PCD	01-NOV-11	No	Yes	No benefit of treatment	4	NCT01445587			Maximum tolerated dose/toxicity	0	0																																								
KRAS	KRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide		Recruiting	NCT03732703	MyDRUGSubProtocol C1	ECD	01-FEB-22	Yes	No		4	NCT03732703			Overall Response Rate	228	228																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Case study	Pembrolizumab + T-cell transfer 		Unknown	NCT02933944				Yes	Yes		1	27959684			Unknown	1	1																															1									
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Atezolizumab + Cobimetinib		Completed	NCT01988896		PCD	01-NOV-19	Yes	Yes		1	30918950			Maximum tolerated dose/toxicity	57	57			9		3-29						2			1.8-2.6										9.5			6.0-17.6				5	12								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Siremadlin + Trametinib		Recruiting	NCT03714958	TRAHD	ECD	01-FEB-21	No	No		4	NCT03714958			Maximum tolerated dose/toxicity	24	24																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	5-Fluorouracil + Radiotherapy + Trametinib		Active, not recruiting	NCT01740648		ECD	01-DEC-21	No	Yes		1	32253228			Maximum tolerated dose/toxicity	18	18																														3			88.9							
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Adavosertib + Irinotecan		Recruiting	NCT02906059		PCD	01-MAR-20	Yes	No		4	NCT02906059			Maximum tolerated dose/toxicity	7	7																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	FOLFOX-6 + Selinexor		Completed	NCT02384850	SENTINEL	PCD	01-MAR-17	No	Yes	Primary outcome not met	1	32598257			Unknown	10	10																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	MK-8353 + Pembrolizumab		Recruiting	NCT02972034		ECD	01-MAR-23	No	No		4	NCT02972034			Maximum tolerated dose/toxicity	182	182																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Selinexor		Unknown	NCT02137356		ECD	01-JUN-17	No	No		4	NCT02137356			Maximum tolerated dose/toxicity	28	28																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Bevacizumab + FOLFIRI + Pelareorep		Completed	NCT01274624	REO 022	ECD	01-OCT-19	Yes	Yes		5	https://www.oncolyticsbiotech.com/press-releases/detail/434/oncolytics-biotech-announces-positive-clinical-trial	Untreated		Maximum tolerated dose/toxicity	6	6												15.1												24.8							3									
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFOX + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Nivolumab + SX682		Recruiting	NCT04599140	STOPTRAFFIC-1	ECD	01-JAN-24	Yes	No		4	NCT04599140			Maximum tolerated dose/toxicity	53	53																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Atezolizumab + Cobimetinib + Hydroxychloroquine		Recruiting	NCT04214418	MEKiAUTO	ECD	01-SEP-22	Yes	No		4	NCT04214418			Maximum tolerated dose/toxicity	175	175																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + FOLFIRI + Onvansertib		Recruiting	NCT03829410		ECD	01-MAY-22	Yes	No		4	NCT03829410			Overall Response Rate	44	44																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Plocabulin		Unknown	NCT03427268		ECD	01-OCT-19	No	Yes	3m PFS 20.7% (95% CI 8.0-39.7) 	8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000257-39/results#endPointsSection	Previously-treated		Progression free survival	29	29											2.6			1.3-2.8										9.8			4.6-999 					9								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Folfirinox		Unknown	NCT01442935		PCD	01-DEC-15	No	No		4	NCT01442935			Percent of patients who become resectable	256	256																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFIRI + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Binimetinib + Palbociclib		Recruiting	NCT03981614		ECD	01-DEC-22	Yes	No		4	NCT03981614			Progression free survival	112	112																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Panitumumab + Trametinib		Recruiting	NCT03087071		ECD	01-DEC-21	Yes	No		4	NCT03087071			Response rate	84	84																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Sorafenib		Completed	NCT00326495		PCD	01-NOV-14	No	Yes	No benefit of treatment	1	25861837			Disease control rate, Clinical benefit rate	51	51																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + FOLFOX-6 + Pelareorep		Completed	NCT01622543	IND 210	PCD	01-JAN-17	No	Yes		4	NCT01622543			Progression free survival	103	51	52	Bevacizumab + FOLFOX-6	52.9	34.6		0.06					7.33	9.13	1.59	1.00-2.53	0.046									19.3	20			0.36												
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Pembrolizumab + T-cell transfer 		Suspended	NCT01174121		ECD	01-DEC-23	No	No		4	NCT01174121			Unknown	91																																									
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFOX-6 + Sorafenib		Completed	NCT00865709	RESPECT	PCD	01-MAR-09	No	Yes	No benefit of treatment, no effect of KRAS or BRAF mutation status	1	23532888			Progression free survival	198	97	101	Placebo									9.1	8.7	.88		0.23									17.5	18.2															
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFOX-4		Unknown	NCT01442935		PCD	01-DEC-15	No	No		4	NCT01442935			Percent of patients who become resectable	256	256																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + Sorafenib		Unknown	NCT01715441	NEXIRI 2-PRODIGE 27	ECD	01-MAR-15	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.3545	Previously-treated		Progression free survival	104	57	57	Sorafenib									3.7	2.1												7.0	5.1															
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + Sorafenib		Unknown	NCT01715441	NEXIRI 2-PRODIGE 27	ECD	01-MAR-15	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.3545	Previously-treated		Progression free survival	103	57	56	Irinotecan									3.7	1.9												7.0	6.3															
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cabozantinib		Active, not recruiting	NCT03542877		ECD	01-MAR-22	No	No		4	NCT03542877	Previously-treated		Progression free survival	43	43																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFIRI		Unknown	NCT01442935		PCD	01-DEC-15	No	No		4	NCT01442935			Percent of patients who become resectable	256	256																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04189055	CETIDYL	ECD	01-APR-21	Yes	No		4	NCT04189055			Response rate	72	72		FOLFIRI																																						
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab		Not yet recruiting	NCT02942706	BLOC-1	ECD	01-OCT-21	Yes	No		4	NCT02942706			Progression free survival	200			FOLFIRI																																						
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Atezolizumab + Cobimetinib		Completed	NCT02788279	IMblaze370	PCD	01-MAR-18	No	Yes	Primary outcome not met	1	31003911	Previously-treated		Overall survival	273	183	90	Regorafenib																						8.87	8.51			0.987												
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Bevacizumab		Completed	NCT00109070		PCD	01-APR-03	No	Yes	Response not correlated with mutation status	1	19144677	Untreated		Unknown	230																																									
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 4	Bevacizumab		Unknown					Yes	Yes	Response not correlated with mutation status	1	29085005			Unknown	141	141																																								
KRAS	KRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Unknown	FOLFIRI + Regorafenib		Completed	NCT03698253		PCD	01-JUN-18	Comparison with wt	Yes		1	30594039	Previously-treated		Progression free survival	41	23	18																				47.8	72.2		6.0	14.4	.4	0.18-0.86	0.014												
KRAS	KRAS_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	Refametinib + Sorafenib		Completed	NCT01915602		PCD	01-JUL-15	Yes	No		4	NCT01915602			Overall Response Rate	14	14																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Binimetinib + Erlotinib		Active, not recruiting	NCT01859026		PCD	01-AUG-19	Yes	No		4	NCT01859026			Maximum tolerated dose/toxicity	43	43																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Pembrolizumab + Trametinib		Recruiting	NCT03299088		ECD	01-APR-21	Yes	No		4	NCT03299088			Maximum tolerated dose/toxicity	42	42																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	RO4987655		Unknown					Yes	No		1	24947927			Unknown	18	18																															2									
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Binimetinib + Docetaxel		Withdrawn	NCT02451865		ECD	01-JUN-18	No	No		4	NCT02451865			Maximum tolerated dose/toxicity	0	0																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	LTT462  + LXH254		Recruiting	NCT02974725		ECD	01-JAN-22	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	195	195																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	LXH254 + Trametinib		Recruiting	NCT02974725		ECD	01-JAN-22	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	195	195																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	LXH254 + Ribociclib		Recruiting	NCT02974725		ECD	01-JAN-22	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	195	195																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Momelotinib + Trametinib		Terminated	NCT02258607		PCD	01-JUL-16	Yes	Yes		1	30087028	Previously-treated		Maximum tolerated dose/toxicity	21	21																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Atezolizumab + Cobimetinib		Completed	NCT01988896		PCD	01-NOV-19	Comparison with wt	Yes		1	30918950				24	12	12		8.0	33.0																																				
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Trametinib		Completed	NCT01362296		PCD	01-SEP-12	Yes	Yes	Response not correlated with mutation status	1	25722381			Progression free survival	129	86	43	Docetaxel									11.7	11.4	1.14		0.52																									
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Selumetinib		Completed	NCT01229150		PCD	01-SEP-13	Yes	Yes		4	NCT01229150				41	30	11	Selumetinib	10	0							2.3	4			0.24						43	89		21.8	10.5			0.81												
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Nivolumab + Rigosertib		Recruiting	NCT04263090		ECD	01-JAN-22	Yes	No		4	NCT04263090			Overall Response Rate	30	30																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Defactinib		Recruiting	NCT04620330		ECD	01-MAR-23	Yes	No		4	NCT04620330			Overall Response Rate	100	100																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Lifirafenib + Mirdametinib		Recruiting	NCT03905148		ECD	01-AUG-22	Yes	No		4	NCT03905148			Maximum tolerated dose/toxicity	75	75																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ponatinib + Trametinib		Active, not recruiting	NCT03704688		ECD	01-APR-21	Yes	No		4	NCT03704688			Overall Response Rate	12	12																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pembrolizumab + Trametinib		Active, not recruiting	NCT03225664		ECD	01-SEP-21	No	No		4	NCT03225664			Overall Response Rate	37	37																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Apatinib + Camrelizumab		Not yet recruiting	NCT03777124		ECD	01-APR-20	Yes	No		4	NCT03777124			Progression free survival	230	230																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Yes	Yes		4	NCT00265317			Progression free survival	65	67		Erlotinib + Placebo									4.64	1.73																												
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Spartalizumab		Recruiting	NCT03693326		ECD	01-JUN-20	Yes	No		4	NCT03693326			Overall Response Rate	70	70																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Durvalumab + Pemetrexed		Not yet recruiting	NCT04470674		ECD	01-OCT-23	Yes	No		4	NCT04470674			Disease free survival, relapse free survival, regression free survival, recurrence free survival	50	50																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		Completed	NCT02276027		PCD	01-OCT-19	Yes	Yes		4	NCT02276027			Overall Response Rate	22	22			9.1																																					
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Durvalumab		Not yet recruiting	NCT04470674		ECD	01-OCT-23	Yes	No		4	NCT04470674			Disease free survival, relapse free survival, regression free survival, recurrence free survival	50	50																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Methotrexate		Recruiting	NCT03520842		ECD	01-JAN-21	Yes	No		4	NCT03520842			Progression free survival	18	18																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Tivantinib		Completed	NCT01395758		PCD	01-AUG-16	Yes	Yes	No benefit of treatment - OS and ORR were greater with control	4	NCT01395758	Previously-treated		Progression free survival	96			Placebo																																						
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Afatinib + Selumetinib		Unknown	NCT02450656		ECD	01-MAY-19	No	No		4	NCT02450656			Progression free survival	320	320																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Paclitaxel + Pelareorep		Completed	NCT00861627	REO 016	PCD	01-SEP-15	No	Yes		1	29748010	Previously-treated		Overall Response Rate	37	37											4			2.9-6.1										13.1			9.2-21.6													
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Docetaxel + Pelareorep		Completed	NCT01708993	IND211	PCD	01-OCT-15	No	Yes	No benefit of treatment	1	29748010	Previously-treated		Progression free survival	166	166																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Pelareorep + Pemetrexed		Completed	NCT01708993	IND211	PCD	01-OCT-15	No	Yes	No benefit of treatment	1	29748010	Previously-treated		Progression free survival	166	166											3	2.8	.9	0.65-1.25	0.53																									
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Docetaxel + Selinexor		Recruiting	NCT03095612		ECD	01-MAY-21	No	Yes		4	NCT03095612	Previously-treated		Maximum tolerated dose/toxicity	59	59																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Salirasib		Completed	NCT00531401		PCD	01-NOV-09	Yes	Yes	No benefit of treatment	1	21847063			Unknown	30	30																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	TVB2640		Recruiting	NCT03808558		ECD	01-DEC-21	Yes	No		4	NCT03808558			Overall Response Rate	12	12																																								
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Sorafenib		Unknown		BATTLE-2			No	Yes	Response not correlated with mutation or expression status	1	27480147	Previously-treated		Unknown																																										
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Abemaciclib		Active, not recruiting	NCT02152631	JUNIPER	PCD	01-SEP-17	No	Yes	Primary outcome not met	3	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9025	Previously-treated		Overall survival	453	270	183	Erlotinib	8.9	2.7		0.01					3.6	1.9	.58	0.47-0.72	p < 0.001																									
KRAS	KRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Sorafenib		Completed	NCT00863746	MISSION	PCD	01-MAR-12	No	Yes	Response not correlated with mutation or expression status	1	26743856	Previously-treated		Overall survival	703	350	353	Placebo									2.8	1.4	.61	0.51-0.72	p<0.0001	2.9	1.4	.54	0.45-0.65	<0.0001																				
KRAS	KRAS_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Carboplatin + Paclitaxel + Pelareorep		Completed	NCT00998192	REO 021	PCD	01-SEP-13	No	Yes		3	http://mct.aacrjournals.org/content/12/11_Supplement/C70	Previously-treated		Overall Response Rate	25	25																															12	10								
KRAS	KRAS_unspecified				ovary / carcinoma / NS	3	Phase 1	Alpelisib + Binimetinib		Completed	NCT01449058		PCD	01-AUG-16	No	Yes		2	10.1200/jco.2014.32.15_suppl.9051			Maximum tolerated dose/toxicity	139	139																																								
KRAS	KRAS_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 1	Pelareorep		Completed	NCT00602277	OSU-07022	PCD	01-AUG-16	No	No		4	NCT00602277	Previously-treated		Maximum tolerated dose/toxicity	70	70																																								
KRAS	KRAS_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 2	Paclitaxel + Pelareorep		Active, not recruiting	NCT01199263	GOG-0186H	PCD	01-JAN-15	No	Yes		5	https://ir.oncolyticsbiotech.com/press-releases/detail/9/oncolytics-biotech-inc-reports-data-from-randomized			Progression free survival	108	54	54	Paclitaxel																												5	7	12								
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 1	siG12D-LODER		Completed	NCT01188785		PCD	01-DEC-13	No	Yes		4	NCT01188785			Unknown	12	12											15.2													38.5							2	10								
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 1	Binimetinib + Hydroxychloroquine		Recruiting	NCT04132505		ECD	01-DEC-21	Yes	No		4	NCT04132505			Maximum tolerated dose/toxicity	39	39																																								
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 1	Pelareorep + Pembrolizumab		Completed	NCT02620423	REO 024	PCD	01-MAR-18	No	Yes		3	http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e15753			Unknown	11	11																															1	2								
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	FOLFIRI		Not yet recruiting	NCT04348045		ECD	01-DEC-22	Yes	No		4	NCT04348045			Progression free survival	307	307																																								
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	Durvalumab + Selumetinib		Not yet recruiting	NCT04348045		ECD	01-DEC-22	Yes	No		4	NCT04348045			Progression free survival	307	307																																								
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	Atezolizumab + Cobimetinib + Hydroxychloroquine		Recruiting	NCT04214418	MEKiAUTO	ECD	01-SEP-22	Yes	No		4	NCT04214418			Maximum tolerated dose/toxicity	175	175																																								
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	NALIRINOX		Recruiting	NCT04010552		ECD	01-AUG-21	No	No		4	NCT04010552			Response rate	20	20																																								
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	Gemcitabine + Pelareorep		Completed	NCT00998322	REO 017	PCD	01-DEC-13	No	Yes		1	29799479			Disease control rate, Clinical benefit rate	34	34																								10.2							1	23								
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	Sargramostim + TG01		Unknown					Yes	Yes		1	20473937			Unknown	13	13																								27.5																
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	Gemcitabine + Sargramostim + TG01		Active, not recruiting	NCT02261714		PCD	01-JUN-18	No	Yes		5	https://www.targovax.com/Pipeline/TG--Neo-antigen-Cancer-Vaccine/default.aspx			Maximum tolerated dose/toxicity	19	19																								33.1																
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	GI-4000 + Gemcitabine		Unknown	NCT00300950		PCD	01-FEB-15	No	Yes		5	https://globeimmune.com/wp-content/uploads/2012/04/Richards-ESMO-GI-2012-oral-poster-6-27-12.pdf			OS, PFS	176			Gemcitabine																						17.2	14.6															
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	Gemcitabine + Nab-paclitaxel + Selinexor		Active, not recruiting	NCT02178436		ECD	01-DEC-22	No	No		4	NCT02178436			Maximum tolerated dose/toxicity	56	56																																								
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	siG12D-LODER		Unknown	NCT01676259	PROTACT	ECD	01-NOV-19	No	No		2	10.1200/JCO.2020.38.15_suppl.TPS4672			Progression free survival	39	39		Chemotherapy																																						
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 2	Carboplatin + Paclitaxel + Pelareorep		Completed	NCT01280058	NCI-8601	PCD	01-JAN-16	No	Yes	PFS, OS greater for control	1	27039845			Progression free survival	73	36	37	Carboplatin + Paclitaxel									4.9	5.2												7.3	8.8															
KRAS	KRAS_unspecified				pancreas / carcinoma / NS	3	Phase 3	Gemcitabine + Rigosertib		Completed	NCT01360853		PCD	01-JUN-15	No	Yes	No benefit of treatment	1	26091808			Overall survival	106	106																																								
KRAS	KRAS_unspecified				prostate / carcinoma / NS	7	Phase 2	Docetaxel + Pelareorep + Prednisone		Completed	NCT01619813	IND209	PCD	01-APR-16	No	Yes	No benefit of treatment	1	29487723			Progression free survival	85	85																																								
KRAS	KRAS_unspecified				soft tissue / sarcoma / NS	3	Phase 2	Pelareorep		Completed	NCT00503295	REO 014	PCD	01-FEB-11	No	Yes		5	https://www.oncolyticsbiotech.com/press-releases/detail/142/oncolytics-biotech-inc-investigators-present-interim-u-s			Disease control rate, Clinical benefit rate	53	53																																11								
KRAS	KRAS_unspecified				soft tissue / sarcoma / NS	3	Phase 3	Trametinib		Recruiting	NCT03784014	MULTISARC	ECD	01-OCT-22	No	No		4	NCT03784014			Unknown	960	960																																								
KRAS	KRAS_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 1	Cetuximab + Selumetinib		Completed	NCT01217450		PCD	01-DEC-12	No	Yes		1	26666244			Maximum tolerated dose/toxicity	33	33																																1								
KRAS	KRAS_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Carboplatin + Paclitaxel + Pelareorep		Completed	NCT00753038	REO 015	PCD	01-JUL-11	No	Yes		3	http://mct.aacrjournals.org/content/10/11_Supplement/C22			Overall Response Rate	13	13																															4	2								
KRAS	KRAS_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2			Completed	NCT02643056	S10PANI01	PCD	01-DEC-15	No	Yes		1	28592616	Previously-treated		Overall Response Rate	33	33			6								2.6										51			9.7							2	15								
KRAS	KRAS_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 3	Carboplatin + Paclitaxel + Pelareorep		Completed	NCT01166542	REO 018	PCD	01-APR-12	No	No		4	NCT01166542			Overall survival	167			Carboplatin + Paclitaxel																																						
KRAS	KRAS_unspecified, TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sintilimab		Recruiting	NCT03574402	TRUMP Arm 16	ECD	01-DEC-22	Yes	No		4	NCT03574402			Response rate	400	400																																								
MAP2K1	MAP2K1_unspecified				NS / neoplasm / NS	3	Phase 2	Cobimetinib		Recruiting	NCT04185831	MEGALiT	ECD	01-DEC-22	Yes	No		4	NCT04185831			Overall Response Rate	154	154																																								
MAP2K1	MAP2K1_unspecified				NS / neoplasm / NS	3	Phase 2	Abemaciclib + LY3214996		Not yet recruiting	NCT04534283		ECD	01-SEP-21	Yes	No		4	NCT04534283			Overall Response Rate	35	35																																								
MAP2K1	MAP2K1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFIRI + Panitumumab		Active, not recruiting	NCT01312857		ECD	01-MAR-21	No	No		4	NCT01312857			Disease free survival, relapse free survival, regression free survival, recurrence free survival	75	75																																								
MAP2K2	MAP2K2_unspecified				NS / neoplasm / NS	3	Phase 2	Abemaciclib + LY3214996		Not yet recruiting	NCT04534283		ECD	01-SEP-21	Yes	No		4	NCT04534283			Overall Response Rate	35	35																																								
MAPK1	MAPK1_unspecified				NS / neoplasm / NS	3	Phase 2	Abemaciclib + LY3214996		Not yet recruiting	NCT04534283		ECD	01-SEP-21	Yes	No		4	NCT04534283			Overall Response Rate	35	35																																								
MAPK3	MAPK3_unspecified				NS / neoplasm / NS	3	Phase 2	Abemaciclib + LY3214996		Not yet recruiting	NCT04534283		ECD	01-SEP-21	Yes	No		4	NCT04534283			Overall Response Rate	35	35																																								
MDM2	MDM2_unspecified				soft tissue / liposarcoma / NS	3	Phase 2	APG115 + Pembrolizumab		Recruiting	NCT03611868		ECD	01-DEC-21	Expression level	No		4	NCT03611868			Overall Response Rate	143	143																																								
MERTK	MERTK_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
MET	MET_N375S	59260365		p.N375S	large intestine / carcinoma / adenocarcinoma	3	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Expression level	Yes		2	10.1200/jco.2015.33.15_suppl.2595			Overall Response Rate	10	10																																2								
MET	MET_N375S	59260365		p.N375S	lung / carcinoma / squamous cell carcinoma	3	Phase 2	Afatinib		Not yet recruiting	NCT04533321		ECD	01-SEP-23	Yes	No		4	NCT04533321	Previously-treated		Unknown	20	20																																								
MET	MET_unspecified				NS / malignant melanoma / NS	3	Phase 2	Capmatinib		Terminated	NCT02587650		PCD	01-JUL-18	Yes	Yes	Lack of funding	4	NCT02587650			Overall Response Rate	1	1																																								
MET	MET_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
MET	MET_unspecified				NS / other / neoplasm	3	Phase 2	Oxazolidine		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
MET	MET_unspecified				NS / other / neoplasm	3	Phase 2	Crizotinib		Recruiting	NCT02693535	TAPUR group 3	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
MET	MET_unspecified				NS / other / neoplasm	3	Phase 2	Crizotinib		Recruiting	NCT03297606	CAPTUR group 3	ECD	01-SEP-21	Yes	No		4	NCT03297606			Overall Response Rate	720	720																																								
MET	MET_unspecified				autonomic ganglia / neuroblastoma / NS	3	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Yes	No		4	NCT02034981			Overall Response Rate	246	246																					40										4	8								
MET	MET_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
MET	MET_unspecified				endometrium / carcinoma / NS	3	Phase 2	Crizotinib		Not yet recruiting	NCT04030429		ECD	01-FEB-21	Yes	No		4	NCT04030429 	Previously-treated		Overall Response Rate	40	40																																								
MET	MET_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Crizotinib		Active, not recruiting	NCT01524926	CREATE	PCD	01-DEC-17	Yes	Yes		1	29741569 			Clinical activity	26	26			3.8		0.1-19.6						4.31										69.2			9.11							1	17								
MET	MET_unspecified				kidney / carcinoma / papillary renal cell carcinoma	3	Phase 2	Crizotinib		Active, not recruiting	NCT01524926	CREATE	PCD	01-DEC-17	Yes	Yes		2	10.1200/JCO.2018.36.6_suppl.580			Clinical activity	4	4			50		6.8-93.7		21.9																								2	1								
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	No		4	NCT02219711			Maximum tolerated dose/toxicity	260	260																																								
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Cabozantinib		Active, not recruiting	NCT03468985		ECD	01-DEC-21	Yes	No		4	NCT03468985			Progression free survival	169	169																																								
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ensartinib		Recruiting	NCT03574402	TRUMP Arm 4	ECD	01-DEC-22	Expression level	No		4	NCT03574402			Response rate	400	400																																								
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		Completed	NCT02276027		PCD	01-OCT-19	Yes	Yes		4	NCT02276027			Overall Response Rate	16	16			18.8																																					
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Crizotinib		Recruiting	NCT03574402	TRUMP Arm 3	ECD	01-DEC-22	Yes	No		4	NCT03574402			Response rate	400	400																																								
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Yes	Yes		1	31584608			Overall Response Rate	28	28			10.7																																					
MET	MET_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Expression level	Yes		1	31584608			Overall Response Rate	25	25			16																																					
MET	MET_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Afatinib		Not yet recruiting	NCT04533321		ECD	01-SEP-23	Yes	No		4	NCT04533321	Previously-treated		Unknown	20	20																																								
MET	MET_unspecified				soft tissue / alveolar soft part sarcoma / NS	3	Phase 2	Crizotinib		Active, not recruiting	NCT01524926	CREATE	PCD	01-DEC-17	Yes	Yes		1	29216400			Clinical activity	40	40			2.5		0.6-80.6																90.0										1	35								
MET	MET_unspecified				soft tissue / rhabdomyosarcoma / alveolar	3	Phase 2	Crizotinib		Active, not recruiting	NCT01524926	CREATE	PCD	01-DEC-17	Yes	Yes		1	29567632			Clinical activity	7	7			14.3		0.3-57.8		1.7				1.3													5.6			0.7-7.0				1									
MLH1	MLH1_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
MLH3	MLH3_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
MLH3	MLH3_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
MLLT3	MLLT3-KMT2A fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Azacitidine + Belinostat		Not yet recruiting	NCT00351975		PCD	01-MAR-13	No	No		4	NCT04088188			Maximum tolerated dose/toxicity	56	56																																								
MLLT3	MLLT3-KMT2A fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Topotecan + Veliparib		Active, not recruiting	NCT00588991		PCD	01-FEB-14	No	No		4	NCT00588991			Maximum tolerated dose/toxicity	12	12																																								
MLLT3	MLLT3-KMT2A fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Carboplatin + Topotecan + Veliparib		Active, not recruiting	NCT00588991		PCD	01-FEB-14	No	No		4	NCT00588991			Maximum tolerated dose/toxicity	12	12																																								
MPL	MPL W515?			p.W515X	haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Pentraxin 2		Active, not recruiting	NCT01981850		PCD	01-JUL-20	No	No		4	NCT01981850			Clinical activity	125	125																																								
MRE11	MRE11_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
MRE11	MRE11_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
MRE11	MRE11_unspecified				NS / neoplasm / NS	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
MRE11	MRE11_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
MRE11	MRE11_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
MRE11	MRE11_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
MRE11	MRE11_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
MRE11	MRE11_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03009682	SUKSES-B	ECD	01-SEP-21	Yes	No		4	NCT03009682			Overall Response Rate	28	28																																								
MRE11	MRE11_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
MSH2	MSH2_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
MSH2	MSH2_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
MSH3	MSH3_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
MSH6	MSH6_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
MSH6	MSH6_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
MTOR	MTOR_unspecified				NS / other / neoplasm	3	Phase 1	Samotolisib		Completed	NCT03155620	Subprotocol D	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
MTOR	MTOR_unspecified				NS / other / neoplasm	3	Phase 2	Sapanisertib		Recruiting	NCT02465060	MATCH Subprotocol L	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
MTOR	MTOR_unspecified				NS / other / neoplasm	3	Phase 2	Temsirolimus		Recruiting	NCT02693535	TAPUR group 6	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
MTOR	MTOR_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Recruiting	NCT04185831	MEGALiT	ECD	01-DEC-22	Yes	No		4	NCT04185831			Overall Response Rate	154	154																																								
MTOR	MTOR_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
MTOR	MTOR_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
MYC	MYC_unspecified				NS / other / neoplasm	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
MYC	MYC_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 4A	ECD	01-APR-22	Expression level	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
NBN	NBN_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
NBN	NBN_unspecified				NS / neoplasm / NS	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
NBN	NBN_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
NBN	NBN_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
NBN	NBN_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
NBN	NBN_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
NBN	NBN_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
NBN	NBN_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
NBN	NBN_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
NBN	NBN_unspecified				prostate / carcinoma / NS	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
NBN	NBN_unspecified				prostate / carcinoma / NS	3	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
NBN	NBN_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
NF1	NF1_unspecified				NS / carcinoma / neuroendocrine carcinoma	3	Phase 2	Everolimus		Terminated	NCT02315625		PCD	01-MAY-19	No	Yes	Slow accrual	4	NCT02315625			Progression free survival	16	16																																								
NF1	NF1_unspecified				NS / malignant melanoma / NS	4	Case study	Trametinib		Unknown					Yes	Yes		2	10.1200/PO.18.00028			Unknown	1	1																															1									
NF1	NF1_unspecified				NS / neoplasm / NS	3	Phase 2	Trametinib		Recruiting	NCT02465060	MATCH Subprotocol S1	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
NF1	NF1_unspecified				NS / neoplasm / NS	3	Phase 2	Cobimetinib + RMC4630		Recruiting	NCT03989115		ECD	01-MAR-22	Yes	No		4	NCT03989115			Maximum tolerated dose/toxicity	168	168																																								
NF1	NF1_unspecified				NS / neoplasm / NS	3	Phase 2	Abemaciclib + LY3214996		Not yet recruiting	NCT04534283		ECD	01-SEP-21	Yes	No		4	NCT04534283			Overall Response Rate	35	35																																								
NF1	NF1_unspecified				NS / neoplasm / NS	3	Phase 2	Cobimetinib		Recruiting	NCT04185831	MEGALiT	ECD	01-DEC-22	Yes	No		4	NCT04185831			Overall Response Rate	154	154																																								
NF1	NF1_unspecified				NS / neoplasm / NS	3	Phase 2	Telaglenastat		Recruiting	NCT03872427		ECD	01-AUG-22	Yes	No		4	NCT03872427			Overall Response Rate	108	108																																								
NF1	NF1_unspecified				NS / neoplasm / NS	3	Phase 2	Everolimus		Completed	NCT02352844		PCD	01-AUG-17	Yes	No		4	NCT02352844			Response rate	12	12																																								
NF1	NF1_unspecified				NS / neoplasm / NS	3	Phase 2	Trametinib		Active, not recruiting	NCT04439318	MATCH-Subprotocol S1	PCD	01-DEC-19	Yes	No		4	NCT04439318			Overall Response Rate	50	50																																								
NF1	NF1_unspecified				breast / carcinoma / NS	3	Phase 1	TAS0612		Recruiting	NCT04586270	Cohort A	ECD	01-JUN-23	Yes	No		4	NCT04586270			Overall Response Rate	200	200																																								
NF1	NF1_unspecified				central nervous system / glioma / NS	3	Phase 2	MLN2480		Recruiting	NCT03429803		ECD	01-DEC-24	No	No		4	NCT03429803		Pediatric	Maximum tolerated dose/toxicity	53	53																																								
NF1	NF1_unspecified				central nervous system / glioma / NS	3	Phase 2	Dabrafenib + Hydroxychloroquine + Trametinib		Recruiting	NCT04201457		ECD	01-FEB-25	Yes	No		4	NCT04201457			Overall Response Rate	75	75																																								
NF1	NF1_unspecified				central nervous system / glioma / NS	3	Phase 2	Bevacizumab + Vinblastine		Recruiting	NCT02840409		ECD	01-AUG-26	No	No		4	NCT02840409		Pediatric	Response rate	150	150																																								
NF1	NF1_unspecified				central nervous system / glioma / NS	3	Phase 2	Everolimus		Completed	NCT01158651	NFC-RAD001	PCD	01-SEP-14	No	Yes		4	NCT01158651	Previously-treated	Pediatric	Overall Response Rate	22	22			68.2			<0.001																																		
NF1	NF1_unspecified				central nervous system / glioma / astrocytoma	3	Phase 2	Sorafenib		Terminated	NCT01338857		PCD	01-MAR-13	No	Yes	No benefit of treatment	4	NCT01338857	Previously-treated	Pediatric	Response rate	12	12																																								
NF1	NF1_unspecified				central nervous system / glioma / astrocytoma Grade I	3	Phase 2	PEG-proline-interferon alpha-2b		Recruiting	NCT02343224		ECD	01-DEC-21	No	No		4	NCT02343224	Previously-treated	Pediatric	Response rate	20	20																																								
NF1	NF1_unspecified				central nervous system / glioma / astrocytoma Grade I	3	Phase 2	Lenalidomide		Active, not recruiting	NCT01553149		PCD	01-JUN-20	No	No		4	NCT01553149	Previously-treated		Overall Response Rate	75	75																																								
NF1	NF1_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Selumetinib		Recruiting	NCT01089101		ECD	01-DEC-22	No	No		4	NCT01089101		Pediatric	Maximum tolerated dose/toxicity	220	220																																								
NF1	NF1_unspecified				central nervous system / other / ganglioglioma	3	Phase 1	Lenalidomide		Completed	NCT00100880		PCD	01-NOV-10	No	Yes		1	21149652	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	1	1																															1									
NF1	NF1_unspecified				central nervous system / other / ganglioglioma	3	Phase 2	Selumetinib		Recruiting	NCT03326388	INSPECT	ECD	01-APR-21	No	No		4	NCT03326388		Pediatric	Maximum tolerated dose/toxicity	30	30																																								
NF1	NF1_unspecified				central nervous system / other / ganglioglioma	3	Phase 2	Lenalidomide		Active, not recruiting	NCT01553149		PCD	01-JUN-20	No	No		4	NCT01553149	Previously-treated		Overall Response Rate	75	75																																								
NF1	NF1_unspecified				central nervous system / other / ganglioglioma	3	Phase 2	PEG-proline-interferon alpha-2b		Recruiting	NCT02343224		ECD	01-DEC-21	No	No		4	NCT02343224	Previously-treated	Pediatric	Response rate	20	20																																								
NF1	NF1_unspecified				central nervous system / other / ganglioglioma	3	Phase 2	Selumetinib		Recruiting	NCT01089101		ECD	01-DEC-22	No	No		4	NCT01089101	Previously-treated	Pediatric	Overall Response Rate	220	220																																								
NF1	NF1_unspecified				central nervous system / other / neoplasm	3	Phase 1	Lenalidomide		Completed	NCT00100880	PBTC-018	PCD	01-NOV-10	No	Yes		1	21149652	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	47	47																															2	23								
NF1	NF1_unspecified				central nervous system / other / neoplasm	3	Phase 1	Pomalidomide		Active, not recruiting	NCT02415153		PCD	01-JUL-19	No	Yes		2	10.1200/JCO.2017.35.15_suppl.10543	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	25	25																																2								
NF1	NF1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / juvenile myelomonocytic leukaemia	3	Phase 2	Etanercept		Terminated	NCT00509600		PCD	01-APR-09	Yes	Yes	Slow accrual	4	NCT00509600			Response rate	1	1																																								
NF1	NF1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Trametinib		Terminated	NCT03232892		PCD	01-SEP-19	Yes	Yes	Slow accrual	4	NCT03232892			Overall Response Rate	1	1																																								
NF1	NF1_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Selumetinib		Withdrawn	NCT03109301		ECD	01-FEB-22	No	Yes	Slow accrual	4	NCT03109301			Response rate	50	50																																								
NF1	NF1_unspecified				soft tissue / malignant peripheral nerve sheath tumour / NS	3	Phase 2	Imatinib		Terminated	NCT00427583		PCD	01-APR-09	No	Yes	No benefit of treatment	4	NCT00427583			Response rate	11	11																																								
NF1	NF1_unspecified				soft tissue / malignant peripheral nerve sheath tumour / NS	3	Phase 2	Bevacizumab + Everolimus		Completed	NCT01661283	SARC016	PCD	01-JUN-17	No	Yes	Primary outcome not met	2	10.1200/JCO.2016.34.15_suppl.11053			Disease control rate, Clinical benefit rate	25	25																					12.0																			
NF1	NF1_unspecified				soft tissue / malignant peripheral nerve sheath tumour / NS	3	Phase 2	Telaglenastat		Recruiting	NCT03872427		ECD	01-AUG-22	Yes	No		4	NCT03872427			Overall Response Rate	108	108																																								
NF1	NF1_unspecified				soft tissue / malignant peripheral nerve sheath tumour / NS	3	Phase 2	Ganetespib + Sirolimus		Completed	NCT02008877	SARC023	PCD	01-APR-18	Expression level	Yes	66% serious adverse events, No benefit of treatment	4	NCT02008877			Maximum tolerated dose/toxicity	10	10																																								
NF1	NF1_unspecified				soft tissue / malignant peripheral nerve sheath tumour / NS	3	Phase 2	Selumetinib + Sirolimus		Recruiting	NCT03433183	SARC031	ECD	01-SEP-21	No	No		4	NCT03433183			Disease control rate, Clinical benefit rate	21	21																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / NS	3	Phase 2	Everolimus		Completed	NCT02332902		PCD	01-MAR-16	No	Yes		1	30284154			Unknown	16	16																															3									
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Approved FDA	Selumetinib + Sirolimus	Not required	Active, not recruiting	NCT01362803	SPRINT	ECD	01-JAN-25	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf		Pediatric	Overall Response Rate	50	50			66.0																												33									
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Case study	Trametinib		Unknown					No	Yes		1	30174724		Pediatric	Unknown	1	1																															1									
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 1	Sorafenib		Completed	NCT00727233		PCD	01-JUN-11	No	No		4	NCT00727233			Maximum tolerated dose/toxicity	9	9																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Trametinib		Recruiting	NCT03741101		ECD	01-JUL-22	No	No		4	NCT03741101		Pediatric	Defined % decrease in tumour volume	15	15																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Pexidartinib		Recruiting	NCT02390752		ECD	01-DEC-21	No	No		4	NCT02390752		Pediatric	Overall Response Rate	81	81																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Tipifarnib		Completed	NCT00021541		PCD	01-FEB-09	No	Yes		1	24500418		Pediatric	Time to treatment failure, Time to progression	60	31	29															19.2	10.6			0.12																				
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Pirfenidone		Completed	NCT00076102		PCD	01-APR-10	No	Yes	No benefit of treatment	1	24753394		Pediatric	Time to treatment failure, Time to progression	36	36																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	PEG-proline-interferon alpha-2b		Completed	NCT00678951		PCD	01-APR-14	No	Yes		1	27510726		Pediatric	DCR, TTP	26	26																29.4	11.8			0.031											3									
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Selumetinib + Sirolimus		Recruiting	NCT02407405	NCI-2015-00456	ECD	01-JAN-25	No	No		4	NCT02407405			Overall Response Rate	60	60																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Selumetinib + Sirolimus		Recruiting	NCT03326388	INSPECT	ECD	01-APR-21	No	No		4	NCT03326388		Pediatric	Maximum tolerated dose/toxicity	30	30																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Binimetinib		Active, not recruiting	NCT03231306	PNOC010	ECD	01-DEC-22	No	No		4	NCT03231306			Overall Response Rate	40	40																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Mirdametinib		Completed	NCT02096471		PCD	01-AUG-17	No	Yes		4	NCT02096471		Pediatric	Defined % decrease in tumour volume	19	19																															8	11								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Sunitinib		Terminated	NCT01402817		PCD	01-OCT-15	No	Yes	Serious adverse events	4	NCT01402817			Disease control rate, Clinical benefit rate	19	19																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Imatinib		Completed	NCT01140360		PCD	01-AUG-16	No	Yes		4	NCT01140360			Disease control rate, Clinical benefit rate	13	13																																13								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Imatinib		Withdrawn	NCT03688568		ECD	01-SEP-20	No	Yes	Enrollment not feasible	4	NCT03688568			Functional airway response	0	0																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Imatinib		Terminated	NCT02177825		ECD	01-DEC-18	No	Yes	Slow accrual	4	NCT02177825			Time to treatment failure, Time to progression	25	25																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Imatinib		Completed	NCT01673009		PCD	01-DEC-11	No	Yes		1	23099009			Defined % decrease in tumour volume	23	23																															6									
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Sirolimus		Completed	NCT00634270		PCD	01-NOV-14	No	Yes		1	25314964			Time to treatment failure, Time to progression	58	58																15.4	11.9			<0.001																				
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Everolimus		Completed	NCT01412892	Nfitor	PCD	01-OCT-13	No	No		4	NCT01412892			Radiographic response rate	30	30																																								
NF1	NF1_unspecified				soft tissue / neurofibroma / plexiform	2	Phase 2	Cabozantinib		Active, not recruiting	NCT02101736	NF105-CABO	ECD	01-MAY-21	No	No		4	NCT02101736			Overall Response Rate	48	48																																								
NF2	NF2_unspecified				NS / neoplasm / NS	3	Phase 2	Everolimus		Completed	NCT02352844		PCD	01-AUG-17	Yes	No		4	NCT02352844			Response rate	12	12																																								
NF2	NF2_unspecified				NS / neoplasm / NS	3	Phase 2	Defactinib		Recruiting	NCT02465060	MATCH Subprotocol U	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
NOTCH1	NOTCH1_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	3	Phase 2	Ibrutinib + Rituximab		Active, not recruiting	NCT02232386	LLC1114	ECD	01-MAY-21	No	No		4	NCT02232386			Progression free survival	156	156																																								
NPM1	NPM1_unspecified				endometrium / carcinoma / NS	3	Phase 2	Anastrozole + Vistusertib		Active, not recruiting	NCT02730923	VICTORIA	ECD	01-NOV-19	No	No		4	NCT02730923			Progression free survival	72			Anastrozole																																						
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	SNDX-5613		Recruiting	NCT04065399	AUGMENT-101	ECD	01-JUL-22	Yes	No		4	NCT04065399	Previously-treated		Complete remission	186	186																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Approved FDA	Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin		Completed	NCT00927498	ALFA 0701	PCD	01-JUL-11	Yes	Yes	Rate of CR+CRp 88.9% vs 85.4% HR 1.37 95% CI 0.40-4.66 p=0.76, 2yr EFS 17.8% vs. 51.1%  HR 0.47 95% CI 0.27-0.81 p=0.006	1	22482940 			Event free survival	45	48																								68.3	46	.5	0.26-0.97	0.04					57.5	21.1	.43	0.23-0.79	0.006			
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 1	KO 539		Recruiting	NCT04067336	KO-MEN-001	ECD	01-FEB-22	No	No		4	NCT04067336	Previously-treated		Maximum tolerated dose/toxicity	100	100																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine		Completed	NCT02450877	AZA-AML-004	PCD	01-OCT-18	No	No		3	https://ash.confex.com/ash/2020/webprogram/Paper137043.html		Pediatric	Progression free survival	0	0																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cytarabine + Daunorubicin + Entospletinib		Recruiting	NCT03013998	BAML-16-001-S6 	ECD	01-DEC-21	No	No		4	NCT03013998			Response rate	2000	2000																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Clofarabine + Cytarabine		Completed	NCT00932412	CLARA	PCD	01-APR-16	No	No		4	NCT00932412			Disease free survival, relapse free survival, regression free survival, recurrence free survival	735			Cytarabine																																						
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Cytarabine + Ponatinib		Recruiting	NCT02428543	PONATINIB-AML	ECD	01-NOV-20	No	No		4	NCT02428543	Previously-treated		Maximum tolerated dose/toxicity	49	49																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Ixazomib		Terminated	NCT02030405		PCD	01-NOV-15	Yes	Yes	Terminated for regulatory reasons	4	NCT02030405			Overall Response Rate	4	4																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Arsenic trioxide		Withdrawn	NCT01835288		ECD	01-MAY-15	Yes	No		4	NCT01835288			Complete remission	0	0																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Arsenic trioxide + Cytarabine + Tretinoin		Recruiting	NCT03031249		ECD	01-DEC-21	Yes	No		4	NCT03031249			Disease free survival, relapse free survival, regression free survival, recurrence free survival	80	80																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Azacitidine + Pembrolizumab		Recruiting	NCT03769532	PEMAZA	ECD	01-AUG-21	Yes	No		4	NCT03769532			Event free survival	28	28																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Chemotherapy + Sorafenib		Completed	NCT00373373		PCD	01-JUL-09	No	No		4	NCT00373373	Untreated	Geriatric	Event free survival	200	200																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 2	Decitabine + Glasdegib		Active, not recruiting	NCT04051996	GLAD-AML	ECD	01-SEP-21	No	No		4	NCT04051996		Geriatric	Complete remission	1	1																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Azacitidine + Pevonedistat		Recruiting	NCT04090736	PEVOLAM	ECD	01-JUN-23	No	No		4	NCT04090736	Untreated		Overall survival	466			Azacitidine																																						
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Gemtuzumab Ozogamicin		Recruiting	NCT02473146	ALFA1401	ECD	01-APR-19	No	No		4	NCT02473146		Geriatric	Event free survival	225	225																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Idarubicin		Completed	NCT01802333	SWOG-S1203	PCD	01-JUN-17	No	Yes	EFS 41 vs 37% p=0.42 primary outcome not met	4	NCT01802333	Untreated		Event free survival	477	261	216	Cytarabine + Idarubicin + Vorinostat																																						
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Etoposide + Tretinoin		Completed	NCT01237808		PCD	01-JUL-18	Yes	No		4	NCT01237808			Overall survival	144	144																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Etoposide + Gemtuzumab Ozogamicin + Idarubicin + Pegfilgrastim + Tretinoin		Active, not recruiting	NCT00893399		ECD	01-SEP-21	Yes	No		4	NCT00893399			Event free survival	588	588																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Daunorubicin		Completed	NCT01802333		PCD	01-JUN-17	No	Yes	EFS 36 vs 37% p=0.84 primary outcome not met	4	NCT01802333	Untreated		Event free survival	477	261	216	Cytarabine + Idarubicin + Vorinostat																																						
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 3	Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin		Completed	NCT00860639	LAM2006IR	PCD	01-SEP-16	No	No		4	NCT00860639			Event free survival	327	327																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	1	Phase 4	Cytarabine + Idarubicin		Recruiting	NCT01296178	PETHEMA-LMA10	ECD	01-DEC-20	No	No		4	NCT01296178			Overall survival	200	200																																								
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	6	5	1	Cytarabine	40	0																																				
NPM1	NPM1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Cytarabine + Idarubicin + Pravastatin		Completed	NCT01831232		PCD	01-FEB-15	No	Yes	Primary outcome not met	4	NCT01831232	Untreated		Complete remission	24	24																														15										
TP53	NRAS Q61K, TP53_V272M, R273C	52661812		p.V272M	large intestine / carcinoma / adenocarcinoma	4	Case study	Bevacizumab + Valproic acid		Unknown					Yes	Yes		1	23400451			Unknown	1	1																															1									
NRAS	NRAS_G12D	54736383		p.G12D	NS / other / neoplasm	3	Phase 2	Aldesleukin + Anti-RAS G12D TCR + Cyclophosphamide + Fludarabine		Suspended	NCT03745326		ECD	01-DEC-27	Yes	No		4	NCT03745326			Response rate	4	4																																								
NRAS	NRAS_G12D	54736383		p.G12D	skin / carcinoma / squamous cell carcinoma	3	Phase 2	Cetuximab		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	Yes	Yes		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																															1									
NRAS	NRAS_G12V	54736974		p.G12V	NS / other / neoplasm	3	Phase 2	Aldesleukin + Anti-RAS G12V TCR + Cyclophosphamide + Fludarabine		Suspended	NCT03190941		ECD	01-JUN-27	Yes	No		4	NCT03190941			Response rate	6	6																																								
NRAS	NRAS_G13D	54736416		p.G13D	NS / malignant melanoma / NS	4	Case study	Tanespimycin		Unknown					Yes	Yes		1	18375819			Unknown	1	1																																1								
NRAS	NRAS_Q61H	54736320 + 54736991		p.Q61H	NS / malignant melanoma / NS	4	Case study	Ipilimumab		Unknown					Yes	Yes		1	26095797			Unknown	1	1																															1									
NRAS	NRAS_Q61K	54736310 + 54742235 + 54754425 + 54762707 + 104538738		p.Q61K	large intestine / carcinoma / adenocarcinoma	4	Case study	Binimetinib + Palbociclib		Unknown	NCT02065063		PCD	01-JUN-16	Yes	Yes		2	10.1158/1535-7163.TARG-15-PR06			Maximum tolerated dose/toxicity	1	1																															1									
NRAS	NRAS_Q61K	54736310 + 54742235 + 54754425 + 54762707 + 104538738		p.Q61K	large intestine / carcinoma / adenocarcinoma	4	Case study	Bevacizumab + Valproic acid		Unknown					Yes	Yes		1	23400451			Unknown	1	1																															1									
NRAS	NRAS_Q61L	54736336 + 54736624 + 54742436		p.Q61L	NS / malignant melanoma / NS	4	Case study	Temozolomide		Unknown					Yes	Yes		1	21576590			Unknown	1	1																																	14							
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Case study	Vemurafenib		Unknown					Yes	Yes		1	24463458			Unknown	1	1																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	Dabrafenib + Nivolumab + Trametinib		Withdrawn	NCT02357732		PCD	01-AUG-15	Yes	Yes	Changed business priorities	4	NCT02357732			Maximum tolerated dose/toxicity	0	0																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	Belvarafenib		Completed	NCT03118817		PCD	01-FEB-20	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3000			Overall Response Rate	9	9																															2									
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	Paclitaxel + Trametinib		Unknown					Yes	Yes		1	25542057			Unknown	8	8											4.6													8.1																
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	Digoxin + Trametinib		Completed	NCT02138292		PCD	01-FEB-17	Yes	Yes		1	28278423			Maximum tolerated dose/toxicity	6	6			83																																					
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	IN10018 		Recruiting	NCT04109456		ECD	01-MAR-21	No	No		4	NCT04109456			Maximum tolerated dose/toxicity	52	52																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	LTT462  + LXH254		Recruiting	NCT02974725		ECD	01-JAN-22	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	315	315																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	LXH254 + Trametinib		Recruiting	NCT02974725		ECD	01-JAN-22	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	315	315																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	LXH254 + Ribociclib		Recruiting	NCT02974725		ECD	01-JAN-22	Yes	No		4	NCT02974725			Maximum tolerated dose/toxicity	315	315																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	Nivolumab + Trametinib		Withdrawn	NCT02357732		PCD	01-AUG-15	Yes	Yes	Changed business priorities	4	NCT02357732			Maximum tolerated dose/toxicity	0	0																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	Dabrafenib + Nivolumab		Withdrawn	NCT02357732		PCD	01-AUG-15	Yes	Yes	Changed business priorities	4	NCT02357732			Maximum tolerated dose/toxicity	0	0																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	FCN-159		Recruiting	NCT03932253		ECD	01-SEP-22	Yes	No		4	NCT03932253			Overall Response Rate	37	37																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 1	Trametinib		Completed	NCT00687622		PCD	01-JUN-11	Yes	Yes		1	22805292 			Maximum tolerated dose/toxicity	7	7																																2								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 2	Trametinib		Recruiting	NCT04059224	TraMel-WT	ECD	01-JUN-21	No	No		4	NCT04059224			Overall Response Rate	58	58																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 2	Adoptive cell transfer + Nivolumab		Recruiting	NCT03374839		ECD	01-MAR-23	No	No		4	NCT03374839			Maximum tolerated dose/toxicity	11	11																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 2	Pimasertib		Completed	NCT01693068		PCD	01-JUL-15	Yes	Yes		4	NCT01693068			Progression free survival	194	130	64	Dacarbazine	26.9	14.1							13	6.86	.59	0.42-0.83	0.0022						33.1	15.6		8.87	10.61															
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 2	Binimetinib + Ribociclib		Completed	NCT01781572		PCD	01-JAN-18	Yes	Yes		2	10.1200/JCO.2017.35.15_suppl.9519			Overall Response Rate	16	16											6.7																				4	7								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 2	CDX-3379 + Trametinib		Terminated	NCT03580382		PCD	01-SEP-18	No	Yes	Changed business priorities	4	NCT03580382			Overall Response Rate	3	3																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 2	HL-085		Recruiting	NCT03973151		ECD	01-MAR-22	Yes	No		4	NCT03973151			Maximum tolerated dose/toxicity	54	54																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 2	Hydroxychloroquine + Trametinib		Not yet recruiting	NCT03979651	CHLOROTRAMMEL	ECD	01-MAR-22	No	No		4	NCT03979651			Response rate	29	29																																								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 2	Binimetinib		Active, not recruiting	NCT01320085		PCD	01-JAN-14	Yes	Yes		1	22805292			Overall Response Rate	30	30																					63										3	13								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 2	Selumetinib		Completed	NCT00866177		PCD	01-SEP-13	No	Yes		4	NCT00866177			Clinical activity	15	15																															1	8								
NRAS	NRAS_unspecified				NS / malignant melanoma / NS	2	Phase 3	Binimetinib		Completed	NCT01763164		PCD	01-DEC-15	Yes	Yes		1	28284557			Progression free survival	402	269	133	Dacarbazine									2.8	1.5	.62	0.47-0.80	<0.001																									
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	RO5126766		Recruiting	NCT02407509	DDU RAF/MEK	ECD	01-DEC-21	No	No		4	NCT02407509			Maximum tolerated dose/toxicity	94	94																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	Alpelisib + Binimetinib		Completed	NCT01449058		PCD	01-AUG-16	No	No		4	NCT01449058			Maximum tolerated dose/toxicity	139	139																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	Afatinib + Capecitabine		Recruiting	NCT02451553		ECD	01-JAN-22	No	No		4	NCT02451553			Maximum tolerated dose/toxicity	48	48																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	BGB-3245		Recruiting	NCT04249843		ECD	01-MAY-23	No	No		4	NCT04249843			Overall Response Rate	69	69																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	KO-947		Active, not recruiting	NCT03051035	KO-ERK-001	ECD	01-DEC-20	No	No		4	NCT03051035			Maximum tolerated dose/toxicity	100	100																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	Binimetinib + Talazoparib		Terminated	NCT03637491		ECD	01-NOV-23	Yes	Yes	Lack of efficacy	4	NCT03637491			Overall Response Rate	36	36																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	Avelumab + Binimetinib		Terminated	NCT03637491		PCD	01-DEC-20	Yes	Yes	Lack of efficacy	4	NCT03637491			Overall Response Rate	36	36																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	ASN007		Completed	NCT03415126	ASN007-101	PCD	01-JUN-20	No	No		4	NCT03415126			Overall Response Rate	49	49																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	Binimetinib + Buparlisib		Completed	NCT01363232		PCD	01-MAR-14	No	Yes	intolerable toxicities	1	31395751			Maximum tolerated dose/toxicity	89	89																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	Binimetinib + Dactolisib		Completed	NCT01337765		PCD	01-MAR-13	No	No		4	NCT01337765			Maximum tolerated dose/toxicity	29	29																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	ARQ 736		Completed	NCT01225536		PCD	01-JAN-13	Yes	No		4	NCT01225536			Maximum tolerated dose/toxicity	24	24																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	Belvarafenib		Recruiting	NCT03118817		PCD	01-APR-20	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3000			Maximum tolerated dose/toxicity	9	9			44																												4									
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 1	Avelumab + Binimetinib + Talazoparib		Terminated	NCT03637491		ECD	01-NOV-23	Yes	Yes	Lack of efficacy	4	NCT03637491			Overall Response Rate	36	36																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 2	Selumetinib		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 2	Ascorbic acid		Recruiting	NCT03146962		ECD	01-JUN-21	No	No		4	NCT03146962			Disease control rate, Clinical benefit rate	50	50																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 2	Dubermatinib		Recruiting	NCT02729298		ECD	01-DEC-21	Yes	No		4	NCT02729298			Maximum tolerated dose/toxicity	177	177																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 2	Navitoclax + Trametinib		Recruiting	NCT02079740		ECD	01-MAR-21	Yes	No		4	NCT02079740			PFS, ORR	130	130																																								
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 2	Binimetinib		Active, not recruiting	NCT04439344	MATCH-Subprotocol Z1A	PCD	01-DEC-19	Yes	Yes	Primary outcome not met	2	10.1158/1538-7445.AM2020-CT061			Overall Response Rate	53	53			2.1								3.5																				1									
NRAS	NRAS_unspecified				NS / other / neoplasm	3	Phase 2	Binimetinib		Recruiting	NCT02465060	MATCH Subprotocol Z1A	ECD	01-JUN-22	No	No		4	NCT02465060			Overall Response Rate	6452	6452																																								
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	8	5	3	Cytarabine	40	0																																				
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Selumetinib		Completed	NCT00588809		PCD	01-APR-12	Yes	Yes	No benefit of treatment	1	24178622	Previously-treated		Response rate	3	3			0																																					
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Ruxolitinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																																								
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / juvenile myelomonocytic leukaemia	3	Phase 2	Etanercept		Terminated	NCT00509600		PCD	01-APR-09	Yes	Yes	Slow accrual	4	NCT00509600			Response rate	1	1																																								
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Out of trials human study	Bortezomib		Unknown					Comparison with wt	Yes		1	24335104			Unknown	74	15	59		7	53		0.016																																		
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Out of trials human study	Dexamethasone		Unknown					Comparison with wt	Yes		1	24335104			Unknown	31	6	25		50	32																																				
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Dabrafenib + Trametinib		Recruiting	NCT03091257		ECD	01-DEC-20	Yes	No		4	NCT03091257	Previously-treated		Progression free survival	60	60																																								
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Afuresertib + Bortezomib + Dexamethasone		Completed	NCT01428492		PCD	01-OCT-15	No	No		4	NCT01428492			Maximum tolerated dose/toxicity	90	90																																								
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Trametinib		Recruiting	NCT03091257		ECD	01-DEC-20	Yes	No		4	NCT03091257	Previously-treated		Progression free survival	60	60																																								
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide		Recruiting	NCT03732703	MyDRUGSubProtocol C1	ECD	01-FEB-22	Yes	No		4	NCT03732703			Overall Response Rate	228	228																																								
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Afuresertib + Bortezomib		Withdrawn	NCT01445587		PCD	01-NOV-11	No	Yes	No benefit of treatment	4	NCT01445587			Maximum tolerated dose/toxicity	0	0																																								
NRAS	NRAS_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Afuresertib		Withdrawn	NCT01445587		PCD	01-NOV-11	No	Yes	No benefit of treatment	4	NCT01445587			Maximum tolerated dose/toxicity	0	0																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Adavosertib + Irinotecan		Recruiting	NCT02906059		PCD	01-MAR-20	Yes	No		4	NCT02906059			Maximum tolerated dose/toxicity	7	7																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Siremadlin + Trametinib		Recruiting	NCT03714958	TRAHD	ECD	01-FEB-21	No	No		4	NCT03714958			Maximum tolerated dose/toxicity	24	24																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	5-Fluorouracil + Midostaurin + Radiotherapy		Completed	NCT01282502		PCD	01-MAR-15	No	Yes		2	10.1200/JCO.2018.36.15_suppl.e15674			Maximum tolerated dose/toxicity	19	19																															3									
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	5-Fluorouracil + Radiotherapy + Trametinib		Active, not recruiting	NCT01740648		ECD	01-DEC-21	No	Yes		1	32253228			Maximum tolerated dose/toxicity	18	18																														3			88.9							
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFOX + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Nivolumab + SX682		Recruiting	NCT04599140	STOPTRAFFIC-1	ECD	01-JAN-24	Yes	No		4	NCT04599140			Maximum tolerated dose/toxicity	53	53																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + PHY906		Completed	NCT00730158		PCD	01-JUN-16	Yes	Yes		4	NCT00730158			Maximum tolerated dose/toxicity	26	14	12	Irinotecan	50.0	83.3							4.01	3.42																												
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Yttrium-90		Recruiting	NCT04108481	iRE-C	ECD	01-OCT-21	No	No		4	NCT04108481			Maximum tolerated dose/toxicity	18	18																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFIRI + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFIRI + Panitumumab		Active, not recruiting	NCT01312857		ECD	01-MAR-21	No	No		4	NCT01312857			Disease free survival, relapse free survival, regression free survival, recurrence free survival	75	75																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	5-Fluorouracil + Imalumab + Leucovorin calcium		Terminated	NCT02448810		PCD	01-MAR-17	No	Yes	No benefit of treatment	4	NCT02448810			Progression free survival	115	115																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Binimetinib + Palbociclib		Recruiting	NCT03981614		ECD	01-DEC-22	Yes	No		4	NCT03981614			Progression free survival	112	112																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Panitumumab + Trametinib		Recruiting	NCT03087071		ECD	01-DEC-21	Yes	No		4	NCT03087071			Response rate	84	84																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cabozantinib		Active, not recruiting	NCT03542877		ECD	01-MAR-22	No	No		4	NCT03542877	Previously-treated		Progression free survival	43	43																																								
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab		Recruiting	NCT04189055	CETIDYL	ECD	01-APR-21	Yes	No		4	NCT04189055			Response rate	72	72		FOLFIRI																																						
NRAS	NRAS_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab		Not yet recruiting	NCT02942706	BLOC-1	ECD	01-OCT-21	Yes	No		4	NCT02942706			Progression free survival	200			FOLFIRI																																						
NRAS	NRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Binimetinib + Docetaxel		Withdrawn	NCT02451865		ECD	01-JUN-18	No	No		4	NCT02451865			Maximum tolerated dose/toxicity	0	0																																								
NRAS	NRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ceritinib		Completed	NCT02276027		PCD	01-OCT-19	Yes	Yes		4	NCT02276027			Overall Response Rate	22	22			9.1																																					
NRAS	NRAS_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Spartalizumab		Recruiting	NCT03693326		ECD	01-JUN-20	Yes	No		4	NCT03693326			Overall Response Rate	70	70																																								
NRAS	NRAS_unspecified				soft tissue / sarcoma / NS	3	Phase 3	Trametinib		Recruiting	NCT03784014	MULTISARC	ECD	01-OCT-22	No	No		4	NCT03784014			Unknown	960	960																																								
NRAS	NRAS_unspecified				thyroid / carcinoma / NS	3	Phase 2	Everolimus + Sorafenib		Active, not recruiting	NCT01263951		PCD	01-DEC-18	No	Yes		2	10.1200/jco.2015.33.15_suppl.6072			Progression free survival	13	13																															1	18								
NRAS	NRAS_unspecified				thyroid / carcinoma / NS	3	Phase 3	Radioiodine + Selumetinib		Terminated	NCT01843062	ASTRA	PCD	01-MAY-18	No	Yes	Primary outcome not met	4	NCT01843062			Complete remission	233	155	78	Placebo + Radioiodine																																						
NRAS	NRAS_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Panitumumab		Completed	NCT02643056	S10PANI01	PCD	01-DEC-15	No	Yes		1	28592616	Previously-treated		Overall Response Rate	33	33			6								2.6										51			9.7							2	15								
NRG1	NRG1_unspecified				NS / other / neoplasm	3	Phase 2	Afatinib		Recruiting	NCT02693535	TAPUR group 18	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
NTRK1	NTRK1_unspecified				NS / malignant melanoma / NS	3	Phase 2	Entrecitinib		Terminated	NCT02587650		PCD	01-JUL-18	Yes	Yes	Lack of funding	4	NCT02587650			Overall Response Rate	1	1																																								
NTRK1	NTRK1_unspecified				NS / other / neoplasm	3	Phase 1	Larotrectinib		Completed	NCT03155620	Subprotocol A	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
NTRK1	NTRK1_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
NTRK1	NTRK1_unspecified				NS / other / neoplasm	3	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	Yes		1	32292573			Disease control rate, Clinical benefit rate	5	5																																1								
NTRK1	NTRK1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	No		4	NCT02219711			Maximum tolerated dose/toxicity	260	260																																								
NTRK1	NTRK1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ensartinib		Recruiting	NCT03574402	TRUMP Arm 6	ECD	01-DEC-22	Yes	No		4	NCT03574402			Response rate	400	400																																								
NTRK2	NTRK2_unspecified				NS / malignant melanoma / NS	3	Phase 2	Entrecitinib		Terminated	NCT02587650		PCD	01-JUL-18	Yes	Yes	Lack of funding	4	NCT02587650			Overall Response Rate	1	1																																								
NTRK2	NTRK2_unspecified				NS / other / neoplasm	3	Phase 1	Larotrectinib		Completed	NCT03155620	Subprotocol A	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
NTRK2	NTRK2_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
NTRK2	NTRK2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ensartinib		Recruiting	NCT03574402	TRUMP Arm 6	ECD	01-DEC-22	Yes	No		4	NCT03574402			Response rate	400	400																																								
NTRK3	NTRK3_unspecified				NS / malignant melanoma / NS	3	Phase 2	Entrecitinib		Terminated	NCT02587650		PCD	01-JUL-18	Yes	Yes	Lack of funding	4	NCT02587650			Overall Response Rate	1	1																																								
NTRK3	NTRK3_unspecified				NS / other / neoplasm	3	Phase 1	Larotrectinib		Completed	NCT03155620	Subprotocol A	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
NTRK3	NTRK3_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Ensartinib		Recruiting	NCT03574402	TRUMP Arm 6	ECD	01-DEC-22	Yes	No		4	NCT03574402			Response rate	400	400																																								
PALB2	PALB2_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
PALB2	PALB2_unspecified				NS / neoplasm / NS	3	Phase 2	Talazoparib		Recruiting	NCT02286687		ECD	01-DEC-20	Yes	No		4	NCT02286687			Disease control rate, Clinical benefit rate	150	150																																								
PALB2	PALB2_unspecified				NS / neoplasm / NS	3	Phase 2	Bevacizumab + Durvalumab + Olaparib		Active, not recruiting	NCT02734004	MEDIOLA	ECD	01-AUG-22	Yes	No		4	NCT02734004			Overall Response Rate	427	427																																								
PALB2	PALB2_unspecified				NS / neoplasm / NS	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
PALB2	PALB2_unspecified				NS / neoplasm / NS	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
PALB2	PALB2_unspecified				NS / neoplasm / NS	3	Phase 2	Durvalumab + Olaparib		Active, not recruiting	NCT02734004	MEDIOLA	ECD	01-AUG-22	Yes	No		4	NCT02734004			Overall Response Rate	427	427																																								
PALB2	PALB2_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
PALB2	PALB2_unspecified				NS / neoplasm / NS	3	Phase 2	Talazoparib		Recruiting	NCT02693535	TAPUR group 19	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
PALB2	PALB2_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
PALB2	PALB2_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
PALB2	PALB2_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
PALB2	PALB2_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	01-JUN-23	Yes	No		4	NCT04335669			Complete response, Pathological complete response	820	820																																								
PALB2	PALB2_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
PALB2	PALB2_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
PALB2	PALB2_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Talazoparib		Active, not recruiting	NCT03377556		ECD	01-MAY-22	Yes	No		4	NCT03377556			Overall Response Rate	64	64																																								
PALB2	PALB2_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort A	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
PALB2	PALB2_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
PALB2	PALB2_unspecified				prostate / carcinoma / NS	1	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
PALB2	PALB2_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
PALB2	PALB2_unspecified				prostate / carcinoma / NS	1	Phase 2	Carboplatin + Docetaxel + Rucaparib 		Recruiting	NCT03442556	PLATI-PARP	ECD	01-MAY-25	No	No		4	NCT03442556	Previously-treated		Progression free survival	20	20																																								
PALB2	PALB2_unspecified				prostate / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
PALB2	PALB2_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
PCNA	PCNA_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
PTEN	PDGFRA_D842V	57264120		p.D842V	soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Crenolanib		Completed	NCT01243346		PCD	01-JUL-14	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.11010			Overall Response Rate	16	16																					31										2	3								
PTEN	PDGFRA_D842V	57264120		p.D842V	soft tissue / gastrointestinal stromal tumour / NS	3	Phase 3	Crenolanib		Recruiting	NCT02847429		ECD	01-AUG-20	Yes	No		4	NCT02847429			Progression free survival	120			Placebo																																						
PTEN	PDGFRA_Exon18				central nervous system / glioma / astrocytoma Grade IV	3	Phase 1	Avapritinib		Unknown	NCT02508532	NAVIGATOR	PCD	01-MAR-20	Yes	Yes	Primary outcome met	2	10.1200/JCO.2019.37.15_suppl.11022	Previously-treated		Overall Response Rate	43	43			86																											3	34	5								
PTEN	PDGFRA_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
PTEN	PDGFRA_unspecified				NS / other / neoplasm	3	Phase 2	Imatinib + Spartalizumab		Recruiting	NCT03609424		ECD	01-AUG-20	No	No		4	NCT03609424	Previously-treated		Disease control rate, Clinical benefit rate	41	41																																								
PTEN	PDGFRA_unspecified				NS / other / neoplasm	3	Phase 2	Ponatinib		Recruiting	NCT02272998		ECD	01-DEC-21	No	No		4	NCT02272998			Overall Response Rate	45	45																																								
PTEN	PDGFRA_unspecified				NS / other / neoplasm	3	Phase 2	Pazopanib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
PTEN	PDGFRA_unspecified				NS / other / neoplasm	3	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	Yes		1	32292573			Disease control rate, Clinical benefit rate	7	7																																2								
PTEN	PDGFRA_unspecified				NS / other / neoplasm	3	Phase 2	Nilotinib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
PTEN	PDGFRA_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
PTEN	PDGFRA_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
PTEN	PDGFRA_unspecified				NS / other / neoplasm	3	Phase 3	Nilotinib		Recruiting	NCT03784014	MULTISARC	ECD	01-OCT-22	No	No		4	NCT03784014			Unknown	960	960																																								
PTEN	PDGFRA_unspecified				biliary tract / other / neoplasm	3	Phase 2	Sunitinib		Completed	NCT01082809		PCD	01-JAN-12	No	Yes	Expression not correlated with treatment efficacy	1	22176869			Progression free survival	56	56			8.9								1.7			1.0-2.4																	5	23								
PTEN	PDGFRA_unspecified				bone / chondrosarcoma / NS	3	Phase 2	Imatinib		Unknown	NCT00928525		ECD	01-DEC-18	Expression level	Yes	Primary outcome not met	1	20925044			Overall Response Rate	26	26											3			2.2-7.7										11.0			6.0-15.0			0	0	8								
PTEN	PDGFRA_unspecified				central nervous system / glioma / NS	3	Phase 2	Sildenafil + Sorafenib + Valproic acid		Active, not recruiting	NCT01817751		PCD	01-AUG-20	Expression level	No		4	NCT01817751			Progression free survival	47	47																																								
PTEN	PDGFRA_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Crenolanib		Completed	NCT02626364		PCD	01-JUL-20	Expression level	No		4	NCT02626364			Progression free survival	11	11																																								
PTEN	PDGFRA_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
PTEN	PDGFRA_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine + Pevonedistat + Venetoclax		Recruiting	NCT03862157		ECD	01-JAN-24	No	No		4	NCT03862157	Untreated		Complete response, Pathological complete response	40	40																																								
PTEN	PDGFRA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	No		4	NCT02219711			Maximum tolerated dose/toxicity	260	260																																								
PTEN	PDGFRA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
PTEN	PDGFRA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	29	29		Erlotinib + Placebo									2.84	2.7	.82	0.27-2.49	0.37																									
PTEN	PDGFRA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		Terminated	NCT02299141		PCD	01-JAN-20	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12								
PTEN	PDGFRA_unspecified				ovary / carcinoma / NS	3	Phase 2	Pazopanib		Completed	NCT01262014		PCD	01-FEB-14	No	No		4	NCT01262014			Disease control rate, Clinical benefit rate	28	28																																								
PTEN	PDGFRA_unspecified				ovary / carcinoma / NS	3	Phase 2	Doxorubicin hydrochloride liposome + Olaratumab		Completed	NCT00913835		PCD	01-OCT-11	No	Yes		4	NCT00913835			Progression free survival	96	49	47										4.2	4	1.043	0.698-1.558	0.837									16.6	16.2	1.098	0.706-1.709	0.678												
PTEN	PDGFRA_unspecified				prostate / carcinoma / NS	3	Phase 2	Mitoxantrone hydrochloride + Olaratumab + Prednisone		Completed	NCT01204710		PCD	01-SEP-12	No	Yes		4	NCT01204710			Progression free survival	121	62	59	Mitoxantrone hydrochloride + Prednisone									2.3	2.4	1.29	0.87-1.9	0.22									14.2	12.8	1.08	0.72-1.61	0.73												
PTEN	PDGFRA_unspecified				prostate / carcinoma / NS	3	Unknown	Sunitinib		Unknown	NCT02208583		ECD	01-DEC-16	Yes	No		4	NCT02208583	Previously-treated		Progression free survival	150	150																																								
PTEN	PDGFRA_unspecified				skin / carcinoma / Merkel cell carcinoma	3	Phase 2	Imatinib		Completed	NCT00068783		PCD	01-JUL-07	No	No		1	20019577			Response rate	40	40																																								
PTEN	PDGFRA_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Experimental	Ripretinib		Recruiting	NCT02571036		ECD	01-JUN-22	Yes	No		4	NCT02571036	Previously-treated		Overall Response Rate	320	320																																								
PTEN	PDGFRA_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 1	Dovitinib + Imatinib		Withdrawn	NCT02268435		ECD	01-AUG-16	No	Yes	Drug unavailable	4	NCT02268435			Maximum tolerated dose/toxicity	0	0																																								
PTEN	PDGFRA_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 1	Dasatinib + Ipilimumab		Completed	NCT01643278		PCD	01-JUN-16	No	Yes		1	28007774			Maximum tolerated dose/toxicity	13	13											2.8			2.7-3.0										13.5							7	3								
PTEN	PDGFRA_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Paclitaxel		Recruiting	NCT03944304		ECD	01-AUG-21	Yes	No		4	NCT03944304			Disease control rate, Clinical benefit rate	40	40																																								
PTEN	PDGFRA_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Olaratumab		Terminated	NCT01316263		PCD	01-MAY-12	Comparison with wt	Yes	Slow accrual	4	NCT01316263			Disease control rate, Clinical benefit rate	21	21																																								
PTEN	PDGFRA_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Imatinib + Regorafenib		Unknown	NCT02365441	ALT GIST	ECD	01-DEC-19	No	No		4	NCT02365441	Untreated		Progression free survival	240	240																																								
PTEN	PDGFRA_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Pazopanib		Completed	NCT01524848		PCD	01-JAN-15	No	No		4	NCT01524848			Disease control rate, Clinical benefit rate	72	72																																								
PTEN	PDGFRA_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Dovitinib		Completed	NCT01440959		PCD	01-MAR-13	No	Yes		4	NCT01440959			Disease control rate, Clinical benefit rate	30	30												3.6		3.5-3.7							13	4.7-30.3		9.7			6.0-13.4													
PTEN	PDGFRA_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Luminespib		Unknown	NCT01389583		ECD	01-MAY-15	No	Yes		2	10.1200/jco.2016.34.4_suppl.134	Previously-treated		Disease control rate, Clinical benefit rate	25	25											2.4			1.6-3.2										9.6			0-21.1													
PTEN	PDGFRA_unspecified				soft tissue / gastrointestinal stromal tumour / NS	3	Phase 2	Imatinib		Completed	NCT00112632	APOLLON			Expression level	No		2	10.1200/jco.2012.30.15_suppl.10031			Disease control rate, Clinical benefit rate	6	6																																								
PTEN	PDGFRA_unspecified				stomach / carcinoma / NS	3	Phase 2	Nab-paclitaxel + Tegafur-gimeracil-oteracil potassium		Completed	NCT01336062		PCD	01-DEC-12	No	No		4	NCT01336062			Overall Response Rate	19	19																																								
PDGFRB	PDGFRB_unspecified				NS / other / neoplasm	3	Phase 2	Sorafenib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
PDGFRB	PDGFRB_unspecified				NS / other / neoplasm	3	Phase 2	Pazopanib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
PDGFRB	PDGFRB_unspecified				NS / other / neoplasm	3	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	Yes		1	32292573			Disease control rate, Clinical benefit rate	5	5																																1								
PDGFRB	PDGFRB_unspecified				NS / other / neoplasm	3	Phase 2	Nilotinib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
PDGFRB	PDGFRB_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
PDGFRB	PDGFRB_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
PDGFRB	PDGFRB_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Anlotinib		Recruiting	NCT04004975		ECD	01-JUL-20	Yes	No		4	NCT04004975			Progression free survival	50	50																																								
PDGFRB	PDGFRB_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine + Pevonedistat + Venetoclax		Recruiting	NCT03862157		ECD	01-JAN-24	No	No		4	NCT03862157	Untreated		Complete response, Pathological complete response	40	40																																								
PDGFRB	PDGFRB_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
PDGFRB	PDGFRB_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	29	32		Erlotinib + Placebo									2.84	12	2.69	0.79-9.14	0.95																									
PDGFRB	PDGFRB_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		Terminated	NCT02299141		PCD	01-JAN-20	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12								
PDGFRB	PDGFRB_unspecified				skin / carcinoma / Merkel cell carcinoma	3	Phase 2	Imatinib		Completed	NCT00068783		PCD	01-JUL-07	No	No		1	20019577			Response rate	40	40																																								
PIK3CA	PIK3CA_E542K	55873227		p.E542K	upper aerodigestive tract / carcinoma / squamous cell carcinoma	7	Retrospective/Meta-analysis	Cetuximab + Cisplatin		Completed	NCT01466257		PCD	01-JAN-12	Yes	Yes	Response not correlated with mutation status	2	10.1200/jco.2013.31.15_suppl.6028			Unknown	70																																									
PIK3CA	PIK3CA_E542K	55873227		p.E542K	urinary tract / carcinoma / transitional cell carcinoma	3	Phase 2	Buparlisib		Active, not recruiting	NCT01551030		PCD	01-SEP-20	Yes	Yes	No benefit of treatment	2	10.1200/jco.2015.33.7_suppl.324	Previously-treated		Progression free survival	1	1																																								
PIK3CA	PIK3CA_E545K	55873239		p.E545K	cervix / carcinoma / NS	4	Phase 1	Capivasertib		Active, not recruiting	NCT01226316		PCD	01-APR-19	Yes	Yes		1	29066505			Maximum tolerated dose/toxicity	1	1																															1									
PIK3CA	PIK3CA_E545K	55873239		p.E545K	upper aerodigestive tract / carcinoma / NS	3	Phase 1	Bimirasilib		Completed	NCT01940133		PCD	01-MAR-15	Yes	Yes		1	29660598			Maximum tolerated dose/toxicity	1	1																																1								
PIK3CA	PIK3CA_E545K	55873239		p.E545K	upper aerodigestive tract / carcinoma / squamous cell carcinoma	7	Retrospective/Meta-analysis	Cetuximab + Cisplatin		Completed	NCT01466257		PCD	01-JAN-12	Yes	Yes	Response not correlated with mutation status	2	10.1200/jco.2013.31.15_suppl.6028			Unknown	70																																									
PIK3CA	PIK3CA_E545Q	55878227		p.E545Q	haematopoietic and lymphoid tissue / lymphoid neoplasm / follicular lymphoma	3	Phase 2	Voxtalisib		Completed	NCT01403636		PCD	01-SEP-14	Yes	Yes		1	29550382	Previously-treated		Overall Response Rate	1	1																														1										
PIK3CA	PIK3CA_E545Q	55878227		p.E545Q	upper aerodigestive tract / carcinoma / squamous cell carcinoma	4	Case study	Cisplatin + Docetaxel + Everolimus		Unknown					Yes	Yes	58% radiologic response	1	23408298			Unknown	1	1																															1									
PIK3CA	PIK3CA_Exon20				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Cetuximab		Not yet recruiting	NCT02942706	BLOC-1	ECD	01-OCT-21	Yes	No		4	NCT02942706			Progression free survival	200																																									
PIK3CA	PIK3CA_Exon_9,20				breast / carcinoma / NS	3	Phase 2	Alpelisib + Fulvestrant		Active, not recruiting	NCT03386162	SAFIR PI3K	ECD	01-FEB-22	No	No		4	NCT03386162	Previously-treated		Progression free survival	90			Chemotherapy																																						
PIK3CA	PIK3CA_Exon_9,20				breast / carcinoma / NS	3	Phase 2	Buparlisib + Lapatinib		Suspended	NCT01589861	PIKHER2	ECD	01-JAN-18	Yes	Yes		1	28950146	Previously-treated		Overall Response Rate	4	4																																2								
PIK3CA	PIK3CA_Exon_9,20				breast / carcinoma / NS	3	Phase 2	Buparlisib + Lapatinib		Suspended	NCT01589861	PIKHER2	ECD	01-JAN-18	No	Yes		1	28950146	Previously-treated		Overall Response Rate	24	24																														1		18								
PIK3CA	PIK3CA_H1047R	55873195		p.H1047R	breast / carcinoma / NS	3	Phase 1	Palbociclib + Taselisib		Active, not recruiting	NCT02389842	PIPA	PCD	01-OCT-18	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3087	Previously-treated			1	1																															1									
PIK3CA	PIK3CA_H1047R	55873195		p.H1047R	urinary tract / carcinoma / transitional cell carcinoma	3	Phase 2	Buparlisib		Active, not recruiting	NCT01551030		PCD	01-SEP-20	Yes	Yes	No benefit of treatment	2	10.1200/jco.2015.33.7_suppl.324	Previously-treated		Progression free survival	1	1																																								
PIK3CA	PIK3CA_I391M	55885079		p.I391M	ovary / carcinoma / NS	3	Phase 1	Bimirasilib		Completed	NCT01940133		PCD	01-MAR-15	Yes	Yes		1	29660598			Maximum tolerated dose/toxicity	1	1																																1								
PIK3CA	PIK3CA_R88Q/N345K/C420R/E542K/E545X/Q546X/M1043I/H1047X/G1049R	55873227 + 55873276 + 55873376 + 55878974 + 55898229 + 55874020 + 55874453 + 55874568		p.C420R + p.E542K + p.E545X + p.G1049R + p.H1047? + p.M1043I + p.N345K + p.Q546X + p.R88Q	endometrium / carcinoma / NS	3	Phase 2	Copanlisib		Active, not recruiting	NCT02728258		PCD	01-JUN-20	Yes	Yes		4	NCT02728258	Previously-treated		Overall Response Rate	11	11			0																																					
PIK3CA	PIK3CA_unspecified				NS / malignant melanoma / NS	3	Phase 1	Alpelisib + Infigratinib		Completed	NCT01928459		PCD	01-AUG-16	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.2500	Previously-treated		Maximum tolerated dose/toxicity	62	62																															8									
PIK3CA	PIK3CA_unspecified				NS / malignant melanoma / NS	3	Phase 4	Everolimus		Recruiting	NCT02645149	MatchMel	ECD	01-APR-23	Yes	No		4	NCT02645149			Unknown	1000	1000																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 1	Alpelisib + Binimetinib		Completed	NCT01449058		PCD	01-AUG-16	No	No		4	NCT01449058			Maximum tolerated dose/toxicity	139	139																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 1	ARQ751 + Paclitaxel		Active, not recruiting	NCT02761694		ECD	01-DEC-20	Yes	No		4	NCT02761694			Maximum tolerated dose/toxicity	100	100																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 1	ARQ751 + Fulvestrant		Active, not recruiting	NCT02761694		ECD	01-DEC-20	Yes	No		4	NCT02761694			Maximum tolerated dose/toxicity	100	100																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 1	ARQ751		Active, not recruiting	NCT02761694		ECD	01-DEC-20	Yes	No		4	NCT02761694			Maximum tolerated dose/toxicity	100	100																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 1	CYH33 + Olaparib		Recruiting	NCT04586335		ECD	01-JAN-24	Yes	No		4	NCT04586335			Overall Response Rate	350	350																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 1	Paxalisib + Radiotherapy		Recruiting	NCT04192981		ECD	01-DEC-22	Yes	No		4	NCT04192981			Maximum tolerated dose/toxicity	36	36																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Copanlisib		Recruiting	NCT02465060	MATCH Subprotocol Z1F	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Copanlisib + Ipilimumab + Nivolumab		Recruiting	NCT04317105		ECD	01-DEC-22	Yes	No		4	NCT04317105			Maximum tolerated dose/toxicity	102	102																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Copanlisib + Nivolumab		Recruiting	NCT04317105		ECD	01-DEC-22	Yes	No		4	NCT04317105			Maximum tolerated dose/toxicity	102	102																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Canagliflozin + Serabelisib		Not yet recruiting	NCT04073680		ECD	01-JUL-21	Yes	No		4	NCT04073680			Response rate	60	60																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Capivasertib + Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	No	No		4	NCT02576444			Overall Response Rate	64	64																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Completed	NCT02449538		PCD	01-APR-16	Expression level	Yes	Primary outcome not met	1	28330462	Previously-treated		Overall Response Rate	10	10																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Completed	NCT02449538		PCD	01-APR-16	Yes	Yes	Primary outcome not met	1	28330462	Previously-treated		Overall Response Rate	10	10																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Taselisib		Recruiting	NCT02465060	MATCH Subprotocol I	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	Taselisib		Active, not recruiting	NCT04439175	MATCH-Subprotocol I	PCD	01-MAY-20	Yes	No		4	NCT04439175			Overall Response Rate	70	70																																								
PIK3CA	PIK3CA_unspecified				NS / other / neoplasm	3	Phase 2	MK2206		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Approved FDA	Alpelisib + Fulvestrant	Required	Active, not recruiting	NCT02437318	SOLAR-1	PCD	01-JUN-18	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	Previously-treated		Progression free survival	341	169	172	Fulvestrant + Placebo	35.7	16.2							11	5.7	.65	0.50-0.85	0.0013																									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Buparlisib + Fulvestrant		Completed	NCT01339442		PCD	01-DEC-16	No	Yes	Response not correlated with PIK3CA mutation status	1	26563128	Untreated	Postmenopausal	Maximum tolerated dose/toxicity	29	29																													58.6											
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Ipatasertib + Pertuzumab + Trastuzumab		Recruiting	NCT04253561		ECD	01-MAR-22	Yes	No		4	NCT04253561			Maximum tolerated dose/toxicity	25	25																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Avelumab + Palbociclib		Recruiting	NCT04360941	PAveMenT	ECD	01-JAN-24	No	No		4	NCT04360941			Overall Response Rate	45	45																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Fulvestrant + MEN1611 + Trastuzumab		Recruiting	NCT03767335	B-PRECISE-01	ECD	01-JUL-20	Yes	No		4	NCT03767335			Maximum tolerated dose/toxicity	48	48																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	MEN1611 + Trastuzumab		Recruiting	NCT03767335	B-PRECISE-01	ECD	01-JUL-20	Yes	No		4	NCT03767335			Maximum tolerated dose/toxicity	48	48																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Paclitaxel + Sapanisertib		Completed	NCT02412722		PCD	01-FEB-16	Yes	Yes		1	29464110			Absorption rate	15	15			20.0																		53.3 									1	2									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Palbociclib + Pictilisib		Unknown	NCT02389842	PIPA	PCD	01-OCT-18	Yes	No		4	NCT02389842	Previously-treated		Maximum tolerated dose/toxicity	93	93																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Alpelisib + Elgemtumab + Trastuzumab		Active, not recruiting	NCT02167854		ECD	01-JUN-21	No	No		4	NCT02167854	Previously-treated		Maximum tolerated dose/toxicity	23	23																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Alpelisib + Trastuzumab-emtansine		Completed	NCT02038010		PCD	01-APR-15	No	Yes	Primary outcome met	4	NCT02038010	Previously-treated		Maximum tolerated dose/toxicity	6	6											10.6																													
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Anastrozole + Fulvestrant + MK2206		Completed	NCT01344031		PCD	01-JUL-11	No	Yes		1	26783290	Previously-treated	Postmenopausal	Maximum tolerated dose/toxicity	26	26																5.8					42										2									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Alpelisib + Enzalutamide		Recruiting	NCT03207529		ECD	01-DEC-20	No	No		4	NCT03207529	Previously-treated		Maximum tolerated dose/toxicity	28	28																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Capivasertib		Active, not recruiting	NCT01226316		PCD	01-APR-19	Yes	Yes	Primary outcome not met	1	29066505			Maximum tolerated dose/toxicity	26	26																															12									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	GDC-0077		Recruiting	NCT03006172		ECD	01-DEC-20	Yes	No		4	NCT03006172			Maximum tolerated dose/toxicity	104	104																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Palbociclib + Taselisib		Active, not recruiting	NCT02389842	PIPA	PCD	01-OCT-18	Yes	No		4	NCT02389842	Previously-treated		Maximum tolerated dose/toxicity	93	93																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Buparlisib + Letrozole		Completed	NCT01248494	VICC BRE 1055	PCD	01-DEC-12	No	Yes	Response not correlated with PIK3CA mutation status	1	24663045	Untreated	Postmenopausal	Unknown	51	51																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 1	Dactolisib + Letrozole		Completed	NCT01248494	VICC BRE 1055	PCD	01-DEC-12	No	No		1	24663045	Untreated	Postmenopausal	Maximum tolerated dose/toxicity	72	72																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Buparlisib + Letrozole		Completed	NCT01923168		PCD	01-JUL-17	Yes	Yes	Serious adverse events	1	28576675	Untreated	Postmenopausal	CR, ORR	340																																									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Fulvestrant + TQB3525		Not yet recruiting	NCT04355520		ECD	01-JUN-21	Yes	No		4	NCT04355520			Maximum tolerated dose/toxicity	42	42																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Copanlisib + Eribulin		Not yet recruiting	NCT04345913		ECD	01-DEC-21	No	No		4	NCT04345913			Progression free survival	106	106																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Copanlisib + Pertuzumab + Trastuzumab		Recruiting	NCT04108858		ECD	01-JUN-22	Yes	No		4	NCT04108858			Progression free survival	12			Pertuzumab + Trastuzumab																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Atezolizumab + Capecitabine + Ipatasertib		Recruiting	NCT03853707		ECD	01-JUN-22	No	No		4	NCT03853707			Progression free survival	40	40																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Ipatasertib		Recruiting	NCT03853707		ECD	01-JUN-22	No	No		4	NCT03853707			Progression free survival	40	40																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Ipatasertib + Paclitaxel		Recruiting	NCT03853707		ECD	01-JUN-22	No	No		4	NCT03853707			Progression free survival	40	40																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Everolimus + Rezvilutamide		Recruiting	NCT03805399	FUTURE	ECD	01-JAN-22	Yes	No		4	NCT03805399			Overall Response Rate	140	140																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Abemaciclib + Copanlisib + Fulvestrant		Recruiting	NCT03939897		ECD	01-NOV-22	Yes	No		4	NCT03939897			Progression free survival	194			Abemaciclib + Fulvestrant																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Abemaciclib + Copanlisib + Fulvestrant		Recruiting	NCT03939897		ECD	01-NOV-22	No	No		4	NCT03939897			Progression free survival	194			Abemaciclib + Fulvestrant																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Canagliflozin + Serabelisib		Not yet recruiting	NCT04073680		ECD	01-JUL-21	Yes	No		4	NCT04073680			Response rate	60	60																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Copanlisib + Letrozole		Suspended	NCT03128619	Arm A	ECD	01-AUG-21	No	No		4	NCT03128619	Untreated	Postmenopausal	Change in Ki-67 expression	10			Letrozole + Palbociclib																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Copanlisib + Fulvestrant		Not yet recruiting	NCT03803761		ECD	01-FEB-23	Yes	No		4	NCT03803761	Previously-treated	Postmenopausal	Maximum tolerated dose/toxicity	66	66																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Copanlisib + Letrozole + Palbociclib		Suspended	NCT03128619	Arm B	ECD	01-AUG-21	No	No		4	NCT03128619	Untreated	Postmenopausal	Change in Ki-67 expression	10			Copanlisib + Letrozole																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Atezolizumab + Carboplatin		Active, not recruiting	NCT03206203		ECD	01-NOV-22	No	No		4	NCT03206203			Progression free survival	106																																									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Capivasertib + Fulvestrant		Completed	NCT01992952	FAKTION	PCD	01-MAR-19	No	Yes		2	10.1200/JCO.2019.37.15_suppl.1005	Previously-treated	Postmenopausal	Progression free survival	140	69	71	Fulvestrant + Placebo									10.3	4.8	.57	0.39-0.84	0.0017									26	20	.59	0.34-1.05	0.071												
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Carboplatin + Gemcitabine + Panitumumab		Completed	NCT00894504		PCD	01-SEP-14	No	Yes	No benefit of treatment, response not correlated with mutation status	1	27340049			Progression free survival	71	71			42.0								4.4													11.6						1	29									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Letrozole + Taselisib		Completed	NCT02273973	LORELEI	PCD	01-MAR-17	No	Yes	Response not correlated with PIK3CA mutation status	2	10.1093/annonc/mdx440.001		Postmenopausal	Overall Response Rate	334			Letrozole + Placebo	50.0	39.3		0.049																																		
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Apitolisib + Fulvestrant		Completed	NCT01437566		PCD	01-APR-16	No	Yes	Serious adverse events	1	27155741	Previously-treated	Postmenopausal	Progression free survival	30			Fulvestrant																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Anastrozole + Goserelin + MK2206		Terminated	NCT01776008		PCD	01-MAY-15	Yes	Yes	Primary outcome not met	4	NCT01776008			Complete response, Pathological complete response	16	16																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Anastrozole + MK2206		Terminated	NCT01776008		PCD	01-MAY-15	Yes	Yes	Primary outcome not met	4	NCT01776008		Postmenopausal	Complete response, Pathological complete response	16	16																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	MK2206		Completed	NCT01277757		PCD	01-AUG-14	Yes	Yes		4	NCT01277757			Overall Response Rate	21	21																															1									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Anastrozole + Palbociclib		Recruiting	NCT01723774		ECD	01-APR-22	Yes	No		4	NCT01723774			Cell cycle arrest	87	87																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Capivasertib + Paclitaxel		Active, not recruiting	NCT02423603	PAKT	ECD	01-JUN-20	No	Yes		2	10.1200/JCO.2018.36.15_suppl.1007			Progression free survival	140			Paclitaxel + Placebo									5.9	4.2	.75	0.52-1.08	0.06									19.1	12.6	.64	0.4-1.01	0.02												
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Capivasertib + Paclitaxel		Active, not recruiting	NCT01625286	BEECH	PCD	01-JAN-17	Yes	Yes	No benefit of treatment	2	10.1093/annonc/mdx365.004			Progression free survival	148																																									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Ipatasertib + Paclitaxel		Active, not recruiting	NCT02162719	LOTUS	PCD	01-JUN-16	No	Yes		1	28800861			Progression free survival	124	62	62	Paclitaxel + Placebo									6.2	4.9	.6	0.37-0.98	0.037																									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Cisplatin + Pictilisib		Terminated	NCT01918306		PCD	01-DEC-14	No	Yes	Serious adverse events	4	NCT01918306			MTD, ORR, Toxicity	11	11																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Fulvestrant + Pictilisib		Completed	NCT01437566	Part 2	PCD	01-APR-16	Yes	Yes	No benefit of treatment	1	27155741	Previously-treated	Postmenopausal		61	41	20	Fulvestrant + Placebo	7.3	5.0		0.73					5.4	10	1.07	0.53-2.18	0.84																									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Fulvestrant + Pictilisib		Completed	NCT01437566	Part 1 	PCD	01-APR-16	Yes	Yes	No benefit of treatment	1	27155741	Previously-treated	Postmenopausal		70	38	32	Fulvestrant + Placebo									6.5	5.1	.73	0.42-1.28	0.27																									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Letrozole		Completed	NCT01923168		PCD	01-JUL-17	Yes	No		3	http://clincancerres.aacrjournals.org/content/clincanres/early/2019/02/05/1078-0432.CCR-18-3160.full.pdf	Untreated	Postmenopausal	CR, ORR	257	131	126	Letrozole + Placebo																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Letrozole		Recruiting	NCT03056755	BYLieve	ECD	01-APR-21	No	No		4	NCT03056755	Previously-treated		Progression free survival	390	390																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Ganitumumab		Terminated	NCT01708161		PCD	01-DEC-14	Yes	Yes	No benefit of treatment	2	10.1016/S0959-8049(16)30205-2			Overall Response Rate	47	47																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Fulvestrant		Recruiting	NCT04544189		ECD	01-NOV-23	Yes	No		4	NCT04544189			Progression free survival	135			Alpelisib + Placebo																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Fulvestrant		Recruiting	NCT04524000		ECD	01-JUN-23	Yes	No		4	NCT04524000			Overall Response Rate	50	50																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Alpelisib + Fulvestrant		Recruiting	NCT03056755	BYLieve	ECD	01-APR-21	No	No		4	NCT03056755	Previously-treated		Progression free survival	390	390																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Copanlisib + Trastuzumab		Recruiting	NCT02705859	Panther	ECD	01-JUN-21	No	No		4	NCT02705859	Previously-treated		CR, ORR	26	26																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Paclitaxel + Pilaralisib + Trastuzumab		Completed	NCT01042925		PCD	01-DEC-12	No	Yes	Response not correlated with PIK3CA mutation status	1	25537644	Previously-treated		Unknown	20	20																															4									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Pilaralisib + Trastuzumab		Completed	NCT01042925		PCD	01-DEC-12	No	Yes	Response not correlated with PIK3CA mutation status	1	25537644	Previously-treated		Unknown	21	21																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Paclitaxel + Pictilisib		Completed	NCT01740336	PEGGY	PCD	01-OCT-15	Yes	Yes	No benefit of treatment	1	27573562	Previously-treated		Unknown	183			Paclitaxel																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 2	Buparlisib + Paclitaxel + Trastuzumab		Suspended	NCT01816594	NeoPHOEBE	PCD	01-FEB-15	Yes	Yes	Serious adverse events	1	28923573	Untreated		Complete response, Pathological complete response	50	50																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Buparlisib + Fulvestrant		Active, not recruiting	NCT01610284	BELLE-2	PCD	01-APR-15	No	Yes		1	28576675	Previously-treated		Progression free survival	1149	576	571	Fulvestrant + Placebo									6.9	5	.78	0.67-0.89	0.00021																									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Alpelisib + Nab-paclitaxel		Recruiting	NCT04251533	EPIK-B3	ECD	01-JUN-23	Yes	No		4	NCT04251533			PFS, ORR	566	566		Nab-paclitaxel + Placebo																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Alpelisib + Pertuzumab + Trastuzumab		Recruiting	NCT04208178		ECD	01-MAY-25	Yes	No		4	NCT04208178			Progression free survival	588			Pertuzumab + Placebo + Trastuzumab																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Atezolizumab + Cyclophosphamide + Paclitaxel + Pertuzumab + Trastuzumab + Trastuzumab-emtansine + doxorubicin hydrochloride		Active, not recruiting	NCT03726879	IMpassion050	ECD	01-APR-21	No	No		4	NCT03726879			Complete response, Pathological complete response	453			Cyclophosphamide + Paclitaxel + Pertuzumab + Placebo + Trastuzumab + Trastuzumab-emtansine + doxorubicin hydrochloride																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Trastuzumab		Completed	NCT00829166	EMILIA	PCD	01-JUL-12	Yes	Yes		1	26920887	Previously-treated		OS, PFS	79	40	39	Capecitabine + Lapatinib									10.9	4.3	.45	0.25-0.82																										
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Anastrozole + Exemstane + Letrozole + Palbociclib + Pertuzumab + Trastuzumab		Recruiting	NCT02947685	PATINA	ECD	01-MAY-21	No	No		4	NCT02947685			Progression free survival	496			Anastrozole + Exemstane + Letrozole + Pertuzumab + Trastuzumab																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Fulvestrant + Palbociclib + Pertuzumab + Trastuzumab		Recruiting	NCT02947685	PATINA	ECD	01-MAY-21	No	No		4	NCT02947685			Progression free survival	496			Fulvestrant + Pertuzumab + Trastuzumab																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Fulvestrant + Taselisib		Active, not recruiting	NCT02340221	SANDPIPER	PCD	01-OCT-17	No	Yes		2	10.1200/JCO.2018.36.18_suppl.LBA1006	Previously-treated	Postmenopausal	Progression free survival	516	340	176	Fulvestrant + Placebo	28.0	11.9		0.0002	8.7	7.2			7.4	5.4	.7		0.0037						51.5	37.3																		
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Ipatasertib + Paclitaxel		Recruiting	NCT03337724	IPATunity130	ECD	01-DEC-21	Yes	Yes	Interim reports suggests improved OS	5	https://www.onclive.com/conference-coverage/asco-2018/data-support-phase-3-trial-with-akt-inhibitor-in-triple-negative-breast-cancer			Progression free survival	450	450		Paclitaxel + Placebo																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Alpelisib + Fulvestrant		Active, not recruiting	NCT03439046	BioItaLEE	ECD	01-JUL-22	Yes	No		4	NCT03439046			Biomarker discovery	287	287																																								
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Buparlisib + Paclitaxel		Completed	NCT01572727	BELLE-4	PCD	01-JUN-15	Yes	Yes	No benefit of treatment	1	27803006	Untreated	Postmenopausal	CR, ORR	416	207	209	Paclitaxel																																						
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Buparlisib + Fulvestrant		Terminated	NCT01633060	BELLE-3	PCD	01-MAY-16	No	Yes	Serious adverse events	1	29223745	Previously-treated		Progression free survival	432	289	143	Fulvestrant + Placebo									3.9	1.8	.67	0.53-0.84	0.0003																									
PIK3CA	PIK3CA_unspecified				breast / carcinoma / NS	1	Phase 3	Buparlisib + Fulvestrant		Active, not recruiting	NCT01610284	BELLE-2	PCD	01-APR-15	Yes	Yes		1	28576675	Previously-treated		Progression free survival	372			Fulvestrant + Placebo									6.8	4	.76	0.60-0.97	0.014																									
PIK3CA	PIK3CA_unspecified				central nervous system / glioma / astrocytoma Grade IV	7	Phase 2	Buparlisib		Completed	NCT01339052		PCD	01-OCT-16	Yes	Yes	No benefit of treatment	2	10.1200/JCO.18.01207	Previously-treated		Progression free survival	65	65																																								
PIK3CA	PIK3CA_unspecified				central nervous system / glioma / astrocytoma Grade IV	7	Phase 2	Sonolisib		Completed	NCT01259869		PCD	01-OCT-14	No	Yes	No benefit of treatment, response not correlated with mutation status	1	25605819	Previously-treated		Overall Response Rate	34	34																																7								
PIK3CA	PIK3CA_unspecified				central nervous system / glioma / oligodendroglioma Grade III	3	Phase 1	Palbociclib + Taselisib		Active, not recruiting	NCT02389842	PIPA	PCD	01-OCT-18	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3087	Previously-treated			1	1																															1									
PIK3CA	PIK3CA_unspecified				cervix / carcinoma / NS	3	Phase 1	Capivasertib		Active, not recruiting	NCT01226316		PCD	01-APR-19	Yes	Yes		1	29066505			Maximum tolerated dose/toxicity	25	25																															14									
PIK3CA	PIK3CA_unspecified				cervix / carcinoma / NS	3	Phase 1	Alpelisib		Active, not recruiting	NCT01219699		PCD	01-MAY-13	Yes	Yes		1	29401002			Maximum tolerated dose/toxicity	3	3																															3									
PIK3CA	PIK3CA_unspecified				endometrium / carcinoma / NS	3	Phase 1	Capivasertib		Active, not recruiting	NCT01226316		PCD	01-APR-19	Yes	Yes		1	29066505			Maximum tolerated dose/toxicity	25	25																															14									
PIK3CA	PIK3CA_unspecified				endometrium / carcinoma / NS	3	Phase 1	Anastrozole + Miransertib		Terminated	NCT02476955		PCD	01-MAY-19	Yes	No		4	NCT02476955			ORR, PFS, OR	41	41																																								
PIK3CA	PIK3CA_unspecified				endometrium / carcinoma / NS	3	Phase 1	Miransertib + Paclitaxel		Terminated	NCT02476955		PCD	01-MAY-19	Yes	No		4	NCT02476955			ORR, PFS, OR	41	41																																								
PIK3CA	PIK3CA_unspecified				endometrium / carcinoma / NS	3	Phase 1	Carboplatin + Miransertib + Paclitaxel		Terminated	NCT02476955		PCD	01-MAY-19	Yes	No		4	NCT02476955			ORR, PFS, OR	41	41																																								
PIK3CA	PIK3CA_unspecified				endometrium / carcinoma / NS	3	Phase 1	Alpelisib		Active, not recruiting	NCT01219699		PCD	01-MAY-13	No	Yes		1	29401002			Unknown	1	1																															1									
PIK3CA	PIK3CA_unspecified				endometrium / carcinoma / NS	3	Phase 2	MK2206		Completed	NCT01307631		PCD	01-JAN-16	Yes	Yes	No benefit of treatment	2	10.1200/jco.2013.31.15_suppl.5524	Previously-treated		PFS, ORR	37	37			5.4																																					
PIK3CA	PIK3CA_unspecified				endometrium / carcinoma / NS	3	Phase 2	Everolimus + Letrozole		Active, not recruiting	NCT01068249		ECD	01-APR-21	No	Yes	Response not correlated with mutation status	1	25624430			Disease control rate, Clinical benefit rate	42	42			32																											9	2									
PIK3CA	PIK3CA_unspecified				endometrium / carcinoma / NS	3	Phase 3	Carboplatin + Metformin + Paclitaxel		Active, not recruiting	NCT02065687		PCD	01-APR-19	No	Yes		4	NCT02065687			OS, PFS	469	234	235	Carboplatin + Paclitaxel									9	8.5												34.6	34															
PIK3CA	PIK3CA_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	3	Phase 2	Voxtalisib		Completed	NCT01403636		PCD	01-SEP-14	No	Yes		1	29550382	Previously-treated		Overall Response Rate	35	35			11.4		3.2-26.7						5.6																				4	23								
PIK3CA	PIK3CA_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / diffuse large B cell lymphoma	3	Phase 2	Pilaralisib		Completed	NCT01587040		PCD	01-MAY-18	Yes	Yes		1	25840972			Maximum tolerated dose/toxicity	1	1																																1								
PIK3CA	PIK3CA_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / diffuse large B cell lymphoma	3	Phase 2	Voxtalisib		Completed	NCT01403636		PCD	01-SEP-14	No	Yes		1	29550382	Previously-treated		Overall Response Rate	41	41			4.9		0.6-16.5																										2	4								
PIK3CA	PIK3CA_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / follicular lymphoma	3	Approved FDA	Copanlisib	Required	Active, not recruiting	NCT01660451	CHRONOS-1	PCD	01-JUN-16	No	Yes		4	NCT01660451	Previously-treated		Overall Response Rate	104	104			59				12.2																							15	46									
PIK3CA	PIK3CA_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / follicular lymphoma	3	Phase 2	Voxtalisib		Completed	NCT01403636		PCD	01-SEP-14	No	Yes		1	29550382	Previously-treated		Overall Response Rate	46	46			41.3		27.0?56.8						13.4																			5	14	14								
PIK3CA	PIK3CA_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / mantle cell lymphoma	3	Phase 2	Voxtalisib		Completed	NCT01403636		PCD	01-SEP-14	No	Yes		1	29550382	Previously-treated		Overall Response Rate	42	42			11.9		4.0-25.6																																			
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Palbociclib + Taselisib		Active, not recruiting	NCT02389842	PIPA	PCD	01-OCT-18	Yes	Yes		2	10.1200/JCO.2019.37.15_suppl.3087	Previously-treated			2	2																																2								
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	5-Fluorouracil + Midostaurin + Radiotherapy		Completed	NCT01282502		PCD	01-MAR-15	No	Yes		2	10.1200/JCO.2018.36.15_suppl.e15674			Maximum tolerated dose/toxicity	19	19																															3									
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Alpelisib + Infigratinib		Completed	NCT01928459		PCD	01-AUG-16	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.2500			Maximum tolerated dose/toxicity	1	1																															1									
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	TVB2640		Recruiting	NCT02980029		ECD	01-SEP-20	No	No		4	NCT02980029			Metabolic endpoints (malonyl carnitine and tripalmitin levels) 	48	48																																								
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Alpelisib		Active, not recruiting	NCT01219699		PCD	01-MAY-13	Yes	Yes		1	29401002			Maximum tolerated dose/toxicity	1	1																															1									
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Alpelisib		Active, not recruiting	NCT01219699		PCD	01-MAY-13	Yes	Yes		1	29401002			Maximum tolerated dose/toxicity	1	1																															1									
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFOX + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	MEN1611 + Trastuzumab		Recruiting	NCT04495621	C-PRECISE-01	ECD	01-JUL-23	Yes	No		4	NCT04495621			Overall Response Rate	42	42																																								
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFIRI + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	FOLFIRI + Panitumumab		Active, not recruiting	NCT01312857		ECD	01-MAR-21	No	No		4	NCT01312857			Disease free survival, relapse free survival, regression free survival, recurrence free survival	75	75																																								
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Irinotecan + Panitumumab		Recruiting	NCT03311750	A-REPEAT	ECD	01-MAR-21	No	No		4	NCT03311750			Overall Response Rate	33	33																																								
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Folfirinox + Panitumumab		Recruiting	NCT01328171	VOLFI	PCD	01-JUN-17	No	Yes		1	31609637	Untreated		Overall Response Rate	96	63	33	Folfirinox	87.3	60.6		0.004																																		
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Capecitabine + Telaglenastat		Recruiting	NCT02861300		ECD	01-AUG-20	Yes	No		4	NCT02861300	Previously-treated		Disease control rate, Clinical benefit rate	53	53																																								
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cabozantinib		Active, not recruiting	NCT03542877		ECD	01-MAR-22	No	No		4	NCT03542877	Previously-treated		Progression free survival	43	43																																								
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	MK2206		Unknown	NCT01802320		PCD	01-JUN-15	Yes	Yes		4	NCT01802320	Previously-treated		Overall Response Rate	18	18			0								1.87													6.8			5.83-7.77													
PIK3CA	PIK3CA_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 3	Aspirin		Recruiting	NCT00565708	ASCOLT	ECD	01-DEC-25	No	No		4	NCT00565708	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	1587			Placebo																																						
PIK3CA	PIK3CA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Crizotinib + Dacomitinib		Completed	NCT01121575		PCD	01-FEB-14	No	Yes	Serious adverse events, no benefit of treatment	1	26899759			Maximum tolerated dose/toxicity	70	70																																								
PIK3CA	PIK3CA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Alpelisib		Completed	NCT02276027		PCD	01-OCT-19	Yes	Yes		4	NCT02276027			Overall Response Rate	2	2			0																																					
PIK3CA	PIK3CA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Carboplatin + Paclitaxel + Pictilisib		Completed	NCT01493843	FIGARO	PCD	01-MAR-16	No	Yes	No benefit of treatment	1	28992562	Untreated		Progression free survival	501																																									
PIK3CA	PIK3CA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Carboplatin + Paclitaxel + Pictilisib		Completed	NCT01493843	FIGARO	PCD	01-MAR-16	No	Yes	No benefit of treatment	1	28992562	Untreated		Progression free survival	501																																									
PIK3CA	PIK3CA_unspecified				ovary / carcinoma / NS	3	Phase 1	Capivasertib		Active, not recruiting	NCT01226316		PCD	01-APR-19	Yes	Yes		1	29066505			Maximum tolerated dose/toxicity	25	25																															14									
PIK3CA	PIK3CA_unspecified				ovary / carcinoma / NS	3	Phase 1	Bimirasilib		Completed	NCT02483858		PCD	01-MAR-19	No	Yes		2	10.1200/JCO.2016.34.15_suppl.2560			Maximum tolerated dose/toxicity	1	1																																1								
PIK3CA	PIK3CA_unspecified				ovary / carcinoma / NS	3	Phase 2	Alpelisib + Ganitumumab		Terminated	NCT01708161		PCD	01-DEC-14	Yes	Yes	No benefit of treatment	4	NCT01708161			Maximum tolerated dose/toxicity	47	47																																								
PIK3CA	PIK3CA_unspecified				prostate / carcinoma / NS	3	Unknown	Everolimus		Unknown	NCT02208583		ECD	01-DEC-16	Yes	No		4	NCT02208583	Previously-treated		Progression free survival	150	150																																								
PIK3CA	PIK3CA_unspecified				stomach / carcinoma / NS	3	Phase 1	Alpelisib + Luminespib		Completed	NCT01613950		PCD	01-MAR-14	Yes	No		4	NCT01613950	Previously-treated		Maximum tolerated dose/toxicity	18	18																																								
PIK3CA	PIK3CA_unspecified				stomach / carcinoma / NS	3	Phase 2	Alpelisib + Paclitaxel		Not yet recruiting	NCT04526470		ECD	01-JUN-23	Yes	No		4	NCT04526470			Progression free survival	55	55																																								
PIK3CA	PIK3CA_unspecified				stomach / carcinoma / NS	3	Phase 2	Alpelisib + Paclitaxel		Not yet recruiting	NCT04526470		ECD	01-JUN-23	Yes	No		4	NCT04526470			Progression free survival	55	55																																								
PIK3CA	PIK3CA_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 1	Alpelisib + Cisplatin		Active, not recruiting	NCT02537223		PCD	01-JUN-18	No	No		4	NCT02537223			Maximum tolerated dose/toxicity	9	9																																								
PIK3CA	PIK3CA_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 1	Alpelisib + Infigratinib		Completed	NCT01928459		PCD	01-AUG-16	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.2500			Maximum tolerated dose/toxicity	1	1																															1									
PIK3CA	PIK3CA_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Cetuximab + Ficlatuzumab		Active, not recruiting	NCT03422536		ECD	01-MAY-21	Yes	No		4	NCT03422536	Previously-treated		Progression free survival	74	74																																								
PIK3CA	PIK3CA_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Cetuximab + Sonolisib		Completed	NCT01252628		PCD	01-NOV-13	No	Yes	No benefit of treatment	1	25524478	Previously-treated		Clinical activity	178	178																																								
PIK3CA	PIK3CA_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Cetuximab + Copanlisib		Active, not recruiting	NCT02822482	COPAN-ORL06	ECD	01-NOV-19	Yes	No		4	NCT02822482			Progression free survival	11	11																																								
PIK3CA	PIK3CA_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Alpelisib		Suspended	NCT03601507		ECD	01-DEC-22	No	No		4	NCT03601507			Clinical activity	14	14																																								
PIK3CA	PIK3CA_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Panitumumab		Completed	NCT02643056	S10PANI01	PCD	01-DEC-15	No	Yes		1	28592616	Previously-treated		Overall Response Rate	33	33			6								2.6										51			9.7							2	15								
PIK3CA	PIK3CA_unspecified				urinary tract / carcinoma / transitional cell carcinoma	3	Phase 2	Buparlisib		Active, not recruiting	NCT01551030		PCD	01-SEP-20	No	Yes		2	10.1200/jco.2015.33.7_suppl.324	Previously-treated		Progression free survival	35	35											2.7																				1	6								
PIK3R1	PIK3R1_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
PML	PML-RARA fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Azacitidine + Belinostat		Not yet recruiting	NCT00351975		PCD	01-MAR-13	No	No		4	NCT04088188			Maximum tolerated dose/toxicity	56	56																																								
PMS1	PMS1_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
PMS2	PMS2_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
PMS2	PMS2_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
POLD1	POLD1_unspecified				NS / neoplasm / NS	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
POLD1	POLD1_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
POLD1	POLD1_unspecified				NS / neoplasm / NS	3	Phase 2	Pembrolizumab		Recruiting	NCT02693535	TAPUR group 15	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
POLE	POLE_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
POLE	POLE_unspecified				NS / other / neoplasm	3	Phase 2	Pembrolizumab		Recruiting	NCT02693535	TAPUR group 15	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
PPP2R2A	PPP2R2A_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
PRKDC	PRKDC_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
PTCH1	PTCH1_unspecified				NS / neoplasm / NS	3	Phase 2	Vismodegib		Recruiting	NCT02465060	MATCH Subprotocol T	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
PTEN	PTEN_unspecified				NS / carcinoma / neuroendocrine carcinoma	3	Phase 2	Everolimus		Terminated	NCT02315625		PCD	01-MAY-19	No	Yes	Slow accrual	4	NCT02315625			Progression free survival	16	16																																								
PTEN	PTEN_unspecified				NS / malignant melanoma / NS	3	Out of trials human study	Pembrolizumab		Unknown					Expression level	Yes	PTEN absent tumours significantly less reduction of tumour size (p=0.029)	1	26645196			Unknown	37	37																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 1	TAS0612		Recruiting	NCT04586270	Cohort C	ECD	01-JUN-23	Yes	No		4	NCT04586270			Overall Response Rate	200	200																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 1	ARQ751 + Paclitaxel		Active, not recruiting	NCT02761694		ECD	01-DEC-20	Yes	No		4	NCT02761694			Maximum tolerated dose/toxicity	100	100																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 1	ARQ751 + Fulvestrant		Active, not recruiting	NCT02761694		ECD	01-DEC-20	Yes	No		4	NCT02761694			Maximum tolerated dose/toxicity	100	100																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 1	ARQ751		Active, not recruiting	NCT02761694		ECD	01-DEC-20	Yes	No		4	NCT02761694			Maximum tolerated dose/toxicity	100	100																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 1	ASN003		Terminated	NCT02961283		PCD	01-FEB-19	Yes	No		4	NCT02961283			Disease control rate, Clinical benefit rate	24	24																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 2	Copanlisib		Recruiting	NCT02465060	MATCH Subprotocol Z1H	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 2	Copanlisib + Ipilimumab + Nivolumab		Recruiting	NCT04317105		ECD	01-DEC-22	Yes	No		4	NCT04317105			Maximum tolerated dose/toxicity	102	102																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 2	Copanlisib + Nivolumab		Recruiting	NCT04317105		ECD	01-DEC-22	Yes	No		4	NCT04317105			Maximum tolerated dose/toxicity	102	102																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 2	Capivasertib + Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	No	No		4	NCT02576444			Overall Response Rate	64	64																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 2	GSK2636771		Active, not recruiting	NCT04439149	MATCH-Subprotocol N	PCD	01-DEC-19	Yes	No		4	NCT04439149			Overall Response Rate	24	24																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 2	GSK2636771		Recruiting	NCT02465060	MATCH Subprotocol N	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Completed	NCT02449538		PCD	01-APR-16	Yes	Yes	Primary outcome not met	1	28330462	Previously-treated		Overall Response Rate	10	10																																								
PTEN	PTEN_unspecified				NS / other / neoplasm	3	Phase 2	MK2206		Active, not recruiting	NCT01306045		ECD	01-DEC-22	Yes	No		4	NCT01306045			Response rate	469	469																																								
PTEN	PTEN_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Approved other	Cyclophosphamide + Epirubicin hydrochloride + Lapatinib + Paclitaxel		Unknown	NCT03273595		ECD	01-JUL-19	Yes	No		4	NCT03273595			Complete response, Pathological complete response	100			Cyclophosphamide + Epirubicin hydrochloride + Paclitaxel + Trastuzumab																																						
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 1	Avelumab + Palbociclib		Recruiting	NCT04360941	PAveMenT	ECD	01-JAN-24	No	No		4	NCT04360941			Overall Response Rate	45	45																																								
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Everolimus + Trastuzumab		Completed	NCT00317720		PCD	01-FEB-13	No	Yes	PTEN loss decreased OS	1	21730275			Disease control rate, Clinical benefit rate	47	47											4.1										34										7	9								
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Copanlisib + Eribulin		Not yet recruiting	NCT04345913		ECD	01-DEC-21	No	No		4	NCT04345913			Progression free survival	106	106																																								
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Copanlisib + Pertuzumab + Trastuzumab		Recruiting	NCT04108858		ECD	01-JUN-22	Yes	No		4	NCT04108858			Progression free survival	12			Pertuzumab + Trastuzumab																																						
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Abemaciclib + Copanlisib + Fulvestrant		Recruiting	NCT03939897		ECD	01-NOV-22	Yes	No		4	NCT03939897			Progression free survival	194			Abemaciclib + Fulvestrant																																						
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 2	Ipatasertib + Paclitaxel		Active, not recruiting	NCT02162719	LOTUS	PCD	01-JUN-16	Expression level	Yes	PFS significantly longer in patients with PIK3CA/AKT1/PTEN-altered tumours	1	28800861	Untreated		Unknown	48												6.2	3.7																												
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Everolimus + Trastuzumab + Vinorelbine		Completed					Yes	Yes		1	27091708			Unknown	49			Trastuzumab + Vinorelbine											.54	0.31-0.96	0.04																									
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Phase 3	Alpelisib + Nab-paclitaxel		Recruiting	NCT04251533	EPIK-B3	ECD	01-JUN-23	Yes	No		4	NCT04251533			PFS, ORR	566	566		Nab-paclitaxel + Placebo																																						
PTEN	PTEN_unspecified				breast / carcinoma / NS	3	Retrospective/Meta-analysis	Trastuzumab		Unknown		BCIRG-005/6			Expression level	Yes	Response not correlated with expression level	1	25649019			Disease free survival, relapse free survival, regression free survival, recurrence free survival	2364																																									
PTEN	PTEN_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Sirolimus		Completed	NCT00047073		PCD	01-JUN-05	Expression level	Yes	No benefit of treatment	1	16452206	Untreated		Maximum tolerated dose/toxicity	15	15																																								
PTEN	PTEN_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 2	Buparlisib + Capmatinib		Terminated	NCT01870726		PCD	01-DEC-16	Yes	Yes	No benefit of treatment	2	10.1093/neuonc/nox168.061	Previously-treated		Progression free survival	43	43																																								
PTEN	PTEN_unspecified				endometrium / carcinoma / NS	2	Case study	Olaparib		Unknown					Yes	Yes		1	21468130			Unknown	1	1																															1									
PTEN	PTEN_unspecified				endometrium / carcinoma / NS	2	Phase 1	Samotolisib		Recruiting	NCT01655225				Yes	Yes		1	29636360			Maximum tolerated dose/toxicity	1	1																															1									
PTEN	PTEN_unspecified				endometrium / carcinoma / NS	2	Phase 2	Pilaralisib		Completed	NCT01013324		PCD	01-MAR-13	Yes	Yes	No benefit of treatment, response not correlated with mutation status	1	25528496	Previously-treated		PFS, ORR	67	67																																								
PTEN	PTEN_unspecified				endometrium / carcinoma / NS	2	Phase 2	Temsirolimus		Completed	NCT00072176		PCD	01-MAY-09	Yes	Yes	Response not correlated with expression level	1	21788564			Overall Response Rate	62	62																																								
PTEN	PTEN_unspecified				endometrium / carcinoma / NS	2	Phase 2	Everolimus		Completed	NCT00870337		PCD	01-MAY-08	Yes	Yes	Response not correlated with mutation or expression status	1	23238879			Progression free survival	44	44																																								
PTEN	PTEN_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	5-Fluorouracil + Midostaurin + Radiotherapy		Completed	NCT01282502		PCD	01-MAR-15	No	Yes		2	10.1200/JCO.2018.36.15_suppl.e15674			Maximum tolerated dose/toxicity	19	19																															3									
PTEN	PTEN_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	MK2206		Unknown	NCT00670488		PCD	01-JUL-11	Yes	Yes		1	21289267			Maximum tolerated dose/toxicity	1	1																															1									
PTEN	PTEN_unspecified				prostate / carcinoma / NS	3	Phase 2	GSK2636771		Completed	NCT01458067		PCD	01-NOV-15	Yes	Yes		1	28645941			Overall Response Rate	7	7																															1									
PTEN	PTEN_unspecified				soft tissue / sarcoma / NS	3	Phase 2	Sapanisertib		Recruiting	NCT02987959		PCD	01-SEP-19	Yes	No		4	NCT02987959			Progression free survival	6	6																																								
PTEN	PTEN_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Panitumumab		Completed	NCT02643056	S10PANI01	PCD	01-DEC-15	Expression level	Yes		1	28592616	Previously-treated		Overall Response Rate	33	33			6								2.6										51			9.7							2	15								
PTEN	PTEN_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Cetuximab + Copanlisib		Active, not recruiting	NCT02822482		ECD	01-NOV-19	Yes	No		4	NCT02822482			Progression free survival	11	11																																								
PTEN	PTEN_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Alpelisib		Suspended	NCT03601507		ECD	01-DEC-21	No	No		4	NCT03601507			Defined % decrease in tumour volume	14	14																																								
PTEN	PTEN_unspecified				urinary tract / carcinoma / transitional cell carcinoma	3	Phase 2	Sapanisertib		Recruiting	NCT03745911		ECD	01-NOV-20	Yes	No		4	NCT03745911			Overall Response Rate	52	52																																								
PTPN11	PTPN11_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
PTPN11	PTPN11_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / juvenile myelomonocytic leukaemia	3	Phase 2	Etanercept		Terminated	NCT00509600		PCD	01-APR-09	Yes	Yes	Slow accrual	4	NCT00509600			Response rate	1	1																																								
RAD50	RAD50_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
RAD50	RAD50_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
RAD50	RAD50_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
RAD50	RAD50_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
RAD50	RAD50_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
RAD50	RAD50_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
RAD51B	RAD51B_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
RAD51B	RAD51B_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
RAD51B	RAD51B_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
RAD51C	RAD51C_unspecified				NS / other / neoplasm	3	Phase 1	Olaparib		Completed	NCT03155620	Subprotocol H	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
RAD51C	RAD51C_unspecified				NS / other / neoplasm	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
RAD51C	RAD51C_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
RAD51C	RAD51C_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
RAD51C	RAD51C_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
RAD51C	RAD51C_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
RAD51C	RAD51C_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	01-JUN-23	Yes	No		4	NCT04335669			Complete response, Pathological complete response	820	820																																								
RAD51C	RAD51C_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
RAD51C	RAD51C_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD51C	RAD51C_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
RAD51C	RAD51C_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
RAD51C	RAD51C_unspecified				prostate / carcinoma / NS	1	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
RAD51C	RAD51C_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD51C	RAD51C_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD51D	RAD51D_unspecified				NS / other / neoplasm	3	Phase 1	Olaparib		Completed	NCT03155620	Subprotocol H	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
RAD51D	RAD51D_unspecified				NS / other / neoplasm	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
RAD51D	RAD51D_unspecified				NS / other / neoplasm	3	Phase 2	Berzosertib		Active, not recruiting	NCT03718091	Cohort 3B	ECD	01-APR-22	Yes	No		4	NCT03718091			Disease control rate, Clinical benefit rate	223	223																																								
RAD51D	RAD51D_unspecified				breast / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03344965		ECD	01-DEC-21	Yes	No		4	NCT03344965			Overall Response Rate	114	114																																								
RAD51D	RAD51D_unspecified				breast / carcinoma / NS	3	Phase 2	HX008 + Niraparib		Not yet recruiting	NCT04508803	CHANGEABLE	ECD	01-FEB-22	Yes	No		4	NCT04508803			Overall Response Rate	50	50																																								
RAD51D	RAD51D_unspecified				breast / carcinoma / NS	3	Phase 2	Talazoparib		Recruiting	NCT02401347		ECD	01-DEC-21	Yes	No		4	NCT02401347			Overall Response Rate	40	40																																								
RAD51D	RAD51D_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	01-JUN-23	Yes	No		4	NCT04335669			Complete response, Pathological complete response	820	820																																								
RAD51D	RAD51D_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
RAD51D	RAD51D_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD51D	RAD51D_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
RAD51D	RAD51D_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD51D	RAD51D_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD51	RAD51_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
RAD51	RAD51_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
RAD51	RAD51_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Olaparib		Recruiting	NCT04042831		ECD	01-SEP-21	Yes	No		4	NCT04042831			Best overall response	36	36																																								
RAD51	RAD51_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD51	RAD51_unspecified				pancreas / carcinoma / NS	3	Phase 2	Olaparib + Selumetinib		Unknown	NCT02511223		ECD	01-SEP-17	No	No		4	NCT02511223			Overall Response Rate	24	24																																								
RAD51	RAD51_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
RAD51	RAD51_unspecified				prostate / carcinoma / NS	3	Phase 2	Olaparib		Recruiting	NCT03012321	BRCAAway	ECD	01-DEC-21	Yes	No		4	NCT03012321			Progression free survival	70	70																																								
RAD51	RAD51_unspecified				prostate / carcinoma / NS	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD51	RAD51_unspecified				prostate / carcinoma / NS	3	Phase 2	Niraparib		Recruiting	NCT04030559		ECD	01-AUG-24	Yes	No		4	NCT04030559			Pathologic Response	30	30																																								
RAD51	RAD51_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD52	RAD52_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
RAD54B	RAD54B_unspecified				NS / malignant melanoma / NS	3	Phase 2	Olaparib + Pembrolizumab		Not yet recruiting	NCT04633902		ECD	01-JUN-23	Yes	No		4	NCT04633902			Overall Response Rate	41	41																																								
RAD54L	RAD54L_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
RAD54L	RAD54L_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD54L	RAD54L_unspecified				prostate / carcinoma / NS	1	Approved FDA	Olaparib		Active, not recruiting	NCT02987543	PROfound cohort A+B	PCD	01-JUN-19	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf			Progression free survival	387	256	131	Enzalutamide									5.8	3.5	.49	0.38-0.63	<0.001																									
RAD54L	RAD54L_unspecified				prostate / carcinoma / NS	1	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAD54L	RAD54L_unspecified				urinary tract / papilloma / typical	3	Phase 2	Atezolizumab + Rucaparib 		Recruiting	NCT04276376	ARIANES	ECD	01-APR-24	Yes	No		4	NCT04276376			Overall Response Rate	1000	1000																																								
RAF1	RAF1_unspecified				NS / other / neoplasm	3	Phase 2	Sorafenib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
RAF1	RAF1_unspecified				NS / other / neoplasm	3	Phase 2	Abemaciclib + LY3214996		Not yet recruiting	NCT04534283		ECD	01-SEP-21	Yes	No		4	NCT04534283			Overall Response Rate	35	35																																								
RAF1	RAF1_unspecified				NS / other / neoplasm	3	Phase 2	Regorafenib		Recruiting	NCT02693535	TAPUR group 13	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RB1	RB1_unspecified				NS / other / neoplasm	3	Phase 2	Prexasertib		Active, not recruiting	NCT02873975		ECD	01-JUN-21	Yes	No		4	NCT02873975			Progression free survival	50	50																																								
RB1	RB1_unspecified				breast / carcinoma / NS	3	Phase 1	Avelumab + Palbociclib		Recruiting	NCT04360941	PAveMenT	ECD	01-JAN-24	No	No		4	NCT04360941			Overall Response Rate	45	45																																								
RB1	RB1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Cisplatin + Etoposide + Osimertinib		Recruiting	NCT03567642		ECD	01-JUN-22	Yes	No		4	NCT03567642			Maximum tolerated dose/toxicity	30	30																																								
RET	RET V804M, M918T	60685905 + 60710027		p.M918T + p.V804M	thyroid / carcinoma / medullary carcinoma	4	Case study	Selpercatinib		Unknown					Yes	Yes		1	29912274	Previously-treated		Unknown	1	1																															1									
RET	RET_C634R	60686093		p.C634R	thyroid / carcinoma / medullary carcinoma	3	Phase 2	Sorafenib		Active, not recruiting	NCT00390325		PCD	01-JAN-17	Yes	Yes		1	20368568			Overall Response Rate	1	1																																1								
RET	RET_M918T	60685905		p.M918T	thyroid / carcinoma / medullary carcinoma	2	Phase 2	Sorafenib		Active, not recruiting	NCT00390325		PCD	01-JAN-17	Yes	Yes		1	20368568			Overall Response Rate	9	9																															1	8								
RET	RET_M918T	60685905		p.M918T	thyroid / carcinoma / medullary carcinoma	2	Phase 2	Vandetanib		Active, not recruiting	NCT00514046		PCD	01-DEC-19	Yes	Yes		1	29187393		Pediatric	Overall Response Rate	17	17											80.4																				10	6								
RET	RET_M918T	60685905		p.M918T	thyroid / carcinoma / medullary carcinoma	2	Phase 3	Cabozantinib		Active, not recruiting	NCT00704730	EXAM	PCD	01-OCT-11	Yes	Yes		1	27525386			Progression free survival	126	81	45										14.08	3.92	.15	0.08-0.28	<0.0001																									
RET	RET_unspecified				NS / malignant melanoma / NS	3	Phase 2	Regorafenib		Terminated	NCT02587650		PCD	01-JUL-18	Yes	Yes	Lack of funding	4	NCT02587650			Overall Response Rate	1	1																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 1	Sunitinib		Recruiting	NCT02450123		ECD	01-AUG-20	No	No		4	NCT02450123			Progression free survival	3	3																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 1	GSK3179106		Completed	NCT02798991		PCD	01-NOV-16	No	No		4	NCT02798991			Maximum tolerated dose/toxicity	46	46																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 1	GSK3179106		Completed	NCT02727283		PCD	01-MAR-16	No	No		4	NCT02727283			Maximum tolerated dose/toxicity	16	16																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 1	DS-5010 		Recruiting	NCT03780517		ECD	01-DEC-21	Yes	No		4	NCT03780517			Maximum tolerated dose/toxicity	114	114																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 1	Sunitinib		Recruiting	NCT02691793		ECD	01-DEC-20	No	No		4	NCT02691793			Progression free survival	25	25																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Sorafenib		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Ribociclib + Siremadlin		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Selpercatinib		Recruiting	NCT03899792	LIBRETTO-121	ECD	01-MAR-23	Yes	No		4	NCT03899792		Pediatric	Overall Response Rate	100	100																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Selpercatinib		Recruiting	NCT03155620	Subprotocol N	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Selpercatinib		Not yet recruiting	NCT03155620	Subprotocol N	ECD	01-SEP-27	Yes	No		4	NCT04096417		Pediatric	Overall Response Rate	1000	1000																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Selpercatinib		Not yet recruiting	NCT04320888		ECD	01-SEP-27	Yes	No		4	NCT04320888			Overall Response Rate	49	49																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Selpercatinib		Active, not recruiting	NCT04280081	LIBRETTO-321	ECD	01-MAR-21	No	No		4	NCT04280081			Overall Response Rate	75	75																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Selpercatinib		Recruiting	NCT03157128	LIBRETTO-001	ECD	01-MAR-22	No	No		4	NCT03157128			Overall Response Rate	970	970																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Pralsetinib		Recruiting	NCT03037385	ARROW	ECD	01-DEC-21	No	No		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf			Overall Response Rate	647	647																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	TPX-0046		Recruiting	NCT04161391		ECD	01-MAY-24	Yes	No		4	NCT04161391			Overall Response Rate	362	362																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Ponatinib		Recruiting	NCT02272998		ECD	01-DEC-21	Yes	No		4	NCT02272998			Overall Response Rate	45	45																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	01-DEC-15	Yes	No		1	32292573			Disease control rate, Clinical benefit rate	12	12																																1								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Alectinib		Recruiting	NCT02314481	DARWIN II	ECD	01-NOV-24	Yes	No		4	NCT02314481			Progression free survival	119	119																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT03239015			Overall Response Rate	300	300																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 2	Regorafenib		Recruiting	NCT02693535	TAPUR group 13	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RET	RET_unspecified				NS / other / neoplasm	3	Phase 3	Alectinib		Active, not recruiting	NCT03194893		ECD	01-JUN-24	Yes	No		4	NCT03194893			Maximum tolerated dose/toxicity	200	200																																								
RET	RET_unspecified				adrenal gland / pheochromocytoma / malignant	3	Phase 2	Lenvatinib		Active, not recruiting	NCT03008369		ECD	01-DEC-20	No	No		4	NCT03008369			Response rate	3	3																																								
RET	RET_unspecified				autonomic ganglia / paraganglioma / malignant	3	Phase 2	Lenvatinib		Active, not recruiting	NCT03008369		ECD	01-DEC-20	No	No		4	NCT03008369			Response rate	3	3																																								
RET	RET_unspecified				breast / carcinoma / NS	3	Phase 2	Vandetanib		Terminated	NCT01934335		PCD	01-DEC-18	No	Yes	Drug unavailable	4	NCT01934335			Change in Ki-67 expression	11	11																																								
RET	RET_unspecified				breast / carcinoma / NS	3	Phase 2	Fulvestrant + Vandetanib		Recruiting	NCT02530411	FURVA	ECD	01-DEC-18	No	No		4	NCT02530411			Progression free survival	160	160																																								
RET	RET_unspecified				breast / carcinoma / NS	3	Phase 2	Lenvatinib		Active, not recruiting	NCT03168074		ECD	01-MAR-21	No	No		4	NCT03168074			Clinical activity	30	30																																								
RET	RET_unspecified				kidney / Wilms tumour / NS	3	Phase 2	Sorafenib		Completed	NCT01502410		PCD	01-JUN-14	No	Yes		1	26207356			Overall Response Rate	10	10			0																																					
RET	RET_unspecified				large intestine / carcinoma / adenocarcinoma	3	Out of trials human study	Agerafenib		Unknown					Comparison with wt	Yes		1	29538669			Unknown		24	291																							14.0	38	4.59	3.64-32.66	<0.001												
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Pralsetinib	Required	Recruiting	NCT03037385	ARROW	ECD	01-MAR-20	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf	Untreated		Overall Response Rate	27	27			70		50-86		9																																	
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	01-MAR-22	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Untreated		Overall Response Rate	39	39			85																												33									
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	01-MAR-22	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Previously-treated		Overall Response Rate	105	105			64				17.5																							2	62									
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Pralsetinib	Required	Recruiting	NCT03037385	ARROW	ECD	01-MAR-20	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf	Previously-treated		Overall Response Rate	87	87			57		46-68																																			
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Case study	Alectinib		Unknown					Yes	Yes		1	27544060			Unknown	2	2																															1	1								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Agerafenib		Completed	NCT01877811		PCD	01-DEC-18	Yes	Yes		2	10.1158/2159-8290.CD-18-0839			Maximum tolerated dose/toxicity	31	31			19																												6	12								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Sitravatinib		Active, not recruiting	NCT02219711		ECD	01-AUG-20	Yes	No		4	NCT02219711			Maximum tolerated dose/toxicity	260	260																																								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alectinib		Terminated	NCT03131206		PCD	01-AUG-18	Yes	Yes	Slow accrual, lack of efficacy	4	NCT03131206			Overall Response Rate	5	5																																								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Agerafenib		Completed	NCT03784378		PCD	01-SEP-20	Yes	No		4	NCT03784378			Clinical activity	2	2																																								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Vandetanib		Completed	NCT01823068		PCD	01-DEC-14	Yes	Yes		1	27803005			Overall Response Rate	17	17			18																		65										3	8								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	7	20		Erlotinib + Placebo									2.4	2.33	.69	0.071-6.765	0.376																									
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Apatinib		Unknown	NCT02540824		ECD	01-DEC-16	Yes	No		4	NCT02540824			Overall Response Rate	40	40																																								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Selpercatinib		Recruiting	NCT04268550		ECD	01-FEB-23	Yes	No		4	NCT04268550			Overall Response Rate	124	124																																								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ponatinib		Completed	NCT01813734		PCD	01-JUN-18	Yes	Yes		4	NCT01813734			Overall Response Rate	9	9			0								3.8										55.6											5								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Luminespib		Completed	NCT01922583		PCD	01-FEB-17	Yes	No		4	NCT01922583			Overall Response Rate	31	31																																								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Alectinib		Recruiting	NCT03445000	ALERT-lung	ECD	01-JUN-22	Yes	No		4	NCT03445000			Best overall response	44	44																																								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib		Recruiting	NCT01639508		ECD	01-JUL-21	Yes	No		4	NCT01639508			Overall Response Rate	68	68			33																												2									
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib		Active, not recruiting	NCT03468985		ECD	01-DEC-21	Yes	No		4	NCT03468985			Progression free survival	169	169																																								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib		Recruiting	NCT04131543	CRETA	ECD	01-AUG-20	Yes	No		4	NCT04131543			Disease control rate, Clinical benefit rate	25	25																																								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Vandetanib		Unknown	UMIN000010095	LURET			Yes	Yes		1	27825616			Unknown	19	19			47								4.7																													
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Alectinib		Recruiting	NCT03178552	B-FAST Cohort B	ECD	01-SEP-21	Yes	No		4	NCT03178552			Overall Response Rate	700	700																																								
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Selpercatinib		Recruiting	NCT04194944	LIBRETTO-431	ECD	01-JAN-23	Yes	No		4	NCT04194944			Progression free survival	250																																									
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Pralsetinib		Recruiting	NCT04222972	AcceleRET	ECD	01-SEP-23	Yes	No		4	NCT04222972	Untreated		Progression free survival	250			Best supportive care																																						
RET	RET_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Nintedanib		Terminated	NCT02299141		PCD	01-JAN-20	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12								
RET	RET_unspecified				ovary / carcinoma / NS	3	Phase 1	Agerafenib		Completed	NCT03784378		PCD	01-SEP-20	Yes	No		4	NCT03784378			Clinical activity	1	1																																								
RET	RET_unspecified				salivary gland / carcinoma / NS	3	Phase 2	Dasatinib		Completed	NCT00859937		PCD	01-JAN-13	Expression level	Yes		4	NCT00859937			Disease control rate, Clinical benefit rate	14	14											2.7			1.8-5.5										4.8			2.2-8.0					7								
RET	RET_unspecified				salivary gland / carcinoma / adenoid cystic carcinoma	3	Phase 2	Dasatinib		Completed	NCT00859937		PCD	01-JAN-13	Expression level	Yes		4	NCT00859937			Disease control rate, Clinical benefit rate	40	40											4.8			1.9-5.5										14.5			8.8-31.7				1	20								
RET	RET_unspecified				soft tissue / rhabdomyosarcoma / NS	3	Phase 2	Sorafenib		Completed	NCT01502410		PCD	01-JUN-14	No	Yes		1	26207356			Overall Response Rate	10	10			0																																					
RET	RET_unspecified				thyroid / carcinoma / NS	1	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	01-MAR-22	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Previously-treated		Overall Response Rate	19	19			79				18.4																							1	14									
RET	RET_unspecified				thyroid / carcinoma / NS	1	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	01-MAR-22	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Untreated		Overall Response Rate	8	8			100																											1	7									
RET	RET_unspecified				thyroid / carcinoma / NS	1	Phase 1	Alectinib		Terminated	NCT03131206		PCD	01-AUG-18	Yes	Yes	Slow accrual, Lack of efficacy	4	NCT03131206			Overall Response Rate	5	5																																								
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	3	Approved FDA	Pralsetinib	Required	Recruiting	NCT03037385	ARROW	ECD	01-MAR-20	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf	Previously-treated																																												
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	3	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	01-MAR-22	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Untreated		Overall Response Rate	88	88			73				22																							7	54									
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	3	Approved FDA	Selpercatinib	Required	Recruiting	NCT03157128	LIBRETTO-001	ECD	01-MAR-22	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Previously-treated		Overall Response Rate	55	55			69																											5	33									
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	3	Phase 2	Sunitinib		Active, not recruiting	NCT00381641		PCD	01-DEC-16	No	Yes		4	NCT00381641			Overall Response Rate	25	25			28.0													19.3			7.7-34.6					65.4			27.0-69.5													
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	3	Phase 2	Ponatinib		Not yet recruiting	NCT03838692		ECD	01-DEC-20	No	No		4	NCT03838692			Overall Response Rate	31	31																																								
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	3	Phase 2	Ponatinib		Terminated	NCT01838642		PCD	01-DEC-15	Comparison with wt	Yes	Changed business priorities	4	NCT01838642			Overall Response Rate	3	3																																								
RET	RET_unspecified				thyroid / carcinoma / medullary carcinoma	3	Phase 3	Cabozantinib		Active, not recruiting	NCT00704730	EXAM	PCD	01-OCT-11	No	Yes		1	27525386			Progression free survival	169	107	62										13.85	4.62	.23	0.14-0.38	<0.0001																									
RFC1	RFC1_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RFC2	RFC2_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RFC3	RFC3_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RFC4	RFC4_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RFC5	RFC5_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RICTOR	RICTOR_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
RICTOR	RICTOR_unspecified				urinary tract / carcinoma / NS	3	Phase 1	Durvalumab + Vistusertib		Active, not recruiting	NCT02546661	BISCAY module E	PCD	01-MAR-20	Yes	Yes		3	https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-bladder-cancer/115221-esmo-2019-biscay-an-adaptive-biomarker-directed-platform-study-in-metastatic-urothelial-cancer-with-durvalumab-in-combination-with-targeted-therapies.html	Previously-treated		Maximum tolerated dose/toxicity	29	29			24.1																																					
RNF2	RNF2_unspecified				kidney / carcinoma / clear cell renal cell carcinoma	3	Phase 2	Olaparib		Recruiting	NCT03786796	ORCHID	ECD	01-MAR-21	Yes	No		4	NCT03786796			Overall Response Rate	20	20																																								
ROS1	ROS1_G2032R	63851612		p.G2032R	lung / carcinoma / non small cell carcinoma	4	Case study	Repotrectinib		Unknown	NCT03093116		ECD	01-MAR-21	Yes	Yes		1	30093503			Unknown	1	1																															1									
ROS1	ROS1_unspecified				NS / malignant melanoma / NS	3	Phase 2	Entrecitinib		Terminated	NCT02587650		PCD	01-JUL-18	Yes	Yes	Lack of funding	4	NCT02587650			Overall Response Rate	1	1																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 1	ASP3026		Completed	NCT01284192		PCD	01-FEB-14	Yes	No		4	NCT01284192			Maximum tolerated dose/toxicity	46	46																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 1	Taletrectinib		Active, not recruiting	NCT02675491		ECD	01-DEC-21	Yes	Yes		1	29805770			Maximum tolerated dose/toxicity	15	15			58.3																																					
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Oxazolidine		Not yet recruiting	NCT03239015		ECD	01-JUN-23	Yes	No		4	NCT04116541			Overall Response Rate	300	300																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Abemaciclib + Entrecitinib		Recruiting	NCT03994796		ECD	01-JUL-21	Yes	No		4	NCT03994796			Overall Response Rate	150	150																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Entrecitinib		Recruiting	NCT04591431	ROME	ECD	01-APR-24	Yes	No		4	NCT04591431			Overall Response Rate	384	384																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Entrecitinib		Recruiting	NCT02650401	STARTRK-NG	ECD	01-AUG-29	Yes	No		4	NCT02650401	Previously-treated	Pediatric	Overall Response Rate	68	68																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Entrecitinib		Recruiting	NCT02568267	STARTRK-2	ECD	01-DEC-22	Yes	No		4	NCT02568267			Overall Response Rate	500	500																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Ensartinib		Recruiting	NCT03155620	Subprotocol F	ECD	01-SEP-27	Yes	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Ensartinib		Recruiting	NCT03213652		ECD	01-SEP-24	Yes	No		4	NCT03213652			Overall Response Rate	98	98																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Brigatinib		Recruiting	NCT03868423		ECD	01-DEC-20	Yes	No		4	NCT03868423			Overall Response Rate	20	20																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Crizotinib		Recruiting	NCT03297606	CAPTUR group 3	ECD	01-SEP-21	Yes	No		4	NCT03297606			Overall Response Rate	720	720																																								
ROS1	ROS1_unspecified				NS / other / neoplasm	3	Phase 2	Crizotinib		Recruiting	NCT02465060	MATCH Subprotocol G	ECD	01-JUN-22	Yes	No		4	NCT02465060			Overall Response Rate	6452	6452																																								
ROS1	ROS1_unspecified				biliary tract / carcinoma / adenocarcinoma	3	Phase 2	Ceritinib		Terminated	NCT02374489		PCD	01-JAN-18	Expression level	Yes	No benefit of treatment	4	NCT02374489			Overall Response Rate	9	9																																								
ROS1	ROS1_unspecified				breast / carcinoma / NS	3	Phase 2	Crizotinib + Fulvestrant		Recruiting	NCT03620643	ROLo	ECD	01-DEC-20	Yes	No		4	NCT03620643			Overall Response Rate	58	58																																								
ROS1	ROS1_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Ceritinib		Terminated	NCT02638909		PCD	01-MAR-18	Yes	Yes	Slow enrollment	4	NCT02638909			Disease control rate, Clinical benefit rate	4	4																																								
ROS1	ROS1_unspecified				lung / carcinoma / adenocarcinoma	3	Out of trials human study	Pemetrexed		Unknown					Comparison with wt	Yes		1	23788756			Unknown	76	5	71		60.0	8.5		0.01						3.3			0.008																									
ROS1	ROS1_unspecified				lung / carcinoma / adenocarcinoma	3	Phase 2	Bevacizumab + Crizotinib		Unknown	NCT02946359	CAMAR	ECD	01-OCT-17	Yes	No		4	NCT02946359			Progression free survival	60	60																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Crizotinib	Required	Active, not recruiting	NCT00585195	PROFILE 1001	PCD	01-APR-20	Yes	Yes		1	30980071			Maximum tolerated dose/toxicity	53	53			72		58-83		24.7		15.2-45.3		19.3			15.2-39.1																6	32	10								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Approved FDA	Entrecitinib		Unknown					Yes	Yes		1	31838015			Unknown	53	53			77		64-88																									3	38									
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Case study	Cabozantinib		Unknown					Yes	Yes		1	30217491			Unknown	4	4			25																												1	3								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Dacomitinib		Completed	NCT01121575		PCD	01-FEB-14	Yes	Yes		1	26899759	Previously-treated		Maximum tolerated dose/toxicity	34	34											2.1			1.4-3.5																	1	11								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Crizotinib + Itraconazole + Rifampicin		Active, not recruiting	NCT00585195	PROFILE 1001	PCD	01-APR-20	Yes	No		4	NCT00585195			Maximum tolerated dose/toxicity	596	596																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Anlotinib + Carboplatin + Pemetrexed		Recruiting	NCT03790228	ALTER-L012	ECD	01-OCT-20	Yes	No		4	NCT03790228			Progression free survival	43	43																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Brigatinib + Midazolam		Active, not recruiting	NCT03420742		PCD	01-MAR-20	Yes	No		4	NCT03420742			Maximum tolerated dose/toxicity	24	24																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Entrecitinib		Active, not recruiting	NCT02097810	STARTRK-1	PCD	01-JUN-20	Yes	No		4	NCT02097810			Overall Response Rate	84	84																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Everolimus		Recruiting	NCT02321501		ECD	01-JUN-23	Yes	No		4	NCT02321501			Maximum tolerated dose/toxicity	66	66																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Alkotinib		Recruiting	NCT03607188		ECD	01-FEB-21	Yes	No		4	NCT03607188	Previously-treated		Maximum tolerated dose/toxicity	18	18																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Binimetinib + Brigatinib		Recruiting	NCT04005144		ECD	01-AUG-22	Yes	No		4	NCT04005144			Maximum tolerated dose/toxicity	18	18																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 1	Ceritinib + Trametinib		Recruiting	NCT03087448		ECD	01-JUN-21	Yes	No		4	NCT03087448			Maximum tolerated dose/toxicity	69	69																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib		Recruiting	NCT01639508		ECD	01-JUL-21	Yes	No		4	NCT01639508			Overall Response Rate	68	68																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Pembrolizumab + Recombinant EphB4-HSA fusion protein		Recruiting	NCT03049618		ECD	01-MAY-21	Yes	No		4	NCT03049618			Overall Response Rate	50	50																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Cabozantinib + Ipilimumab + Nivolumab		Active, not recruiting	NCT03468985		ECD	01-DEC-21	Yes	No		4	NCT03468985			Progression free survival	169	169																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Nivolumab + Plinabulin		Terminated	NCT02846792		PCD	01-JUL-18	Yes	Yes	Changed business priorities	4	NCT02846792			Overall Response Rate	5	5																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Foretinib		Withdrawn	NCT02034097		PCD	01-APR-14	Yes	Yes	Development discontinued	4	NCT02034097			Unknown	0	0																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Anlotinib + Pemetrexed		Recruiting	NCT03778138	ALTER-L025	ECD	01-DEC-19	Yes	No		4	NCT03778138			Progression free survival	51	51																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Avelumab + Axitinib + Palbociclib		Recruiting	NCT03386929	SPRING	ECD	01-OCT-23	Yes	No		4	NCT03386929			Progression free survival	130	130																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Docetaxel + Sintilimab		Recruiting	NCT03798743	Success	ECD	01-JUN-21	Yes	No		4	NCT03798743			Overall Response Rate	30	30																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Radiotherapy		Not yet recruiting	NCT04193007	BRATR	ECD	01-DEC-21	Yes	No		4	NCT04193007			Progression free survival	100	100																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	WX-0593		Recruiting	NCT03389815		ECD	01-JUN-20	Yes	No		4	NCT03389815			Maximum tolerated dose/toxicity	48	48																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	TQ-B3101		Recruiting	NCT03972189		ECD	01-MAR-21	Yes	No		4	NCT03972189			Overall Response Rate	111	111																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Lorlatinib		Unknown	NCT03439215	PFROST	ECD	01-DEC-19	Yes	No		4	NCT03439215	Previously-treated		Response rate	20	20																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Repotrectinib		Recruiting	NCT04094610		ECD	01-DEC-22	Yes	No		4	NCT04094610			Maximum tolerated dose/toxicity	75	75																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Repotrectinib		Recruiting	NCT03093116	TRIDENT-1	ECD	01-MAR-21	Yes	No		4	NCT03093116			Overall Response Rate	450	450																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Entrecitinib		Recruiting	NCT02568267	STARTRK-2	ECD	01-DEC-22	Yes	No		4	NCT02568267			Overall Response Rate	500	500																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Stereotactic Body Radiation Therapy		Recruiting	NCT02314364		ECD	01-NOV-21	Yes	No		4	NCT02314364			Unknown	30	30																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed		Recruiting	NCT04042558		ECD	01-JUN-21	Yes	No		4	NCT04042558	Previously-treated		Overall Response Rate	149	149																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Luminespib		Completed	NCT01922583		PCD	01-FEB-17	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib + Onalespib lactate		Completed	NCT01712217		PCD	01-DEC-16	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.9059			Overall Response Rate	136	68	68		55.4	45.3																																				
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Recruiting	NCT03574402	TRUMP Arm 5	ECD	01-DEC-22	Yes	No		4	NCT03574402			Response rate	400	400																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ensartinib		Recruiting	NCT03608007		ECD	01-MAR-20	Yes	No		4	NCT03608007			Overall Response Rate	69	69																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Brigatinib		Active, not recruiting	NCT01449461		PCD	01-NOV-15	Yes	No		4	NCT01449461			Overall Response Rate	137	137																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Not yet recruiting	NCT04621188	ALBATROS	ECD	01-JUL-23	Yes	No		4	NCT04621188	Previously-treated		Overall Response Rate	84	84																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Recruiting	NCT02927340		ECD	01-MAY-21	Yes	No		4	NCT02927340			Disease control rate, Clinical benefit rate	30	30																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Not yet recruiting	NCT03612154		ECD	01-DEC-22	Yes	No		4	NCT03612154			Overall Response Rate	35	35																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Active, not recruiting	NCT01970865		PCD	01-MAR-17	Yes	Yes		1	31669155 	Previously-treated		Overall Response Rate	40	40			35				13.8																																	
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Lorlatinib		Active, not recruiting	NCT01970865		PCD	01-MAR-17	Yes	Yes		1	31669155 	Untreated		Overall Response Rate	21	21			62				25.3																																	
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02276027		PCD	01-OCT-19	Yes	Yes		4	NCT02276027			Overall Response Rate	26	26			73.1																																					
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Completed	NCT02186821	SIGNATURE	PCD	01-DEC-17	Yes	No		4	NCT02186821			Disease control rate, Clinical benefit rate	47	47																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Recruiting	NCT03399487		ECD	01-MAY-20	Yes	No		4	NCT03399487			Overall Response Rate	46	46																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Ceritinib		Recruiting	NCT01964157		ECD	01-DEC-19	Yes	Yes		1	28520527			Overall Response Rate	32	32			62		45-77		21		17-25		9.3										81			24			5-43													
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Recruiting	NCT02664935		ECD	01-OCT-22	Yes	No		4	NCT02664935			Overall Response Rate	549	549																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Withdrawn	NCT03088930		PCD	01-MAY-18	Yes	Yes	Slow accrual	4	NCT03088930	Untreated		Overall Response Rate	0	0																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Not yet recruiting	NCT04084717	CROME	ECD	01-DEC-24	Yes	No		4	NCT04084717			Response rate	50	50																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Unknown	NCT02499614	METROS	ECD	01-JUN-18	Yes	Yes		1	31416808			Response rate	26	26			65				21.4		12.7-30.1		22.8			15.2-30.3							85									1	16									
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Active, not recruiting	NCT02183870	EUCROSS	PCD	01-APR-17	Yes	Yes		1	30978502			Overall Response Rate	30	30			73		54-88																83																			
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Recruiting	NCT01964157		ECD	01-DEC-19	Yes	No		4	NCT01964157			Overall Response Rate	32	32																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Active, not recruiting	NCT01945021		PCD	01-JUL-15	Yes	Yes		1	29596029			Overall Response Rate	129	129			71.7		63-79		19.7		14.1-NR		15.9			12.9-24																17	74									
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 2	Crizotinib		Active, not recruiting	NCT02034981	AcSe	PCD	01-JUN-19	Yes	Yes		1	31584608			Overall Response Rate	37	37			47.2																																					
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 3	Entrecitinib		Recruiting	NCT03178552	B-FAST Cohort D	ECD	01-SEP-21	Yes	No		4	NCT03178552			Overall Response Rate	700	700																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Phase 4	Crizotinib		Recruiting	NCT03672643		ECD	01-DEC-26	Yes	No		4	NCT03672643	Previously-treated		Maximum tolerated dose/toxicity	75	75																																								
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Retrospective/Meta-analysis	Crizotinib		Unknown		EUROS1			Yes	Yes		1	25667280			Unknown	29	29			80								9.1										86.6																			
ROS1	ROS1_unspecified				lung / carcinoma / non small cell carcinoma	1	Retrospective/Meta-analysis	Entrecitinib		Unknown					Yes	Yes		1	33646820				108	108			67.1		59.3-74.3						15.7																													
ROS1	ROS1_unspecified				soft tissue / inflammatory myofibroblastic tumour / NS	3	Phase 3	Crizotinib		Recruiting	NCT03874273		ECD	01-FEB-21	Yes	No		4	NCT03874273			Overall Response Rate	25	25																																								
RPA1	RPA1_unspecified				NS / neoplasm / NS	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RPA1	RPA1_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
RPA2	RPA2_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RPA3	RPA3_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RPA4	RPA4_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
RPTOR	RPTOR_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Recruiting	NCT02029001	MOST plus	ECD	01-JAN-23	Yes	No		4	NCT02029001			Progression free survival	560	560																																								
RTEL1	RTEL1_unspecified				pancreas / carcinoma / ductal carcinoma	3	Phase 2	Olaparib + Pembrolizumab		Recruiting	NCT04666740	POLAR Cohort B	ECD	01-JAN-24	Yes	No		4	NCT04666740	Previously-treated		Progression free survival	63	63																																								
RUNX1	RUNX1-RUNX1T1 fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Veliparib		Active, not recruiting	NCT01139970		PCD	01-MAR-14	No	Yes		1	27503200			Maximum tolerated dose/toxicity	48	48																								5.3			3.3-8.3			8		8								
RUNX1	RUNX1-RUNX1T1 fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Carboplatin + Topotecan + Veliparib		Active, not recruiting	NCT00588991		PCD	01-FEB-14	No	No		4	NCT00588991			Maximum tolerated dose/toxicity	12	12																																								
RUNX1	RUNX1-RUNX1T1 fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Topotecan + Veliparib		Active, not recruiting	NCT00588991		PCD	01-FEB-14	No	No		4	NCT00588991			Maximum tolerated dose/toxicity	12	12																																								
RUNX1	RUNX1-RUNX1T1 fusion				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine		Completed	NCT02450877	AZA-AML-004	PCD	01-OCT-18	No	No		3	https://ash.confex.com/ash/2020/webprogram/Paper137043.html		Pediatric	Progression free survival	3	3																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Hematopoietic Stem Cell Transplant + Lenalidomide		Completed	NCT01254578		PCD	01-NOV-12	No	No		4	NCT01254578			Maximum tolerated dose/toxicity	17	17																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	35	28	7	Cytarabine	36	0																																				
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute leukaemia	3	Phase 1	Bortezomib + Tipifarnib		Completed	NCT00383474		PCD	01-JUN-12	No	No		1	21233404	Previously-treated		Maximum tolerated dose/toxicity	27	27																															2	5								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Cytarabine + Idarubicin + Lenalidomide		Completed	NCT01132586		PCD	01-JAN-14	No	No		4	NCT01132586			Maximum tolerated dose/toxicity	61	61																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Azacitidine + Etoposide + Mitoxantrone hydrochloride		Terminated	NCT01260714	A-NOVE	PCD	01-MAR-15	No	Yes	Slow accrual	4	NCT01260714		Geriatric	Maximum tolerated dose/toxicity	13	13																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Azacitidine + Belinostat		Completed	NCT00351975		PCD	01-MAR-13	No	No		4	NCT00351975			Maximum tolerated dose/toxicity	56	56																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Erlotinib		Active, not recruiting	NCT01664897		PCD	01-OCT-18	No	Yes	mEFS  1.16	3	https://doi.org/10.1159/000490092			Overall Response Rate	29	29																								3.23																
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Mitoxantrone hydrochloride + Venetoclax		Not yet recruiting	NCT04330820	RELAX	ECD	01-JUN-22	No	No		4	NCT04330820	Previously-treated		Overall Response Rate	60	60																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine + Gemtuzumab Ozogamicin		Active, not recruiting	NCT00658814		PCD	01-JAN-13	No	Yes		1	24092933	Previously-treated	Geriatric	Complete remission	133	133																								11.0									7.5							
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Daunorubicin + Samalizumab		Recruiting	NCT03013998	BAML-16-001-S1 	ECD	01-DEC-21	No	No		4	NCT03013998	Untreated		Overall Response Rate	2000	2000																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Busulfan + Cytarabine + Daunorubicin + Decitabine + Etoposide + Filgrastim + Hematopoietic Stem Cell Transplant		Completed	NCT00416598		PCD	01-JAN-11	No	Yes	No benefit of treatment	1	27624549	Untreated		Unknown	134	234																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine + Entinostat		Completed	NCT00313586		PCD	01-JUL-13	No	Yes	Serious adverse events	1	26577691			Composite complete remission	197	197																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Anti-thymocyte globulin + Azacitidine + Busulfan + Fludarabine + Hematopoietic Stem Cell Transplant + Methotrexate + Tacrolimus		Active, not recruiting	NCT01168219	NSC#102816	PCD	01-NOV-15	No	Yes	PFS at 5 years 26.9%	4	NCT01168219		Geriatric	Progression free survival	68	68																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Filgrastim + Fludarabine + Gemtuzumab Ozogamicin + Idarubicin		Recruiting	NCT00801489		ECD	01-APR-20	No	No		4	NCT00801489	Untreated		Complete remission	200	200																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + MK-8776		Completed	NCT01870596		PCD	01-DEC-14	No	No	No benefit of treatment	1	28957699			Overall Response Rate	32	32																								5.91	4.48			0.93												
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Hematopoietic Stem Cell Transplant + Lenalidomide		Terminated	NCT02038153		PCD	01-JAN-15	No	Yes	Slow accrual	4	NCT02038153		Geriatric	Disease free survival, relapse free survival, regression free survival, recurrence free survival	3	3																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Daunorubicin + Sorafenib		Active, not recruiting	NCT01253070		PCD	01-OCT-14	No	No		4	NCT01253070		Geriatric	Overall survival	54	54																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Decitabine + Glasdegib		Active, not recruiting	NCT04051996	GLAD-AML	ECD	01-SEP-21	No	No		4	NCT04051996		Geriatric	Complete remission	1	1																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Tipifarnib		Completed	NCT01361464		PCD	01-NOV-14	No	No	Primary outcome not met	4	NCT01361464	Previously-treated	Geriatric	Complete remission	21	21																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Tipifarnib		Completed	NCT00093470		PCD	01-FEB-15	No	Yes		4	NCT00093470			Disease free survival, relapse free survival, regression free survival, recurrence free survival	144	73	71	Clinical observation																															8.87	5.26	.76	0.54-1.07	0.026			
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Ruxolitinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Azacitidine + Deferasirox		Terminated	NCT02159040		PCD	01-JUN-15	Yes	Yes	Serious adverse events	4	NCT02159040			Overall Response Rate	1	1																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myeloproliferative neoplasm	3	Phase 1	Sorafenib		Completed	NCT00217646		PCD	01-DEC-10	No	No		1	20952518			Maximum tolerated dose/toxicity	50	50																																								
RUNX1	RUNX1_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	3	Phase 3	Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Vincristine		Recruiting	NCT03117751	TOT17	ECD	01-SEP-26	No	No		4	NCT03117751	Untreated		Event free survival	1000	1000																																								
SF3B1	SF3B1_K700E	59205318		p.K700E	pancreas / carcinoma / NS	3	Phase 1	Bortezomib + E7107		Suspended	NCT00459823		ECD	01-JUN-09	No	Yes		1	23983259			Maximum tolerated dose/toxicity	40	40																															1									
SF3B1	SF3B1_K700E	59205318		p.K700E	pancreas / carcinoma / NS	3	Phase 1	Bortezomib + E7107		Suspended	NCT00499499		ECD	01-JUN-09	No	Yes		1	24258465			Maximum tolerated dose/toxicity	26	26																																								
SF3B1	SF3B1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	H3B-8800		Active, not recruiting	NCT02841540		ECD	01-DEC-20	No	No		2	10.1097/01.HS9.0000562432.36004.ed			Maximum tolerated dose/toxicity	200	200																																								
SF3B1	SF3B1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Gilteritinib		Recruiting	NCT03013998	BAML-16-001-S8 	ECD	01-DEC-21	No	No		4	NCT03013998			Complete remission	2000	2000																																								
SF3B1	SF3B1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Mitoxantrone hydrochloride + Venetoclax		Not yet recruiting	NCT04330820	RELAX	ECD	01-JUN-22	No	No		4	NCT04330820	Previously-treated		Overall Response Rate	60	60																																								
SF3B1	SF3B1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 1	H3B-8800		Recruiting	NCT02841540		ECD	01-DEC-20	No	No		4	NCT02841540			Maximum tolerated dose/toxicity	200	200																																								
SF3B1	SF3B1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Vemurafenib		Terminated	NCT01586195		PCD	01-APR-15	Yes	Yes		2	10.1200/jco.2014.32.15_suppl.9075			PFS, ORR	1	1																															1									
SF3B1	SF3B1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 1	H3B-8800		Active, not recruiting	NCT02841540		ECD	01-DEC-20	No	No		2	10.1097/01.HS9.0000562432.36004.ed			Maximum tolerated dose/toxicity	200	200																																								
SF3B1	SF3B1_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	3	Phase 2	Vemurafenib		Terminated	NCT01586195		PCD	01-APR-15	Yes	Yes		2	10.1200/jco.2014.32.15_suppl.9075			PFS, ORR	1	1																															1									
SF3B1	SF3B1_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	3	Phase 2	Ibrutinib + Rituximab		Active, not recruiting	NCT02232386	LLC1114	ECD	01-MAY-21	No	No		4	NCT02232386			Progression free survival	156	156																																								
SLX4	SLX4_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
SMARCA4	SMARCA4_unspecified				NS / other / neoplasm	3	Phase 1	Tazemetostat hydrobromide		Completed	NCT03155620	Subprotocol C	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
SMARCB1	SMARCB1_unspecified				NS / other / neoplasm	3	Phase 1	Tazemetostat hydrobromide		Completed	NCT03155620	Subprotocol C	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
SMO	SMO_A459V	50825992		p.A459V	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759019			Unknown	1	1																																								
SMO	SMO_C469Y	50827270		p.C469Y	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759019			Unknown	1	1																																								
SMO	SMO_D473G			p.D473G	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759020			Unknown	3	3																																								
SMO	SMO_D473G			p.D473G	skin / carcinoma / basal cell carcinoma	4	Case study	Sonidegib		Unknown					Yes	Yes	No benefit of treatment	1	26546616			Unknown	1	1																																								
SMO	SMO_D473H	50830986		p.D473H	central nervous system / primitive neuroectodermal tumour-medulloblastoma / NS	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	19726788			Unknown	1	1																																								
SMO	SMO_D473H	50830986		p.D473H	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759020			Unknown	1	1																																								
SMO	SMO_D473H	50830986		p.D473H	skin / carcinoma / basal cell carcinoma	4	Case study	Sonidegib		Unknown					Yes	Yes	No benefit of treatment	1	26546616			Unknown	1	1																																								
SMO	SMO_D473N	99976277		p.D473N	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759020			Unknown	1	1																																								
SMO	SMO_D473Y	50837084		p.D473Y	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Completed	NCT01367665		PCD	01-JUN-17	Yes	Yes	CR at 5 months, PD at 11 months	1	25306392			Unknown	1	1																																								
SMO	SMO_G497W	50829974		p.G497W	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Completed	NCT01367665		PCD	01-JUN-17	Yes	Yes	PD at 2 months	1	25306392			Unknown	1	1																																								
SMO	SMO_H231R			p.H231R	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759020			Unknown	2	2																																								
SMO	SMO_I408V	50824941		p.I408V	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759019			Unknown	1	1																																								
SMO	SMO_L412F	50824425		p.L412F	bone / other / ameloblastoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	24859340			Unknown	1	1																																								
SMO	SMO_P641A	50852667		p.P641A	lung / carcinoma / non small cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes		2	10.1200/PO.17.00149	Previously-treated		Unknown	1	1																															1									
SMO	SMO_Q477E			p.Q477E	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759020			Unknown	1	1																																								
SMO	SMO_Q477E			p.Q477E	skin / carcinoma / basal cell carcinoma	4	Case study	Sonidegib		Unknown					Yes	Yes	No benefit of treatment	1	26546616			Unknown	1	1																																								
SMO	SMO_Q477E			p.Q477E	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	26546616			Unknown	1	1																																								
SMO	SMO_S533N	50828491		p.S533N	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	9422511			Unknown	1	1																																								
SMO	SMO_S533N	50828491		p.S533N	skin / carcinoma / basal cell carcinoma	4	Case study	Sonidegib		Unknown					Yes	Yes	No benefit of treatment	1	26546616			Unknown	1	1																																								
SMO	SMO_S533N	50828491		p.S533N	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	26546616			Unknown	1	1																																								
SMO	SMO_S533N	50828491		p.S533N	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759019			Unknown	1	1																																								
SMO	SMO_T241M	50825320		p.T241M	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759019			Unknown	1	1																																								
SMO	SMO_V321M	50828671		p.V321M	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25199678			Unknown	1	1																																								
SMO	SMO_W281C	50825106		p.W281C	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25199678			Unknown	1	1																																								
SMO	SMO_W281C	50825106		p.W281C	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759020			Unknown	2	2																																								
SMO	SMO_W535L	50824509		p.W535L	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	25759020			Unknown	3	3																																								
SMO	SMO_W535L	50824509		p.W535L	skin / carcinoma / basal cell carcinoma	4	Case study	Sonidegib		Unknown					Yes	Yes		1	26546616			Unknown	1	1																																1								
SMO	SMO_W535L	50824509		p.W535L	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	26546616			Unknown	1	1																																								
SMO	SMO_W535L	50824509		p.W535L	skin / carcinoma / basal cell carcinoma	4	Case study	Vismodegib		Unknown					Yes	Yes	No benefit of treatment	1	9422511			Unknown	1	1																																								
SMO	SMO_unspecified				NS / other / neoplasm	3	Phase 2	Vismodegib		Active, not recruiting	NCT02091141		ECD	01-MAR-21	Yes	No		4	NCT02091141			Overall Response Rate	658	658																																								
SMO	SMO_unspecified				NS / other / neoplasm	3	Phase 2	Sonidegib		Terminated	NCT02002689	SIGNATURE	PCD	01-MAR-15	Yes	Yes	Slow accrual	4	NCT02002689			Overall Response Rate	10	10																																								
SMO	SMO_unspecified				NS / other / neoplasm	3	Phase 2	Vismodegib		Recruiting	NCT02465060	MATCH Subprotocol T	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
SMO	SMO_unspecified				NS / other / neoplasm	3	Phase 2	Vismodegib		Recruiting	NCT03297606	CAPTUR group 13 	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
SMO	SMO_unspecified				NS / other / neoplasm	3	Phase 2	Vismodegib		Recruiting	NCT02925234	DRUP	ECD	01-AUG-22	Yes	No		4	NCT02925234			Unknown	950	950																																								
SMO	SMO_unspecified				bone / chondrosarcoma / NS	3	Phase 2	Vismodegib		Active, not recruiting	NCT01267955		PCD	01-JUN-18	No	Yes	Primary outcome not met	4	24170610			Disease control rate, Clinical benefit rate	39	39											3.5										25.6			12.4																
SMO	SMO_unspecified				central nervous system / primitive neuroectodermal tumour-medulloblastoma / NS	3	Phase 2	Sonidegib		Completed	NCT01125800		PCD	01-OCT-14	No	Yes		4	NCT01125800		Pediatric	Overall Response Rate	60	60			3.3																											2		5								
SMO	SMO_unspecified				central nervous system / primitive neuroectodermal tumour-medulloblastoma / NS	3	Phase 2	Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine + Vismodegib		Recruiting	NCT01878617		ECD	01-JUN-23	No	No		4	NCT01878617			Progression free survival	625	625																																								
SMO	SMO_unspecified				central nervous system / primitive neuroectodermal tumour-medulloblastoma / NS	3	Phase 2	Temozolomide + Vismodegib		Terminated	NCT01601184		PCD	01-SEP-17	No	Yes	No benefit of treatment	4	NCT01601184			Maximum tolerated dose/toxicity	24			Temozolomide																																						
SMO	SMO_unspecified				central nervous system / primitive neuroectodermal tumour-medulloblastoma / NS	3	Phase 2	Sonidegib		Completed	NCT01125800		PCD	01-OCT-14	No	Yes		4	NCT01125800			Overall Response Rate	16	16			18.8																											2	1	6								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Cytarabine + Glasdegib		Recruiting	NCT02038777		ECD	01-NOV-20	No	No		4	NCT02038777			Maximum tolerated dose/toxicity	48	48																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Cytarabine + Daunorubicin + Glasdegib		Recruiting	NCT02038777		ECD	01-NOV-20	No	No		4	NCT02038777			Maximum tolerated dose/toxicity	48	48																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Azacitidine + Glasdegib		Recruiting	NCT02038777		ECD	01-NOV-20	No	No		4	NCT02038777			Maximum tolerated dose/toxicity	48	48																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Vismodegib		Terminated	NCT01880437		PCD	01-NOV-14	No	Yes	No benefit of treatment	4	NCT01880437			Overall Response Rate	38	38																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	BMS-833923 + Dasatinib		Terminated	NCT01357655		PCD	01-JAN-16	No	Yes	Slow accrual	4	NCT01357655	Untreated		Unknown	70	70																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	BMS-833923 + Dasatinib		Completed	NCT01218477		PCD	01-APR-13	No	Yes	Development discontinued	4	NCT01218477			Maximum tolerated dose/toxicity	33	33																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 1	Azacitidine + Sonidegib		Completed	NCT02129101		PCD	01-DEC-16	No	No		4	NCT02129101			Best overall response	63	63																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 1	Cytarabine + Daunorubicin + Glasdegib		Recruiting	NCT02038777		ECD	01-AUG-20	No	No		4	NCT02038777			Maximum tolerated dose/toxicity	49	49																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 1	Decitabine + Sonidegib		Completed	NCT02129101		PCD	01-DEC-16	No	No		4	NCT02129101			Best overall response	63	63																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Vismodegib		Terminated	NCT01880437		PCD	01-NOV-14	No	Yes	No benefit of treatment	4	NCT01880437			Overall Response Rate	38	38																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Vismodegib		Recruiting	NCT03297606	CAPTUR group 13	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
SMO	SMO_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 2	Vismodegib		Recruiting	NCT02925234	DRUP	ECD	01-AUG-22	No	No		4	NCT02925234			Unknown	950	950																																								
SMO	SMO_unspecified				meninges / meningioma / NS	3	Phase 2	Vismodegib		Suspended	NCT02523014		ECD	01-AUG-21	Yes	No		4	NCT02523014			PFS, ORR	69	69																																								
SMO	SMO_unspecified				pancreas / carcinoma / NS	3	Phase 2	Gemcitabine + Vismodegib		Completed	NCT01064622		PCD	01-DEC-12	No	Yes		1	26527777			Progression free survival	106	53	53	Gemcitabine									4	2.5	.81		0.30									6.9	6.1	1.04	0.69-1.58	0.84												
SMO	SMO_unspecified				prostate / carcinoma / NS	3	Phase 2	Goserelin + Leuprolide Acetate  + Vismodegib		Terminated	NCT01163084		PCD	01-JUN-12	No	No		4	NCT01163084			Unknown	10	10																																								
SMO	SMO_unspecified				skin / carcinoma / basal cell carcinoma	3	Case study	Sonidegib		Completed	NCT01327053	BOLT	PCD	01-JUN-13	No	Yes		1	9422511			Overall Response Rate	66	66			56		43-68		26.1																							3	34									
SMO	SMO_unspecified				skin / carcinoma / basal cell carcinoma	3	Phase 2	Vismodegib		Completed	NCT00833417		PCD	01-NOV-10	No	No		1	22670903			Overall Response Rate	33	33			30.0		16-48	0.001	7.6				9.5																													
SMO	SMO_unspecified				skin / carcinoma / basal cell carcinoma	3	Phase 2	Nivolumab + Vismodegib		Withdrawn	NCT03767439		ECD	01-DEC-19	No	Yes	Changed business priorities	4	NCT03767439			Disease control rate, Clinical benefit rate	0	0																																								
SMO	SMO_unspecified				skin / carcinoma / basal cell carcinoma	3	Phase 2	Pembrolizumab + Vismodegib		Completed	NCT02690948		PCD	01-NOV-17	No	Yes		4	NCT02690948			Overall Response Rate	16	7	9	Pembrolizumab	29	44																																				
SMO	SMO_unspecified				skin / carcinoma / basal cell carcinoma	3	Phase 2	Buparlisib + Sonidegib		Terminated	NCT02303041		PCD	01-APR-17	No	Yes	Changed business priorities	4	NCT02303041			Overall Response Rate	10	10																																								
SMO	SMO_unspecified				skin / carcinoma / basal cell carcinoma	3	Phase 2	Vismodegib		Completed	NCT01543581	Erivedge	PCD	01-JUN-13	No	Yes	Slow accrual	4	NCT01543581			Unknown	3	3																																								
SMO	SMO_unspecified				skin / carcinoma / basal cell carcinoma	3	Phase 2	Vismodegib		Completed	NCT00833417		PCD	01-NOV-10	No	Yes		1	22670903			Overall Response Rate	63	63			43		30-65	0.001	7.6				9.5																			13										
SMO	SMO_unspecified				stomach / carcinoma / NS	3	Phase 2	Vismodegib		Active, not recruiting	NCT03052478		ECD	01-DEC-19	Expression level	No		4	NCT03052478			Overall Response Rate	10	10																																								
SRSF2	SRSF2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Ruxolitinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																																								
SRSF2	SRSF2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelofibrosis	3	Phase 2	Pentraxin 2		Active, not recruiting	NCT01981850		PCD	01-JUL-20	No	No		4	NCT01981850			Clinical activity	125	125																																								
SSBP1	SSBP1_unspecified				NS / other / neoplasm	3	Phase 2	Ipilimumab + Nivolumab		Recruiting	NCT02693535	TAPUR group 16	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
STK11	STK11_unspecified				NS / neoplasm / NS	3	Phase 2	Everolimus		Completed	NCT02352844		PCD	01-AUG-17	Yes	Yes		4	NCT02352844			Response rate	1	1																														1										
STK11	STK11_unspecified				NS / neoplasm / NS	3	Phase 2	Telaglenastat		Recruiting	NCT03872427		ECD	01-AUG-22	Yes	No		4	NCT03872427			Overall Response Rate	108	108																																								
TEK	TEK_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	24	15	9	Cytarabine	47	11																																				
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Decitabine + Peripheral blood stem cell transplantation  + Prophylactic donor lymphocytes		Not yet recruiting	NCT03771222		ECD	01-DEC-20	No	No		4	NCT03771222			Cumulative incidence of relapse	40	40																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Enasidenib		Recruiting	NCT04522895		ECD	01-JUN-24	Yes	No		4	NCT04522895			Maximum tolerated dose/toxicity	60	60																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Out of trials human study	Cytarabine + Etoposide + Hematopoietic Stem Cell Transplant + Idarubicin		Unknown					Comparison with wt	Yes		1	22430270			Unknown	783	60	723		73	71																																				
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Out of trials human study	Cytarabine + Etoposide + Idarubicin		Unknown					Comparison with wt	Yes		1	22430270			Unknown	783	60	723		73	71																																				
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Cytarabine + Fludarabine + Natural killer cell immunotherapy		Not yet recruiting	NCT04220684		ECD	01-DEC-21	No	No		1	NCT04220684			Maximum tolerated dose/toxicity	44	44																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Decitabine + Fludarabine + Natural killer cell immunotherapy		Not yet recruiting	NCT04220684		ECD	01-DEC-21	No	No		1	NCT04220684			Maximum tolerated dose/toxicity	44	44																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Gilteritinib		Recruiting	NCT03013998	BAML-16-001-S8 	ECD	01-DEC-21	No	No		4	NCT03013998			Complete remission	2000	2000																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Mitoxantrone hydrochloride + Venetoclax		Not yet recruiting	NCT04330820	RELAX	ECD	01-JUN-22	No	No		4	NCT04330820	Previously-treated		Overall Response Rate	60	60																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Decitabine + Glasdegib		Active, not recruiting	NCT04051996	GLAD-AML	ECD	01-SEP-21	No	No		4	NCT04051996		Geriatric	Complete remission	1	1																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine + BI 836858		Recruiting	NCT03013998	BAML-16-001-S2	ECD	01-DEC-21	Yes	No		4	NCT03013998	Untreated		Overall Response Rate	2000	2000																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Cytarabine + Daunorubicin		Completed	NCT01802333		PCD	01-JUN-17	No	Yes	EFS 36 vs 37% p=0.84 primary outcome not met	4	NCT01802333	Untreated		Event free survival	477	261	216	Cytarabine + Idarubicin + Vorinostat																																						
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Cytarabine + Idarubicin		Completed	NCT01802333	SWOG-S1203	PCD	01-JUN-17	No	Yes	EFS 41 vs 37% p=0.42 primary outcome not met	4	NCT01802333	Untreated		Event free survival	477	261	216	Cytarabine + Idarubicin + Vorinostat																																						
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Ruxolitinib		Recruiting	NCT03722407	MCC-19727	ECD	01-MAY-22	No	No		4	NCT03722407			Disease control rate, Clinical benefit rate	29	29																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myelomonocytic leukaemia	3	Phase 2	Decitabine		Completed	NCT01098084		PCD	01-JUN-09	Comparison with wt	Yes		1	21828134			Clinical activity	38	13	25		54	28																				50	44															
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Azacitidine + Donor lymphocyte infusion + Lenalidomide		Completed	NCT02472691	AZALENA	PCD	01-APR-20	No	Yes		2	10.1182/blood-2018-99-113776			Maximum tolerated dose/toxicity	24	24			68																																					
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Azacitidine + Lenalidomide		Completed	NCT00352001		PCD	01-SEP-11	No	Yes		1	22915641			Overall Response Rate	1	1																														1										
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Ascorbic acid + Azacitidine		Active, not recruiting	NCT03397173	CASE1917	ECD	01-JAN-21	Yes	No		4	NCT03397173			Overall Response Rate	12	12																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Ascorbic acid		Suspended	NCT03433781		ECD	01-JUL-25	Yes	No		4	NCT03433781			Vitamin C serum bioavailability	18	18																																								
TET2	TET2_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / peripheral T cell lymphoma unspecified	3	Phase 2	Cyclophosphamide + Etoposide + Romidepsin + Vincristine + doxorubicin hydrochloride		Recruiting	NCT02223208	FIL_PTCL13	PCD	01-OCT-20	No	No		4	NCT02223208		Pediatric	Progression free survival	92	92																																								
TET2	TET2_unspecified, IDH1_unspecified, IDH2_unspecified, KRAS_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Azacitidine + Lenalidomide		Completed	NCT00352001		PCD	01-SEP-11	No	Yes		1	22915641			Overall Response Rate	1	1																														1										
TET2	TET2_unspecified, IDH1_unspecified, IDH2_unspecified, SRSF2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Azacitidine + Lenalidomide		Completed	NCT00352001		PCD	01-SEP-11	No	Yes		1	22915641			Overall Response Rate	1	1																														1										
TNFRSF25	TNFRSF25_unspecified (DDR3_unspecified)				NS / other / neoplasm	3	Phase 1	CYH33 + Olaparib		Recruiting	NCT04586335		ECD	01-JAN-24	Yes	No		4	NCT04586335			Overall Response Rate	350	350																																								
TOP1	TOP1_unspecified				NS / other / neoplasm	3	Phase 1	Ceralasertib + Trastuzumab Deruxtecan		Not yet recruiting	NCT04704661	DASH	ECD	01-MAR-23	Expression level	No		4	NCT04704661			Maximum tolerated dose/toxicity	15	15																																								
TP53	TP53_Y220C	52661282		p.Y220C	NS / other / neoplasm	3	Phase 2	PC14586		Recruiting	NCT04585750		ECD	01-NOV-24	Yes	No		4	NCT04585750			Response rate	130	130																																								
TP53	TP53_unspecified				NS / malignant melanoma / NS	3	Phase 1	ALT-801		Completed	NCT00496860		PCD	01-OCT-09	Expression level	Yes		2	10.1158/1078-0432.CCR-11-1817 			Maximum tolerated dose/toxicity	1	1																														1										
TP53	TP53_unspecified				NS / malignant melanoma / NS	3	Phase 2	Aldesleukin + Cyclophosphamide + Filgrastim + Fludarabine + p53 TCR-transduced lymphocytes		Completed	NCT00393029		PCD	01-NOV-08	Expression level	Yes	No serious adverse events	4	NCT00393029			Clinical activity	2	2																																								
TP53	TP53_unspecified				NS / malignant melanoma / NS	3	Phase 2	ALT-801 + Cisplatin		Completed	NCT01029873	QUILT-2.008	PCD	01-NOV-11	No	No		4	NCT01029873			Overall Response Rate	25	25																																								
TP53	TP53_unspecified				NS / malignant melanoma / NS	3	Phase 4	Bortezomib		Not yet recruiting	NCT02645149	MatchMel	ECD	01-APR-23	Yes	No		4	NCT02645149			Unknown	1000	1000																																								
TP53	TP53_unspecified				NS / malignant melanoma / NS	3	Phase 4	Palbociclib		Not yet recruiting	NCT02645149	MatchMel	ECD	01-APR-23	Yes	No		4	NCT02645149			Unknown	1000	1000																																								
TP53	TP53_unspecified				NS / other / neoplasm	3	Phase 1	Apatinib + Fluzoparib		Unknown	NCT03645200		ECD	01-DEC-19	Yes	No		4	NCT03645200	Previously-treated		Maximum tolerated dose/toxicity	60	60																																								
TP53	TP53_unspecified				NS / other / neoplasm	3	Phase 1	Ceralasertib + Trastuzumab Deruxtecan		Not yet recruiting	NCT04704661	DASH	ECD	01-MAR-23	Yes	No		4	NCT04704661			Maximum tolerated dose/toxicity	15	15																																								
TP53	TP53_unspecified				NS / other / neoplasm	3	Phase 1	Pazopanib + Vorinostat		Completed	NCT01339871		PCD	01-JUN-17	Comparison with wt	Yes		1	25669829			Maximum tolerated dose/toxicity	36	11	25										3.5	2												12.7	7.4															
TP53	TP53_unspecified				NS / other / neoplasm	3	Phase 1	ALT-801		Completed	NCT00496860		PCD	01-OCT-09	No	Yes		4	NCT00496860	Previously-treated		Maximum tolerated dose/toxicity	26	26																														1		10								
TP53	TP53_unspecified				NS / other / neoplasm	3	Phase 1	Prexasertib		Active, not recruiting	NCT02808650		PCD	01-DEC-19	No	No		4	NCT02808650	Previously-treated	Pediatric	Maximum tolerated dose/toxicity	30	30																																								
TP53	TP53_unspecified				NS / other / neoplasm	3	Phase 1	Atorvastin		Unknown	NCT03560882		ECD	01-AUG-19	No	No		4	NCT03560882			Reduced target expression level	50	50																																								
TP53	TP53_unspecified				NS / other / neoplasm	3	Phase 2	Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	No	No		4	NCT02576444			Overall Response Rate	64	64																																								
TP53	TP53_unspecified				NS / other / neoplasm	3	Phase 2	Aldesleukin + Cyclophosphamide + Filgrastim + Fludarabine + p53 TCR-transduced lymphocytes		Completed	NCT00393029		PCD	01-NOV-08	No	Yes	No serious adverse events	4	NCT00393029			Clinical activity	12	12																																								
TP53	TP53_unspecified				NS / other / neoplasm	3	Phase 2	Adavosertib + Olaparib		Active, not recruiting	NCT02576444	OLAPCO	ECD	01-AUG-21	No	No		4	NCT02576444			Overall Response Rate	64	64																																								
TP53	TP53_unspecified				breast / carcinoma / NS	3	Out of trials human study	Tamoxifen		Unknown					Comparison with wt	Yes		1	10786679			Unknown					31	66							3	9.6																												
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 1	Ad5CMV-p53 gene + Chemotherapy		Completed	NCT00004038		PCD	01-MAY-01	No	No		4	NCT00004038			Clinical activity	20	20																																								
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Atezolizumab + Cobimetinib		Active, not recruiting	NCT03566485	BRE 17107	ECD	01-JUL-23	Yes	No		4	NCT03566485			Overall Response Rate	12	12																																								
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Ad5CMV-p53 gene + Docetaxel + doxorubicin hydrochloride		Completed	NCT00044993		PCD	01-AUG-04	No	No		4	NCT00044993			Not defined																																										
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Olaparib + Radiotherapy		Active, not recruiting	NCT02624973	PETREMAC	PCD	01-JUN-20	Yes	No		4	NCT02624973			Biomarker discovery	200	200																																								
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Letrozole + Pertuzumab + Radiotherapy + Trastuzumab		Active, not recruiting	NCT02624973	PETREMAC	PCD	01-JUN-20	Yes	No		4	NCT02624973			Biomarker discovery	200	200																																								
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Goserelin + Pertuzumab + Radiotherapy + Tamoxifen + Trastuzumab		Active, not recruiting	NCT02624973	PETREMAC	PCD	01-JUN-20	Yes	No		4	NCT02624973			Biomarker discovery	200	200																																								
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Goserelin + Radiotherapy + Tamoxifen		Active, not recruiting	NCT02624973	PETREMAC	PCD	01-JUN-20	Yes	No		4	NCT02624973			Biomarker discovery	200	200																																								
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide + Docetaxel + Letrozole + Radiotherapy		Active, not recruiting	NCT02624973	PETREMAC	PCD	01-JUN-20	Yes	No		4	NCT02624973			Biomarker discovery	200	200																																								
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 2	Cyclophosphamide		Recruiting	NCT02965950	The p53 Breast Cancer Trial 	ECD	01-MAY-22	Yes	No		4	NCT02965950			Overall Response Rate	190	190																																								
TP53	TP53_unspecified				breast / carcinoma / NS	3	Phase 3	Capecitabine + Platinum-based chemotherapy		Recruiting	NCT04335669	NordicTrip	ECD	01-JUN-23	Yes	No		4	NCT04335669			Complete response, Pathological complete response	820	820																																								
TP53	TP53_unspecified				central nervous system / glioma / NS	3	Out of trials human study	Temozolomide		Unknown					No	Yes		1	24248532			Unknown																										34.3																
TP53	TP53_unspecified				central nervous system / glioma / NS	3	Out of trials human study	Semustine		Unknown					No	Yes		1	24248532			Unknown																										18.2																
TP53	TP53_unspecified				central nervous system / glioma / NS	3	Phase 1	Ad5CMV-p53 gene		Completed	NCT00004041		PCD	01-JUL-02	No	No		4	NCT00004041			Unknown																																										
TP53	TP53_unspecified				central nervous system / glioma / NS	3	Phase 2	Temozolomide + Transferrin receptor-targeted liposomal p53 cDNA		Terminated	NCT02340156		PCD	01-NOV-18	No	No		4	NCT02340156			Progression free survival	1	1																																								
TP53	TP53_unspecified				endometrium / carcinoma / NS	3	Phase 2	Olaparib		Suspended	NCT03660826		ECD	01-SEP-22	No	No		4	NCT03660826	Previously-treated		Overall Response Rate	120	120																																								
TP53	TP53_unspecified				endometrium / carcinoma / NS	3	Phase 2	Cediranib maleate		Suspended	NCT03660826		ECD	01-SEP-22	No	No		4	NCT03660826	Previously-treated		Overall Response Rate	120	120																																								
TP53	TP53_unspecified				endometrium / carcinoma / NS	3	Phase 2	Cediranib maleate + Olaparib		Suspended	NCT03660826		ECD	01-SEP-22	No	No		4	NCT03660826	Previously-treated		Overall Response Rate	120	120																																								
TP53	TP53_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Pembrolizumab		Active, not recruiting	NCT02589496		ECD	01-DEC-21	No	No		4	NCT02589496	Previously-treated		Response rate	81	81																																								
TP53	TP53_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Bone marrow transplantation + Cisplatin + Etoposide + Mitomycin C		Unknown					Comparison with wt	Yes		1	14514923			Unknown		8																								18.5	10.2			0.044												
TP53	TP53_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Adavosertib + Irinotecan		Recruiting	NCT02448329		ECD	01-DEC-19	Yes	No		4	NCT02448329	Previously-treated		Overall Response Rate	25	25																																								
TP53	TP53_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Berzosertib + Irinotecan		Not yet recruiting	NCT03641313		ECD	01-JUL-22	Yes	No		4	NCT03641313			Overall Response Rate	28	28																																								
TP53	TP53_unspecified				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	Phase 2	Capecitabine + Cetuximab + Cisplatin		Completed	NCT00477711	EXTRA	PCD	01-DEC-08	No	No		4	NCT00477711	Untreated		Response rate	41	41																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Belinostat + Pevonedistat		Recruiting	NCT03772925		ECD	01-JUL-21	No	No		4	NCT03772925	Previously-treated		Maximum tolerated dose/toxicity	45	45																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	RO5045337		Completed	NCT00623870		PCD	01-NOV-12	Comparison with wt	Yes		1	26459177			Maximum tolerated dose/toxicity	28	22	6		0	18.8																																				
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 1	Arsenic trioxide + Decitabine		Recruiting	NCT03855371	PANDA-T0	ECD	01-JUL-21	Yes	No		4	NCT03855371			Maximum tolerated dose/toxicity	3	3																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Azacitidine		Terminated	NCT02159040		PCD	01-JUN-15	No	Yes	Serious adverse events	4	NCT02159040			Overall Response Rate	1	1																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Decitabine + Peripheral blood stem cell transplantation  + Prophylactic donor lymphocytes		Not yet recruiting	NCT03771222		ECD	01-DEC-20	No	No		4	NCT03771222			Cumulative incidence of relapse	40	40																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	APR-246 + Azacitidine		Recruiting	NCT03931291		ECD	01-JUL-21	Yes	No		4	NCT03931291			Disease free survival, relapse free survival, regression free survival, recurrence free survival	31	31																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Azacitidine + Deferasirox		Terminated	NCT02159040		PCD	01-JUN-15	No	Yes	Serious adverse events	4	NCT02159040			Overall Response Rate	1	1																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Decitabine + Venetoclax		Recruiting	NCT03404193		ECD	01-DEC-23	No	No		4	NCT03404193			Overall Response Rate	400	400																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Azacitidine + Pevonedistat		Active, not recruiting	NCT03268954	PANTHER 	ECD	01-JUL-22	No	No		4	NCT03268954			Event free survival	454			Azacitidine																																						
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	APR-246 + Azacitidine		Active, not recruiting	NCT03745716		ECD	01-NOV-20	Yes	No		4	NCT03745716			Composite complete remission	154	154																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 3	Busulfan + Cyclophosphamide + Decitabine		Recruiting	NCT04123392		ECD	01-SEP-22	Expression level	No		4	NCT04123392			Response rate	196	196																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Decitabine + Nivolumab + Venetoclax		Suspended	NCT04277442		ECD	01-FEB-22	Yes	No		4	NCT04277442			Overall Response Rate	13	13																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	APR-246 + Azacitidine + Venetoclax		Recruiting	NCT04214860		ECD	01-DEC-21	Yes	No		4	NCT04214860			Maximum tolerated dose/toxicity	80	80																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Decitabine		Recruiting	NCT03063203		ECD	01-JUL-23	Yes	No		4	NCT03063203	Previously-treated		Overall survival	60	60																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Mitoxantrone hydrochloride + Venetoclax		Not yet recruiting	NCT04330820	RELAX	ECD	01-JUN-22	No	No		4	NCT04330820	Previously-treated		Overall Response Rate	60	60																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Decitabine + Entospletinib		Recruiting	NCT03013998	BAML-16-001-S5	ECD	01-DEC-21	Yes	No		4	NCT03013998			Overall Response Rate	2000	2000																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cenersen + Chemotherapy		Withdrawn	NCT00967512		ECD	01-JAN-12	No	Yes	Lack of funding	4	NCT00967512			Composite complete remission	0	0																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Decitabine + Quizartinib + Venetoclax		Recruiting	NCT03661307		ECD	01-JAN-22	No	No		4	NCT03661307			Overall Response Rate	52	52																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Arsenic trioxide + Cytarabine + Decitabine		Not yet recruiting	NCT03381781		ECD	01-NOV-19	Yes	No		4	NCT03381781			Disease free survival, relapse free survival, regression free survival, recurrence free survival	100	100																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 3	Cytarabine + Idasanutlin 		Active, not recruiting	NCT02545283	MIRROS 	PCD	01-NOV-19	No	Yes	No benefit of treatment	4	NCT02545283			Overall survival	447			Cytarabine + Placebo																																						
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 2	Azacitidine + Lenalidomide		Completed	NCT00352001		PCD	01-SEP-11	No	Yes		1	22915641			Overall Response Rate	2	2																														2										
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 3	Arsenic trioxide + Decitabine		Unknown	NCT03377725		ECD	01-NOV-19	Yes	No		4	NCT03377725			Disease free survival, relapse free survival, regression free survival, recurrence free survival	300	200	100	Decitabine																																						
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myeloproliferative neoplasm	3	Phase 2	APR-246 + Azacitidine		Active, not recruiting	NCT03072043		ECD	01-MAY-20	Yes	No		4	NCT03072043			Complete remission	56	56																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myeloproliferative neoplasm	3	Phase 2	APR-246 + Azacitidine		Active, not recruiting	NCT03588078		ECD	01-MAY-20	Yes	No		4	NCT03588078			Overall survival	53	53																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / B cell lymphoma unspecified	3	Phase 1	GSK3326595 		Recruiting	NCT02783300		ECD	01-DEC-21	No	No		4	NCT02783300			Maximum tolerated dose/toxicity	412	412																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Case study	Alemtuzumab		Unknown					Yes	Yes		1	12167696			Unknown	1	1																														1										
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Out of trials human study	Venetoclax		Unknown					No	Yes	Response not correlated with mutation status	1	28473407			Unknown	67	67																														17	41	9								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Out of trials human study	Alemtuzumab		Unknown					Yes	Yes		1	14726385			Unknown	15	15																															6									
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 2	Ibrutinib + Rituximab		Active, not recruiting	NCT02232386	LLC1114	ECD	01-MAY-21	No	No		4	NCT02232386			Progression free survival	156	156																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 2	Cyclophosphamide + Fludarabine + Ibrutinib + Rituximab		Active, not recruiting	NCT02251548	iFCR	PCD	01-JAN-19	No	Yes	Primary outcome met	1	31208944			Unknown	85	85																														28										
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 2	Dexamethasone + Lenalidomide		Completed	NCT01459211	LenD	PCD	01-FEB-16	No	No		4	NCT01459211	Previously-treated		Overall Response Rate	12	12																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 2	Daratumumab + Ibrutinib		Recruiting	NCT03734198	IDA53	ECD	01-DEC-26	Yes	No		4	NCT03734198			Complete remission	44	44																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 2	Acalabrutinib		Active, not recruiting	NCT02337829		PCD	01-JUN-20	Yes	No		4	NCT02337829	Previously-treated		Overall Response Rate	48	48																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 2	Fludarabine + Ibrutinib + Pembrolizumab		Recruiting	NCT03204188		ECD	01-DEC-27	No	No		4	NCT03204188			Complete remission	30	30																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 2	Ibrutinib + Obinutuzumab + Venetoclax		Active, not recruiting	NCT02758665	CLL2-GiVe	ECD	01-DEC-20	Yes	No		4	NCT02758665			Composite complete remission	40	40																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 2	Venetoclax		Active, not recruiting	NCT01889186		ECD	01-OCT-20	Yes	No		4	NCT01889186			Overall Response Rate	158	158																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 2	Rituximab + Venetoclax		Active, not recruiting	NCT03455517	VeRitAs	ECD	01-AUG-21	No	No		4	NCT03455517			Complete remission	77	77																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 2	Ibrutinib + Venetoclax		Active, not recruiting	NCT03226301		ECD	01-JAN-26	No	No		4	NCT03226301			Progression free survival	230	230																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 3	Lenalidomide		Active, not recruiting	NCT01556776	CLLM1	PCD	01-MAR-16	No	Yes		1	28916311	Previously-treated		Progression free survival	87	58	29	Placebo										13.3	.186	0.074-0.379																										
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 3	Bendamustine + Ofatumumab		Unknown	NCT01678430	RIAltO	ECD	01-DEC-17	No	No		4	NCT01678430			Progression free survival	670	670																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 3	Chlorambucil  + Ofatumumab		Unknown	NCT01678430	RIAltO	ECD	01-DEC-17	No	No		4	NCT01678430			Progression free survival	670	670																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 3	Idelalisib + Ofatumumab		Terminated	NCT01659021		PCD	01-AUG-18	No	Yes		4	NCT01659021			Progression free survival	261	174	87	Ofatumumab	75.3	17.2	8.17-34.76	0.0001					16.6	8	.26	0.18-0.37	<0.0001																									
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 3	Ibrutinib + Obinutuzumab		Completed	NCT02264574	iLLUMINATE	PCD	01-MAR-18	Yes	Yes		1	30522969			Progression free survival	229	113	116	Chlorambucil  + Obinutuzumab										19	.23	0.15-0.37	<0.0001																									
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 3	Acalabrutinib		Recruiting	NCT04178798		ECD	01-OCT-24	No	No		4	NCT04178798			Event free survival	130	130																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 3	Venetoclax		Active, not recruiting	NCT02756611	VENICE I	PCD	01-APR-19	No	Yes	cCR 25.4%	4	NCT02756611	Previously-treated, platinum-resistant			67																																									
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 3	Venetoclax		Active, not recruiting	NCT02980731	VENICE II	ECD	01-JUN-22	No	No		4	NCT02980731			Quality of life	210	210																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / chronic lymphocytic leukaemia-small lymphocytic lymphoma	2	Phase 3	Venetoclax		Active, not recruiting	NCT02756611	VENICE I	PCD	01-APR-19	No	Yes	cCR=35.1% p<0.001	4	NCT02756611	Untreated		Composite complete remission	191	191																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / diffuse large B cell lymphoma	3	Phase 2	Cyclophosphamide + Rituximab + Sintilimab + Vincristine + doxorubicin hydrochloride liposome		Not yet recruiting	NCT04023916		ECD	01-JUL-20	Yes	No		4	NCT04023916			Complete remission	30	30																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / mantle cell lymphoma	3	Phase 2	Ibrutinib + Tisagenlecleucel 		Not yet recruiting	NCT04234061	TARMAC	ECD	01-SEP-27	Yes	No		4	NCT04234061			Complete remission	20	20																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / mantle cell lymphoma	3	Phase 2	Bendamustine + Cytarabine + Rituximab + Venetoclax		Recruiting	NCT03567876	V-RBAC	ECD	01-FEB-21	No	No		4	NCT03567876		Geriatric	Progression free survival	130	130																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / mantle cell lymphoma	3	Phase 3	Ibrutinib + Venetoclax		Recruiting	NCT03112174	SYMPATICO	ECD	01-MAR-22	No	No		4	NCT03112174			Progression free survival	362	562																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	7	Phase 2	ALT-801		Terminated	NCT01670994	QUILT-3.020	PCD	01-AUG-13	No	Yes	No benefit of treatment	4	NCT01670994			Maximum tolerated dose/toxicity	6	6																																								
TP53	TP53_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	7	Phase 2	Bortezomib + Dexamethasone + doxorubicin hydrochloride		Completed	NCT00872521		PCD	01-MAY-11	Comparison with wt	Yes		4	NCT00872521	Untreated		Overall Response Rate	89	14	75		78.6	81.3																																				
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 1	Siremadlin + Trametinib		Recruiting	NCT03714958	TRAHD	ECD	01-FEB-21	No	No		4	NCT03714958			Maximum tolerated dose/toxicity	24	24																																								
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFIRI		Unknown	NCT01442935		PCD	01-DEC-15	No	No		4	NCT01442935			Percent of patients who become resectable	256	256																																								
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + Folfirinox		Unknown	NCT01442935		PCD	01-DEC-15	No	No		4	NCT01442935			Percent of patients who become resectable	256	256																																								
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cyclophosphamide		Terminated	NCT03149679	The p53 colorectal cancer trial	PCD	01-AUG-20	Yes	Yes	No response to treatment	4	NCT03149679			Overall Response Rate	12	12																																								
TP53	TP53_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Cetuximab + FOLFOX-4		Unknown	NCT01442935		PCD	01-DEC-15	No	No		4	NCT01442935			Percent of patients who become resectable	256	256																																								
TP53	TP53_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 1	Ad5CMV-p53 gene		Terminated	NCT00003147		PCD	01-JUN-03	No	No		4	NCT00003147			Unknown	30	30																																								
TP53	TP53_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	rAD-p53		Unknown	NCT02509169		ECD	01-DEC-16	No	Yes		4	NCT02509169			Overall survival	60	60																														9	15									
TP53	TP53_unspecified				liver / carcinoma / hepatocellular carcinoma	3	Phase 2	rAD-p53		Unknown	NCT02418988		ECD	01-MAY-17	No	No		4	NCT02418988			Overall survival	120	120																																								
TP53	TP53_unspecified				lung / carcinoma / bronchioloalveolar adenocarcinoma	3	Phase 1	Ad5CMV-p53 gene		Completed	NCT00003649		PCD	01-JUN-07	No	No		4	NCT00003649			Unknown																																										
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Cisplatin + Etoposide + Osimertinib		Recruiting	NCT03567642		ECD	01-JUN-22	Yes	No		4	NCT03567642			Maximum tolerated dose/toxicity	30	30																																								
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	Ad5CMV-p53 gene + Radiotherapy		Completed	NCT00004225				No	No		4	NCT00004225			Unknown																																										
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Bevacizumab + Cisplatin + Olaparib + Paclitaxel		Not yet recruiting	NCT04318938		ECD	01-DEC-25	No	No		4	NCT04318938			Progression free survival	116	116																																								
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	rAD-p53		Unknown	NCT01574729	rAd-p53	ECD	01-AUG-15	No	No		4	NCT01574729			Overall survival	120	120																																								
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Adavosertib		Terminated	NCT02688907		PCD	01-DEC-17	Yes	Yes	Change regimen	4	NCT02688907			Overall Response Rate	7	7																																								
TP53	TP53_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 3	Nintedanib		Terminated	NCT02299141		PCD	01-JAN-20	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12								
TP53	TP53_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Adavosertib		Unknown	NCT02593019		PCD	01-JUN-18	No	No		4	NCT02593019			Overall Response Rate	24	24																																								
TP53	TP53_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Ad5CMV-p53 gene		Completed	NCT00617409		PCD	01-SEP-15	No	Yes		4	NCT00617409			Disease control rate, Clinical benefit rate	38	20	18																				30.0	44.4		6.3	12.2															
TP53	TP53_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Ad5CMV-p53 gene + Tretinoin		Completed	NCT00617409		PCD	01-SEP-15	No	Yes		4	NCT00617409			Disease control rate, Clinical benefit rate	49	31	18																				38.7	44.4		6.2	12.2															
TP53	TP53_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	ALRN-6924		Recruiting	NCT04022876		ECD	01-MAR-21	Yes	No		4	NCT04022876			Clinical activity	120	120																																								
TP53	TP53_unspecified				lung / carcinoma / squamous cell carcinoma	3	Phase 2	Afatinib		Not yet recruiting	NCT04533321		ECD	01-SEP-23	Yes	No		4	NCT04533321	Previously-treated		Unknown	20	20																																								
TP53	TP53_unspecified				ovary / carcinoma / NS	3	Phase 1	rAD-p53		Completed	NCT00003588		PCD	01-MAR-02	No	No		4	NCT00003588	Previously-treated		Unknown	30	30																																								
TP53	TP53_unspecified				ovary / carcinoma / mixed carcinoma	2	Phase 1	rAD-p53		Active, not recruiting	NCT00003450		PCD	01-JAN-99	No	No		4	NCT00003450			Unknown	20	20																																								
TP53	TP53_unspecified				ovary / carcinoma / mixed carcinoma	2	Phase 1	Gemcitabine + MVAp53		Completed	NCT02275039		PCD	01-APR-18	No	Yes	Primary outcome met	2	10.1200/JCO.2016.34.15_suppl.e17040			Maximum tolerated dose/toxicity	5	5																																								
TP53	TP53_unspecified				ovary / carcinoma / mixed carcinoma	2	Phase 2	Gemcitabine		Active, not recruiting	NCT02101775		ECD	01-JUN-21	No	No		4	NCT02101775	Previously-treated		Progression free survival	100	100																																								
TP53	TP53_unspecified				ovary / carcinoma / mixed carcinoma	2	Phase 2	Atezolizumab + Bevacizumab		Not yet recruiting	NCT04510584	HEARTBEAT-OV	ECD	01-SEP-23	Yes	No		4	NCT04510584			Marker correlation with progression	20	20																																								
TP53	TP53_unspecified				ovary / carcinoma / mixed carcinoma	2	Phase 2	MVAp53 + Pembrolizumab		Recruiting	NCT03113487		ECD	01-JAN-21	No	No		4	NCT03113487			Overall Response Rate	28	28																																								
TP53	TP53_unspecified				ovary / carcinoma / mixed carcinoma	2	Phase 2	Adavosertib + Gemcitabine		Active, not recruiting	NCT02101775		ECD	01-JUN-21	No	No		4	NCT02101775	Previously-treated		Progression free survival	100	100																																								
TP53	TP53_unspecified				ovary / carcinoma / mixed carcinoma	2	Phase 2	Adavosertib + Carboplatin + Paclitaxel		Completed	NCT01357161		PCD	01-AUG-16	No	Yes		4	NCT01357161			Progression free survival	136	59	52	Carboplatin + Paclitaxel									34.1	31.9	.63	0.45-0.89	0.08																									
TP53	TP53_unspecified				ovary / carcinoma / mixed carcinoma	2	Phase 2	Chemotherapy + rAD-p53		Unknown	NCT02435186		ECD	01-AUG-18	No	No		4	NCT02435186	Previously-treated		Progression free survival	100	100																																								
TP53	TP53_unspecified				ovary / carcinoma / serous carcinoma	3	Phase 2	APR-246 + doxorubicin hydrochloride liposome		Completed	NCT03268382	PiSARRO-R	PCD	01-JUL-19	No	No		4	NCT03268382	Previously-treated		Overall Response Rate	36	36																																								
TP53	TP53_unspecified				pancreas / carcinoma / NS	3	Phase 2	Gemcitabine + Nab-paclitaxel		Recruiting	NCT02340117		ECD	01-DEC-21	No	No		4	NCT02340117			Progression free survival	28	28																																								
TP53	TP53_unspecified				prostate / carcinoma / NS	3	Phase 2	sEphB4-HSA		Recruiting	NCT04033432		ECD	01-JUN-21	No	No		4	NCT04033432			Disease free survival, relapse free survival, regression free survival, recurrence free survival	25	25																																								
TP53	TP53_unspecified				prostate / carcinoma / NS	3	Phase 2	CEP-11981 + Nivolumab		Not yet recruiting	NCT04159896		ECD	01-MAR-22	No	No		4	NCT04159896			Clinical activity	49	49																																								
TP53	TP53_unspecified				prostate / carcinoma / NS	3	Phase 3	Cabazitaxel + Prednisone		Recruiting	NCT02961257	CABASTY	ECD	01-MAY-21	No	No		4	NCT02961257			Clinical activity	170	170																																								
TP53	TP53_unspecified				thymus / thymic carcinoma / NS	3	Phase 4	Radioiodine + rAD-p53		Unknown	NCT00902122		ECD	01-AUG-12	No	No		4	NCT00902122			Overall Response Rate	600	600																																								
TP53	TP53_unspecified				thyroid / carcinoma / anaplastic carcinoma	3	Phase 2	Cisplatin + Crolibulin		Completed	NCT01240590		PCD	01-AUG-15	No	Yes		2	10.1200/jco.2013.31.15_suppl.6074			Progression free survival	8	8																														1		1								
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / NS	3	Phase 2	Nivolumab + Radiotherapy		Active, not recruiting	NCT03715946		ECD	01-MAY-21	No	No		4	NCT03715946			Progression free survival	42	42																																								
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Erlotinib		Active, not recruiting	NCT02748707	ERLO-XIB	PCD	01-FEB-18	No	No		4	NCT02748707			Reduced target expression level	16	8	8	Observation																																						
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Cisplatin + Radiotherapy		Recruiting	NCT02734537		ECD	01-MAY-22	No	No		4	NCT02734537			Disease free survival, relapse free survival, regression free survival, recurrence free survival	189	189																																								
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Chemotherapy + Radioiodine + rAD-p53		Unknown	NCT02429037		ECD	01-DEC-18	No	No		4	NCT02429037			Progression free survival	60	60																																								
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Celecoxib		Active, not recruiting	NCT02748707	ERLO-XIB	PCD	01-FEB-18	No	No		4	NCT02748707			Reduced target expression level	16	8	8	Observation																																						
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Ad5CMV-p53 gene		Unknown	NCT00003257				No	No		4	NCT00003257			Unknown	39	39																																								
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	rAD-p53		Completed	NCT00064103		PCD	01-AUG-07	No	No		4	NCT00064103			Maximum tolerated dose/toxicity	51	51																																								
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Ad5CMV-p53 gene + Chemotherapy		Terminated	NCT00017173		PCD	01-MAY-07	No	Yes	1yr PFS 92%	4	NCT00017173			Maximum tolerated dose/toxicity	13	13																																								
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 2	Celecoxib + Erlotinib		Active, not recruiting	NCT02748707	ERLO-XIB	PCD	01-FEB-18	No	Yes		2	10.1200/JCO.2019.37.15_suppl.6054			Reduced target expression level	16	8	8	Observation	60																												5	2								
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 4	rAD-p53		Unknown	NCT00902083		ECD	01-JUL-12	No	No		4	NCT00902083			Overall Response Rate	600	600																																								
TP53	TP53_unspecified				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	Phase 4	Chemotherapy + Radioiodine + rAD-p53		Unknown	NCT00894153		ECD	01-JUN-12	No	No		4	NCT00894153			Response rate	1200	1200																																								
TP53	TP53_unspecified				urinary tract / carcinoma / NS	3	Phase 1	Ad5CMV-p53 gene		Completed	NCT00003167		PCD	01-DEC-02	No	No		4	NCT00003167			Maximum tolerated dose/toxicity	24	24																																								
TSC1	TSC1_unspecified				NS / other / neoplasm	3	Phase 1	Samotolisib		Completed	NCT03155620	Subprotocol D	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
TSC1	TSC1_unspecified				NS / other / neoplasm	3	Phase 2	Sapanisertib		Recruiting	NCT02465060	MATCH Subprotocol M	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
TSC1	TSC1_unspecified				NS / other / neoplasm	3	Phase 2	Temsirolimus		Recruiting	NCT02693535	TAPUR group 6	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
TSC1	TSC1_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Recruiting	NCT04185831	MEGALiT	ECD	01-DEC-22	Yes	No		4	NCT04185831			Overall Response Rate	154	154																																								
TSC1	TSC1_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Completed	NCT02352844		PCD	01-AUG-17	Yes	No		4	NCT02352844			Response rate	12	12																																								
TSC1	TSC1_unspecified				urinary tract / carcinoma / NS	3	Phase 1	Durvalumab + Vistusertib		Active, not recruiting	NCT02546661	BISCAY module E	PCD	01-MAR-20	Yes	Yes		3	https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-bladder-cancer/115221-esmo-2019-biscay-an-adaptive-biomarker-directed-platform-study-in-metastatic-urothelial-cancer-with-durvalumab-in-combination-with-targeted-therapies.html	Previously-treated		Maximum tolerated dose/toxicity	29	29			24.1																																					
TSC2	TSC2_W358*	54765859 + 54773870		p.W358*	soft tissue / perivascular epithelioid cell tumour (PEComa) / NS	4	Case study	Everolimus		Unknown					Yes	Yes		1	22927055			Unknown	1	1																															1									
TSC2	TSC2_unspecified				NS / other / neoplasm	3	Phase 1	Samotolisib		Completed	NCT03155620	Subprotocol D	ECD	01-SEP-27	No	No		4	NCT03155620		Pediatric	Overall Response Rate	1500	1500																																								
TSC2	TSC2_unspecified				NS / other / neoplasm	3	Phase 2	Sapanisertib		Recruiting	NCT02465060	MATCH Subprotocol M	ECD	01-JUN-22	Yes	No		4	NCT02465060	Previously-treated		Overall Response Rate	6452	6452																																								
TSC2	TSC2_unspecified				NS / other / neoplasm	3	Phase 2	Temsirolimus		Recruiting	NCT02693535	TAPUR group 6	ECD	01-DEC-23	Yes	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
TSC2	TSC2_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Recruiting	NCT04185831	MEGALiT	ECD	01-DEC-22	Yes	No		4	NCT04185831			Overall Response Rate	154	154																																								
TSC2	TSC2_unspecified				NS / other / neoplasm	3	Phase 2	Everolimus		Completed	NCT02352844		PCD	01-AUG-17	Yes	No		4	NCT02352844			Response rate	12	12																																								
TSC2	TSC2_unspecified				urinary tract / carcinoma / NS	3	Phase 1	Durvalumab + Vistusertib		Active, not recruiting	NCT02546661	BISCAY module E	PCD	01-MAR-20	Yes	Yes		3	https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-bladder-cancer/115221-esmo-2019-biscay-an-adaptive-biomarker-directed-platform-study-in-metastatic-urothelial-cancer-with-durvalumab-in-combination-with-targeted-therapies.html	Previously-treated		Maximum tolerated dose/toxicity	29	29			24.1																																					
TYRO3	TYRO3_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
U2AF1	U2AF1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
VEGFA	VEGFA_unspecified				NS / other / neoplasm	3	Phase 2	Cabozantinib		Not yet recruiting	NCT04116541	MegaMOST	ECD	01-FEB-22	Yes	No		4	NCT04116541			Progression free survival	100	100																																								
VEGFA	VEGFA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Sunitinib		Completed	NCT00372775		PCD	01-DEC-09	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																													
VEGFA	VEGFA_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Erlotinib + Sunitinib		Completed	NCT00265317	SUN1058	PCD	01-JAN-10	Expression level	Yes		4	NCT00265317			Progression free survival	25	27		Erlotinib + Placebo									3.69	2.33	.91		0.44																									
VHL	VHL_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	01-SEP-21	No	No		4	NCT03297606			Overall Response Rate	720	720																																								
VHL	VHL_unspecified				NS / other / neoplasm	3	Phase 2	Sunitinib		Recruiting	NCT02693535	TAPUR group 5	ECD	01-DEC-23	Expression level	No		4	NCT02693535			Overall Response Rate	3378	3378																																								
WRN	WRN_unspecified				NS / neoplasm / NS	3	Phase 2	Niraparib		Recruiting	NCT03207347	UF-STO-ETI-001	ECD	01-DEC-21	Yes	No		4	NCT03207347			Overall Response Rate	47	47																																								
WT1	WT1_unspecified				NS / other / neoplasm	3	Phase 2	WT1 mRNA transfected autologous DC vaccine		Unknown	NCT01291420		ECD	01-FEB-14	No	No		4	NCT01291420			Immune response	10	10																																								
WT1	WT1_unspecified				autonomic ganglia / neuroblastoma / NS	3	Phase 1	Tumor-associated antigen cytotoxic T cells		Recruiting	NCT02789228	REST	ECD	01-SEP-20	Expression level	Yes		1	31356143			Maximum tolerated dose/toxicity	2	2																																								
WT1	WT1_unspecified				bone / Ewings sarcoma-peripheral primitive neuroectodermal tumour / NS	3	Phase 1	Tumor-associated antigen cytotoxic T cells		Recruiting	NCT02789228	REST	ECD	01-SEP-20	Expression level	No		1	31356143			Maximum tolerated dose/toxicity	1	1																																								
WT1	WT1_unspecified				bone / osteosarcoma / NS	3	Phase 1	Tumor-associated antigen cytotoxic T cells		Recruiting	NCT02789228	REST	ECD	01-SEP-20	Expression level	Yes		1	31356143			Maximum tolerated dose/toxicity	1	1																																								
WT1	WT1_unspecified				breast / carcinoma / NS	3	Phase 2	WT1-A10/AS01B immunotherapeutic GSK2130579A		Terminated	NCT01220128	INDUCT	PCD	01-NOV-14	Expression level	Yes	Study termination due to negative Ph III of another study product from same technology platform	4	NCT01220128			Maximum tolerated dose/toxicity	66	66																																								
WT1	WT1_unspecified				breast / carcinoma / NS	3	Phase 2	Carboplatin + Cyclophosphamide + Paclitaxel + WT1, Cyclin B1, CEF antigen-loaded autologous DC vaccine + doxorubicin hydrochloride		Completed	NCT02018458		PCD	01-SEP-19	Expression level	Yes		2	10.1200/JCO.2016.34.15_suppl.1086			Maximum tolerated dose/toxicity	10	10																														5										
WT1	WT1_unspecified				breast / carcinoma / basal (triple-negative) carcinoma	3	Phase 2	Galinpepimut-S + Pembrolizumab + Sargramostim		Recruiting	NCT03761914		ECD	01-DEC-20	Expression level	No		4	NCT03761914			Complete response, Pathological complete response	90	90																																								
WT1	WT1_unspecified				central nervous system / NS / NS	3	Phase 1	Tumor-associated antigen cytotoxic T cells		Recruiting	NCT03652545	REMIND	ECD	01-MAR-23	Expression level	No		4	NCT03652545			Maximum tolerated dose/toxicity	32	32																																								
WT1	WT1_unspecified				central nervous system / glioma / NS	3	Phase 2	Temozolomide + WT1 mRNA transfected autologous DC vaccine		Recruiting	NCT02649582	ADDIT-GLIO	ECD	01-DEC-23	No	No		4	NCT02649582			Overall survival	20	20																																								
WT1	WT1_unspecified				central nervous system / glioma / astrocytoma Grade IV	3	Phase 1	WT2725		Completed	NCT01621542		PCD	01-MAY-17	Expression level	Yes	2 pts survived > 2 yrs	2	10.1200/JCO.2017.35.15_suppl.2066			Maximum tolerated dose/toxicity	21	21																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Cytarabine + Daunorubicin + Glasdegib		Completed	NCT01546038	BRIGHT AML 1003	PCD	01-JAN-17	Yes	Yes		1	30555165			Overall survival	4	3	1	Cytarabine	33	0																																				
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / NS	3	Phase 2	Enasidenib		Recruiting	NCT04522895		ECD	01-JUN-24	Yes	No		4	NCT04522895			Maximum tolerated dose/toxicity	60	60																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Out of trials human study	Chemotherapy		Unknown					Comparison with wt	Yes		1	18591546			Unknown	470	47	423																							26	47	1.91	1.23-2.95	0.007					22	44	2.16	1.32-3.55	0.005			
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Out of trials human study	Chemotherapy		Unknown					Comparison with wt	Yes		1	18559874			Unknown	196	21	175																																13	50			<0.001			
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	WT2725		Completed	NCT01621542		PCD	01-MAY-17	Expression level	No		4	NCT01621542			Maximum tolerated dose/toxicity	64	64																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	WT1 peptide vaccine OCV-501		Completed	NCT01475370		PCD	01-DEC-16	Expression level	No		4	NCT01475370			Maximum tolerated dose/toxicity	18	18																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	WT1 peptide vaccine OCV-501		Completed	NCT01440920		PCD	01-MAR-13	No	Yes	No adverse events >2	4	NCT01440920			Maximum tolerated dose/toxicity	9	9																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	WT1 mRNA transfected autologous DC vaccine		Completed	NCT00834002		PCD	01-NOV-07	Expression level	Yes		1	20631300			Maximum tolerated dose/toxicity	10	10																															5									
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Basiliximab + WT1 126-134 peptide vaccine 		Completed	NCT01842139		PCD	01-FEB-15	No	No	No adverse events >2	4	NCT01842139			Clinical activity	7	7																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Montanide + WT1 126-134 peptide vaccine 		Completed	NCT01842139		PCD	01-FEB-15	No	Yes	No adverse events >2	1	29344432			Clinical activity	7	7																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	WT1 126-134 peptide vaccine  + poly ICLC		Completed	NCT01842139		PCD	01-FEB-15	No	Yes	No adverse events >2	1	29344432			Clinical activity	7	7																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	WT1-A10/AS01B immunotherapeutic GSK2130579A		Completed	NCT01051063		PCD	01-APR-16	No	Yes		4	NCT01051063			Best overall response	17	17																														5	3	7								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	WT1-A10/AS01B immunotherapeutic GSK2130579A		Completed	NCT00725283		PCD	01-JUN-16	No	Yes	8 serious adverse events	4	NCT00725283			Maximum tolerated dose/toxicity	34	34																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 1	Multiple pathogen-specific T cells + WT1-specific allogenic cytotoxic T cells		Recruiting	NCT02895412	INTACT-WT1	ECD	01-DEC-20	Expression level	No		4	NCT02895412			Maximum tolerated dose/toxicity	20	20																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Azacitidine + BI 836858		Recruiting	NCT03013998	BAML-16-001-S2	ECD	01-DEC-21	Yes	No		4	NCT03013998	Untreated		Overall Response Rate	2000	2000																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Cytarabine + Ponatinib		Recruiting	NCT02428543	PONATINIB-AML	ECD	01-NOV-20	No	No		4	NCT02428543	Previously-treated		Maximum tolerated dose/toxicity	49	49																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Galinpepimut-S + Pembrolizumab + Sargramostim		Recruiting	NCT03761914		ECD	01-DEC-20	Expression level	No		4	NCT03761914			Complete response, Pathological complete response	90	90																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Galinpepimut-S		Completed	NCT01266083		PCD	01-FEB-18	Expression level	Yes		1	29386195			Overall survival	22	22																																	16.9							
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Allogeneic CD25/Treg-depleted donor lymphocytes + WT1-A10/AS01B immunotherapeutic GSK2130579A		Unknown	NCT01513109	ASCI	ECD	01-DEC-13	Expression level	No		4	NCT01513109			Maximum tolerated dose/toxicity	20	20																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	p.DOM-WT1-126 + p.DOM-WT1-37		Completed	NCT01334060	WIN	PCD	01-FEB-13	Expression level	No		4	NCT01334060			Overall survival	23	23																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Keyhole limpet hemocyanin + Sargramostim + WT1 126-134 peptide vaccine 		Unknown	NCT00153582	HaemaCBFWT102			Expression level	Yes		1	19389880			Target-specific T cell activity 	17	17																																10								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Aldesleukin + WT1-TCRc4 gene-transduced autologous CD8-positive Tcm/Tn lymphocytes		Active, not recruiting	NCT02770820		ECD	01-JUN-20	Expression level	No		4	NCT02770820			Maximum tolerated dose/toxicity	9	9																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	Montanide + PR1 leukemia peptide vaccine + Sargramostim + WT1 126-134 peptide vaccine 		Completed	NCT00488592		PCD	01-APR-10	Expression level	Yes	2 serious adverse events	1	21134985			Immune response	7	7																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	WT1 mRNA transfected autologous DC vaccine		Recruiting	NCT01686334	WIDEA	ECD	01-JUL-24	No	No		4	NCT01686334			Overall survival	130	130																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	WT1 mRNA transfected autologous DC vaccine		Unknown	NCT00965224		ECD	01-DEC-14	No	Yes		1	28830889			Immune response	50	50																															13	4								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	WT1 mRNA transfected autologous DC vaccine		Unknown	NCT03083054		ECD	01-JUL-20	No	No		4	NCT03083054			Disease free survival, relapse free survival, regression free survival, recurrence free survival	50	50																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	PRAME mRNA transfected autologous DC vaccine + WT1 mRNA transfected autologous DC vaccine		Active, not recruiting	NCT02405338		PCD	01-NOV-19	No	Yes		3	https://www.targetedonc.com/view/dc-vaccine-demonstrates-feasibility-and-safety-in-phase-iii-aml-study			Maximum tolerated dose/toxicity	20	20											55			31-74										80			55-92													
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	WT1, PRAME and CMV pp65 transfected TLR7/8 matured DC vaccine		Completed	NCT01734304		PCD	01-MAR-18	No	No		4	NCT01734304			Immune response	13	13																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / acute myeloid leukaemia	3	Phase 2	WT1, BCR/ABL PR1 peptide-loaded autologous DC vaccine		Recruiting	NCT02543749		ECD	01-JUL-21	No	No		4	NCT02543749			Maximum tolerated dose/toxicity	30	30																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	p.DOM-WT1-126 + p.DOM-WT1-37		Completed	NCT01334060	WIN	PCD	01-FEB-13	Expression level	No		4	NCT01334060			Molecular response	23	23																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	WT1, BCR/ABL PR1 peptide-loaded autologous DC vaccine		Recruiting	NCT02543749		ECD	01-JUL-21	No	No		4	NCT02543749			Maximum tolerated dose/toxicity	30	30																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / myelodysplastic syndrome	3	Phase 1	Chimeric antigen receptor T cells + WT1-specific DC vaccine		Recruiting	NCT03291444		ECD	01-MAR-21	Expression level	No		4	NCT03291444			Maximum tolerated dose/toxicity	30	30																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / acute lymphoblastic leukaemia	3	Phase 1	WT1, PRAME, Survivin-specific autologous cytotoxic T cells		Recruiting	NCT02475707	STELLA	PCD	01-OCT-19	No	No		4	NCT02475707			Maximum tolerated dose/toxicity	40	40																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	WT1, MAGEA3, CT7 autologous DC vaccine		Active, not recruiting	NCT01995708		ECD	01-NOV-21	Expression level	No		4	NCT01995708			Maximum tolerated dose/toxicity	28	28																																								
WT1	WT1_unspecified				haematopoietic and lymphoid tissue / lymphoid neoplasm / plasma cell myeloma	3	Phase 1	Anti-thymocyte globulin + Busulfan + Fludarabine + Melphalan + T cell depleted HSCT + WT1-specific allogenic cytotoxic T cells		Active, not recruiting	NCT01758328		ECD	01-DEC-21	Expression level	No		4	NCT01758328			Maximum tolerated dose/toxicity	29	29																																								
WT1	WT1_unspecified				kidney / Wilms tumour / NS	3	Phase 1	Tumor-associated antigen cytotoxic T cells		Recruiting	NCT02789228	REST	ECD	01-SEP-20	Expression level	Yes		1	31356143			Maximum tolerated dose/toxicity	7	7																																2								
WT1	WT1_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Galinpepimut-S + Pembrolizumab + Sargramostim		Recruiting	NCT03761914		ECD	01-DEC-20	Expression level	No		4	NCT03761914			Complete response, Pathological complete response	90	90																																								
WT1	WT1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 1	WT2725		Completed	NCT01621542		PCD	01-MAY-17	Expression level	No		4	NCT01621542			Maximum tolerated dose/toxicity	64	64																																								
WT1	WT1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	Aldesleukin + Cyclophosphamide + WT1-TCRc4 gene-transduced autologous CD8-positive Tcm/Tn lymphocytes		Active, not recruiting	NCT02408016		ECD	01-JUN-20	Expression level	No		4	NCT02408016			Maximum tolerated dose/toxicity	20	20																																								
WT1	WT1_unspecified				lung / carcinoma / non small cell carcinoma	3	Phase 2	WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ? K-HELP, MUC1-22 peptide loaded autologous DC vaccine		Recruiting	NCT04199559		ECD	01-JAN-21	No	No		4	NCT04199559			Progression free survival	30	30																																								
WT1	WT1_unspecified				lung / carcinoma / small cell carcinoma	3	Phase 2	Galinpepimut-S + Pembrolizumab + Sargramostim		Recruiting	NCT03761914		ECD	01-DEC-20	Expression level	No		4	NCT03761914			Complete response, Pathological complete response	90	90																																								
WT1	WT1_unspecified				oesophagus / carcinoma / NS	3	Phase 1	Tumor-associated antigen cytotoxic T cells		Recruiting	NCT02789228	REST	ECD	01-SEP-20	Expression level	No		1	31356143			Maximum tolerated dose/toxicity	32	32																																								
WT1	WT1_unspecified				ovary / carcinoma / NS	3	Phase 1	Galinpepimut-S + Montanide + Nivolumab + Sargramostim		Active, not recruiting	NCT02737787		ECD	01-APR-22	Expression level	Yes	1yr PFS 64%	2	10.1200/JCO.2018.36.15_suppl.5553			Maximum tolerated dose/toxicity	20	20																																								
WT1	WT1_unspecified				ovary / carcinoma / NS	3	Phase 2	KLH peptide loaded autologous DC vaccine + MUC1 peptide loaded autologous DC vaccine + WT1 peptide loaded autologous DC vaccine		Recruiting	NCT00703105		ECD	01-JUL-20	No	No		4	NCT00703105			Immune response	36	36																																								
WT1	WT1_unspecified				ovary / carcinoma / NS	3	Phase 2	Galinpepimut-S + Pembrolizumab + Sargramostim		Recruiting	NCT03761914		ECD	01-DEC-20	Expression level	No		4	NCT03761914			Complete response, Pathological complete response	90	90																																								
WT1	WT1_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 1	Cyclophosphamide + Filgrastim + Fludarabine + WT1-specific cytotoxic T cells		Active, not recruiting	NCT00562640		ECD	01-DEC-21	Expression level	No		4	NCT00562640			Maximum tolerated dose/toxicity	21	21																																								
WT1	WT1_unspecified				ovary / carcinoma / mixed carcinoma	3	Phase 1	Filgrastim + WT1-specific cytotoxic T cells		Active, not recruiting	NCT00562640		ECD	01-DEC-21	Expression level	No		4	NCT00562640			Maximum tolerated dose/toxicity	21	21																																								
WT1	WT1_unspecified				pancreas / carcinoma / NS	3	Phase 2	WT1, MUC1 peptide loaded autologous DC vaccine		Completed	NCT03114631		PCD	01-MAY-19	Expression level	No		4	NCT03114631			Overall Response Rate	30	30																																								
WT1	WT1_unspecified				pancreas / carcinoma / NS	3	Phase 2	Tumour lysate loaded autologous DC vaccine		Completed	NCT03114631		PCD	01-MAY-19	Expression level	No		4	NCT03114631			Overall Response Rate	30	30																																								
WT1	WT1_unspecified				pleura / mesothelioma / NS	3	Phase 1	Galinpepimut-S + Nivolumab + Sargramostim		Recruiting	NCT04040231		ECD	01-JUL-21	Expression level	No		4	NCT04040231			Maximum tolerated dose/toxicity	10	10																																								
WT1	WT1_unspecified				pleura / mesothelioma / NS	3	Phase 2	Galinpepimut-S + Montanide + Sargramostim		Completed	NCT01265433		PCD	01-JUL-17	Expression level	Yes		2	10.1200/JCO.2016.34.15_suppl.8519			Progression free survival	40	19	21										11.4	5.7	.69		0.3									21.4	16.6	.52		0.14												
WT1	WT1_unspecified				pleura / mesothelioma / NS	3	Phase 2	Cisplatin + Pemetrexed + WT1 mRNA transfected autologous DC vaccine		Recruiting	NCT02649829	MESODEC	ECD	01-DEC-23	No	No		4	NCT02649829			Maximum tolerated dose/toxicity	20	20																																								
WT1	WT1_unspecified				pleura / mesothelioma / NS	3	Phase 2	Galinpepimut-S + Montanide + Sargramostim		Active, not recruiting	NCT01890980		ECD	01-APR-20	Expression level	Yes		1	28972039			Progression free survival	41	20	21										10.1	7.4	.78		0.46									22.8	18.3	.79		0.54												
WT1	WT1_unspecified				soft tissue / rhabdomyosarcoma / NS	3	Phase 1	Tumor-associated antigen cytotoxic T cells		Recruiting	NCT02789228	REST	ECD	01-SEP-20	Expression level	Yes		1	31356143			Maximum tolerated dose/toxicity	3	3																																3								
XRCC3	XRCC3_unspecified				large intestine / carcinoma / adenocarcinoma	3	Phase 2	Trifluridine and tipiracil hydrochloride		Recruiting	NCT04166604	LONGBOARD	ECD	01-NOV-21	No	No		4	NCT04166604			Maximum tolerated dose/toxicity	250	250																																								
ZRSR2	ZRSR2_unspecified				haematopoietic and lymphoid tissue / haematopoietic neoplasm / chronic myeloid leukaemia	3	Phase 2	Dasatinib + Imatinib + Nilotinib		Not yet recruiting	NCT04147533	HALF	ECD	01-DEC-24	No	No		4	NCT04147533			Clinical activity	150	150																																								
